CURRENT Practice Guidelines in Primary Care 2018

Concise summaries of the latest disease-screening, prevention, and management guidelines

JOSEPH S. ESHERICK • EVAN D. SLATER • JACOB A. DAVID

McGraw Hill Education LANGE
CURRENT Practice Guidelines in Primary Care 2018

Joseph S. Esherick, MD, FAAFP
Director of Medicine
Ventura County Medical Center
Associate Clinical Professor of Family Medicine
David Geffen School of Medicine
Los Angeles, California

Evan D. Slater, MD
Ventura County Medical Center
Assistant Clinical Professor of Medicine
David Geffen School of Medicine
Los Angeles, California

Jacob A. David, MD, FAAFP
Associate Program Director
Family Medicine Residency Program
Ventura County Medical Center
Clinical Instructor
UCLA School of Medicine
Los Angeles, California
This book is dedicated to all of our current and former residents at the Ventura County Medical Center.
Contents

Preface xiii

1. DISEASE SCREENING

Abdominal Aortic Aneurysm 1
Adenocarcinoma of Gastroesophageal Junction 4
Alcohol Abuse and Dependence 5
Anemia 6
Attention-Deficit/Hyperactivity Disorder 8
Autism Spectrum Disorder 9
Bacteriuria, Asymptomatic 9
Bacterial Vaginosis 10
Barrett Esophagus 10
Cancer

Bladder 11
Breast 13
Testing for Brca 1 and 2 Mutations 20

Cervical 22
Colorectal 26
Endometrial 32
Gastric 34
Liver (Hepatocellular Carcinoma) 34
Lung 35
Oral 37
Ovarian 38
Pancreatic 40
Prostate 41
Skin (Melanoma) 46
Testicular 47
Thyroid 48
Carotid Artery Stenosis (Asymptomatic) 49
Celiac Disease 50
Chlamydia 51

Cholesterol and Lipid Disorders 53
Chronic Obstructive Pulmonary Disease 60
Coronary Artery Disease 60

Dementia 64
Depression 64
Developmental Dysplasia of the Hip 66
Diabetes Mellitus

Gestational 67
Type 2 67
Falls in the Elderly 69
Family Violence and Abuse 70

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Fetal Aneuploidy 71
Glaucoma 72
Gonorrhea 72
Group B Streptococcal Disease 73
Growth Abnormalities, Infant 74
Hearing Impairment 74
Hemochromatosis (Hereditary) 75
Hemoglobinopathies 77
Hepatitis B Virus Infection 77
Hepatitis C Virus Infection, Chronic 79
Herpes Simplex Virus, Genital 80
Human Immunodeficiency Virus 81
Hypertension
  Children and Adolescents 82
  Adults 83
Illicit Drug Use 85
Kidney Disease, Chronic 86
Lead Poisoning 86
Motor Vehicle Safety 88
Newborn Screening 88
Obesity 89
Osteoporosis 90
√ Pelvic Examinations 92
  Phenylketonuria 93
  Rh (D) Incompatibility 93
  Scoliosis 94
+ Sleep Apnea 94
  Speech and Language Delay 94
√ Syphilis 95
+ Thyroid Disease 96
  Tobacco Use 98
  Tuberculosis, Latent 99
  Visual Impairment, Glaucoma, or Cataract 100
  Vitamin D Deficiency 101

2. DISEASE PREVENTION 103
√ Asthma 103
  Back Pain, Low 104
  Breast Cancer 104
  Cervical Cancer 107
  Colorectal Cancer 108
  Endometrial Cancer 110
  Esophagus Cancer 111
  Gastric 111
  Liver Cancer 112
  Lung Cancer 113
  Oral Cancer 113
  Ovarian Cancer 114

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Prostate Cancer 115
Skin Cancer 116
Catheter-Related Bloodstream Infections 116
Cesarean Section 117
Colitis, *Clostridium Difficile* 118
Concussion 119
√ COPD Exacerbation 120
Dental Caries 121
√ Diabetes Mellitus, Type 2 121
Domestic Violence 122
Driving Risk 122
Endocarditis 123
Falls in the Elderly 124
Fractures 125
Gonorrhea, Ophthalmia Neonatorum 125
Gout 126
Group B Streptococcal Infection 127
Hormone Replacement Therapy 127
Human Immunodeficiency Virus, Opportunistic Infections 128
Hypertension 138
Immunizations
  Adults 140
  Infants and Children 140
+ Influenza
  Chemoprophylaxis 140
  Vaccination 141
Kidney Injury, Acute 142
Motor Vehicle Injury 143
Myocardial Infarction
  Aspirin Therapy 144
  Dietary Therapy 145
  Statin Therapy 146
  Special Populations 148
√ Neural Tube Defects 152
√ Obesity 153
Osteoporotic Hip Fractures 154
Otitis Media 155
Postpartum Hemorrhage 155
Preeclampsia 156
Preterm Birth 156
Pressure Ulcers 157
Sexually Transmitted Infections 158
Stroke 159
  Atrial Fibrillation 159
  Special Populations 163
√ Sudden Infant Death Syndrome 167
Surgical Site Infections 168
Tobacco Use 168

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Venous Thromboembolism  
  Prophylaxis in Nonsurgical Patients  169
In Surgical Patients  173

3. DISEASE MANAGEMENT

Abdominal Aortic Aneurysm  177
+ Abnormal Liver Chemistries  181
+ Active Surveillance for the Management of Localized Prostate Cancer  183
Adrenal Incidentalomas  184
+ Adult Psychiatric Patients in the Emergency Department  185
Alcohol Use Disorders  185
Anaphylaxis  186
Androgen Deficiency Syndrome  187
Anemia–Use of Erythropoietic Agents  188
+ Ankylosing Spondylitis and Spondyloarthritis  189
Anxiety  190
Apnea
  Central Sleep  190
  Obstructive Sleep  191
Ascites, Due to Cirrhosis  192
Asthma  193
Asymptomatic Bacteriuria  196
Atrial Fibrillation  197
Attention-Deficit Hyperactivity Disorder  212
Autism  214
Autism Spectrum Disorders  215
Back Pain, Low  216
Barrett Esophagus  219
Bell's Palsy  220
Benign Prostatic Hyperplasia  221
Breast Cancer Follow-Up Care  222
Bronchitis, Acute  224
+ Carbon Monoxide Poisoning  224
Carotid Artery Disease  225
Cataract  227
√ Celiac Disease  228
  Cerumen Impaction  228
  Chronic Obstructive Pulmonary Disease
    Exacerbations  229
    Stable  230
Cobalamin (B₁₂) Deficiency  233
Colitis, *Clostridium Difficile*  235
Colorectal Cancer Follow-Up Care  237
Common Cold  238
Concussions  238
Constipation, Idiopathic  239
Contraception  240
Contraception, Emergency  253

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Coronary Artery Disease  254
Cushing's Syndrome  266
Delirium  266
  Postoperative  267
Dementia  267
  Alzheimer Disease  268
  Feeding Tubes  269
Depression  269
Diabetic Foot Problems, Inpatient Management  270
Diabetes Mellitus
  Gestational  270
  Type 1  271
  Type 2  273
+  Diarrhea, Acute  280
  Diffuse Large β Cell Lymphoma Stage I Through IV  282
Dyspepsia  283
Dysphagia  285
Eating Disorders  285
Ectopic Pregnancy  286
Epilepsy  287
Erectile Dysfunction  288
Gallstones  289
+  Gastrointestinal Bleeding, Lower  289
  Gastrointestinal Bleeding, Upper (Ugib)  291
Geriatrics  293
Glaucoma, Chronic Open Angle  312
Gout, Acute Attacks  313
Headache  315
  Migraine Prophylaxis  315
Hearing Loss, Sudden  324
Heart Failure  324
Helicobacter Pylori Infection  330
+  Hematuria  331
  Hepatitis B Virus  332
    Infection  333
    Treatment  334
  Hepatitis C Virus  335
  Hereditary Hemochromatosis  336
  Hip Fractures  337
Hoarseness  338
  Human Immunodeficiency Virus  339
    Antiretroviral Therapy  340
    Antiretroviral Use  341
    Pregnancy  342
  Hyperlipidemia  343
  Hypertension  358
  Hypogonadism, Male  371
  Identifying Risk of Serious Illness in Children Under 5 Y  372
  Indwelling Urinary Catheters or Intermittent Catheterization  373

\(\checkmark\) denotes major 2018 updates.
+ denotes new topic for 2018.
Contents

Infertility, Male 374
Inflammatory Bowel Disease
  Crohn's Disease 374
  Ulcerative Colitis 375
  Ulcerative Colitis, Surgical Treatment 376
Influenza 377
Iron Deficiency Anemia 378
Irritable Bowel Syndrome 383
Kidney Disease
  Chronic 384
  Chronic–Mineral and Bone Disorders 385
Kidney Injury, Acute 386
Kidney Stones 387
Laryngitis, Acute 389
Malignant Spinal Cord Compression 390
  Management of Venous Thrombosis in Patients with Cancer 391
Meningitis, Bacterial 393
Menopause 394
Metabolic Syndrome 395
Methicillin-Resistant Staphylococcus Aureus Infections 397
Multiple Sclerosis 399
  Muscle Cramps 399
  Neurocysticercosis 400
  Neutropenia, Febrile 400
  Non-Small Cell Lung Cancer Follow-Up Care 402
  Normal Pressure Hydrocephalus 403
  Obesity 404
  Osteoarthritis 405
  Osteoporosis 407
    Glucocorticoid-Induced 409
Otitis Externa, Acute 411
Otitis Media, Acute 411
Ovarian Cancer Follow-Up Care 413
  Pain, Chronic 414
  Cancer Related 416
    Pain, Neuropathic 419
    Palliative Care of Dying Adults 419
    Pancreatitis, Acute (Ap) 421
    Pap Smear, Abnormal 423
    Paracentesis 429
    Peripheral Arterial Disease 429
    Pharyngitis, Acute 431
    Platelet Transfusion 433
  Pleural Effusion, Malignant 434
  Polycystic Ovary Syndrome 436
  Pneumonia 437
  Pregnancy
    Postpartum Hemorrhage 440
    Premature Rupture of Membranes 441
    Preterm Labor 441

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Contents

Preterm Labor, Tocolysis 442
Routine Prenatal Care 443
Substance Abuse 446
Preoperative Clearance 446
Pressure Ulcers 446
Procedural Sedation 447
Prostate Cancer Follow-Up Care 448
Psoriasis
  Psoriatic Arthritis 450
  Plaque-Type 451
Psychiatric Patients in the Emergency Department 453
Pulmonary Nodules 453
Red Blood Cell Transfusion 454
Renal Cancer Follow-Up Care 458
Renal Masses, Small 464
Respiratory Tract Infections
  Lower 465
  Upper 466
Restless Legs Syndrome and Periodic Limb Movement Disorders 467
Rheumatoid Arthritis, Biologic Disease-Modifying Antirheumatic Drugs 468
Rhinitis 469
Sciatica 470
Seizures 471
  Febrile 472
Sexually Transmitted Diseases 473
Sinusitis 480
  Acute Bacterial 480
  Stroke
  Acute Ischemic 481
  Recurrence 483
Syncope 490
Syphilis 493
Thrombocytopenia-Immune Mediated 493
Thrombocytopenia, Heparin-Induced 498
Thrombocytopenia, Thrombotic Purpura 501
Thyroid Disease
  Hyperthyroidism 504
  Pregnancy and Postpartum 506
Thyroid Nodules 508
Tinnitus 509
Tobacco Abuse, Smoking Cessation 509
Tonsillectomy 513
Transfusion Therapy, Alternatives to Red Blood Cell Transfusion 513
Transfusion Therapy
  Cryoprecipitate 514
  Fresh Frozen Plasma 514
  Platelet Transfusion 515
  Prothrombin Complex Concentrate 516
  Red Blood Cell Transfusion 516

√ denotes major 2018 updates.
+ denotes new topic for 2018.
Traumatic Brain Injury 516
Tremor, Essential 517
Tuberculosis
Diagnosis 517
Extrapulmonary Diagnosis 518
Extra-Pulmonary Management 518
Management 519
Management of Latent Tb 521
Multidrug-Resistant 522
Tympanostomy Tubes 522
Ulcers, Stress 523
Urinary Incontinence
Overactive Bladder 523
Stress 524
Urinary Tract Infections 528
Urinary Tract Symptoms, Lower 530
+ Valvular Heart Disease 531
Venous Thromboembolism
Deep Venous Thrombosis 534
Pulmonary Embolus 539
Vertigo, Benign Paroxysmal Positional 540
Vitamin Deficiencies 541

4. APPENDICES
Screening Instruments
Alcohol Abuse 544
Depression 547
Geriatric Depression Scale 552
Modified Checklist for Autism in Toddlers, Revised with Follow-Up 553
Functional Assessment Screening in the Elderly 555
Vulnerable Seniors: Preventing Adverse Drug Events 558
Select Medications to Avoid in Older Adults with Chronic Conditions 561
Select Medications to Use with Caution in Older Adults 564
Screening and Prevention Guidelines in Perspective: Ppgc 2012 565
95Th Percentile of Blood Pressure
For Boys 568
For Girls 569
Body Mass Index Conversion Table 570
Estimate of 10-Y Cardiac Risk
For Men 571
For Women 573
Estimate of 10-Y Stroke Risk
For Men 575
For Women 577
Immunization Schedule 579
Professional Societies and Governmental Agencies 591

Index 595
√ denotes major 2018 updates.
+ denotes new topic for 2018.
Preface

*Current Practice Guidelines in Primary Care, 2018* is intended for all clinicians interested in updated, evidence-based guidelines for primary care topics in both the ambulatory and hospital settings. This pocket-sized reference consolidates information from nationally recognized medical associations and government agencies into concise recommendations and guidelines of virtually all ambulatory care topics. This book is organized into topics related to disease screening, disease prevention, and disease management for quick reference to the evaluation and treatment of the most common primary care disorders.

The 2018 edition of *Current Practice Guidelines in Primary Care* contains updates or new chapters in over 80 primary care topics. It is a great resource for residents, medical students, midlevel providers, and practicing physicians in family medicine, internal medicine, pediatrics, and obstetrics and gynecology.

Although painstaking efforts have been made to find all errors and omissions, some errors may remain. If you find an error or wish to make a suggestion, please e-mail us at EditorialServices@mheducation.com.

Joseph S. Esherick, MD, FAAFP
Evan D. Slater, MD
Jacob A. David, MD, FAAFP
Disease Screening

ABDOMINAL AORTIC ANEURYSM

Population
– Men age 65–75 y who have ever smoked.

Recommendations
– Screen once, with ultrasoundography.
– In men in this age group who have never smoked, no recommendation for or against screening.

Sources

Population
– Men/women at high risk.

Recommendations
★ Canadian Society for Vascular Surgery 2008
– All men age 65–75 y be screened for AAA.
– Individual selective screening for those at high risk for AAA:
  a. Women older than 65 y at high risk secondary to smoking, cerebrovascular disease, and family history.
  b. Men younger than 65 y with positive family history.

Source
Population
– Women who have never smoked.

Recommendation
► USPSTF 2014
– Routine screening is not recommended.

Source

Population
– Women age 65–75 y who have ever smoked.

Recommendation
► UPSTF 2014
– Current evidence is insufficient to assess the balance of benefits and harms.

Source

Population
– Men age 65–75 y who have smoked at least 100 cigarettes in their lifetime or people at risk who have a family history of AAA.

Recommendation
► ESVS 2011
– Men should be screened with a single scan at age 65 y. Screening should be considered at an earlier age in those at higher risk for AAA.

Source

Comments
1. Cochrane review (2007): Significant decrease in AAA-specific mortality in men (OR, 0.60, 95% CI 0.47–0.99) but not for women. (Cochrane Database Syst Rev. 2007;2:CD002945; http://www.thecochranelibrary.com)


3. Surgical repair of AAA should be considered if diameter ≥5.5 cm or if AAA expands ≥0.5 cm over 6 mo to reduce higher risk of rupture. Meta-analysis: endovascular repair associated with fewer postoperative adverse events and lower 30-d and aneurysm-related
mortality but not all-cause mortality compared with open repair. 
(\textit{Br J Surg}. 2008;95(6):677)

4. Asymptomatic AAA between 4.4 and 5.5 cm should have regular ultrasound surveillance with surgical intervention when AAA expands >1 cm in a year or diameter reaches 5.5 cm. (\textit{Cochrane Database Syst Rev}. 2008, CD001835; http://www.thecochranelibrary.com)


**Populations**
- Male > 65 y.
- Female > 65 y.

**Recommendations**

- **ESC 2014**
  - Ultrasound screening is recommended in all men > 65 y of age.
  - Ultrasound screening may be considered if history of current/past smoking is present.
  - Screening is not recommended in female nonsmokers without family history of AAA.
  - Targeted screening for AAA with ultrasound should be considered in first-degree siblings of a patient with AAA.

**Sources**

**Comment**
- Abdominal echocardiography used for mass screening in subgroups at risk was associated with a significant 45% decreased risk of AAA-related mortality at 10 y.

**Populations**
- Male ≥ 65 y.
- Female ≥ 65 y with cardiovascular risk factors.

**Recommendations**

- **ACR\textsuperscript{a}/AIUM/SRU 2014**
  - Ultrasound screening is recommended in all men ≥ 65 y and women ≥ 65 y with cardiovascular risk factors.
  - Patients ≥ 50 y with a family history of aortic and/or peripheral vascular aneurysmal disease.

\textsuperscript{a}ACR, American College of Radiology
--Patients with a personal history of peripheral vascular aneurysmal disease.
--Groups with additional risk include patients with a history of smoking, hypertension, or certain connective tissue diseases (eg, Marfan syndrome).

Source
--ACR-AIUM-SRU Practice Parameter for the Performance of Diagnostic and Screening Ultrasound of the Abdominal Aorta in Adults. 2014.

ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION

Population

Recommendation
▷ ASGE 2011
--Barrett’s Follow-up
  • No dysplasia—scope every 3 y.
  • Mild dysplasia—scope in 6 mo, then yearly.
  • High-grade dysplasia—surgery or endoscopic therapy. (Gastrointest Cancer Res. 2012;5:49)

Source
--Gastrointest Endosc. 2006;63:570

Comments
--In 2016, 16,910 Americans diagnosed with esophageal cancer and 15,690 died from this malignancy. Fourfold increase in males compared to females.
--Adenocarcinoma most common (4:1 versus squamous cell CA).
--Squamous cell cancer most common in African Americans (6:1).
--Risk of adeno CA increases with gastroesophageal reflux disease (GERD) and high BMI (>30kg/m2) Squamous cell related to tobacco use, alcohol, malnutrition and HPV infection.
--Benefits: There is fair evidence that screening would result in no decrease in gastric CA mortality in the United States. Harms: There is good evidence that esophagogastroduodenoscopy screening would result in rare but serious side effects, such as perforation, cardiopulmonary events, aspiration pneumonia, and bleeding. (NCI, 2008)
ALCOHOL ABUSE AND DEPENDENCE

Population
– Adults older than 18 y of age.

Recommendation
► AAFP 2010, USPSTF 2013, VA/DOD 2009, ICSI 2010
– Screen all adults in primary care settings, including pregnant women, for alcohol misuse.
– Provide persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce alcohol misuse.
– Provide brief intervention to those who have a positive alcohol misuse screen. Brief interventions during future visits.

Sources
– ISCI Preventive Services for Adults, 20th ed. 2014.

Comments
1. Screen annually using validated tool.
2. AUDIT score ≥4 for men and ≥3 for women and SASQ reporting of ≥5 drinks in a day (men) or ≥4 drinks in a day (women) in the past year are valid and reliable screening instruments for identifying unhealthy alcohol use.
3. The TWEAK and the T-ACE are designed to screen pregnant women for alcohol misuse.

Population
– Children and adolescents.

Recommendation
► AAFP 2010, USPSTF 2013, ICSI 2010
– Insufficient evidence to recommend for or against screening or counseling interventions to prevent or reduce alcohol misuse by adolescents.

Sources

*AUDIT, alcohol use disorders identification test; SASQ, single alcohol screening question.
Comments
1. AUDIT and CAGE questionnaires have not been validated in children or adolescents.
2. Reinforce not drinking and driving or riding with any driver under the influence.
3. Reinforce to women the harmful effects of alcohol on fetuses.

ANEMIA

Population
- Infants age 6–24 mo.

Recommendation
► USPSTF 2015, AAFP 2015
- Current evidence is insufficient to recommend for or against screening.
- Consider selective screening in high-risk children with malnourishment, low birth weight, or symptoms of anemia.

Sources
- AAFP Clinical Recommendations: Iron Deficiency Anemia
- USPSTF: Iron Deficiency in Young Children: Screening. 2015.

Comment
- Reticulocyte hemoglobin content is a more sensitive and specific marker than is serum hemoglobin level for iron deficiency.
- One-third of patients with iron deficiency will have a hemoglobin level >11 g/dL.

Population
- Infants and young children 0–3 y.

Recommendation
► AAP 2010
- Universal screening of Hgb at 12 mo. If anemic, measure ferritin, C-reactive protein, and reticulocyte hemoglobin content.

*Includes infants living in poverty, Blacks, Native Americans, Alaska natives, immigrants from developing countries, preterm and low-birth-weight infants, and infants whose principal dietary intake is unfortified cow’s milk or soy milk. Less than two servings per day of iron-rich foods (iron-fortified breakfast cereals or meats).
Source
– *Pediatrics*. 2010;126(5):1040-1050

Comment
– Use of transferring receptor 1 (TfR1) assay as screening for iron deficiency is under investigation.

Population
– Pregnant women.

Recommendation

**USPSTF 2015, AAFP 2015**
– Screen all women with hemoglobin or hematocrit at first prenatal visit.

Sources

Comments
– Insufficient evidence to recommend for or against routine use of iron supplements for non-anemic pregnant women (USPSTF).
– When acute stress or inflammatory disorders are not present, a serum ferritin level is the most accurate test for evaluating iron deficiency anemia. Among women of childbearing age, a cutoff of 30 ng/mL has sensitivity of 92%, specificity of 98%. (*Blood*. 1997;89:1052-1057).
– Severe anemia (hemoglobin <6) associated with abnormal fetal oxygenation and transfusion should be considered. In iron-deficient women intolerant of oral iron or non compliant, intravenous iron sucrose or iron dextran should be given.
– IV iron preferred in 3rd trimester with hemoglobin less than 10 g/dL. Cobalamin and folate deficiency should be excluded. (*Blood*. 2017; 129:940)
CHAPTER 1

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Population

– Children age 4–18 y with academic or behavioral problems and inattention, hyperactivity, or impulsivity.

Recommendation

AAFP 2016, AAP 2011

– Initiate an evaluation for ADHD. Diagnosis requires the child meet DSM-IV criteria and direct supporting evidence from parents or caregivers and classroom teacher.

– Evaluation of a child with ADHD should include assessment for coexisting disorders and alternative causes of the behavior.

Source


“DSM-IV Criteria for ADHD:
I: Either A or B.
A: Six or more of the following symptoms of inattention have been present for at least 6 mo to a point that is disruptive and inappropriate for developmental level. Inattention: (1) Often does not give close attention to details or makes careless mistakes in schoolwork, work, or other activities. (2) Often has trouble keeping attention on tasks or play activities. (3) Often does not seem to listen when spoken to directly. (4) Often does not follow instructions and fails to finish schoolwork, chores, or duties in the workplace (not due to oppositional behavior or failure to understand instructions). (5) Often has trouble organizing activities. (6) Often avoids, dislikes, or does not want to do things that take a lot of mental effort for a long period of time (such as schoolwork or homework). (7) Often loses things needed for tasks and activities (eg, toys, school assignments, pencils, books, or tools). (8) Is often easily distracted. (9) Is often forgetful in daily activities.

B: Six or more of the following symptoms of hyperactivity-impulsivity have been present for at least 6 mo to an extent that is disruptive and inappropriate for developmental level. Hyperactivity: (1) Often fidgets with hands or feet or squirms in seat. (2) Often gets up from seat when remaining in seat is expected. (3) Often runs about or climbs when and where it is not appropriate (adolescents or adults may feel very restless). (4) Often has trouble playing or enjoying leisure activities quietly. (5) Is often “on the go” or often acts as if “driven by a motor.” (6) Often talks excessively.

Impulsivity: (1) Often blurts out answers before questions have been finished. (2) Often has trouble waiting one’s turn. (3) Often interrupts or intrudes on others (eg, butts into conversations or games).

II: Some symptoms that cause impairment were present before age 7 y.

III: Some impairment from the symptoms is present in two or more settings (eg, at school/work and at home).

IV: There must be clear evidence of significant impairment in social, school, or work functioning.

V: The symptoms do not happen only during the course of a pervasive developmental disorder, schizophrenia, or other psychotic disorder. The symptoms are not better accounted for by another mental disorder (eg, mood disorder, anxiety disorder, dissociative disorder, or a personality disorder).
DISEASE SCREENING

Comments
1. Stimulant prescription rates continue to rise. (Lancet. 2016;387(10024); 1240-1250)
2. Current estimates are that 7.2% of children/adolescents meet criteria for ADHD. (Pediatrics. 2015;135(4):e994.)
3. The U.S. Food and Drug Administration (FDA) approved a “black box” warning regarding the potential for cardiovascular side effects of ADHD stimulant drugs. (N Engl J Med. 2006;354:1445)

AUTISM SPECTRUM DISORDER

Population
- Children, age 12–36 mo.

Recommendation
- USPST 2016
  - Insufficient evidence to screen routinely.

Source
- JAMA. 2016;315(7):691-6

Recommendation
- AAP 2014
  - General developmental screening at routine 9-, 18-, and 24-mo visits, with autism-specific tool at 18 mo (M-CHAT is most commonly use—see Appendix).

Source

Comment
- Listen & respond to concerns raised by caregivers; signs may be identifiable by 9 mo of age.
- Prevalence is 1 in 68; 4.5:1 male:female ratio. (MMWR Surveill Summ. 2016;65(3):1–23.)

BACTERIURIA, ASYMPTOMATIC

Population
- Pregnant women.

Recommendation
- USPSTF 2008
  - Recommend screening for bacteriuria at first prenatal visit or at 12–16 wk' gestation.
Population
- Men and nonpregnant women.

Recommendation
- USPSTF 2008
  - Recommend against routine screening for bacteriuria.

Sources
- USPSTF. Asymptomatic Bacteriuria in Adults: Screening. 2008.

BACTERIAL VAGINOSIS

Population
- Pregnant women at high risk* for preterm delivery

Recommendation
- USPSTF 2008
  - Insufficient evidence to recommend for or against routine screening.

Population
- Low-risk pregnant women.

Recommendation
- USPSTF 2008
  - Do not screen routinely.

Sources

BARRETT ESOPHAGUS (BE)

Populations
- General population with GERD.
- High-risk population with GERD (multiple risk factors including age >50, male gender, white, chronic GERD, hiatal hernia, BMI >30, intra-abdominal body fat distribution or tobacco use.)

Recommendations
- AGA 2011
  - Against screening general population with GERD for BE (strong recommendation).

*Risk factors: African-American race or ethnicity, body mass index less than 20 kg/m², previous preterm delivery, vaginal bleeding, shortened cervix <2.5 cm, pelvic infection, bacterial vaginosis.
DISEASE SCREENING

High Risk Factors

- Screening should be strongly considered in this population, especially patients with multiple risk factors (weak recommendation).
- If Barrett’s found without dysplasia follow-up endoscopy in 1 y then every 3–5 y. (JAMA. 2013;310(6):627-636) (Gastroenterology. 2016;151:822)
- If low grade dysplasia confirmed by endoscopy eradication therapy is indicated.
- High grade dysplasia should be treated with endoscopic eradication rather than esophagectomy. (N Engl J Med. 2014;371:836)

Source


Comment

- Clinical Aspects
  - Despite lack of evidence for benefit of screening general population with GERD for BE, endoscopic screening is common and widespread.
  - 40% of patients with BE and esophageal cancer have not had chronic GERD symptoms.
  - The diagnosis of dysplasia in BE should be confirmed by at least one additional pathologist, preferably one who is an expert in esophageal pathology. (Gastroenterology. 2011;140:1084) (N Engl J Med. 2014;371:836)
  - All patients with BE should be treated with a proton pump inhibitor even if not symptomatic. (Gut. 2014;63:1229)

CANCER, BLADDER

Population

- Asymptomatic persons.

Recommendation

- AAFP 2011, USPSTF 2016
  - Recommends against routine screening for bladder cancer (CA) in adults. Evidence is insufficient to assess balance of benefits and harms of screening for bladder CA in asymptomatic adults. (No major organization recommends screening for bladder cancer in asymptomatic adults).

Sources

Comments

– Benefits and Harms

• There is inadequate evidence to determine whether screening for bladder CA would have any impact on mortality. Based on fair evidence, screening for bladder CA would result in unnecessary diagnostic procedures and over diagnosis (70% of bladder CA is in situ) with attendant morbidity. (NCI, 2017)

– Clinical Awareness

• Urinary biomarkers (nuclear matrix protein 22, tumor associated antigen p300, presence of DNA ploidy) do not have significant sensitivity or specificity to be utilized in clinical practice. Microscopic hematuria leads to a diagnosis of bladder cancer in only 5% of patients.

• There are 79,000 of bladder expected in 2017 in the United States with the majority being non-invasive (70%) but still 16,900 americans are expected to die of bladder cancer in 2017. (Ann Inter Med. 2010;153:461) (Eur Urol. 2013;63:4)

• A high index of suspicion should be maintained in anyone with a history of smoking (4- to 7-fold increased risk\textsuperscript{a}), an exposure to industrial toxins (aromatic amines, benzene), therapeutic pelvic radiation, cyclophosphamide chemotherapy, a history of Schistosoma haematobium cystitis, hereditary nonpolyposis colon CA (Lynch syndrome), and history of transitional cell carcinoma of ureter (50% risk of subsequent bladder CA). Large screening studies in these high-risk populations have not been performed.

• Voided urine cytology with sensitivity of 40% but only 10% positive predictive value, urinary biomarkers (nuclear matrix protein 22, telomerase) with suboptimal sensitivity and specificity. Screening for microscopic hematuria has <10% positive predictive value.

\textsuperscript{a}Individuals who smoke are 4–7 times more likely to develop bladder CA than are individuals who have never smoked. Additional environmental risk factors: exposure to aminobiphenyls; aromatic amines; azo dyes; combustion gases and soot from coal; chlorination by-products in heated water; aldehydes used in chemical dyes and in the rubber and textile industries; organic chemicals used in dry cleaning, paper manufacturing, rope and twine making, and apparel manufacturing; contaminated Chinese herbs; arsenic in well water. Additional risk factors: prolonged exposure to urinary S. haematobium bladder infections, cyclophosphamide, or pelvic radiation therapy for other malignancies.
CANCER, BREAST

Population
– Women age 20–44 y.

Recommendations
▶ ACS 2016
– Inform women of benefits and limitations of breast self-examination (BSE). Educate concerning reporting a lump or breast symptoms.
– Breast imaging not indicated for average-risk women. Women 40–44 y old should have the opportunity to begin annual screening if they desire.

Source
– http://www.cancer.org

Population
– Women age 40–49 y.

Recommendation
▶ USPSTF 2012

Sources
– Ann Intern Med. 2012;156:609

Comment
– Harm and Benefit of Mammography Screening
  • Harms: Based on solid evidence, screening mammography may lead to potential harm by overdiagnosis (indolent tumors that are not life-threatening) and unnecessary biopsies for benign disease. It is estimated that 20%–25% of diagnosed breast cancers are indolent and unlikely to be clinically significant. (CA Cancer J Clin. 2012;62:5) (Ann Intern Med. 2012;156:491)
• BSE does not improve breast CA mortality (*Br J Cancer*. 2003;88:1047) and increases the rate of false-positive biopsies. (*J Natl Cancer Inst*. 2002;94:1445)

• Twenty-five percent of breast CAs diagnosed before age 40 y are attributable to *BRCA1* or *2* mutations.

• The sensitivity of annual screening of young (age 30–49 y) high-risk women with magnetic resonance imaging (MRI) and mammography is superior to either alone, but MRI is associated with a significant increase in false positives. (*Lancet*. 2005;365:1769) (*Lancet Oncol*. 2011;378:1804)

• Computer-aided detection in screening mammography appears to reduce overall accuracy (by increasing false-positive rate), although it is more sensitive in women age <50 y with dense breasts. (*N Engl J Med*. 2007;356:1399)


• Estimated 252,710 new cases of invasive breast cancer (63,400 with DCIS) expected in 2017 with 40,600 expected deaths (NCI: 2017)


**Population**

—Women age ≥40 y.

**Recommendation**

► AAFP 2013

—Mammography, with or without Clinical Breast Exam, every 1–2 y after counseling about potential risks and benefits.

**Source**


**Comments**

1. Evidence is insufficient to recommend for or against routine CBE alone, or teaching or performing a routine BSE; recommend against screening women >75 y old.

2. Breast MRI annually for *BRCA 1* and *2* mutation carriers or women with therapeutic chest radiation between ages 15–35.
DISEASE SCREENING

Population
– Women age 45–54 y.

Recommendation
► ACS 2016

Source
– http://www.cancer.org

Comment
– In 2016, 246,000 new invasive breast cancer cases per year with 40,500 deaths. Mortality rates have declined by 1.9%/year from 1998-2012. Will these guidelines increase the risk of breast cancer deaths?
– It is estimated that 1.6 million breast biopsies are performed each year in the U.S. with the overwhelming majority having benign disease. JAMA. 2015; 313:1122.

Population
– Average risk women ≥55 y.

Recommendations
► ACS 2016
– Women age ≥55 y should transition to biannual screening or have the opportunity to continue screening annually.
– Women should continue screening mammography as long as their overall health is good and they have a life expectancy ≥10 y.
– The ACS does not recommend clinical breast examination for breast cancer screening among average risk women at any age.

Comment
Population
- High-risk patients.
- Women with family history associated with increased risk for deleterious mutations in BRCA 1 or 2.

Recommendations
ACS 2016
- If >20% risk of breast CA, annual mammogram alternating in 6 mo intervals with MRI is recommended. BRCA1 and 2 mutation-positive women should begin MRI and mammogram screening at age 30 y or younger, depending on family history. Lymphoma survivors with a history of mediastinal radiation should begin mammography and MRI yearly 10 y after radiation.
- Dense breasts (>50%) by itself is not yet an indication for MRI screening. Adding full breast ultrasound to routine mammogram willin these patients increase early detection of breast cancer. Ultrasound has been shown to be superior to Tomosynthesis in this population. Tomosynthesis doubles the radiation exposure compared to routine mammogram.

Sources
- CA Cancer J Clin. 2015;65:30
- J Clin Oncol. 2016; 34:1882
- JAMA. 2012; 307:1394
- J Clin Oncol. 2016; 34:1840

Comment
- High Risk Clinical Issues
  - In high-risk women, probability of breast CA when mammogram is negative = 1.4% (1.2%–1.6%) vs. when mammogram plus MRI are negative = 0.3% (0.1%–0.8%). (Ann Intern Med. 2008;148:671) MRI is 2–3 times as sensitive as mammogram, but 2-fold increase in false positives—use in selected high-risk population only. (J Clin Oncol. 2005;23:8469) (J Clin Oncol. 2009;27:6124) (J Clin Oncol. 2011; 29:1664).
  - Tomosynthesis (three-dimensional mammography) under study with increase in sensitivity and specificity and reduction in false positives vs. film or digital mammography. There is double the dose of radiation compared to mammogram which may limit its use. (JAMA. 2014;311:2499) (JAMA. 2014;311:2488) (Effectiveness of Tomosynthesis: JAMA. 2016;2:737)
• If lifetime risk of breast CA is between 15% and 20%, women should discuss risks/benefits of adding annual MRI to mammography screening. Sensitivity of MRI is superior to mammography, especially in higher-risk women age <50 y with dense breasts (increasing breast density increases risk of breast CA and lowers sensitivity of mammogram). A >75% breast density increases risk of breast CA 5-fold. (J Clin Oncol. 2010;28:3830) (N Engl J Med. 2015;372:2243) (Ann Intern Med. 2015;162:157)


Population
– Women age 50–74 y.
– Women age 40–50 y.

Recommendations
► USPSTF 2016
– Biennial screening mammography for women aged 50–74 y.
– Breast Self Exam teaching not recommended.
– Inconclusive data for screening women age >75 y.
– At present insufficient evidence to assess benefits and harms of tomosynthesis, ultrasound and MRI imaging for women with dense breasts.

Source

Comment
– These recommendations for women age 40–50 y have been widely criticized and largely ignored by other advisory organizations as inconsistent with available data. Subsequent trial from Norway showed significant benefit in mortality reduction (28%) in the age 40–49 y subset. Analysis of data sets continues, but there has been no major change in practice patterns. (AJR Am J Roentgenol. 2011;196:112) (J Am Coll Radiol. 2010;7:18) (Cancer. 2011;117:7) (Eur J Cancer. 2010;46:3137) (CA Cancer J Clin. 2012;62:129)
Populations
- Age 25–40 y (average risk).
- Age >40 y (average risk).
- Acquired increased risk—prior thoracic radiation therapy.

Recommendations

NCCN 2016
- CBE every 1–3 y—breast awareness education in patients <40 with average risk.
- Annual CBE, mammogram yearly but MRI not recommended in average-risk patients. Women older than 80 or with limited life expectancy should not be screened.
- CBE q 6–12 mo, annual mammogram and annual MRI beginning 8–10 y after radiation therapy or age 40 y, whichever comes first.
- Breast MRI should be performed days 7–15 of menstrual cycle to maximize accuracy.
- BRCA 1 or 2 patients should be followed with CBE q 3–6 mo with alternating mammogram and MRI every 6 mo.
- BRCA 1 and 2 patients should be referred for genetic counseling.

Source
- www.nccn.org

Comment
- Continued Controversy Over Screening
  - The Canadian National Breast Screening study began in 1980 found no survival benefit for mammography in 40–59 y old women but the study is thought to be flawed by most experts in the United States because of study design. (BMJ. 2014;348:g366) (N Engl J Med. 2014;370:1965)
  - A recent meta-analysis (JAMA. 2014; 311:1327) from Harvard found an overall reduction of breast cancer mortality of 19% (15% for women in their 40s and 32% for women in their 60s). They were concerned about over diagnosis and other potential harms of screening including false positive findings and unnecessary biopsies. (N Engl J Med. 2016; 375: 1438).
  - Recent trials have led to an increase in further screening studies based on the predicted individual risk of breast cancer occurrence. These also include a history of lobular carcinoma in situ, atypical hyperplasia or history of breast CA (invasive and DCIS). Ann Intern Med. 2016; 165:700. Ann Intern Med. 2016; 165:737.
DISEASE SCREENING

- A woman with mediastinal radiation at age 10–30 y will have a 75-fold increased risk of breast CA at age 35 y vs. age-matched controls.
- Salpingo-oophorectomy will decrease risk of breast CA in BRCA1 and 2 carriers by 50% and decrease risk of ovarian CA by 90%–95%.

Populations
- Lifetime risk of breast CA >20% based on personal and family history (utilize Gail model, BRCAPRO model, or Tyrer-Cuzick model) and genetic predisposition (BRCA 1 or 2), PALB 2, CHEK 2 (http://www.cancer.gov/bcrisktool/).

Recommendations

NCCN 2015
- Age <25 y, annual CBE, breast awareness education, and referral to genetic counselor.
- Age >25 y, annual mammogram, and MRI, CBE q 6–12 mo, consider risk-reducing strategies (surgery, chemoprevention).

Source
- www.nccn.org

Comments

1. Tamoxifen or raloxifene have not been studied as de novo chemo prevention in BRCA1 or 2 patients, but tamoxifen will decrease risk of contralateral breast CA by 50% in BRCA-mutated breast CA patients. (Int J Cancer. 2006;118:2281)
2. Risk-reducing bilateral mastectomy in BRCA1 and 2 mutation car-
riers results in a 90% risk reduction in incidence of breast CA and a 90% rate of satisfaction among patients who underwent risk-reducing surgery at 10 y follow-up. (N Engl J Med. 2001;345:159) (JAMA. 2010;304:967)
CANCER, BREAST <TESTING FOR BRCA 1 AND 2 MUTATIONS>

Population
—Women <60 y old.

Recommendations
▶ NCCN 2016

—Who to screen – patients without cancer
- Individual from a family with known deleterious BRCA1 and 2 gene mutation
- Test only for the known mutation, not full genetic evaluation.
- If strong family history (FH) but unable to test family member with cancer (not alive or unavailable to be tested) then do full genetic evaluation—strong FH includes 2 primary breast cancers in a single close relative (1st, 2nd, and 3rd degree relatives) Breast cancer (BC), primaries on same side of family with at least one diagnosis occurring in a patient <50 y old, and ovarian cancer or male breast cancer at any age.

—Who to screen – patients with breast, ovarian, pancreas and prostate cancer.
- A known mutation in a cancer susceptibility gene within a family.
- Early age onset of breast CA (<50 y old).
- Triple negative (ER-PR-, Her2-) breast cancer diagnosed <60 y old.
- An individual of Ashkenazi Jewish descent with breast, ovarian or pancreatic cancer at any age.
- All women with ovarian cancer (epithelial and non-mucinous) at any age should be tested for BRCA 1 and 2 mutations.

Comments
1. BRCA 2 related breast cancer is more like sporadic BC with 75% of patients with hormonal receptor positivity and significant decrease in aggressive growth. Only 15% of BRCA2 patients will develop ovarian cancer with the average time of onset being in the mid 50’s.
2. One in forty Ashkenazi Jewish men and women carry a deleterious BRCA1 or 2 gene (BRCA1-185del AG, 5382insA mutations, and BRCA2 - 6174 delT mutation).
3. Some experts believe all men and women of Ashkenazi descent should be tested for these 3 genes even with no personal or family history of malignancy. (N Engl J Med. 2016; 374:454)
## CANCER, BREAST
### TABLE A: HARMs OF SCREENING MAMMOGRAPHY

<table>
<thead>
<tr>
<th>Harm</th>
<th>Internal Validity</th>
<th>Consistency</th>
<th>Magnitude of Effects</th>
<th>External Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of insignificant CAs (overdiagnosis of indolent cancer) can result in breast deformity, lymphedema, thromboembolic events, and chemotherapy-induced toxicities. <em>(Ann Intern Med. 2016; 164:215)</em></td>
<td>Good</td>
<td>Good</td>
<td>Approximately 20%–30% of breast CAs detected by screening mammograms represent overdiagnosis. <em>(BMJ. 2009;339:2587)</em> Oncotype DX (a predictive panel of 15 breast CA genes) can reduce the use of chemotherapy by 50% in node-negative hormone receptor-positive patients. <em>(N Engl J Med. 2015;375:2005)</em></td>
<td>Good</td>
</tr>
<tr>
<td>Additional testing (false positives)</td>
<td>Good</td>
<td>Good</td>
<td>Estimated to occur in 30% of women screened annually for 10 y, 7%–10% of whom will have biopsies. This creates anxiety and negative quality of life impact. <em>(Ann Intern Med. 2009;151:738)</em> <em>(Ann Intern Med. 2011;155:481)</em> <em>(Br J Cancer. 2013; 108:2205)</em></td>
<td>Good</td>
</tr>
<tr>
<td>False sense of security, delay in CA diagnosis (false negatives)</td>
<td>Good</td>
<td>Good</td>
<td>Approximately 10%–30% of women with invasive CA will have negative mammogram results, especially if young with dense breasts or with lobular or high-grade CAs. <em>(Radiology. 2005;235:775)</em> All suspicious lumps should be biopsied even with negative mammogram. <em>(Ann Intern Med. 2016; 164:226)</em></td>
<td>Good</td>
</tr>
</tbody>
</table>

CHAPTER 1

CANCER, CERVICAL

Populations
- Women <21 y old: no screening.\(^a\)
- Women between 21 and 29 y old.
- Average-risk women 30–65 y old.

 Recommendation
- ACS 2017
  - Guidelines ACS
    - Cytology alone (PAP smear) every 3 y until age 30 y.
    - Human papillomavirus (HPV) DNA testing not recommended if age <30 y (majority of young patients will clear the infection).
    - HPV and cytology "cotesting" every 5 y (preferred) or cytology alone every 3 y (acceptable). If HPV positive/cytology negative—either 12-mo follow-up with cotesting or test for HPV 16 or 18 genotypes with referral to colposcopy if positive. Continue to screen more frequently if high-risk factors present.\(^b,c,d\)
    - 10% of women age 30–34 y will have normal cytology but a positive HPV test and will need more frequent testing. In women 60–65 y old only 2.5% will have negative cytology but positive HPV testing.

Population
- Age >65 y after hysterectomy.

 Recommendations
- ACS 2015
  - No screening following adequate prior screening with negative results.
  - No screening in women without a cervix and no history of CIN2 or worse in last 20 y or cervical CA ever.

 Sources
- [http://www.cancer.org](http://www.cancer.org)
- [http://www.survivorshipguidelines.org](http://www.survivorshipguidelines.org)

\(^a\)Sexual history in patients <21 y old not considered in beginning cytologic screening, which should start at age 21.
\(^c\)High-risk factors include DES exposure before birth, HIV infection, or other forms of immunosuppression, including chronic steroid use.
\(^d\)Women with a history of cervical CA, DES exposure, HIV infection, or a weakened immune system should continue to have screenings as long as they are in >5-y life expectancy.
DISEASE SCREENING

Populations
- Women 21–29 y.
- Women 30–65 y.
- Women younger than 21 y.
- Women younger than 30 y.

Recommendation

- USPSTF 2015

- Screening by Age
  - Screen with cytology (Pap smear) every 3 y (age 21-29 y).
  - Screen with cytology every 3 y or co-testing (cytology/HPV testing) every 5 y (age 30-65 y).
  - Do not screen (age less than 21 y).
  - Do not screen with HPV testing alone or with cytology in 21–29 y old women.

Sources
- http://www.uspreventiveservicestaskforce.org/

Comments

- Clinical Concerns
  - In the U.S. in 2017 it is estimated that 12,820 cases of invasive cervical cancer will be diagnosed and 4210 women die of disease (American Cancer Society: facts and figures 2017).
  - Cervical CA is causally related to infection with HPV (>70% associated with either HPV-18 or HPV-16 genotype).
  - Immunocompromised women (organ transplantation, chemotherapy, chronic steroid therapy, or human immunodeficiency virus [HIV]) should be tested twice during the first year after initiating screening and annually thereafter. (CA Cancer J Clin. 2011;61:8) (Ann Intern Med. 2011;155:698)
  - Women with a history of cervical CA or in utero exposure to diethylstilbestrol (DES) should continue average-risk protocol for women age <30 y indefinitely.
  - HPV vaccination of young women is now recommended by ACIP, UK-NHS, and others. Cervical CA screening recommendations have not changed for women receiving the vaccine because the vaccine covers only 70% of HPV serotypes that cause cervical CA. (MMWR. 2007;56(RR-2):1-24) (CA cancer J Clin. 2014;64:30) (N Engl J Med. 2015;372:711)

**Benefits:** Based on solid evidence, regular screening of appropriate women with the Pap test reduces mortality from cervical CA. Screening is effective when starting at age 21 y. **Harms:** Based on solid evidence, regular screening with the Pap test leads to additional diagnostic procedures and treatment for low-grade squamous intraepithelial lesions (LSILs), with uncertain long-term consequences on fertility and pregnancy. Harms are greatest for younger women, who have a higher prevalence of LSILs. LSILs often regress without treatment. False positives in postmenopausal women are a result of mucosal atrophy. (NCI, 2008)

A study with 43,000 women ages 29–61 with both HPV DNA and cervical cytology cotesting every 5 y found the cumulative incidence of cervical cancer in women negative for both tests at baseline was 0.01% at 9 y and 0.07% after 14 y. (BMJ. 2016; 355:4924).

There is basically now no significant difference in guidelines for screening for cervical cancer in average-risk women among ACOG, ACS, USPSTF.

The risk of developing invasive cervical cancer is 3–10 times greater in women who have not been screened. (CA Cancer J Clin. 2017; 67:106).

**Population**

–Begin at age 21 y independent of sexual history.

**Recommendation**

► ACOG 2009

–Every 2 y from age 21 to 29.

**Source**


**Comment**

–ACOG SUMMARY

• Women age ≥30 y can extend interval to every 2–3 y if three consecutive negative screens, no history of cervical intraepithelial neoplasia 2 or 3, not immunocompromised, no HIV, and not exposed to DES.

• No more often than 3 y if cervical cytology and HPV testing combined.
Population
– Women age >65 y.

Recommendation
➤ USPSTF 2015
– Recommends against routine screening if woman has had adequate recent screening and normal Pap smear results and is not otherwise at high risk for cervical CA.³

Source

Population
– Women age ≥70 y.

Recommendation
➤ ACS 2016
– Discontinue screening if ≥3 normal Pap smear results in a row and no abnormal Pap smear results in the last 10 y.⁴

Source
– http://www.cancer.org

Comment
– Beyond age 70 y, there is little evidence for or against screening women who have been regularly screened in previous y. Individual circumstances, such as the patient’s life expectancy, ability to undergo treatment if CA is detected, and ability to cooperate with and tolerate the Pap smear procedure, may obviate the need for cervical CA screening.

Population
– Women without a cervix and no history of high-grade pre-cancer or cervical cancer.

Recommendation
➤ ACS 2016, ACOG 2009, USPSTF 2015
– Recommends against routine Pap smear screening in women who have had a total hysterectomy or removal of the cervix for benign disease and no history of abnormal cell growth.

Sources
– http://www.cancer.org
– ACOG practice bulletin-109 12/09
CHAPTER 1

CANCER, COLORECTAL (CRC)

Recommendation

▶ ACS 2013, USMTFCC\(^a\) 2012
  – See table on page 29. Tests that find polyps and CA are preferred.

Sources


Comment

– Screening Works
  • Although colonoscopy is the de facto gold standard for colon CA screening, choice of screening technique depends on risk, comorbidities, insurance coverage, patient preference, and availability. Above all, do something to screen for colon CA. (CA Cancer J Clin. 2016; 66:95)
  • There is a rising incidence of CRC in younger patients (<50 y old) - beware of symptoms and strong family history. (JAMA Surgery. 2015; 150:17).

Population

– Age ≥50 y at average risk.\(^b\)

Recommendations

▶ AAFP 2015, USPSTF 2016

– Screen with one of the following strategies\(^c,d,e\)
  • Fecal occult blood test (gFOBT-guaiac based or iFOBT-immunochemical based—iFOBT is preferred) annually.\(^f\)

\(^{a}\)U.S. Multisociety Task Force on Colorectal Cancer (ACG, ACP, AGA, ASGE).


\(^{A}\)A positive result on an FOBT should be followed by colonoscopy. An alternative is flexible sigmoidoscopy and air-contrast barium enema.

\(^{d}\)FOBT should be performed on 2 samples from 3 consecutive specimens obtained at home. A single stool guaiac during annual physical examination is not adequate.

\(^{e}\)USPSTF did not find direct evidence that a screening colonoscopy is effective in reducing CRC mortality rates.

\(^{f}\)Use the guaiac-based test with dietary restriction, or an immunochemical test without dietary restriction. Two samples from each of three consecutive stools should be examined without rehydration. Rehydration increases the false-positive rate.
**DISEASE SCREENING**

- Flexible sigmoidoscopy every 5 y with reflex colonoscopy if abnormal.
- FOBT<sup>d</sup> annually plus flexible sigmoidoscopy every 5 y.
- Colonoscopy every 10 y.<sup>f</sup>
- CT colonoscopy.
- Multi-targeted stool DNA testing (cologuard)—now approved—92% colon cancers detected in asymptomatic average risk persons but <50% of polyps detected, 10% false positives and cost $600/test.
- Circulating methylated 5EPT9 DNA test also available for screening tested on peripheral blood but low sensitivity (48%). (*GYT*. 2014; 63:317) (*JAMA*. 2014;312:2566)

**Follow-up colonoscopy according to findings**
- Normal or small hyperplastic polyps—10 y.
- 1 or 2 <10 mm tubular adenomas—5–10 y.
- Small serrated polyps without dysplasia—5 y.
- 3–10 tubular adenomas, a tubular adenoma, or serrated polyp >10 mm, adenoma with high-grade dysplasia—3 y. (*N Engl J Med.* 2014;370:1298)

**Sources**
- http://www.cancer.org
- *Gastrointest Endosc.* 2006;63:546

**Population**
- Women at average risk age ≥50 y.

**Recommendations**

**ACOG 2007**

**Preferred Method Guidelines**
- Colonoscopy every 10 y.
- Other appropriate methods:
  - FOBT annually.
  - Flexible sigmoidoscopy every 5 y.
  - FOBT annually plus flexible sigmoidoscopy every 5 y.
  - Double-contrast barium enema every 5 y.

**Sources**
- *Gastroenterology.* 2003;124:544
- ACOG Committee Opinion, No. 357, Nov 2007

#Population-based retrospective analysis: risk of developing CRC remains decreased for >10 y following negative colonoscopy findings (*JAMA*. 2006;295:2366).
CHAPTER 1


Population
– Persons at increased risk based on family history but without a definable genetic syndrome.

Recommendations

ACS 2016, USMTFCC\(^a\) 2012
– Group I: Screening colonoscopy at age 40 y, or 10 y younger than the earliest diagnosis in the immediate family, and repeat every 5 y.\(^h\)
– Group II: Follow average-risk recommendations, but begin at age 40 y.\(^h\)

Source
– CA Cancer J Clin. 2008;58:130

Comment
– Practical Points of CRC Screening
  • The USPSTF “strongly recommends” colorectal cancer (CRC) screening in this group up to age 75 y.
  • Screening patients >75 should be individualized based on overall health and risk.
  • Flexible sigmoidoscopy and one-time FOBT mandating a colonoscopy if either yields positive results will miss 25% of significant proximal neoplasia. This strategy should include yearly FOBT. (N Engl J Med. 2001;345:555) (N Engl J Med. 2012;366:2345)
  • FOBT alone decreased CRC mortality by 33% compared with those who were not screened. (Gastroenterology. 2004;126:1674)
  • Multi-targeted DNA stool testing vs. iFOBT with more cancers detected (92.3% vs. 73.8%) but more false positives with DNA test. (N Engl J Med. 2014;370:1287-1297) (N Engl J Med. 2014;370: 1298-1306)
  • Percentage of U.S. adults receiving some form of CRC screening increased from 44% in 1999 to 63% in 2008. The goal is 80%

\(^a\)Group I: First-degree relative with colon CA or adenomatous polyps at age <60 y or 2 first-degree relatives with CRC or adenomatous polyps at any time. Group II: First-degree relative with CRC or adenomatous polyps at age ≥60 y or 2 second-degree relatives with CRC. Revised Bethesda criteria for testing for HNPCC (Lynch syndrome)—screen for tumor microsatellite instability if CRC diagnosed in a patient age <50 y, presence of synchronous, metachronous CRC or other HNPCC defining tumor at any age. CRC with microsatellite unstable-type histology (mucinous, signet ring, infiltrating lymphocytes) in patients age <60 y. CRC diagnosed in 1 or more first-degree relatives with HNPCC-related tumor with one of the cancers diagnosed at age <50 y. CRC diagnosed younger than age 50 y. CRC diagnosed in 2 or more first-degree or second-degree relatives with HNPCC-related tumors regardless of age. Confirmation of HNPCC is made by genetic evaluation of the involved genes (J Natl Cancer Inst. 2004;96:261).
DISEASE SCREENING

by 2018. (CA Cancer J Clin. 2015;65:30) (Arch Intern Med. 2011;171:647) (Arch Intern Med. 2012;172:575) In 2016, it is estimated that 134,000 new cases of CRC will be diagnosed and 49,000 Americans will die from CRC. Median age of diagnosis is 68. (CA Cancer J Clin. 2016;66:7)


### Populations

- **Very-high-risk** hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome); 5% of patients with CRC will have HNPCC.
- Evaluate if the patient <50 y old or Bethesda or Amsterdam criteria met.
- Test for microsatellite instability (MSI - high) or immunohistochemistry to identify missing genes.

### Recommendation

**ACS 2016, USMTFCC**

- Colonoscopy every 2 y beginning at age 20–25 y then yearly at age 40 y. If a colorectal cancer occurs total colectomy is favored. (A J Gastroenterol. 2014; 109:1159)

### Comments

1. In follow-up with curable CRC, CEA every 3 mo for 2 y followed by every 6 mo for 3 y was equivalent to CT scans every 6 mo for 2 y and then every 12 mo for 3 y in discovering recurrence of CRC and length of overall survival. (JAMA. 2014;311:263)
3. NCCN recommends screening for Lynch syndrome in all patients with CRC <70 y old. Do DNA mismatch repair analysis or immunohistochemistry followed by PCR study to confirm.
4. Lynch syndrome with right-sided lesions, poorly differentiated with lymphocyte infiltration—better outcome compared to sporadic CRC. (JAMA. 2012; 308:1555)

### Population

- Classic familial adenomatous polyposis (FAP).

### Recommendation

**ACS 2016, USMTFCC**

- Preferred Approach
  - At-risk children should be offered genetic testing at age 10–12 y.
• Flexible sigmoidoscopy or colonoscopy every 12 mo starting at age 10–12 y.
• Elective colectomy based on number and histology of polyps—usually done by early 20s.
• Upper endoscopy every 5 y if no gastric or duodenal polyps starting in early 20s.

Sources
– Am J Gastroenterol. 2009;104:739
– Gut. 2008;57:704
– JAMA. 2006;296:1507

Comment
– Broad Spectrum of Cancers
  • Extraintestinal tumors in FAP include hepatoblastoma (AFP screening recommended in families with this tumor), adrenal tumors, osteomas, brain tumors, skin CA, and thyroid CA.

CANCER, COLORECTAL
The following options are acceptable choices for CRC screening in average-risk adults beginning at age 50 y. As each of the following tests has inherent characteristics related to prevention potential, accuracy, costs, and potential harms, individuals should have an opportunity to make an informed decision when choosing one of the following options.

In the opinion of the guidelines development committee, colon CA prevention should be the primary goal of CRC screening. Tests that are designed to detect both early CA and adenomatous polyps should be encouraged if resources are available and patients are willing to undergo an invasive test.

Chart of Tests that Detect Adenomatous Polyps and Cancer

<table>
<thead>
<tr>
<th>Test</th>
<th>Interval</th>
<th>Key Issues for Informed Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSIG with insertion to 40 cm or to the splenic flexure</td>
<td>Every 5 y</td>
<td>Complete or partial bowel prep is required. Because sedation usually is not used, there may be some discomfort during the procedure. The protective effect of sigmoidoscopy is primarily limited to the portion of the colon examined. NCI study of 77,000 patients showed a significant decrease in CRC incidence (both distal and proximal) and a 50% reduction in mortality (distal only) (J Natl Cancer Inst. 2012;104:1). Twenty-five percent of colon cancers are missed by this strategy. Patients should understand that positive findings on sigmoidoscopy usually result in a referral for colonoscopy.</td>
</tr>
<tr>
<td>Test</td>
<td>Interval</td>
<td>Key Issues for Informed Decisions</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Every 10 y</td>
<td>Complete bowel prep is required. Procedural sedation is used in most centers; patients will miss a day of work and will need a chaperone for transportation from the facility. Risks include perforation and bleeding, which are rare but potentially serious; most of the risk is associated with polypectomy (Ann Intern Med. 2009;150;1).</td>
</tr>
<tr>
<td>Double Contrast Barium Enema (DCBE)</td>
<td>Every 5 y</td>
<td>Complete bowel prep is required. If patients have one or more polyps ≥6 mm, colonoscopy will still be needed for biopsy or polyp removal; follow-up colonoscopy will require complete bowel prep. Risks of DCBE are low; rare cases of perforation have been reported—radiation exposure is a concern. USPSTF does not recommend DCBE because of lower sensitivity than other methods. (N Engl J Med. 2007;357:1403)</td>
</tr>
<tr>
<td>CT Colonoscopy (CTC)</td>
<td>Every 5 y</td>
<td>Complete bowel prep usually required. (Ann Intern Med. 2012;156:692) If patients have one or more polyps ≥6 mm, colonoscopy will be recommended; if same-day colonoscopy is not available, a second complete bowel prep will be required before colonoscopy. Risks of CTC are low; rare cases of perforation have been reported. Extracolonic abnormalities may be identified on CTC that could require further evaluation (7%–15% of CT examinations). Not as sensitive as colonoscopy for polyps &lt;1 cm, especially for polyps ≤6 mm that are flat or serrated polyps.</td>
</tr>
</tbody>
</table>

**TESTS THAT PRIMARILY DETECT CANCER**

<table>
<thead>
<tr>
<th>Test</th>
<th>Interval</th>
<th>Key Issues for Informed Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>gFOBT with high sensitivity for CA</td>
<td>Annual</td>
<td>Depending on manufacturer’s recommendations, 2–3 stool samples collected at home are needed to complete testing; a single stool gathered during a digital examination in the clinical setting is not an acceptable stool test and should not be done. Any positive result from stool samples collected at home should lead to early colonoscopy evaluation</td>
</tr>
<tr>
<td>FIT (iFOBT) with high sensitivity for CA</td>
<td>Annual</td>
<td>Specificity of iFOBT superior to gFOBT but more expensive. Positive test results are associated with an increased risk of colon CA and advanced neoplasia; colonoscopy should be recommended if the test results are positive. If the test result is negative, it should be repeated annually. Patients should understand that one-time testing is likely to be ineffective.</td>
</tr>
</tbody>
</table>
CHAPTER 1

CANCER, ENDOMETRIAL

Population

– All postmenopausal women.

Recommendation

ACS 2008

– No Routine Screening

• Inform women about risks and symptoms of endometrial CA and strongly encourage them to report any unexpected bleeding or spotting. This is especially important for women with an increased risk of endometrial CA (history of unopposed estrogen therapy, tamoxifen therapy, late menopause, nulliparity, infertility or failure to ovulate, obesity, diabetes, or hypertension).

Source

– http://www.cancer.org

Comment

– Clinical Facts

• Benefits: There is inadequate evidence that screening with endometrial sampling or transvaginal ultrasound (TVU) decreases mortality. Harms: Based on solid evidence, screening with TVU will result in unnecessary additional exams because of low specificity. Based on solid evidence, endometrial biopsy may result in discomfort, bleeding, infection, and, rarely, uterine perforation. (NCI, 2008)

• Presence of atypical glandular cells on Pap test from postmenopausal (age >40 y) women not taking exogenous hormones is abnormal and
DISEASE SCREENING

requires further evaluation (TVU and endometrial biopsy). Pap test is not sensitive for endometrial screening.

- Endometrial thickness of <4 mm on TVU is associated with low risk of endometrial CA. (*Am J Obstet Gynecol.* 2001;184:70)
- Most cases of endometrial CA are diagnosed as a result of symptoms reported by patients (uterine bleeding), and a high proportion of these cases are diagnosed at an early stage and have high rates of cure. Type II endometrial CA accounts for 15% of patients. Histology is serous or clear cell with 5 y survival 55% vs. 85% at 5 y compared to endometrial Type I cancer (NCI, 2008) (*Lancet.* 2016; 387:1094)
- Tamoxifen use for 5 y raises the risk of endometrial CA 2- to 3-fold, but CAs are low stage, low grade, with high cure rates. (*J Natl Cancer Inst.* 1998; 90:1371)
- In 2016, there were 60,050 new cases of endometrial cancer with 10,170 deaths. The mean age at diagnosis is 60 y old.

**Population**

- All women at high risk for endometrial CA\(^a\) (patients with known or high suspicion for HNPCC mutation carrier).

**Recommendations**

- **ACS 2016**
  - Annual screening beginning at age 35 y with endometrial biopsy.
  - International guidelines advise transvaginal ultrasound and annual endometrial biopsy beginning at 25 y old.

**Source**

- *JAMA.* 1997; 277:915
- http://www.cancer.org

**Comment**

- **High Risk Women – Lynch Syndrome - lifetime risk 60%**
  - Variable screening with ultrasound among women (age 25–65 y; \(n = 292\)) at high risk for HNPCC mutation detected no CAs from ultrasound. Two endometrial cancers occurred in the cohort that presented with symptoms. (*Cancer.* 2002;94:1708) (*Gynecol Oncol.* 2007; 107:159).
  - The death rate from sporadic endometrial cancer and Lynch syndrome related uterine cancer is the same.
  - The Women’s Health Initiative (WHI) demonstrated that combined estrogen and progestin did not increase the risk of endometrial CA but did increase the rate of endometrial biopsies and ultrasound exams prompted by abnormal uterine bleeding. (*JAMA.* 2003:290)

\(^a\)High-risk women are those known to carry HNPCC-associated genetic mutations, or at high risk to carry a mutation, or who are from families with a suspected autosomal dominant predisposition to colon CA (45%–50% lifetime risk of endometrial CA).
CANCER, GASTRIC

Population
- Average-risk population.
- In the United States there were 22,370 patients diagnosed with gastric cancer with 10,990 deaths. 95% of these cancers were adenocarcinoma.
- Lynch syndrome patients should consider upper endoscopy baseline repeated every 5–10 y.
- Helicobacter pylori infections, atrophic gastritis, pernicious anemia, and partial gastrectomy patients have a higher risk of gastric CA.

Recommendation
> NCI 2015
- There are currently no recommendations regarding screening for gastric CA.

Comment
- Clinical Considerations in Gastric Cancer
  • Endoscopic screening for gastric CA in moderate- to high-risk population subgroups is cost-effective but not shown to be beneficial in the United States. (Clin Gastroenterol Hepatol. 2006;4:709)
  • Beware of hereditary gastric cancer CDH1 gene which regulates mutation of E-cadherin, an adhesion protein which increases risk of gastric cancer to >70%. Risk reduction gastrectomy recommended at 20-30 y old. (J Med Genet. 2015; 52:361)
  • No randomized trials evaluating impact of screening on mortality from gastric cancer have been reported. (NEJM. 2014; 371:2499) (https://www.cancer.gov/types/esophageal/hp/esophageal-screening-pdq

CANCER, LIVER (HEPATOCELLULAR CARCINOMA [HCC])

Population
- Adults at high risk for HCC, especially those awaiting liver transplantation, should be entered into surveillance programs.

Recommendation
> AASLD® 2010 Update
- Screening Tests
  • Surveillance with ultrasound at 6-mo intervals.

Sources
- Hematology. 2005;42:1208
- J Hepatol. 2015; 63:1156
DISEASE SCREENING

Population
— Adults

Recommendations

► British Society of Gastroenterologya 2003
— Surveillance with abdominal ultrasound and alpha-fetoprotein (AFP) every 6 mo should be considered for high-risk groups.b
— This is low strength recommendation for screening. It identifies early-stage HCC but whether overall survival is improved is not known. (Ann Intern Med. 2014;161:261)

Sources
— Gut. 2003;52 (suppl III):iii
— http://www.bsg.org.uk/

Comment

1. HCC is the 5th most common cancer in the world. There will be 39,230 new cases of hepatocellular cancer (HCC) and 27,170 deaths due to this disease in the U.S. (NCI. February update 2017).
2. AFP alone should not be used for screening unless ultrasound is not available (low sensitivity — 60% positive).

CANCER, LUNG

Population
— Asymptomatic persons with >30 pack-year smoking history.

Recommendation

► ACCP and ASCO 2013

— Survival Benefit with CT Screening
  • Based on good evidence, routine screening for lung CA with chest x-ray (CXR) and sputum cytology is not recommended.
  • Screening with low-dose CT (LDCT) is now recommended following the strict eligibility criteria of the National Lung Screening Trial (NLST). This includes age 50–74 y with a 30 pack-year smoking history.

a Only two organizations recommending screening for HCC in high-risk populations (low-level evidence).
b HBsAg persons (carriers): Asian males age ≥ 40 y, Asian females age ≥ 40 y; all cirrhotics; family history of HCC; Africans age > 20 y. Nonhepatitis B carriers: hepatitis C; alcoholic cirrhosis; genetic hemochromatosis; primary biliary cirrhosis, alpha-1-antitrypsin deficiency with cirrhosis, hepatitis C with cirrhosis; hemochromatosis with cirrhosis, NASH (steatosis) with cirrhosis. (Hepatol. 2014;60:1767) (Clin Gastroenterol Hepatol. 2011;9:428)
history. People who have not smoked in the last 15 y or who have significant comorbidities are excluded.

Sources

Population
–Asymptomatic persons with >30-pack-year smoking history.

Recommendations
ACS 2013, NCCN 2013
–Guidance in shared decision making regarding screening of high-risk persons.
–Screening with LDCT for 3 consecutive y is recommended for patients meeting the eligibility criteria for the NLST (>30 pack-year smoking history, age 50–74 y, no major medical comorbidities) and the presence of a minimum of a highly skilled support team to evaluate LDCT scans, schedule appropriate follow-ups, and perform lung biopsies safely when indicated. (Most patients receiving low-dose CT screening repeat the study yearly as long as they meet criteria.)

Sources
–http://www.cancer.org
–http://www.cancer.gov/nlst

Comment
–Clinical Insight
• Counsel all patients against tobacco use, even when age >50 y. Smokers who quit gain ~10 y of increased life expectancy and have maximum reduction in risk of lung CA after 15 y of no tobacco use. (Br Med J. 2004:328)
• Spiral CT screening can detect greater number of lung CAs in smokers with a >10-pack-year exposure. (N Engl J Med. 2006;355:1763-1771)
• The NCI has reported data from the NLST, a randomized controlled trial comparing LDCT and CXR yearly × 3 with 8-y follow-up. A total of 53,500 men and women age 50–74 y, 30-pack/year smokers were randomized. A 20.3% reduction in deaths from lung CA was reported for the LDCT group (estimated that 10,000–15,000 lives could be saved per year). Problems with false-positives (25% have lung nodules <1 cm that are not cancer) and cost of workup were noted, but benefits have led to a change in guidelines. ACS 2013 guidelines on lung cancer screening recommends adults between the ages of 55 and 74 y (80 y/o for USPSTF) who meet eligibility criteria
DISEASE SCREENING


- There is an increasing concern regarding the cost of lung cancer screening. Twenty-five percent of patients screened will have indeterminate abnormal findings requiring repeat imaging at intervals and in a significant number of patients biopsied are done showing benign disease. Also many patients are screened yearly instead of just 3 consecutive years of screening that was done in the randomized trials. (JAMA. 2012; 307:2418) (JAMA Intern Med. 2014; 174:269).

- Lung cancer prediction models will help designate who needs to be screened and how often. (J Clin Oncol. 2017; 35:861).

CANCER, ORAL

Population

- Asymptomatic persons.

Recommendation

- AAFP 2008, USPSTF 2014
  - No Screening
    - Evidence is insufficient to recommend for or against routinely screening adults for oral asymptomatic CA.
Sources

Comment
–Risk factors: regular alcohol or tobacco use.
–A randomized controlled trial of visual screening for oral CA (at 3- y intervals) showed decreased oral CA mortality among screened males (but not females) who were tobacco and/or alcohol users over an 8- y period. (Lancet. 2005;365:1927)
–48,370 new cases of oral cancer in 2016 with 9570 deaths

Comments
–Significant increase in HPV (subtypes 16 and 18)-related squamous cell cancer of the oropharynx (base of tongue and tonsil) in nonsmokers.
–There is a 30%–40% improvement in cure rate in HPV positive non-smokers vs. cure for smoking-related cancers. (N Engl J Med. 2010;363:24)
–>70% of oropharyngeal squamous cell cancers are HPV positive. (J Clin Onc. 2013;31:2708) (J Clin Onc. 2010;28:4142)
–Prevalence of oral HPV infection in the United States is 6.9%. (JAMA. 2012;307:693)
–Studies ongoing to determine if less therapy in HPV-positive patients will result in the same curability with less long-term and short-term toxicity. (J Natl Cancer Inst. 2008;180:261) (Compr Canc Netw. 2011;9:665)

CANCER, OVARIAN

Population
–Asymptomatic women at average risk.

Recommendation
–USPSTF 2012

–No Benefit from Screening

“Lifetime risk of ovarian CA in a woman with no affected relatives is 1 in 70. If 1 first-degree relative has ovarian CA, lifetime risk is 5%. If 2 or more first-degree relatives have ovarian CA, lifetime risk is 7%. Women with 2 or more family members affected by ovarian cancer have a 3% chance of having a hereditary ovarian cancer syndrome. If BRCA1 mutation, lifetime risk of ovarian CA is 45%–50%; if BRCA2 mutation, lifetime risk is 15%–20%. Lynch syndrome = 8%–10% lifetime risk of ovarian CA.

aUSPSTF recommends against routine referral for genetic counseling or routine BRCA testing of women whose family history is not associated with increased risk for deleterious mutation in BRCA1 or 2 genes.
DISEASE SCREENING

Sources

Population
– Women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or 2 genes.

Recommendations

USPSTF 2013
– Recommends referral for genetic counseling and evaluation for BRCA testing. Does not recommend routine screening in this group.
– Screening with CA-125, TVU, and pelvic exam can be considered, but there is no evidence in this population that screening reduces risk of death from ovarian CA.
– A woman with ovarian cancer at any age should be tested for BRCA1 and 2 mutations. (USPSTF-publication#12 Dec. 2013) (NCCN guideline version 2; 2017)

Source

Population
– High-risk patients with BRCA1 or 2 mutations or strong family history of ovarian CA.

Recommendations

ACOG 2009, NCCN 2011
– Recommends screening with CA-125 and TVU at age 30–35 y or 5–10 y earlier than earliest onset of ovarian CA in family members.
– Risk-reducing salpingo-oophorectomy should be strongly considered. (JAMA. 2010;304:967)

Source

Comment
– Clinical Issues
  • Risk factors: age >60 y; low parity; personal history of endometrial, colon, or breast CA; family history of ovarian CA; and hereditary breast/ovarian CA syndrome. Use of oral contraceptives for 5 y decreases the risk of ovarian CA by 50%. (JAMA. 2004;291:2705)
  • Benefit: There is inadequate evidence to determine whether routine screening for ovarian CA with serum markers such as CA-125 levels, TVU, or pelvic examinations would result in a decrease in mortality from ovarian CA. Harm: Problems have
been lack of specificity (positive predictive value) and need for invasive procedures to make a diagnosis. Based on solid evidence, routine screening for ovarian CA would result in many diagnostic laparoscopies and laparotomies for each ovarian CA found. (NCI, 2008) (JAMA. 2011;305:2295)

- Additionally, cancers found by screening have not consistently been found to be lower stage. (Lancet Oncol. 2009;10:327)
- Preliminary results from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: At the time of baseline examination, positive predictive value for invasive cancer was 3.7% for abnormal CA-125 levels, 1% for abnormal TVU results, and 23.5% if both tests showed abnormal results. (Am J Obstet Gynecol. 2005;193:1630)

CANCER, PANCREATIC

Population
- Asymptomatic persons.

Recommendation
- USPSTF 2010
  - Screening of No Benefit
    - Recommends against routine screening.

Source

Comment
- Risk Factors – Acquired and Genetic
  - Cigarette smoking has consistently been associated with increased risk of pancreatic CA. BRCA2 mutation is associated with a 5% lifetime risk of pancreatic CA. Blood group O with lower risk and diabetes with a 2-fold higher risk of pancreatic CA. (J Natl Cancer Inst. 2009;101:424) (J Clin Oncol. 2009;27:433)
  - USPSTF concluded that the harms of screening for pancreatic CA—the very low prevalence, limited accuracy of available screening tests, invasive nature of diagnostic tests, and poor outcomes of treatment—exceed any potential benefits.
  - Patients with a strong family history (≥2 first-degree relatives with pancreatic CA) should undergo genetic counseling and
may benefit from interval screening with CA 19–9, CT scan, and magnetic resonance cholangiopancreatography (MRCP). (Nat Rev Gastroenterol Hepatol. 2012;9:445-453)

CANCER, PROSTATE

Population

– Men age ≥50 y.a

Recommendations

► ACS 2010

– Discuss annual prostate-specific antigen (PSA) and digital rectal exam (DRE) if ≥10-y life expectancy.b
– Discuss risks and benefits of screening strategy to enable an informed decision.

Source

– http://www.cancer.org

Comment

– Prevalence of Prostate CA

• There are 220,800 new cases of prostate cancer and 27,500 deaths expected in 2017.

Population

– Asymptomatic men.

Recommendation

► USPSTF 2012

– Recent Guidelines

• Do not use PSA-based screening for prostate CA. There is convincing evidence that PSA-based screening results in the detection of many cases of asymptomatic prostate CA and that a substantial percentage of men will have a tumor that will progress so slowly that it would remain asymptomatic for the patient’s lifetime.
• Because of the current inability to distinguish tumors that will remain indolent from those destined to be lethal, many men are subjected to the harms of treatment for a prostate CA that would never become symptomatic.

a Men in high-risk groups (1 or more first-degree relatives diagnosed before age 65 y, African Americans) should begin screening at age 45 y. Men at higher risk because of multiple first-degree relatives affected at an early age could begin testing at age 40 y (http://www.cancer.org/).

b Men who ask their doctor to make the decision should be tested. Discouraging testing or not offering testing is inappropriate.
• The benefits of PSA-based screening for prostate CA do not outweigh the harms (this recommendation applies to high-risk patients as well—African American/positive family history). There is ongoing significant criticism of the USPSTF prostate screening recommendations. (JAMA. 2011;306:2715) (JAMA. 2011;306:2719) (JAMA. 2011;306:2721)

-USPSTF 2017 update prostate cancer - in progress
- Below age 55 - no screening
- From 55-69, discuss potential benefits and harms of PSA screening (false positive results) over diagnosis and over treatment and treatment complications vs. small potential benefit of reducing the chance of dying of prostate cancer.
- USPSTF recommends individualized decision making so that each man can understand the potential benefits and harms of screening and make his decision.
- Men older than age 70 - USPSTF recommends no PSA based screening for this group
- In high risk patients (African Americans, 1st degree family members with prostate cancer and BRCA 1and 2, the recommendation is to again help the patient weigh benefits and risks. The decision is whether to screen or not is left to the patient. Screening after age 70 is not recommended.

Sources
- UPDATE 2017

Population
- Asymptomatic men.

Recommendation

ACP 2013

• Statement of guidance
  • For men between age 50 and 69 y, discuss limited benefits and substantial harm of screening for prostate CA. Do not do PSA testing unless patient expresses a clear preference for screening.
  • Do not screen PSA in average-risk men younger than 50 or older than 70 y or in men with a life expectancy of <10 y.

Sources
- Ann Intern Med. 2013;159:761-769
Comment

-Risks and Benefits of Prostate Screening

- There is good evidence that PSA can detect early-stage prostate CA (2-fold increase in organ-confined disease at presentation with PSA screening), but mixed and inconclusive evidence that early detection improves health outcomes or mortality.

- Two long-awaited studies add to the confusion. A U.S. study of 76,000 men showed increased prostate CA in screened group, but no reduction in risk of death from prostate CA. A European study of 80,000 men showed a decreased rate of death from prostate CA by 20% but significant overdiagnosis (there was no difference in overall death rate). To prevent 1 death from prostate CA, 1410 men needed to be screened and 48 cases of prostate CA found. Patients older than age 70 y had an increased death rate in the screened group. (N Engl J Med. 2009;360:1310,1320) (N Engl J Med. 2012;366:981) (N Engl J Med. 2012;366:1047)

- These 2 very large studies set the framework for new PC guidelines. The U.S. study (prostate, lung, colorectal and ovarian cancer screening trial) showed no evidence for overall survival benefit from PSA screening and postulated that many patients with low grade cancers were treated aggressively leading to morbidity and mortality. Subsequent evaluation found that approximately 90% of patients in the control arm had undergone PSA testing during the course of the trial. This fact makes the trial result uninterpretable. The European study found that PSA screening did reduce prostate specific mortality by 20%. In this trial 781 men needed to be invited to screening to prevent one death. What should be the response to this new data? First we can improve survival by recognizing low risk patients to be followed by active surveillance and not exposed to treatment until evidence of disease progression. Recognized high risk patients (African Americans and men with 1st degree relatives with prostate cancer) should be screened early and frequently. Average risk men can be screened by PSA twice between the ages of 45 and 55 and if the PSA is 0.70 ng/mL their risk of lethal prostate cancer is quite low. Guideline groups are presently working on new guidelines for PC screening to minimize over treatment of this disease but at the same time screening a higher risk population for aggressive prostate cancer at a stage that can be treated with conservative intent.

- J Clin Onc. 2016; 34:3499-3501
- J Clin Onc. 2016; 34:3481-3491
• Benefit: Insufficient evidence to establish whether a decrease in mortality from prostate CA occurs with screening by DRE or serum PSA. Harm: Based on solid evidence, screening with PSA and/or DRE detects some prostate CAs that would never have caused important clinical problems. Based on solid evidence, current prostate CA treatments result in permanent side effects in many men, including erectile dysfunction and urinary incontinence. (NCI, 2008)

• Men with localized, low-grade prostate CAs (Gleason score 2–4) have a minimal risk of dying from prostate CA during 20 y of follow-up (6 deaths per 1000 person-years) (JAMA. 2005;293:2095) (N Engl J Med. 2014;370:932)


• Increase in prostate cancer distant metastases at diagnosis in the United States over the last 3 y. (JAMA Oncol. 2016; 2:1657).

Population

Asymptomatic men.

Recommendation

EAU 2010

There is a lack of evidence to support or disregard widely adopted, population-based screening programs for early detection of prostate CA.

Source

www.uroweb.org

Comments


PSA velocity (>0.5–0.75 ng/y rise) is predictive for the presence of prostate CA, especially with a PSA of 4–10. (Eur Urol. 2009;56:573)

Multi-parametric MRI scanning is emerging as a tool for more accurate detection of early prostate cancer as well as distinguishing indolent from high-grade cancers. (J Urol. 2011;185:815) (Nat Rev Clin Oncol. 2014;11:346)
DISEASE SCREENING

- African American men have double the risk of prostate cancer and a >2-fold risk of prostate cancer–specific death. These patients and those with first-degree relatives <65 y with prostate cancer are at high enough risk to justify PSA screening until a definitive study of this population is available. (JAMA. 2014;311:1143)

Population
- Asymptomatic men.

Recommendation
- NCCN 2016

-NCCN GUIDELINES 2016
  - Informed decision making.
  - Obtain PSA testing in healthy men age 45–75 y
  - PSA <1 ng/mL—DRE normal—repeat testing @ 2–4 y intervals
  - PSA 1–3 ng/mL—DRE normal—repeat testing @ 1–2 y intervals
  - PSA >3 ng/mL or suspicious DRE—consider biopsy and work-up for benign disease.
  - After age 70 PSA testing should be individualized and indications for biopsy carefully evaluated.
  - Refer patients for prostate biopsy if serum PSA rises >0.9 ng/mL in 1 y.

Sources
- www.cancerscreening.nhs.uk
- NCCN Guidelines 2016

Comments
1. PSA screening is confounded by the morbidity and mortality associated with the treatment of prostate cancer. Molecular profiling that can stratify patients into high-risk and low-risk groups is a critical need for individualized adaptive therapies, which could minimize toxicity and maximize benefit from there in many patients (oncotype, Decipher and Polaris are now available to look at molecular profiling).

2. This NCCN recommendation aims to strike a balance between testing too seldom and testing too often to “maximize benefit and minimize harm.”
CHAPTER 1

CANCER, SKIN (MELANOMA)

Recommendations

USPSTF 2016

- Evidence is insufficient to recommend for or against routine screening using a total-body skin examination for early detection of cutaneous melanoma, basal cell carcinoma, or squamous cell skin CA.\(^\text{a,b}\) (\textit{JAMA}. 2016;316:429)
- Recommends counseling children, adolescents, and young adults age 10–24 y who have fair skin to minimize exposure to ultraviolet radiation to reduce the risk of skin cancer.

Source

Comment
- Benefits and Harms
  - Benefits: Evidence is inadequate to determine whether visual exam of the skin in asymptomatic individuals would lead to a reduction in mortality from melanoma skin CA. 76,400 U.S. men and women will develop melanoma in 2016 and 10,100 will die from the disease.
  - Harms: Based on fair though unqualified evidence, visual examination of the skin in asymptomatic persons may lead to unavoidable increases in harmful consequences. This includes misdiagnosis, overdiagnosis, and resulting cosmetic adverse effects from biopsy and overtreatment. (\textit{NCI}, 2016)
  - 28 million people in the United States use UV indoor tanning salons, increasing risk of squamous, basal cell cancer, and malignant melanoma. (\textit{J Clin Oncol}. 2012;30:1588)
  - The frequency of melanoma has been increasing for at least 30 y.
  - In the last 5 y the rates of melanoma have plateaued or declined in individuals <50 y/o.
  - Risk of melanoma increases with age. Median age at diagnosis is 63 y and median age at death is 69 y.

\(^\text{a}\)Clinicians should remain alert for skin lesions with malignant features when examining patients for other reasons, particularly patients with established risk factors. Risk factors for skin CA include evidence of melanocytic precursors (atypical moles), large numbers of common moles (>50), immunosuppression, any history of radiation, family or personal history of skin CA, substantial cumulative lifetime sun exposure, intermittent intense sun exposure or severe sunburns in childhood, freckles, poor tanning ability, and light skin, hair, and eye color.

\(^\text{b}\)Consider educating patients with established risk factors for skin CA (see above) concerning signs and symptoms suggesting skin CA and the possible benefits of periodic self-examination. Alert at-risk patients to significance of asymmetry, border irregularity, color variability, diameter >6 mm, and evolving change in previous stable mole. All suspicious lesions should be biopsied (excisional or punch, not a shave biopsy) (\textit{Ann Intern Med}. 2009;150:188) (USPSTF; ACS; COG).
• Clinical features of increased risk of melanoma (family history, multiple nevi previous melanoma) are linked to sites of subsequent malignant melanoma, this may be helpful in surveillance. *JAMA Dermatol.* 2017; 153:23.

• There are no guidelines for patients with familial syndromes (familial atypical mole and melanoma [FAM-M]), although systematic surveillance is warranted.\(^c\)

\(^c\)Consider dermatologic risk assessment if family history of melanoma in ≥2 blood relatives, presence of multiple atypical moles, or presence of numerous actinic keratoses.

### CANCER, TESTICULAR

#### Population
- Asymptomatic adolescent and adult males.\(^a\)

#### Recommendations

**AAFP 2008, USPSTF 2011**
- Recommend against routine screening. Be aware of risk factors for testicular CA—previous testis CA (2%–3% risk of second cancer), cryptorchid testis, family history of testis CA, HIV (increased risk of seminoma), and Klinefelter syndrome.

**Sources**

#### Population
- Asymptomatic men.

#### Recommendation

**ACS 2004**
- Testicular exam by physician as part of routine cancer-related checkup. (*Ann Int Med.* 2011;154:483) If there is any concern on exam, an ultrasound of the testis will be reliable in discovery of malignancy as small as 1-2 mm in size but benign lesions are also found by ultrasound in this population. (*J Urol.* 2003; 170:1783)

**Source**
- [http://www.cancer.org](http://www.cancer.org)

\(^a\)Patients with history of cryptorchidism, orchiopexy, family history of testicular CA, or testicular atrophy should be informed of their increased risk for developing testicular CA and counseled about screening. Such patients may then elect to be screened or to perform testicular self-examination. Adolescent and young adult males should be advised to seek prompt medical attention if they notice a scrotal abnormality. (USPSTF)
Population
– High-risk males.

Recommendation
EAU 2008
– Self-physical exam is advisable.

Source
– www.uroweb.org

Comment
– Benefits and Harms
  • Benefits: Based on fair evidence, screening would not result in appreciable decrease in mortality, in part because therapy at each stage is so effective.
  • Harms: Based on fair evidence, screening would result in unnecessary diagnostic procedures and occasional removal of a noncancerous testis. (NCI, 2011)
  • In 2016 approximately 8850 men in the U.S. were diagnosed with testicular cancer but only 400 men died of this disease. Worldwide there are approximately 72,000 cases and 9000 deaths annually. (CA Cancer J Clin. 2017; 67:7)

CANCER, THYROID

Population
– Asymptomatic persons.

Recommendations
USPSTF 2017
– Recommends against the use of ultrasound screening in asymptomatic persons.

Sources
– http://www.cancer.org
Comment

– Clinical Facts
  • Neck palpation for nodules in asymptomatic individuals has sensitivity of 15%–38% and specificity of 93%–100%. Only a small proportion of nodular thyroid glands are neoplastic, resulting in a high false-positive rate. (USPSTF 2016) JAMA. 2017; 317:1882.
  • Fine-needle aspiration (FNA) is the procedure of choice for evaluation of thyroid nodules. (Otolaryngol Clin North Am. 2010;43:229-238)

CAROTID ARTERY STENOSIS (CAS) (ASYMPTOMATIC)

Population
  – Asymptomatic adults.

Recommendations

  – Screening of the general population or a selected population based on age, gender, or any other variable alone is not recommended.
  – Inappropriate to screen asymptomatic adult.

Sources

  – J Neuroimaging. 2007;17:19-47
  – USPSTF. Carotid Artery Stenosis: Screening. 2014.
  – Stroke. 2011;42(2):e26

Recommendation

  – Indications for carotid ultrasound: evaluation of patients with a cervical bruit.

Source

  – Stroke. 2011;42(8):e464-e540

Recommendation

  ➤ Society of Thoracic Surgeons 2013
  – Recommends against routine evaluation of carotid artery disease prior to cardiac surgery in the absence of symptoms or other high-risk criteria.
CHAPTER 1

Source

Comments
1. The prevalence of internal CAS of ≥70% varies from 0.5%–8% based on population-based cohort utilizing carotid duplex ultrasound. For population age >65 y estimated prevalence is 1%. No risk stratification tool further distinguishes the importance of CAS. No evidence suggests that screening for asymptomatic CAS reduces fatal or nonfatal strokes.
2. Carotid duplex ultrasonography to detect CAS ≥60%; sensitivity, 94%; specificity, 92%. (Ann Intern Med. 2007;147(12):860)
3. If true prevalence of CAS is 1%, number needed to screen to prevent 1 stroke over 5 y = 4368; to prevent 1 disabling stroke over 5 y = 8696. (Ann Intern Med. 2007;147(12):860)

CELIAC DISEASE

Population
– Children and adults.

Recommendation
 sprawl
– USPSTF 2017, AAFP 2017
  – Insufficient evidence regarding screening of asymptomatic people.

Source

Recommendation
 sprawl
– NICE 2015
  – Serologic testing to rule out celiac disease should be performed for any of the following signs, symptoms, or associated conditions: persistent unexplained abdominal or gastrointestinal symptoms, faltering growth, prolonged fatigue, unexpected weight loss, severe or persistent mouth ulcers, unexplained iron, vitamin B12 or folate deficiency, type 1 diabetes, autoimmune thyroid disease, irritable bowel syndrome (in adults).
  – Screen first-degree relatives of people with coeliac disease.
  – General population screening not recommended.

Source
Comments
1. Patients must continue a gluten-containing diet during diagnostic testing.
2. IgA tissue transglutaminase (TTG) is the test of choice (>90% sensitivity/specificity), along with total IgA level.
3. IgA endomysial antibody test is indicated if the TTG test is equivocal.
4. Avoid antigliadin antibody testing.
5. Consider serologic testing for any of the following: Addison disease; amenorrhea; autoimmune hepatitis; autoimmune myocarditis; chronic immune thrombocytopenic purpura (ITP); dental enamel defects; depression; bipolar disorder; Down syndrome; Turner syndrome; epilepsy; lymphoma; metabolic bone disease; chronic constipation; polyneuropathy; sarcoidosis; Sjögren syndrome; or unexplained alopecia.

CHLAMYDIA

Population
–Women age ≤25 y who are sexually active.

Recommendation
➤ CDC 2015, AAP 2014
–Screen for chlamydia annually.

Sources

Population
–Women age <25 y who are sexually active

Recommendation
➤ USPSTF 2014
–Screen for chlamydia and gonorrhea. Screening interval to be determined by patient’s sexual practices.

Sources
–USPSTF. Chlamydia and Gonorrhea: Screening.

Population
–Young heterosexual men; nonpregnant women >25 y without risk factors.

Recommendation
➤ CDC 2015, USPSTF 2014
–Insufficient evidence for or against routine screening.
–Consider screening in high prevalence clinical settings.
Sources
– USPSTF. Chlamydia and Gonorrhea: Screening.

Comments
1. **Chlamydia** is a reportable infection to the Public Health Department in every state.

Population
– Men who have sex with men.

Recommendation
➤ CDC 2015
– Annual testing, regardless of condom use.
– Frequency of q 3–6 mo for high risk activity.

Source
– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Comments
1. Urine nucleic amplification acid test (NAAT) for **Chlamydia** for men who have had insertive intercourse.
2. NAAT of rectal swab for men who have had receptive anal intercourse.

Population
– Pregnant women.

Recommendations
➤ CDC 2015
– Recommends screening for chlamydial infection for all pregnant women <25y old and for older women at increased risk.
– Test at first contact, then re-test in 3rd trimester.

Source
– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Recommendations
➤ AAP/ACOG 2012
– Screen all women for chlamydial infection at first prenatal visit.
– AAP & ACOG. Guidelines for Perinatal Care, 7th Ed. 2012.
POPULATION

- Infants, children, adolescents, or young adults (age <20 y).

RECOMMENDATIONS

USPSTF 2016, NLA 2011

- In familial hypercholesterolemia (FH), universal screening at age 9–11 y with a fasting lipid panel or nonfasting non-HDL-C. If non-HDL-C ≥145 m/dL, perform fasting lipid panel.
- Genetic screening for FH is generally not needed for diagnosis or clinical management.
- Cascade screening: testing lipid levels in all first-degree relatives of diagnosed FH patients.
- Insufficient evidence to recommend for or against routine universal lab screening.

Source

- J Clin Lipidol. 2011;5:S1-S8

RECOMMENDATION

AHA 2007

- Selective screening: patients age >2 y with a parent age <55 y with coronary artery disease, peripheral artery disease, cerebrovascular disease, or hyperlipidemia should be screened with fasting panel.

Source


COMMENTS

1. Childhood drug treatment of dyslipidemia lowers lipid levels but effect on childhood or adult outcomes is uncertain.
2. Lifestyle approach is recommended starting after age 2 y.

RECOMMENDATIONS

National Heart, Lung and Blood Institute Integrated Guidelines 2012

- Selective screening age >2 y: positive family history (FH) of dyslipidemia, presence of dyslipidemia, or the presence of overweight, obesity, hypertension, diabetes, or a smoking history.
- Universal screening in adolescents regardless of FH between age 9 and 11 y and again between age 18 and 21 y.
Source

Comments
-Fasting lipid profile is recommended. If within normal limits repeat testing in 3–5 y is recommended.
-Fasting lipid profile or nonfasting non–high-density lipoprotein (HDL) cholesterol level.

Population
-Asymptomatic adults 40–79 y.

Recommendations

ACC/AHA 2013
-Perform 10-y ASCVD Risk Score.
-High-risk categories include:
  1. Primary elevation of LDL-C ≥ 190 mg/dL.
  2. Diabetes (type 1 or 2) with LDL-C 70–189 mg/dL and without clinical ASCVD.
  3. Without clinical ASCVD or diabetes with LDL-C 70–189 mg/dL and estimated 10-y ASCVD risk score ≥7.5%.

Sources
-Circulation. 2013;2013;01.cir.0000437738.63853.7a

Comment
-Prior to initiating statin therapy perform lipid panel, ALT, HgbA1c to R/O DM, and baseline CK (if patient is at increased risk for muscle events based on personal or family history of statin intolerance).

Population
-Adults with diabetes.

Recommendations

ADA 2013
-Measure fasting lipids at least annually in adults with diabetes.
-Every 2 y for adults with low-risk lipid values (LDL-C <100 mg/dL, HDL-C >50 mg/dL, TG <150 mg/dL).

Source
-Diabetes Care. 2013;36(suppl 1):S11–S66
**DISEASE SCREENING**

**Population**
- Adults >40 y old.

**Recommendations**

- **ESC 2016**
  - Perform SCORE risk assessment tool available at: www.heartscore.org
  - Secondary hyperlipidemia should be ruled out.
  - Total Cholesterol and LDL-C primary target: goal LDL ≤ 70 mg/dL in patients with very high CV risk, LDL ≤ 100 mg/dL in patients with high CV risk.
  - Secondary targets are non-HDL-C and ApoB.
  - HDL is not recommended as a target for treatment.

**Source**
- European Society of Cardiology. Dyslipidaemias 2016.

**Comment**
- No overt CVD: LDL-C goal <100 mg/dL (2.6 mmol/L).

**Population**
- Adults >20 y.

**Recommendations**

- **NLA 2014**
  - Fasting lipid profile (LDL-C and TG) or nonfasting lipid panel (non-HDL-C and HDL-C) should be measured at least every 5 y.
  - Also assess ASCVD risk.
  - Non-HDL-C (primary target), ApoB (secondary target) have more predictive power than LDL-C.
  - Apolipoprotein B (ApoB) is considered an optional, secondary target for therapy. More predictive power than LDL-C, but not consistently superior to non-HDL-C.
  - HDL-C is not recommended as a target therapy.

**Sources**

**Comment**
- Non-HDL-C values:
  - Desirable <130 mg/dL.
  - Above desirable 130–159.
  - Borderline high 160–189.
  - High 190–219.
  - Very high ≥ 220.
Recommendation

NCEP III 2004

- Check fasting lipoprotein panel (if testing opportunity is nonfasting, use nonfasting total cholesterol [TC] and HDL) every 5 y if in desirable range; otherwise, see management algorithm.

Sources

- Circulation. 2002;106:3143-3421
- Circulation. 2004;110:227-239

Population

- Men ≥ 40 y.
- Women ≥ 50 y or postmenopausal.
- All patients with any of the following conditions, regardless of age: smoking actively, diabetes, HTN, family history CVD or HLD, erectile dysfunction, CKD, inflammatory disease, HIV, COPD, clinical evidence of atherosclerosis or AAA, clinical manifestation of HLD, obesity with BMI > 27.

Recommendations

Canadian Cardiovascular Society CCS 2012

- For all, screening should be performed with history and examination, LDL, HDL, TG, and non-HDL.
- Optional: ApoB (instead of standard lipid panel), urine albumin:creatinine ratio (if eGFR >60, HTN, diabetes).
- If Framingham Risk Score <5%, repeat every 4-5 y.
- If Framingham Risk Score ≥5%, repeat every year.

Source

- Can J Cardiol. 2013:29:151-167
## CHOLESTEROL GUIDELINES

<table>
<thead>
<tr>
<th>Source</th>
<th><strong>Recommended Lipoprotein Measurements for Risk Assessment</strong></th>
<th><strong>Recommended Lipoprotein Targets of Therapy</strong></th>
<th><strong>Recommended Risk Assessment Algorithm</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>National Cholesterol Education Program Adult Treatment Panel III[^9]</td>
<td>Fasting lipid panel Calculation of non-HDL-C when TG &gt;200 mg/dL</td>
<td>Primary target: LDL-C Secondary target: non-HDL-C</td>
<td>Identify number of CHD risk factors Framingham 10-y absolute CHD risk</td>
</tr>
<tr>
<td>International Atherosclerosis Society[^16]</td>
<td>Fasting lipid panel with calculation of non-HDL-C</td>
<td>Non-HDL-C LDL-C is considered alternative target of therapy</td>
<td>Lifetimes risk of total ASCVD morbidity/ mortality (by Framingham, CV Lifetime Risk pooling project, or QRisk)</td>
</tr>
<tr>
<td>European Society of Cardiology/European Atherosclerosis Society[^22]</td>
<td>Fasting lipid panel with calculation of non-HDL-C and TC/HDL-C ratio ApoB or ApoB/ apoA1 ratio are considered alternative risk markers</td>
<td>Primary target: LDC-C Secondary targets: non-HDL or ApoB in patients with cardiometabolic risk</td>
<td>10-y risk of total fatal ASCVD by the Systematic Coronary Risk Evaluation (SCORE) system</td>
</tr>
<tr>
<td>Canadian Cardiovascular Society[^27]</td>
<td>European Society of Cardiology/ European Atherosclerosis Society</td>
<td>Primary target: LDL-C Secondary targets: non-HDL-C and ApoB</td>
<td>10-y risk of total ASCVD events by the Framingham Risk Score</td>
</tr>
<tr>
<td>American Association of Clinical Endocrinologists[^31]</td>
<td>Fasting lipid panel Calculation of non-HDL-C more accurate risk assessment if TG in between 200 and 500 mg/dL, diabetes, insulin resistance, or established CAD</td>
<td>Primary targets: LDL-C Secondary targets: non-HDL-C in patients with cardiometabolic risk or established CAD ApoB recommended to assess success of LDL-C-lowering therapy</td>
<td>Men: Framingham Risk Score (10-y risk of coronary event) Women: Reynolds Risk Score (10-y risk of coronary event, stroke, or other major heart disease)</td>
</tr>
</tbody>
</table>


[^16]: International Atherosclerosis Society[^16] recommends fasting lipid panel with calculation of non-HDL-C.

[^22]: European Society of Cardiology/European Atherosclerosis Society[^22] recommends fasting lipid panel with calculation of non-HDL-C and TC/HDL-C ratio ApoB or ApoB/ apoA1 ratio are considered alternative risk markers.

[^27]: Canadian Cardiovascular Society[^27] recommends European Society of Cardiology/ European Atherosclerosis Society.

[^31]: American Association of Clinical Endocrinologists[^31] recommends fasting lipid panel Calculation of non-HDL-C more accurate risk assessment if TG in between 200 and 500 mg/dL, diabetes, insulin resistance, or established CAD.
### CHOLESTEROL GUIDELINES (Continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Recommended Lipoprotein Measurements for Risk Assessment</th>
<th>Recommended Lipoprotein Targets of Therapy</th>
<th>Recommended Risk Assessment Algorithm</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Diabetes Association/ American Heart Association Statement on Cardiometabolic Risk[^38]</td>
<td>Stronger risk discrimination provided by non-HDL-C, ApoB, LDL-P</td>
<td>Strong recommendation for ApoB and non-HDL-C as secondary targets</td>
<td>30-y/lifetime global ASCVD risk</td>
</tr>
<tr>
<td>American Diabetes Association: Standards of Medical Care in Diabetes[^39]</td>
<td>Fasting lipid panel</td>
<td>LDL-C</td>
<td>Not applicable in setting of diabetes (CHD risk equivalent)</td>
</tr>
<tr>
<td>Kidney Disease: Improving Global Outcomes: Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease[^41]</td>
<td>Fasting lipid panel to screen for more severe forms of dyslipidemia and secondary causes of dyslipidemia</td>
<td>None: therapy guided by absolute risk of coronary event based on age, and stage of CKD or eGFR</td>
<td>CKD considered CHD risk equivalent Treatment with evidence-based statins/statin doses based on age, and stage of CKD or eGFR</td>
</tr>
<tr>
<td>Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults: A Scientific Statement from the American Heart Association[^36]</td>
<td>Fasting lipid panel Calculation of non-HDL-C when TG &gt;200 mg/dL</td>
<td>Primary target: LDL-C Secondary target: non-HDL-C</td>
<td>N/A</td>
</tr>
<tr>
<td>National Lipid Association: Familial Hypercholesterolemia[^40]</td>
<td>Fasting lipid panel</td>
<td>LDL-C</td>
<td>Not applicable due to extremely high lifetime risk</td>
</tr>
</tbody>
</table>
### AHA Women's Cardiovascular Disease Prevention Guidelines

<table>
<thead>
<tr>
<th>Fasting lipid panel</th>
<th>LDL-C</th>
<th>Updated Framingham risk profile (coronary, cerebrovascular, and peripheral arterial disease and heart failure events) Reynolds Risk Score (10-y risk of coronary event, stroke, or other major heart disease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider hs-CRP in women &gt;60 y and CHD risk &gt;10%</td>
<td>Updated LDL-C measured for assessment of therapeutic response and compliance Therapy guided by identification of 40 categories of patients who benefit from high- or moderate-dose statin therapy</td>
<td></td>
</tr>
</tbody>
</table>

### 2013 American College of Cardiology/American Heart Association: Blood Cholesterol Guidelines for ASCVD Prevention

<table>
<thead>
<tr>
<th>LDL-C measured for assessment of therapeutic response and compliance</th>
<th>LDL-C</th>
<th>CV Risk Calculator based on Pooled Risk Equations (10-y risk of total ASCVD events) Lifetime risk provided for individuals 20–59 y of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting lipid panel to screen for more severe forms of dyslipidemia and secondary causes of dyslipidemia</td>
<td>Updated LDL-C measured for assessment of therapeutic response and compliance Therapy guided by identification of 40 categories of patients who benefit from high- or moderate-dose statin therapy</td>
<td>CV Risk Calculator based on Pooled Risk Equations (10-y risk of total ASCVD events) Lifetime risk provided for individuals 20–59 y of age</td>
</tr>
</tbody>
</table>

### ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; LDL-P, low-density lipoprotein particle; TC, total cholesterol; TG, triglycerides. |

CHAPTER 1

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Population
– Adults, asymptomatic.

Recommendation
► USPSTF 2016
– Do not screen asymptomatic adults for COPD

Sources

Comment
– Detection while asymptomatic doesn’t alter disease course or improve outcomes.
– Several symptom-based questionnaires have high sensitivity for COPD.
– In symptomatic patients (ie, dyspnea, chronic cough or sputum production with a history of exposure to cigarette smoke or other toxic fumes), diagnostic spirometry to measure FEV1/FVC ratio is indicated.

CORONARY ARTERY DISEASE

Population
– Adults at low risk of CHD events

Recommendation
– Do not routinely screening in men and women at low risk for CHD risk. with resting electrocardiogram (ECG), exercise treadmill test (ETT), stress echocardiogram, or electron-beam CT for coronary calcium.
– Do not screen with stress cardiac imaging or advanced non-invasive imaging in the initial evaluation of patients without cardiac symptoms, unless high-risk markers are present
– Do not perform annual stress cardiac imaging or advanced non-invasive imaging as part of routine follow-up in asymptomatic patients.

“Increased risk for CHD events: older age, male gender, high BP, smoking, elevated lipid levels, diabetes, obesity, sedentary lifestyle. Risk assessment tool for estimating 10-y risk of developing CHD events available online, http://cvdrisk.nhlbi.nih.gov/calculator.asp or see Appendices VI and VII.

“AHA scientific statement (2006): Asymptomatic persons should be assessed for CHD risk. Individuals found to be at low risk (<10% 10-y risk) or at high risk (>20% 10-y risk) do not benefit from coronary calcium assessment. High-risk individuals are already candidates for intensive risk-reducing therapies. In clinically selected, intermediate-risk patients, it may be reasonable to use electron-beam CT or multidetector computed tomography (MDCT) to refine clinical risk prediction and select patients for more aggressive target values for lipid-lowering therapies (Circulation. 2006;114:1761-1791).
DISEASE SCREENING

Sources


Comment

– USPSTF recommends against screening asymptomatic individuals because of the high false-positive results, the low mortality with asymptomatic disease, and the iatrogenic diagnostic and treatment risks.

Populations

– All asymptomatic adults age ≥20 y.
– Risk Score Assessment

Recommendations

▶ ACC/AHA 2013, ESC 2012

– ASCVD Risk Score has replaced the FRS in the United States for patients age 40–79 y.
– Assess 10-y ASCVD risk score every 4–6 y.
– Framingham Risk Score (FRS), including blood pressure (BP) and cholesterol level, should be obtained in asymptomatic adults age ≥20 y.
– The SCORE Risk Score remains the screening choice in Europe.
– No benefit in genetic testing, advanced lipid testing, natriuretic peptide testing, high-sensitivity C-reactive protein (CRP), ankle-brachial index, carotid intima-medial thickness, coronary artery score on electron-beam CT, homocysteine level, lipoprotein (a) level, CT angiogram, MRI, or stress echocardiography regardless of CHD risk.

Sources

– *Circulation.* 2007;115:402-426
– *J Am Coll Cardiol.* 2010;56(25): 2182-2199
Population

– Adults at intermediate risk of CHD events.

Recommendations

➤ ACC/AHA 2013, ESC 2012

– May be reasonable to consider use of coronary artery calcium and high-sensitivity CRP (hsCRP) measurements in patients at intermediate risk.

– hs-CRP is not recommended in low- or high-risk individuals.

Sources

– *Eur Heart J*. 2012;33:1635-1701

Comment

– 10-y ASCVD risk calculator (The Pooled Cohort Equation) can be found at: http://tools.acc.org/ASCVD-Risk-Estimator/

Population

– Adults at high risk of CHD events.

Recommendations

➤ AAFP 2012, AHA 2007, USPSTF 2012

– Insufficient evidence to recommend for or against routine screening with ECG, ETT.

– In addition, there is insufficient evidence to recommend routine MRI.

Sources

– *Arch Intern Med*. 2011;171(11): 977-982

Population

– Men and Women with no History of CHD.

Recommendation

➤ USPSTF 2009

– Insufficient evidence to assess the balance of benefits and harms of using the nontraditional risk factors to prevent CHD events (hs-CRP, ankle-brachial index [ABI], leukocyte count, fasting blood glucose level, periodontal disease, carotid intima-media thickness, coronary artery calcification [CAC] score on electron-beam computed tomography, homocysteine level, and lipoprotein[a] level).
**DISEASE SCREENING**

*Source*

*Comment*
– 10-yr ASCVD risk calculator (The Pooled Cohort Equation) can be found at: http://tools.acc.org/ASCVD-Risk-Estimator/

*Population*
– Women.

*Recommendations*

► ACCF/AHA 2011
– Cardiac risk stratification by the Framingham Risk Score should be used. High risk in women should be considered when the risk is ≥10% rather than ≥20%.
– An alternative 10-yr risk score to consider is the Reynolds Risk Score, although it requires measurement of hs-CRP.

*Source*
– *J Am Coll Cardiol.* 2011;57(12):1404-1423

*Population*
– Adults with stable CAD.

*Recommendations*

► CCS 2013
– Risk assessment by Framingham Risk Score should be completed every 3–5 y for men age 40–75 y and women age 50–75 y. Frequency of measurement should increase if history of premature cardiovascular disease (CVD) is present. Calculate and discuss a patient’s “cardiovascular age” to improve the likelihood that the patient will reach lipid targets and that poorly controlled hypertension will be treated.

*Source*
– *Can J Cardiol.* 2013;29:151-167

*Recommendation*

► AAFP 2009, AHA/APA 2008
– All patients with acute myocardial infarction (MI) to be screened for depression at regular intervals during and post hospitalization.

*Source*
– *Circulation.* 2008;118:1768-1775
DEMENTIA

Population
– Adults.

Recommendation
► ICSI 2014
– Insufficient evidence to recommend for or against routine dementia screening.

Source
– ISCI. Preventive Services for Adults, 20th Ed. 2014.

Population
– Adults over 65 y.

Recommendation
► CTFPHC 2016
– Do not screen asymptomatic adults for cognitive impairment.

Source
– CMAJ. 2016 Jan 5;188(1):37-46

Recommendation
► USPSTF 2014
– Insufficient evidence to recommend for or against routine dementia screening.

Source

Comments
– False positive rate for screening is high, and treatment interventions do not show consistent benefits.

DEPRESSION

Population
– Children age 7–11 y.

Recommendation
► USPSTF 2016
– Insufficient evidence to recommend for or against routine screening.

Source
Population
- Adolescents.

Recommendation
- USPSTF 2016
  - Screen all adolescents age 12–18 y for major depressive disorder (MDD). Systems should be in place to ensure accurate diagnosis, appropriate psychotherapy, and adequate follow-up.

Source

Comments
1. Screen in primary care clinics with the Patient Health Questionnaire for Adolescents (PHQ-A) (73% sensitivity; 94% specificity) or the Beck Depression Inventory-Primary Care (BDI-PC) (91% sensitivity; 91% specificity). See Appendix I.
2. Treatment options include pharmacotherapy (fluoxetine and escitalopram have FDA approval for this age group), psychotherapy, collaborative care, psychosocial support interventions, and CAM approaches.
3. SSRI may increase suicidality in some adolescents, emphasizing the need for close follow-up.

Population
- Adults.

Recommendation
- USPSTF 2016, ICSI 2016
  - Recommend screening adults for depression, including pregnant and postpartum women. Have staff-assisted support systems in place for accurate diagnosis, effective treatment, and follow-up.

Sources
- JAMA. 2016;315(4):380-7
- ICSI. Depression, Adult in Primary Care, 17th Ed. 2016.

Comments
1. PHQ-2 is as sensitive (96%) as longer screening tools:
   a. “Over the past 2 wk, have you felt down, depressed, or hopeless?”
   b. “Over the past 2 wk, have you felt little interest or pleasure in doing things?”
2. Optimal screening interval is unknown.
DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH)

Population

– Infants.

Recommendation


– Evidence is insufficient to recommend routine screening for DDH in infants as a means to prevent adverse outcomes.

Comment

– There is evidence that screening leads to earlier identification; however, 60%–80% of the hips of newborns identified as abnormal or suspicious for DDH by physical examination, and >90% of those identified by ultrasound in the newborn period, resolve spontaneously, requiring no intervention.
– The USPSTF was unable to assess the balance of benefits and harms of screening for DDH, but was concerned about the potential harms associated with treatment, both surgical and nonsurgical, of infants identified by routine screening.

Sources


Population

– Infants up to 6 mo.

Recommendations

AAOS 2014

1. Recommend against universal ultrasound screening of newborns.
2. Ultrasound recommended for infants before 6 mo for a history of breech presentation, family history, or history of clinical hip instability.
3. Limited evidence supports brace treatment for hips in infants with a positive instability examination.

Source

DISEASE SCREENING

DIABETES MELLITUS, GESTATIONAL (GDM)

Population
– Pregnant women after 24 wk of gestation.

Recommendation
► USPSTF 2014
– Recommends screening for gestational diabetes mellitus in asymptomatic pregnant women.

Source
– USPSTF. Gestational Diabetes Mellitus, Screening. 2014.

Recommendations
► ACOG 2013
– 1-h glucose screening test with 50-g anhydrous glucose load should be performed between 24 and 28 gestational weeks with a cutoff value of either 135 or 140 mg/dL.
– A 3-h glucose tolerance test should be performed if the 1-h glucose screening test is abnormal.
  • May use either the Carpenter and Coustan criteria or the National Diabetes Data Group criteria.
– Screen women with GDM 6–12 wk postpartum for overt diabetes.

Source

Comment
– Insufficient evidence to support screening for gestational diabetes prior to 24 gestational weeks.

DIABETES MELLITUS (DM), TYPE 2

Population
– Pregnant women.

Recommendations
► ADA 2012
1. Screen for undiagnosed DM type 2 at first prenatal visit if age ≥45 y or if risk factors for DM are present.a
2. For all other women, screen at 24–28 wk with a 75-g 2-h oral glucose tolerance test (OGTT) in the morning after an overnight fast of at least 8 h.
Population
–Children at start of puberty or age ≥10 y.

Recommendation
ADA 2012
–Screen all children at risk for DM type 2.

Comments
1. Preexisting diabetes if:
   a. Fasting glucose ≥126 mg/dL.
   b. 2-h glucose ≥200 mg/dL after 75-g glucose load.
   c. Random glucose ≥200 mg/dL with classic hyperglycemic symptoms.
   d. Hemoglobin A1c ≥6.5%.
2. Criteria for GDM by 75-g 2-h OGTT if any of the following are abnormal:
   a. Fasting ≥92 mg/dL (5.1 mmol/L).
   b. 1 h ≥180 mg/dL (10.0 mmol/L).
   c. 2 h ≥153 mg/dL (8.5 mmol/L).

Population
–Adults.

Recommendation
ADA 2011
–Screen asymptomatic adults age ≥45 y or if risk factors for DM are present.

Source

Population
–Adults.

Recommendation
–Screen asymptomatic adults age ≥45 y or if risk factors for DM are present.

Source

Footnotes:

1. Test asymptomatic children if BMI >85% for age/gender, weight for height >85th percentile, or weight >120% of ideal for height plus any two of the following: FH of DM in first- or second-degree relative; high-risk ethnic group (eg, Native American, African American, Latino, Asian American, or Pacific Islander); Acanthosis nigricans; HTN; dyslipidemia, polycystic ovary syndrome; small-for-gestational-age birth weight; maternal history of DM or GDM during the child’s gestation.

2. DM risk factors: overweight (BMI ≥25 kg/m2) and an additional risk factor: physical inactivity; first-degree relative with DM; high-risk ethnicity (eg, African American, Latino, Native American, Asian American, Pacific Islander); history of GDM; prior baby with birth weight >9 lb; hypertension (HTN) on therapy or with BP ≥140/90 mm Hg; HDL-C level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level ≥250 mg/dL (2.82 mmol/L); polycystic ovary syndrome; history of impaired glucose tolerance or HgbA1c ≥5.7%; Acanthosis nigricans; or cardiovascular disease.
**DISEASE SCREENING**

**Population**
- Adults

**Recommendation**
- USPSTF 2015
  - Screen as part of cardiovascular risk assessment if age 40–70 y and BMI >25.

**Sources**
- USPSTF. Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Screening. 2015.

**Comment**
- Screen at least every 3 y in asymptomatic adults.

**FALLS IN THE ELDERLY**

**Population**
- All older persons.

**Recommendation**
  - Ask at least yearly about falls.

**Sources**

**Population**
- All persons admitted to long-term care facilities.

**Recommendation**
- CTF 2005
  - Recommend programs that target the broad range of environmental and resident-specific risk factors to prevent falls and hip fractures.a

**Source**

---

*aPostfall assessments may detect previously unrecognized health concerns.*
CHAPTER 1

Comments
1. Individuals are at increased risk if they report at least 2 falls in the previous year, or 1 fall with injury. Risk factors: Intrinsic: lower-extremity weakness, poor grip strength, balance disorders, functional and cognitive impairment, visual deficits. Extrinsic: polypharmacy (≥4 prescription medications), environment (poor lighting, loose carpets, lack of bathroom safety equipment).

2. Calcium and vitamin D supplementation reduces falls by 45% over 3 y in women, but no effect is seen in men. (Arch Intern Med. 2006;166:424)

3. A fall prevention clinic appears to reduce the number of falls among the elderly. (Am J Phys Med Rehabil. 2006;85:882)

4. All who report a single fall should be observed as they stand up from a chair without using their arms, walk several paces, and return (see Appendix II). Those demonstrating no difficulty or unsteadiness need no further assessment. Those who have difficulty or demonstrate unsteadiness, have ≥1 fall, or present for medical attention after a fall should have a fall evaluation.


6. Of US adults age ≥65 y, 15.9% fell in the preceding 3 mo; of these, 31.3% sustained an injury that resulted in a doctor visit or restricted activity for at least 1 d. (MMWR Morb Mortal Wkly Rep. 2008;57(9):225)

7. See also page 126 for Fall Prevention and Appendix II.

FAMILY VIOLENCE AND ABUSE

Population
–Children, women, and older adults.

Recommendation

USPSTF 2013

–Women of childbearing age should be screened for intimate partner violence.
–Insufficient evidence to recommend for or against routine screening of parents or guardians for the physical abuse or neglect of children, or of older adults or their caregivers for elder abuse.

Sources
DISEASE SCREENING

Comments
1. Screening for intimate partner violence in emergency departments and pediatric clinics shows high prevalence (10%–20%) and does not increase harm. (Ann Emerg Med. 2008;51:433) (Pediatrics. 2008;121:e85)
2. In screening for intimate partner violence, women often prefer self-completed approaches (written or computer-based) over face-to-face questioning. (JAMA. 2006;296:530)
3. All providers should be aware of physical and behavioral signs and symptoms associated with abuse and neglect, including burns, bruises, and repeated suspect trauma.

FETAL ANEUPLOIDY

Population
– Pregnant women.

Recommendations
► ACOG 2016
1. All women should be offered screening. The decision should be reached through informed patient choice, including discussion of sensitivity, positive screening and false-positive rates and risks/benefits of diagnostic testing (amniocentesis and chorionic villous sampling).
2. No one screening test is superior.

Comments
– Risk of chromosomal anomaly by maternal age at term:
  • 20 y old: 1 in 525.
  • 30 y old: 1 in 384.
  • 35 y old: 1 in 178.
  • 40 y old: 1 in 62.
  • 45 y old: 1 in 18

Source
– Obstet Gynecol. 2016:127(5);e123-e137
GLAUCOMA

Population
– Adults.

Recommendations
► USPSTF 2013
– Insufficient evidence to recommend for or against screening adults for glaucoma.

Sources

GONORRHEA

Population
– Women age ≤25 y who are sexually active, and older women at high risk.

Recommendation
► CDC 2015, AAP 2014
– Screen for gonorrhea annually.

Source
CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Population
– Women age <25 y who are sexually active.

Recommendation
► USPSTF 2014
– Screen for chlamydia and gonorrhea. Screening interval to be determined by patient’s sexual practices.

Source

*Women age <25 y are at highest risk for gonorrhea infection. Other risk factors that place women at increased risk include a previous gonorrhea infection, the presence of other sexually transmitted diseases (STDs), new or multiple sex partners, inconsistent condom use, commercial sex work, and drug use.
**DISEASE SCREENING**

**Population**
- Young heterosexual men

**Recommendation**
- CDC 2015, USPSTF 2014
  - Insufficient evidence for or against routine screening.
  - Consider screening in high prevalence clinical settings.

**Sources**
- USPSTF. Chlamydia and Gonorrhea: Screening. 2014.
- CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

**Population**
- Men who have sex with men.

**Recommendation**
- CDC 2015
  - Annual testing, regardless of condom use.
  - Frequency of q 3–6 mo for high risk activity.

**Source**
- CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

**Comment**
- Gonorrhea is a reportable illness to state Public Health Departments.

**GROUP B STREPTOCOCCAL (GBS) DISEASE**

**Population**
- Pregnant women.

**Recommendation**
- CDC 2010, AAFP 2015
  - Universal screening of all women at 35–37 gestational weeks for GBS colonization with a vaginal–rectal swab.

**Source**

**Comment**
- Women who are colonized with GBS should receive intrapartum antibiotic prophylaxis to prevent neonatal GBS sepsis.
GROWTH ABNORMALITIES, INFANT

Population
− Children 0–59 mo.

Recommendation
➤ CDC 2010
− Use the 2006 World Health Organization (WHO) international growth charts for children age <24 mo.

Source

Comments
1. The Centers for Disease Control and Prevention (CDC) and American Academy of Pediatricians (AAP) recommend the WHO as opposed to the CDC growth charts for children age <24 mo.
2. The CDC growth charts should still be used for children age 2–19 y.
3. This recommendation recognizes that breast-feeding is the recommended standard of infant feeding, and therefore the standard against which all other infants are compared.

HEARING IMPAIRMENT

Population
− Newborns.

Recommendation
➤ USPSTF 2008, ISCI 2013
− Routine screening of all newborn infants for hearing loss.

Sources
− ISCI. Preventive Services for Children and Adolescents, 19th Ed. 2013.

Comments
1. Screening involves either a 1-step or a 2-step process.
2. The 2-step process includes otoacoustic emissions (OAEs) followed by auditory brainstem response (ABR) in those who fail the OAE test.
3. The 1-step process uses either OAE or ABR testing.
DISEASE SCREENING

Population
– Adults age >50 y.

Recommendation
► ICSI 2014, USPSTF 2012
– Insufficient evidence regarding screening the general population.
– Question older adults periodically about hearing impairment, counsel about availability of hearing aid devices, and make referrals for abnormalities when appropriate. See also Appendix II: Functional Assessment Screening in the Elderly.

Sources
– ISCI. Preventive Services for Adults. 2014.
– USPSTF. Hearing Loss in Older Adults: Screening. 2012.

Comments
1. Adults of age >50 y 20%–40%, and >80% of adults age ≥80 y, have some degree of hearing loss.
2. Additional research is required to determine if hearing loss screening can lead to improved health outcomes.
3. No harm from hearing loss screening.
4. No harm related to hearing aid use.

HEMOCHROMATOSIS (HEREDITARY)

Population
– Adults.

Recommendation
► AASLD 2011
– Guidelines
  • Screen people with iron studies and a serum HFE mutation analysis if they have first-degree relatives with HFE-related hemochromatosis. (Blood. 2008;111:3373)

Sources
– http://www.ahrq.gov/clinic/uspstf/uspshemoch.htm
Population
– Asymptomatic adults.

Recommendation

AAPF 2008, USPSTF 2006
– Recommend against routine genetic screening for hemochromatosis in asymptomatic adults. Patients with a family history should be counseled with further testing based on clinical considerations. (Arch Intern Med. 2006;166:269) (Blood. 2008;111:3373)

Sources
– http://www.ahrq.gov/clinic/uspstf/uspshemoch.htm

Comment
– Clinical Implications
  • There is fair evidence that clinically significant disease caused by hereditary hemochromatosis is uncommon in the general population. Male homozygotes for C282Y gene mutation have a 2-fold increase in the incidence of iron overload-related symptoms, compared with females.
  • There is poor evidence that early therapeutic phlebotomy improves morbidity and mortality in screening-detected vs. clinically detected individuals.
  • Both men and women who have a heterozygote C282Y gene mutation rarely develop iron overload.

Population
– Adults.

Recommendations

ACP 2005
– Insufficient evidence to recommend for or against screening.4

Sources
– Ann Intern Med. 2005;143:517-521
– http://www.acponline.org/clinical/guidelines/

4Discuss the risks, benefits, and limitations of genetic testing in patients with a positive FH of hereditary hemochromatosis, or those with elevated serum ferritin levels or transferrin saturation.
**Comments**

- If testing is performed, cutoff values for serum ferritin levels >200 μg/L in women and >300 μg/L in men and transferrin saturation >45% may be used as criteria for case-finding, but there is no general agreement about diagnostic criteria.
- For clinicians who choose to screen, one-time screening of non-Hispanic white men with serum ferritin level and transferrin saturation has highest yield.

**HEMOGLOBINOPATHIES**

**Population**

- Newborns.

**Recommendation**

- AAFP 2010, USPSTF 2007
  - Recommend screening all newborns for hemoglobinopathies (including sickle cell disease).

**Sources**

- [http://www.uspreventiveservicestaskforce.org/uspstf07/sicklecell/sicklers.htm](http://www.uspreventiveservicestaskforce.org/uspstf07/sicklecell/sicklers.htm)

**Comment**

- Newborn screen tests for phenylketonuria (PKU), hemoglobinopathies, and hypothyroidism.

**HEPATITIS B VIRUS INFECTION**

**Population**

- Adults.

**Recommendations**

- NICE 2013
  - Offer transient elastography as the initial test of liver cirrhosis for all adults with HBV infection.
  - Liver ultrasound and α-fetoprotein every 6 mo for HBV infection with cirrhosis to screen for hepatocellular carcinoma.

**Source**

Population
– Pregnant women.

Recommendation
– Screen all women with HBsAg at their first prenatal visit.

Sources
– AAP/ACOG. Guidelines for Perinatal Care, 7th Ed. 2012.
– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Population
– Adults and children.

Recommendations
▶ USPSTF 2014, CDC 2008
1. Recommend routine screening for HBV infection of newly arrived immigrants from countries where the HBV prevalence rate is >2%.a
2. People with behavioral exposures should be screened (ie, men who have sex with men, intravenous drug users)
3. People receiving cytotoxic or immunosuppressive therapy should be screened.
4. Hepatitis B testing should be part of the workup for unexplained liver disease (ie, elevated alanine transaminase (ALT)).
5. To prevent transmission, the following groups should be tested for HBsAg: hemodialysis patients, pregnant women, and persons known or suspected of having been exposed to HBV (ie, infants born to HBV-infected mothers, household contacts and sex partners of infected persons, and persons with known occupational or other exposures to infectious blood or body fluids.

Sources
– Weinbaum, CM; Williams, I; Mast E; et al. CDC MMWR; Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. 2008 / 57(RR08);1-20
– Hepatology. 2016 Jan;63(1):261-83

*aImmigrants from Asia, Africa, South Pacific, Middle East (except Israel), Eastern Europe (except Hungary), the Caribbean, Malta, Spain, Guatemala, and Honduras.
Comments
1. Breast-feeding is not contraindicated in women with chronic HBV infection if the infant has received hepatitis B immunoglobulin (HBIG)-passive prophylaxis and vaccine-active prophylaxis.
2. All pregnant women who are HBsAg-positive should be reported to the local Public Health Department to ensure proper follow-up.
3. Immunoassays for HBsAg have sensitivity and specificity >98% (MMWR. 1993;42:707).

HEPATITIS C VIRUS (HCV) INFECTION, CHRONIC

Population
– Pregnant women at increased risk.

Recommendation
► ACOG 2012, CDC 2015
– Perform routine counseling and testing at the first prenatal visit.

Sources
– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Comments
1. Route of delivery has not been shown to influence rate of vertical transmission of HCV infection. Cesarean section should be reserved for obstetric indications only.
2. Breast-feeding is not contraindicated in women with chronic HCV infection.

Populations
– Persons at increased risk for HCV infection.
– Adults born between 1945 and 1965.

Recommendations
► AASLD 2014, USPSTF 2013, WHO 2014, CDC 2012
– Recommend HCV antibody testing by enzyme immunoassay in all high-risk adults.
– One-time HCV antibody testing for HCV screening in all adults born between 1945 and 1965.

HCV risk factors: HIV infection; sexual partners of HCV-infected persons; persons seeking evaluation or care for STDs, including HIV; history of injection-drug use; persons who have ever been on hemodialysis; intranasal drug use; history of blood or blood component transfusion or organ transplant prior to 1992; hemophilia; multiple tattoos; children born to HCV-infected mothers; and health care providers who have sustained a needlestick injury.
Sources

– USPSTF. Hepatitis C: Screening. 2013.

Comments

1. HCV RNA testing should be performed for:
   a. Positive HCV antibody test result in a patient.
   b. When antiviral treatment is being considered.
   c. Unexplained liver disease in an immunocompromised patient with a negative HCV antibody test result.
   d. Suspicion of acute HCV infection.
2. HCV genotype should be determined in all HCV-infected persons prior to interferon treatment.
3. Seroconversion may take up to 3 mo.
4. Of persons with acute hepatitis C, 15%–25% resolve their infection; of the remaining, 10%–20% develop cirrhosis within 20–30 y after infection, and 1%–5% develop hepatocellular carcinoma.
5. Patients testing positive for HCV antibody should receive a nucleic acid test to confirm active infection. A quantitative HCV RNA test and genotype test can provide useful prognostic information prior to initiating antiviral therapy. (*JAMA*. 2007;297:724)

HERPES SIMPLEX VIRUS (HSV), GENITAL

Population

– Adolescents, adults, and pregnant women.

Recommendation

– CDC 2015, USPSTF 2016
– Recommend against routine serologic screening for HSV.

Sources

– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Comments

1. In women with a history of genital herpes, routine serial cultures for HSV are not indicated in the absence of active lesions.
2. Women who develop primary HSV infection during pregnancy have the highest risk for transmitting HSV infection to their infants.
HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Population
– Pregnant women.

Recommendations
 ► AAFP 2010, USPSTF 2013
  – Clinicians should screen all pregnant women for HIV.

 ► CDC 2015
  – Include HIV testing in panel of routine prenatal screening tests.
  – Retest high-risk women at 36 wk’ gestation.
  – Rapid HIV testing of women in labor who have not received prenatal HIV testing.

Sources
– CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

Comment
– Rapid HIV antibody testing during labor identified 34 HIV-positive women among 4849 women with no prior HIV testing documented (prevalence: 7 in 1000). Eighty-four percent of women consented to testing. Sensitivity was 100%, specificity was 99.9%, positive predictive value was 90%. (JAMA. 2004;292:219).

Population
– Adolescents and adults

Recommendation
 ► AAFP 2013
  – Screen everyone age 18–65 y. Consider screening high risk individuals\(^a\) of other ages.

 ► USPSTF 2013
  – Screen everyone age 15–65 y old. Consider screening high risk individuals of other ages.

\(^a\) Risk factors for HIV: men who have had sex with men after 1975; multiple sexual partners; history of intravenous drug use; prostitution; history of sex with an HIV-infected person; history of sexually transmitted disease; history of blood transfusion between 1978 and 1985; or persons requesting an HIV test.
CHAPTER 1

**CDC 2015**

- Screen everyone age 13 y old to 64 y old. Consider screening high-risk individuals of other ages.

**Sources**

- AAFP Clinical Recommendations: HIV Infection, Adolescents and Adults
- CDC. 2015 Sexually Transmitted Diseases Treatment Guidelines.

**Comments**

1. HIV testing should be voluntary and must have a verbal consent to test. Patients may “opt out” of testing.
2. Educate and counsel all high-risk patients regarding HIV testing, transmission, risk-reduction behaviors, and implications of infection.
3. If acute HIV is suspected, also use plasma RNA test.
4. False-positive results with electroimmunoassay (EIA): nonspecific reactions in persons with immunologic disturbances (eg, systemic lupus erythematosus or rheumatoid arthritis), multiple transfusions, recent influenza, or rabies vaccination.
5. Confirmatory testing is necessary using Western blot or indirect immunofluorescence assay.
6. Awareness of HIV positively reduces secondary HIV transmission risk and high-risk behavior and viral load if on highly active antiretroviral therapy (HAART). (CDC, 2006)

**HYPERTENSION (HTN), CHILDREN AND ADOLESCENTS**

**Population**

- Age 3–20 y

**Recommendations**

- Pediatrics 2011, NHLBI 2012

- Children age ≥3 y should have BP measured at each encounter with health care provider.

**Sources**

- Pediatrics. 2004;114:555-576

*In children age <3 y, conditions that warrant BP measurement include: prematurity, very low birth weight, or neonatal complications; congenital heart disease; recurrent urinary tract infections (UTIs), hematuria, or proteinuria; renal disease or urologic malformations; FH of congenital renal disease; solid-organ transplant; malignancy or bone marrow transplant; drugs known to raise BP; systemic illnesses; increased intracranial pressure.*
DISEASE SCREENING


Recommendation

► AAFP 2013, USPSTF 2013
– Evidence is insufficient to recommend for or against routine screening.

Sources

Comments

1. Hypertension: average systolic blood pressure (SBP) or diastolic blood pressure (DBP) ≥95th percentile for gender, age, and height on 3 or more occasions. See Appendixes.
2. Prehypertension: average SBP or DBP 90th–95th percentile.
3. Adolescents with BP ≥120/80 mm Hg are prehypertensive.
4. Evaluation of hypertensive children: assess for additional risk factors. Follow-up BP: if normal, repeat in 1 y; if prehypertensive, repeat BP in 6 mo; if stage 1, repeat in 2 wk; if symptomatic or stage 2, refer or repeat in 1 wk.
6. Screening for hypertension in children and adolescents hasn’t been proven to reduce adverse cardiovascular outcomes in adults.

HYPERTENSION (HTN), ADULTS

Population
– Adults age >18 y.

Recommendations


1. Screen for HTN.
2. HTN is >140/90 mm Hg on two or more BP readings.
3. All adults should have their BP assessed at all appropriate clinical visits.
4. Ambulatory BP monitoring (ABPM) is the standard to confirm diagnosis.
5. Annual F/U of patients with high-normal BP (2-y risk of developing HTN is 40%).

Sources
– USPSTF: High Blood Pressure in Adults: Screening. 2015.
– Hypertension Canada: http://www.hypertension.ca/en/chep
– J Hypertens. 2007;25:1105
– Eur Heart J. 2013;34:2159–2219

Recommendations
ESH/ESC 2013
– In cases of severe BP elevation, especially if associated with end-organ damage, the diagnosis can be based on measurements taken at a single visit.
– In asymptomatic subjects with hypertension but free of CVD, chronic kidney disease (CKD), and diabetes, total cardiovascular risk stratification using the SCORE model is recommended as a minimal requirement.

Sources
– J Hypertens. 2007;25:1105
– Eur Heart J. 2013;34:2159–2219

Comments
1. Electronic (oscillometric) measurement methods are preferred to manual measurements. Routine auscultatory Office BP Measurements (OBPMs) are 9/6 mm Hg higher than standardized research BPs (primarily using oscillometric devices). (CHEP, 2015)
3. ABPM has better predictive ability than OBPM.
4. Home BP Measurement (HBPM) is recommended if ABPM is not tolerated, not readily available or due to patient preference. 15%–30% of elevations by OBPM will have lower BP at home. (USPSTF, 2015)
5. Assess global cardiovascular risk in all hypertensive patients. Informing patients of their global risk (“vascular age”) improves the effectiveness of risk factor modification.
**DISEASE SCREENING**

**Population**
- Age > 18 y.

**Recommendation**
- **JNC 8 2014**
  - Treatment thresholds:
    - Age ≥ 60: 150/90.
    - Age < 60: 140/90.
    - DM or CKD: 140/90.

*Source*
- *JAMA*. 2014;311(5):507-520

*Comment*
- “Hypertension” and “pre-hypertension” are no longer defined.

**Population**
- Age > 65 y.

**Recommendation**
- **ACCF/AHA 2011**
  - Identification and treatment of systolic and diastolic HTN in the very elderly are beneficial in reduction in all-cause mortality and stroke death.

*Source*
- *J Am Coll Cardiol*. 2011;57(20):2037-2110

*Comments*
- Increased frequency of systolic HTN compared with younger patients.
- HTN is more likely associated with end-organ damage and more often associated with other risk factors.

---

**ILLICIT DRUG USE**

**Population**
- Adults, adolescents, and pregnant women.

**Recommendation**
- **USPSTF 2008, ICSI 2014**
  - Insufficient evidence to recommend for or against routine screening for illicit drug use.

*Sources*
- ISCI Preventive Services for Adults, 20th ed. 2014.
KIDNEY DISEASE, CHRONIC (CKD)

Population
– Adults.

Recommendations

USPSTF 2012
1. Insufficient evidence to recommend for or against routine screening.

Source

ACP 2013, AAFP 2014
1. Do not screen adults unless they have symptoms or risk factors.
2. Adults taking an ACE inhibitor or ARB should not be tested for proteinuria, regardless of diabetes status.

Sources

NICE 2014
1. Monitor glomerular filtration rate (GFR) at least annually in people prescribed drugs known to be nephrotoxic.
2. Screen renal function in people at risk for CKD.

Source

Examples: calcineurin inhibitors, lithium, or nonsteroidal anti-inflammatory drugs (NSAIDs).
DM, HTN, CVD, structural renal disease, nephrolithiasis, benign prostatic hyperplasia (BPH), multisystem diseases with potential kidney involvement (eg, systemic lupus erythematosus [SLE]), FH of stage 5 CKD or hereditary kidney disease, or personal history of hematuria or proteinuria.

LEAD POISONING

Population
– Children age 1–5 y.

Recommendations

1. Insufficient evidence to recommend for or against routine screening in asymptomatic children at increased risk.

Child suspected by parent, health care provider, or Health Department to be at risk for lead exposure: sibling or playmate with elevated blood lead level; recent immigrant, refugee, or foreign adoptee; child’s parent or caregiver works with lead; household member uses traditional folk or ethnic remedies or cosmetics or who routinely eats food imported informally from abroad; residence near a source of high lead levels.
2. Recommends against screening in asymptomatic children at average risk.

Sources

Comments
1. CDC recommends that children who receive Medicaid benefits should be screened unless high-quality, local data demonstrates the absence of lead exposure among this population.
2. Screen at ages 1 and 2 y, or by age 3 y if a high-risk child has never been screened.
3. As of 2012, the threshold for elevated blood lead level has been lowered to 5 μg/dL (Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention. CDC. 2012.

Population
- Pregnant women.

Recommendation
► AAFP 2006
- Recommends against screening in asymptomatic pregnant women.

Source

► CDC 2010
- Routine blood lead testing of pregnant women is recommended in clinical settings that serve populations with specific risk factors for lead exposure.

Source

Important risk factors for lead exposure in pregnant women include recent immigration, pica practices, occupational exposure, nutritional status, culturally specific practices such as the use of traditional remedies or imported cosmetics, and the use of traditional lead-glazed pottery for cooking and storing food.
**Comments**

1. Risk assessment should be performed during prenatal visits and continue until age 6 y.
2. CDC personal risk questionnaire:
   a. Does your child live in or regularly visit a house (or other facility, eg, daycare) that was built before 1950?
   b. Does your child live in or regularly visit a house built before 1978 with recent or ongoing renovations or remodeling (within the last 6 mo)?
   c. Does your child have a sibling or playmate who has or did have lead poisoning? (http://www.cdc.gov/nceh/lead/publications/screening.htm)

**MOTOR VEHICLE SAFETY**

**Population**

– Children and adolescents.

**Recommendation**

- ICSI 2013
  - Recommend that all health care providers ask about
    a. Car seats.
    b. Booster seats.
    c. Seat belt use.
    d. Helmet use while riding motorcycles.

**Source**

– Preventive Services for Children and Adolescents, 19th Ed. ISCI. 2013.

**Comment**

– One study demonstrated a 21% reduction in mortality with the use of child restraint systems vs. seat belts in children age 2–6 y involved in motor vehicle collisions. (Arch Pediatr Adolesc Med. 2006;160:617-621)

**NEWBORN SCREENING**

**Population**

– Newborns

**Recommendation**

- ICSI 2013
  - All newborns should receive a newborn metabolic screening test prior to hospital discharge.

**Source**

– Preventive Services for Children and Adolescents, 19th Ed. ISCI. 2013.
Comment
– The newborn screen should be performed after 24 h of age. Infants who receive their newborn screen before 24 h of age should have it repeated before 2 wk of age.

**OBESITY**

**Population**
– Children age ≥6 y.

**Recommendation**
➤ AAFP 2010, USPSTF 2010
– The AAFP recommends that clinicians screen children age 6 y and older for obesity.

**Source**

**Comment**
– Obese children should be offered intensive counseling and behavioral interventions to promote improvement in weight status.

**Population**
– Children age ≥2 y

**Recommendation**
➤ ICSI 2013
– Height, weight, and body mass index (BMI) should be recorded annually starting at age 2 y.

**Source**
– Preventive Services for Children and Adolescents, 19th Ed. ISCI. 2013.

**Comments**
1. Children with a BMI ≥25 are 5 times more likely to be overweight as adults when compared with their normal-weight counterparts.
2. Overweight children should be counseled about wholesome eating, 30–60 min of daily physical activity, and avoiding soft drinks.

**Population**
– Adults age >18 y.

**Recommendation**
➤ AAFP 2012, USPSTF 2012
– Recommends screening all adults and offering intensive counseling and behavioral interventions to promote sustained weight loss in obese adults with BMI ≥30 kg/m².
Source
– USPSTF. Obesity in Adults: Screening and Management. 2012.

Comment
– Intensive counseling involves more than one session per month for at least 3 mo.

Recommendation

ICSI 2014
– Height, weight, and BMI should be measured at least annually.

Source
– Preventive Services for Adults, 20th Ed. ISCI. 2014.

Comment
– Intensive intervention to promote weight loss should be offered to all obese adults (BMI ≥30 or waist circumference ≥40 in. [men] or ≥35 in. [women])

Recommendations

VA/DoD 2014
1. Height, weight, and BMI should be measured at least annually.
2. Consider annual measurement of waist circumference as well.

Source

Comment
1. Intensive intervention to promote weight loss should be offered to
   a. Obese adults (BMI ≥30 or waist circumference ≥40 in. [men] or ≥35 in. [women]).
   b. Overweight adults (BMI 25–29.9) with an obesity-associated condition."

OSTEOPOROSIS

Population
– Women age ≥65y, and younger women at increased risk.

Recommendation

– Routine screening for women using either dual-energy x-ray absorptiometry (DXA) of the hip and lumbar spine, or quantitative ultrasonography of the calcaneus.

"HTN, DM type 2, dyslipidemia, obstructive sleep apnea, degenerative joint disease, or metabolic syndrome.
DISEASE SCREENING

Sources
- Preventive Services for Adults, 20th Ed. ISCI. 2014.

Comments
1. USPSTF specifically defines ‘increased risk’ as having a fracture risk equivalent to that of a 65-y white woman.
2. The optimal screening interval is unclear.
3. Screening should not be performed more frequently than every 2 y.
4. ACOG: If FRAX score does not suggest treatment, DEXA should be repeated every 15 y if T-score >=1.5, every 5 y if T-score -1.5 to -1.99, and annually if T-score is -2.0 to -2.49.
5. Ten-year risk for osteoporotic fractures can be calculated for individuals by using the FRAX tool (http://www.shef.ac.uk/FRAX/).
6. Quantitative ultrasonography of the calcaneus predicts fractures of the femoral neck, hip, and spine as effectively as does DXA.
7. The criteria for treatment of osteoporosis rely on DXA measurements.

Population
- Older men.

Recommendation
- USPSTF 2011
- Insufficient evidence to recommend for or against routine osteoporosis screening.

Source

Population
- Men age ≥70 y.

Recommendation
- NOF 2008, ACPM 2009
- Recommend routine screening via bone mineral density (BMD).
- Consider screening men age 50-69 with risk factors.

Source

Comment
- Repeat every 3–5 y if “normal” baseline score; if high risk, then every 1–2 y.
PELVIC EXAMINATIONS

Population
- Asymptomatic, nonpregnant women.

Recommendation
- AAFP 2017, ACP 2014
  - Do not perform routine screening pelvic examinations.

Source

Recommendation
- USPSTF 2017
  - Insufficient evidence to recommend for or against screening pelvic examinations.

Source
- JAMA. 2017;317(9):947-953

Recommendation
- ACOG 2012
  - Screen all women age 21+ with annual pelvic exam

Source
- Obstet Gynecol. 2012;120:421-4

Comments
- Pelvic examination remains a necessary component of evaluation for many complaints.
- While tradition and patient or physician experience may support an annual exam, outcome data does not (nor does the data clearly refute the exam).
- Potential harms associated with screening include overdiagnosis, fear/anxiety/embarrassment, discomfort, additional diagnostic procedures.
PHENYLKETONURIA (PKU)

Population
– Newborns.

Recommendation
▶ Advisory Committee on Heritable Disorders in Newborns and Children 2015, USPSTF 2008
– Recommend screening all newborns for PKU as part of a uniform screening panel.

Sources
– Advisory Committee on Heritable Disorders in Newborns and Children. 2015.

Comment
– Newborn screen tests for PKU, hemoglobinopathies, hypothyroidism, and several other heritable disorders.

RH (D) INCOMPATIBILITY

Population
– Pregnant women.

Recommendations
▶ AAFP 2010, USPSTF 2007
1. Recommend blood typing and Rh (D) antibody testing for all pregnant women at their first prenatal visit.
2. Repeat Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24–28 wk’ gestation.

Sources

Comment
– Rh (D) antibody testing at 24–28 wk can be skipped if the biologic father is known to be Rh (D)-negative.
SCOLIOSIS

Population
- Adolescents.

Recommendation
- AAFP 2013, USPSTF 2004
  - Recommend against routine screening of asymptomatic adolescents for idiopathic scoliosis.

Sources

SLEEP APNEA

Population
- Asymptomatic Adults

Recommendation
- USPSTF 2017, AAFP 2017
  - Insufficient evidence to recommend for or against routine screening.

Sources

SPEECH AND LANGUAGE DELAY

Population
- Preschool children.

Recommendation
- AAFP 2015, USPSTF 2015
  - Evidence is insufficient to recommend for or against routine use of brief, formal screening instruments in primary care to detect speech and language delay in children up to age 5 y.

Sources
- AAFP Clinical Recommendation. Speech and Language Delay. 2015.
- Pediatrics. 2015;136(2):e474-81
DISEASE SCREENING

Comments
1. Fair evidence suggests that interventions can improve the results of short-term assessments of speech and language skills; however, no studies have assessed long-term consequences.
2. In a study of 9000 toddlers in the Netherlands, 2-time screening for language delays reduced the number of children who required special education (2.7% vs. 3.7%) and reduced deficient language performance (8.8% vs. 9.7%) at age 8 y. (Pediatrics. 2007;120:1317)
3. Studies have not fully addressed the potential harms of screening or interventions for speech and language delays, such as labeling, parental anxiety, or unnecessary evaluation and intervention.
4. Insufficient evidence to recommend a specific test, but parent-administered tools are best (examples: Communicative Development Inventory, Infant-Toddler Checklist, Language Development Survey, Ages and Stages Questionnaire).

SYMPHILIS

Population
–Pregnant women.

Recommendation
★ CDC 2015, AAFP 2009, USPSTF 2009
–Strongly recommend routine screening of all pregnant women at the first prenatal visit.

Sources
–2015 Sexually Transmitted Diseases Treatment Guidelines. CDC.

Population
–Persons at increased risk.*

Recommendation
★ USPSTF 2016, AAFP 2016, CDC 2015
–Screen high-risk persons.

Sources
–JAMA. 2016;315(21):2321-7
–2015 Sexually Transmitted Diseases Treatment Guidelines. CDC.

*High risk includes commercial sex workers, persons who exchange sex for money or drugs, persons with other STDs (including HIV), sexually active homosexual men, and sexual contacts of persons with syphilis, gonorrhea, Chlamydia, or HIV infection.


**Comments**

1. A nontreponemal test (Venereal Disease Research Laboratory [VDRL] test or rapid plasma reagent [RPR] test) should be used for initial screening.
2. All reactive nontreponemal tests should be confirmed with a fluorescent treponemal antibody absorption (FTA-ABS) test.
3. Women at high risk for syphilis or who are previously untested should be tested again at 28 gestational weeks. Consider testing a third time at the time of delivery.
4. Syphilis is a reportable disease in every state.

## THYROID DISEASE

**Population**

– Adults.

**Recommendations**

- AAFP 2010, ICSI 2010, USPSTF 2015
  – Insufficient evidence to recommend for or against routine screening for thyroid disease.

- ATA 2012
  – ATA recommends screening men and women older than age 35 y for hypothyroidism every 5 y.

- AACE 2012
  – AACE recommends screening older adults with a thyroid-stimulating hormone (TSH) measurement.

**Sources**

– Preventive Services for Adults, 20th Ed. ICSI. 2014.

**Population**

– Newborns.

**Recommendation**

  – Recommend screening for congenital hypothyroidism in newborns.
DISEASE SCREENING

Sources
– Advisory Committee on Heritable Disorders in Newborns and Children

Comments
– <1% of adults have subclinical hypothyroidism; outcomes data to support treatment are lacking.
– Individuals with symptoms and signs potentially attributable to thyroid dysfunction and those with risk factors for its development may require TSH testing.
– Higher risk individuals are those with an autoimmune disorder, pernicious anemia, history of neck radiation, first-degree relative with a thyroid disorder, and those with psychiatric disorders.

Population
– Women who are pregnant or immediately postpartum.

Recommendation

ATA 2017
– Insufficient evidence to recommend for or against routine screening of all women
– TSH levels should be obtained at confirmation of pregnancy if:
  1. A history or current symptoms of thyroid dysfunction.
  2. Known thyroid antibody positivity or presence of a goiter.
  3. History of head or neck radiation or prior thyroid surgery.
  4. Age >30 y.
  5. Autoimmune disorders.
  6. History of pregnancy loss, preterm delivery, or infertility.
  7. Multiple prior pregnancies.
  8. Family history of thyroid disease.
  9. BMI ≥40 kg/m².
10. Use of amiodarone or lithium, or recent administration of iodinated radiologic contrast.
11. Residing in an area of known moderate to severe iodine insufficiency.

Source
– Thyroid. 2017;27(3):315
TOBACCO USE

Population
– Adults.

Recommendation
► AAFP 2015, USPSTF 2015, ICSI 2014
– Recommend screening all adults for tobacco use and provide tobacco cessation interventions for those who use tobacco products.

Population
– Pregnant women.

Recommendation
► AAFP 2015, USPSTF 2015, ICSI 2014
– Recommend screening all pregnant women for tobacco use and provide pregnancy-directed counseling and literature for those who smoke.

Sources
– Preventive Services for Adults, 20th Ed. ICSI. 2014.

Comment
– The “5-A” framework is helpful for smoking cessation counseling:
  a. Ask about tobacco use.
  b. Advise to quit through clear, individualized messages.
  c. Assess willingness to quit.
  d. Assist in quitting.
  e. Arrange follow-up and support sessions.

Population
– Children and adolescents.

Recommendations
► AAFP 2013
– Evidence is insufficient to recommend for or against routine screening.
– Counsel school-aged children and adolescents against starting use.
► ICSI 2013
– Screen for tobacco use beginning at age 10, and reassess at every opportunity.
**DISEASE SCREENING**

*Sources*
- Preventive Services for Children and Adolescents, 19th Ed. ICSI, 2013.

*Comment*
- The avoidance of tobacco products by children and adolescents is desirable. It is uncertain whether advice and counseling by health care professionals in this area is effective.

---

**TUBERCULOSIS, LATENT**

*Population*
- Persons at increased risk of developing tuberculosis (TB).

*Recommendation*
- USPSTF 2016, CDC 2010
  - Screening by tuberculin skin test (TST) or interferon-gamma release assay (IGRA) is recommended. Frequency of testing is based on likelihood of further exposure to TB and level of confidence in the accuracy of the results.

*Sources*
- *JAMA*. 2016;316(9):962-9
- *CDC MWR*. 2010;59(RR-5)

*Comments*
1. Risk factors include birth or residence in a country with increased TB prevalence and residence in a congregate setting (shelters, correctional facilities).
2. Typically, a TST is used to screen for latent TB.
3. IGRA is preferred if:
   a. Testing persons who have a low likelihood of returning to have their TST read.
   b. Testing persons who have received a bacille Calmette-Guérin (BCG) vaccination.
CHAPTER 1

VISUAL IMPAIRMENT, GLAUCOMA, OR CATARACT

Population
– Older adults.

Recommendation
▶ USPSTF 2016
– Insufficient evidence to recommend for or against visual acuity screening or glaucoma screening in older adults.

Source
– JAMA. 2016 Mar 1;315(9):908-14

Recommendation
▶ ICSI 2014
– Objective vision testing (Snellen chart) recommended for adults age ≥65 y.

Source
– Preventive Services for Adults, 20th Ed. ICSI. 2014.

Population
– Children ≤4 y.

Recommendation
▶ ICSI 2013
– Vision screening recommended for children age ≤4 y.

Source

Comment
– Screen for amblyopia, strabismus, or decreased visual acuity.

Populations
– Children 3–5 y.
– Children <3 y.

Recommendations
▶ USPSTF 2011
– Vision screening for all children 3–5 y at least once to detect amblyopia.
– Insufficient evidence for vision screening in children <3 y of age.

Source

Comment
– May screen with a visual acuity test, a stereoacuity test, a cover–uncover test, and the Hirschberg light reflex test.
VITAMIN D DEFICIENCY

Population
—Nonpregnant adults age 18 y or older.

Recommendations
▶ USPSTF 2015, Endocrine Society 2011
—Insufficient evidence to screen for vitamin D deficiency in asymptomatic adults.
—Serum 25-hydroxyvitamin D level recommended as diagnostic test in patients at risk* for deficiency.

Sources
—J Clin Endocrinol Metab. 2011;96(7):1911-1930.
—Ann Intern Med. 2015;162(2):133-40

*Indications for screening include rickets, osteomalacia, osteoporosis, CKD, hepatic failure, malabsorption syndromes, hyperparathyroidism, certain medications (anticonvulsants, glucocorticoids, AIDS drugs, antifungals, cholestyramine), African-American and Hispanic race, pregnancy and lactation, older adults with history of falls or nontraumatic fractures, BMI >30, and granulomatous diseases.
Disease Prevention

**ASTHMA**

**Population**
- Children.

**Recommendation**

- Global Initiative for Asthma (GINA) 2017
  - Advise pregnant women and parents of young children not to smoke.
  - Encourage vaginal delivery.
  - Minimize use of acetaminophen and broad spectrum antibiotics during first year of life

**Source**

**Comments**
- Environmental exposures such as automobile exhaust and dust mites are associated with higher rates of asthma, while others (household pets and farm animals) may be protective. Avoiding tobacco smoke and air pollution is protective, but allergen avoidance measures have not been shown to be effective primary prevention.
- Public health interventions to reduce childhood obesity, increase fruit and vegetable intake, improve maternal-fetal health, and reduce socioeconomic inequality would address major risk factors. (Lancet. 2015;386:1075-85)
BACK PAIN, LOW

Population
- Adults.

Recommendation

- AAFP 2004, USPSTF 2004
  - Insufficient evidence for or against the use of interventions to prevent low-back pain in adults in primary care settings.

Sources

Comment
- Insufficient evidence to support back strengthening exercises, mechanical supports, or increased physical activity to prevent low-back pain.

Primary Prevention of Cancer (Ca): NCI Evidence Summary 2017

BREAST CANCER

Minimize Known Risk Factor Exposure

- **Hormone Replacement Therapy**
  - Approximately 26% increased incidence of invasive breast cancer with combination hormone replacement therapy (HRT) (estrogen and progesterone-Prempro).
  - Estrogen alone with mixed evidence—unlikely to increase risk of breast cancer significantly (decreases risk in African Americans).

- **Ionizing Radiation to Chest and Mediastinum**
  - Increased risk begins approximately 10 y after exposure. Risk depends on dose and age at exposure (woman with radiation from age 15–30 y at highest risk). These patients often have received mediastinal radiation for Hodgkin Lymphoma.

- **Obesity**
  - In Women's Health Initiative (WHI), relative risk (RR) = 2.85 for breast CA for women >82.2 kg compared with women <58.7 kg only in post menopausal women

- **Alcohol**
  - RR for intake of 4 alcoholic drinks/day is 1.32.
  - RR increases approximately 7% for each drink per day.
DISEASE PREVENTION

• Family history—risk is doubled if a single first-degree relative develops breast cancer. Five-fold increased risk if 2 first degree relative are diagnosed with breast cancer. (Breast CA Res Treat. 2012; 133:1097).

Factors of Unproven or Disproven Association

• Abortions.
• Environmental factors.
• Diet and vitamins.
• Underarm deodorant/anti-persperpants - no evidence to support increased risk of breast ca. (J Natl Cancer Inst. 2002; 94:1578).

• Active and passive cigarette smoking.
• Use of statin drugs.
• Use of low-dose daily aspirin.

Population-based studies have shown reduction in breast CA risk with one 81 mg aspirin daily but more data needed. (J Clin Oncol. 2010; 25:1467) (Lancet Oncol. 2012;13:518)
• Use of bisphosphonates for >1 y with 28% relative reduction in risk for postmenopausal breast CA. (J Clin Oncol. 2010; 28:3577) (J Ntl Cancer Inst. 2011;103:1752)
• New large study from Kaiser Permanente Northern California shows serum Vitamin D levels independently associated with breast cancer prognostic characteristics and patient prognosis. A randomized trial is needed. Underarm deoderants/antiperspirants—no evidence to support. (JAMA Oncol.2017; 3:351-357) (J Natl Cancer Inst. 2002; 94:1578)

Therapeutic Approaches to Reduce Breast Cancer Risk

Tamoxifen (Postmenopausal and High-Risk Premenopausal Women)
• Treatment with tamoxifen for 5 y reduced breast CA risk by 40%–50%. USPSTF reemphasizes discussion with women at increased risk of breast cancer to strongly consider chemoprevention with selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs in post menopausal women only). (Ann Intern Med. 2013;159:698-718)
• Meta-analysis shows RR = 2.4 (95% confidence interval [CI], 1.5–4.0) for endometrial CA and 1.9 (95% CI, 1.4–2.6) for venous thromboembolic events.
– Raloxifene (Postmenopausal Women)
  • Similar effect as tamoxifen in reduction of invasive breast CA, but does not reduce the incidence of noninvasive tumors—studied only in postmenopausal women.
  • Similar risks as tamoxifen for venous thrombosis, but no risk of endometrial CA or cataracts. (Lancet. 2013;381:1827)

– Aromatase Inhibitors
  • Anastrozole reduces the incidence of new primary breast CAs by 50% compared with tamoxifen; similar results have been reported with letrozole and exemestane treatment (Lancet. 2014;383:1041). Aromatase inhibitor use as a prevention of breast cancer will reduce the risk of developing breast cancer by 3-5%.
  • There is a 65% reduction in the risk of breast CA occurrence in postmenopausal women treated with exemestane for 5 y (chemoprevention). (N Engl J Med. 2011;364:2381)
  • Harmful effects of aromatase inhibitors include decreased bone mineral density and increased risk of fracture, hot flashes, increased falls, decreased cognitive function, fibromyalgia, and carpal tunnel syndrome. There are no life-threatening side effects.
  • Fracture rate for women being treated with anastrozole was 5.9% compared with 3.7% for those being treated with tamoxifen. The use of calcium, vitamin D, biphosphonates and denosamab for patients at bone risk on aromatase inhibitors reduces the risk. (J Clin Onc. 2012;30:3665)

– Prophylactic Bilateral Mastectomy (High-Risk Women)
  • Reduces risk of breast cancer as much as 90%
  • Approximately 6% of high risk women undergoing bilateral mastectomies were dissatisfied with their decision after 10 y. Regrets about mastectomy were less common among women who opted not to have breast reconstruction.

– Prophylactic Salpingo-oophorectomy among BRCA-Positive Women
  • Breast CA incidence decreased as much as 50%.
  • Nearly all women experience some sleep disturbances, mood changes, hot flashes, and bone demineralization, but the severity of these symptoms varies greatly.
  • Salpingo-oophorectomy should be done in BRCA 1 patients at 35 y of age and >40 y of age in BRCA 2 patients.
  • In patients who have uterus removed as well, it is safe to give estrogen replacement. (Eur J Cancer. 2016;52:138)

– Exercise
  • Exercising >120 min/wk results in average risk reduction of developing breast cancer by 30%–40%. There is also a 30%
reduction in breast cancer recurrence in patients who have had breast CA. (Eur J Cancer. 2016;52:138)
- The effect may be greatest for premenopausal women of normal or low body weight.

- **Breast-Feeding**
  - The RR of breast CA is decreased 4.3% for every 12 mo of breast-feeding, in addition to 7% for each birth.

- **Pregnancy before Age 20 y**
  - Approximately 50% decrease in breast CA compared with nulliparous women or those who give birth after age 35 y.

- **Dense Breasts**
  - Women have increased risk of breast CA proportionate to breast density. Relative risk 1.79 for 50% density and 4.64 for women with >75% breast density. (Cancer Epidemiol Biomarkers Prev. 2006;15:1159) (Br J Cancer. 2011;104:871)
  - No known interventional method to reduce breast density.
  - Adding ultrasound to mammography will improve sensitivity and specificity and is more accurate than tomosynthesis without radiation exposure. (J Clin Onc. 2016;34:1882) (J Clin Onc. 2016;34:1840)

---

**CERVICAL CANCER**

**Minimize Risk Factor Exposure**

- **Human Papillomavirus (HPV) Infection**
  - Abstinence from sexual activity; condom and/or spermicide use (RR, 0.4).
  - HPV vaccination ideally at age 9–13 y—also given to females age 13–26 y if no previous vaccination.

- **Cigarette Smoke (Active or Passive)**
  - Increased risk of high-grade cervical intraepithelial neoplasia (CIN) or invasive cancer 2- to 3-fold among HPV-infected women.

- **High Parity**
  - HPV-infected women with 7 or more full-term pregnancies have a 4-fold increased risk of squamous cell CA of the cervix compared with nulliparous women.

- **Long-Term Use of Oral Contraceptives (>5 y)**
  - Increases risk by 3-fold.
  - Longer use related to even higher risk.

---

Methods to minimize risk of HPV infection include abstinence from sexual activity and the use of barrier contraceptives and/or spermicidal gel during sexual intercourse.
Therapeutic Approaches

- HPV-16/HPV-18 Vaccination
  - Reduces incidence and persistent infections with efficacy of 91.6% (95% CI, 64.5–98.0) and 100% (95% CI, 45–100), respectively; duration of efficacy is not yet known; impact on long-term cervical CA rates also unknown but likely to be significant. 2 doses of vaccine if 9–14 y/o, 3 doses if 15-26 y/o. (Lancet. 2009;374:1975) (N Engl J Med. 2015;372:711) (N Engl J Med. 2015;372:775)
  - Also will likely decrease risk of other HPV-driven malignancies (oropharynx and anal CA).

- Screening with PAP Smears
  - Estimates from population studies suggest that screening may decrease CA incidence and mortality by <80%. Adding screening for HPV after age 30 y increases sensitivity and reduces frequency of screening to every 5 y if both are negative.
  - HPV screening only, without a PAP smear, is being studied in developing countries.

On June 8, 2006, the U.S. Food and Drug Administration (FDA) announced approval of Gardasil, the first vaccine developed to prevent cervical CA, precancerous genital lesions, and genital warts caused by HPV types 6,11,16, and 18. The vaccine is approved for use in females age 9–26 y (http://www.fda.gov). A bivalent vaccine, Cervarix, is also FDA approved with activity against HPV subtypes 16 and 18 (N Engl J Med. 2006;354:1109-1112).

COLORECTAL CANCER

Minimize Risk Factor Exposure

- Risk Factor CRC
  - Excessive alcohol use, RR is 1.41 for >45 g/d (>4.5 drinks/d).
  - Cigarette smoking—RR for current smokers vs. never smokers- 1.18
  - Obesity—RR for woman with a body mass index (BMI) >29 is 1.45. Similar increase seen in colorectal CA (CRC) mortality. (N Engl J Med. 2003; 348:1625)

- Preventive Strategy
  - Regular physical activity—a meta-analysis of 52 studies showed a 24% reduction in incidence of CRC.
  - Increased consumption of fruits and reduction in red meat and processed meat consumption may lower the risk of CRC. (JAMA. 2005; 293:172) (Cancer Res. 2010; 70:2401).
  - B6 (pyridoxal-5’-phosphate) levels are inversely associated with risk of colon CA. B6 found in cereals, meat, fish, vegetables, bananas, and avocado. (JAMA. 2010;303:1077)

*Cereal fiber supplementation and diets low in fat and high in fiber, fruits, and vegetables do not reduce the rate of adenoma recurrence over a 3- to 4-y period.*
DISEASE PREVENTION

• If family history of CRC (no genetic abnormality) increase frequency of surveillance. (*Gasterenterology*. 2015; 149:1438).

Therapeutic Approaches

• Based on solid evidence, nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of adenomas, but how much this reduces the risk of CRC is uncertain. Harms include upper gastrointestinal (UGI) bleeding (4–5/1000 people/y), chronic kidney disease (CKD), and cardiovascular (CV) events.¹

• Based on solid evidence, daily aspirin use for at least 5 y reduces CRC incidence and mortality (40%), with an absolute risk reduction from 3.1% to 1.9%. Harm of low-dose aspirin use includes approximately 10 to 30 extra cases of UGI bleeding complications per 1000 users over a 1-y period. Risk increases with age. Benefit shown in other GI cancers as well. (*Lancet*. 2011;377:31) (*JAMA*. 2015;313:1133).


• Postmenopausal Combination Hormone Replacement (Not Estrogen Alone)
  • Based on solid evidence (WHI), 44% reduction seen in CRC incidence among HRT users.
  • Based on solid evidence (WHI), combination HRT users have a 26% increased invasive breast CA risk, a 29% increase in coronary heart disease (CHD) events, and a 41% increase in stroke rates. These risks obviate use of HRT for CRC prevention. Estrogen-only HRT does not impact on the incidence or survival of CRC.

• Polyp Removal
  • Based on fair evidence, complications of polyp removal include perforation of the colon and bleeding estimated at 7–9 events per 1000 procedures.

• Interventions without Benefit
  • Statins do not reduce the incidence or mortality of CRC.
  • Data are inadequate to show a reduction in the risk of CRC from calcium or vitamin D supplementation. Fair data that calcium

¹There is solid evidence that NSAIDs reduce the risk of adenomas, but the extent to which this translates into a reduction in CRC is uncertain.

- Low-fat, high-fiber diet does not reduce the risk of CRC to a significant degree.
- USPSTF recommends against use of beta-carotene or vitamin E supplements. (Ann Inter Med. 2014;160:558)

ENDOMETRIAL CANCER

Minimize Risk Factor Exposure

- **Unopposed estrogen is a significant risk factor for the development of uterine cancer**
  - Unopposed estrogen use in post menopausal women for 5 or more years, more than doubled the risk of endometrial CA compared to women who did not use estrogen. Other significant events include stroke (39% relative increase) and pulmonary embolus (34% relative increase). (Lancet. 2005; 365:1543) (JAMA. 2004;291:1701).
  - Obesity—risk increases 1.59-fold for each 5 kg/m² change in body mass.
  - Lack of exercise—regular exercise (2 h/wk) with 38%–48% decrease in risk.
  - Tamoxifen—used for >2 y has a 2.3- to 7.5-fold increased risk of endometrial CA (usually stage I— 95% cure rate with surgery).
  - Nulliparous women have a 35% increased risk of endometrial CA.
  - Endometrial hyperplasia and atypia—50% go on to develop uterine cancer. Most often occurs in women over 50 y old. (Gynecol. 1995;5:233).

Therapeutic Approaches

- **Oral Contraception (Estrogen and Progesterone Containing)**
  - Use of oral contraceptives for 4 y reduces the risk of endometrial CA by 56%; 8 y, by 67%; and 12 y, by 72%, but will increase risk of breast cancer by 26%.

- **Increasing Parity and Lactation**
  - 35% reduction vs. nulliparous women-increasing length of breast-feeding with decreasing risk.

- **Weight Loss**
  - Insufficient evidence to conclude weight loss is associated with a decreased incidence of endometrial cancer.
ESOPHAGUS CANCER

Minimize Risk Factor Exposure

- Risk Factors
  - Avoidance of tobacco and alcohol abuse would significantly decrease risk of squamous cell CA of esophagus. (*Natl Cancr Inst.* 2003; 95:1404)
  - The combined use of alcohol and smoking is associated with a 3- to 7-fold increased risk of esophageal cancer (account for 90% squamous cell esophageal CA).
  - Diet high in cruciferous vegetables will decrease risk of esophageal CA.
  - Avoid ingestion of coffee or tea at temperatures >149° F. (*Inst J Cancer.* 2009;125:491)
  - ASA or NSAID use decreases the risk of developing or dying from esophageal CA by 43%. (*Gastroenterology.* 2003;124:47-56)

- Therapeutic Approaches
  - Risk Reduction
    - Randomized controlled trial has shown that radiofrequency ablation of Barrett’s esophagus (BE) with moderate or severe dysplasia may lead to eradication of dysplasia and reduced risk of progression to malignancy. (*N Engl J Med.* 2009;360:2277-2288)
    - Longstanding GERD associated with BE and increased risk of esophageal CA (*PLOS.* 2014; 9:e103508)
    - Uncertain if elimination of GERD by surgical or medical therapy will reduce the risk of esophageal adenocarcinoma although a few trials show benefit. (*Gastroenterology.* 2010; 138:1297).
    - No trials in the United States have shown any benefit from the use of chemoprevention with vitamins and/or minerals to prevent esophageal cancer. (*Am J Gastroenterology.* 2014;109:1215)

GASTRIC

Minimize Risk Factor Exposure

- Risk Factors
  - *Helicobacter pylori* eradication with decreased risk of gastric cancer from 1.7% to 1.1%.
  - Deficient consumption of fruits/vegetables.
  - Avoid salted, smoked, or poorly preserved foods.
• Smoking—relative risk = 1.6. (Tumor. 2009;95:13)
• Workers in rubber and coal industry.

Therapeutic Approaches

Clinical Considerations

• Anti-\(H.\) pylori therapy may reduce risk but effect on mortality unclear. A study over 15 y showed a 40% reduction in risk of gastric CA with \(H.\) pylori eradication. (Ann Intern Med. 2009;151:121) (J Natl Cancer Inst. 2012;104:488) \(H.\) pylori eradication will also reduce the risk of mucosa-associated lymphoid tumor (MALT lymphoma).

• Dietary interventions—eating more fruits, vegetables, and less processed foods reduces risk of gastric cancer by 10%–15%.

• Smoking cessation will reduce risk by 20%–30%.

• Patients with hereditary susceptibility (HNPCC, e-cadherin mutation, Li-Fraumeni syndrome), pernicious anemia, atrophic gastritis, partial gastrectomy or gastric polyps should be followed carefully for early cancer symptoms and for upper endoscopy at intervals according to risk.

LIVER CANCER

Minimize Risk Factor Exposure

Risk Factor

• Avoidance of cirrhosis (hepatitis B and C, excessive alcohol use, hepatic steatosis (NASH), alpha 1 anti-trypsin deficiency, Wilson’s disease, and hemochromatosis).

• Aflatoxins from improperly stored grains and nuts, most prominent in Africa. (Lancet. 1992; 339:943)

Therapeutic Approaches

• HBV vaccination of newborns of Taiwanese mothers reduced the incidence of hepatocellular carcinoma (HCC) from 0.7 to 0.36 per 100,000 children after about 10 y. (Clin Cancer Res. 2005;11:7953)

• New effective anti-viral therapy for hepatitis C. Ledipasvir and Sofobuvir (Harvoni) will very likely decrease the risk for HCC in near future (N Engl J Med. 2013;368:1907)

• Irradication of HCV occurs in over 95% of patients treated with this new anti viral therapy
**LUNG CANCER**

▶ Minimize Risk Factor Exposure

- **Risk Factors for Lung CA**
  - Cigarette smoking (20-fold increased risk) and second-hand exposure to tobacco smoke (20% increased risk) both medication and counseling better than either alone in increasing cessation rates.
  - Beta-carotene, in pharmacologic doses, actually increases the risk of lung CA, especially in high-intensity smokers.
  - Avoid radon gas exposure, severe air pollution (*Am J Respir Crit Care Med.* 2006;173:667)
  - Avoid occupational exposures (asbestos, arsenic, nickel, and chromium).
  - Air pollution—40% increased risk of lung CA with highest pollution exposure.

▶ Therapeutic Approaches

- **Minimize Risk of Lung CA**
  - No evidence that vitamin E/tocopherol, retinoids, vitamin C, or beta-carotene in any dose reduces the risk of lung CA. (*Ann Intern Med.* 2013;159:824)
  - Minimize indoor exposure to radon, (can be measured in home), especially if smoker. Avoid occupational exposures (asbestos, arsenic, nickel, chromium, beryllium, and cadmium)
  - Stopping tobacco use will lower the risk of lung and other cancers but at 15 y there is still a 2- to 3-fold increased risk of lung cancer.
  - At least 2/3 of patients newly diagnosed with lung cancer will die of their disease. Early detection is critical. (*Chest.* 2017; 151:193).

**ORAL CANCER**

▶ Minimize Risk Factor Exposure

- **Risk Factors**
  - Tobacco cessation (in any form, including smokeless).
  - Betel-quid chewing. (*Cancer.* 2014;135:1433)
  - Oral HPV infection—found in 6.9% of general population and found in 70%–75% of patients with oropharyngeal squamous cell cancer (*N Engl J Med.* 2007; 356:1944)
  - Lip cancer—avoid chronic sun exposure and smokeless tobacco.
Therapeutic Approaches

Clinical Features
• Oropharyngeal squamous cell CAs (tonsil and base of tongue) are related to HPV infection (types 16 and 18) in 75% of patients. This correlates with sexual practices, number of partners, and may be prevented by HPV vaccine. HPV (+), non-smokers have improved cure rate by 35%–45%. \( \textit{N Engl J Med.} \ 2010;363:82 \) \( \textit{N Engl J Med.} \ 2010;363:24 \) There is inadequate evidence to suggest change in diet will reduce risk of oral cancer.

OVARIAN CANCER

Minimize Risk Factor Exposure

Risk Factors
• Postmenopausal use of unopposed estrogen replacement will lead to a 3.2-fold increased risk of OC after >20 y of use.
• Talc exposure and use of fertility drugs have inadequate data to show increased risk of ovarian CA – remains controversial.
• If a woman is newly diagnosed with ovarian cancer she should be tested for BRCA 1 or 2 at any age—if positive, family members should be tested for that specific gene mutation and undergo genetic counseling.

Obesity and height of OC
• Elevated BMI including during adolescence associated with increased mortality from ovarian CA. \( \textit{J Natl Cancer Inst.} \ 2003;95:1244 \)
• Taller women with higher risk of OC. RR of OC per 5 cm increase in height is 1.07

Therapeutic Approaches

Risk Reduction

Oral Contraceptives
• 5%–10% reduction in ovarian CA per year of use, up to 80% maximum risk reduction.
• Increased risk of deep venous thrombosis (DVT) with oral contraceptive pill (OCP). The risk amounts to about 3 events per 10,000 women per year; increased breast CA risk among long-term OCP users of about 1 extra case per 100,000 women per year.
• Tubal ligation decreases the risk of ovarian cancer (30% reduction).
• Breast feeding associated with an 8% decrease in OC with every 5 mo of breast feeding.
- **Prophylactic Salpingo-oophorectomy**—in high-risk women (eg, *BRCA1* or *2* gene mutation).
  - Ninety percent reduction in ovarian CA risk and 50% reduction in breast cancer with bilateral salpingo-oophorectomy.
  - If prophylactic salpingo-oophorectomy is done prior to menopause, approximately 50% of women experience vasomotor symptoms; there is a 4.5-fold increased risk of heart disease especially in women <40 y old following oophorectomy.
  - <40 y old following oophorectomy.

### PROSTATE CANCER

#### Minimize Risk Factor Exposure
- Family history of prostate CA in men age <60 y defines risk. One first-degree relative with prostate CA increases the risk 3-fold, 2 first-degree relatives increase the risk 5-fold. The incidence of prostate CA in African Americans is increased by 2-fold, occurs at a younger age and is more virulent with increased death rate compared to caucasian men.
- High dietary fat intake does not increase risk for prostate CA but is associated with more aggressive cancers and shorter survivals.

#### Therapeutic and Preventive Approaches

- **Finasteride**
  - Decreased 7-y prostate CA incidence from 25% (placebo) to 18% (finasteride), but no change in mortality.
  - Trial participants report reduced ejaculate volume (47%–60%); increased erectile dysfunction (62%–67%); increased loss of libido (60%–65%); increased gynecomastia (3%–4.5%).

- **Dutasteride**
  - Absolute risk reduction of 22.8%.

- **Vitamins and Minerals**
  - Vitamin E/alfa-tocopherol—inadequate data—one study showed a 17% increase in prostate CA with vitamin E alone. *(JAMA.* 2011;306:1549)
  - Selenium—no study shows benefit in reducing risk of prostate CA.
  - Lycopene—largest trials to date show no benefit. *(Am J Epidemiol.* 2010;172:566)
CHAPTER 2

SKIN CANCER

Minimize Risk Factor Exposure
- Avoid sunburns and tanning booths, especially severe blistering sunburns at a younger age.

Therapeutic Approaches
- Sunscreen, protective clothing, limited time in the sun, avoiding blistering sunburn in adolescence and young adults
- Self exam of skin looking for changes that could possibly be cancer; higher risk patients need to be examined by dermatologist every 6–12 mo.
- Nicotinamide (Vitamin B₃) shows promise in preventing skin cancers but further studies are required. ([Invest Dermatol. 2012; 132:1498]
- Chemopreventive agents (beta carotene, isoretinoin, selenium and celecoxib) have not shown prevention of new skin cancers in randomized clinical trials. ([Arch Dermatol. 2000; 136:179]

Source

CATHETER-RELATED BLOODSTREAM INFECTIONS

Population
- Adults and children requiring intravascular catheters.

Recommendations
IDSA 2011, CDC 2011
1. Educate staff regarding proper procedures for insertion and maintenance of intravascular catheters.
2. The arm is preferred over the leg for catheter insertion.
3. Use a central venous catheter (CVC) when the duration of IV therapy is likely to exceed 6 d.
4. Avoid the femoral vein for central venous access in adult patients.
5. Subclavian vein is preferred over femoral or internal jugular vein to minimize infection risk for nontunneled CVC.
6. Use ultrasound guidance to place CVCs to minimize mechanical complications.
7. Promptly remove a CVC that is no longer essential.
8. Wash hands before and after catheter insertion, replacement, accessing, or dressing an intravascular catheter.

Twenty-eight million Americans per year use indoor tanning salons—increased risk of squamous cell and basal cell cancers greater than melanoma. Source: http://www.cancer.gov/cancertopics/pdq/prevention.
9. Use maximal sterile barrier precautions including a cap, mask, sterile gown, sterile gloves, and a sterile full-body drape for the insertion of CVCs.

10. Chlorhexidine skin antisepsis preferred over povidone-iodine.

11. Avoid antibiotic ointments on insertion sites.

Sources
– CDC Intravascular Catheter-related Infection: https://www.cdc.gov/infectioncontrol/guidelines/BSI/index.html

Comment
– Clean gloves should be worn when changing the catheter dressings.

### CESAREAN SECTION

#### Population
– Pregnant women with history of prior cesarean delivery.

#### Recommendations

**AAFP 2014, ACOG 2010**

1. Attempting a vaginal birth after cesarean (VBAC) is safe and appropriate for most women.

2. Encourage and facilitate planning for VBAC. If necessary, refer to a facility that offers trial of labor after cesarean (TOLAC).

Sources

Comments

1. Obtained informed consent for VBAC, including risk to patient, fetus, future fertility, and the capabilities of local delivery setting.

2. Develop facility guidelines to promote access to VBAC and improve quality of care for women who elect TOLAC.

3. A calculator for probability for successful VBAC is available here: https://mfmu.bsc.gwu.edu/PublicBSC/MFMU/VGBirthCalc/vagbirth.html

#### Population
– Women in labor.

#### Recommendations

**ACOG/SMFM/NICHHD 2013**

1. Induce labor only for medical indications. If induction performed for nonmedical reasons, ensure that gestational age is >39 weeks and cervix is favorable.
2. Do not diagnose failed induction or arrest of labor until sufficient time has passed.
3. Consider intermittent auscultation rather than continuous fetal monitoring if heart rate is normal.

Source

Comments
1. If fetal heart rate variability is moderate, other factors have little association with fetal neurologic outcomes.
2. Doctors who are salaried have lower cesarean rates than those paid fee-for-service.
3. Informed consent for the first cesarean should include discussion of effect on future pregnancies, including risks of uterine rupture and abnormal implantation of placenta.

COLITIS, CLOSTRIDIUM DIFFICILE

Population
– Adults and children taking antibiotics.

Recommendation
▶ Cochrane Database of systematic reviews 2013
– Recommend probiotics for prevention of C. difficile-associated diarrhea (CDAD) after a course of antibiotics.

Source

Population
– Adults and children.

Recommendations
▶ ACG 2013
– Hospital-based infection control programs can decrease the spread of CDI.
– Recommend antibiotic stewardship programs.
– Contact precautions should be maintained until the patient no longer has diarrhea.

*Failed induction:* inability to generate contractions every 3 min and cervical change after 24 h of oxytocin administration and rupture of membranes, if feasible. **Arrest of labor, first stage:** 6 cm dilation, membrane rupture, and 4 h of adequate contractions or 6 h of inadequate contractions without cervical change. **Arrest of labor, second stage:** no descent or rotation for 4 h (nulliparous woman with epidural), 3 h (nulliparous woman without epidural or multiparous woman with epidural), or 2 h (multiparous woman without epidural).
DISEASE PREVENTION

– Patients with CDI should be treated in a private room.
– Hand hygiene and barrier precautions, including gloves and gowns, should be used by all health care workers and visitors entering the room of any patient with known or suspected CDI.
– Single-use disposable equipment should be used for prevention of CDI transmission. Nondisposable medical equipment should be dedicated to the patient's room and other equipment should be thoroughly cleaned after use in a patient with CDI.
– Disinfection of environmental surfaces is recommended using an Environmental Protective Agency (EPA)—registered disinfectant with *C. difficile* sporicidal label claim or 5000 ppm. Chlorine-containing cleaning agents in areas of potential contamination by *C. difficile*.
– Although there is moderate evidence that 2 probiotics (*Lactobacillus rhamnosus* GG and *Saccharomyces boulardii*) decrease the incidence of antibiotic associated diarrhea, there is insufficient evidence that probiotics prevent *C. difficile* infection.

Source

Comment
– Probiotics lower the incidence of CDAD by about 65% after a course of antibiotics.

CONCUSSION

Population
– Children and young adults.

Recommendations

AAN 2013
– School-based professionals should be educated by licensed healthcare professionals to understand the risks of a concussion.
– Licensed health care professionals should educate athletes about concussion risks.
– Athletes with a concussion should be prohibited from returning to play or practice in contact sports until a licensed healthcare provider has cleared them to return.
– Licensed healthcare providers should recommend retirement for any athlete with repeated concussions who has chronic, persistent neurologic or cognitive deficits.

Source
– *Neurology*. 2013;80(24):2250
CHAPTER 2

COPD EXACERBATION

Population
– Adults with COPD.

Recommendations
» GOLD 2017
– Recommend smoking cessation. Support with pharmacotherapy and nicotine replacement.
– Give influenza and pneumococcal vaccines.
– Pulmonary rehabilitation improves symptoms and quality of life.
– Pharmacotherapy reduces exacerbations.
– If no history of hospitalization and <2 lifetime exacerbations:
  – Rare symptoms: SABA
  – Persistent symptoms: LAMA, LABA, or both
– If history of hospitalization and 2+ lifetime exacerbations:
  – Rare symptoms: LAMA; add LABA or ICS if further exacerbations
  – Persistent symptoms: LAMA & LABA & ICS

Source

» ACCP 2015
– Recommend annual flu vaccine, smoking cessation counseling, monthly follow-up visit, and written action plans.
– If recent exacerbation, pulmonary rehabilitation.
– If moderate to severe disease, inhaled maintenance therapy.
  – First line: ICS + LABA.
  – Second line: LAMA + LABA or LAMA alone.

Source
– Chest. 2015;147:894-942.

Comments
– LABA: Long-acting beta agonist.
– LAMA: Long-acting muscarinic agonist.
– ICS: Inhaled corticosteroid.
– SABA: Short-acting beta agonist
– See Chapter 3, page 229 for specifics of COPD management.
DISEASE PREVENTION

DENTAL CARIES

Population
– Infants and children up to age 5 y.

Recommendations
  1. Recommends application of fluoride varnish to the primary teeth of all infants and children starting at the age of primary teeth eruption.
  2. Recommends oral fluoride supplementation starting at age 6 mo for children whose water supply is fluoride deficient (<0.7 mg/L).

Source
– AAFP Clinical Recommendation 2014

Comments
• Fluoride mouthwash used regularly by children under 16 reduces risk of dental caries by >25%. (Cochrane Database Syst Rev. 2016;7:CD002284)
• The CDC’s My Water’s Fluoride resource provides county-level information on content of fluoride in the water system.

DIABETES MELLITUS (DM), TYPE 2

Population
– Persons with impaired glucose tolerance (IGT). a

Recommendations
– ADA 2017
  1. Intensive lifestyle modification with a goal of sustained 7% weight loss.
  2. Moderate physical activity such as brisk walking at least 150 min/week.
  3. Consider initiation of metformin for patients at highest risk for developing diabetes (eg, BMI 35 kg/m2 or greater, those age 60 y or younger, and those with prior gestational diabetes mellitus [GDM]).

Source

Comments
  1. Recommendations for disease prevention:
     a. Annual influenza vaccine.
     b. Pneumococcal polysaccharide vaccine if 2 y or older with one-time revaccination when over 64 y.

aIGT if fasting glucose 110-125 mg/dL, 2-h glucose after 75-g anhydrous glucose load 140-199 mg/dL, or HgbA1c 5.7%-6.4%.
c. Hepatitis B vaccine series if unvaccinated and 19–59 y of age.
d. Aspirin 81 mg daily for primary prevention if 10- y risk of significant
CAD is at least 10% (by Framingham Risk Score); includes most men
over 50 y and most women over 60 y.

**Population**
- Persons with abnormal blood glucose or BMI >25.

**Recommendation**
- USPSTF 2016
  - Intensive behavioral intervention to promote healthy diet and physical
    activity.

**Source**

---

**DOMESTIC VIOLENCE**

**Population**
- Adolescents and adult women.

**Recommendation**
- WHO 2010
  - Recommend school-based programs that emphasize preventing dating
    violence.

**Source**
- World Health Organization. Preventing intimate partner and sexual
  violence against women. 2010.

**Comments**
- Interventions of possible, but not proven, efficacy include:
  1. School-based programs that teach children to recognize and avoid
     sexually abusive situations.
  2. Empowerment and relationship skills training for women.
  3. Programs that change social and cultural gender norms.

---

**DRIVING RISK**

**Population**
- Adults with dementia.
DISEASE PREVENTION

Recommendations

AAN 2010

- Assess patients with dementia for the following characteristics that place them at increased risk for unsafe driving:
  1. Caregiver’s assessment that the patient’s driving ability is marginal or unsafe.
  2. History of traffic citations.
  3. History of motor vehicle collisions.
  4. Reduced driving mileage.
  5. Self-reported situational avoidance.
  7. Aggressive or impulsive personality.

Source

- Neurology. 2010;74(16):1316

ENDOCARDITIS

Populations

- Endocarditis is more likely a result of random exposure to bacteremia rather than associated with procedures.
- Certain persons are at highest risk for adverse sequelae from endocarditis.¹

Recommendations

AHA 2007, ESC 2015

1. Dental procedures: give prophylaxis² for certain procedures,³ give prophylaxis for highest-risk patients.⁴

¹Patients with prosthetic valves; previous endocarditis; selected patients with congenital heart disease (unrepaired cyanotic congenital heart disease; completely repaired congenital heart defect with prosthetic material or device during first 6 mo after procedure; repaired cyanotic CHD with residual defects at or near-repair site); and cardiac transplant recipients who develop valvulopathy.
²Standard prophylaxis regimen: amoxicillin (adults 2 g; children 50 mg/kg orally 1 h before procedure). If unable to take oral medications, give ampicillin (adults 2.0 g IM or IV; children 50 mg/kg IM or IV within 30 min of procedure). If penicillin-allergic, give clindamycin (adults 600 mg; children 20 mg/kg orally 1 h before procedure) or azithromycin or clarithromycin (adults 500 mg; children 15 mg/kg orally 1 h before procedure). If penicillin-allergic and unable to take oral medications, give clindamycin (adults 600 mg; children 20 mg/kg IM or IV within 30 min before procedure). If allergy to penicillin is not anaphylaxis, angioedema, or urticaria, options for nonoral treatment also include cefazolin (1 g IM or IV for adults, 50 mg/kg IM or IV for children); and for penicillin-allergic, oral therapy includes cephalexin 2 g PO for adults or 50 mg/kg PO for children (IM, intramuscular; IV, intravenous; PO, by mouth, orally).
³Such procedures include treatment of respiratory tract infections, gastrointestinal or genitourinary infections, skin and soft tissue infections, and implantation of cardiac valve, graft, or pacemakers.
⁴Highest risk patients are those with prosthetic valve, history of cardiac repair with prosthetic material, previous episode of IE, or congenital heart disease.
2. Other procedures: consider prophylaxis for highest-risk patients for invasive procedures through infected tissue.¹
3. Antibiotic prophylaxis is no longer indicated for native valvular heart disease unless previous endocarditis is present.

Sources
– Circulation. 2007;116:1736
– Circulation. 2008;52:676-685

Comments
1. Emphasis is on providing prophylaxis to patients at greatest risk of endocarditis.
2. General consensus suggests few cases of infective endocarditis can be prevented by preprocedure prophylaxis with antibiotics.

FALLS IN THE ELDERLY

Population
– Older adults.

Recommendations
➤ USPSTF 2012, Cochrane Database of Systematic Reviews 2012
1. Recommend vitamin D supplementation (800 international units [IU] orally daily).
2. Recommend home-hazard modification (eg, adding nonslip tape to rugs and steps, provision of grab bars, etc.) for all homes of persons age >65 y.
3. Recommend exercise or physical therapy interventions targeting gait and balance training.
4. Insufficient evidence to recommend a multifactorial assessment and management approach for all elderly persons (65 y and older).
5. Recommend vitamin D supplementation to elderly patients in care facilities. This reduces the rate of falls by 37%.

Sources
– USPSTF. Falls Prevention in Older Adults: Counseling and Preventive Medication. 2012

¹Consider prophylaxis for procedures involving manipulation of gingival or periapical region or perforation of oral mucosa. Do not give prophylaxis for superficial caries, suture removal, placement of appliances, etc.
Comments

1. 30%–40% of all community-dwelling persons age >65 y fall at least once a year.
2. Falls are the leading cause of fatal and nonfatal injuries among persons age >65 y.
3. A review and modification of chronic medications, including psychotropic medications, is important although not proven to reduce falls. Please see appendix for Beers List of potentially problematic medications.

FRACTURES

Population
Noninstitutionalized postmenopausal women.

Recommendation

USPSTF 2013

Recommends against daily supplementation with ≤400 IU Vitamin D and ≤1000 mg calcium for primary prevention of fractures.

Source
Ann Intern Med. 2013;158(9):691

Comment
Insufficient evidence for vitamin D and calcium supplementation in anyone for the primary prevention of fractures.

GONORRHEA, OPHTHALMIA NEONATORUM

Population
Newborns.

Recommendation

USPSTF 2011

Recommend prophylactic ocular topical medication against gonococcal ophthalmia neonatorum for all newborns.

Source
USPSTF: Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum. 2011
Comments
– Erythromycin 0.5% ointment is only agent available in U.S. for this application.
– Canadian Paediatric Society now recommends against universal prophylaxis given incomplete efficacy of erythromycin, rarity of the condition, and disruption in maternal-infant bonding. Instead, they recommend screening mothers for gonorrhea and chlamydia infection and, if infected with gonorrhea at the time of delivery, treating the infant with ceftriaxone (Paediatr Child Health. 2015;20:93-96).

GOUT

Population
– Adults.

Recommendations
– American College of Rheumatology 2012
  – Recommend a urate-lowering diet and lifestyle measures for patients with gout to prevent exacerbations.
  – Urate-lowering medications\(^a\) are indicated for gout with Stage 2–5 CKD or recurrent gout attacks and hyperuricemia (uric acid >6 mg/dL)
  – Anti-inflammatory prophylaxis\(^b\) indicated for 6 mo after an attack and for 3 mo after uric acid level falls <6 mg/dL

Source

Comments
– Minimize or avoid alcohol and purine-rich meat and seafood.
– Limit consumption of high-fructose corn syrup-sweetened soft drinks and energy drinks.
– Increase low-fat dairy products and vegetable intake.

\(^a\) Colchicine 0.6 mg daily-bid; naproxen 250mg bid is second-line; low-dose prednisone is third-line.
\(^b\) Allopurinol, febuxostat, probenecid; goal uric acid level <6 mg/dL.
GROUP B STREPTOCOCCAL (GBS) INFECTION

Population
– Pregnant women.

Recommendations

CDC 2010
1. Intrapartum antibiotic prophylaxis (IAP) to prevent early-onset invasive GBS disease in newborns is indicated for high-risk pregnancies.  
2. IAP is not indicated for GBS colonization or GBS bacteriuria during a previous pregnancy, negative vaginal-rectal GBS culture, or if a cesarean delivery is performed with intact membranes and before the onset of labor (regardless of GBS screening culture status).

Source
– CDC MMWR. 2010;59(RR10);1-32

Comments
1. Penicillin G is the agent of choice for IAP.
2. Ampicillin is an acceptable alternative to penicillin G.
3. Cefazolin may be used if the patient has a penicillin allergy that does not cause anaphylaxis, angioedema, urticaria, or respiratory distress.
4. Clindamycin or erythromycin may be used if the patient has a penicillin allergy that causes anaphylaxis, angioedema, urticaria, or respiratory distress.

HORMONE REPLACEMENT THERAPY

Population
– Postmenopausal women.

Recommendation

AAFP 2012, USPSTF 2012
– Recommend against the use of combined estrogen and progestin for the prevention of chronic conditions (eg, osteoporosis).

Source

*Indications for IAP: previous infant with invasive GBS disease; history of GBS bacteriuria during current pregnancy; positive GBS vaginal-rectal screening culture within 5 wk of delivery; unknown GBS status with any of the following: preterm labor at <37 gestational weeks, amniotic membrane rupture ≥18 h, intrapartum fever ≥100.4°F (≥38°C); intrapartum nucleic acid amplification test positive for GBS.
Population
– Postmenopausal women who have had a hysterectomy.

Recommendation
▶ AAFP 2012, USPSTF 2012
– Recommend against the use of estrogen for the prevention of chronic conditions (eg, osteoporosis).

Source

Comment
– This recommendation does not apply to women under the age of 50 y who have undergone a surgical menopause and require estrogen for hot flashes and vasomotor symptoms.

HUMAN IMMUNODEFICIENCY VIRUS (HIV), OPPORTUNISTIC INFECTIONS

Population
– HIV-infected adults and adolescents.

Recommendation
▶ CDC 2009
– See the following table (from the clinical practice guidelines at CDC MMWR. 2009;58(RR04);1-198).

Source
– CDC MMWR. 2009;58(RR04);1-198

Population
– HIV-infected children.

Recommendation
▶ CDC 2009
– See table below (from the clinical practice guidelines at CDC MMWR. 2009;58(RR04);1-198).

Source
– CDC MMWR. 2009;58(RR04);1-198

Comment
– This recommendation does not apply to women under the age of 50 who have undergone a surgical menopause and require estrogen for hot flashes and vasomotor symptoms.
# Prophylaxis to Prevent First Episode of Opportunistic Disease Among HIV-Infected Adults

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Pneumocystis carinii</em> pneumonia (PCP)</td>
<td>CD4+ count &lt;200 cells/µL (AII) or oropharyngeal candidiasis (AII)</td>
<td>Trimethoprim-sulfamethoxazole (TMP-SMX), 1 DS PO daily (AII); or 1SS daily (AII)</td>
<td>• TMP-SMX 1 DSPOIW (BII); or</td>
</tr>
<tr>
<td></td>
<td>CD4+ &lt;14% or history of AIDS-defining illness (BII)</td>
<td></td>
<td>• Dapsone 100 mg PO daily or 50 mg PO bid (BII); or</td>
</tr>
<tr>
<td></td>
<td>CD4+ count &gt;200 but &lt;250 cells/µL if monitoring</td>
<td></td>
<td>• Dapsone 50 mg PO daily + pyrimethamine 50 PO weekly + leucovorin 25 mg PO weekly (BII); or</td>
</tr>
<tr>
<td></td>
<td>CD4+ count every 1–3 mo is not possible (BIII)</td>
<td></td>
<td>• Aerosolized pentamidine 300 mg via Respirgard III nebulized every month (BII); or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Atovacuone 1500 mg PO daily (BII); or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Atovacuone 1500 mg + pyrimethamine 25 mg + leucovorin 10 mg PO daily (CIII)</td>
</tr>
<tr>
<td><em>Toxoplasma gondii</em> encephalitis</td>
<td>Toxoplasma IgG-positive patients with CD4+ count &lt;100 cells/µL (AII)</td>
<td>TMP-SMX 1 DS PO daily (AII)</td>
<td>• TMP-SMX 1 DSPOIW (BII); or</td>
</tr>
<tr>
<td></td>
<td>Seronegative patients receiving PCP prophylaxis not active against toxoplasmosis should have toxoplasma serology retested if CD4+ count declines to &lt;100 cells/µL (CIII)</td>
<td></td>
<td>• TMP-SMX 1 SS PO daily (BIII);</td>
</tr>
<tr>
<td></td>
<td>Prophylaxis should be initiated if seroconversion occurred (AII)</td>
<td></td>
<td>• Dapsone 50 mg PO daily + pyrimethamine 50 mg PO weekly + leucovorin 25 mg PO weekly (BII); or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• (Dapsone 200 mg + pyrimethamine 75 mg + leucovorin 25 mg) PO weekly (BIII);</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• (Atovacuone 1500 mg ± pyrimethamine 25 mg + leucovorin 10 mg) PO daily (CIII)</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em> infection (TB) (treatment of latent TB infection [LTBI])</td>
<td>(+) diagnostic test for LTBI, no evidence of active TB, and no prior history of treatment for active or latent TB (AII)</td>
<td>Isoniazid (INH) 300 mg PO daily (AII) or 900 mg PO biw (BII) for 9 mo—both plus pyridoxine 50 mg PO daily (BII)</td>
<td>• Rifampin (RIF) 600 mg PO daily × 4 mo (BIII); or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Isoniazid (INH) for 6 mo; or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Isoniazid (INH) 900 mg and Rifapentene (RPT) 900 mg weekly × 3 mo</td>
</tr>
</tbody>
</table>
## PROPHYLAXIS TO PREVENT FIRST EPISODE OF OPPORTUNISTIC DISEASE AMONG HIV-INFECTED ADULTS (Continued)

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-) diagnostic test for LTBI and</td>
<td>no evidence of active TB, but close contact with a person with infectious</td>
<td>For persons exposed to drug-resistant TB, selection of drugs after consultation</td>
<td>• RFB 300 mg PO daily (BI) (dosage adjustment based on drug–drug interactions with ART); rule out active TB</td>
</tr>
<tr>
<td>no evidence of active TB, but</td>
<td>pulmonary TB (AII)</td>
<td>with public health authorities (AII)</td>
<td>before starting RFB</td>
</tr>
<tr>
<td>close contact with a person with</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious pulmonary TB (AII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A history of untreated or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>inadequately treated healed TB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ie, old fibrotic lesions)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>regardless of diagnostic tests for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTBI and no evidence of active TB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(AII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disseminated</td>
<td>CD4+ count &lt;50 cells/µL—after ruling out active MAC infection (AI)</td>
<td>Azithromycin 1200 mg PO once weekly (AI); or Clarithromycin 500 mg PO bid (AI);</td>
<td></td>
</tr>
<tr>
<td><strong>Mycobacterium avium</strong> complex</td>
<td></td>
<td>or azithromycin 600 mg PO twice weekly (BIII)</td>
<td></td>
</tr>
<tr>
<td>(MAC) disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4+ count &gt;200 cells/µL and no</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>receipt of pneumococcal vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in the last 5 y (AII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4+ count &lt;200 cells/µL—vaccination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>can be offered (CIII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients who received</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>polysaccharide pneumococcal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vaccination (PPV) when CD4+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>count &lt;200 cells/µL but has</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>increased to &gt;200 cells/µL in</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>response to ART (CIII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td></td>
<td>23-valent PPV 0.5 mL IM × 1 (BII) Revaccination every 5 y may be considered</td>
<td></td>
</tr>
<tr>
<td>infection</td>
<td></td>
<td>(CIII)</td>
<td></td>
</tr>
</tbody>
</table>

(RFB = rifabutin; ART = antiretroviral therapy; MAC = Mycobacterium avium complex; LTBI = latent tuberculosis infection; PPV = pneumococcal polysaccharide vaccine; IM = intramuscular; PO = by mouth.)
<table>
<thead>
<tr>
<th>Disease and Vaccine Precautions</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza A and B virus infection</strong></td>
<td>All HIV-infected patients (All)</td>
</tr>
<tr>
<td>Inactivated influenza vaccine 0.5 mL IM annually (AllI)</td>
<td></td>
</tr>
<tr>
<td><strong>Histoplasma capsulatum infection</strong></td>
<td>CD4⁺ count &gt;150 cells/µL and at high risk because of occupational exposure or live in a community with a hyperendemic rate of histoplasmosis (&gt;10 cases/100 patient-y) (Cl)</td>
</tr>
<tr>
<td>Itraconazole 200 mg PO daily (Cl)</td>
<td></td>
</tr>
<tr>
<td><strong>Coccidioidomycosis</strong></td>
<td>Positive IgM or IgG serologic test in a patient from a disease-endemic area, and CD4⁺ count &lt;250 cells/µL (CIII)</td>
</tr>
<tr>
<td>Fluconazole 400 mg PO daily (CIII)</td>
<td></td>
</tr>
<tr>
<td>Itraconazole 200 mg PO bid (CIII)</td>
<td></td>
</tr>
<tr>
<td><strong>Varicella-zoster virus (VZV) infection</strong></td>
<td>Preexposure prevention: Patient with CD4⁺ count &gt;200 cells/µL who have not been vaccinated, have no history of varicella or herpes zoster, or who are seronegative for VZV (CIII)</td>
</tr>
<tr>
<td>Note: Routine VZV serologic testing in HIV-infected adults is not recommended</td>
<td></td>
</tr>
<tr>
<td>Preexposure prevention: Primary varicella vaccination (Varivax), 2 doses (0.5 mL SQ) administered 3 mo apart (CIII)</td>
<td></td>
</tr>
<tr>
<td>If vaccination results in disease because of vaccine virus, treatment with acyclovir is recommended (AllI)</td>
<td></td>
</tr>
<tr>
<td>Postexposure therapy: Varicella-zoster immune globulin (VZIG) 125 IU per 10 kg (maximum of 625 IU) IM, administered within 96 h after exposure to a person with active varicella or herpes zoster (AllI)</td>
<td></td>
</tr>
<tr>
<td>• VZV-susceptible household contacts of susceptible HIV-infected persons should be vaccinated to prevent potential transmission of VZV to their HIV-infected contacts (BIII)</td>
<td></td>
</tr>
<tr>
<td>Alternative postexposure therapy:</td>
<td></td>
</tr>
<tr>
<td>• Postexposure varicella vaccine (Varivax) 0.5 mL SQ × 2 doses, 3 mo apart if CD4⁺ count &gt;200 cells/µL (CIII); or</td>
<td></td>
</tr>
<tr>
<td>• Preemptive acyclovir 800 mg PO 5×/d for 5 d (CIII)</td>
<td></td>
</tr>
<tr>
<td>• These two alternatives have not been studied in the HIV population</td>
<td></td>
</tr>
</tbody>
</table>
### PROPHYLAXIS TO PREVENT FIRST EPISODE OF OPPORTUNISTIC DISEASE AMONG HIV-INFECTED ADULTS (Continued)

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human papillomavirus (HPV) infection</td>
<td>Women age 15–26 y (CIII)</td>
<td>HPV quadrivalent vaccine 0.5 mL IM months 0, 2, and 6 (CIII)</td>
<td>Note: As of June 2007, VZIG can be obtained only under a treatment IND (1-800-843-7477, FFF Enterprises)</td>
</tr>
<tr>
<td>Hepatitis A virus (HAV) infection</td>
<td>HAV-susceptible patients with chronic liver disease, or who are injection-drug users, or men who have sex with men (AII). Certain specialists might delay vaccination until CD4&lt;sup&gt;+&lt;/sup&gt; count &gt;200 cells/µL (CIII)</td>
<td>Hepatitis A vaccine 1 mL IM × 2 doses—at 0 and 6–12 mo (AII) IgG antibody response should be assessed 1 mo after vaccination; nonresponders should be revaccinated (BIII)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B virus (HBV) infection</td>
<td>All HIV patients without evidence of prior exposure to HBV should be vaccinated with HBV vaccine, including patients with CD4&lt;sup&gt;+&lt;/sup&gt; count &lt;200 cells/µL (AII) <em>Patients with isolated anti-HBc</em>: (BIII) (consider screening for HBV DNA before vaccination to rule out occult chronic HBV infection)</td>
<td>Hepatitis B vaccine IM (Engerix-B 20 µg/mL or Recombivax HB 10 µg/mL) at 0, 1, and 6 mo (AII) Anti-HBs should be obtained 1 mo after receipt of the vaccine series (BIII)</td>
<td>Some experts recommend vaccinating with 40-µg doses of either vaccine (CIII)</td>
</tr>
</tbody>
</table>
**Vaccine nonresponders:** Defined as anti-HBs <10 IU/mL 1 mo after a vaccination series. For patients with low CD4+ count at the time of first vaccination series, certain specialists might delay revaccination until after a sustained increase in CD4+ count with ART.

Revaccinate with a second vaccine series (BIII).

Some experts recommend revaccinating with 40 µg doses of either vaccine (CIII).

<table>
<thead>
<tr>
<th>Disease</th>
<th>Situation</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria</td>
<td>Travel to disease-endemic area</td>
<td>Recommendations are the same for HIV-infected and noninfected patients. One of the following three drugs is usually recommended, depending on location: atovaquone/proguanil, doxycycline, or mefloquine. Refer to the following website for the most recent recommendations based on region and drug susceptibility: <a href="http://www.cdc.gov/malaria/">http://www.cdc.gov/malaria/</a> (AII)</td>
</tr>
</tbody>
</table>

**BID,** twice daily; **BIW,** two times weekly; **DS,** double strength; **IM,** intramuscular; **PO,** by mouth; **SS,** single strength; **SQ,** subcutaneous; **TIW,** three times weekly.
CHAPTER 2

PROPHYLAXIS TO PREVENT FIRST EPISODE OF OPPORTUNISTIC INFECTIONS AMONG HIV-EXPOSED AND HIV-INFECTED INFANTS AND CHILDREN, UNITED STATES

<table>
<thead>
<tr>
<th>Preventive Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathogen</strong></td>
</tr>
<tr>
<td><strong>Pneumocystis pneumoniae</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Malaria</strong></td>
</tr>
<tr>
<td>Disease Prevention</td>
</tr>
<tr>
<td>--------------------</td>
</tr>
</tbody>
</table>
| • Mefloquine 5 mg/kg body weight orally 1 time weekly (max 250 mg)  
• Atovaquone/proguanil (Malarone) 1 time daily  
• 11–20 kg = 1 pediatric tablet (62.5 mg/25 mg)  
• 21–30 kg = 2 pediatric tablets (125 mg/50 mg)  
• 31–40 kg = 3 pediatric tablets (187.5 mg/75 mg)  
• >40 kg = 1 adult tablet (250 mg/100 mg) |
| Mycobacterium tuberculosis | Tuberculin skin test (TST) reaction >5 mm or prior positive TST result without treatment, regardless of current TST result |
| Isoniazid-sensitive | • Isoniazid 10–15 mg/kg body weight (max 300 mg) orally daily for 9 mo (AII); or 20–30 mg/kg body weight (max 900 mg) orally 2 times weekly for 9 mo (BII) |
| Isoniazid-resistant | • Rifampin 10–20 mg/kg body weight (max 600 mg) orally daily for 4–6 mo (BIII) |
| Isoniazid-sensitive | TST result and previous treatment, close contact with any person who has Contagious TB. TB disease must be excluded before start of treatment |
| Isoniazid-resistant | Same as previous pathogen; increased probability of exposure to isoniazid-resistant TB |
| | • Rifampin 10–20 mg/kg body weight (max 600 mg) orally daily for 4–6 mo (BIII) |
| | • Uncertain |
**Preventive Regimen**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multidrug-resistant (isoniazid and rifampin)</td>
<td>Same as previous pathogen; increased probability of exposure to multidrug-resistant TB</td>
<td>• Choice of drugs requires consultation with public health authorities and depends on susceptibility of isolate from source patient</td>
<td></td>
</tr>
<tr>
<td><strong>Mycobacterium avium complex</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>For children age &gt;6 y with CD4 count of &lt;50 cells/mm&lt;sup&gt;3&lt;/sup&gt;; age 2–5 y with CD4 count of &lt;75 cells/mm&lt;sup&gt;3&lt;/sup&gt;; age 1–2 y with CD4 count of &lt;500 cells/mm&lt;sup&gt;3&lt;/sup&gt;; age &lt;1 y with CD4 count of &lt;750 cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>• Clarithromycin 7.5 mg/kg body weight (max 500 mg) orally 2 times daily (AII), or azithromycin 20 mg/kg body weight (max 1200 mg) orally weekly (AII)</td>
<td>• Azithromycin 5 mg/kg body weight (max 250 mg) orally daily (AII); children age &gt;6 y, rifabutin 300 mg orally daily (BI)</td>
</tr>
<tr>
<td><strong>Varicella-zoster virus</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Substantial exposure to varicella or shingles with no history of varicella or zoster or seronegative status for VZV by a sensitive, specific antibody assay or lack of evidence for age-appropriate vaccination</td>
<td>• VZIG 125 IU per 10 kg (max 625 IU) IM, administered within 96 h after exposure&lt;sup&gt;c&lt;/sup&gt; (AIII)</td>
<td>• If VZIG is not available or &gt;96 h have passed since exposure, some experts recommend prophylaxis with acyclovir 20 mg/kg body weight (max 800 mg) per dose orally 4 times a day for 5–7 d. Another alternative to VZIG is intravenous immune globulin (IVIG), 400 mg/kg, administered once. IVIG should be administered within 96 h after exposure (CIII)</td>
</tr>
<tr>
<td><strong>Vaccine-preventable pathogens</strong></td>
<td>Standard recommendations for HIV-exposed and HIV-infected children</td>
<td>Routine vaccinations</td>
<td></td>
</tr>
</tbody>
</table>
### Toxoplasma gondii

**Immunoglobulin G (IgG) antibody to Toxoplasma and severe immunosuppression:** HIV-infected children age <6 y with CD4 15%; HIV-infected children age >6 y with CD4 100 cells/mm³

- TMP-SMX, 150/750 mg/m² body surface area daily orally in 2 divided doses (BIII)
- Acceptable alternative dosage schedules for same dosage (AI): single dose orally 3 times weekly on consecutive days; 2 divided doses orally daily; or 2 divided doses orally 3 times weekly on alternate days
- Dapsone (children age >1 mo) 2 mg/kg body weight or 15 mg/m² body surface area (max 25 mg) orally daily; pyrimethamine 1 mg/kg body weight (max 25 mg) orally daily; leucovorin 5 mg orally every 3 d (BII)
- Atovaquone (children age 1–3 mo and >24 mo, 30 mg/kg body weight orally daily; children age 4–24 mo, 45 mg/kg body weight orally daily) with or without pyrimethamine 1 mg/kg body weight or 15 mg/m² body surface area (max 25 mg) orally daily; leucovorin 5 mg orally every 3 d (CIII)

### Invasive bacterial infection

**Hypogammaglobulinemia (ie, IgG <400 mg/dL)**

- IVIG (400 mg/kg body weight every 2–4 wk) (AI)

### Cytomegalovirus (CMV)

**CMV antibody positivity and severe immunosuppression (CD4 <50 cells/mm³)**

- Valganciclovir 900 mg orally 1 time daily with food for older children who can receive adult dosing (CIII)

---

**Abbreviations:** CMV, cytomegalovirus; FDA, Food and Drug Administration; HIV, human immunodeficiency virus; IgG, immunoglobulin G; IM, intramuscularly; IVIG, intravenous immune globulin; PCP, Pneumocystis pneumonia; TB, tuberculosis; TMP-SMX, trimethoprim-sulfamethoxazole; TST, tuberculin skin test; VZV, varicella-zoster virus.

**Letters and roman numerals in parentheses indicate the strength of the recommendation and the quality of the evidence supporting it.**

**Daily trimethoprim-sulfamethoxazole (TMP-SMX) reduces the frequency of certain bacterial infections. TMP-SMX, dapsone-pyrimethamine, and possibly atovaquone (with or without pyrimethamine) protect against toxoplasmosis; however, data have not been prospectively collected. Compared with weekly dapsone, daily dapsone is associated with lower incidence of PCP but higher hematologic toxicity and mortality. Patients receiving therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against PCP and do not need TMP-SMX.**

**Substantial drug interactions can occur between rifamycins (ie, rifampin and rifabutin) and protease inhibitors and nonnucleoside reverse transcriptase inhibitors. A specialist should be consulted.**

**Children routinely being administered IVIG should receive VZIG if the last dose of IVIG was administered >21 d before exposure.**

**As of 2007, VZIG can be obtained only under a treatment investigational New Drug protocol.**

**Protection against toxoplasmosis is provided by the preferred anti-Pneumocystis regimens and possibly by atovaquone.**
HYPERTENSION (HTN)

Population
– Persons at risk for developing HTN.

Recommendations

  - Recommend weight loss, reduced sodium intake, moderate alcohol consumption, increased physical activity, potassium supplementation, and modification of eating patterns.
  - Above the normal replacement levels, supplementation of K, Ca, and Mg is not recommended for the prevention or treatment of HTN.

Sources
– Hypertension Canada
– JAMA. 2014;311(5):507-520
– Eur Heart J. 2013;34:2159-2219

Population
– Patients age >65 y.

Recommendation

- ACCF/AHA 2011
  - Lifestyle management is effective in all ages.

Source

Comments

1. A 5 mm Hg reduction in systolic blood pressure in the population would result in a 14% overall reduction in mortality from stroke, a 9% reduction in mortality from CHD, and a 7% decrease in all-cause mortality.
2. Weight loss of as little as 10 lb (4.5 kg) reduces blood pressure and/or prevents HTN in a large proportion of overweight patients.

a Family history of HTN; African American (black race) ancestry; overweight or obesity; sedentary lifestyle; excess intake of dietary sodium; insufficient intake of fruits, vegetables, and potassium; excess consumption of alcohol.
b Canadian Hypertension Education Program.
LIFESTYLE MODIFICATIONS FOR PREVENTION OF HYPERTENSION

• Maintain a healthy body weight for adults (BMI, 18.5–24.9 kg/m²; waist circumference <102 cm for men and <88 cm for women).
• Reduce dietary sodium intake to no more than 100 mmol/d (approximately 6 g of sodium chloride or 2.4 g of sodium/d). Per CHEP 2015: adequate intake 2000 mg daily (all >19 y old) (80% in processed foods; 10% at the table or in cooking). 2000 mg sodium (Na) = 87 mmol sodium (Na)= 5 g of salt (NaCl) ~1 teaspoon of table salt.
• Engage in regular aerobic physical activity, such as brisk walking, jogging, cycling, or swimming (30–60 min per session, 4 –7 d/wk), in addition to the routine activities of daily living. Higher intensities of exercise are not more effective. Weight training exercise does not adversely influence BP.
• Limit alcohol consumption to no more than 2 drinks (eg, 24 oz [720 mL] of beer, 10 oz [300 mL] of wine, or 3 oz [90 mL] of 100-proof whiskey) per day in most men and to no more than one drink per day in women and lighter-weight persons.
• Maintain adequate intake of dietary potassium (>90 mmol [3500 mg]/d). Above the normal replacement levels, supplementation of potassium, calcium, and magnesium is not recommended for prevention or treatment of hypertension.
• Daily K dietary intake > 80 mmol
• Consume a diet that is rich in fruits and vegetables and in low-fat dairy products with a reduced content of saturated and total fat (Dietary Approaches to Stop Hypertension [DASH] eating plan).
• Advice in combination with pharmacotherapy (varenicline, bupropion, nicotine replacement therapy) should be offered to all smokers with a goal of smoking cessation.
• Stress management should be considered as an intervention in hypertensive patients in whom stress may be contributing to BP elevation.

IMMUNIZATIONS, ADULTS

Population
- Adults.

Recommendation
- CDC 2013
  - Recommends immunizing adults according to the Centers for Disease Control and Prevention (CDC) recommendations unless contraindicated (see Appendix IX).

Source
- CDC: Adult Immunization Schedule

IMMUNIZATIONS, INFANTS AND CHILDREN

Population
- Infants and children age 0–18 y.

Recommendation
- CDC 2013
  - Recommends immunizing infants and children according to the CDC recommendations unless contraindicated (see Appendix IX).

Sources
- CDC: Child and Adolescent Schedule
- CDC: Catch-Up Immunization Schedule

INFLUENZA, CHEMOPROPHYLAXIS

Population
- Children and adults.

Recommendation
- AAP 2016
  - The following situations warrant chemoprophylaxis
    1. Children at high risk for complications who cannot receive vaccine, or within 2 wk of receiving vaccine.
    2. Family members or health care providers who are unimmunized and likely to have ongoing exposure to high-risk or unimmunized children younger than 24 mo of age.
    3. Unimmunized staff and children in an institutional setting during an outbreak.
5. Post-exposure prophylaxis for close contacts of infected person who are at high risk of complications.
6. Children at high risk and their close contacts if circulating viral strains are not well matched by vaccine.

IDSA 2009, CDC 2011, AAP 2016

1. Consider antiviral chemoprophylaxis for adults and children age >1 y at high risk of influenza complications (see the Influenza, Vaccination section) when any of the following conditions are present:
   a. Influenza vaccination is contraindicated (anaphylactic hypersensitivity to eggs, acute febrile illness, history of Guillain-Barré syndrome within 6 wk of a previous influenza vaccination.)
   b. Unvaccinated adults or children when influenza activity has been detected in the community. Vaccinate simultaneously.
   c. Unvaccinated adults and children in close contact with people diagnosed with influenza.
   d. Residents of extended-care facilities with an influenza outbreak.

Sources
– CID 2009;48:1003-32
– CDC: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

Comments
1. Influenza vaccination is the best way to prevent influenza.
2. Antiviral chemoprophylaxis is not a substitute for influenza vaccination.
3. Agents for chemoprophylaxis of influenza A (H1N1) and B: zanamivir or oseltamivir.
4. Children at high risk of complications include those with chronic diseases such as asthma, diabetes, cardiac disease, immune suppression and neurodevelopmental disorders.

INFLUENZA, VACCINATION

Population
– All persons age >6 mo.

Recommendations
CDC 2016, AAP 2016

1. All persons age >6 mo should receive the seasonal influenza vaccine annually.
2. All children age 6 mo to 8 y should receive 2 doses of the vaccine (>4 wk apart) during their first season of vaccination.
3. The live attenuated influenza vaccine (Flumist quadrivalent) should not be used due to low efficacy.
Comment

1. Highest-risk groups for influenza complications are:
   - Pregnant women.
   - Children age 6 mo to 5 y.
   - Adults age >50 y.
   - Persons with chronic medical conditions.¹
   - Residents of extended-care facilities.
   - Morbidly obese (BMI >40) persons.
   - Health care personnel.
   - Household contacts of persons with high-risk medical conditions or caregivers of children age <5 y or adults age >50 y.
   - Children and adolescents receiving long-term aspirin therapy.
   - American Indians or Alaska Natives.

KIDNEY INJURY, ACUTE

Population

- Adults and children.

Recommendations

NICE 2013, VA/DoD 2014

- Recommend volume expansion to at risk adults who will receive intravenous iodinated contrast.
  - CKD with eGFR <40 mL/min.
  - CHF.
  - Renal transplant.
  - 75 y or over.
- Consult a pharmacist to assist with drug dosing in adults or children at risk for AKI.

Sources


¹Chronic heart, lung, renal, liver, hematologic, cancer, neuromuscular, or seizure disorders, severe cognitive dysfunction, diabetes, HIV infection, or immunosuppression.
**DISEASE PREVENTION**

Comment
--Inconsistent evidence for N-acetylcysteine use to prevent contrast-induced nephropathy.

**MOTOR VEHICLE INJURY**

**Population**
--Infants, children, and adolescents.

**Recommendations**

---ICSI 2013
1. Providers should ask the family about the use of car seats, booster seats, and seat belts.
2. Ask children and adolescents about helmet use in recreational activities.

**Source**

**Comments**
1. Head injury rates are reduced by approximately 75% in motorcyclists who wear helmets compared with those who do not.
2. Properly used child restraint systems can reduce mortality up to 21% compared with seat belt usage in children age 2–6 y.

**Population**
--Elderly.

**Recommendation**

---EAST 2015
--Screen for risk factors for MVC-related injury (alcohol abuse, frailty, DM, hearing impairment, visual impairment, CAD).

**Source**
--J Trauma Acute Care Surg. 2015;79(1):152

**Comment**
--Behavioral interventions (ie, seat-belt reminder signs near senior centers) improve safety practices.
CHAPTER 2

MYOCARDIAL INFARCTION (MI), ASPIRIN THERAPY

Population

- Asymptomatic adults.

Recommendations

► ACCP 2012, USPSTF 2016

- Age 50–59 y: Initiate aspirin if 10-y CVD risk is >10%, life expectancy is >10 y, and willing to take low-dose aspirin consistently for 10 y.
- Age 60–69 y: “Consider” aspirin if 10-y CVD risk is >10%, especially if at low risk for bleeding, have life expectancy > 10 y, and are willing to take aspirin consistently for 10 y (fewer MIs are prevented and more GI bleeds are provoked compared to the 50–59 y age group).
- Age <50 y: evidence insufficient, benefit likely less because CVD risk is likely lower.
- Age >70 y: evidence insufficient, risk of bleeding increases significantly.

► FDA 2016

- Data do not support the general use of aspirin for primary prevention of a heart attack or stroke. Aspirin is associated with “serious risks,” including increased risk of intracerebral and GI bleeding.

Sources

- USPSTF: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. 2016.
- Chest. 2012;141(2 Suppl):e637S-68S.

Comments

- ACC/AHA “ABCS” of primary prevention presents risk reduction for ASCVD for mainstays of primary prevention: Aspirin therapy in appropriate patients (RR 0.90), Blood pressure control (RR 0.84 for CHD, 0.64 for Stroke), Cholesterol management (RR 0.75) and Smoking cessation (RR 0.73). JACC. 2017;69(12):1617-1636.
- Risks of aspirin therapy: hemorrhagic stroke and GI bleeding (risk factors include age, male sex, GI ulcers, upper GI pain, concurrent NSAID/anticoagulant use, and uncontrolled hypertension).
- Establish risk factors by the ACC/AHA pooled cohort equation in all adults.
In a report showing a 50% reduction in the population’s CHD mortality rate, 81% was attributable to primary prevention of CHD through tobacco cessation and lipid- and blood pressure-lowering activities. Only 19% of CHD mortality reduction occurred in patients with existing CHD (secondary prevention). *BMJ*. 2005;331:614.

**MYOCARDIAL INFARCTION (MI), DIETARY THERAPY**

**Population**

– All adults.

**Recommendations**

▶ AHA/ACC 2013, ESC 2012, AHA/ACCF 2011

– Dietary guidelines: (1) Balance calorie intake and physical activity to achieve or maintain a healthy body weight. (2) Consume diet rich in vegetables and fruits. (3) Choose whole grain, high-fiber foods. (4) Consume fish, especially oily fish, at least twice a week. (5) Limit intake of saturated fats to <7% energy, trans fats to <1% energy, and cholesterol to <300 mg/d by:
  - Choosing lean meats and vegetable alternatives.
  - Selecting fat-free (skim), 1% fat, and low-fat dairy products.
  - Minimizing intake of partially hydrogenated fats. (6) Minimize intake of beverages and foods with added sugars. (7) Choose and prepare foods with little or no salt. (8) If you consume alcohol, do so in moderation. (9) Follow these recommendations for food consumed/prepared inside and outside of the home.

– Recommended diets: DASH, USDA Food Pattern, or AHA Diet. *Avoid use of and exposure to tobacco products.*

▶ CCS 2012

– The Mediterranean, Portfolio, or DASH diets are recommended to improve lipid profiles or decrease cardiovascular disease (CVD) risk.

**Sources**


MYOCARDIAL INFARCTION (MI), STATIN THERAPY

Population
- Asymptomatic adults.

Recommendations

ACC/AHA 2013
- 10-y ASCVD risk score (updated ATP III guidelines): 3 high-risk groups identified, based on ASCVD score and LDL-C levels.
- Lifestyle management and drug therapy recommended in all three categories.
- Statin drugs remain the treatment of choice based upon outcome data.
- For therapy see Chapter 3 (page 258).

Source

Cochrane 2011
- Statin therapy should be employed in primary prevention only in high-risk patients (Framingham risk >20%).
- Restraint should be exercised in patients at low or intermediate 10-y risk (<10%; 10%-20%).
- If low or intermediate 10-y risk, calculate lifetime risk to better assess benefit of statin therapy.

Sources
- Cochrane Database Syst Rev. 2011;(1):CD004816
- Circulation. 2006;113:791-798
ACP 2004

- Statins should be used for primary prevention of macrovascular complications if patient has type 2 DM and other CV risk factors (age >55 y, left ventricular hypertrophy, previous cerebrovascular disease, peripheral arterial disease, smoking, or HTN).

**Comments**

2. Statin therapy can safely reduce the 5-y incidence of major CVD events (coronary revascularization, stroke) by about one-fifth per mmol/L reduction in LDL cholesterol. (*Lancet.* 2005;366(9493):1267-1278)

**CCS 2013**

- An increased risk of new-onset type 2 diabetes might apply to statin therapy. A recent review of the existing data suggest that potential mechanisms include increased insulin levels, reduced insulin sensitivity, and selection bias. However, the overall data strongly suggest that the reduction in CVD events outweighs the minor effect on glucose homeostasis.

**Source**


**Society of General Internal Medicine 2015**

- Statin use was associated with an increased likelihood of new diagnoses of DM, diabetic complications, and overweight/obesity in healthy people taking statin for primary prevention.

**Source**


**FDA Warning 2012, CCS 2013**

- Statins may cause nonserious reversible cognitive side effects as well as increased blood sugar and HbA1c levels.

**Sources**

Population
   - History of CVA.

Recommendation
   - AHA/ASA 2012
     - Large-vessel ischemic stroke is a CHD risk. Small-vessel disease, may be considered CHD risk equivalent.

Source

Comment
   - Meta-analysis concludes ASA prophylaxis reduces ischemic stroke risk in women (−17%) and MI events in men (−32%). No mortality benefit is seen in either group. Risk of bleeding is increased in both groups to a similar degree as the event rate reduction. Initiation of therapy based on a case by case basis. (*JAMA*. 2006;295:306-313) (*Arch Intern Med*. 2012;172:209-216)

---

MYOCARDIAL INFARCTION (MI), SPECIAL POPULATIONS

Population
   - Adults with HTN.

Recommendations
   - JNC 8, 2013
     - See Chapter 3, page 360 for JNC 8 treatment algorithms.

Source
   - *JAMA*. 2014;311(5):507-520

     - Goal: blood pressure (BP) <140/90 mm Hg for population with stable CAD.
     - BP target <140/90 mm Hg is reasonable for the secondary prevention of CV events in patients with HTN and CAD. Class IIa, level of evidence, B.
     - BP target <130/80 mm Hg may be appropriate in some individuals with CAD, previous MI, stroke or TIA, or CAD risk equivalents (carotid artery disease, PAD, abdominal aortic aneurysm). Class IIb, level of evidence, B.
     - In patients with an elevated DBP and CAD with evidence of myocardial ischemia, BP should be lowered slowly, and caution is advised in inducing decreases in DBP <60 mm Hg in any patients with DM or
who is >60 y. In older hypertensive patients with wide pulse pressures, lowering SBP may cause very low DBP values <60 mm Hg. This should alert clinicians to assess carefully any untoward signs or symptoms, especially those resulting from myocardial ischemia. Class IIa, level of evidence, C.

–If ventricular dysfunction is present, lowering the goal to 120/80 mm Hg may be considered.

Sources
–Circulation. 2007;115:2761-2788
–Circulation. 2012;26:3097-3137

►CHEP 2015, ESC 2014
–Recommends low-dose ASA for vascular protection, in hypertensive patients ≥ 50 y; caution should be exercised if BP is not controlled.
–Low-dose ASA for hypertensives with h/o CV events; consider in hypertensives without prior history who are at higher risk

Sources
–Hypertension Canada: https://guidelines.hypertension.ca

►ESC/ECH 2013
–<130/80 mm Hg goal in diabetics and other high-risk patients has not been supported by trials. No benefit and possible harm is suggested with SBP <130 mm Hg.
–Elderly patients’ SBP goal is <160 mm Hg.

Source
–J Hypertens. 2013;31:1281-1357

Population
–Diabetes mellitus.

Recommendation
►ADA 2014
–Lipid Goals: Normal fasting glucose (≤130 mg/dL) and HbA1c (<7.5%), BP <140/80 mm Hg; low-density-lipoprotein cholesterol (LDL-C) <100 mg/dL (or <70 for high risk), high-density-lipoprotein cholesterol (HDL-C) >50 mg/dL and triglycerides <150 mg/dL.
–Consider ASA (75–162 mg/d) if at increased CV risk (10-y > 10% based on Framingham risk score (see Chapter 4, pages 536–539), and in men age >50 y or women age >60 y with one additional risk factor.
Sources

Population
– Smoking.

Recommendation
▶ AHA 2006, ADA 2014
– Advise all patients not to smoke.

Sources
– *Diabetes Care.* 2014;37(1)
– *Circulation.* 2006;114:82-96

Comments
1. Intensive glucose lowering should be avoided in patients with a history of hypoglycemic spells, advanced microvascular or macrovascular complications, long-standing DM, or if extensive comorbid conditions are present.
2. DM with BP readings of 130–139/80–89 mm Hg that persist after lifestyle and behavioral therapy should be treated with angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) agents. Multiple agents are often needed. *Administer at least one agent at bedtime.*

Recommendation
▶ ESC 2012
– Avoid passive smoking.

Source
– *Eur Heart J.* 2012;33:1635-1701

Comment
– New evidence on the health effects of passive smoking strengthens the recommendation on passive smoking. Smoking bans in public places, by law, lead to a decrease in incidence of myocardial infarction.
**DISEASE PREVENTION**

**Population**
- Women.

**Recommendations**

**AHA 2011**
- Standard CVD lifestyle recommendations, plus:
  - Waist circumference <35 in.
  - Omega-3 fatty acids if high risk (EPA 1800 mg/d).\(^a\)
  - BP <120/80 mm Hg.
  - Lipids: LDL-C <100 mg/dL, HDL-C >50 mg/dL, triglycerides <150 mg/dL.
  - ASA (75–325 mg/d) indicated only in high-risk women.\(^a\)
- In women age >65 y, consider ASA (81 mg daily or 100 mg every other day) if BP is controlled and the benefit of ischemic stroke and MI prevention is likely to outweigh the risk of a GI bleed and hemorrhagic stroke.

**Source**
- *J Am Coll Cardiol*. 2011;57(12):1404-1423

**Comments**
1. Estrogen plus progestin hormone therapy should not be used or continued.
2. Antioxidants (vitamins E and C, and β-carotene), folic acid, and B\(_{12}\) supplementation are not recommended to prevent CHD.
3. ASA is not indicated to prevent MI in low-risk women age <65 y.

**Population**
- Adults at risk of CV disease.

**Recommendations**

**ESC 2007, ESC 2012**
- Smoking cessation.
- Weight reduction if BMI >25 kg/m\(^2\) or waist circumference >88 cm in women and >102 cm in men.
- No further weight gain if waist circumference 80–88 cm in women and 94–102 cm in men.
- Thirty minutes of moderately vigorous exercise on most days of the week.
- Healthy diet.
- Antihypertensives when BP >140/90 mm Hg. Statins when total cholesterol >190 mg/dL or LDL >115 mg/dL.
- In patients with known CV disease: ASA and statins.
- In patients with DM: glucose-lowering drugs.

\(^a\)High risk: CHD or risk equivalent or 10-y absolute CHD risk >20% based on Framingham risk score (see Appendix VI, pages 536–539).
–Psychosocial risk factor. 
–Low socioeconomic status, lack of social support, stress at work and in family life, depression, anxiety, hostility, and the type D personality contribute both to the risk of developing CVD and the worsening of clinical course and prognosis of CVD. These factors act as barriers to treatment adherence and efforts to improve lifestyle, as well as to promoting health and well-being in patients and populations. In addition, distinct psychobiologic mechanisms have been identified, which are directly involved in the pathogenesis of CVD. 
–Psychological interventions can counteract psychosocial stress and promote healthy behaviors and lifestyle. 
–Cognitive-behavioral methods are effective in supporting persons in adopting a healthy lifestyle. 
–More evidence on the impact of total diet/dietary patterns such as the Mediterranean type of diet has gained interest in recent years. 
–Antihypertensive treatment is beneficial in patients age >80 y. 
–Aspirin is no longer recommended for primary prevention in people with diabetes. 
–Nurse-coordinated prevention programs are effective across a variety of practice settings. 

Sources
–Eur Heart J. 2007;28:2375
–Eur Heart J. 2012;33:1635-1701

Comment
–European Society of Cardiology recommends using the SCORE Risk System to estimate risk of atherosclerotic CV disease.

NEURAL TUBE DEFECTS

Population
–Women of childbearing age.

Recommendation
–Women should take a daily supplement containing 400–800 µg of folic acid if planning or capable of pregnancy.

Sources
–JAMA. 2017;317(2):183-189
Comments

1. Folic acid supplementation should start at least 1 mo before conception and continue through the first 2–3 mo of pregnancy.
2. The CDC, ACOG, AAFP and AAP recommend 4 mg/d folic acid for women with a history of a child affected by a neural tube defect.

OBESITY

Population

– Adolescents and adults.

Recommendations

1. Recommends a team approach for weight management in all persons of normal weight (BMI 18.5–24.9) or overweight (BMI 25–29.9) including:
   b. Physical activity.
   c. Lifestyle changes.
   d. Screen for depression.
   e. Screen for eating disorders.
   f. Review medication list and assess if any medications can interfere with weight loss.
2. Recommends regular follow-up to reinforce principles of weight management.

Source


Comments

1. Recommend 30–60 min of moderate physical activity on most days of the week.
2. Nutrition education focused on decreased caloric intake, encouraging healthy food choices, and managing restaurant and social eating situations.
3. Weekly weight checks.
4. Encourage nonfood rewards for positive reinforcement.
5. Stress management techniques.
6. 5–10% weight loss can produce a clinically significant reduction in heart disease risk.
Population
– Children.

Recommendations
Endocrine Society 2017
1. Educate children and parents about healthy diets and the importance of regular physical activity.
2. Encourage school systems to promote healthy eating habits and provide health education courses.
3. Foster healthy sleep patterns.
4. Balance screen time with opportunities for physical activity.
5. Clinicians should help educate families and communities about healthy dietary and activity habits.

Source

Comments
1. Avoid the consumption of calorie-dense, nutrient-poor foods (eg, juices, soft drinks, “fast food” items, and calorie-dense snacks).
   Consume whole fruits rather than juices.
2. Control calorie intake by portion control.
3. Reduce saturated dietary fat intake for children age >2 y.
4. Increase dietary fiber, fruits, and vegetables.
5. Eat regular, scheduled meals and avoid snacking.
6. Limit television, video games, and computer time to 2 h daily.

OSTEOPOROTIC HIP FRACTURES

Population
– Postmenopausal women.

Recommendation
USPSTF 2012
– Recommends against the routine use of combined estrogen and progestin for the prevention of osteoporotic fractures.

Population
– Postmenopausal women who have had a hysterectomy.

Recommendation
USPSTF 2012
– Recommends against the routine use of estrogen for the prevention of osteoporotic fractures in postmenopausal women who have had a hysterectomy.
DISEASE PREVENTION

Source

Comment
– The results of studies including the WHI and the Heart and Estrogen/Progestin Replacement Study reveal that HRT probably reduces osteoporotic hip and vertebral fractures and may decrease the risk of colon CA; however, HRT may lead to an increased risk of breast CA, stroke, cholecystitis, dementia, and venous thromboembolism. HRT does not decrease the risk of coronary artery disease (CAD).

OTITIS MEDIA

Population
– Children 6 mo to 12 y.

Recommendations
➤ AAP 2013
– Do not use prophylactic antibiotics to reduce the frequency of episodes of AOM in children with recurrent AOM.
– Exclusive breast-feeding for at least the first 6 mo of life.
– Vaccines recommended for all children to prevent bacterial AOM:
  • Pneumococcal vaccine.
  • Influenza vaccine.
  • Avoid tobacco exposure.

Source

POSTPARTUM HEMORRHAGE

Population
– Pregnant women.

Recommendations
➤ WHO 2012
– Uterotonic medications should be given to all women during the third stage of labor.
  • Oxytocin 10 IU, IV, or IM is first choice.
  • Methylergometrine or oral/rectal misoprostol is the alternative.
– Controlled cord traction is recommended for removal of the placenta.
Source

PREECLAMPSIA

Population
– Pregnant women at increased risk of preeclampsia.

Recommendation
– USPSTF 2014
  – Use of aspirin 81 mg/d after 12th wk of gestation in women with ≥ 1 major risk factor for preeclampsia.

Source
– Ann Intern Med. 2014;161:819-826

Comment

PRETERM BIRTH

Population
– Pregnant women.

Recommendations
– ACOG 2012
  – Advise against the use of maintenance tocolytics to prevent preterm birth.
  – Avoid antibiotics for the purpose of prolonging gestation or improving neonatal outcome in preterm labor and intact membranes.
  – In women with prior spontaneous preterm delivery, progesterone therapy should be started between 16–24 wk gestation.

Source

Comments
– No evidence to support the use of prolonged tocolytics for women with preterm labor.
– No evidence to support strict bed rest for the prevention of preterm birth.
– The positive predictive value of a positive fetal fibronectin test or a short cervix for preterm birth is poor in isolation.
PRESSURE ULCERS

Population
- Adults or children with impaired mobility.

Recommendations

NICE 2014, ACP 2015
1. Recommend a risk assessment of all persons in both outpatient and inpatient settings (eg, the Braden Scale in adults and Braden Q Scale in children).
2. Recommend education of patient, family, and caregivers regarding the causes and risk factors of pressure ulcers.
3. Recommend caution when using compression stockings with lower-extremity arterial disease.
4. Avoid thigh-high stockings when compression stockings are used.
   a. Avoid dragging patient when moving.
   b. Pad skin-to-skin contact.
   c. Lubricate or powder bed pans prior to placing under patient.
   d. Keep skin moisturized.
5. Recommend minimizing pressure on skin, especially areas with bony prominences.
   a. Turn patient side-to-side every 2 h.
   b. Pad areas over bony prominences.
   c. Use heel protectors or place pillows under calves.
   d. Consider a bariatric bed for patients weighing over 300 lb.
   e. Consider high-specification foam (not air) mattress for high-risk patients admitted to secondary care or who are undergoing surgery.
6. Recommend managing moisture.
   a. Moisture barrier protectant on skin.
   b. Frequent diaper changes.
   c. Scheduled toileting.
   d. Treat candidiasis if present.
   e. Consider a rectal tube for stool incontinence with diarrhea.
7. Recommend maintaining adequate nutrition and hydration.
8. Recommend keeping the head of the bed at or <30° elevation.

Sources
### Comment

1. Outpatient risk assessment for pressure ulcers:
   a. Is the patient bed or wheelchair bound?
   b. Does the patient require assistance for transfers?
   c. Is the patient incontinent of urine or stool?
   d. Any history of pressure ulcers?
   e. Does the patient have a clinical condition placing the patient at risk for pressure ulcers?
      i. DM.
      ii. Peripheral vascular disease.
      iii. Stroke.
      iv. Polytrauma.
      v. Musculoskeletal disorders (fractures or contractures).
      vi. Spinal cord injury.
      viii. Multiple sclerosis.
      ix. CA.
      x. Chronic obstructive pulmonary disease.
      xi. Coronary heart failure.
      xii. Dementia.
      xiii. Preterm neonate.
      xiv. Cerebral palsy.
   f. Does the patient appear malnourished?
   g. Is equipment in use that could contribute to ulcer development (e.g., oxygen tubing, prosthetic devices, urinary catheter)?

### SEXUALLY TRANSMITTED INFECTIONS (STIS)

#### Population

- Sexually active adolescents and high-risk adults.

#### Recommendation

- **USPSTF 2014**

  - Recommend high-intensity behavioral counseling to prevent STIs for all sexually active adolescents and for adults at increased risk for STIs. Include basic information about STIs, condom use, communication about safe sex, problem solving, and goal setting.

#### Source

- USPSTF: Sexually Transmitted Infections. 2014.
**STROKE**

**Population**
- Adults.

**Recommendations**
- **AHA/ASA 2011**
  - Treat known CV risk factors.*

- **FDA 2014**
  - FDA does not support the general use of aspirin for primary prevention of strokes or heart attacks, given risk of cerebral and gastrointestinal bleeding.

**Sources**
- FDA Consumer Updates 2014: https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm
- *Stroke.* 2011;42:517-584

---

**STROKE, ATRIAL FIBRILLATION**

**Population**
- Atrial fibrillation.

**Recommendations**
- **AHA/ACC 2014, 2015**
  1. Prioritize rate control; consider rhythm control if this is the first event, and if it occurs in a young patient with minimal heart disease or if symptomatic.
  2. Rate control goal is <110 beats/min in patients with stable ventricular function (ejection fraction [EF] >40%).
  3. Antithrombotic therapy is required. Anticoagulation or antiplatelet therapy is determined by ACC/AHA or CHA2DS2VASc (nonvalvular atrial fibrillation) guidelines.
  4. For patients with AF who have mechanical valves, warfarin is recommended with an INR target of 2–3 or 2.5–3.5, depending on the type and location of prosthesis.
  5. For patients with non-valvular AF with a history of stroke, TIA or CHA2DS2VASc ≥2, oral anticoagulation is recommended: warfarin (INR: 2–3) or DOACs (novel oral anticoagulation agents)—see treatment.

*Major modifiable risk factors: hypertension, cigarette smoke exposure, diabetes, atrial fibrillation, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, obesity.
6. In patients treated with warfarin, INR should be performed weekly until INR is stable and at least monthly when INR is in range and stable.

7. Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be reevaluated when clinically indicated and at least annually.

8. Initially clinicians should identify low-risk AF patients who do not require antithrombotic therapy (CHA\textsubscript{2}DS\textsubscript{2}VASc score, 0 for men, 1 for women). Patients with at least 1 risk factor (except when the only risk is being a woman) should be offered OAC. The patient's individual risk of bleeding should be addressed (BP control, discontinuing unnecessary medications such as ASA or non-steroidal anti-inflammatory drugs).

9. In non-valvular AF with CHA\textsubscript{2}DS\textsubscript{2}VASc = 0 no antithrombotic therapy or treatment with ASA or an OAC may be considered.

10. Following coronary revascularization (PCI or surgical) in patients with CHA\textsubscript{2}DS\textsubscript{2}VASc ≥2, may be reasonable to use Clopidogrel with OAC but without ASA.

Sources

Comments
1. Strokes and nonfatal strokes are reduced in diabetic patients by lower BP targets (<130/80 mm Hg). In the absence of harm, this benefit appears to justify the lower BP goal.

2. Average stroke rate in patients with risk factors is approximately 5% per year.

3. Adjusted-dose warfarin and antiplatelet agents reduce absolute risk of stroke.

4. Women have a higher prevalence of stroke than men.

5. Women have unique risk factors for stroke, such as pregnancy, hormone therapy, and higher prevalence of hypertension in older ages.

Population
- Atrial fibrillation.

Recommendations
- ECS 2010, 2012

- ESC recommends the CHA\textsubscript{2}DS\textsubscript{2}VASc score as more predictive for stroke risk, especially with a low CHADS\textsubscript{2} score. DOACs offer better efficacy, safety, and convenience compared with OAC with VKAs.

- In high-risk patient unsuitable for anticoagulation, dual antiplatelet therapy (ASA plus clopidogrel) is reasonable.
Comments

1. Absolute cerebrovascular accident (CVA) risk reduction with dual antiplatelet Rx is 0.8% per year balanced by increased bleeding risk 0.7% ACTIVE Trial.
2. In high-risk patients with history of TIA/minor ischemic stroke, dual antiplatelet therapy (ASA+Plavix), started in the first 24 h, is superior to ASA alone in preventing stroke in the first 90 d, without having increased risk of hemorrhage.

Population

- Atrial fibrillation.

Recommendations

FDA Warning 2011

- Dronedarone should not be used in patients who have chronic AF with associated severe HF or LV systolic dysfunction.
- See Management Algorithm. For therapy, see Chapter 3, page 194 pharmacologic and antithrombotic recommendations.
- Dronedarone is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II–III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic.
- Dronedarone reduces the incidence of AF recurrences, hospitalization, and death in patients with paroxysmal or persistent AF. However, dronedarone should not be used in high-risk patients with permanent AF or patients with unstable chronic heart failure (HF) due to safety concerns. *J Clin Pharm Ther.* 2014;39(2):112-117.

Sources


Comment

- Dronedarone doubles rate of CV death, stroke, and heart failure in patients with chronic atrial fibrillation.

Population

- Atrial fibrillation.

Recommendations

HRS 2014, 2015

- Given the impact of AF on stroke and the association of AF with cognitive dysfunction, brain imaging may improve the care of AF patients by helping to stratify stroke risk in AF patients. Presence of
subclinical brain infarcts is robustly associated with the subsequent risk of stroke. Short-term risk of stroke after transient ischemic attack (TIA) was 3-fold higher in patients with a brain infarct on MRI compared to those without.

– Compared to warfarin, DOACs offer relative efficacy, safety, and convenience. Warfarin efficacy and safety depend on the quality of anticoagulation control, as reflected by the average time in therapeutic range (TTR). Due to the difficulty of achieving therapeutic international normalized ratios (INRs) quickly after starting warfarin, an increased risk of stroke has been observed in the 30 d after initiation of warfarin.

– In patients with nonvalvular atrial fibrillation, a high SAMe-TT2R2 score (reflecting poor anticoagulation control with poor time in therapeutic range) was associated with more bleeding, adverse cardiovascular events, and mortality during follow-up.

Sources

Population
– Atrial fibrillation.

Recommendations

CCS 2012
– All patients should be stratified using CHADS2 and HASBLED risk scores. Patients with CHADS2 = 0 should have CHADS2-VaSc score calculated. All patients with CHADS2 = 2 and most of the ones with CHADS2 = 1 should have OAC therapy.

– When OAC therapy is recommended, dabigatran and rivaroxaban are preferred over warfarin. Rate control goal is <100 beats/min. In stable CAD, ASA (75–325 mg) for CHADS2 = 0, OAC for most CHADS2 = 1. In high-risk patients with ACS, ASA + clopidogrel + OAC might be required (with adequate assessment of risk of stroke, recurrent CAD events, and hemorrhage).

Source
STROKE, a SPECIAL POPULATIONS

Population
− HTN.

Recommendations
➤ JNC 8
− Treat to goal SBP <140 mm Hg.
− If age ≥60 y, treat to <150/90.
− If comorbid diabetes or chronic kidney disease, treat to <140/90 mm Hg.

➤ AHA/ASA 2011
− Treat to goal <140/90 mmHg.
− If HTN with diabetes or renal disease, treat to <130/80 mm Hg.

Comments
− See Chapter 3 (page 360) for JNC-8 treatment algorithms.

Sources
− Stroke. 2011;42:517-584

Population
− DM.

Recommendations
➤ AHA/ASA 2011
1. Six-fold increase of stroke.
2. Short-term glycemic control does not lower macro vascular events.
3. HgA1c goal is <6.5%.
4. Goal is <130/80 mm Hg.
5. Statin therapy.
6. Consider ACE inhibitor or ARB therapy for further stroke risk reduction.

Source
− Stroke. 2011;42:517-584

Population
− Asymptomatic CAS.

Recommendations
➤ USPSTF 2014, AHA/ASA 2011
1. No indication for general screening for CAS with ultrasonography.
2. Screen for other stroke risk factors and treat aggressively.

3. ASA unless contraindicated.
4. Prophylactic carotid endarterectomy (CEA) for patients with high-grade (>70%) CAS by ultrasonography when performed by surgeons with low (<3%) morbidity/mortality rates may be useful in selected cases depending on life expectancy, age, sex, and comorbidities.
5. However, recent studies have demonstrated that “best” medical therapy results in a stroke rate <1%.
6. The number needed to treat (NNT) in published trials to prevent one stroke in 1 y in this asymptomatic group varies from 84 up to 2000. 

(J Am Coll Cardiol. 2011;57(8):e16-e94)

Sources
2. Neurology. 2011;77:751-758

Population
– Symptomatic CAS.

Recommendations

>> ASA/ACCF/AHA/AANN/AANS/ACR/CNS 2011
– Optimal timing for CEA is within 2 wk of posttransient ischemic attack.
– CEA plus medical therapy is effective within 6 mo of symptom onset with >70% CAS.
– Intense medical therapy alone is indicated if the occlusion is <50%.
– Intensive medical therapy plus CEA may be considered with obstruction 50%–69%.
– Surgery should be limited to male patients with a low perioperative stroke/death rate (<6%) and should have a life expectancy of at least 5 y.

Sources
– J Am Coll Cardiol. 2011;57(8):1002-1038
– Arch Intern Med. 2011;171(20):1794-1795
– Stroke. 2011;42:517-584
– Stroke. 2011;42:227-276

Comments
– Medical treatment of asymptomatic CAS should be aggressive.
– Surgical intervention should be individualized, guided by comparing comorbid medical conditions and life expectancy to the surgical morbidity and mortality.
DISEASE PREVENTION

– Atherosclerotic intracranial stenosis: ASA should be used in preference to warfarin.
– Warfarin—significantly higher rates of adverse events with no benefit over ASA. (N Engl J Med. 2005;352(13):1305-1316)
– Qualitative findings (embolic signals and plaque ulceration) may identify patients who would benefit from asymptomatic CEA.

Populations
– Cryptogenic CVA.
– Hyperlipidemia.

Recommendations

ASA/ACCF/AHA/AANN/AANS/ACR/CNS 2011
– Carotid artery stenting is associated with increased nonfatal stroke frequency but this is offset by decreased risk of MI post-CEA.
– Cryptogenic CVA with patent foramen ovale should receive ASA 81 mg/d.

Sources

Comments
– Consider referral to tertiary center for enrollment in randomized trial to determine optimal Rx.
– Closure I trial demonstrated no benefit at 2 y of patent foramen ovale (PFO) closure device over medical therapy.
– In 2013, the PC Trial also failed to demonstrate significant benefit in reducing recurrent embolic events in patients undergoing PFO closure compared to medical therapy, at 4 y follow-up.

Population
– Sickle cell disease.

Recommendations

ASA/ACCF/AHA/AANN/AANS/ACR/CNS 2011
– Transfusion therapy (target reduction of hemoglobin S from a baseline of >90% to <30%) is effective for reducing stroke risk in those children at elevated stroke risk (Class I; level of evidence, B).
– Begin screening with transcranial Doppler (TCD) at age 2 y.
– Transfusion therapy is recommended for patients at high-stroke risk per TCD (high cerebral blood flow velocity >200 cm/s).
– Frequency of screening not determined.
Population
- Primary prevention in women.

Recommendations

ACC/ASA 2014
- Higher lifetime risk, third leading cause of death in women, 53.5% of new recurrent strokes occur in women.
- Sex-specific risk factors: pregnancy, preeclampsia, gestational diabetes, oral contraceptive use, postmenopausal hormone use, changes in hormonal status.
- Risk factors with a stronger prevalence in women: migraine with aura, atrial fibrillation, diabetes, hypertension, depression, psychosocial stress.

Source
- Circulation. 2011;123:1243-1262

Population
- Oral contraceptives/menopause, postmenopausal hormone therapy.

Recommendations

ACC/ASA 2014
- Stroke risk with low-dose OC users is about 1.4–2 times that of non-OC users.
- Measurement of BP is recommended prior to initiation of hormonal contraception therapy.
- Routine screening for prothrombotic mutations prior to initiation of hormonal contraception is not useful.
- Among OC users, aggressive therapy of stroke risk factors may be reasonable.
- Hormone therapy (conjugated equine estrogen with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women.
- Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke.

Source
- Stroke. 2014;45:1545-1588
**DISEASE PREVENTION**

### SAMe-TT.R2 SCORE

<table>
<thead>
<tr>
<th>Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female)</td>
<td>1</td>
</tr>
<tr>
<td>Age &gt; 60</td>
<td>1</td>
</tr>
<tr>
<td>Medical history (&gt; 2 comorbidities: HTN, DM, CAD/MI, PAD, CHF, history of stroke, pulmonary disease, hepatic or renal disease)</td>
<td>1</td>
</tr>
<tr>
<td>Treatment (rhythm control strategy) (interacting medications, eg, beta-blocker, verapamil, amiodarone)</td>
<td>1</td>
</tr>
<tr>
<td>Tobacco use (within 2 y)</td>
<td>2</td>
</tr>
<tr>
<td>Race (non-white)</td>
<td>2</td>
</tr>
<tr>
<td>Maximum points</td>
<td>8</td>
</tr>
</tbody>
</table>

**Interpretation**

- Score > 2 = DOAC
- Score 0–2 = VKA with TTR > 65%–70%

Source: Fauchier L, Angoulvant D, Lip GY. The SAMe-TT.R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. doi: http://dx.doi.org/10.1093/europace/euv088.

---

### SUDDEN INFANT DEATH SYNDROME (SIDS)

**Population**

- Newborns and infants.

**Recommendation**

- AAP 2016
  - Place their infants to sleep on their backs
  - Use a firm sleep surface without soft objects or loose bedding.
  - Breastfeed.
  - For the first 6–12 m, infants should sleep in parents’ room (but not in parents’ bed).
  - Avoid smoke exposure, alcohol and illicit drug use, overheating.

**Source**


**Comments**

- Stomach and side sleeping have been identified as major risk factors for SIDS.
- Pacifiers may be protective.
SURGICAL SITE INFECTIONS (SSI)

Population
– Women undergoing cesarean sections.

Recommendations
Cochrane Database of Systematic Reviews 2014
– Recommend a vaginal preparation with povidone-iodine solution immediately prior to cesarean delivery.
– Recommend administration of prophylactic IV antibiotics preoperatively within 60 min of skin incision as opposed to administration after cord clamping.

Source

Comments
– A vaginal prep prior to cesarean section reduces the incidence of postpartum endometritis. This benefit was especially true for women in active labor or with rupture membranes.
– The incidence of maternal infectious morbidity is decreased (RR 0.54) when prophylactic antibiotics are administered preoperatively as opposed to after cord clamping.

TOBACCO USE

Population
– School-aged children and adolescents.

Recommendation
AAFP/USPSTF 2013
– Recommends that primary care clinicians provide interventions including education or brief counseling to prevent the initiation of tobacco use.

Comment
– The efficacy of counseling to prevent tobacco use in children and adolescents is uncertain.

Source
– USPSTF: Tobacco Use in Children and Adolescents: Primary Care Interventions. 2013.
### CLINICAL RECOMMENDATIONS FOR USE OF PROFESSIONALLY APPLIED OR PRESCRIPTION-STRENGTH, HOME-USE TOPICAL FLUORIDE AGENTS FOR CARIES PREVENTION IN PATIENTS AT ELEVATED RISK OF DEVELOPING CARIES

<table>
<thead>
<tr>
<th>Age Group or Dentition Affected</th>
<th>Professionally Applied Topical Fluoride Agent</th>
<th>Prescription-Strength, Home-Use Topical Fluoride Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Younger than 6 y</td>
<td>2.26% fluoride varnish at least every 3 to 6 mo (In Favor)</td>
<td></td>
</tr>
<tr>
<td>6–18 y</td>
<td>2.26% fluoride varnish at least every 3 to 6 mo (In Favor) or 1.23% fluoride (acidulated phosphate fluoride [APF]) gel for 4 min at least every 3 to 6 mo (In Favor)</td>
<td>0.09% fluoride mouthrinse at least weekly (In Favor) or 0.5% fluoride gel or paste twice daily (Expert Opinion For)</td>
</tr>
<tr>
<td>Older than 18 y</td>
<td>2.26% fluoride varnish at least every 3 to 6 mo (Expert Opinion For) or 1.23% fluoride (APF) gel for at least 4 min every 3 to 6 mo (Expert Opinion For)</td>
<td>0.09% fluoride mouthrinse at least weekly (Expert Opinion For) or 0.5% fluoride gel or paste twice daily (Expert Opinion For)</td>
</tr>
<tr>
<td>Adult Root Caries</td>
<td>2.26% fluoride varnish at least every 3 to 6 mo (Expert Opinion For) or 1.23% fluoride (APF) gel for 4 min at least every 3 to 6 mo (Expert Opinion For)</td>
<td>0.09% fluoride mouthrinse daily (Expert Opinion For) or 0.5% fluoride gel or paste twice daily (Expert Opinion For)</td>
</tr>
</tbody>
</table>

### Additional Information:
- 0.1% fluoride varnish, 1.23% fluoride (APF) foam, or prophylaxis pastes are not recommended for preventing coronal caries in all age groups (Expert Opinion Against). See American Dental Association (ADA) publication for recommendation strength by age group. The full report, which includes more details, is available at ebd.ada.org.
- No prescription-strength or professionally applied topical fluoride agents except 2.26% fluoride varnish are recommended for children younger than 6 y (Expert Opinion Against), but practitioners may consider the use of these other agents on the basis of their assessment of individual patient factors that alter the benefit to harm relationship.
- Prophylaxis before 1.23% fluoride (APF) gel application is not necessary for coronal caries prevention in all age groups (Expert Opinion Against). See ADA publication for recommendation strength by age group. No recommendation can be made for prophylaxis prior to application of other topical fluoride agents. The full report, which includes more details, is available at the ebd.ada.org.
- Patients at low risk of developing caries may not need additional topical fluorides other than over-the-counter fluoridated toothpaste and fluoridated water.

CHAPTER 2

VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN NONSURGICAL PATIENTS

Populations
– Medical patients with low risk (Padua Prediction score—see Table I).
– Medical patients with high risk (JAMA. 2012;307:306) (Padua Prediction score—see Table I).

Recommendations
ACCP 2016, ACP 2011
– Recommend against the use of pharmacologic prophylaxis or mechanical prophylaxis in low risk patients.
– Recommend anticoagulant in high risk patients
  • Thromboprophylaxis with low-molecular-weight heparin (LMWH)—equivalent of enoxaparin 40 mg SQ daily; fondaparinux 2.5 mg SQ daily. Low-dose unfractionated heparin (UFH) 5000 units bid or tid should be used only in patients with significant renal disease. UFH has a 10-fold increased risk of heparin induced thrombocytopenia (HIT). Women are 2.5 times likely to develop HIT compared to men.
  • If patient bleeding or high risk of bleeding (see Table II), mechanical prophylaxis with graduated compression stockings (GCS) or intermittent pneumatic compression (IPC) recommended.
  • When bleeding risk decreases, substitute pharmacologic thromboprophylaxis for mechanical prophylaxis.
  • Continue thromboprophylaxis for duration of hospital stay.
  • Extended prophylaxis after discharge not recommended for medical patients but should be considered if patient has underlying thrombotic risk (See Table III).

Sources
– Chest 2016; 149: 315-352
– http://www.uwhealth.org/files/uwhealth/docs/anticoagulation/VTE

Comments
– Clinical Perspective
  • Routine ultrasound screening for DVT is not recommended in any group.
  • 150–200,000 deaths from VTE in the United States per year.
    Hospitalized patients have a VTE risk which is 130-fold greater than that of community residents. (Mayo Clin Proc. 2001;76:1102)
  • Neither heparin nor warfarin is recommended prophylactically for patients with central venous catheters.
• In higher risk long-distance travelers, frequent ambulation, calf muscle exercises, aisle seat, and below-the-knee graduated compression stockings (GCS) are recommended over aspirin or anticoagulants.

• Hospitalized Inpatients with solid tumors without additional risk factors for VTE (history of DVT, thrombophilic drugs, immobilization), should be treated with prophylactic dose LMWH.

• Be cautious in patients with Ccr <20 to 30 mL/min—UFH or dalteparin (half dose) preferred.

• Consider adjusted LMWH dose in patients <50 kg or >110 kg in weight. Monitor with heparin anti 10a activity testing.

• Inferior vena cava (IVC) filter indicated in patients with diagnosed DVT with or without pulmonary embolism (PE) who cannot be anticoagulated because of bleeding. There are no other situations where a filter has been proven to be beneficial.

• IVC filter should not be used prophylactically.

• Although several studies have shown survival benefit for VTE prophylaxis in surgical patients, this has not been proven in medical patients. (N Engl J Med. 2011;365:2463) (N Engl J Med. 2007;356:1438)

• In patients with cancer and VTE use LMWH. The new oral anticoagulants are being tested and will probably have a role in cancer related VTE in the near future. Warfarin is inferior to LMWH. (Lancet Oncol. 2008;9:577) (Thromb Res. 2012;130:853)

• In patients with mechanical heart valves use warfarin for anticoagulation. The direct oral anticoagulants (DOACs) are inferior. (N Engl J Med. 2013;369:1206)

### TABLE I

| RISK FACTORS FOR VTE IN HOSPITALIZED MEDICAL PATIENTS—PADUA PREDICTIVE SCALE |
|-------------------------------|------------------|
| **Risk Factor**               | **Points**       |
| Active cancer<sup>a</sup>     | 3                |
| Previous VTE                  | 3                |
| Reduced mobility<sup>b</sup>  | 3                |
| Underlying thrombophilic disorder<sup>c</sup> | 3 |
| Recent (<1 mo) trauma or surgery | 2        |
| Age (>70 y)                   | 1                |
| Congestive heart failure (CHF) or respiratory failure | 1 |
### TABLE II

**RISK FACTORS FOR BLEEDING (CHEST. 2011;139:69-79)**

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>N = 10,866% of Patients</th>
<th>Overall Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active gastroduodenal ulcer</td>
<td>2.2</td>
<td>4.15</td>
</tr>
<tr>
<td>G1 bleed &lt;3 mo previous</td>
<td>2.2</td>
<td>3.64</td>
</tr>
<tr>
<td>Platelet count &lt;50 K</td>
<td>1.7</td>
<td>3.37</td>
</tr>
<tr>
<td>Age ≥85 y (vs. 40 y)</td>
<td>10</td>
<td>2.96</td>
</tr>
<tr>
<td>Hepatic failure (INRᵃ &gt;1.5)</td>
<td>2</td>
<td>2.18</td>
</tr>
<tr>
<td>Renal failure (GFRᵇ &lt;30 mL/min)</td>
<td>11</td>
<td>2.14</td>
</tr>
<tr>
<td>ICU admission</td>
<td>8.5</td>
<td>2.10</td>
</tr>
<tr>
<td>Current cancer</td>
<td>10.7</td>
<td>1.78</td>
</tr>
<tr>
<td>Male sex</td>
<td>49.4</td>
<td>1.48</td>
</tr>
</tbody>
</table>

---

ᵃInternational normalized ratio.
ᵇGlomerular filtration rate.
ᶜAlthough not studied in medical patients, antiplatelet therapy would be expected to increase risk of bleeding.
ᵈGo to [www.outcomes-umassmed.org/IMPROVE/risk_score/vte/index.html](http://www.outcomes-umassmed.org/IMPROVE/risk_score/vte/index.html) to calculate the risk of bleeding for individual patients.

---

### RISK FACTORS FOR VTE IN HOSPITALIZED MEDICAL PATIENTS—PADUA PREDICTIVE SCALE (Continued)

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute MI or stroke</td>
<td>1</td>
</tr>
<tr>
<td>Acute infection or inflammatory disorder</td>
<td>1</td>
</tr>
<tr>
<td>Obesity (BMI &gt; 30)</td>
<td>1</td>
</tr>
<tr>
<td>Thrombophilic drugs (hormones, tamoxifen, erythroid stimulating agents, lenalidomide, bevacizumab)</td>
<td>1</td>
</tr>
</tbody>
</table>

High risk: >4 points—11% risk of VTE without prophylaxis

Low risk: <3 points—0.3% risk of VTE without prophylaxis

ᵃLocal or distant metastasis, chemotherapy or radiation within last 6 mo.
ᵇBed rest for >3 d.
ᶜHereditary thrombophilia (see Table III) and antiphospholipid antibody syndrome, nephrotic syndrome, hemolytic anemia.
TABLE III

HEREDITARY THROMBOPHILIC DISORDERS

<table>
<thead>
<tr>
<th>Disorder</th>
<th>% of U.S. Population</th>
<th>Increase in Lifetime of Risk of Clot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resistance to activated protein C (factor V Leiden mutation)</td>
<td>5–6</td>
<td>3×</td>
</tr>
<tr>
<td>Prothrombin gene mutation</td>
<td>2–3</td>
<td>2.5×</td>
</tr>
<tr>
<td>Elevated factor 8 (&gt;175% activity)</td>
<td>6–8</td>
<td>2–3×</td>
</tr>
<tr>
<td>Elevated homocysteine</td>
<td>10–15</td>
<td>1.5–2×</td>
</tr>
<tr>
<td>Protein C deficiency</td>
<td>0.37</td>
<td>10×</td>
</tr>
<tr>
<td>Protein S deficiency</td>
<td>0.5</td>
<td>10×</td>
</tr>
<tr>
<td>Antithrombin deficiency</td>
<td>0.1</td>
<td>25×</td>
</tr>
<tr>
<td>Homozygous factor V Leiden</td>
<td>0.3</td>
<td>60×</td>
</tr>
</tbody>
</table>

VENOUS THROMBOEMBOLISM (VTE) IN SURGICAL PATIENTS

Populations

Risk Stratification

- SURGICAL
  - Low risk—<40 y, minor surgery, no risk factor, Caprini score <2 (see Table IV).
  - Intermediate risk—minor surgery plus risk factors, age 40–60 y, major surgery with no risk factors, Caprini score 3–4.
  - High risk—major surgery plus risk factors, high-risk medical patient, major trauma, spinal cord injury, craniotomy, total hip or knee arthroplasty (THA, TKA) thoracic, abdominal, pelvic cancer surgery.

Recommendation

- ACCP 2016

Preventive Measures

- Early ambulation—consider mechanical prophylaxis and intermittent pneumatic compression, graduated compression stocking (IPC or GCS).
- UFH 5000 U SQ q 8-12 h should ONLY be used in patients with renal disease with a Ccr <20 to 30 mL/min.

*a Eye, ear, laparoscopy, cystoscopy, and arthroscopic operations.
*b Prior VTE, cancer, stroke, obesity, congestive heart failure pregnancy, thrombophilic medications (tamoxifen, raloxifene, lenalidomide, thalidomide, erythropoiesis-stimulating agents).
• LMWH equivalent to enoxaparin 40 mg SQ 2 h before surgery then daily or 30 mg q12h SQ starting 8–12 h postop.
• Fondaparinux 2.5 mg SQ daily starting 8–12 h postop.
• LMWH—equivalent to enoxaparin 40 mg SQ 2 h preoperative then daily or 30 mg SQ q12h starting 8–12 h postop and also use mechanical prophylaxis with IPC or GCS.
• Extend prophylaxis for as long as 28–35 d in high-risk patients.

In THA, TKA ortho patients, acceptable VTE prophylaxis also includes rivaroxaban 10 mg/d, dabigatran 225 mg/d, adjusted dose warfarin, and aspirin, although LMWH is preferred. DOACs are likely to play a larger role in the future as trials continue to show superiority over warfarin. (Ann Int Med. 2013;159:275) (Thromb Haemot. 2011;105:444)


• Do not use UFH for prophylaxis if Ccr is >20 cc/min. There is a 10 fold increased risk of HIT compared to LMWH.

Source
– Chest. 2016;149:315

Comment
– Clinical Points
  • 75%–90% of surgical bleeding is structural. VTE prophylaxis adds minimally to risk of bleeding.
  • With creatinine clearance <20 to 30 cc/min UFH with partial thromboplastin time (PTT) monitoring is preferred (decrease dose if PTT prolonged). In all other situations LMWH or DOACs are preferred to reduce the risk HIT.
  • Patients with liver disease and prolonged INR are still at risk for clot. Risk-to-benefit ratio of VTE prophylaxis should be individualized.
  • Epidural anesthesia— to place catheter wait 18 h after daily prophylactic dose of LMWH, and 24 h after prophylactic dose of fondaparinux. For patients on BID therapeutic LMWH anticoagulation or once daily LMWH wait more than 24 hrs before placing epidural catheter. Patients on DOACs should hold their anticoagulation for 3-5 days. After placing or removing an epidural catheter hold on starting anticoagulation for 6 to 8 h.
  • Prophylactic IVC filter for high-risk surgery is not recommended.
  • For cranial and spinal surgery patients at low risk for VTE use mechanical prophylaxis—high-risk patients should have pharmacologic prophylaxis added to mechanical prophylaxis once hemostasis is established and bleeding risk decreased.
Patients at high risk of bleeding with major surgery should have mechanical prophylaxis (IPC, GCS) — initiate anticoagulant prophylaxis if risk lowered.

Surgical patients receive indicated prophylaxis 60% of the time compared to 40% in medical patients.

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm

**SELECTED FACTORS IN THE RISING RISK OF MAJOR BLEEDING COMPLICATIONS**

**General Risk Factors**
Active bleeding, previous major bleed, known untreated bleeding disorder, renal or liver failure, thrombocytopenia, acute stroke, uncontrolled high BP, concomitant use of anticoagulants, or antiplatelet therapy

**Procedure-Specific Risk Factors**
Major abdominal surgery — extensive cancer surgery, pancreatic-duodenectomy, hepatic resection, cardiac surgery, thoracic surgery (pneumonectomy or extended resection). Procedures where bleeding complications have especially severe consequences: craniotomy, spinal surgery, spinal trauma.

**TABLE IV**

<table>
<thead>
<tr>
<th>CAPRINI RISK STRATIFICATION MODEL</th>
<th>1 Point</th>
<th>2 Points</th>
<th>3 Points</th>
<th>5 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 41–60 y</td>
<td>• Minor surgery</td>
<td>• BMI &gt;251 g/m²</td>
<td>• Swollen legs</td>
<td>• Varicose veins</td>
</tr>
<tr>
<td>Minor surgery</td>
<td>• Pregnancy or postpartum</td>
<td>• History of recurrent spontaneous abortion</td>
<td>• Sepsis (&lt;1 mo)</td>
<td>• Lung disease</td>
</tr>
<tr>
<td>BMI &gt;251 g/m²</td>
<td>• History of acute MI</td>
<td>• Congestive heart failure (CHF) (&lt;1 mo)</td>
<td>• History of inflammatory bowel disease</td>
<td>• Medical patient at bed rest</td>
</tr>
<tr>
<td>Swollen legs</td>
<td>• Arthroscopic surgery</td>
<td>• Major open surgery &gt;45 min</td>
<td>• Laparoscopic surgery</td>
<td>• Malignancy</td>
</tr>
<tr>
<td>Varicose veins</td>
<td>• Major open surgery &gt;45 min</td>
<td>• Malignancy</td>
<td>• Confined to bed</td>
<td>• Immobilizing cast</td>
</tr>
<tr>
<td>Pregnancy or postpartum</td>
<td>• Arthroscopic surgery</td>
<td>• Malignancy</td>
<td>• Confined to bed</td>
<td>• Central venous catheter</td>
</tr>
<tr>
<td>History of recurrent spontaneous abortion</td>
<td>• Malignancy</td>
<td>• Confined to bed</td>
<td>• Central venous catheter</td>
<td></td>
</tr>
</tbody>
</table>

Caprini Score <3: low risk
Caprini Score 3–4: intermediate risk
Caprini Score >5: high risk

*http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm*
Disease Management

ABDOMINAL AORTIC ANEURYSM (AAA)

Risk Factors of Developing AAA
- Age >60 y. About 1 person in 1000 develops an abdominal aortic aneurysm between the ages of 60 and 65. Screening studies have shown that abdominal aortic aneurysms occur in 2% to 13% of men and 6% of women >65 y.
- Smoking markedly increases risk for AAA. The risk is directly related to number of years smoking and decreases in the years following smoking cessation.
- Men develop AAA 4–5 times more often than women.
- AAA is more common in white population compared to other ethnicities.
- History of CHD, PAD, HTN, and hypercholesterolemia.
- Family history of AAA increases the risk of developing the condition and accentuates the risks associated with age and gender. The risk of developing an aneurysm among brothers of a person with a known aneurysm who are >60 y of age is as high as 18%.

Risk of Expansion
- Age >70 y, cardiac or renal transplant, previous stroke, severe cardiac disease, tobacco use.

Risk of AAA Rupture
- The evidence suggests that aneurysms expand at an average rate of 0.3–0.4 cm y.
- The annual risk of rupture based upon aneurysm size is estimated as follows:
  - <4.0 cm in diameter = <0.5%.
  - Between 4.0 and 4.9 cm in diameter = 0.5%–5%.
  - Between 5.0 and 5.9 cm in diameter = 3%–15%.
- Between 6.0 and 6.9 cm in diameter = 10%–20%.
- Between 7.0 and 7.9 cm in diameter = 20%–40%.
- ≥8.0 cm in diameter = 30%–50%.

-- Aneurysms that expand rapidly (>0.5 cm over 6 mo) are at high risk of rupture.
-- Growth tends to be more rapid in smokers and less rapid in patients with peripheral artery disease or diabetes mellitus.
-- The risk of rupture of large aneurysms (≥5.0 cm) is significantly greater in women (18%) than in men (12%).
-- Other risk factors for rupture: cardiac or renal transplant, decreased forced expiratory volume in 1 s, higher mean BP, larger initial AAA diameter, current tobacco use—length of time smoking is more significant than amount smoked.

**ACCF/AHA 2005/2011 Recommendations**

**Pharmacologic Therapy**

-- All patients with AAA should have BP and fasting serum lipids monitored and controlled as recommended for patients with atherosclerotic disease (Class I, LOE C).
-- Smoking cessation: Counseling and medications should be provided to all patients with AAA or family history of AAA.
-- Patients with infrarenal or juxtarenal AAA 4.0–5.4 cm in diameter should be monitored by ultrasounds or CT scans every 6–12 mo to detect expansion (Class I, LOE A).
-- In patients with AAA <4.0 cm in diameter, monitoring by ultrasound every 2–3 y is reasonable (Class IIa, LOE B).
-- Perioperative administration of β-adrenergic blocking agents, in the absence of contraindications, is indicated to reduce the risk of adverse cardiac events and mortality in patients with coronary artery disease undergoing surgical repair of atherosclerotic aortic aneurysms (Class I, LOE A).

**Surgical Therapy**

-- Patients with infrarenal or juxtarenal AAAs ≥5.5 cm in diameter should undergo repair to eliminate risk of rupture (Class I, LOE B).
-- Repair is probably indicated in patients with suprarenal or type IV thoracoabdominal aortic aneurysm >5.5–6.0 cm in diameter (Class IIa, LOE B).
-- Intervention is not indicated for asymptomatic infrarenal or juxtarenal AAA if <5.0 cm in diameter in men or <4.5 cm in diameter in women (Class III, LOE A).
-- In patients with clinical triad of abdominal and/or back pain, a pulsatile abdominal mass, and hypotension, immediate surgical evaluation is indicated (Class I, LOE B).
In patients with symptomatic AAA, repair is indicated regardless of diameter (Class I, LOE C).

Open or endovascular repair of infrarenal AAAs and/or common iliac aneurysms is indicated in patients who are good surgical candidates (Class I, LOE A).

Periodic long-term surveillance imaging should be performed to monitor for vascular leak, document shrinkage/stability of the excluded aneurysm sac, confirm graft position, and determine the need for further intervention in patients who have undergone endovascular repair of infrarenal aortic and/or iliac aneurysms (Class I, LOE A).

Open aneurysm repair is reasonable to perform in patients who are good surgical candidates but who cannot comply with the periodic long-term surveillance required after endovascular repair (Class IIa, LOE C).

Endovascular repair of infrarenal aortic aneurysm in patients who are at high surgical or anesthetic risk (presence of coexisting severe cardiac, pulmonary, and/or renal disease) is of uncertain effectiveness (Class IIb, LOE B).

ESC 2014 Recommendations

**Pharmacologic Therapy**

- Smoking cessation is recommended to slow the growth of the AAA.
- Patients with HTN and AAA should be treated with β-blockers as a first-line treatment.
- ACEI and statins should be considered in patients with AAA to reduce risk of cardiovascular risk.
- Enlargement of AAA is usually associated with the development of an intraluminal mural thrombus. Overall data on the benefits of ASA in reducing AAA growth are contradictory; however, given the strong association between AAA and other atherosclerotic diseases, the use of ASA may be considered according to the presence of other cardiovascular comorbidities.
- Surveillance is indicated and safe in patients with AAA with a maximum diameter <5.5 cm and slow growth <1 cm/y.
- In patients with small AAA, imaging should be considered:
  - Every 4 y for AAA 2.5–2.9 cm diameter.
  - Every 3 y for AAA 3.0–3.9 cm diameter.
  - Every 2 y for AAA 4.0–4.4 cm diameter.
  - Every year for AAA >4.5 cm diameter.

**Surgical Therapy**

- AAA repair is indicated if:
  - AAA >5.5 cm in diameter.
  - Aneurysm growth >1 cm/y.
–If a large aneurysm is anatomically suitable for EVAR, either open or endovascular repair is recommended in patients with acceptable surgical risk.
–If a large aneurysm is anatomically unsuitable for EVAR, open aortic repair is recommended.
–In patients with asymptomatic AAA, who are unfit for open repair, EVAR, along with best medical, treatment may be considered.
–In patients with suspected rupture of AAA, immediate abdominal ultrasound or CT is recommended.
–In case of ruptured AAA, emergency repair is indicated.
–In case of symptoms but nonruptured AAA, urgent repair is indicated.
–In case of symptomatic AAA anatomically suitable for EVAR, either open or endovascular aortic repair is recommended.

*EVAR, endovascular aortic repair.
# ABNORMAL LIVER CHEMISTRIES

## Recommendations

**American College of Gastroenterology 2017**

### ALGORITHM FOR EVALUATION OF ASPARTATE AMINOTRANSFERASE (AST) AND/OR ALANINE AMINOTRANSFERASE (ALT) LEVEL

<table>
<thead>
<tr>
<th>Borderline elevation &lt;2x ULN</th>
<th>Mild elevation 2-5x ULN</th>
</tr>
</thead>
<tbody>
<tr>
<td>History and physical exam</td>
<td>History and physical exam</td>
</tr>
<tr>
<td>Discontinue hepatotoxic meds</td>
<td>Discontinue hepatotoxic meds</td>
</tr>
<tr>
<td>Assess for risk factors for fatty liver and viral hepatitis</td>
<td>Assess for risk factors for fatty liver and viral hepatitis</td>
</tr>
<tr>
<td>CBC/platelet count, AST/ALT, ALK Phos, TB, albumin, PT/INR</td>
<td>CBC/platelet count, AST/ALT, ALK Phos, TB, albumin, PT/INR</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HBsAb, HCV Ab with PCR confirmation if +, iron panel, abdominal ultrasound</td>
<td>HBsAg, HBcAb, HBsAb, HCV Ab with PCR confirmation if +, iron panel, abdominal ultrasound</td>
</tr>
<tr>
<td>If negative, consider observation for 3–6 mo with repeat AST/ALT, Alk Phos, TB or ...</td>
<td>If negative, consider observation for 3 mo with repeat AST/ALT, Alk Phos, TB or continue investigation</td>
</tr>
<tr>
<td>If persistently elevated, continue investigation: ANA, ASMA, gamma-globulin, ceruloplasmin, alpha-1 antitrypsin phenotype and may consider additional tests based on history (eg celiac sprue, tick-borne disease, thyroid disease, and muscle disorders)</td>
<td>If persistently elevated, continue investigation: ANA, ASMA, gamma-globulin, ceruloplasmin, alpha-1 antitrypsin phenotype and may consider additional tests based on history (eg celiac sprue, tick-borne disease, thyroid disease, and muscle disorders)</td>
</tr>
<tr>
<td>If normal, further testing at discretion of clinician or refer to hepatologist for consideration of liver biopsy</td>
<td>If no diagnosis, consider diagnostic liver biopsy</td>
</tr>
</tbody>
</table>

HCV, hepatitis C virus.
CHAPTER 3

ALGORITHM FOR EVALUATION OF ELEVATED SERUM ALKALINE PHOSPHATASE

1. Normal total bilirubin and serum transaminases
   - History and physical exam
   - Confirm with serum GGT

2. Elevated serum transaminases ± elevated bilirubin
   - History and physical exam
   - Check right upper quadrant ultrasound

   - If GGT normal → evaluate for non-hepatobiliary etiologies
   - If GGT abnormal → obtain right upper quadrant ultrasound, evaluate for potential hepatotoxic medications, check AMA, ANA, and SMA

   - If ductal dilatation → ERCP, MRCP
   - If no ductal dilatation → check AMA, ANA, and SMA

   - If AMA positive → evaluate for primary biliary cirrhosis/cholangitis
   - If AMA negative and alkaline phosphatase > 2x ULN → consider liver biopsy or MRCP
   - If AMA negative and alkaline phosphatase 1-2x ULN → consider observation

3. Elevated total bilirubin (predominant unconjugated)
   - History and physical exam
   - Assess liver transaminases and serum alkaline phosphatase

   - Review medications
   - Evaluate for hemolysis
   - Evaluate for Gilbert’s syndrome

   - If persistent elevation is otherwise unexplained, may consider diagnostic testing for Gilbert’s syndrome (UGT1A1 genotype) and evaluate for uncommon etiologies in Table 6

   - If persistent elevation is otherwise unexplained, is symptomatic, is worsening over time, and/or associated with abnormal transaminases → consider liver biopsy

ALGORITHM FOR EVALUATION OF ELEVATED SERUM TOTAL BILIRUBIN

1. Elevated total bilirubin (predominant unconjugated)
   - History and physical exam
   - Assess liver transaminases and serum alkaline phosphatase

   - Review medications
   - Evaluate for hemolysis
   - Evaluate for Gilbert’s syndrome

   - If persistent elevation is otherwise unexplained, may consider diagnostic testing for Gilbert’s syndrome (UGT1A1 genotype) and evaluate for uncommon etiologies in Table 6

   - If persistent elevation is otherwise unexplained, is symptomatic, is worsening over time, and/or associated with abnormal transaminases → consider liver biopsy

2. Elevated total bilirubin (predominant conjugated)
   - History and physical exam
   - Assess liver transaminases and serum alkaline phosphatase

   - Review medications
   - Evaluate for clinically overt etiologies: sepsis, TPN, cirrhosis, and biliary obstruction
   - Perform right upper quadrant ultrasound

   - If ductal dilatation → ERCP or MRCP
   - If no ductal dilatation → check AMA, ANA, and SMA

   - If persistent elevation is otherwise unexplained, is symptomatic, is worsening over time, and/or associated with abnormal transaminases → consider liver biopsy
DISEASE MANAGEMENT

Source

ACTIVE SURVEILLANCE (AS) FOR THE MANAGEMENT OF LOCALIZED PROSTATE CANCER

Population
– Men with early clinically localized prostate cancer (Stages T1 and T2 and Gleason score less than or equal to 7).

Recommendations
► CCO 2016, ASCO 2016
– For most patients with low-risk (Gleason score of 6 or less) localized prostate cancer with a PSA < 10, active surveillance (AS) is the recommended disease management strategy.
– Younger age, high-volume Gleason 6 cancer, patient preference, and/or African American ethnicity should be taken into account since definitive therapy may be warranted for select patients.
– For patients with limited life expectancy (<5 y) and low-risk cancer watchful waiting may be more appropriate than active surveillance.
– Active treatment (radical prostatectomy (RP) or radiation therapy (RT)) is recommended for most patients with intermediate-risk (Gleason score 7) localized prostate cancer. For select patients with low volume, intermediate-risk (Gleason score 3 + 4 = 7) localized prostate cancer, AS may be offered.
– The AS protocol should include the following tests:
  • A PSA test every 3–6 mo.
  • Direct rectal exam at least once a year.
  • At least a 12 core confirmatory transrectal ultrasound-guided biopsy (including anterior directed cores) within 6 to 12 mo and then serial biopsy every 2 to 5 y thereafter or more frequently if clinically warranted. Men with limited life expectancy may transition to watchful waiting and avoid further biopsies.
– For patients undergoing AS who are reclassified to a high-risk category (Gleason score now 7 or greater and/or significant increase in volume of Gleason 6 tumor consideration should be given to active therapy (RP or RT).
Comments

1. There are other ancillary tests that may make a difference in deciding when definitive therapy is indicated. The multiparametric MRI (mpMRI) and genomic testing of the malignant prostate cancer may reveal larger tumor size or unfavorable mutations that put the patient in a higher risk category which will need definitive therapy.

2. Data at 10-y follow-up from both observational and randomized trials show a very similar survival, although patients on surveillance had an increase in frequency of metastatic disease and clinical progression. (N Engl J Med. 2016;375:1415)

3. This approach is especially beneficial to patients older than 65 who after have comorbidities and higher risk of complications. Active surveillance also significantly avoids over-treatment and therapy-related morbidity. A recent 10-y follow-up comparing monitoring, surgery, and radiation therapy treatment outcomes resulted in very similar overall survival.

Sources

– ASCO J Clin Oncol. 2016;34:2182-2190
– Eur Urol. 2015;67:233

ADRENAL INCIDENTALOMAS

Population

– Adults.

Recommendations

▲ AACE 2009

– Recommends clinical, biochemical, and radiographic evaluation for evidence of hypercortisolism, aldosteronism, the presence of pheochromocytoma, or a malignant tumor.
– Patients who will be managed expectantly should have reevaluation at 3–6 mo and then annually for 1–2 y.

Source


Comments

1. A 1-mg overnight dexamethasone suppression test can be used to screen for hypercortisolism.

2. Measure plasma-fractionated metanephrines and normetanephrines to screen for pheochromocytoma.

3. Measure plasma renin activity and aldosterone concentration to assess for primary or secondary aldosteronism.
ADULT PSYCHIATRIC PATIENTS IN THE EMERGENCY DEPARTMENT

Populations
- Adult patients presenting to ED with psychiatric symptoms.
- Adults with abnormal liver chemistries.

Recommendations
- No role for routine laboratory testing. Medical history, examination, and previous psychiatric diagnoses should guide testing.
- No role for routine neuroimaging studies in the absence of focal neurological deficits.
- Risk assessment tools should not be used in isolation to identify low-risk adults who are safe for ED discharge if they presented with suicidal ideations.
- Ketamine is one option for immediate sedation in severely agitated adults who may be violent or aggressive.

Source

ALCOHOL USE DISORDERS

Population
- Adults.

Recommendations
- ICSI 2010, NICE 2010, VA/DoD 2009
  - For patients identified with alcohol dependence, schedule a referral to a substance use disorders specialist before the patient has left the office.
  - Refer all patients with alcohol abstinence syndrome to a hospital for admission.
  - Recommend prophylactic thiamine for all harmful alcohol use or alcohol dependence.
  - Refer suitable patients with decompensated cirrhosis for consideration of liver transplantation once they have been sober from alcohol for ≥3 mo.
  - Recommend pancreatic enzyme supplementation for chronic alcoholic pancreatitis with steatorrhea and malnutrition.
CHAPTER 3

Sources
–https://www.icsi.org/_asset/gtjr9h/PrevServAdults.pdf

Comments
1. Assess all patients for a coexisting psychiatric disorder (dual diagnosis).
2. Addiction-focused psychosocial intervention is helpful for patients with alcohol dependence.
3. Consider adjunctive pharmacotherapy under close supervision for alcohol dependence:
   a. Naltrexone.
   b. Acamprosate.

ANAPHYLAXIS

Population
–Children and adults.

Recommendations
NICE 2011, EACCI 2014
–Blood samples for mast cell tryptase testing should be obtained at onset and after 1–2 h.
–All people ≥16 y suspected of having an anaphylactic reaction should be observed for at least 6–12 h before discharge.
–All children younger than age 16 y suspected of having an anaphylactic reaction should be admitted for observation.
–Patients treated for an anaphylactic reaction should be referred to an allergy specialist.
–Treat anaphylaxis with epinephrine (1:1000) 0.01 mg/kg (maximum 0.5 mg) SC; may repeat as necessary IM every 15 min.
–Patients should be prescribed an epinephrine injector (eg, EpiPen).
–Patients with circulatory instability should be placed supine with lower extremities raised and given intravenous saline 20 mL/kg bolus.
–Recommend inhaled β-2 agonists and glucocorticoids for wheezing or signs of bronchoconstriction.
–H1- and H2-blockers can be added for cutaneous signs of anaphylaxis.

Sources
Comment
— Anaphylaxis is defined as a severe, life-threatening, generalized hypersensitivity reaction. It is characterized by the rapid development of:
- Airway edema.
- Bronchospasm.
- Circulatory dysfunction.

ANDROGEN DEFICIENCY SYNDROME

Population
— Adult men.

Recommendations
Endocrine Society 2010
1. Recommends an AM total testosterone level for men with symptoms and signs of androgen deficiency.
2. Measure a serum luteinizing hormone (LH) and follicular stimulating hormone (FSH) in all men with testosterone deficiency.
3. Recommends a dual-energy x-ray absorptiometry scan for all men with testosterone deficiency.
4. Testosterone therapy indicated for androgen deficiency syndromes unless contraindications exist.

Source

Comment
1. Testosterone therapy options:
   a. Testosterone enanthate or cypionate 150–200 mg IM every 2 wk.
   b. Testosterone patch 5–10 mg qhs.
   c. 1% testosterone gel 5–10 g daily.
   d. Testosterone 30 mg to buccal mucosa q12h.

*Lethargy, easy fatigue, lack of stamina or endurance, reduced libido, mood changes, irritability, and loss of libido and motivation.

*Breast cancer (CA), prostate CA, hematocrit >50%, untreated severe obstructive sleep apnea, severe obstructive urinary symptoms, or uncontrolled heart failure.
ANEMIA–USE OF ERYTHROPOIETIC AGENTS

Population
- Adult patients with cancer and anemia.

Recommendation
- American Society of Hematology/American Society of Clinical Oncology (ASH/ASCO) 2010

Approach to Anemic Cancer Patients
- History, physical exam, and diagnostic studies to exclude other causes of anemia aside from chemotherapy or malignant marrow infiltration.
- The FDA label now limits the use of Erythrocyte Stimulating Agents (ESA) ONLY to anemic cancer patients receiving chemotherapy with palliative intent. *(N Engl J Med. 2007;356:2448)* ESA is NOT to be used in patients with curable malignancies or in patients with cancer not on chemotherapy. Side effects of thrombosis and potentially increased cancer growth should be discussed with the patient. *(J Natl Cancer Inst. 2013;105:1018)*
- Epoetin and darbepoetin are equal in efficacy.
- ESA should not be used if hemoglobin >10 g/dL. The main benefit of ESA is to reduce transfusion need. *(Br J Cancer. 2010;102:301)*
- FDA-approved starting dose of epoetin is 150 U/kg 3 times/wk or 40,000 U weekly. For darbepoetin the dose is 2.25 µg/kg weekly or 500 µg every 3 wk subcutaneously.
- Stop ESAs at 6–8 wk if no evidence of a response. Check for underlying tumor progression, iron deficiency, or other causes of anemia.
- Dose of ESAs should be lowest concentration needed to avoid transfusion. Keep hemoglobin <12.
- Periodic monitoring of ferritin and iron studies is recommended since ESAs will not improve hemoglobin if the patient is iron deficient.
- Use of ESAs in lower-risk myelodysplastic syndrome to decrease transfusions is approved if erythropoietin level is <500 mU/mL. The use of low dose filgrastin (100 µg once or twice/wk) will increase responsiveness to ESAs.

Source
Comment
– Important Facts about ESAs
• Early studies raising hemoglobin level to >12 g/dL resulted in significant increased risk of venous thromboembolus.
• Beware of clot risk when using ESAs with other thrombophilic drugs (tamoxifen, BCP, lenalidomide).
• The molecular structure of darbepoetin increases its half-life, allowing for less frequent injections.
• 50% of cancers will have erythropoietin receptors on the cell surface. It has NOT been proven that ESAs interaction with cell surface receptors leads to cellular proliferation.
• When patients stop chemotherapy for whatever reason, ESAs must be stopped and transfusion therapy substituted according to FDA guidelines.
• The addition of intravenous iron to ESAs will increase hemoglobin more rapidly since iron is sequestered in the reticuloendothelial system in the cancer-associated anemia of chronic disease. (N Engl J Med. 2005; 352:1011)
• ESAs widely used in chronic renal insufficiency, reducing need for transfusion significantly. Iron often given to these patients to keep ferritin level between 100 and 500 ng/mL and transferrin saturation 20%–50%. (N Engl J Med. 2010;362:3).

ANKYLOSING SPONDYLITIS AND SPONDYLOARTHRITIS

Population
– Adults with ankylosing spondylitis (AS) or nonradiographic spondyloarthritis.

Recommendations
► ACR/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015
– Recommendations for treatment of ankylosing spondylitis
  • Scheduled NSAIDs.
  • Tumor necrosis factor inhibitor (TNFi) therapy.
  • Recommends addition of slow-acting anti-rheumatic drugs when TNFi medications contraindicated.
  • Local parenteral corticosteroids for active sacroiliitis, active enthesitis, or peripheral arthritis for symptoms refractory to NSAIDs.
  • Avoid systemic corticosteroid use.
  • Refer to an ophthalmologist for concomitant iritis.
• Recommend TNFi monoclonal antibody therapy for AS with inflammatory bowel disease.
• Physical therapy program.
• Screen for fall risk, osteoporosis.

Recommendations for treatment of nonradiographic axial spondyloarthritis
• NSAIDs.
• Tumor Necrosis Factor inhibitor (TNFi) therapy.

Source

ANXIETY

Population
– Adults.

Recommendations
► NICE 2011
– Recommends cognitive behavioral therapy for generalized anxiety disorder (GAD).
– Recommends sertraline if drug treatment is needed.
– If sertraline is ineffective, recommend a different selective serotonin reuptake inhibitor (SSRI) or selective noradrenergic reuptake inhibitor (SNRI).
– Avoid long-term benzodiazepine use or antipsychotic therapy for GAD.

Source

APNEA, CENTRAL SLEEP (CSAS)

Population
– Adults.

Recommendations
► American Academy of Sleep Medicine 2012
– Primary CSAS
  • Positive airway pressure therapy may be used to treat primary CSAS.
**DISEASE MANAGEMENT**

- Limited evidence to support the use of acetazolamide for CSAS.
- Zolpidem or triazolam may be used to treat CSAS if patients are not at high risk for respiratory depression.

---

**CSAS related to CHF**
- Nocturnal oxygen therapy.
- CPAP therapy targeted to normalize the apnea-hypopnea index.

---

**CSAS related to ESRD**
- Options for therapy include CPAP, nocturnal oxygen, and bicarbonate buffer use during dialysis.

**Source**

---

**APNEA, OBSTRUCTIVE SLEEP (OSA)**

**Population**
- Adults.

**Recommendations**

---

**AASM 2017**
- Recommends that diagnostic testing for OSA be performed in conjunction with a comprehensive sleep evaluation.
- Recommends that a polysomnogram, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA.
- Recommends that a polysomnogram, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, and history of stroke or severe insomnia.
- Recommends that if a single home sleep apnea testing is negative, inconclusive, or technically inadequate, a polysomnogram be performed for the diagnosis or exclusion of OSA.

**Sources**
ACP 2013

– All overweight adults diagnosed with OSA should lose weight.
– Recommends nocturnal CPAP (continuous positive airway pressure) therapy as first-line therapy for OSA.
– Option to use mandibular advancement devices for those patients intolerant of CPAP.

Source

ASCITES, DUE TO CIRRHOSIS

Population
– Adults with cirrhosis.

Recommendations

AASLD 2013

– Diagnostic paracentesis is recommended for all patients with new-onset ascites.
– The routine use of platelets or fresh frozen plasma prior to a paracentesis is not recommended.
– Ascitic fluid analysis:
  • Cell count with differential.
  • Albumin.
  • Protein.
  • Bedside inoculation of aerobic and anaerobic culture bottles.
– Management of cirrhotic ascites:
  • Alcohol cessation.
  • <2 g sodium/d.
  • Oral furosemide and spironolactone in a 2:5 ratio.
  • Fluid restriction not necessary unless serum sodium <125 mmol/L.
  • All patients with cirrhosis and ascites should be considered for liver transplantation.
  • Avoid NSAIDs.
  • Cautious use of ACEI or ARB.
– Management of refractory cirrhotic ascites
  • Avoid propranolol.
  • Avoid ACEI or ARB.
  • Consider use of oral midodrine.
  • Serial therapeutic paracentesis is a treatment option.
DISEASE MANAGEMENT

- Transjugular intrahepatic portosystemic shunt (TIPSS) is a therapeutic option in carefully selected patients.
- Albumin 6–8 g/L ascitic fluid removed indicated for large volume paracentesis >5 L.

–Management of spontaneous bacterial peritonitis (SBP)
  - Recommend cefotaxime 2 g IV q8h.
  - Alternative is ofloxacin 400 mg PO bid.
  - Add albumin 1.5 g/kg/d on day 1 and 1 g/kg/d on day 3 if creatinine >1 mg/dL, BUN >30 mg/dL, or bilirubin >4 mg/dL.

–SBP prophylaxis
  - Cefotaxime or oral norfloxacin for 7 d in patients admitted for upper gastrointestinal bleed.
  - Long-term oral trimethoprim-sulfamethoxazole or norfloxacin for any patient with a history of SBP.
  - Consider SBP prophylaxis if ascitic fluid protein <1.5 g/dL in association with creatinine >1.2 mg/dL or sodium <130 mmol/L or bilirubin >3 mg/dL.

–Hepatorenal syndrome options for treatment
  - Midodrine + SQ Octreotide + albumin.
  - Norepinephrine infusion + albumin.
  - Referral for liver transplantation.

–Hepatic hydrothorax
  - Chest tube is contraindicated.
  - Dietary sodium restriction and diuretics is first-line therapy.
  - TIPSS is an option for refractory cases.

–Avoid percutaneous gastrotomy tube placement in patients with ascites.

Source

ASTHMA

Population
- Children age >5 y, adolescents, and adults.

Recommendations
- GINA 2017

1. Diagnosis of asthma by history: typical symptoms are a combination of shortness of breath, cough, wheezing, and chest tightness; variability over time and in intensity; frequent triggers; FEV1 and FEV1/FVC ratio are reduced and increase by more than 12% after a bronchodilator challenge.
2. Recommend classification of asthma by level of symptom control.
3. Recommend a chest radiograph at the initial visit to exclude alternative diagnoses.
4. Recommend assessing for tobacco use and strongly advise smokers to quit.
5. Recommend spirometry with bronchodilators to determine the severity of airflow limitation and its reversibility.
   a. Repeat spirometry at least every 1–2 y for asthma monitoring.
6. Consider allergy testing for history of atopy, rhinitis, rhinorrhea, and seasonal variation or specific extrinsic triggers.
7. Recommend an asthma action plan based on peak expiratory flow (PEF) monitoring for all patients.
8. Recommend allergen and environmental or occupational trigger avoidance.
9. Physicians should help educate patients, assist them in self-management, develop goals of treatment, create an asthma action plan, and regularly monitor asthma control.

### STEPWISE APPROACH TO ASTHMA MANAGEMENT

**Stepwise approach to asthma treatment**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Asthma medications</th>
<th>Non-pharmacological strategies</th>
<th>Treat modifiable risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom control &amp; risk factors (including lung function)</td>
<td>Symptom control &amp; risk factors</td>
<td>Non-pharmacological strategies</td>
<td>Treat modifiable risk factors</td>
</tr>
<tr>
<td>Inhaler technique &amp; adherence</td>
<td>Inhaled corticosteroid</td>
<td>Non-pharmacological strategies</td>
<td>Treat modifiable risk factors</td>
</tr>
<tr>
<td>Symptom control &amp; risk factors (including lung function)</td>
<td>As-needed SABA or other options</td>
<td>Non-pharmacological strategies</td>
<td>Treat modifiable risk factors</td>
</tr>
</tbody>
</table>

**PREFERRED CONTROLLER CHOICE**

- Low dose ICS

**RELIEVER**

- As-needed short-acting beta₂-agonist (SABA)

**STEPWISE APPROACH TO ASTHMA MANAGEMENT**

**STEP 1**

- Low dose ICS
  - Consider low dose ICS
  - Leukotriene receptor antagonist (LTRA)
  - Low dose theophylline

**STEP 2**

- Low dose ICS/LABA
  - Med/high dose ICS/LABA
  - High dose ICS + LTRA

**STEP 3**

- Med/high dose ICS/LABA
  - Add tiotropium
  - Add high dose ICS + LTRA

**STEP 4**

- Refer for add-on treatment
  - e.g. tiotropium
  - anti-IgE
  - anti-IL5

**STEP 5**

- Add low dose OCS
1. Asthma exacerbations should be treated with:
   a. Corticosteroids.
      - Prednisolone 1 mg/kg PO daily (up to 50 mg) or equivalent × 7 d for mild-to-moderate exacerbations.
      - Methylprednisolone 1 mg/kg IV q6h initially for severe exacerbations.
   b. Magnesium sulfate 2 g IV.
   c. Oxygen to keep SpO₂ >90%.
   d. Rapid-acting β-agonists (4–10 puffs albuterol pMDI with spacer or 2.5-5 mg nebulized every 20 min for 1 h).
   e. Ipratropium bromide stepwise approach.
   f. Consider bilevel positive airway pressure (Bi-PAP) for acute asthma exacerbations.
   g. No role for routine antibiotics. Use antibiotics only for definite bacterial infections.

2. Develop a chronic medication regimen for patients adjusted based on their asthma action plan.

Source
– 2017 Global Initiative for Asthma (http://www.ginasthma.org)

Comments
1. Controlled asthma defined by:
   a. Daytime symptoms ≤2×/wk.
   b. No limitations of daily activities.
   c. No nocturnal symptoms.
   d. Need for reliever medicines ≤2×/wk.
   e. Normal or near-normal lung function.
   f. No exacerbations.

2. Partially controlled asthma if:
   a. Daytime symptoms >2×/wk.
   b. Any limitations of daily activities or any nocturnal symptoms.
   c. Need for reliever medicines ≤2×/wk.
   d. <80% predicted PEF or forced expiratory volume at 1 s (FEV₁).
   e. Any exacerbations.

3. Uncontrolled asthma if there are ≥3 features of partially controlled asthma in any week.

4. Risk factors for adverse asthma events:
   a. Poor clinical control.
   b. Frequent asthma exacerbations.
   c. History of ICU admission for asthma exacerbation.
   d. FEV₁ <60% predicted.
   e. Exposure to cigarette smoke.
   f. Need for high-dose medications.
5. Recommend an inhaled corticosteroid for partially controlled or uncontrolled asthma.
6. Add a long-acting β-agonist or leukotriene inhibitor for incomplete control with inhaled corticosteroid alone.
7. Short-acting β₂-agonists should be used as needed for relief of acute asthma symptoms or 20 min prior to planned exercise in exercise-induced asthma. Alternatives for exercise-induced asthma include a leukotriene inhibitor or cromolyn.
8. For difficult-to-control asthma:
   a. Treat potentially aggravating conditions: rhinitis, gastroesophageal reflux disease (GERD), nasal polyps.
   b. Consider alternative diagnoses: chronic obstructive pulmonary disease (COPD) or vocal cord dysfunction.

### ASYMPOTOMATIC BACTERIURIA

**Population**
- Nonpregnant women.

**Recommendation**
- IDSA 2015
  - Do not treat asymptomatic bacteriuria with antibiotics.

**Source**

### ATOPIC DERMATITIS (AD)

**Population**
- Adults and children.

**Recommendations**
- AAD 2014
  - Generous application of skin moisturizers after bathing.
  - Recommend limited use of hypoallergenic non-soap cleansers.
  - Consider wet-wrap therapy with topical corticosteroids for moderate-to-severe AD during flares.
  - Twice-daily topical corticosteroids are the first-line therapy for AD.
  - Topical calcineurin inhibitors (tacrolimus or pimecrolimus) can be used for maintenance AD therapy.
  - Recommend against topical antihistamine therapy for AD.
DISEASE MANAGEMENT

- Phototherapy is second-line treatment for refractory cases.
- Consider systemic immunomodulating agents for severe cases refractory to topical agents and phototherapy.

**Sources**

**Comment**
- Systemic immunomodulating agents that have been studied in AD are azathioprine, cyclosporine, or methotrexate.

---

### ATRIAL FIBRILLATION

#### ATRIAL FIBRILLATION: MANAGEMENT OVERVIEW HEART RATE CONTROL

**Classification of Atrial Fibrillation (AF)**
- Paroxysmal = Self-terminating
- Recurrent = Two or more episodes
- Persistent = Lasts >7 days
- Silent = Detected by monitor
- Lone = Unassociated with heart disease

**Initiate Treatment**
- Slow the ventricular rate
- Establish anticoagulation
- Consider rhythm conversion

**Determine Etiology**
- Hypertension/coronary artery disease
- Cardiomyopathy/heart valve disease
- Pulmonary disease/hyperthyroidism
- Sinus node disease

- Expected ventricular heart rate (HR) in untreated AF is between 110 and 210 beats/min.
  - If HR <110 beats/min, atrioventricular (AV) node disease present.
  - If HR >220 beats/min, preexcitation syndrome (WPW) present.
- Initial choice of AV nodal slowing agent to be determined by:
  - Ventricular rate/blood pressure (BP).
  - Presence of heart failure (HF) or asthma.
  - Associated cardiovascular (CV) symptoms (chest pain/shortness of breath [SOB]).

**Urgent electrical cardioversion** should be considered if hemodynamic instability or persistent symptoms of ischemia, HF, or if inadequate HR control with optimal medications.
ATRIAL FIBRILLATION: MANAGEMENT OVERVIEW HEART RATE CONTROL  (Continued)

- **Resting HR goal and exercise HR goal** should be determined. Holter monitor best measures the adequacy of the chronic HR control. In acute medical conditions when the patient has noncardiac illness (ie, pneumonia), the resting HR may be allowed to increase to simulate physiologic demands (mimic HR if sinus rhythm was present).

  - **Lenient Target**
    - Resting HR <110 beats/min
    - May be considered in younger or patients without CV symptoms.

  - **Aggressive Target**
    - Resting HR <80 beats/min
    - Exercise HR <110 beats/min
    - Treatment choice if decreased ejection fraction (EF) <40% if symptoms at higher rates.

(ESC recommends HR target <110 beats/min; CCS recommends <100 beats/min; ACCF/AHA/HRS recommends HR target <110 beats/min only if EF >40%.)

- **Consider AV nodal ablation** when chronic HR target cannot be achieved with maximal medical therapy with placement of ventricular pacemaker.

ACCF, American College of Cardiology Foundation; AHA, American Heart Association; CCS, Canadian CV Society; ESC, European Society of Cardiology; HRS, Heart Rhythm Society.


Data suggest that stopping anticoagulation with warfarin prior to the ablation (even if patients are bridged with low-molecular-weight heparin) is associated with an increased risk of complications compared with an uninterrupted anticoagulation approach. In COMPARE study, patients with CHADS2 score of >1 undergoing catheter ablation for nonvalvular AF, bridged with low-molecular-weight heparin, had a >10-fold increased risk of ischemic stroke or transient ischemic attack in the 48 h after ablation compared with those on uninterrupted warfarin. Patients with atrial fibrillation frequently stop oral anticoagulation therapy following radiofrequency catheter ablation despite an increased risk for stroke, transient ischemic attack, or systemic embolism in the first 3 mo after the procedure, according to the results of a new analysis. If the patient is at a lower risk for stroke, the type of patient that might not need to be anticoagulated to begin with, then the medication can be stopped after 3 mo. Everybody else should remain on oral anticoagulation for at least 12 mo after the ablation. At that point, physicians can reassess a patient’s risk factors to determine whether the oral anticoagulation should continue.


For patients undergoing catheter ablation for nonvalvular atrial fibrillation, continuing with uninterrupted rivaroxaban appears to be as safe as uninterrupted oral anticoagulant therapy with warfarin.


Choosing Wisely American Society of Echocardiography (2013) recommends against transesophageal echocardiography to detect cardiac sources of embolization if a source has been identified and patient management will not change.

### 2014 AHA/ACC/HRS Guidelines for Prevention of Thromboembolism in Patients with AF

- Antithrombotic therapy based on shared decision making, discussion of risks of stroke and bleeding, and patient’s preferences.
- Antithrombotic therapy selection based on risk of thromboembolism.
- CHA$_2$DS$_2$-VASc score recommended to assess stroke risk.
- Warfarin recommended with mechanical heart valves. Target INR intensity should be based on the type and location of prosthesis.
- With prior stroke, TIA, or CHA$_2$DS$_2$-VASc score ≥2, oral anticoagulants are recommended. Options include warfarin or DOACs: dabigatran, rivaroxaban, or apixaban.
- With warfarin, determine INR at least weekly during initiation and monthly when stable.
- Direct thrombin or factor Xa inhibitor recommended over warfarin for nonvalvular AFib.
- Apixiban, rivaroxaban, and dabigatran all are equally efficacious for ischemic stroke and systemic embolism prevention; however, apixiban has decreased incidence of major bleeding and GI bleeding compared to other DOACs.
- Reevaluate the need for anticoagulation at periodic intervals.
- Bridging therapy with LMWH or UFH recommended with a mechanical heart valve or with mitral stenosis if warfarin is interrupted. Bridging therapy should balance risks of stroke and bleeding.
- Without a mechanical heart valve, bridging therapy decisions should balance stroke and bleeding risks against the duration of time patient will not be anticoagulated.
- Evaluate renal function prior to initiation of direct thrombin or factor Xa inhibitors, and reevaluate when clinically indicated and at least annually.
- For atrial flutter, antithrombotic therapy is recommended as for AF.

• New oral anticoagulation agents (DOACs) are alternative agents to the use of warfarin.
• Quantitative indicators of the function are not clinically available for direct thrombin inhibitors (DTIs) or factor X inhibitors (FXa).
• Qualitative indicators of the presence of DTI agent (dabigatran) and FXa inhibitors (rivaroxaban and apixaban) are available.
  - Activated partial thromboplastin time (aPTT) is a measure of DTI presence.
  - Prothrombin time (PT) is a measure of FXa inhibitor presence.
• Drug interactions with DOAC agents are generally less than with warfarin but still need to be considered.
• Rivaroxaban should be taken with food to optimize absorption and bioavailability. No other DOAC agents are influenced to food ingestion.
• No interaction is noted between DOAC agents and proton pump inhibitor (PPI) agents and H₁ blockers exist.
• All DOAC agents require dose reduction with renal dysfunction.
• DOAC agents have a short action of duration of 12–24 h and therefore should be avoided in patients with poor medicine adherence.
• No specific antidotes for DOAC agents exist.
  - If no bleeding, hold subsequent doses and observe.
  - If clinical bleeding noted, expert opinion suggests the use of prothrombin complex concentrates (PCCs) 50 U/kg is recommended.
• Preoperatively with normal renal function should hold DOAC agent >=24h before surgery with low bleeding risk and CrCl>80 ml/min; hold DOAC 48-72 hours before surgery with high bleeding risk and CrCl>80 ml/min.

DIRECT ORAL ANTICOAGULANTS (DOACS)  
DABIGATRAN ETEXILATE (PRADAXA®)

• Direct thrombin inhibitor.
• Dosage:
  ° 150 mg 1 tab bid (CICr >50 mL/min).
  ° 75 mg 1 tab bid (CICr 15–30 mL/min).
  ° Not recommended in end-stage CKD on or not on dialysis.
• Pharmacokinetics/pharmacodynamics: Cytochrome P450 metabolism: none; half-life: 12–14 h; renal elimination: 80%.
• ACC/AHA recommends it as a useful alternative to warfarin in patients who have nonvalvular AF and do not have severe renal and liver disease.
• ESC recommends it in patients with nonvalvular AF with at least one moderate risk factor.
• RE-LY Trial (150 mg bid)—similar reduction in stroke and systemic embolism vs. warfarin (2.07% vs. 2.78% per year). Increased GI bleeds compared to warfarin, especially in patients ≥75 y old.
• By FDA 12/2012, risk of bleeding did not appear to be higher in patients with new use of dabigatran compared to new use of warfarin.

• Switching patients from warfarin to dabigatran: Discontinue warfarin and start dabigatran when the INR is <2.0.
• Switching patients from dabigatran to warfarin: Adjust the starting time of warfarin based on creatinine clearance as follows:
  ° For CrCl ≥50 mL/min, start warfarin 3 d before discontinuing dabigatran.
  ° For CrCl 30–50 mL/min, start warfarin 2 d before discontinuing dabigatran.
  ° For CrCl 15–30 mL/min, start warfarin 1 d before discontinuing dabigatran.
• Converting from/to parenteral anticoagulants
  ° For patients currently receiving a parenteral anticoagulant, start dabigatran 0–2 h before the time that the next dose of parenteral drug was to be administered or at the time of discontinuation of a continuously administered parenteral drug (eg, intravenous unfractionated heparin).
  ° For patients currently taking dabigatran, wait 12 h (CrCl ≥30 mL/min) or 24 h (CrCl <30 mL/min) after the last dose of dabigatran, before initiating treatment with a parenteral anticoagulant.
• If possible, discontinue dabigatran 1–2 d (CrCl ≥50 mL/min) or 3–5 d (CrCl <50 mL/min) before invasive or surgical procedures. Consider longer times for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, in whom complete hemostasis may be required. Restart as soon as possible.
• Discontinuation on Pradaxa without adequate continuous anticoagulation increases the risk of stroke.
• To measure adherence for dabigatran, measure thrombin level. If low, the patient is not taking the medicine.
• Idarucizumab is now approved by the FDA and rapidly reverses direct thrombin inhibition.

+ (XARELTO®)

- Direct factor Xa inhibitor.
- FDA indication: Nonvalvular AF, DVT, PE.
- Dosage in nonvalvular AF:
  - 20 mg 1 tab qhs with meal (CrCl >50 mL/min).
  - 15 mg 1 tab qhs with meal (CrCl 15–50 mL/min).
  - Not recommended in end-stage CKD on or not on dialysis.
- Pharmacokinetics/pharmacodynamics: cytochrome P450 metabolism: 32%; half-life: 9–13 h; renal elimination: 33%.
- ROCKET AF trial: Noninferior to warfarin regarding prevention of stroke and systemic embolism. No reduction in rates of mortality or ischemic stroke, but a significant reduction in hemorrhagic stroke and intracranial hemorrhage. Compared to warfarin it was nonsignificantly different in nonmajor bleeding; had significant reduction in fatal bleeding and increased GI bleeding and bleeds requiring transfusion).
- 5 phase III trials of dabigatran vs. warfarin: Patients with major bleeding on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in ICU, and had a trend to lower mortality compared with those who had major bleeding on warfarin.
- Switching from warfarin to rivaroxaban: Discontinue warfarin and start XARELTO as soon as INR <3.
- **Switching from rivaroxaban to warfarin:** No clinical trial data are available to guide converting patients. Company recommends to discontinue rivaroxaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of rivaroxaban would be taken.
- **Rivaroxaban should be stopped at least 24 h before surgeries** or other invasive procedures and should be resumed as soon as possible. If oral medication cannot be taken, consider administering a parenteral anticoagulant.
- Premature discontinuation of rivaroxaban increases the risk of stroke.
- To measure adherence for rivaroxaban, measure factor Xa activity. If low, the patient is not taking the medicine.

Andexanet alfa, an antidote to the factor Xa inhibitor, ANNEXA-R trial, awaiting results of phase 3 summer 2015.

APIXABAN (ELIQUIS®)

- Direct factor Xa inhibitor.
- Indication: Nonvalvular AF, DVT prophylaxis after hip or knee replacement surgery.
- Dosage:
  - 5 mg 1 tab bid.
  - 2.5 mg 1 tab bid on patients ≥80 y old, weight ≤60 kg, Cr ≥1.5 mg/dL or patients taking P450 and P-glycoprotein inhibitors.
  - Not recommended in severe CKD or end-stage CKD on or not on dialysis.
  - Avoid concomitant use of rivaroxaban with strong CYP3A4 inhibitors and combined P-gp.
- Pharmacokinetics/pharmacodynamics: Cytochrome P450 metabolism: 15%; half-life: 8–15 h; renal elimination: 40%.
- AVERROES trial: Apixaban was superior in preventing stroke vs. ASA in patients who could not tolerate or were intolerant to warfarin.
- ARISTOTLE trial: Apixaban was superior to warfarin in reducing stroke or systemic embolism by 21%. Also 31% reduction in major bleeding and 11% reduction in all-cause mortality (not CV). Rates of hemorrhagic stroke and ISH (but not ischemic stroke) were lower in apixaban group. GI bleeding was similar in both groups. Apixaban was better tolerated than warfarin with slightly fewer discontinuations.

- **Switching from warfarin to apixaban**: Warfarin should be discontinued and apixaban started when INR <2.
- **Switching from apixaban to warfarin**: Discontinue apixaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of apixaban would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.
- **Discontinue apixaban at least 48 h prior to elective surgeries** or invasive procedures with high risk of bleeding and 24 h prior to invasive procedures with low risk of bleeding. Bridging is not generally required. Resume it after surgery as soon as possible.
  - Premature discontinuation of apixaban has increased risk of thrombotic events.
  - To measure adherence for apixaban, measure factor Xa activity. If low, the patient is not taking the medicine.

Andexanet alfa, an antidote to the factor Xa inhibitor, ANNEXA-A Study, currently seeking approval to FDA. (http://www.medscape.com/viewarticle/832648)

Sources:
  - http://www.pradaxa.com
  - http://www.xarelto-us.com
  - http://www.eliquis.com
EDOXABAN (SAVAYSA®)

- Factor X inhibitor.
- FDA indication: nonvalvular AF, DVT, PE.
- Dosage in nonvalvular AF:
  - 60 mg once daily in patients with CrCl >50 to ≤95 mL/min (CrCl with Cockcroft–Gault equation).
  - 30 mg daily in patients with CrCl 15–50 mL/min.
  - Do not use in patients with CrCl >95 mL/min because of increased risk of ischemic stroke compared to warfarin.
  - Not recommended in patients with moderate or severe hepatic impairment (Child–Pugh B and C).
- Contraindications: active pathological bleeding.
- There is no established way to reverse the anticoagulant effects of edoxaban, which can be expected to persist for approximately 24 h after the last dose. The anticoagulant effect of edoxaban cannot be reliably monitored with standard laboratory testing. Hemodialysis does not significantly contribute to edoxaban clearance.
- Epidural or spinal hematomas may occur in patients treated with edoxaban who are receiving neuroaxial anesthesia or undergoing spinal puncture.
- Concomitant use of drugs affecting hemostasis may increase the risk of bleeding. These include aspirin and other antiplatelet agents, other anti-thrombotic agents, fibrinolytic therapy, and chronic use of nonsteroidal anti-inflammatory drugs.
- Pharmacokinetics/pharmacodynamics: peak plasma concentration: 1–2 h, half-life: 10–14 h; renal elimination: 50%. Steady-state concentrations are achieved in 3 d.

**The ENGAGE AF-TIMI 48 study:**

The median study drug exposure for the edoxaban and warfarin treatment groups was 2.5 y. Bleeding led to treatment discontinuation in 3.9% and 4.1% of patients in the edoxaban 60 mg and warfarin treatment groups, respectively. Treatment arms of edoxaban were noninferior to warfarin for the primary efficacy endpoint of stroke or systemic embolism. However, the 30 mg (15 mg dose-reduced) treatment arm was numerically less effective than warfarin for the primary endpoint, and was also markedly inferior in reducing the rate of ischemic stroke. Approximately half of the edoxaban dose is eliminated by the kidney, and edoxaban blood levels are lower in patients with better renal function, averaging about 30% less in patients with CrCl of >80 mL/min, and 40% less in patients with CrCl >95 mL/min when compared to patients with a CrCl of >50 to ≤80 mL/min. Given the clear relationship of dose and blood levels to effectiveness in the ENGAGE AF-TIMI 48 study, it could be anticipated that patients with better renal function would show a smaller effect of edoxaban compared to warfarin than would patients with mildly impaired renal function, and this was in fact observed.

**Switching to edoxaban**

- **Switching patients from warfarin to edoxaban:** Discontinue warfarin and start edoxaban when INR ≤2.5.
- **Switching patients from OAC other than warfarin or other VKA:** Discontinue the current oral anticoagulant and start edoxaban at the time of the next scheduled dose of the other oral anticoagulant.
· **Switching patients from LMWH to edoxaban**: Discontinue LMWH and start edoxaban at the time of the next scheduled administration of LMWH.

· **Switching patients from unfractionated heparin to edoxaban**: Discontinue the infusion and start edoxaban 4 h later.

· **Switching from edoxaban**
  · **Switching patients from edoxaban to warfarin**
    · **ORAL**: For patients taking 60 mg of edoxaban, reduce the dose to 30 mg and begin warfarin concomitantly. For patients receiving 30 mg of edoxaban, reduce the dose to 15 mg and begin warfarin concomitantly. INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the influence of edoxaban on INR measurements. Once a stable INR ≥2.0 is achieved, edoxaban should be discontinued and the warfarin continued.
    
    PARENTERAL: Discontinue edoxaban and administer a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Once a stable INR ≥2.0 is achieved the parenteral anticoagulant should be discontinued and the warfarin continued.
  
  · **Switching patients from edoxaban to non-VKA anticoagulants**: Discontinue edoxaban and start the other oral anticoagulant at the time of the next dose of edoxaban.
  
  · **Switching patients from edoxaban to parenteral anticoagulants**: Discontinue edoxaban and start the parenteral anticoagulant at the time of the next dose of edoxaban.

· If possible, discontinue edoxaban at least 24 h before invasive or surgical procedures because of the risk of bleeding. It can be restarted after the surgical or other procedure as soon as adequate hemostasis has been established noting that the time to onset of pharmacodynamic effect is 1–2 h. Administer a parenteral anticoagulant and then switch to oral edoxaban, if oral medication cannot be taken during or after surgical intervention.

· Discontinuation of edoxaban without adequate continuous anticoagulation increases the risk of stroke.

Source: http://www.savaysa.com/
### DOAC COMPARISON CHART

<table>
<thead>
<tr>
<th></th>
<th>Warfarin</th>
<th>Dabigatran</th>
<th>Rivaroxaban</th>
<th>Apixaban</th>
<th>Edoxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular target</td>
<td>Vitamin-dependent clotting factor</td>
<td>Thrombin</td>
<td>Factor X₃</td>
<td>Factor X₃</td>
<td>Factor X₃</td>
</tr>
<tr>
<td>Dosing in AF</td>
<td>Once daily</td>
<td>Twice daily</td>
<td>Once daily</td>
<td>Twice daily</td>
<td>Once daily</td>
</tr>
<tr>
<td>Time to peak plasma concentration (min)</td>
<td>240</td>
<td>85–150</td>
<td>30–180</td>
<td>30–120</td>
<td>30–60</td>
</tr>
<tr>
<td>Time to peak effect (h)</td>
<td>96–120</td>
<td>2</td>
<td>2–3</td>
<td>1–2</td>
<td>1–2</td>
</tr>
<tr>
<td>Half-life (h)</td>
<td>40</td>
<td>14–17</td>
<td>5–9 (increased to 11–13 in elderly)</td>
<td>8–15</td>
<td>9–11</td>
</tr>
<tr>
<td>Renal clearance</td>
<td>&lt;1%</td>
<td>80%</td>
<td>33%</td>
<td>25%</td>
<td>35%</td>
</tr>
<tr>
<td>Hepatic excretion</td>
<td></td>
<td>20%</td>
<td>66%</td>
<td>75% (hepatic-biliary-intestinal)</td>
<td>65%</td>
</tr>
<tr>
<td>Food and drug interactions</td>
<td>Foods rich in vitamin K, substrates of CYP2C9, CYP3A4, and CYP1A2</td>
<td>Strong P-gp inhibitors and inducers</td>
<td>Strong CYP3A4 inducers, strong inhibitors of both CYP3A4 and P-gp</td>
<td>Strong inhibitors and inducers of CYP3A4 and P-gp</td>
<td>Strong P-gp inhibitors</td>
</tr>
<tr>
<td>Creatinine clearance below which drug is contraindicated</td>
<td>n/a</td>
<td>&lt;30 mL/min</td>
<td>&lt;15 mL/min</td>
<td>&lt;15 mL/min</td>
<td>&lt;30 mL/min (Japan)</td>
</tr>
</tbody>
</table>

### Antithrombotic Strategies Following Coronary Artery Stenting in Patients with AF at Moderate to High Thromboembolic Risk (in Whom Oral Anticoagulation Therapy Is Required)

<table>
<thead>
<tr>
<th>Hemorrhagic Risk</th>
<th>Clinical Setting</th>
<th>Stent Implanted</th>
<th>Anticoagulation Regimen</th>
</tr>
</thead>
</table>
| Low or intermediate (eg, HAS-BLED score 0–2) | Elective | Bare metal | 1 mo: triple therapy of VKA (INR 2.0–2.5) + aspirin ≤100 mg/d + clopidogrel 75 mg/d  
Up to 12th mo: combination of VKA (INR 2.0–2.5) + clopidogrel 75 mg/d (or aspirin 100 mg/d)  
Lifelong: VKA (INR 2.0–3.0) alone |
|                  | Elective | Drug eluting | 3 (sirolimus* group) to 6 (paclitaxel) mo: triple therapy of VKA (INR 2.0–2.5) + aspirin ≤100 mg/d + clopidogrel 75 mg/d  
Up to 12th mo: combination of VKA (INR 2.0–2.5) + clopidogrel 75 mg/d (or aspirin 100 mg/d)  
Lifelong: VKA (INR 2.0–3.0) alone |
| ACS              | Bare metal/drug eluting | 6 mo: triple therapy of VKA (INR 2.0–2.5) + aspirin ≤100 mg/d + clopidogrel 75 mg/d  
Up to 12th mo: combination of VKA (INR 2.0–2.5) + clopidogrel 75 mg/d (or aspirin 100 mg/d)  
Lifelong: VKA (INR 2.0–3.0) alone |
| High (eg, HAS-BLED score ≥3) | Elective | Bare metal* | 2–4 wk: triple therapy of VKA (INR 2.0–2.5) + aspirin ≤100 mg/d + clopidogrel 75 mg/d  
Lifelong: VKA (INR 2.0–3.0) alone |
| ACS              | Bare metal* | 4 wk: triple therapy of VKA (INR 2.0–2.5) + aspirin ≤100 mg/d + clopidogrel 75 mg/d  
Up to 12th mo: combination of VKA (INR 2.0–2.5) + clopidogrel 75 mg/d (or aspirin 100 mg/d)  
Lifelong: VKA (INR 2.0–3.0) alone |

ACS, acute coronary syndrome; AF, atrial fibrillation; INR, international normalized ratio; VKA, vitamin K antagonist. Gastric protection with a proton pump inhibitor (PPI) should be considered where necessary.

*Sirolimus, everolimus, and tacrolimus.

†Drug-eluting stents should be avoided as far as possible, but, if used, consideration of more prolonged (3–6 mo) triple antithrombotic therapy is necessary.

‡Combination of VKA (INR 2.0–3.0) + aspirin ≤100 mg/d (with PPI, if indicated) may be considered as an alternative.

CHAPTER 3

ATRIAL FIBRILLATION: MANAGEMENT OF RHYTHM CONTROL DRUG AND NONPHARMACOLOGIC THERAPY

• AFFIRM, RACE, PIAF, and STAF trials found no difference in quality of life between rate and rhythm control in atrial fibrillation (AF). The AFFIRM and RACE trials demonstrated no difference in stroke rate or mortality between rate and rhythm control in AF.

Asymptomatic in AF
- Older patients
- Advanced heart disease
- Comorbid conditions
- Persistent AF

Favors Rate Control

Continued symptoms in AF
- Younger patients
- LONE or minimal heart disease
- Few comorbid conditions
- Recent onset/paroxysmal AF

Favors Rhythm Control

VS

• Rhythm control:
Fifty percent of patients with new-onset AF spontaneously convert to sinus in 48 h.

• 2, 3, 4 Cardioversion rule
- New-onset AF <2 d in duration—may be considered for acute electrical or drug conversion to sinus rhythm while on heparin.
- Onset of AF >2 d or of unknown duration—requires either 3 wk of therapeutic oral anticoagulation (INR 2–3) or a negative transesophageal echocardiogram (TEE) to exclude clot before conversion while on heparin.
- In either approach to conversion, oral anticoagulation (OAC) must be continued at least 4 wk postconversion because of the possibility of delayed return of atrial contraction and clot release. In high-risk patients, lifelong OAC should be considered.
• FDA Warning 2011: Dronedarone should not be used in chronic atrial fibrillation; it doubles rate of cardiovascular (CV) death, stroke, and HF.

• Nonpharmacologic approach
- AF catheter ablation/MAZE procedure (open surgical approach):
  Consider if antiarrhythmic drug therapy fails or if AF coexists with preexcitation pathway. AF ablation is more effective in younger patients with paroxysmal AF; catheter ablation maintains sinus rhythm approximately 80% as opposed to approximately 40% with drugs at 5 y. May require repeat procedures (average: 1.8 procedures). Long-term anticoagulation should be continued even after successful ablation in patients at high risk for thromboembolism. In low-embolic-risk patients, warfarin may be converted to aspirin (ASA) therapy after 3 mo. (J Am Coll Cardiol. 2010;55:735–743)
- Consider MAZE procedure if performing open heart surgery for other reasons or if vascular or cardiac anatomy prevents the less invasive catheter approach.
- Consider implantable atrial defibrillators: least commonly used treatment.

• Prevention of atrial remodeling
- Calcium channel blockers.
- Angiotensin-converting enzyme (ACE) inhibitors.
- Angiotensin receptor blocker (ARB) agents.
- Statins.
STRATEGIES FOR RHYTHM CONTROL IN PATIENTS WITH PAROXYSMAL and PERSISTENT AF FROM 2014 AHA/ACC/HRS GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION

HF, heart failure; LVH, left ventricular hypertrophy.
* Catheter ablation is only recommended as first-line therapy for patients with paroxysmal AF (Class IIa recommendation).
* Drugs are listed alphabetically.
* Depending on patient preference when performed in experienced centers.
* Not recommended with severe LVH (wall thickness >1.5 cm).
* Should be used with caution in patients at risk for torsades de pointes ventricular tachycardia.
* Should be combined with AV nodal blocking agents. AF indicates atrial fibrillation; CAD, coronary artery disease.

Recommendation
Heart Rhythm Society 2014
– Recommends against use of Class Ic antiarrhythmic drugs (Vaughan-Williams) as a first-line agent for the maintenance of sinus rhythm in patients with ischemic heart disease who have experienced prior MI.

Source
–http://www.choosingwisely.org/societies/heart-rhythm-society/
# HAS-BLED BLEEDING RISK SCORE FOR WARFARIN THERAPY

<table>
<thead>
<tr>
<th>Letter</th>
<th>Clinical Characteristics</th>
<th>Points Awarded</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>Hypertension (systolic blood pressure [SBP] &gt;160 mm Hg)</td>
<td>1</td>
</tr>
<tr>
<td>A</td>
<td>Abnormal renal function (presence of chronic dialysis or renal transplantation or serum creatinine ≥2.6 mg/dL) and abnormal liver function (chronic hepatic disease or biochemical evidence of significant hepatic derangement (bilirubin &gt;2× upper limit of normal, in association with glutamic-oxaloacetic transaminase [GOT]/glutamic-pyruvic transaminase [GPT] &gt;3× upper limit normal) <strong>1 point each</strong></td>
<td>1 or 2</td>
</tr>
<tr>
<td>S</td>
<td>Stroke</td>
<td>1</td>
</tr>
<tr>
<td>B</td>
<td>Bleeding (previous bleeding history and/or predisposition to bleeding, eg, bleeding diathesis, anemia)</td>
<td>1</td>
</tr>
<tr>
<td>L</td>
<td>Labile INRs (unstable/high INRs or poor time in therapeutic range, eg, &lt;60%)</td>
<td>1</td>
</tr>
<tr>
<td>E</td>
<td>Elderly (age &gt;65 y)</td>
<td>1</td>
</tr>
<tr>
<td>D</td>
<td>Drugs or alcohol (concomitant use of drugs such as antiplatelet agents, nonsteroidal anti-inflammatory drugs, or alcohol abuse) <strong>1 point each</strong></td>
<td>1 or 2</td>
</tr>
</tbody>
</table>

**Maximum 9 points**

### Interpretation

The risk of (spontaneous) major bleeding (intracranial, hospitalization, hemoglobin decrease 2 g/L, and/or transfusion) within 1 y in patients with atrial fibrillation enrolled in the Euro Heart Survey expressed as bleeds per 100 patient-years:

- Score 0: 1.13
- Score 4: 8.70
- Score 3: 3.74
- Score 6–9: insufficient data to quantify risk

**Sources:**
## Thromboembolic Risk Scores in Nonvalvular Atrial Fibrillation

<table>
<thead>
<tr>
<th>CHADS&lt;sub&gt;2&lt;/sub&gt;</th>
<th>Points</th>
<th>CHA&lt;sub&gt;2&lt;/sub&gt;DS&lt;sub&gt;-VASc&lt;/sub&gt;</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>1</td>
<td>Congestive heart failure</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(or left ventricular systolic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>dysfunction [LVEF] ≤40%)</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>1</td>
<td>Hypertension (BP consistently</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;140/90 mm Hg or treated HTN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>on medication)</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>1</td>
<td>Age ≥75 y</td>
<td>2</td>
</tr>
<tr>
<td>D</td>
<td>1</td>
<td>Diabetes mellitus</td>
<td>1</td>
</tr>
<tr>
<td>S&lt;sub&gt;2&lt;/sub&gt;</td>
<td>2</td>
<td>Prior stroke or transient</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ischemic attack (TIA)</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
<td>Vascular disease (eg, coronary</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>artery disease, peripheral</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>artery disease, myocardial</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>infarction [MI], aortic plaque)</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>1</td>
<td>Age 65–74 y</td>
<td>1</td>
</tr>
<tr>
<td>Sc</td>
<td>1</td>
<td>Sex category (ie, female gender)</td>
<td>1</td>
</tr>
<tr>
<td>Max.</td>
<td>6</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

### Stroke Risk Stratification with the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>-VASc</sub> Scores

| CHADS<sub>2</sub> score acronym | Adjusted Stroke Rate (% per year) |
|--------------------------------|--|----------------------------------|
| 0                              | 1.9                              |
| 1                              | 2.8                              |
| 2                              | 4.0                              |
| 3                              | 5.9                              |
| 4                              | 8.5                              |
| 5                              | 12.5                             |
| 6                              | 18.2                             |
### STROKE RISK STRATIFICATION WITH THE CHADS\(_2\) AND CHA\(_2\)DS\(_2\)-VASC SCORES  (Continued)

<table>
<thead>
<tr>
<th>CHADS(_2)-VAS(_2) score acronym(^b)</th>
<th>Adjusted Stroke Rate (% per year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>1.3</td>
</tr>
<tr>
<td>2</td>
<td>2.2</td>
</tr>
<tr>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td>4</td>
<td>4.0</td>
</tr>
<tr>
<td>5</td>
<td>6.7</td>
</tr>
<tr>
<td>6</td>
<td>9.8</td>
</tr>
<tr>
<td>7</td>
<td>9.6</td>
</tr>
<tr>
<td>8</td>
<td>6.7</td>
</tr>
<tr>
<td>9</td>
<td>15.20</td>
</tr>
</tbody>
</table>

\(^a\) C, CHF; H, hypertension; A, age > 75 y; D, diabetes mellitus; S, history of stroke or TIA.

\(^b\) C, CHF; H, hypertension; A, age 65–74 y; D, diabetes mellitus; S, history of stroke or TIA; V, vascular disease; A, age 75 y or older; S, female sex.

### RISK FACTORS FOR STROKE AND THROMBOEMBOLISM IN NONVALVULAR AF

<table>
<thead>
<tr>
<th>“Major” Risk Factors</th>
<th>“Clinically Relevant Nonmajor” Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous</td>
<td>• Heart failure or moderate-to-severe left ventricular (LV) systolic dysfunction (LVEF ≤40%)</td>
</tr>
<tr>
<td>• Stroke</td>
<td>• Hypertension</td>
</tr>
<tr>
<td>• TIA</td>
<td>• Diabetes mellitus</td>
</tr>
<tr>
<td>• Systemic embolism</td>
<td>• Female sex</td>
</tr>
<tr>
<td>• Age ≥75 y</td>
<td>• Age 65–74 y</td>
</tr>
<tr>
<td></td>
<td>• Vascular disease</td>
</tr>
</tbody>
</table>


### ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

#### Population
- Children 4–18 y old.

#### Recommendations
- **AAP 2011**
  - Initiate an evaluation for ADHD in any child who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity.
Consider children with ADHD as children with special health care needs.
For children age 4–5 y, parent- or teacher-administered behavior therapy is the treatment of choice.
Methylphenidate is reserved for severe refractory cases.
For children age 6–18 y, first-line treatment is with FDA-approved medications for ADHD ± behavior therapy.

Source
http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654.full.pdf

Population
Children, young adults, and adults.

Recommendations

NICE 2013
Health care and education professionals require training to better address the needs of people with ADHD.
Recommends against universal screening for ADHD in nursery, primary, and secondary schools.
A diagnosis of ADHD should only be made by a specialist psychiatrist, pediatrician, or other appropriately qualified health care professional with training and expertise in the diagnosis of ADHD.
Health care professionals should stress the value of a balanced diet, good nutrition, and regular exercise for children, young people, and adults with ADHD.
Drug treatment is not recommended for preschool children with ADHD.
Drug treatment is not indicated as the first-line treatment for all school-age children and young people with ADHD. It should be reserved for those with severe symptoms and impairment or for those with moderate levels of impairment who have refused nondrug interventions.
Where drug treatment is considered appropriate, methylphenidate, atomoxetine, and dexamfetamine are recommended, within their licensed indications, as options for the management of ADHD in children and adolescents.
For adults with ADHD, drug treatment should be the first-line treatment.
- Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first.
- Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate.
Source

Comments
1. Essential to assess any child with ADHD for concomitant emotional, behavioral, developmental, or physical conditions (eg, mood disorders, tic disorders, seizures, sleep disorders, learning disabilities, or disruptive behavioral disorders).
2. For children 6–18 y, evidence is best to support stimulant medications and less strong to support atomoxetine, ER guanfacine, and ER clonidine for ADHD.

AUTISM

Population
–Children and young adults.

Recommendations
▶ NICE 2011
–Consider autism for regression in language or social skills in children <3 y.
–Clinical signs of possible autism have to be seen in the context of a child’s overall development, and cultural variation may pertain.
–An autism evaluation by a specialist is indicated for any of the following signs of possible autism:
  • Language delay.
  • Regression in speech.
  • Echolalia.
  • Unusual vocalizations or intonations.
  • Reduced social smiling.
  • Rejection of cuddles by family.
  • Reduced response to name being called.
  • Intolerance of others entering into their personal space.
  • Reduced social interest in people or social play.
  • Reduced eye contact.
  • Reduced imagination.
  • Repetitive movements like body rocking.
  • Desire for unchanged routines.
  • Immature social and emotional development.

Source
Cochrane Database of Systematic Reviews 2014
– Recommends against chelation therapy for autism spectrum disorders.

Source
– http://www.cochrane.org/CD010766/BEHAV_chelation-for-autism-spectrum-disorder-asd

Comment
– Differential diagnosis of autism includes:
  • Neurodevelopmental disorders.
  • Mood disorders.
  • ADHD.
  • Oppositional defiant disorder.
  • Conduct disorder.
  • Obsessive-compulsive disorder (OCD).
  • Rett syndrome.
  • Hearing or vision impairment.
  • Selective mutism.

AUTISM SPECTRUM DISORDERS (ASDS)

Population
– Children with ASDs.

Recommendations
– American College of Medical Genetics and Genomics 2013
  – Every child with an ASD should have a medical home.
  – A genetic consultation should be offered to all patients with an ASD and their families.
  – Three-generation family history with pedigree analysis.
  – Initial evaluation to identify known syndromes or associated conditions.
    • Examination with special attention to dysmorphic features.
    • If specific syndromic diagnosis is suspected, proceed with targeted testing.
    • If appropriate clinical indicators present, perform metabolic and/or mitochondrial testing (alternatively, consider a referral to a metabolic specialist).
    • Chromosomal microarray: oligonucleotide array-comparative genomic hybridization or single-nucleotide polymorphism array.
• Deoxyribonucleic acid (DNA) testing for fragile X (to be performed routinely for male patients only).
  –Methyl-CPG-binding protein 2 (MECP2) sequencing to be performed for all females with autism spectrum disorders (ASDs).
  –MECP2 duplication testing in males, if phenotype is suggestive.
  –Phosphatase and tensin homolog (PTEN) testing only if the head circumference is >2.5 standard deviation (SD) above the mean.

Source

## BACK PAIN, LOW

**Population**
–Adults.

**Recommendations**

ACP 2017

–Consider nonpharmacologic treatments for acute or subacute low-back pain including superficial heat, massage, acupuncture, or spinal manipulation.

–If pharmacologic treatments needed, start with NSAIDs or skeletal muscle relaxants.

–For chronic low back pain, start a trial of nonpharmacologic treatments including exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, biofeedback, cognitive behavioral therapy, or spinal manipulation.

–For persistent chronic low-back pain, pharmacologic therapy with NSAIDs as first-line therapy and tramadol or duloxetine as second-line therapy.

–Use opiates for chronic low-back pain only if patients have failed all other therapies and only if the potential benefits outweigh the risks of dependency, addiction, overdose, and misuse.

**Sources**

**NICE 2009**

1. Educate patients and promote self-management of low-back pain.
2. Recommends offering one of the following treatment options:
   a. Structure exercise program.
   b. Manual therapy.*
   c. Acupuncture.
3. Consider a psychology referral for patients with a high disability and/or who experience significant psychological distress from their low-back pain.
4. Recommends against routine lumbar spine x-rays.
5. Recommends an MRI scan of lumbar spine only if spinal fusion is under consideration.
6. Consider a referral for surgery in patients with refractory, severe non-specific low-back pain who have completed the programs above and would consider spinal fusion.

**Source**

**ICSI 2010**
- See table.

**Source**
- [https://www.icsi.org/health_initiatives/other_initiatives/low_back_pain/](https://www.icsi.org/health_initiatives/other_initiatives/low_back_pain/)

**Comment**

1. Analgesic ladder for low-back pain
   a. Recommend scheduled acetaminophen.
   b. Add NSAIDs and/or weak opioids.
   c. Consider adding a tricyclic antidepressant.
   d. Consider a strong opioid for short-term use for people in severe pain.
   e. Refer for specialist assessment for people who may require prolonged use of strong opioids.

---

* Manual therapy includes spinal manipulation, spinal mobilization, and massage.
EVALUATION AND MANAGEMENT OF ACUTE LOW-BACK PAIN

Definitions

Acute low-back pain (LBP) or sciatica/radiculopathy

- Acute low-back pain (LBP) has a duration ≤6 wk and does NOT radiate past the knee
- Acute sciatica/radiculopathy has a duration >6 weeks and pain radiates past the knee

Emergent or urgent evaluation?

- Bowel or bladder incontinence
- Related to trauma
- Sudden bilateral leg weakness
- Saddle numbness
- Fever ≥100.4°F for ≥48 h
- Unrelenting night pain or pain at rest
- Progressive pain with distal leg numbness or leg weakness
- Progressive neurological deficit

No

Yes

Refer to ER for evaluation

Red Flags for metastases?

- ≥50 y
- History of cancer
- Unexplained weight loss
- Unrelenting back pain despite 4–6 wk of conservative LBP therapy

Red Flags for spine infection?

- IV drug use
- Immunosuppression
- History of tuberculosis
- Unrelenting back pain with fever ≥38°C
- Urinary tract infection

Red Flags for spine fracture?

- Onset after trauma
- Osteoporosis
- Chronic steroid use

Red Flags for cord or nerve root compression?

- New onset urinary incontinence or urinary retention
- Saddle anesthesia
- Acute sciatica
- Acute radiculopathy
- New onset numbness and weakness in the legs

Any of the following present?

- Back pain lasting longer than 6 wk
- Unexplained weight loss (greater than 10 lb in 6 mo)
- Over age 50
- History of cancer
- Moderate-to-severe new onset back pain or leg pain

No

Yes

Patient should be seen in 2–7 d

Patient should be seen within 7 d

Treatment of Acute LBP

- Light duty activities
- Regular walking
- Avoid heavy lifting
- Acetaminophen and NSAIDs
- Opioids can be used to control refractory pain for the short term
- Muscle relaxants may be beneficial as needed for the first several days
- Apply ice packs or heat to affected area
- Identify and manage stressors

Evaluation and Management

- Lumbar x-rays if fracture or metastases suspected
- Blood work if cancer or infection suspected
- MRI of lumbar spine if a spine infection or cord compression is suspected
- Specially referral dependent upon etiology
- Early referral to physical therapy for any disabling back or leg pain is present

Elements of Back Pain Evaluation

- Screen for mood disorders
- Assess functional limitations
- Palpate for spine tenderness
- Assess posture, gait, range of motion
- Strength testing
- Reflex testing
- Sensory testing
- Straight leg raise
- Lumbar x-rays if fracture or metastases suspected
- Blood work if cancer or infection suspected

Treatment of Persistent Pain

- Physical therapy
- Graded exercise program
- Practice good body mechanics to avoid exacerbations of back pain
- Consider a referral to a spine specialist
- Consider lumbar x-rays
- Consider an epidural steroid injection for radiculopathy

Source: ICSI, November 2010.
BARRETT ESOPHAGUS

Population
– Patients with biopsy diagnosis of Barrett esophagus (metaplastic columnar epithelium in distal esophagus).

Recommendations

AGA 2011
– No dysplasia
  Endoscopic surveillance (ES) every 3–5 y.
– Low-grade dysplasia
  • ES every 6–12 mo—consider radiofrequency ablation (RFA)—90% complete eradication of dysplasia.
– High-grade dysplasia
  • ES every 3 mo if no eradication therapy.
– Eradication therapy
  • RFA, photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) is preferred over ES in high-grade dysplasia (strong recommendation).

Sources
– JAMA. 2013; 310:627

Comment
– Clinical Facts
  • In patients with Barrett esophagus without dysplasia, 0.12% develop esophageal cancer per year compared to 0.5% with low-grade dysplasia.
  • Progression from high-grade dysplasia to cancer is 6% per year. (N Engl J Med. 2011;365:1375)
  • Esophagectomy for high-grade dysplasia is an option, but less morbidity with ablation therapy. (N Engl J Med. 2009;360:2277)
  • 40% of patients with Barrett esophagus and esophageal cancer have no history of chronic GERD symptoms.
  • Long-term high-dose PPIs or antireflux therapy have been shown to decrease risk of neoplastic progression in patients with Barrett esophagus. (Clin Gastroenteral Hepatol. 2013;11:382)
  • Risk of developing cancer is higher among men, older patients (>65 y old) and patients with long segments of Barrett’s mucosa or dysplasia. (Am J Gastroenterol. 2011;106:1231) (Gat. 2016;65:196)
BELL’S PALSY

Population
– Adults with Bell’s palsy.

Recommendation

▶ AAN 2012
– For patients with recent-onset Bell’s palsy (<72 h of symptoms)
  • Steroids are recommended to increase the probability of facial nerve recovery.
    ◦ Prednisone 1 mg/kg PO daily × 7 d.
  • Antivirals (eg, acyclovir or valacyclovir) × 7 d given with steroids marginally improves outcomes compared with steroid monotherapy.

Source

Comment
– Antivirals are thought to have a marginal effect at best of facial nerve recovery when added to steroids. The benefit is <7%.

Population
– Adult and children with Bell’s palsy.

Recommendations

▶ AAO 2013, Cochrane Database of Systematic Reviews 2015
– No routine lab studies needed for unequivocal Bell’s palsy.
– Recommend against routine diagnostic imaging for straightforward Bell’s palsy.
– Recommend oral steroids for Bell’s palsy with or without antiviral medications if initiated within 72 h of symptom onset in patients 16 y and older.
– Recommend against antiviral monotherapy for Bell’s palsy.
– Recommend eye protection for patients with incomplete eye closure.
– Inadequate evidence to support surgical decompression with Bell’s palsy.
– Recommend against electrodagnostic testing for Bell’s palsy with incomplete facial paralysis.
– Recommend against physical therapy or acupuncture for Bell’s palsy.

Sources
– http://www.cochrane.org/CD001869/NEUROMUSC_antiviral-treatment-for-bells-palsy
Comment
– Cochrane analysis found no benefit of adding antivirals to corticosteroids vs. corticosteroid monotherapy.

BENIGN PROSTATIC HYPERPLASIA (BPH)

Population
– Adult men.

Recommendations

AUA 2010
1. Routine measurement of serum creatinine is not indicated in men with BPH.
2. Do not recommend dietary supplements or phytotherapeutic agents for lower urinary tract symptoms (LUTS) management.
3. Patients with LUTS with no signs of bladder outlet obstruction by flow study should be treated for detrusor overactivity.
   a. Alter fluid intake.
   b. Behavioral modification.
   c. Anticholinergic medications.
4. Options for moderate-to-severe LUTS from BPH (AUA symptom index score ≥8).
   a. Watchful waiting.
   b. Medical therapies.
      i. α-blockers.a
      ii. 5-Alfa-reductase inhibitors.b
      iii. Anticholinergic agents.
      iv. Combination therapy.
   c. Transurethral needle ablation.
   d. Transurethral microwave thermotherapy.
   e. Transurethral laser ablation or enucleation of the prostate.
   f. Transurethral incision of the prostate.
   g. Transurethral vaporization of the prostate.
   h. Transurethral resection of the prostate.
   i. Laser resection of the prostate.
   j. Photoselective vaporization of the prostate.
   k. Prostatectomy.
5. Surgery is recommended for BPH causing renal insufficiency, recurrent urinary tract infections (UTIs), bladder stones, gross hematuria, or refractory LUTS.

a Alfa-blockers: alfuzosin, doxazosin, tamsulosin, and terazosin. All have equal clinical effectiveness.
b 5-Alfa-reductase inhibitors: dutasteride and finasteride.
CHAPTER 3

Source

Comments
1. Combination therapy with alfa-blocker and 5-alfa-reductase inhibitor is effective for moderate-to-severe LUTS with significant prostate enlargement.
2. Men with planned cataract surgery should have cataract surgery before initiating alfa-blockers.
3. 5-Alfa-reductase inhibitors should not be used for men with LUTS from BPH without prostate enlargement.
4. Anticholinergic agents are appropriate for LUTS that are primarily irritative symptoms and patient does not have an elevated postvoid residual (>250 mL).
5. The choice of surgical method should be based on the patient’s presentation, anatomy, surgeon’s experience, and patient’s preference.

BREAST CANCER FOLLOW-UP CARE

Population
–Early-stage women with curable breast cancer.

Recommendation
➤ American Society of Clinical Oncology (ASCO) 2013

—Mode of Surveillance
• Careful history and physical examination every 3–6 mo for first 3 y after primary therapy (with or without adjuvant treatment), then every 6–12 mo for next 2 y and then annually.
• Counsel patients about symptoms of recurrence including new lumps, bone pain, chest pain, dyspnea, abdominal pain, or persistent headaches.
• High-risk women for familial breast CA syndromes should be referred for genetic counseling—high-risk criteria include Ashkenazi Jewish heritage, history of ovarian CA at any age in the patient or any first-degree relatives; any first-degree relative with breast CA before age 50; two or more first- or second-degree relatives diagnosed with breast CA at any age; patient or relative with bilateral breast CA; and history of breast CA in male relative.
• All women should be counseled to perform monthly self-breast examinations.
• Mammography—women treated with breast-conserving therapy should have first posttreatment mammogram no earlier than 6 mo after radiation. Subsequent mammograms every 6–12 mo for surveillance (yearly preferred if stability of mammogram achieved).
DISEASE MANAGEMENT

• Regular gynecology follow-up with pelvic examination. Tamoxifen increases risk of uterine cancer and patients should be advised to report any vaginal bleeding if they are taking tamoxifen.
• Coordination of care: Risk of recurrence continues through more than 15 y (especially in woman who are hormone receptor positive). Continuity of care by physicians experienced in surveillance of patients and in breast examination is recommended. Follow-up by a primary care physician (PCP) leads to the same outcome as specialist follow-up. If the patient desires transfer of care to PCP, 1 y after definitive therapy is appropriate.

Sources
– NCCN Guidelines. 2015;BINV-16:27

Comments
1. Reduce Routine Investigative Testing
   • The following routine studies are NOT recommended for routine breast cancer surveillance:
     a. CBC and automated chemistry studies.
     b. Routine chest x-ray.
     c. Bone scans.
     d. Liver ultrasound.
     e. Routine CT scanning.
     f. Routine FDG-PET scanning.
     g. Breast MRI (unless patient has BRCA1 or BRCA2 mutation or previous mediastinal radiation at young age).
     h. Tumor markers including CA27.29, CA15-3, or CEA are not recommended for routine surveillance. (JAMA. 1994;27:1587-1592)
2. Although studies have shown no survival benefit for routine surveillance testing, many oncologists will do routine blood studies including tumor markers especially in higher risk women. The most important follow-up strategy is to make certain patients know and report early signs or symptoms that may reflect recurrent disease.
3. There is a significant difference in the behavior of hormone receptor (HR) positive vs. hormone receptor negative disease. HR-negative disease tends to recur earlier (2–3 y) than HR-positive breast cancer (>50% of relapses occur after 5 y).
4. There is also a 3- to 4-fold increase in risk of brain metastasis in HR-negative women vs. HR-positive women.
5. Overexpression of Her2 is found in 20% of breast cancer patients and targeted therapy in this group has significantly improved prognosis. Her2 overexpressed patients, however, are also at increased risk for brain metastasis.
6. HR-positive patients have a 4-fold increased risk of bone metastasis compared to HR-negative patients in whom metastases to liver, lung, and brain are more common. \(\text{N Engl J Med. 2007;357:39}\)

### BRONCHITIS, ACUTE

**Population**
- Adults age ≥18 y.

**Recommendations**
- Michigan Quality Improvement Consortium 2010
  1. Recommends against a chest x-ray if all the following are present:
     a. Heart rate <100 beats/min.
     b. Respiratory rate <24 breaths/min.
     c. Temperature <100.4°F (38°C).
  2. Recommends against antibiotics.

**Source**

**Comments**
2. β₂ agonists or mucolytic agents should not be used routinely to alleviate cough.

### CARBON MONOXIDE POISONING

**Population**
- Adults presenting to ED with suspected or known carbon monoxide poisoning.

**Recommendations**
1. Do not use noninvasive carbon monoxide measurements to diagnose carbon monoxide poisoning.
2. Use hyperbaric oxygen or high-flow oxygen therapy for acute carbon monoxide poisoning.

**Source**
CAROTID ARTERY DISEASE

CAROTID ARTERY STENOSIS

Extracranial carotid stenosis

Asymptomatic

Stenosis <70%

• Age ≥79 y
• Unstable cardiac disease
• Experienced surgeon unavailable

Surgical risk <3%

Endarterectomy

Medical therapy (risk-factor control, antiplatelet drugs, statins, and ACE inhibitors)

Symptomatic (within 6 mo)

Stenosis ≥70%

• Age ≥79 y
• Stable cardiac disease
• Experienced surgeon available

Surgical risk ≥3%

Lower risk of carotid stroke

Endarterectomy

Stenosis ≥70%

Mild stenosis (<50%)

• Less severe stenosis
• Age <75 y
• Female sex
• Stroke ≥3 mo earlier
• Visual symptoms alone
• No intracranial stenosis
• Microvascular ischemia

Moderate stenosis (50%–69%)

• More severe stenosis
• Age ≥75 y
• Male sex
• Stroke 3 mo earlier or less
• Hemispheric symptoms
• Intracranial stenosis
• No microvascular ischemia

Severe stenosis (≥70%)

Higher risk of carotid stroke

Endarterectomy

• More severe stenosis
• Age ≥75 y
• Male sex
• Stroke ≥3 mo earlier
• Hemispheric symptoms
• Intracranial stenosis
• No microvascular ischemia

CAS (carotid artery stenting) is indicated as an alternative to CEA (carotid endarterectomy) for symptomatic patients at average or low risk of complications associated with endovascular intervention when the diameter of the lumen of the internal carotid artery is reduced by >70% by noninvasive imaging or >50% by catheter-based imaging or noninvasive imaging with corroboration, and the anticipated rate of periprocedural stroke or death is <6% (Class IIa; Level of Evidence (LOE) B).

It is reasonable to consider patient's age in choosing between CAS and CEA. For older patients (≥70 y), CEA may be associated with improved outcome compared with CAS, particularly when arterial anatomy is unfavorable for endovascular intervention. For younger patients, CAS is equivalent to CEA in terms of risk for periprocedural complication (ie, stroke, MI, or death) and long-term risk for ipsilateral stroke (Class IIa; LOE B).

CAS and CEA in the above settings should be performed by operators with established periprocedural stroke and mortality rates of <6% for symptomatic patients, similar to that observed in trials comparing CEA to medical therapy and more recent observational studies (Class I; LOE B).

Routine, long-term follow-up imaging of the extracranial carotid circulation with carotid duplex ultrasonography is not recommended (Class III; Level of Evidence B).

For patients with recurrent or progressive ischemic symptoms ipsilateral to a stenosis or occlusion of a distal (surgically inaccessible) carotid artery, or occlusion of a midcervical carotid artery after institution of optimal medical therapy, the usefulness of EC/IC bypass is considered investigational (Class IIB; LOE C).

Women only:

For women with recent TIA or IS and ipsilateral moderate (50%–69%) carotid stenosis, CEA is recommended depending on patient-specific factors, such as age and comorbidities, if the perioperative morbidity and mortality risk is estimated to be <6%.

In women who are to undergo CEA, aspirin is recommended unless contraindicated, because aspirin was used in every major trial that demonstrated efficacy of CEA.

For women with recent TIA or IS within the past 6 mo and ipsilateral severe (70%–99%) carotid artery stenosis, CEA is recommended if the perioperative morbidity and mortality risk is estimated to be <6%.

If a high-risk female patient (ie, 10-y predicted CVD risk ≥10%) has an indication for aspirin but is intolerant to it, the patient should be placed on clopidogrel.

Aspirin therapy (75–325 mg/d is reasonable in women with diabetes mellitus unless contraindicated.

When CEA is indicated for women with TIA or stroke, surgery within 2 w is reasonable rather than delaying surgery if there are no contraindications to early revascularization.

Aspirin therapy can be useful in women >65 y of age (81 mg daily or 100 mg every other day) if blood pressure is controlled and benefit for ischemic and myocardial infarction prevention is likely to outweigh risk of gastrointestinal bleeding and hemorrhagic stroke (Class IIa; Level of Evidence B) and may be reasonable for women <65 y of age for ischemic stroke prevention.

CATARACT

CATARACT IN ADULTS: EVALUATION AND MANAGEMENT ALGORITHM

1. Patient complaining of vision impairment
2. Comprehensive eye and vision examination; cataract identified as cause?
   - Yes
     - Treat as appropriate
     - Surgery, postoperative care, and follow-up
     - Patient counseling and decision
   - No
     - Nonsurgical measures and follow-up at 4–12-mo intervals
     - Prefer nonsurgical measures
       - Degree of functional impairment sufficient to warrant surgery?
         - Yes
           - Ophthalmic or medical contraindications to surgery?
             - Yes
               - Prefers surgery
             - No
               - Nonsurgical measures
                 - Patient education
                 - Determine whether functional disability develops
         - No
           - Prefer nonsurgical measures
             - Strong bifocals or magnifying glasses
             - Pupillary dilation

3. Patient counseling and decision

4. Degree of functional impairment sufficient to warrant surgery?

5. Comprehensive eye and vision examination; cataract identified as cause?

*Begin evaluation only when patients complain of a vision problem or impairment. Identifying impairment in visual function during routine history and physical examination constitutes sound medical practice.

*Essential elements of the comprehensive eye and vision exam:
   - Patient history: Consider cataract if acute or gradual onset of vision loss; vision problems under special conditions (e.g., low contrast, glare); difficulties performing various visual tasks. Ask about refractive history, previous ocular disease, amblyopia, eye surgery, trauma, general health history, medications, and allergies. It is critical to describe the actual impact of the cataract on the person’s function and quality of life. There are several instruments available for assessing functional impairment related to cataract, including VF-14, Activities of Daily Vision Scale, and Visual Activities Questionnaire.
   - Ocular examination includes Snellen acuity and refraction; measurement of intraocular pressure; assessment of pupillary function; external exam; slit-lamp exam; and dilated exam of fundus.
   - Supplemental testing: May be necessary to assess and document the extent of the functional disability and to determine whether other diseases may limit preoperative or postoperative vision. Most elderly patients presenting with visual problems do not have a cataract that causes functional impairment. Refractive error, macular degeneration, and glaucoma are common alternative etiologies for visual impairment.

*Once cataract has been identified as the cause of visual disability, patients should be counseled concerning the nature of the problem, its natural history, and the existence of both surgical and nonsurgical approaches to management. The principal factor that should guide decision making with regard to surgery is the extent to which the cataract impairs the ability to function in daily life. The findings of the physical examination should corroborate that the cataract is the major contributing cause of the functional impairment, and that there is a reasonable expectation that managing the cataract will positively impact the patient’s functional activity. Preoperative visual acuity is a poor predictor of postoperative functional improvement: The decision to recommend cataract surgery should not be made solely on the basis of visual acuity.

*Patients who complain of mild-to-moderate limitation in activities due to a visual problem, those whose corrected acuities are near 20/40, and those who do not yet wish to undergo surgery may be offered nonsurgical measures for improving visual function. Treatment with nutritional supplements is not recommended. Smoking cessation retards cataract progression. Indications for surgery: Cataract-impaired vision no longer meets the patient’s needs; evidence of lens-induced disease (e.g., phacomorphic glaucoma, phacoelastic glaucoma); necessary to visualize the fundus in an eye that has the potential for sight (e.g., diabetic patient at risk of diabetic retinopathy).
CATARACT IN ADULTS: EVALUATION AND MANAGEMENT ALGORITHM (Continued)

- Contraindications to surgery: The patient does not desire surgery; glasses or vision aids provide satisfactory functional vision; surgery will not improve visual function; the patient's quality of life is not compromised; the patient is unable to undergo surgery because of coexisting medical or ocular conditions; a legal consent cannot be obtained; or the patient is unable to obtain adequate postoperative care. Routine preoperative medical testing (12-lead EKG, CBC, measurement of serum electrolytes, BUN, creatinine, and glucose), while commonly performed in patients scheduled to undergo cataract surgery, does not appear to measurably increase the safety of the surgery.

- Patients with significant functional and visual impairment due to cataract who have no contraindications to surgery should be counseled regarding the expected risks and benefits of and alternatives to surgery.

Sources:

CELIAC DISEASE

Population
- Children and adults with celiac disease.

Recommendations

- NICE 2015
  - Serological testing for suspected celiac disease:
    - Test for total IgA and IgA tissue transglutaminase (tTG).
    - Use IgA endomysial antibody test if IgA tTG is weakly positive.
  - Refer individuals with positive serological tests to a GI specialist for endoscopic duodenal biopsy to confirm the diagnosis.
  - For refractory celiac disease despite strict adherence to gluten-free diet:
    - Review certainty of diagnosis.
    - Consider coexisting conditions such as irritable bowel syndrome, lactose intolerance, microscopic colitis, or inflammatory bowel disease.

Source
- https://guidelines.gov/summaries/summary/49592

CERUMEN IMPACTION

Population
- Children and adults.

Recommendations

- AAO-HNS 2008
  1. Strongly recommended treating cerumen impaction when it is symptomatic or prevents a needed clinical examination.
2. Clinicians should treat the patient with cerumen impaction with an appropriate intervention:
   a. Ceruminolytic agents.
   b. Irrigation.

*Source*

– http://www.entnet.org/practice/cerumenimpaction.cfm

*Comment*

– Ceruminolytic agents include Cerumenex, addax, Debex, or dilute solutions of acetic acid, hydrogen peroxide, or sodium bicarbonate.

---

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), EXACERBATIONS**

**Population**

– Adults.

**Recommendations**

> ERS/ATS 2017

**ERS/ATS RECOMMENDATIONS FOR COPD EXACERBATIONS**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 For ambulatory patients with an exacerbation of COPD, we suggest a short course (≤14 days) of oral corticosteroids</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
<tr>
<td>2 For ambulatory patients with an exacerbation of COPD, we suggest the administration of antibiotics</td>
<td>Conditional</td>
<td>Moderate</td>
</tr>
<tr>
<td>3 For patients who are hospitalised with a COPD exacerbation, we suggest the administration of oral corticosteroids rather than intravenous corticosteroids if gastrointestinal access and function are intact</td>
<td>Conditional</td>
<td>Low</td>
</tr>
<tr>
<td>4 For patients who are hospitalised with a COPD exacerbation associated with acute or acute-on-chronic respiratory failure, we recommend the use of noninvasive mechanical ventilation</td>
<td>Strong</td>
<td>Low</td>
</tr>
<tr>
<td>5 For patients with a COPD exacerbation who present to the emergency department or hospital, we suggest a home-based management programme (hospital-at-home)</td>
<td>Conditional</td>
<td>Moderate</td>
</tr>
<tr>
<td>6 For patients who are hospitalised with a COPD exacerbation, we suggest the initiation of pulmonary rehabilitation within 3 weeks after hospital discharge</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
<tr>
<td>7 For patients who are hospitalised with a COPD exacerbation, we suggest not initiating pulmonary rehabilitation during hospitalisation</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
</tbody>
</table>

*Source*

NICE 2010, GOLD 2017

- Recommend noninvasive positive pressure ventilation for moderate-to-severe hypercapnic respiratory failure.
- Prednisolone 30–40 mg orally, or its equivalent IV, should be prescribed for 5–7 d.
- Recommend antibiotics for 5–7 d for COPD exacerbations associated with more purulent sputum or need for mechanical ventilation.
- Bronchodilators can be delivered by either nebulizers or meter-dosed inhalers depending on the patient's ability to use the device during a COPD exacerbation. Bilevel positive airway pressure (Bi-PAP) is indicated for moderate-to-severe COPD exacerbations.
- Bi-PAP decreases mortality, need for mechanical ventilation, infectious complications, and hospital length of stay.
- Subcutaneous heparin or low-molecular-weight heparin for DVT prophylaxis.
- Monitor fluid balance.
- Methylxanthines are not recommended due to its side effect profile.

Sources


Cochrane Database of Systematic Reviews 2014

- Short-course corticosteroids (7 d or less) is sufficient treatment for adults with a COPD exacerbation.

Source


Comment

- Initial empiric antibiotics should be an aminopenicillin, macrolide, or a tetracycline and should be given for 5–10 d.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), STABLE

NICE 2010, GOLD 2017

Population

- Adults.
Recommendations

- Recommends confirming all suspected COPD with postbronchodilator spirometry.
- Recommends spirometry in all persons age >35 y who are current or ex-smokers and have a chronic cough to evaluate for early-stage COPD.
- Recommends smoking cessation counseling.
- GOLD initiative assesses severity of COPD by GOLD Grades 1-4 based on spirometry and GOLD Stages A-D based on symptoms and exacerbation history.

### REVISED GOLD COPD GRADING AND STAGING

<table>
<thead>
<tr>
<th>Spirometrically confirmed diagnosis</th>
<th>Assessment of airflow limitation</th>
<th>Assessment of symptoms/risk of exacerbations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt;/FVC &lt; 0.7</td>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; (% predicted)</td>
<td>Exacerbation history</td>
</tr>
<tr>
<td>GOLD 1</td>
<td>≥ 80</td>
<td>≤ 2 or ≥ 1 leading to hospital admission</td>
</tr>
<tr>
<td>GOLD 2</td>
<td>50–79</td>
<td>0 or 1 (not leading to hospital admission)</td>
</tr>
<tr>
<td>GOLD 3</td>
<td>30–49</td>
<td></td>
</tr>
<tr>
<td>GOLD 4</td>
<td>&lt; 30</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>mMRC 0–1</td>
</tr>
<tr>
<td>mMRC ≥ 2</td>
</tr>
</tbody>
</table>

1. Stepwise medication approach:
   a. Short-acting β-agonist (SABA) and short-acting muscarinic agonist (SAMA) as needed (PRN).
   b. If persistent symptoms, add:
      i. FEV<sub>1</sub> ≥50% of predicted, add either a long-acting β-agonist (LABA) or long-acting muscarinic agonist (LAMA).
      ii. FEV<sub>1</sub> <50% of predicted, add either LABA + inhaled corticosteroid (ICS), or LAMA.
   c. If persistent symptoms, add:
      i. LAMA to LABA + ICS.
      ii. Roflumilast, a phosphodiesterase-4 inhibitor, improves lung function and reduces moderate-to-severe exacerbations for patients with severe COPD.
      iii. Consider azithromycin 250 mg/d for severe COPD with frequent exacerbations.

#ICS: beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, and triamcinolone; LABA: arformoterol, formoterol, or salmeterol; LAMA: tiotropium; SABA: albuterol, fenoterol, levalbuterol, metaproterenol, pirbuterol, and terbutaline.
2. Recommend pulmonary rehabilitation for symptomatic patients with moderate-to-severe COPD (FEV$_1$ <50% of predicted).
3. Continuous oxygen therapy should be prescribed for COPD patients with room air hypoxemia (PaO$_2$ ≤55 mm Hg or SpO$_2$ ≤88%).
4. All patients should have a pneumococcal vaccine and annual influenza vaccines.
5. Recommend screening COPD patients for osteoporosis and depression.
6. Recommend against regular mucolytic therapy.
7. Nutritional support indicated for patients with severe COPD with malnutrition.
8. Recommend calculating the BODE index (BMI, airflow obstruction, dyspnea, and exercise capacity on a 6-min walk test) to calculate the risk of death in severe COPD.\(^b\)

### COMMON MEDICATIONS FOR THE MANAGEMENT OF COPD

<table>
<thead>
<tr>
<th>Drug</th>
<th>Inhaler (µg/dose)</th>
<th>Nebulizer (mg/mL)</th>
<th>Drug</th>
<th>Inhaler (µg/dose)</th>
<th>Nebulizer (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting β$_2$-agonists</strong></td>
<td></td>
<td></td>
<td><strong>Combination β$_2$-agonist-anticholinergics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albuterol</td>
<td>100–200 M/D</td>
<td>5</td>
<td>Albuterol-ipratropium</td>
<td>100/20 M/D</td>
<td>1 vial</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>45–90 M</td>
<td>0.21, 0.42</td>
<td><strong>Methylxanthines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting β$_2$-agonists</strong></td>
<td></td>
<td></td>
<td><strong>Inhaled corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arformoterol</td>
<td>4.5–12 M/D</td>
<td>0.075</td>
<td>Theophylline SR</td>
<td>100–600 mg pill PO</td>
<td></td>
</tr>
<tr>
<td>Formoterol</td>
<td></td>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indacaterol</td>
<td>75–300 D</td>
<td></td>
<td>Beclomethasone</td>
<td>50–400 M/D</td>
<td>0.2–0.4</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>25–50 M/D</td>
<td></td>
<td>Budesonide</td>
<td>100,200,400 D</td>
<td>0.2, 0.25, 0.5</td>
</tr>
<tr>
<td><strong>Short-acting anticholinergics</strong></td>
<td></td>
<td></td>
<td><strong>Combination β$_2$-agonist-corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>20, 40 M</td>
<td>0.25–0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting anticholinergics</strong></td>
<td></td>
<td></td>
<td><strong>Phosphodiesterase-4 inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aclidinium bromide</td>
<td>322 D</td>
<td></td>
<td>Formoterol-budesonide</td>
<td>4.5/160 M, 9/320 M</td>
<td></td>
</tr>
<tr>
<td>Tiotropium</td>
<td>18 M, 5 SMI</td>
<td></td>
<td>Formoterol-mometasone</td>
<td>10/200 M or 10/400 M</td>
<td></td>
</tr>
<tr>
<td><strong>Phosphodiesterase-4 inhibitors</strong></td>
<td></td>
<td></td>
<td>Salmeterol-fluticasone</td>
<td>50/100, 50/250, 50/500 M</td>
<td>25/50, 25/125, 25/250 M</td>
</tr>
<tr>
<td>Roflumilast</td>
<td>500 µg PO daily</td>
<td></td>
<td>Vilaunterol-fluticasone</td>
<td>25/100 D</td>
<td></td>
</tr>
</tbody>
</table>

M = metered dose inhalers
D = dry powder inhalers
SMI = Soft mist inhalers


Source: Data from GOLD Guide to COPD Diagnosis, Management and Prevention. ([http://goldcopd.org](http://goldcopd.org))
**DISEASE MANAGEMENT**

**Sources**

**Comments**
1. FEV₁/FVC <0.7 confirms the presence of airflow obstruction and COPD.
2. Classification of COPD by spirometry:
   a. Mild COPD = FEV₁ ≥80% of predicted.
   b. Moderate COPD = FEV₁ 50–79% of predicted.
   c. Severe COPD = FEV₁ 30–49% of predicted.
   d. Very severe COPD = FEV₁ <30% of predicted.
4. Consider roflumilast, a phosphodiesterase-4 inhibitor, to reduce exacerbations for patients with severe chronic bronchitis with frequent exacerbations.

---

**COBALAMIN (B₁₂) DEFICIENCY**

**Population**
- Adults ≥19 y of age.

**Recommendations**
- British Colombia Medical Services Commission 2012

1. **Who to test:**
   a. Unexplained neurologic symptoms including paresthesias, numbness, poor motor coordination, and cognitive and personality changes.
   b. Macrocytic anemia with oval macrocytes, hypersegmented neutrophils, or pancytopenia.
   c. Elderly (≥75 y old), history of inflammatory bowel disease, gastric or small bowel resection, prolonged vegan diet and specific medications (histamine receptor antagonist, proton pump inhibitors, and metformin).

2. **How to test:**
   a. Perform a complete blood count, peripheral blood smear, and serum B₁₂ level.
   b. <220 pmol/L is most recognized cut-off with increasing probability of clinical deficiency. If B₁₂ <75 Pmol/L, clinical signs and symptoms are highly likely. In borderline patients with normal renal function, methylmalonic acid levels will be elevated in B₁₂ deficient patients.
   c. Elevated LDH, indirect bilirubin, and low haptoglobin are common findings.
3. Treatment—Early

a. Therapy of cobalamin deficiency is important because neurologic symptoms may be irreversible if treatment delayed.

b. Oral crystalline cyanocobalamin is as effective as parenteral B₁₂. 1000 μg/d is the recommended dose but parenteral administration (1000 μg/d for 5–10 d) should be given to patients with neurological symptoms.

c. In these patients 1000–2000 μg/d given orally should follow parenteral administration.

d. Retest serum cobalamin levels after 2–4 mo to ensure they are in the normal range.

Sources


– Blood. 2008;112:2214-2221.


Comments

1. Pernicious anemia (the most common cause of B₁₂ deficiency) is an autoimmune illness with antibodies to parietal cells and intrinsic factor resulting in gastric atrophy and malabsorption of food-derived B₁₂.

2. Cobalamin is found exclusively in animal products such as meat, seafood, dairy products, and eggs. Consider supplemental oral B₁₂ in patients who are long-term vegans.

3. No matter what the cause of B₁₂ deficiency, oral B₁₂ (1000–2000 μ) daily will correct lower B₁₂ levels.

4. With pure B₁₂ deficiency the mean corpuscular volume (MCV) is usually >110. If iron deficiency is also present due to bleed or atrophic gastritis the MCV can be <100.

5. Patients with elevated MCV who are folate deficient must have B₁₂ deficiency ruled out since treatment with folate in patients with B₁₂ deficiency will accelerate peripheral neuropathy.

6. The incidence of B₁₂ deficiency in the elderly (>70 y old) is 5%–10%.

7. Less frequent causes of B₁₂ deficiency include Helicobacter pylori infection, Diphyllobothrium latum infection, nitrous oxide exposure, alcoholism, Zollinger-Ellison syndrome, small bowel diverticulum, and following gastric bypass surgery.

8. Drugs that can cause folate deficiency include trimethoprim, pyrimethamine, methotrexate, and phenytoin.

9. When treating B₁₂ and folate deficiency, the MCV may become decreased due to acquired iron deficiency as iron is incorporated into red cell precursors in response to B₁₂ and/or folate therapy.
COLITIS, CLOSTRIDIUM DIFFICILE

**Population**
- Adults.

**Recommendation**

- IDSA SHEA 2010
  - Treatment of *C. difficile* infection.
    - Discontinue antibiotics as soon as possible.
    - Avoid antiperistaltic agents.
    - Mild-to-moderate *C. difficile* infection: metronidazole 500 mg PO tid × 10–14 d.
    - Severe *C. difficile* infection: vancomycin 125 mg PO qid × 10–14 d.
    - Severe complicated *C. difficile* infection taking POs: vancomycin 500 mg PO qid ± metronidazole 500 mg IV q8h.
    - Severe complicated *C. difficile* infection and NPO: 500 mg in 100 mL normal saline enema per rectum qid ± metronidazole 500 mg IV q8h.
    - Administer vancomycin as a tapered regimen for recurrent *C. difficile* infection.

**Source**

**Comments**
1. Testing for *C. difficile* or its toxins should be performed only on diarrheal stool.
2. Testing of stool on asymptomatic patients should be avoided.
3. Enzyme immunoassay (EIA) testing for *C. difficile* toxins A and B is rapid but is less sensitive than the cell cytotoxin assay.
4. Stool for *C. difficile* toxins by polymerase chain reaction (PCR) is rapid and very sensitive and specific.

**Population**
- Adults and children.

**Recommendations**

- ACG 2013
  - Only diarrheal stools should be tested for *C. difficile*.
  - Nucleic acid amplification tests (NAAT) for *C. difficile* toxin genes such as polymerase chain reaction (PCR) are superior to toxins A+B enzyme immunoassay (EIA) testing as a standard diagnostic test for *C. difficile* infection (CDI).
  - Do not perform repeat testing.
  - Avoid testing for cure.
Management of mild-to-moderate *C. difficile* infection (CDI)

- Stop all unnecessary antibiotics.
- Recommend empiric therapy of CDI regardless of test results if high pretest probability of CDI.
- First-line therapy.
  - Metronidazole 500 mg PO tid × 10 d.
- Second-line therapy.
  - Vancomycin 125 mg PO qid × 10 d.
  - Indicated for intolerance of metronidazole, lack of improvement after 5–7 d on metronidazole, pregnancy, or breast-feeding.
  - Avoid antiperistaltic meds.

Severe or complicated CDI

- Vancomycin 125 mg PO qid AND metronidazole 500 mg IV q8h × 10 d.
- If ileus or severe abdominal distension, use vancomycin 500 mg PO qid AND 500 mg enema PR qid AND metronidazole 500 mg IV q8h × 10 d.
  - IV hydration.
  - Electrolyte repletion.
  - DVT prophylaxis.
  - Surgical consult for all patients with complicated CDI.

Recurrent CDI

- Consider fetal microbiota transplant after third recurrence.

Source


Comments

1. Limited evidence that probiotics decrease risk of recurrent CDI.
2. The following patients should be tested for CDI:
   - IBD patients with a flare.
   - IBD patients with a surgically created pouch who develop abdominal pain.
3. Immunosuppressed patients with an acute diarrheal illness.
4. Pregnant patients who develop diarrhea.

Population

- Adult patients with *C. difficile*-associated disease.

Recommendations

- If surgery is indicated, recommend a subtotal or total colectomy.
- For severe CDAD, patients should undergo surgery prior to the development of shock and need for vasopressors.
COLORECTAL CANCER FOLLOW-UP CARE

Population
- Adults with nonmetastatic colorectal cancer (Stages II and III).

Recommendation
- American Society of Clinical Oncology Cancer Care Ontario (CCO) 2013

- Follow-up for Recurrence
  - Surveillance guided by risk of recurrence and functional status of the patient. Early detection of relapse would lead to treatment including surgery for possible cure.
  - Highest risk of recurrence during first 4 y after diagnosis. 95% of relapses occur in first 5 y.
  - Medical history, physical exam, and CEA testing every 3–6 mo for 5 y. The higher the risk, the more frequent the follow-up.
  - Abdominal and chest CT scan is recommended annually for 3 y. Highest risk patients (Stage III, >4 nodes+) should consider imaging every 4–6 mo.
  - Routine PET scan not recommended for surveillance.
  - Patients with rectal cancer should also have pelvic CT annually for 3–5 y.
  - A surveillance colonoscopy should be performed 1 y after initial surgery. If normal, repeat colonoscopy every 5 y. If complete colonoscopy not performed before diagnosis perform it as soon as the patient recovers from adjuvant therapy.
    a. Any new or persistent worsening of symptoms warrant consideration of recurrence.

Source
- J Clin Oncol. 2013;31:4465–4470

Comment
- Clinical Correlation
  - Stage I colon cancer with very low risk of recurrence. Colonoscopy follow-up every 5 y but CEA and imaging not needed.
  - Colon cancer with >90% to liver as the first site of metastasis. In rectal cancer, 50% of first metastasis is to lung and 50% to liver. (CA Cancer J Clin. 2015;65:5)
  - Patients found to have resectable metastatic disease (liver, lungs) or local recurrence who are rendered disease free by surgical or radiofrequency
ablation (RFA) should be followed with frequent surveillance. 10-y survival is in 30%–40% range. (J Clin Onc. 2010;28:2300)

- **BRAF** mutation prognostic for early relapse and chemotherapy resistance with shortened survival. (PloS One. 2013;8:eb5995)

- Patients with CRC younger than 50 y old or with significant family history should be evaluated for Lynch syndrome with microsatellite instability and immune histochemistry testing. (N Engl J Med. 2009;361:2449)

- Patients with Stage II CRC with microsatellite instability will have a shorter survival if given adjuvant 5-fluorouracil compared to placebo. (Clin Genet. 2009;76:1)

- Uncertainty remains regarding use of cyclooxygenase inhibitor to reduce risk of recurrence but aspirin is now approved to decrease risk of CRC.

- Exercise (>150 min/wk), weight loss for high BMI, smoking cessation, and healthy diet advised—evidence suggests a decrease in disease recurrence.

## COMMON COLD

**Population**
- Children and adults.

**Recommendation**
- Cochrane Database of Systematic Reviews 2013
  - Recommends zinc at a dose of at least 75 mg/d started within 24 h of the onset of a common cold.

**Source**

**Comment**
- Zinc at this dose reduces the duration of the common cold by about 1 d, but did not affect the severity of symptoms.

## CONCUSSIONS

**Population**
- Children and young adults.

**Recommendations**
- AAN 2013
  - Standardized sideline assessment tools should be used to assess athletes with suspected concussions.
Teams should immediately remove from play any athlete with a suspected concussion. Teams should not permit an athlete to return to play until he/she has been cleared to play by a licensed health care professional.

**Source**

### CONSTIPATION, IDIOPATHIC

**Population**
- Children age ≤18 y.

**Recommendations**

- **NICE 2010**
  - Assess all children for fecal impaction.
  - Recommends polyethylene glycol (PEG) as first-line agent for oral disimpaction.
  - Add a stimulant laxative if PEG therapy is ineffective after 2 wk.
  - Recommends sodium citrate enemas for disimpaction only if all oral medications have failed.
  - Recommends a maintenance regimen with PEG for several months after a regular bowel pattern has been established.
  - Recommends gradually tapering maintenance dose over several months as bowel pattern allows.
  - Recommends adequate fluid intake.

**Source**

**Comment**
- Minimal fluid intake for age

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–3</td>
<td>1300</td>
</tr>
<tr>
<td>4–8</td>
<td>1700</td>
</tr>
<tr>
<td>9–13</td>
<td>2200</td>
</tr>
<tr>
<td>14–18</td>
<td>2500</td>
</tr>
</tbody>
</table>

**Population**
- Adults.

**Recommendations**

- **AGA 2013**
  - Digital examination to evaluate resting sphincter tone.
  - Discontinue all medications that can cause constipation.
--Assess for hypercalcemia, hypothyroidism.
--Trial of laxatives and fiber
   • Bisacodyl.
   • Milk of magnesia.
   • Polyethylene glycol.
   • Senna.
--Refractory constipation may require biofeedback or pelvic floor retraining.
   • Severe cases of refractory slow transit constipation may require a total colectomy with ileorectal anastomosis.

Source
--http://www.gastrojournal.org/article/S0016-5085(12)01545-4/fulltext

### CONTRACEPTION

<table>
<thead>
<tr>
<th>% of Women Experiencing an Unintended Pregnancy Within the First Year of Use</th>
<th>Typical Use&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Perfect Use&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Women Continuing Use at 1 Y&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>R16 No method&lt;sup&gt;d&lt;/sup&gt;</td>
<td>85</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>R15 Spermicides&lt;sup&gt;e&lt;/sup&gt;</td>
<td>28</td>
<td>18</td>
<td>42</td>
</tr>
<tr>
<td>R12 Withdrawal</td>
<td>22</td>
<td>4</td>
<td>46</td>
</tr>
<tr>
<td>R13 Fertility awareness-based methods</td>
<td>24</td>
<td>5</td>
<td>47</td>
</tr>
<tr>
<td>Standard Days method&lt;sup&gt;f&lt;/sup&gt;</td>
<td>0.4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Two-Day method&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Ovulation method&lt;sup&gt;f&lt;/sup&gt;</td>
<td>0.4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Symptothermal method&lt;sup&gt;f&lt;/sup&gt;</td>
<td>0.4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Sponge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R11 Parous women</td>
<td>24</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Nulliparous women</td>
<td>12</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>R9 Diaphragm</td>
<td>12</td>
<td>6</td>
<td>57</td>
</tr>
<tr>
<td>Condom&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R10 Female (fc)</td>
<td>21</td>
<td>5</td>
<td>41</td>
</tr>
<tr>
<td>Male</td>
<td>18</td>
<td>2</td>
<td>43</td>
</tr>
<tr>
<td>R8 Combined pill and Progestin-only pill</td>
<td>9</td>
<td>0.3</td>
<td>67</td>
</tr>
<tr>
<td>R7 Evra patch*</td>
<td>9</td>
<td>0.3</td>
<td>67</td>
</tr>
</tbody>
</table>
### Emergency Contraceptive Pills:

Treatment with COCs initiated within 120 h after unprotected intercourse reduces the risk of pregnancy by at least 60–75%. Pregnancy rates lower if initiated in first 12 h. Progestin-only EC reduces pregnancy risk by 89%.

**Lactational Amenorrhea Method:** LAM is a highly effective, temporary method of contraception.

*Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom the oral contraceptive pill, and Depo-Provera are taken from the 1995 National Survey of Family Growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods.

*Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. See the text for the derivation of the estimate for each method.

*Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 y.

*The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within 1 y. This estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 y among women now relying on reversible methods of contraception if they abandoned contraception altogether.

*Foams, creams, gels, vaginal suppositories, and vaginal film.

*The Ovulation and Two-Day methods are based on evaluation of cervical mucus. The Standard-Days method avoids intercourse on cycle days 8 through 19. The Symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day.

*Without spermicides.

*With spermicidal cream or jelly.

** ella, Plan B One-Step and Next Choice are the only dedicated products specifically marketed for emergency contraception. The label for Plan B One-Step (one dose is 1 white pill) says to take the pill within 72 h after unprotected intercourse. Research has shown that all of the brands listed here are effective when used within 120 h after unprotected sex. The label for Next Choice (one dose is 1 peach pill) says to take 1 pill within 72 h after unprotected intercourse and another pill 12 h later. Research has shown that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 h after unprotected sex. The Food and Drug Administration has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: Ogestrel (1 dose is 2 white pills), Nordette (1 dose is 4 light-orange pills), Cryselle, Levora, Low-Ogestrel, Lo/Ovral, or Quasence (1 dose is 4 white pills), Jolesa, Portia, Seasonale or Trivora (1 dose is 4 pink pills), Seasonique (1 dose is 4 light-blue-green pills), Enpresse (one dose is 4 orange pills), Lessina (1 dose is 5 pink pills), Aviane or LoSeasonique (one dose is 5 orange pills), Lutera or Sonyx (one dose is 5 white pills), and Lybrel (one dose is 6 yellow pills).

*However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 mo of age.

### SUMMARY OF CHANGES IN CLASSIFICATIONS FROM WHO MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE, 4TH EDITION\(^{3,4}\)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sub-Condition</th>
<th>Cu-IUD</th>
<th>LNG-IUD</th>
<th>Implant</th>
<th>DMPA</th>
<th>POP</th>
<th>CJK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>Menarche to &lt;20 yrs 2</td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Menarche to &gt;20 yrs 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Menarche to &gt;20 yrs 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Menarche to &gt;20 yrs 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Menarche to &gt;20 yrs 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anatomical abnormalities</td>
<td>Distorted uterine cavity</td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Other abnormalities</td>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benign ovarian tumors</td>
<td>Including cysts</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>a) Unilateral mass</td>
<td>1</td>
<td>2</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
</tr>
<tr>
<td>b) Bilateral mass</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>c) History of cancer</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>d) Breast cancer(a)</td>
<td>i) Current</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>ii) Past and no evidence of current disease for 5 years</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Breastfeeding</td>
<td>a) &lt;31 days postpartum</td>
<td></td>
<td></td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>4*</td>
</tr>
<tr>
<td></td>
<td>b) 21 to 30 days postpartum</td>
<td></td>
<td></td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>c) 30-42 days postpartum</td>
<td></td>
<td></td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>i) With other risk factors for VTE</td>
<td></td>
<td></td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>ii) Without other risk factors for VTE</td>
<td></td>
<td></td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>2) With other risk factors for VTE</td>
<td></td>
<td></td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>2) Without other risk factors for VTE</td>
<td></td>
<td></td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
</tr>
<tr>
<td></td>
<td>2) Days postpartum</td>
<td></td>
<td></td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
</tr>
<tr>
<td>Cervical ectropion</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Cervical intraepithelial neoplasia</td>
<td></td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>a) Mild (compensated)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Severe (decompensated)</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Cystic fibrosis(a)</td>
<td></td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td>Deep venous thrombosis (DVT)/Pulmonary embolism (PE)</td>
<td>a) History of DVT/PE, not receiving anticoagulant therapy</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>i) Higher risk for recurrent DVT/PE</td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>ii) Lower risk for recurrent DVT/PE</td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>b) Acute DVT/PE</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>c) DVT/PE and established anticoagulant therapy for at least 3 months</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4*</td>
</tr>
<tr>
<td></td>
<td>i) Higher risk for recurrent DVT/PE</td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>ii) Lower risk for recurrent DVT/PE</td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>d) Family history (first-degree relatives)</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>e) Major surgery</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>i) With prolonged immobilization</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>ii) Without prolonged immobilization</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>f) Minor surgery without immobilization</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Key:**
1. No restriction (method can be used)
2. Theoretical or proven risks usually outweigh the advantages
3. Advantages generally outweigh theoretical or proven risks
4. Unacceptable health risk (method not to be used)
<table>
<thead>
<tr>
<th>Condition</th>
<th>Sub-Condition</th>
<th>Cu-IUD</th>
<th>LNG-IUD</th>
<th>Implant</th>
<th>DMPP</th>
<th>POP</th>
<th>CNC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>a) History of gestational disease</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Nonvascular disease</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>i) Non-insulin dependent</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>ii) Insulin dependent</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>c) Nephropathy/retinopathy/neuropathy</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3/4</td>
<td>3/4</td>
</tr>
<tr>
<td></td>
<td>d) Other vascular disease or diabetes</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3/4</td>
</tr>
<tr>
<td></td>
<td>of &gt;20 years’ duration</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3/4</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>Severe</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td></td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Endometriosis</td>
<td></td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>(see also Drug Interactions)</td>
<td>1</td>
<td>1</td>
<td>1*</td>
<td>1</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td>Gallbladder disease</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1*</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Gestational trophoblastic</td>
<td>a) Suspected GTD (immediate postevacuation)</td>
<td>1</td>
<td>2</td>
<td>1*</td>
<td>1</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td>disease</td>
<td>b) Nonobstructed GTD</td>
<td>2</td>
<td>2</td>
<td>1*</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>i) Folic acid levels</td>
<td>1</td>
<td>2</td>
<td>1*</td>
<td>1</td>
<td>1</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>ii) Medical treatment</td>
<td>2</td>
<td>2</td>
<td>1*</td>
<td>1</td>
<td>1</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>With folic acid levels</td>
<td>2</td>
<td>2</td>
<td>1*</td>
<td>1</td>
<td>1</td>
<td>1*</td>
</tr>
<tr>
<td>History of bariatric</td>
<td>a) Restrictive procedures</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>surgery</td>
<td>b) Malabsorptive procedures</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>History of cholestasis</td>
<td>a) Pregnancy related</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>History of high blood</td>
<td>a) Prior CDC related</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>pressure during pregnancy</td>
<td>b) High risk for HIV</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>History of Pelvic surgery</td>
<td>a) High risk for HIV</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>i) Clinically well receiving ARV therapy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>ii) Not clinically well or not receiving ARV</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>therapy*</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
| Abbreviations: Cu-IUD=copper-containing intrauterine device; LNG-IUD=levonorgestrel-releasing intrauterine device; DMPP=progestin-only pill; POP=progestin-only pill; P/R=packing; COCs=combined oral contraceptives; NN=not applicable; ARV=antiretroviral treatment. *Please see the complete guidance for a clarification to this classification: www.cdc.gov/reproductivehealth/unintendedpregnancy/USMECT.htm.
SUMMARY OF CHANGES IN CLASSIFICATIONS FROM WHO MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE, 4TH EDITION

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sub-Condition</th>
<th>Cu-IUD</th>
<th>LNG-IUD</th>
<th>Implant</th>
<th>DMHP</th>
<th>POP</th>
<th>CHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>a) Adequately controlled hypertension</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>b) Elevated blood pressure levels (properly taken measurements)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) Systolic $\geq$ 140-159 or diastolic $\geq$ 90-99</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>ii) Systolic $\geq$ 160 or diastolic $\geq$ 100</td>
<td>1*</td>
<td>2*</td>
<td></td>
<td>3*</td>
<td>2*</td>
<td>4*</td>
</tr>
<tr>
<td></td>
<td>c) Vascular disease</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
<td>2*</td>
<td>4*</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>(Ulcerative colitis, Crohn’s disease)</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2/3*</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>Current and history of</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Known thrombogenic mutations</td>
<td>(Continued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver tumors</td>
<td>a) Benign</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) Focal nodular hyperplasia</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii) Hepatocellular adenoma</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Malignant (hepatoma)</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Malaria</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple risk factors for atherosclerotic cardiovascular disease</td>
<td>(e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels)</td>
<td>1</td>
<td>2</td>
<td>2*</td>
<td>3*</td>
<td>2*</td>
<td>3/4*</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>a) With prolonged immobility</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>b) Without prolonged immobility</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Obesity</td>
<td>a) Body mass index (BMI) $\geq$ 30 kg/m²</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>b) Menarche to &lt;18 years and BMI $\geq$ 30 kg/m²</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td>a) Nulliparous</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Parous</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past ectopic pregnancy</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic inflammatory disease</td>
<td>a) Past</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>i) With subsequent pregnancy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>ii) Without subsequent pregnancy</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Current</td>
<td>4*</td>
<td>2*</td>
<td>2*</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Peripartum cardiomyopathy</td>
<td>a) Normal or mildly impaired cardiac function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) &lt;6 months</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>ii) &gt;6 months</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>b) Moderately or severely impaired cardiac function</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Postabortion</td>
<td>a) First trimester</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>b) Second trimester</td>
<td>2*</td>
<td>2*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>c) Immediate postpartum abortion</td>
<td>4*</td>
<td>4*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td>Postpartum (non-breastfeeding women)</td>
<td>a) &lt;24 days</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) With other risk factors for VTE</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii) Without other risk factors for VTE</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) &gt;24 days</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postpartum (breastfeeding or non-breastfeeding women, including cesarean delivery)</td>
<td>a) &lt;10 minutes after delivery of the placenta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) Breastfeeding</td>
<td>1*</td>
<td>2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii) Nonbreastfeeding</td>
<td>1*</td>
<td>1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) 10 minutes after delivery of the placenta to &lt;4 weeks</td>
<td>2*</td>
<td>2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) &gt;4 weeks</td>
<td>1*</td>
<td>1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>d) Postpartum sepsis</td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Sub-Condition</td>
<td>Cu-IUD</td>
<td>LNG-IUD</td>
<td>Implant</td>
<td>DMPA</td>
<td>POP</td>
<td>PNC</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------</td>
<td>---------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>Pregnancy</td>
<td></td>
<td>IC</td>
<td>IC</td>
<td>IC</td>
<td>IC</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>a) On immunosuppressive therapy</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>b) Not on immunosuppressive therapy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td>a) Uncomplicated</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Fibrosis of the liver</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sexually transmitted diseases (STDs)</td>
<td>a) Current purulent cervicitis or chlamydial infection or gonococcal infection</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Vaginitis (including trichomonas vaginalis and bacterial vaginosis)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>c) Other factors relating to STDs</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Smoking</td>
<td>a) Age &lt;30</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>b) Age ≥35, &lt;15 cigarettes/day</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>c) Age ≥35, ≥15 cigarettes/day</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Solid organ transplantation*</td>
<td>a) Complicated</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>b) Uncomplicated</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Stroke†</td>
<td>a) History of cerebrovascular accident</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Superficial venous disorders</td>
<td>a) Varicose veins</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Superficial venous thrombosis (acute or history)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Systemic lupus erythematosus†</td>
<td>a) Positive (or unknown) antiphospholipid antibodies</td>
<td>1*</td>
<td>1*</td>
<td>3*</td>
<td>3*</td>
<td>3*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>b) Severe thrombocytopenia</td>
<td>3*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>4*</td>
</tr>
<tr>
<td></td>
<td>c) Immunosuppressive therapy</td>
<td>2*</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
</tr>
<tr>
<td></td>
<td>d) None of the above</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
</tr>
<tr>
<td>Thyroid disorders</td>
<td>a) Simple goiter/hyperthyroid/hypothyroid</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tuberculosis†</td>
<td>a) Nonpelvic</td>
<td>1</td>
<td>1</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>b) Pelvic</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td>Unexplained vaginal bleeding</td>
<td>(suspicious for serious condition) before evaluation</td>
<td>4*</td>
<td>2*</td>
<td>4*</td>
<td>2*</td>
<td>3*</td>
<td>2*</td>
</tr>
<tr>
<td>Uterine fibroids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>a) Uncomplicated</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>b) Complicated†</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Vaginal bleeding pattern</td>
<td>a) Irregular pattern without heavy bleeding</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Heavy or prolonged bleeding</td>
<td>2*</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>2*</td>
<td>1*</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>a) Acute or Flare</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3*</td>
<td>3*</td>
<td>2*</td>
</tr>
<tr>
<td></td>
<td>b) Carrier/Chronic</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Drug Interactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral therapy</td>
<td>All other ARVs are 1 or 2 for all methods.</td>
<td>1</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>Fosamprenavir (FPV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anticonvulsant therapy</td>
<td>a) Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, phenidone, toipamide, oscarbazepine)</td>
<td>1</td>
<td>1</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>b) Lamotrigine</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3*</td>
<td>3*</td>
</tr>
<tr>
<td>Antimicrobial therapy</td>
<td>a) Broad spectrum antibiotics</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Antiinflammum</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>c) Antiparastigene</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>d) Rifampin or rifabutin therapy</td>
<td>1</td>
<td>1</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
<td>3*</td>
</tr>
<tr>
<td>SSRLs</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>St. John’s wort</td>
<td></td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Updated July 2016. This summary sheet only contains a subset of the recommendations from the US MEC. For complete guidance, see https://www.cdc.gov/reproductivehealth/unintendedpregnancy/SMARCH/Smarch.htm. Most contraceptive methods do not protect against sexually transmitted diseases (STDs). Consistent and correct use of the male latex condom reduces the risk of STDs and HIV.
<table>
<thead>
<tr>
<th>Condition</th>
<th>COC/P/R</th>
<th>POP</th>
<th>DMPA</th>
<th>Implants</th>
<th>LNG-IUD</th>
<th>Cu-IUD</th>
<th>Clarification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast-feeding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>The U.S. Department of Health and Human Services recommends that infants be exclusively breast-fed during the first 4–6 mo of life, preferably for a full 6 mo. Ideally, breast-feeding should continue through the first year of life</em> (1). <em>(Not included in WHO MEC)</em></td>
</tr>
<tr>
<td>a. &lt;1 mo postpartum (WHO: &lt;6 wk postpartum)</td>
<td>3(^{b}) (4)</td>
<td>2(^{b}) (3)</td>
<td>2(^{b}) (3)</td>
<td>2(^{b}) (3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. 1 mo to &lt;6 mo (WHO: ≥6 wk to &lt;6 mo postpartum)</td>
<td>2(^{b}) (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postpartum (in breast-feeding or non-breast-feeding women), including postcesarean section</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 {1 if not breast-feeding and 3 if breast-feeding}</td>
<td>2 {3}</td>
<td></td>
</tr>
<tr>
<td>a. &lt;10 min after delivery of the placenta (WHO: &lt;48 h, including insertion immediately after delivery of the placenta)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. 10 min after delivery of the placenta to &lt;4 wk (WHO: ≥48 h to &lt;4 wk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 {3}</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Deep venous thrombosis (DVT)/pulmonary embolism (PE)

<table>
<thead>
<tr>
<th>Category</th>
<th>Risk Factor</th>
<th>Risk Factors</th>
<th>Risk Factors</th>
<th>Risk Factors</th>
<th>Risk Factors</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. History of DVT/PE, not on anticoagulant therapy</td>
<td>i. Lower risk for recurrent DVT/PE (no risk factors)</td>
<td>3 {4}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {1}</td>
</tr>
<tr>
<td>b. Acute DVT/PE</td>
<td></td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {1}</td>
</tr>
<tr>
<td>c. DVT/PE and established on anticoagulant therapy for at least 3 mo</td>
<td>i. Higher risk for recurrent DVT/PE (≥1 risk factors)</td>
<td>3b {4}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {3}</td>
<td>2 {1}</td>
</tr>
<tr>
<td></td>
<td>• Known thrombophilia, including antiphospholipid syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Active cancer (metastatic, on therapy, or within 6 mo after clinical remission), excluding nonmelanoma skin cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• History of recurrent DVT/PE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii. Lower risk for recurrent DVT/PE (no risk factors)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Women on anticoagulant therapy are at risk for gynecologic complications of therapy such as hemorrhagic ovarian cysts and severe menorrhagia. Hormonal contraceptive methods can be of benefit in preventing or treating these complications. When a contraceptive method is used as a therapy, rather than solely to prevent pregnancy, the risk/benefit ratio may be different and should be considered on a case-by-case basis. (Not included in WHO MEC)
### SUMMARY OF CHANGES IN CLASSIFICATIONS FROM WHO MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE, 4TH EDITION<sup>a,b</sup>  (Continued)

<table>
<thead>
<tr>
<th>Condition</th>
<th>COC/P/R</th>
<th>POP</th>
<th>DMPA</th>
<th>Implants</th>
<th>LNG-IUD</th>
<th>Cu-IUD</th>
<th>Clarification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valvular heart disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Complicated (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (2)</td>
</tr>
<tr>
<td><strong>Ovarian cancer</strong>&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 {Initiation = 3, Continuation = 2}</td>
</tr>
<tr>
<td><strong>Uterine fibroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 {1 if no uterine distortion and 4 if uterine distortion is present}</td>
</tr>
</tbody>
</table>

COC, combined oral contraceptive; Cu-IUD, copper intrauterine device; DMPA, depot medroxyprogesterone acetate; DVT, deep venous thrombosis; LNG-IUD, levonorgestrel-releasing intrauterine device; P, combined hormonal contraceptive patch; PE, pulmonary embolism; POP, progestin-only pill; R, combined hormonal vaginal ring; VTE, venous thromboembolism; WHO, World Health Organization.

<sup>a</sup> For conditions for which classification changed for ≥1 methods or the condition description underwent a major modification, WHO conditions and recommendations appear in curly brackets.

<sup>b</sup> Consult the clarification column for this classification.

<sup>c</sup> Condition that exposes a women to increased risk as a result of unintended pregnancy.
### SUMMARY OF RECOMMENDATIONS FOR MEDICAL CONDITIONS ADDED TO THE U.S. MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE

<table>
<thead>
<tr>
<th>Condition</th>
<th>COC/P/R</th>
<th>POP</th>
<th>DMPA</th>
<th>Implants</th>
<th>LNG-IUD</th>
<th>Cu-IUD</th>
<th>Clarification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History of bariatric surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Restrictive procedures:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>b. Malabsorptive procedures:</td>
<td>COCs: 3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass, biliopancreatic diversion)</td>
<td>P/R: 1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>COC/P/R</td>
<td>POP</td>
<td>DMPA</td>
<td>Implants</td>
<td>LNG-IUD</td>
<td>Cu-IUD</td>
<td>Clarification</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------</td>
<td>-----</td>
<td>------</td>
<td>----------</td>
<td>---------</td>
<td>--------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Peripartum cardiomyopathy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Normal or mildly impaired cardiac function (New York Heart Association Functional Class I or II: patients with no limitation of activities or patients with slight, mild limitation of activity) (2)</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>i. &lt;6 mo</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>ii. ≥6 mo</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>b. Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: patients with marked limitation of activity or patients who should be at complete rest) (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>Initiation</td>
<td>Continuation</td>
<td>Initiation</td>
<td>Continuation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. On immunosuppressive therapy</td>
<td>2</td>
<td>1</td>
<td>2/3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Not on immunosuppressive therapy</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>DMPA use among women on long-term corticosteroid therapy with a history of, or risk factors for, nontraumatic fractures is classified as Category 3. Otherwise, DMPA use for women with rheumatoid arthritis is classified as Category 2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease (IBD)</td>
<td>2/3</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ulcerative colitis, Crohn disease)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>For women with mild IBD, with no other risk factors for VTE, the benefits of COC/P/R use generally outweigh the risks (Category 2). However, for women with IBD with increased risk for VTE (eg, those with active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficiencies, fluid depletion), the risks for COC/P/R use generally outweigh the benefits (Category 3).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## SUMMARY OF RECOMMENDATIONS FOR MEDICAL CONDITIONS ADDED TO THE U.S. MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE* (Continued)

<table>
<thead>
<tr>
<th>Condition</th>
<th>COC/P/R</th>
<th>POP</th>
<th>DMPA</th>
<th>Implants</th>
<th>LNG-IUD</th>
<th>Cu-IUD</th>
<th>Clarification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid organ transplantation*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Complicated: graft failure</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>Women with Budd-Chiari syndrome should not use COC/P/R because of the increased risk for thrombosis.</td>
</tr>
<tr>
<td>(acute or chronic), rejection, cardiac allograft vasculopathy</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>b. Uncomplicated</td>
<td>2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*COC, combined oral contraceptive; Cu-IUD, copper intrauterine device; DMPA, depot medroxyprogesterone acetate; IBD, inflammatory bowel disease; LNG-IUD, levonorgestrel-releasing intrauterine device; P, combined hormonal contraceptive patch; POP, progestin-only pill; R, combined hormonal vaginal ring; VTE, venous thromboembolism.


*Condition that exposes a woman to increased risk as a result of unintended pregnancy.

*Consult the clarification column for this classification.

## SUMMARY OF ADDITIONAL CHANGES TO THE U.S. MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE

<table>
<thead>
<tr>
<th>Condition/Contraceptive Method</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency contraceptive pills</td>
<td>History of bariatric surgery, rheumatoid arthritis, inflammatory bowel disease, and solid organ transplantation was given a Category 1.</td>
</tr>
<tr>
<td>Barrier methods</td>
<td>For six conditions—history of bariatric surgery, peripartum cardiomyopathy, rheumatoid arthritis, endometrial hyperplasia, IBD, and solid organ transplantation—the barrier methods are classified as Category 1.</td>
</tr>
<tr>
<td>Sterilization</td>
<td>In general, no medical conditions would absolutely restrict a person’s eligibility for sterilization. Recommendations from the WHO Medical Eligibility Criteria for Contraceptive Use about specific settings and surgical procedures for sterilization are not included here. The guidance has been replaced with general text on sterilization.</td>
</tr>
<tr>
<td>Other deleted items</td>
<td>Guidance for combined injectables, levonorgestrel implants, and norethisterone enanthate has been removed because these methods are not currently available in the United States. Guidance for “blood pressure measurement unavailable” and “history of hypertension, where blood pressure cannot be evaluated (including hypertension in pregnancy)” has been removed.</td>
</tr>
<tr>
<td>Unintended pregnancy and increased health risk</td>
<td>The following conditions have been added to the WHO list of conditions that expose a woman to increased risk as a result of unintended pregnancy: history of bariatric surgery within the past 2 y, peripartum cardiomyopathy, and receiving a solid organ transplant within 2 y.</td>
</tr>
</tbody>
</table>

## CONTRACEPTION, EMERGENCY

### Population

Women of childbearing age who had unprotected or inadequately protected sexual intercourse within the last 5 d and who do not desire pregnancy.

### Recommendations

ACOG 2010

The levonorgestrel-only regimen is more effective and is associated with less nausea and vomiting compared with the combined estrogen-progestin regimen.
–The two 0.75-mg doses of the levonorgestrel-only regimen are equally effective if taken 12–24 h apart.
–The single-dose 1.5-mg levonorgestrel-only regimen is as effective as the 2-dose regimen.
–Recommend an antiemetic agent 1 h before the first dose of the combined estrogen-progestin regimen to reduce nausea.
–Treatment with emergency contraception should be initiated as soon as possible after unprotected or inadequately protected intercourse.
–Emergency contraception should be made available to patients who request it up to 5 d after unprotected intercourse.

Source

Comments
1. No clinician examination or pregnancy testing is necessary before provision or prescription of emergency contraception.
2. The copper intrauterine device (IUD) is appropriate for use as emergency contraception for women who desire long-acting contraception.
3. Information regarding effective long-term contraceptive methods should be made available whenever a woman requests emergency contraception.

CORONARY ARTERY DISEASE (CAD)

CAD with Chronic Stable Angina

Population
–Patients with chronic stable angina, with CAD, in sinus rhythm, with resting HR ≥70 bpm, that are either treated with optimal tolerated dose of β-blocker or cannot tolerate/have contraindication to β-blockers.

Recommendation

EMA Review 2014
–Ivabradine (Corlentor®, Procoralan*) is used to treat symptoms of long-term stable angina.

Source
DISEASE MANAGEMENT

Comments

1. 2014 EMA review based on SIGNIFY study showed that ivabradine has not been shown to provide benefits such as reducing the risk of heart attack or cardiovascular death; therefore, the medicine should only be used to alleviate symptoms of angina. Doctors should consider stopping the treatment if there is no improvement in angina symptoms after 3 mo or if the improvement is only limited.

2. Should not be used in combination with verapamil or diltiazem.

3. The risk of AF is increased in the patient treated with ivabradine and doctors should monitor patients for AF.

4. If during treatment HR <50 bpm at rest and patients are symptomatic, the dose should be decreased to 2.5 mg 1 tab bid.

STABLE CORONARY DISEASE ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
GUIDELINES 2012, 2014

- Patients presenting with angina pectoris should be classified as stable or unstable.
- Acute coronary syndrome (ACS) includes high-risk unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI).
- Resting ECG testing is recommended with all symptoms of chest pain (typical or atypical in nature).
- Exercise treadmill is the preferred initial test to be employed if the baseline is normal, the patient can exercise, and the pretest likelihood of coronary disease is intermediate (10%–90%).
- If unable to perform an exercise treadmill, then either a nuclear myocardial perfusion imaging study (MPI) or exercise echocardiogram should be employed if the pretest likelihood is >10%.
- Exercise and imaging studies should be repeated when there is a change in clinical status or if needed for exercise prescription.
- Coronary computed tomography angiogram (CTA) is a reasonable alternative in patients with an intermediate pretest probability of CAD (FRS) in whom symptoms persist despite prior normal testing, with equivocal stress tests, or in patients who cannot be studied otherwise. CTA in not indicated with known moderate or severe coronary calcification or in the presence of prior stents.
- An echocardiogram is recommended to assess resting LV function and valve disease in patients with suspected CAD, pathological Q waves, presence of heart failure, or ventricular arrhythmias.
- Patients with stable coronary disease should receive:
  - Lifestyle guidance (diet, weight loss, smoking cessation, and exercise education): BP threshold of <140/90 mm Hg is projected to be the new JCN 8 goal.
  - Associated risk factor assessment: Presence of chronic kidney disease and psychosocial factors such as depression, anxiety, and poor social support have been added to the classic risk factors.
  - Appropriate medicine prescription: (ASA 75–162 mg daily, moderate statin dosage, BP control and diabetic control, β-blocker therapy, and sublingual NTG).
STABLE CORONARY DISEASE ACCF/AHA/ACP/AATS/PCNA/SCAI/STS GUIDELINES 2012, 2014 (Continued)

- Coronary angiography should be considered in patients surviving sudden cardiac death, with high-risk noninvasive test results (large areas of silent ischemia often associated with malignant ventricular arrhythmias) and in patients in whom the anginal symptoms cannot be controlled with optimal medical therapy.\(^a\)
- Coronary bypass grafting surgery (CABG) is preferred to angioplasty in diabetic patients with multivessel disease (FREEDOM trial 2012).\(^b\)

(exclusive of stress testing) indicate a high likelihood of severe IHD and who are amenable to, and candidates for, coronary revascularization. Coronary angiography is reasonable in patients with suspected symptomatic SIHD who cannot undergo diagnostic stress testing, or have indeterminate or nondiagnostic stress tests, when there is a high likelihood that the findings will result in important changes to therapy. Coronary angiography might be considered in patients with stress test results of acceptable quality that do not suggest the presence of CAD when clinical suspicion of CAD remains high and there is a high likelihood that the findings will result in important changes to therapy.

\(^a\)A Heart Team approach to revascularization is recommended in patients with diabetes mellitus and complex multivessel CAD. CABG is generally recommended in preference to PCI to improve survival in patients with diabetes mellitus and multivessel CAD for which revascularization is likely to improve survival (3-vessel CAD or complex 2-vessel CAD involving the proximal LAD), particularly if a LIMA graft can be anastomosed to the LAD artery, provided the patient is a good candidate for surgery.


CORONARY ARTERY DISEASE: SEXUAL FUNCTION—AHA AND PRINCETON CONSENSUS PANEL RECOMMENDATIONS 2013

- Erectile dysfunction (ED) is associated with CAD and often precedes the diagnosis of CAD.
- ED was associated with an increased risk for CV events and all-cause mortality.
- Angina pectoris during sexual activity represents <5% of all angina attacks.
- Patients with CAD with angina pectoris should undergo full medical evaluation prior to partaking in sexual activity.
- Patients should be able to perform 3–5 metabolic equivalents (METs) on a treadmill or climb 2 flights of stairs or walk briskly without angina before engaging in sexual activity.
- Post-uncomplicated MI if no symptoms on mild-to-moderate activity exist >1 wk, patient may resume sexual activity.
- Post-angioplasty within 1-wk sexual activity is reasonable if the radial groin site is healed.

\(^a\)Coronary angiography is useful in patients with presumed SIHD who have unacceptable ischemic symptoms revascularization. Coronary angiography is reasonable to define the extent and severity of coronary artery disease (CAD) in patients with suspected SIHD whose clinical characteristics and results of noninvasive testing.
• Sexual activity is reasonable after 6–8 wk post coronary bypass, being limited by the sterna healing or pain.
• If residual coronary lesions persist post revascularization, exercise stress testing is recommended to evaluate for significant ischemia.
• Sexual activity is contraindicated in patients with angina at low effort, refractory angina or unstable angina.
• Nitrate therapy is contraindicated with phosphodiesterase 5 (PDE5) inhibitor therapy.
• Following sildenafil (Viagra) or vardenafil (Levitra) at least 24 h must elapse before nitrates can be started; ≥48 h if tadalafil (Cialis) is used.
• Beta-blockers, calcium channel blockers, and Ranolazine are not contraindicated; however, they may impair erectile dysfunction.

CHAPTER 3

CORONARY ARTERY DISEASE: THERAPY FOR UNSTABLE ANGINA—NSTEMI ACCF/AHA 2012 CLASS I RECOMMENDATIONS (Continued)

• Nasal oxygen is indicated if arterial saturation is <90%, if respiratory distress is present, or other high-risk features for hypoxemia.
• Sublingual and intravenous nitroglycerin (NTG) are indicated for clinical angina.
• Oral β-blockers should be administered within the first 24 h unless contraindicated. Intravenous beta-blocker if chest pain is ongoing.
• ACE inhibitors should be administered within 24 h in patients with clinical heart failure (HF) with decreased ejection fraction (≤40%), if not contraindicated.
• Consider percutaneous coronary intervention (PCI) of the culprit coronary vessel with staged PCIs for other significant but less critical lesions. Consider CABG for significant left main lesion, double- or triple-vessel disease with decreased ejection fraction. The SYNTAX score may have predictive value in selecting PCI vs. CABG.
• Myocardial perfusion imaging (MPI) is indicated prior to discharge if conservative therapy is chosen.
• Dual antiplatelet (ASA 81 mg and clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily) is indicated for at least 12 mo. ASA should be continued lifelong.
• If warfarin is indicated postcoronary stent, see Anticoagulation with Stent section.
• Postdischarge medications include ASA, clopidogrel 75 mg, β-blocker dose to control heart rate, statin agent, and possible ACE inhibitor if decreased ejection fraction or clinical heart failure, diabetes, or hypertension is present.

Patients with ST-elevation myocardial infarction with ischemic symptoms within 12 h should be treated by PCI.

Primary PCI should be performed within 90 min from initial medical contact by an experienced catheterization cardiologist.

Emergency transport to PCI-capable hospital is recommended. The term “Code STEMI” is often used to confer the time urgency of the transfer. In-ambulance ECG monitoring should be used to identify ST-segment elevation.

Emergency transfer from a non-PCI capable to a PCI-capable hospital should be considered if transfer to catheterization laboratory is capable within 120 min.

Fibrinolytic therapy should be considered if PCI is not capable within the optimal time frame. If fibrinolytic therapy is considered, it should be started with 30 min of hospital arrival.

ASA 162–325 mg should be administered before primary PCI and continued indefinitely at 81 mg daily.

P2Y12 receptor inhibitor should be given upstream or during primary PCI and should be continued for 1 y with either bare metal stent or drug-eluting stents. Options include clopidogrel, prasugrel, and ticagrelor. P2Y12 receptor inhibitors: clopidogrel 75 mg daily, prasugrel 10 mg daily (5 mg daily—in patients <60 kg or ≥75 y old), ticagrelor 90 mg bid. Prasugrel should not be administered to patients with a history of prior stroke or TIA.

Anticoagulation therapy with unfractionated heparin and bivalirudin should be discussed with the invasive cardiologist.

Urgent PCI of the infarct artery should be addressed urgently with stent placement. Noninfarct artery occlusions should be evaluated postinfarction to evaluate ischemia requiring subsequent PCI.

Urgent coronary artery bypass surgery is indicated if the coronary anatomy is not amenable to PCI.

Therapy with statin agents, β-blockers, and ACE inhibitors are indicated as with NSTEMIs.

Elevated troponin levels are an imperfect diagnostic test and are dependent upon the probability of underlying CAD. New high-sensitivity troponin assays require further testing.

Establishing high pretest probability and global risk scores (TIMI, GRACE, PERSUIT) are often needed to determine the significance of elevated troponin levels.

Clinical factors that establish a high pretest probability include a history of typical angina, typical ECG changes consistent with ischemia (ST-segment changes), history of established coronary risk factors, or the history of known CAD.

Elevated troponin levels in patients with high pretest probability of CAD (typical chest pain and ECG changes of ischemia) have a predictive accuracy of ≥95% to establish acute coronary syndrome.

Elevated troponin levels in patients with low pretest probability of CAD (atypical chest pain and nonspecific ECG changes) have a predictive accuracy of only 50% to establish ACS.

Global risk scores should be employed to further establish the role of early conservative vs. early invasive therapy in patients with elevated troponin levels and a high pretest probability.

Cardiac causes for elevated troponin levels are ACS, coronary spasm or embolism, cocaine or methamphetamine use, stress cardiomyopathy, congestive heart failure, myocarditis or pericarditis, trauma, infiltrative diseases, postprocedure (ablation, electric shock, coronary bypass surgery, and post-coronary angioplasty).

Noncardiac causes for elevated troponin levels are pulmonary embolus, renal failure, stroke, sepsis, drug toxicity (anthracycline), and hypoxia.

CORONARY ARTERY DISEASE: LONG-TERM ANTIPLATELET THERAPY—AMERICAN COLLEGE OF CHEST PHYSICIANS 2012

- ASA is recommended for persons ≥50 y old without symptomatic CVD at 75–100 mg daily.
- Mono antiplatelet therapy with ASA 75–100 mg or clopidogrel 75 mg is recommended with established CAD.
- Dual antiplatelet therapy (ticagrelor 90 mg twice daily plus ASA 81 mg or clopidogrel 75 mg plus ASA 75–100 mg daily) for 1-y post-ACS with PCI with or without stent placement.
- Dual antiplatelet therapy with elective PCI without stent should receive clopidogrel 75 mg or ASA 75–100 mg daily for 1 mo, then long-term ASA therapy is recommended.
- Dual antiplatelet therapy with elective PCI and bare metal stent (BMS) is recommended for at least 1 mo and for drug eluting stent (DES) is recommended for at least 6 mo.
- No antiplatelet or OAC is recommended with systolic dysfunction without thrombus. If LV thrombus is present, OAC is recommended for 3 mo.


CORONARY ARTERY DISEASE: STENT THERAPY USE OF TRIPLE ANTICOAGULATION TREATMENT—AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION/EUROPEAN SOCIETY OF CARDIOLOGY

The prudent use of triple anticoagulation therapy with aspirin, clopidogrel, and warfarin in AF patients at high risk of thromboembolism and recent coronary stent placement remains a matter of clinical judgment, balancing the risk of thrombotic vs. bleeding events.

Facts:
- Bare-metal stents are the stents of choice if TAT is required.
- Drug-eluting stents should be reserved for high-risk clinical or anatomic situations (diabetic patients or if the coronary lesions are unusually long, totally occlusive, or in small blood vessels) if TAT is required.
- Dual antiplatelet therapy with clopidogrel (75 mg/d) and ASA (81 mg/d) is the most effective therapy to prevent coronary stent thrombosis.
- Warfarin anticoagulation is the most effective therapy to prevent thromboembolism in high-risk AF patients as defined by the CHA2DS2-VASc risk score (≥2).
- In nonvalvular AF okay to consider NOACs. Following coronary revascularization, in high-risk patients with AF it may be reasonable to use clopidogrel 75 mg daily concurrently with OAC but without ASA.
- TAT is the most effective therapy to prevent both coronary stent thrombosis and the occurrence of embolic strokes in high-risk patients.
• However, the addition of DAPT to warfarin increases the bleeding risk by 3.7-fold.
• Therefore, awaiting a definitive clinical trial (WOEST trial), risk stratification of patients to evaluate the thromboembolic potential of AF vs. the bleeding potential should be performed.
• The HAS-BLED (see table page 210) bleeding risk score is the best measure of bleeding risk. A high risk of bleeding is defined by a score >3.


Hypertension (≥160 mm Hg), abnormal kidney function (creatinine ≥2, chronic dialysis, transplant), abnormal liver function (cirrhosis, bilirubin >2×, AST >3×), stroke, bleeding history or anemia, labile INR (<60% within range), elderly (age ≥65 y), drugs/alcohol (use of ASA or clopidogrel) or alcohol (≥8 alcoholic drinks/wk). Each risk factor is assigned 1 point for a total of 9 points.

• If DAPT or TAT is required, prophylactic GI therapy with an H2 blocker (except cimetidine) or PPI agent should be maintained. If omeprazole (Prilosec) is considered, the risk-to-benefit ratio needs to be considered because of its possible interference with clopidogrel function.
• In patients with a high risk of bleeding, TAT should be reserved for AF patients with a high thromboembolic risk. If the bleeding risk is high but the AF thromboembolic risk is low, DAPT therapy is suggested.

AF, atrial fibrillation; ASA, aspirin; AST, aspartate transaminase; DAPT, dual antiplatelet therapy; INR, international normalized ratio; GI, gastrointestinal; PPI, proton pump inhibitor; TAT, triple anticoagulation therapy.

CORONARY ARTERY DISEASE: STENT THERAPY USE OF TRIPLE ANTICOAGULATION TREATMENT

High Embolic Risk AF (CHA₂DS₂-VASc score ≥2)
- Lifelong warfarin Rx (INR 2–3)
- Low-risk bleeding HAS-BLED score 0–2
- CCS
  - BMS/DES
  - TAT 1 mo (BMS)
  - 3–6 mo (DES)
- High-risk bleeding HAS-BLED score ≥3
- CCS
  - BMS/DES
  - TAT 1 mo

ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, aspirin; BMS, bare-metal stent; CCS, patient with chronic coronary syndrome (stable coronary artery disease); DES, drug eluting stent; INR, international normalized ratio; Rx, therapy (warfarin (INR 2–2.5) + aspirin (81 mg daily) + clopidogrel (75 mg daily)); TAT, triple anticoagulation therapy.

*DES stents if sirolimus, everolimus, or tacrolimus require 3-mo dual platelet therapy (ASA plus clopidogrel). If DES stent is paclitaxel, 6-mo dual therapy is required.

Sources:

CAD IN WOMEN

- CVD is the leading cause of mortality in women.
- AHA recommends the risk assessment of CVD in women should begin at age 20 y, identifying women at higher risk.
- There are racial/ethnic differences in risk factors, with black and Hispanic women having a higher prevalence of hypertension and diabetes. The highest CVD morbidity and mortality occurs in black women.
- Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis) and preeclampsia are significant risk factors for CVD in women.
- Psychological stress (anxiety, depression) and socioeconomic disadvantages are associated with a higher CVD risk in women.
- Microvascular disease with endothelial dysfunction, also known as female pattern disease, is the etiology of ischemia in more women than men.
- Women are more likely to have atypical cardiovascular symptoms such as sudden or extreme fatigue, dyspnea, sleep disturbances, anxiety, nausea, vomiting, and indigestion.
- ACC/AHA guidelines recommend a routine exercise stress test as the initial evaluation in symptomatic women who have a good exercise capacity and a normal baseline ECG. Exercise stress perfusion study (myocardial perfusion scintigraphy [MPS]) or exercise echo should be reserved for symptomatic women with higher pretest likelihood for CAD or indeterminate routine testing.
- Women often receive less medical therapy and lifestyle counseling than men.
- After PCI procedure, women experience higher rate of complications and mortality than men.
- Management of stable CAD should be the same as in men which include ASA, β-blocker, statin, ACE inhibitor (ejection fraction [EF] <40%), and nitrate/calcium channel blocker (CCB) for angina management.
- In microvascular disease, β-blockers have shown to be superior to CCB for angina management. Statins, ACE inhibitors, ranolazine, and exercise can improve angina scores and endothelial dysfunction in female pattern disease.

Evaluation of CVD risk:
- Medical history/family history/pregnancy complication history
- Symptoms of CVD
- Depression screening in women with CVD
- Physical examination including blood pressure, body mass index, waist size
- Laboratory tests including fasting lipoproteins and glucose
- Framingham risk assessment if no CVD or diabetes

**Implement Class I Recommendations (for all):**
- Smoking cessation
- DASH-like diet
- Regular physical activity
- Weight management

**Is women at high risk of CVD (having ≥1 of the following)?**
- Clinically established CHD
- Cerebrovascular disease
- Peripheral arterial disease
- Abdominal aortic aneurysm
- Diabetes mellitus
- Chronic kidney disease
- 10-y predicted CVD risk ≥10%

**Recent cardiovascular event, procedure, or congestive heart failure symptoms?**
- Yes
  - Refer to cardiac rehabilitation
- No
  - **Implement Class I Recommendations:**
    - Blood pressure control
    - LDL-C–lowering therapy (goal <100 mg/dL)
    - β-Blocker
    - Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

**History of paroxysmal atrial fibrillation?**
- No
- Yes
  - **Implement Class I Recommendations:**
    - Warfarin or
    - Aspirin or
    - Dabigatran

**Consider Class II Recommendations:**
- LDL-C–lowering therapy (goal <70 mg/dL in very high-risk women)
- Non–HDL-C–lowering therapy (goal <130 mg/dL in very high-risk women with recent ACS or multiple poorly controlled cardiovascular risk factors)
- Glycemic control in diabetes
- Aspirin/antiplatelet agents
- Omega-3 fatty acids

ACS, acute coronary syndrome; CHD, coronary heart disease; CVD, cardiovascular disease; DASH, dietary approaches to stop hypertension; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

CUSHING’S SYNDROME (CS)

Population
– Pediatric and adult patients with Cushing’s syndrome.

Recommendations
Endocrine Society 2015
– Treatment goals for Cushing’s syndrome
  • Normalize cortisol levels to eliminate the signs and symptoms of CS.
– Recommend vaccinations against:
  • Influenza, herpes zoster, pneumococcus
– Recommend perioperative thromboprophylaxis for venous thromboembolism.
– Recommend surgical resection of primary adrenal or ectopic focus underlying CS.
– Assess postoperative serum cortisol levels.

Source

DELIRIUM

Population
– Adults age ≥18 y in the hospital or in long-term care facilities.

Recommendations
NICE 2010
1. Perform a short Confusion Assessment Method (CAM) screen to confirm the diagnosis of delirium.
2. Recommended approach to the management of delirium:
   a. Treat the underlying cause.
   b. Provide frequent reorientation and reassurance to patients and their families.
   c. Provide cognitively stimulating activities.
   d. Ensure adequate hydration.
   e. Prevent constipation.
   f. Early mobilization.
   g. Treat pain if present.
   h. Provide hearing aids or corrective lenses if sensory impairment is present.
   i. Promote good sleep hygiene.
   j. Consider short-term antipsychotic use (<1 wk) for patients who are distressed or considered at risk to themselves or others.
American Geriatrics Society 2015
- Do not use physical restraints for behavioral control in elderly patients with delirium.

Source
- http://www.choosingwisely.org/societies/american-geriatrics-society/

Comment
- Recommended antipsychotics are haloperidol or olanzapine given at the lowest effective dose.

DELIRIUM, POSTOPERATIVE

Population
- Older adults at risk for or who have postoperative delirium.

Recommendations
- AGS 2015
  - Institutions should enact multi-component intervention programs to manage delirium.
  - Consider regional anesthesia at the time of surgery to improve postoperative pain control.
  - Avoid inappropriate medications postoperatively in older adults.
  - Use antipsychotics at the lowest effective dose and for the shortest duration possible to treat severe agitated delirium.
  - Avoid benzodiazepines for postoperative delirium.
  - Avoid pharmacologic therapy for hypoactive delirium.

Source
- https://guidelines.gov/summaries/summary/49932

DEMENTIA

Population
- Adults with dementia.

Recommendations
- ACP 2008, AAFP 2008
  1. Recommend a trial of therapy with a cholinesterase inhibitor or memantine based on individual assessment of relative risks vs. benefits.
2. The choice of medication is based on tolerability, side effect profile, ease of use, and medication cost.
3. The evidence is insufficient to compare the relative efficacy of different medications for dementia.
4. Evidence is insufficient to determine the optimal duration of therapy.

Source
–http://www.annals.org/content/148/5/370.full.pdf

Comments
1. A beneficial effect of cholinesterase inhibitors or memantine is generally observed within 3 mo.
2. Good-quality data in mild-to-moderate Alzheimer disease and vascular dementia show that cholinesterase inhibitors provide a modest improvement in global assessment, but no clinically important cognitive improvement. Subsets of patients may have significant cognitive improvement.
3. Five high-quality studies evaluated memantine use in moderate-to-severe Alzheimer disease and vascular dementia and show statistically significant improvement in global assessment, but no clinically important cognitive improvement.

DEMENTIA, ALZHEIMER DISEASE

Population
–Adults.

Recommendations

NICE 2011
–Donepezil, galantamine, and rivastigmine are recommended as options for mild-to-moderate Alzheimer disease.
–Memantine is recommended as an option for managing moderate Alzheimer disease in patients who cannot tolerate acetylcholinesterase inhibitors.

Source

Comments
1. Common adverse effects of acetylcholinesterase inhibitors include diarrhea, nausea, vomiting, muscle cramps, and insomnia.
2. Common adverse effects of memantine are dizziness, headache, constipation, somnolence, and hypertension.
DEMENTIA, FEEDING TUBES

Population
– Patients with advanced dementia.

Recommendations
► American Geriatrics Society 2013
– Percutaneous feeding tubes are not recommended for older adults with advanced dementia.
– Careful hand-feeding should be offered.

Source
– http://americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/

Comment
– Careful hand-feedings and tube-feedings have identical outcomes of death, aspiration pneumonia, functional status, and patient comfort. In addition, tube-feeding is associated with agitation, increased use of physical and chemical restraints, and worsening pressure ulcers.

DEPRESSION

Population
– Children and adolescents.

Recommendations
► USPSTF 2009
– Adequate evidence showed that SSRIs, psychotherapy, and combined therapy will decrease symptoms of major depressive disorder in adolescents age 12–18 y.
– Insufficient evidence to support screening and treatment of depression in children age 7–11 y.

Source

Comments
1. Good evidence showed that SSRIs may increase absolute risk of suicidality in adolescents by 1%–2%. Therefore, SSRIs should be used only if close clinical monitoring is possible.
2. Fluoxetine and citalopram yielded statistically significant higher response rates than did other SSRIs
DIABETIC FOOT PROBLEMS, INPATIENT MANAGEMENT

Population

– Hospitalized adults older than 18 y with diabetic foot problems.

Recommendations

► NICE 2011

– Every hospital should have a multidisciplinary foot care team to assess and treat any diabetic patient with foot problems.
– Every patient with a diabetic foot problem should undergo an assessment for:
  • Need for debridement, pressure off-loading.
  • Vascular inflow.
  • Infection of the foot.
  • Glycemic control.
  • Neuropathy.
– If osteomyelitis is suspected, obtain an x-ray, and if x-ray is normal, obtain an MRI.
– Provide off-loading for diabetic foot ulcers.
– For mild diabetic foot infections, treat with empiric antibiotics that provide good gram-positive organisms coverage.
– For moderate-to-severe diabetic foot infections, treat with empiric antibiotics that provide coverage of gram-positive, gram-negative, and anaerobic bacteria.

Source


Comment

– The diabetic foot care team should include:
  • Diabetologist.
  • Surgeon with expertise managing DM foot problems.
  • DM nurse specialist.
  • Podiatrist.
  • Tissue viability nurse.

DIABETES MELLITUS, GESTATIONAL (GDM)

Population

– Pregnant women.

Recommendations

► ACOG 2013

– Women with gestational diabetes should be treated with nutrition therapy.
- For pharmacologic therapy of GDM, oral medications and insulin are equivalent in efficacy.
- Women with GDM and estimated fetal weight of 4500 g or more should be counseled regarding option of scheduled cesarean delivery vs. vaginal trial of labor.
- Women with GDM should follow fasting and 1 h postprandial glucose levels.

**Source**

---

## DIABETES MELLITUS (DM), TYPE 1

### Population
- Adults and children

### Recommendations

**ADA 2013**

1. Recommends intensive insulin therapy with >3 injections daily using either basal and prandial insulin or an insulin pump.
2. Self-monitoring blood glucose >3 times daily in all patients using multiple insulin injections or an insulin pump.
4. Recommends glucose (15–20 g) for all conscious patients with hypoglycemia.
5. Advise all patients not to smoke.
6. Recommends beginning these screening tests after 5 y with type 1 DM
   a. Urine albumin-to-creatinine ratio and serum creatinine annually.
   b. Dilated funduscopic exam annually.
   c. Monofilament screening for diabetic neuropathy annually.
   d. Comprehensive foot examination at least annually.
7. Recommends screening at diagnosis for other autoimmune conditions
   a. Tissue transglutaminase IgA antibodies.
   b. Thyroperoxidase and thyroglobulin antibodies.
   c. TSH.
8. Fasting lipid panel at age 10 y or at puberty (consider as early as age 2 y for a strong family history of hyperlipidemia).
   a. Repeat annually if results abnormal or every 5 y if results acceptable.
9. Consider statin therapy if age ≥10 y and LDL >160 mg/dL despite good glycemic control and lifestyle modification.
10. Aspirin 75–162 mg/d if:
   b. Primary prevention of CVD if 10-y risk of coronary artery disease (CAD) >10%.
   c. Secondary prevention of CVD.

Source
   - http://care.diabetesjournals.org/content/36/Supplement_1/S11.full

Comments
1. Glycemic control recommendations for toddlers (age 0–6 y).
   a. Before meals, capillary blood gas (CPG) 100–180 mg/dL.
   b. Bedtime, CPG 110–200 mg/dL.
   c. HgbA1c <8.5%.
2. Glycemic control recommendations for school-age (age 6–12 y).
   a. Before meals, CPG 90–180 mg/dL.
   b. Bedtime, CPG 100–180 mg/dL.
   c. HgbA1c <8%.
   a. Before meals, CPG 90–130 mg/dL.
   b. Bedtime, CPG 90–150 mg/dL.
   c. HgbAlc <7.5%.

Population
   - Adults with type 1 diabetes.

Recommendations
   ▶ NICE 2015
   - Confirm diagnosis by checking C-peptide levels and auto-antibody testing.
   - Provide all adults with DM 1 a structured education program.
   - Offer carbohydrate counting education.
   - Offer peer support groups.
   - Measure glycohemoglobin every 3–6 mo.
     • Fructosamine level is an alternative test for anemic patients.
   - Recommend self-glucose monitoring at least 4 times daily.
   - Glucose targets are:
     • 90–126 mg/dL fasting.
     • 72–126 mg/dL before meals.
   - Basal insulin
     • Daily insulin glargine.
     • Insulin detemir bid.
   - Recommend rapid-acting prandial insulin before meals.
–Consider referral for islet cell transplantation in those with recurrent severe hypoglycemia.
–Screen adults with low BMI for celiac disease.
–Measure a TSH annually.
–Recommend therapy with ACEI or ARB for patients with hypertension or diabetic nephropathy.
–Offer digital retinopathy screening annually.
–Offer men with DM 1 and erectile dysfunction a phosphodiesterase-5 inhibitor.

Source
https://guidelines.gov/summaries/summary/49529

DIABETES MELLITUS (DM), TYPE 2

Population
–Nonpregnant adults.

Recommendations

AACE 2010
1. Endorses the use of HgbA1c ≥6.5% as a means of diagnosing type 2 DM.
2. HgbA1c is not recommended for diagnosing type 1 DM or gestational diabetes.

Source

Population
–Adults.

Population
–Adults and children.

Recommendations

ADA 2017
1. Self-monitoring blood glucose ≥3 times daily in all patients using multiple insulin injections or an insulin pump.
2. Recommends HgbA1c every 3 mo if therapy has changed or if blood glucose control is inadequate.
3. Provide diabetes self-management education, including education about hypoglycemia management and adjustments during illness.
4. Provide family planning for women of reproductive age.
5. Provide medical nutrition therapy.
6. Weight loss is recommended for all overweight or obese diabetic patients.
7. Keep saturated fat intake <7% of total calories.
8. Reduction of protein intake to 0.8–1.0 g/kg/d for early stages of CKD and 0.8 g/kg/d for later stages of CKD.
9. Recommends at least 150 min/wk of moderate physical activity.
10. The glucose range for critically ill patients is 100–180 mg/dL.
11. The glucose range for noncritically ill patients in the hospital is <140 mg/dL premeal (<7.8 mmol/L) and random blood glucose <180 mg/dL (<10 mmol/L).
12. Recommends the following:
   a. Immunizations
      i. Annual influenza vaccination if age ≥6 mo.
      ii. Pneumococcal polysaccharide vaccine if age >2 y.
      iii. 1× revaccination if age ≥65 y.
      iv. Hepatitis B vaccination if unvaccinated and age 19–59 y.
   b. Target BP <130/80 mm Hg.
   c. Statin therapy if:
      i. Overt CVD present.
      ii. Age >40 y and ≥1 CV risk factor.\(^\text{b}\)
      iii. LDL >100 mg/dL despite lifestyle modification.
      iv. LDL >70 mg/dL if DM2 and overt cardiovascular disease.
   d. ASA 75–162 mg/d if:
      i. Primary prevention of CVD if 10-y risk of CAD >10%.
      ii. Secondary prevention of CVD.
   e. Annual check of urine albumin-to-creatinine ratio and serum creatinine.
   f. Annual serum creatinine and fasting lipid profile.
   g. Annual dilated funduscopic exam.
   h. Annual monofilament screening for diabetic neuropathy.
   i. At minimum, annual comprehensive foot exam.

Source

Comments
1. Glycemic control recommendations:
   a. Preprandial CPG 70–130 mg/dL.
   b. Postprandial CPG <180 mg/dL (1–2 h postmeals).
   c. HgbA1c <7%.
2. Consider bariatric surgery if BMI >35 kg/m\(^2\) and if diabetes is difficult to control with lifestyle modification and medications.
3. Angiotensin-converting enzyme inhibitors (ACEIs) or ARBs are first-line antihypertensives.
4. Second-line antihypertensives are a thiazide diuretic if GFR ≥30 mL/min/1.73 m² or a loop diuretic if GFR <30 mL/min/1.73 m².
5. Clopidogrel 75 mg/d is an alternative for persons ASA intolerant.
6. Nephrology referral indicated if GFR <60 mL/min/1.73 m², or if heavy proteinuria or structural kidney disease present.
7. Consider a serum TSH in women age >50 y.
8. Consider assessing patients for the following comorbidities that are increased with DM:
   a. Hearing impairment.
   b. Obstructive sleep apnea.
   c. Fatty liver disease.
   d. Low testosterone in men.
   e. Periodontal disease.

Population
- Adults older than 18 y.

Recommendations

ACP 2012
- Oral pharmacologic therapy should be added for treatment of type 2 DM when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately control hyperglycemia.
- Recommends metformin as the initial pharmacologic agent to treat most patients with type 2 DM.
- Recommends adding another oral agent to metformin if patients have persistent hyperglycemia despite metformin and lifestyle modifications.

Source

Comments
1. All dual-regimens were more effective than monotherapy and decreased the HbA1c levels by an average of 1% more.
2. Most monotherapy regimens had similar efficacy and reduced HbA1c levels by an average of 1%.
3. Studies suggest that metformin decreases all-cause mortality slightly more than sulfonylureas with a much lower rate of hypoglycemia.

Population
- Hospitalized adults older than 18 y.

Recommendations

ACP 2011
- Avoid intensive insulin therapy in hospitalized patients (even if in SICU/MICU).
– Recommends a target blood glucose level of 140–200 mg/dL if insulin therapy is used in SICU/MICU patients.

**Source**

**Comment**
– Intensive insulin therapy (targeting blood glucose levels of 80–110 mg/dL) in SICU/MICU patients does not improve mortality, but has a 5-fold increased risk of hypoglycemia.

**Population**
– Children and adolescents with newly diagnosed DM2.

**Recommendations**

**AAP 2013**
– Insulin therapy should be initiated for children with:
  • Diabetic ketoacidosis.
  • HbA1c > 9%.
  • Random glucose > 250 mg/dL.
– Diet, exercise, and metformin are initial therapy for other situations.
– Recommend moderate-to-vigorous exercise for 60 min daily.
– Limit nonacademic screen time < 2 h/d.
– Monitor HbA1c every 3 mo.
– Desire HbA1c < 7%.

**Source**
– pediatrics.aappublications.org/content/131/2/364.full.pdf
## Oral Diabetes Mellitus Type 2 Agents—CPG 2015

<table>
<thead>
<tr>
<th>Category</th>
<th>Metformin</th>
<th>DDP-4I</th>
<th>GLP-1 RA</th>
<th>TZD</th>
<th>AGI</th>
<th>Colesevelam</th>
<th>BCR-QR</th>
<th>SU/MGN</th>
<th>Insulin</th>
<th>SGLT-2</th>
<th>Pramlintide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycemia</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Moderate/severe/mild</td>
<td>Moderate/severe</td>
<td>Neutral</td>
<td>Neutral</td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>Slight loss</td>
<td>Neutral</td>
<td>Loss</td>
<td>Gain</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Gain</td>
<td>Gain</td>
<td>Loss</td>
<td>Loss</td>
</tr>
<tr>
<td>Renal/GU</td>
<td>Cl if CrCl&gt;1.4 (W) Cl if CrCl&gt;1.5 (M) Cl if CrCl&lt;30 mL/min</td>
<td>Dose adjust if CrCl&lt;30 mL/min</td>
<td>Fluid retention</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Renal impairment increases hypoglycemia</td>
<td>Renal impairment increases hypoglycemia</td>
<td>Infection; Cl if CrCl&lt;45 mL/min</td>
<td>Neutral</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal*</td>
<td>Moderate</td>
<td>Neutral</td>
<td>Moderate</td>
<td>Cl in cirrhosis</td>
<td>Moderate</td>
<td>Mild</td>
<td>Moderate</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Moderate</td>
</tr>
<tr>
<td>CHF</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Moderate</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
</tr>
<tr>
<td>CVD</td>
<td>Benefit</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Slight risk</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Unclear</td>
<td>Orthostasis in elderly</td>
<td>Neutral</td>
<td></td>
</tr>
<tr>
<td>Bone loss</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Moderate</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Small</td>
<td>Neutral</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>β₁₂ deficiency</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>SiADH/ headaches</td>
<td>–</td>
<td>–</td>
<td>Avoid with gastroparesis; headache</td>
</tr>
</tbody>
</table>

AGI, alphaglucosidase inhibitors; BCR-QR, bromocriptine quick release; Cl, contraindicated; CVD, cardiovascular disease; DPP-4I, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor antagonist; GI, genitourinary; MGN, meglinitides; SIADH, syndrome of inappropriate antidiuretic hormone; SGLT-2, salt glucose cotransporter 2; SU, sulfonylurea; TZD, thiazolidinediones.

*GI symptoms can include nausea, vomiting, flatulence, diarrhea, anorexia, and pancreatitis (for GLP-1 RA).

### Initiate Basal Insulin
Usually with metformin +/- other noninsulin agent

- **Start**: 10 U/day or 0.1–0.2 U/kg/day
- **Adjust**: 10–15% or 2–4 units once or twice weekly to reach FBG target
- **For hypo**: Determine & address cause; if no clear reason for hypo,
  - dose by 4 units or 10–20%

#### Add 1 rapid-acting insulin injection before largest meal

- **Start**: 4 units, 0.1 U/kg, or 10% basal dose. If A1C <8%, consider ↓ basal by same amount.
- **Adjust**: ↑ dose by 1–2 units or 10–15% once or twice weekly until SMBG target reached
- **For hypo**: Determine and address cause; if no clear reason for hypo,
  - corresponding dose by 2–4 units or 10–20%

#### Add ≥2 rapid-acting insulin injections before meals (‘basal-bolus’)

- **Start**: 4 units, 0.1 U/kg, or 10% basal dose/meal. If A1C <8%, consider ↓ basal by same amount.
- **Adjust**: ↑ dose(s) by 1–2 units or 10–15% once or twice weekly to achieve SMBG target
- **For hypo**: Determine and address cause; if no clear reason for hypo,
  - corresponding dose by 2–4 units or 10–20%

#### Add GLP-1 RA

- **If not tolerated or A1C target not reached, change to 2 injection insulin regimen**
- **Change to premixed insulin twice daily (before breakfast and supper)**
  - **Start**: Divide current basal dose into ½ AM, ½ PM or ½ AM, ½ PM
  - **Adjust**: ↑ dose by 1–2 units or 10–15% once or twice weekly until SMBG target reached
  - **For hypo**: Determine and address cause; if no clear reason for hypo,
    - corresponding dose by 2–4 units or 10–20%

#### Change to premixed analog insulin 3 times daily (breakfast, lunch, supper)

- **Start**: Add additional injection before lunch
  - **Adjust**: ↑ doses by 1–2 units or 10–15% once or twice weekly to achieve SMBG target
  - **For hypo**: Determine and address cause; if no clear reason for hypo,
    - corresponding dose by 2–4 units or 10–20%

#### If A1C not controlled, consider combination injectable therapy

- **If A1C not controlled, advance to basal-bolus**
- **If A1C not controlled, advance to 3rd injection**

#### If goals not met, consider changing to alternative insulin regimen
DIABETES MELLITUS TYPE 2 MANAGEMENT

Start with Monotherapy unless:
- HbA1c greater than or equal to 9%, consider Dual Therapy.
- HbA1c greater than or equal to 10%, blood glucose is greater than or equal to 300 mg/dL, or patient is markedly symptomatic, consider Combination Injectable Therapy.

<table>
<thead>
<tr>
<th>Monotherapy</th>
<th>Metformin</th>
<th>Lifestyle Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFFICACY*</td>
<td>high</td>
<td></td>
</tr>
<tr>
<td>HYPO RISK</td>
<td>low risk</td>
<td></td>
</tr>
<tr>
<td>WEIGHT</td>
<td>neutral/loss</td>
<td></td>
</tr>
<tr>
<td>SIDE EFFECTS</td>
<td>lactic acidosis</td>
<td></td>
</tr>
<tr>
<td>COSTS*</td>
<td>low</td>
<td></td>
</tr>
</tbody>
</table>

If HbA1c target not achieved after approximately 3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference—choice dependent on a variety of patient- & disease-specific factors):

<table>
<thead>
<tr>
<th>Dual Therapy</th>
<th>Metformin +</th>
<th>Lifestyle Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFFICACY*</td>
<td>high</td>
<td></td>
</tr>
<tr>
<td>HYPO RISK</td>
<td>high</td>
<td></td>
</tr>
<tr>
<td>WEIGHT</td>
<td>low risk</td>
<td></td>
</tr>
<tr>
<td>SIDE EFFECTS</td>
<td>edema, HF, fxs</td>
<td></td>
</tr>
<tr>
<td>COSTS*</td>
<td>low</td>
<td></td>
</tr>
</tbody>
</table>

If HbA1c target not achieved after approximately 6 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference—choice dependent on a variety of patient- & disease-specific factors):

<table>
<thead>
<tr>
<th>Triple Therapy</th>
<th>Metformin +</th>
<th>Lifestyle Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFFICACY*</td>
<td>moderate risk</td>
<td></td>
</tr>
<tr>
<td>HYPO RISK</td>
<td>low risk</td>
<td></td>
</tr>
<tr>
<td>WEIGHT</td>
<td>neutral</td>
<td></td>
</tr>
<tr>
<td>SIDE EFFECTS</td>
<td>edema, HF, fxs</td>
<td></td>
</tr>
<tr>
<td>COSTS*</td>
<td>neutral</td>
<td></td>
</tr>
</tbody>
</table>

If HbA1c target not achieved after approximately 3 months of triple therapy and patient (1) on oral combination, move to basal insulin or GLP-1 RA, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1 RA or mealtime insulin. Metformin therapy should be maintained, while other oral agents may be discontinued on an individual basis to avoid unnecessarily complex or costly regimens (i.e., adding a fourth antihyperglycemic agent).

Combination Injectable Therapy

<table>
<thead>
<tr>
<th>Combination Injectable Therapy</th>
</tr>
</thead>
</table>
- Prolonged metformin use can lead to vitamin B12 deficiency. SGLT-2 inhibitors are favored over sulfonylureas as an add-on to metformin in terms of cardiovascular mortality.

Sources

## DIARRHEA, ACUTE

### Population
- Adults with acute diarrheal illness.

### Recommendations

### APPROACH TO EMPIRIC THERAPY AND DIAGNOSTIC-DIRECTED MANAGEMENT OF THE ADULT PATIENT WITH ACUTE DIARRHEA (SUSPECT INFECTIOUS ETIOLOGY)

- Passage of ≥3 unformed stools in 24 h plus an enteric symptom (nausea, vomiting, abdominal pain/cramps, tenesmus, fecal urgency, moderate to severe flatulence)

- Oral fluid therapy: for all cases, hydrate through fluid and salt intake
  - Food: soups, broths, saltine crackers, broiled and baked foods

- Watery diarrhea
  - Mild illness*
  - Moderate-to-severe illness

- Dysenteric diarrhea (passage of grossly bloody stools)
  - No or low-grade fever (≤100°F)
  - Fever (≥101°F)

- Travel-associated
  - Non-travel-associated

- Microbiologic assessment then anti-microbial agent directed to cause for all but infection

- Empiric treatment, Azithromycin 1 g in single dose or 500 mg once daily for 3 d

- Persistent diarrhea (14–30 days) should be worked up by culture and/or culture-independent microbiologic assessment, then treatment with anti-microbial agent directed to cause

*Illness severity:
  - Severe:-total disability due to diarrhea; Moderate = able to function but with forced change in activities due to illness; Mild = no change in activities
ACUTE DIARRHEA ANTIBIOTIC TREATMENT RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dose</th>
<th>Treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levofoxacin</td>
<td>500 mg by mouth</td>
<td>Single dose&lt;sup&gt;b&lt;/sup&gt; or 3-d course</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>750 mg by mouth or 500 mg by mouth</td>
<td>Single dose&lt;sup&gt;b&lt;/sup&gt; or 3-d course</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>400 mg by mouth</td>
<td>Single dose&lt;sup&gt;b&lt;/sup&gt; or 3-d course</td>
</tr>
<tr>
<td>Azithromycin&lt;sup&gt;cd&lt;/sup&gt;</td>
<td>1,000 mg by mouth or 500 mg by mouth</td>
<td>Single dose&lt;sup&gt;b&lt;/sup&gt; or 3-d course&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rifaximin&lt;sup&gt;f&lt;/sup&gt;</td>
<td>200 mg by mouth 3 times daily</td>
<td>3-d</td>
</tr>
</tbody>
</table>

ETEC, Enterotoxigenic *Escherichia coli*.

<sup>a</sup>Antibiotic regimens may be combined with loperamide, 4 mg first dose, and then 2 mg dose after each loose stool, not to exceed 16 mg in a 24-h period.

<sup>b</sup>If symptoms are not resolved after 24 h, complete a 3-d course of antibiotics.

<sup>c</sup>Use empirically as first line in Southeast Asia and India to cover fluoroquinolone-resistant *Campylobacter* or in other geographical areas if *Campylobacter* or resistant ETEC are suspected.

<sup>d</sup>Preferred regimen for dysentery or febrile diarrhea.

<sup>e</sup>Do not use if clinical suspicion for *Campylobacter, Salmonella, Shigella*, or other causes of invasive diarrhea.

- The use of probiotics or prebiotics for the treatment of acute diarrhea in adults is not recommended.
- Bismuth subsalicylates can be administered to control rates of passage of stool and may help travelers function better during bouts of mild-to-moderate illness.
- In patients receiving antibiotics for traveler’s diarrhea, adjunctive loperamide therapy should be administered to decrease duration of diarrhea and increase chance for a cure.
- Use of antibiotics for community-acquired diarrhea should be discouraged as epidemiological studies suggest that most community-acquired diarrhea is viral in origin (norovirus, rotavirus, and adenovirus) and is not shortened by the use of antibiotics.

**Source**

CHAPTER 3

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) STAGE I THROUGH IV

Population

– Complete remission of DLBCL following treatment with negative PET-CT scan.

Recommendations

NCCN 2016

– Clinical Follow-up Stages I and II

  • History and physical exam and labs (CBC, metabolic panel including LDH) every 3–6 mo for 5 y then yearly as clinically indicated.

– Imaging

  • Repeat CT or PET scan only as clinically indicated (symptoms, palpable nodes, or abnormal labs—especially increased LDH).
  • If recurrence is suspected, re-biopsy is mandatory to guide salvage therapy.

– Clinical Decisions Stages III and IV

  • Observation or consider radiation therapy (RT) to initial area of bulky (>10 cm) disease or consider high-dose chemotherapy with autologous stem cell rescue in very high risk patients who have Stage IV disease and a significant chance of relapse.

– Clinical Follow-up

  • History and physical with labs (CBC, metabolic panel including LDH every 2–4 mo for 5 y and then yearly or as clinically indicated).

– Imaging

  • Controversial—either CT scans every 6 mo or only when signs or symptoms are suggestive of recurrence.

Sources


Comments

1. Lymphoma Facts

  • DLBCL most common non-Hodgkin’s lymphoma (NHL)—30%.
  • Follicular lymphoma 2nd most common at 20%.
  • 71,000 cases of NHL with 19,000 deaths yearly. Total number of NHL diagnosis is increasing by 1% to 2% per year.

2. Ann Arbor staging system

  • Stage I—single nodal group either side of diaphragm.
  • Stage II—more than 1 nodal group involvement either side of diaphragm.
  • Stage III—nodal groups on both sides of the diaphragm.
  • Stage IV—disseminated disease to bone marrow and/or visceral organs.
DISEASE MANAGEMENT

- β symptoms include fever, night sweats, and weight loss.
- Bulk disease (>10 cm) increases risk of recurrence.
- There has been a reduction in frequency of surveillance CT scans due to concern about increased radiation exposure. (JAMA.2012;307:2400)
- Monitor for late events—secondary cancers, cardiovascular disease, hypothyroidism, and fertility issues.
- Bone marrow injury may evolve to myelodysplasia and acute myeloid leukemia.
- Always biopsy recurrent disease—10% to 15% will be follicular lymphoma with indolent biology.
- CNS prophylaxis in aggressive DLBCL (testis, sinus, bone marrow)—intrathecal vs. high-dose methotrexate with rescue.

DYSPEPSIA

American College of Gastroenterology/Canadian Association of Gastroenterology 2017

Population
- Adults with dyspepsia.

WORK-UP OF UNDIAGNOSED DYSPEPSIA

<table>
<thead>
<tr>
<th>≥ 60 years of age</th>
<th>Adult dyspepsia patient</th>
<th>&lt; 60 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organic pathology</td>
<td>Manage according to functional dyspepsia algorithm</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>Manage according to functional dyspepsia algorithm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. pylori test and treat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>No response</td>
<td>PPI</td>
</tr>
<tr>
<td></td>
<td>Response</td>
<td>H. pylori eradication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TCA or prokinetic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider psychotherapy</td>
</tr>
</tbody>
</table>

PPI = proton pump inhibitor; TCA = tricyclic antidepressant; prokinetic = metoclopramide
**Recommendation**

Recommends against routine motility studies for patients with functional dyspepsia unless there is a strong suspicion for gastroparesis in which case a motility study is indicated.

**Source**


NICE 2014

**Population**

Adults

**Recommendations**

1. Recommend smoking cessation and weight reduction.
2. Consider discontinuation of offending medications (calcium channel blockers, nitrates, theophylline, bisphosphonates, steroids, and NSAIDs).
3. Consider testing for *H. pylori* after a 2-wk washout off proton pump inhibitors.
4. Empiric trial of proton pump inhibitor therapy.
5. Consider laparoscopic fundoplication for patients who do not wish to continue with acid suppressive therapy long term.
6. Consider specialist referral for:
   a. Dyspepsia refractory to meds.
   b. Consideration of surgery.
   c. Refractory *H. pylori* infection.
   d. Barrett esophagus.

*Source*

### DYSPHAGIA

**Population**
– Adults.

**Recommendations**

- ASGE 2014
  - Recommend endoscopic dilation for benign esophageal strictures or eosinophilic esophagitis.
  - Recommend through-the-scope balloon dilation for complex esophageal strictures.
  - Concomitant antisecretory therapy with dilation for peptic strictures.
  - Reserve esophageal stents for refractory esophageal strictures.
  - Options for endoscopic management of achalasia include pneumatic dilation or botulinum toxin injections.

*Source*

### EATING DISORDERS

**Population**
– Adults and children with eating disorders.

**Recommendations**

- APA 2013
  - Psychiatric management begins with the establishment of a therapeutic alliance.
  - Recommend a multidisciplinary approach with a psychiatrist, dietician, social worker, and physician.
  - Components of the initial evaluation include:
    - A thorough history and physical examination.
    - Assessment of the social history.
    - An evaluation of the height and weight history.
    - Any family history of eating disorders or mental health disorders?
• Assess attitude of eating, exercising, and appearance.
• Assess for suicidality.
• Assess for substance abuse.
• Recommend nutritional rehab for seriously underweight patients.
  ◦ Recommend nasogastric tube feeding over parenteral nutrition for patients not meeting caloric requirements with oral feeds alone.
• Psychosocial rehab for patients with both anorexia nervosa and bulimia nervosa.
• Prozac is preferred agent to prevent relapse during maintenance phase of bulimia nervosa.
• Labs
  ◦ CBC.
  ◦ Chemistry panel.
  ◦ TSH.
• Additional testing
  ◦ Bone mineral densitometry if amenorrhea for more than 6 mo.
  ◦ Dental evaluation for history of purging.

Source

ECTOPIC PREGNANCY

Population
–Pregnant women.

Recommendations

NICE 2012
–Recommended evaluation for stable women with an early pregnancy.
  • Transvaginal ultrasound (TVUS) with a crown-rump length ≥7 mm but no cardiac activity.
    ◦ Repeat ultrasound in 7 d.
    ◦ Quantitative β-hCG q48h × 2 levels.
  • TVUS with gestational sac ≥25 mm and no fetal pole.
    ◦ Repeat ultrasound in 7 d.
    ◦ Quantitative β-hCG q48h × 2 levels.
–Management of ectopic pregnancies.
  • Methotrexate candidates.
    ◦ No significant pain.
    ◦ Adnexal mass <3.5 cm.
    ◦ No cardiac activity on TVUS.
    ◦ β-hCG <5000 IU/L.
    ◦ Dose is 50 mg/m2 IM.
DISEASE MANAGEMENT

- Laparoscopy if:
  - Unstable patient.
  - Severe pain.
  - Adnexal mass >3.5 cm.
  - Cardiac activity seen.
  - β-hCG >5000 IU/L.
- Rhogam 250 IU to all Rh-negative women who undergo surgery for an ectopic.

Source
- www.guidelines.gov/content.aspx?id=39274

Comments
1. Ectopic pregnancy can present with:
   - Abdominal or pelvic pain.
   - Vaginal bleeding.
   - Amenorrhea.
   - Breast tenderness.
   - GI symptoms.
   - Dizziness.
   - Urinary symptoms.
   - Rectal pressure.
   - Dyschezia.
2. Most normal intrauterine pregnancies will show an increase in β-hCG level by at least 63% in 48 h.
3. Intrauterine pregnancies are usually apparent by TVUS if β-hCG >1500 IU/L.

EPILEPSY

Population
- Children and adults.

Recommendations
- NICE 2012
- Educate adults about all aspects of epilepsy.
- Diagnosis of epilepsy should be made by a specialist in epilepsy.
- Evaluation of epilepsy
  - Electroencephalogram.
  - Sleep-deprived EEG if standard EEG is inconclusive.
  - Neuroimaging to evaluate for any structural brain abnormalities.
  - MRI is preferred for children <2 y, adults, refractory seizures, and focal seizures.
• Measurement of prolactin is not recommended.
• Chemistry panel.
• ECG in adults.
• Urine toxicology screen.
  – Antiepileptic drugs (AED)
    • Start AED only after the diagnosis of epilepsy is made.
    • Focal seizures.
      ° Carbamazepine.
      ° Lamotrigine.
      ° Adjunctive AED: levetiracetam, oxcarbazepine, or sodium valproate.
    • Generalized tonic-clonic seizures.
      ° Sodium valproate.
      ° Lamotrigine.
      ° Carbamazepine.
      ° Oxcarbazepine.
      ° Adjunctive AED: levetiracetam or topiramate.
  • Absence seizures.
    ° Ethosuximide.
    ° Sodium valproate.
    ° Alternative: lamotrigine.
  • Myoclonic seizures.
    ° Sodium valproate.
    ° Alternatives: levetiracetam or topiramate.

Source

Comment
– AED can decrease the efficacy of combined oral contraceptive pills.

## ERECTILE DYSFUNCTION (ED)

### Population
– Adult men.

### Recommendations

> **EAU 2009**

– Recommends a medical and psychosexual history on all patients.
– Recommends a focused physical examination to assess CV status, neurologic status, prostate disease, penile abnormalities, and signs of hypogonadism.
– Recommends checking a fasting glucose, lipid profile, and total testosterone levels.
– Recommends psychosexual therapy for psychogenic ED.
DISEASE MANAGEMENT

– Recommends testosterone therapy for androgen deficiency if no contraindications present.¹
– Selective phosphodiesterase 5 (PDE5) inhibitors are first-line therapy for idiopathic ED.

Source

Comments
1. Selective PDE5 inhibitors:
   a. Sildenafil.
   b. Tadalafil.
   c. Vardenafil.
2. Avoid nitrates and use α-blockers with caution when prescribing a selective PDE5 inhibitor.

GALLSTONES

Population
– Adults with or suspected of having gallstones.

Recommendations
  ▶ NICE 2014
  1. Obtain liver function tests and ultrasound if suspected gallstone disease.
  2. Consider magnetic resonance cholangiopancreatography (MRCP) if ultrasound has not detected common bile duct stones but the:
     a. Common bile duct is dilated.
     b. Liver function tests are abnormal.
  3. Offer cholecystectomy for symptomatic gallstones or acute cholecystitis.
  4. Offer percutaneous cholecystostomy for acute cholecystitis or gallbladder empyema if surgery is contraindicated.
  5. Options for choledocholithiasis:
     a. Cholecystectomy and intraoperative clearance of CBD stones.
     b. ERCP prior to cholecystectomy.

Source

GASTROINTESTINAL BLEEDING, LOWER

Population
– Adults with suspected lower GI bleeding.

Recommendations
▶ ACG 2016

¹Prostate CA, breast CA, or signs of prostatism.
ALGORITHM FOR THE MANAGEMENT OF PATIENTS PRESENTING WITH ACUTE LGIB STRATIFIED BY BLEEDING SEVERITY

**High-risk patients**
- Multiple high-risk clinical features,
- Hemodynamic instability, signs and symptoms of ongoing bleeding, serious comorbid disease
- Resuscitate with IV fluids and blood product transfusion
- Radiographic intervention (angiography, consider preceding CTA for localization)
- Consult surgery
- Elective colonoscopy after bleeding resolves
- Colonoscopy performed <24 h from presentation after hemodynamic resuscitation and 4–6 l of PEG solution given over 3–4 h until rectal effluent is clear of blood and stool
- Consider repeat colonoscopy with endoscopic hemostasis for patients with evidence of recurrent bleeding

**Low-risk patients**
- No or few high-risk clinical features,
- Hemodynamically stable, no ongoing bleeding, or serious comorbid disease
- Resuscitate if needed with IV fluids and blood product transfusion
- Manage on regular hospital floor
- Colonoscopy next available after 4–6 l of PEG solution until rectal effluent is clear of blood and stool

**Clinical assessment, vital signs, laboratory**

- **UGI source per EGD**
- **Remains hemodynamically unstable and intolerant to colonoscopy prep**
- **Manage as indicated**
- **Radiographic intervention** (angiography, consider preceding CTA for localization)
- **Consult surgery**
- **Elective colonoscopy after bleeding resolves**
- **Colonoscopy performed <24 h from presentation after hemodynamic resuscitation and 4–6 l of PEG solution given over 3–4 h until rectal effluent is clear of blood and stool**
- **Consider repeat colonoscopy with endoscopic hemostasis for patients with evidence of recurrent bleeding**

**Aspirin for secondary cardiovascular prevention should not be discontinued. Aspirin for primary prevention should be avoided in LGIB. Dual antiplatelet therapy (DAPT, thienopyridine) should generally be resumed within 7 days. The exact timing of the thienopyridine resumption depends on cardiovascular risk and adequacy of bleeding control. DAPT should not be discontinued in the 90 days post acute coronary syndrome and 30 days post coronary stenting.**

---

CTA, computed tomographic angiography; DAPT, dual antiplatelet therapy; EGD, esophagogastroduodenoscopy; LGIB, lower gastrointestinal bleeding; NGT, nasogastric tube; PEG, polyethylene glycol; UGIB, upper gastrointestinal bleeding.

Platelet transfusion should be considered to maintain a platelet count of 50,000 in patients with severe bleeding and those requiring endoscopic hemostasis.

Reversal of anticoagulation should be considered before endoscopy in patients with an INR >2.5.

Source

**GASTROINTESTINAL BLEEDING, UPPER (UGIB)**

**Population**
- Adults.

**Recommendations**

- **NICE 2012**
  - Recommend a formal risk assessment for patients with an UGIB.
    - Blatchford score at first assessment.
    - Rockall score after endoscopy.
  - Avoid platelet transfusions in patients who are not actively bleeding and are hemodynamically stable.
  - For UGIB, give FFP if:
    - Fibrinogen <100 mg/dL.
    - Partial thromboplastin time >1.5× normal.
  - Prothrombin complex concentrate (PCC) indicated for UGIB on warfarin.
  - Timing of endoscopy.
    - Immediately for unstable patients.
    - Within 24 h for stable patients.
  - Management of nonvariceal bleeding
    - Surgical clips.
    - Thermal coagulation.
    - Epinephrine injection.
    - Fibrin or thrombin glue.
    - Proton pump inhibitors.
    - Recurrent bleeding can be assessed by repeat endoscopy or by interventional radiology angioembolization.
Management of variceal bleeding.
  - Esophageal variceal band ligation.
  - Terlipressin or octreotide infusions.
  - Prophylactic third-generation cephalosporin.
  - Transjugular intrahepatic portosystemic shunt for recurrent esophageal variceal bleeding or gastric variceal bleeding.

Source

Comments
1. Patients should stop NSAIDs.
2. Alcohol cessation if a factor.
3. Low-dose aspirin can be resumed if needed for secondary prevention of vascular events once hemostasis has been achieved.
4. Ongoing use of thienopyridine agents (eg, clopidogrel, ticagrelor, or prasugrel) should be only after discussion with appropriate specialist.
Medication Use in Older Adults, Potentially Inappropriate

### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS

<table>
<thead>
<tr>
<th>Organ System/Therapeutic Category/Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergics (exclude TCAs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-generation antihistamines (as single agent or as part of combination products)</td>
<td>Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; increased risk of confusion, dry mouth, constipation, and other anticholinergic effects/toxicity. Use of diphenhydramine in special situations such as acute treatment of severe allergic reaction may be appropriate.</td>
<td>Avoid</td>
<td>Hydroxyzine and promethazine: high; all others: moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Antiparkinson agents</td>
<td>Not recommended for prevention of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>

- **Avoid**: Discontinue drug. Consult with primary care provider.
- **Strong**: High-quality evidence (level A) and/or high strength of recommendation (level 1).
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS (Continued)

<table>
<thead>
<tr>
<th>Organ System/Therapeutic Category/Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antispasmodics • Belladonna alkaloids • Clidinium-chlordiazepoxide • Dicyclomine • Hyoscine • Propantheline • Scopolamine</td>
<td>Highly anticholinergic, uncertain effectiveness.</td>
<td>Avoid except in short-term palliative care to decrease oral secretions.</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>

**Antithrombotics**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipyridamole, oral short-acting* (does not apply to the extended-release combination with aspirin)</td>
<td>May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Ticlopidine*</td>
<td>Safer, effective alternatives available.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>

**Anti-infective**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrofurantoin</td>
<td>Potential for pulmonary toxicity; safer alternatives available; lack of efficacy in patients with CrCl &lt;60 mL/min due to inadequate drug concentration in the urine.</td>
<td>Avoid for long-term suppression; avoid in patients with CrCl &lt;60 mL/min.</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>
### Cardiovascular

#### Alpha blockers
- Doxazosin
- Prazosin
- Terazosin

<table>
<thead>
<tr>
<th></th>
<th>High risk of orthostatic hypotension; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile.</th>
<th>Avoid use as an antihypertensive.</th>
<th>Moderate</th>
<th>Strong</th>
</tr>
</thead>
</table>

#### Alpha blockers, central
- Clonidine
- Guanabenz
- Guanfacine
- Methyldopa
- Reserpine (>0.1 mg/d)

<table>
<thead>
<tr>
<th></th>
<th>High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension.</th>
<th>Avoid clonidine as a first-line antihypertensive. Avoid others as listed.</th>
<th>Low</th>
<th>Strong</th>
</tr>
</thead>
</table>

#### Antiarrhythmic drugs (Class Ia, Ic, III)
- Amiodarone
- Dofetilide
- Dronedarone
- Flecainide
- Ibutilide
- Procainamide
- Propafenone
- Quinidine
- Sotalol

<table>
<thead>
<tr>
<th></th>
<th>Data suggest that rate control yields better balance of benefits and harms than rhythm control for most older adults. Amiodarone is associated with multiple toxicities, including thyroid disease, pulmonary disorders, and QT interval prolongation.</th>
<th>Avoid antiarrhythmic drugs as first-line treatment of atrial fibrillation.</th>
<th>High</th>
<th>Strong</th>
</tr>
</thead>
</table>

#### Disopyramide

<table>
<thead>
<tr>
<th></th>
<th>Disopyramide is a potent negative inotrope and therefore may induce heart failure in older adults; strongly anticholinergic; other antiarrhythmic drugs preferred.</th>
<th>Avoid</th>
<th>Low</th>
<th>Strong</th>
</tr>
</thead>
</table>
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS (Continued)

<table>
<thead>
<tr>
<th>Organ System/Therapeutic Category/Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dronedarone</td>
<td>Worse outcomes have been reported in patients taking dronedarone who have permanent atrial fibrillation or heart failure. In general, rate control is preferred over rhythm control for atrial fibrillation.</td>
<td>Avoid in patients with permanent atrial fibrillation or heart failure</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Digoxin &gt;0.125 mg/d</td>
<td>In heart failure, higher dosages associated with no additional benefit and may increase risk of toxicity; decreased renal clearance may lead to increased risk of toxic effects.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Nifedipine, immediate release</td>
<td>Potential for hypotension; risk of precipitating myocardial ischemia.</td>
<td>Avoid</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>Spironolactone &gt;25 mg/d</td>
<td>In heart failure, the risk of hyperkalemia is higher in older adults if taking &gt;25 mg/d.</td>
<td>Avoid in patients with heart failure or with a CrCl &lt;30 mL/min.</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>
### Central Nervous System

**Tertiary TCAs, alone or in combination:**
- Amitriptyline
- Chlordiazepoxide-amitriptyline
- Clomipramine
- Doxepin >6 mg/d
- Imipramine
- Perphenazine-amitriptyline
- Trimipramine

| Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (≤6 mg/d) is comparable to that of placebo. | Avoid | High | Strong |

**Antipsychotics, first- (conventional) and second- (atypical) generation**

| Increased risk of cerebrovascular accident (stroke) and mortality in persons with dementia. | Avoid use for behavioral problems of dementia unless nonpharmacologic options have failed and patient is threat to self or others. | Moderate | Strong |

**Thioridazine**

| Highly anticholinergic and greater risk of QT-interval prolongation. | Avoid | Moderate | Strong |

**Mesoridazine**

| Barbiturates
- Amobarbital
- Butabarbital
- Butalbital
- Mephobarbital
- Pentobarbital
- Phenobarbital
- Secobarbital

| High rate of physical dependence; tolerance to sleep benefits; greater risk of overdose at low dosages. | Avoid | High | Strong |
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS (Continued)

<table>
<thead>
<tr>
<th>Organ System/Therapeutic Category/Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td>Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents. In general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents in older adults.</td>
<td>Avoid benzodiazepines (any type) for treatment of insomnia, agitation, or delirium.</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>Short- and intermediate-acting:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Alprazolam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Estazolam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Lorazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Oxazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Temazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Triazolam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting:</td>
<td>May be appropriate for seizure disorders, rapid eye movement sleep disorders, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, periprocedural anesthesia, end-of-life care.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chlorazepate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chlordiazepoxide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chlordiazepoxide-amitriptyline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Clidinium-chlordiazepoxide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Clonazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Diazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Flurazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Quazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlora hydroxide</td>
<td>Tolerance occurs within 10 d and risk outweighs the benefits in light of overdose with doses only 3 times the recommended dose.</td>
<td>Avoid</td>
<td>Low</td>
<td>Strong</td>
</tr>
<tr>
<td>Meprobamate</td>
<td>High rate of physical dependence; very sedating.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Nonbenzodiazepine hypnotics</td>
<td>Benzodiazepine-receptor agonists that have adverse events similar to those of benzodiazepines in older adults (e.g., delirium, falls, fractures); minimal improvement in sleep latency and duration.</td>
<td>Avoid chronic use (&gt;90 d)</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Ergot mesylates&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Lack of efficacy.</td>
<td>Avoid</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>Isoxsuprine&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Androgens</td>
<td>Potential for cardiac problems and contraindicated in men with prostate cancer.</td>
<td>Avoid unless indicated for moderate-to-severe hypogonadism.</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td>- Methyltestosterone&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Testosterone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desiccated thyroid</td>
<td>Concerns about cardiac effects; safer alternatives available.</td>
<td>Avoid</td>
<td>Low</td>
<td>Strong</td>
</tr>
<tr>
<td>Estrogens with or without progestins</td>
<td>Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women. Evidence that vaginal estrogens for treatment of vaginal dryness is safe and effective in women with breast cancer, especially at dosages of estradiol &lt; 25 μg twice weekly.</td>
<td>Avoid oral and topical patch. Topical vaginal cream: Acceptable to use low-dose intravaginal estrogen for the management of dyspareunia, lower urinary tract infections, and other vaginal symptoms.</td>
<td>Oral and patch: high Topical: moderate</td>
<td>Oral and patch: strong Topical: weak</td>
</tr>
<tr>
<td>Organ System/Therapeutic Category/Drug(s)</td>
<td>Rationale</td>
<td>Recommendation</td>
<td>Quality of Evidence</td>
<td>Strength of Recommendation</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Growth hormone</td>
<td>Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose.</td>
<td>Avoid, except as hormone replacement following pituitary gland removal.</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>Insulin, sliding scale</td>
<td>Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Megestrol</td>
<td>Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Sulfonylureas, long-duration • Chlorpropamide • Glyburide</td>
<td>Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH Glyburide: higher risk of severe prolonged hypoglycemia in older adults.</td>
<td>Avoid</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Can cause extrapyramidal effects including tardive dyskinesia; risk may be further increased in frail older adults.</td>
<td>Avoid, unless for gastroparesis.</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>
### Mineral oil, given orally
Potential for aspiration and adverse effects; safer alternatives available.  
Avoid  Moderate  Strong

### Trimethobenzamide
One of the least effective antiemetic drugs; can cause extrapyramidal adverse effects.  
Avoid  Moderate  Strong

### Pain Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect Description</th>
<th>Avoidance Level</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meperidine</td>
<td>Not an effective oral analgesic in dosages commonly used; may cause neurotoxicity; safer alternatives available.</td>
<td>Avoid</td>
<td>High</td>
</tr>
</tbody>
</table>

### Non-COX-selective NSAIDs, oral
- Aspirin >325 mg/d
- Diclofenac
- Diflunisal
- Etodolac
- Fenoprofen
- Ketoprofen
- Melofenamate
- Mefenamic acid
- Meloxicam
- Nabumetone
- Naproxen
- Oxaprozin
- Piroxicam
- Sulindac
- Tolmetin
- Increases risk of GI bleeding/peptic ulcer disease in high-risk groups, including those >75 y old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents. Use of proton pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3–6 mo, and in about 2%–4% of patients treated for 1 y. These trends continue with longer duration of use.  
- Avoid chronic use unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol).  
- All others: moderate  Strong
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS (Continued)

<table>
<thead>
<tr>
<th>Organ System/Therapeutic Category/Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indomethacin Ketorolac, includes parenteral</td>
<td>Increases risk of GI bleeding/peptic ulcer disease in high-risk groups (see above Non-COX-selective NSAIDs) Of all the NSAIDs, indomethacin has most adverse effects.</td>
<td>Avoid</td>
<td>Indomethacin: moderate Ketorolac: high</td>
<td>Strong</td>
</tr>
<tr>
<td>Pentazocine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Opioid analgesic that causes CNS adverse effects, including confusion and hallucinations, more commonly than other narcotic drugs; is also a mixed agonist and antagonist; safer alternatives available.</td>
<td>Avoid</td>
<td>Low</td>
<td>Strong</td>
</tr>
<tr>
<td>Skeletal muscle relaxants • Carisoprodol • Chlorzoxazone • Cyclobenzaprine • Metaxalone • Methocarbamol • Orphenadrine</td>
<td>Most muscle relaxants poorly tolerated by older adults, because of anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>

ACEI, angiotensin converting-enzyme inhibitors; ARB, angiotensin receptor blockers; CNS, central nervous system; COX, cyclooxygenase; CrCl, creatinine clearance; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone secretion; TCAs, tricyclic antidepressants.

<sup>a</sup>Infrequently used drugs.

*The primary target audience is the practicing clinician. The intentions of the criteria include (1) improving the selection of prescription drugs by clinicians and patients; (2) evaluating patterns of drug use within populations; (3) educating clinicians and patients on proper drug usage; and (4) evaluating health-outcome, quality of care, cost, and utilization data.*
<table>
<thead>
<tr>
<th>Disease or Syndrome</th>
<th>Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>NSAIDs and COX-2 inhibitors, Nondihydropyridine CCBs (avoid only for systolic heart failure) • Diltiazem • Verapamil • Pioglitazone, rosiglitazone • Cilostazol • Dronedarone</td>
<td>Potential to promote fluid retention and/or exacerbate heart failure.</td>
<td>Avoid</td>
<td>NSAIDs: moderate CCBs: moderate Thiazolidinediones (glitazones): high Cilostazol: low Dronedarone: moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Syncope</td>
<td>Acetylcholinesterase inhibitors (AChEIs) • Peripheral alpha blockers • Doxazosin • Prazosin • Terazosin • Tertiary TCAs • Chlorpromazine, thioridazine, and olanzapine</td>
<td>Increases risk of orthostatic hypotension or bradycardia.</td>
<td>Avoid</td>
<td>AChEIs and alpha blockers: high TCAs and antipsychotics: Moderate</td>
<td>AChEIs and TCAs: strong Alpha blockers and antipsychotic: weak</td>
</tr>
</tbody>
</table>
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS DUE TO DRUG-DISEASE OR DRUG-SYNDROME INTERACTIONS THAT MAY EXACERBATE THE DISEASE OR SYNDROME (Continued)

<table>
<thead>
<tr>
<th>Disease or Syndrome</th>
<th>Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Nervous System</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic seizures or epilepsy</td>
<td>Bupropion</td>
<td>Lowers seizure threshold; may be acceptable in patients with well-controlled seizures in whom alternative agents have not been effective.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td></td>
<td>Chlorpromazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clozapine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maprotiline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olanzapine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thioridazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thiothixene</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tramadol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delirium</td>
<td>All TCAs</td>
<td>Avoid in older adults with or at high risk of delirium because of inducing or worsening delirium in older adults; if discontinuing drugs used chronically, taper to avoid withdrawal symptoms.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td></td>
<td>Anticholinergics (see “Drugs with Strong Anticholinergic Properties” table for full list)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Benzodiazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chlorpromazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>H2-receptor antagonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meperidine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sedative hypnotics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thioridazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dementia and cognitive impairment</td>
<td>Anticholinergics (see &quot;Drugs with Strong Anticholinergic Properties&quot; table for full list)</td>
<td>Avoid due to adverse CNS effects. Avoid antipsychotics for behavioral problems of dementia unless non-pharmacologic options have failed and patient is a threat to themselves or others. Antipsychotics are associated increased risk of cerebrovascular accident (stroke) and mortality in persons with dementia.</td>
<td>Avoid</td>
<td>High</td>
<td>Strong</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------</td>
<td>-----</td>
<td>-------</td>
</tr>
<tr>
<td>History of falls or fractures</td>
<td>Anticonvulsants Antipsychotics Benzodiazepines Nonbenzodiazepine hypnotics • Eszopiclone • Zaleplon • Zolpidem TCAs/SSRIs</td>
<td>Ability to produce ataxia, impaired psychomotor function, syncope, and additional falls; shorter-acting benzodiazepines are not safer than long-acting ones.</td>
<td>Avoid unless safer alternatives are not available; avoid anticonvulsants except for seizure.</td>
<td>High</td>
<td>Strong</td>
</tr>
</tbody>
</table>
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS DUE TO DRUG-DISEASE OR DRUG-SYNDROME INTERACTIONS THAT MAY EXACERBATE THE DISEASE OR SYNDROME (Continued)

<table>
<thead>
<tr>
<th>Disease or Syndrome</th>
<th>Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insomnia</td>
<td>Oral decongestants (• Pseudoephedrine • Phenylephrine • Stimulants • Amphetamine • Methylphenidate • Pemoline • Theobromines • Theophylline • Caffeine)</td>
<td>CNS stimulant effects</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Parkinson disease</td>
<td>All antipsychotics (except for quetiapine and clozapine) Antiemetics (• Metoclopramide • Prochlorperazine • Promethazine)</td>
<td>Dopamine receptor antagonists with potential to worsen parkinsonian symptoms. Quetiapine and clozapine appear to be less likely to precipitate worsening of Parkinson disease.</td>
<td>Avoid</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Oral antimuscarinics for urinary incontinence</td>
<td>Ability to worsen constipation; agents for urinary incontinence: antimuscarinics overall differ in incidence of constipation; response variable; consider alternative agent if constipation develops.</td>
<td>Avoid unless no other alternatives</td>
<td>For urinary incontinence: high All others: moderate/low</td>
<td>Weak</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>-------</td>
</tr>
</tbody>
</table>
| Chronic constipation | - Darifenacin  
- Fesoterodine  
- Oxybutynin (oral)  
- Solifenacin  
- Tolterodine  
- Trospium  
Nondihydropyridine CCB  
- Diltiazem  
- Verapamil  
First-generation antihistamines as single agent or part of combination products  
- Brompheniramine (various)  
- Carbinoxamine  
- Chlorpheniramine  
- Clemastine (various)  
- Cyproheptadine  
- Dextromethorphan  
- Dextramethorphan (various)  
- Diphenhydramine  
- Doxylamine  
- Hydroxyzine  
- Promethazine  
- Triprolidine | | | | |
<table>
<thead>
<tr>
<th>Disease or Syndrome</th>
<th>Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
</table>
| **Anticholinergics/antispasmodics** (see “Drugs with Strong Anticholinergic Properties” table for full list of drugs with strong anticholinergic properties) | • Antipsychotics
• Belladonna alkaloids
• Clidinium-chlordiazepoxide
• Dicyclomine
• Hyoscyamine
• Propantheline
• Scopolamine
• Tertiary TCAs (amitriptyline, clomipramine, doxepin, imipramine, and trimipramine) | May exacerbate existing ulcers or cause new/additional ulcers. Avoid unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol). | Moderate          | Strong              |}

| History of gastric or duodenal ulcers | Aspirin (>325 mg/d)
Non-COX-2 selective NSAIDs | May exacerbate existing ulcers or cause new/additional ulcers. Avoid unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol). | Moderate          | Strong              |
### Kidney/Urinary Tract

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drugs</th>
<th>Effects</th>
<th>Avoidance</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic kidney disease stages IV and V</td>
<td>NSAIDs, Triamterene (alone or in combination)</td>
<td>May increase risk of kidney injury. May increase risk of acute kidney injury.</td>
<td>Avoid</td>
<td>NSAIDs: moderate NSAIDs: strong Triamterene: low Triamterene: weak</td>
</tr>
<tr>
<td>Urinary incontinence (all types) in women</td>
<td>Estrogen oral and transdermal (excludes intravaginal estrogen)</td>
<td>Aggravation of incontinence.</td>
<td>Avoid in women</td>
<td>High Strong</td>
</tr>
<tr>
<td>Lower urinary tract symptoms, benign prostatic hyperplasia</td>
<td>Inhaled anticholinergic agents</td>
<td>May decrease urinary flow and cause urinary retention.</td>
<td>Avoid in men</td>
<td>Moderate Inhaled agents: strong All others: weak</td>
</tr>
<tr>
<td>Stress or mixed urinary incontinence</td>
<td>Alpha-blockers: Doxazosin, Prazosin, Terazosin</td>
<td>Aggravation of incontinence.</td>
<td>Avoid in women</td>
<td>Moderate Strong</td>
</tr>
</tbody>
</table>

*ACHEIs, acetylcholinesterase inhibitors; CCBs, calcium channel blockers; CNS, central nervous system; COX, cyclooxygenase; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.*

*The primary target audience is the practicing clinician. The intentions of the criteria include (1) improving the selection of prescription drugs by clinicians and patients; (2) evaluating patterns of drug use within populations; (3) educating clinicians and patients on proper drug usage; and (4) evaluating health-outcome, quality of care, cost, and utilization data.*
### 2012 AGS BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATIONS TO BE USED WITH CAUTION IN OLDER ADULTS

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Rationale</th>
<th>Recommendation</th>
<th>Quality of Evidence</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin for primary prevention of cardiac events</td>
<td>Lack of evidence of benefit versus risk in individuals ≥80 y old.</td>
<td>Use with caution in adults ≥80 y old.</td>
<td>Low</td>
<td>Weak</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Increased risk of bleeding compared with warfarin in adults ≥75 y old; lack of evidence for efficacy and safety in patients with CrCl &lt; 30 mL/min</td>
<td>Use with caution in adults ≥75 y old or if CrCl &lt; 30 mL/min.</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Increased risk of bleeding in older adults; risk may be offset by benefit in highest-risk older patients (eg, those with prior myocardial infarction or diabetes).</td>
<td>Use with caution in adults ≥75 y old.</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td>Antipsychotics Carbamazepine Carboxplatin Cisplatin Mirtazapine Carboplatin Mirtazapine SNRIs SSRIs SNRIs SSRIs TCAs Vincristine</td>
<td>May exacerbate or cause SIADH or hyponatremia; need to monitor sodium level closely when starting or changing dosages in older adults due to increased risk.</td>
<td>Use with caution.</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>May exacerbate episodes of syncope in individuals with history of syncope.</td>
<td>Use with caution.</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
</tbody>
</table>

CrCl, creatinine clearance; SIADH, syndrome of inappropriate antidiuretic hormone secretion; SNRIs, serotonin–norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.

The primary target audience is the practicing clinician. The intentions of the criteria include (1) improving the selection of prescription drugs by clinicians and patients; (2) evaluating patterns of drug use within populations; (3) educating clinicians and patients on proper drug usage; and (4) evaluating health-outcome, quality of care, cost, and utilization data.
### DRUGS WITH STRONG ANTICHOLINERGIC PROPERTIES

<table>
<thead>
<tr>
<th>Category</th>
<th>Examples</th>
</tr>
</thead>
</table>
| **Antihistamines**                | • Brompheniramine  
• Carbinoxamine  
• Chlorpheniramine  
• Clemastine  
• Cyproheptadine  
• Dimenhydrinate  
• Diphenhydramine  
• Hydroxyzine  
• Loratadine  
• Meclizine |
| **Antiparkinson agents**          | • Benztropine  
• Trihexyphenidyl |
| **Skeletal muscle relaxants**     | • Carisoprodol  
• Cyclobenzaprine  
• Orphenadrine  
• Tizanidine |
| **Antidepressants**               | • Amitriptyline  
• Amoxapine  
• Clomipramine  
• Desipramine  
• Doxepin  
• Imipramine  
• Nortriptyline  
• Paroxetine  
• Protriptyline  
• Trimipramine |
| **Antipsychotics**                | • Chlorpromazine  
• Clozapine  
• Fluphenazine  
• Loxapine  
• Olanzapine  
• Perphenazine  
• Piriprazole  
• Prochlorperazine  
• Promethazine  
• Thioridazine  
• Thiothixene  
• Trifluoperazine |
| **Antimuscarinics (urinary incontinence)** | • Darifenacin  
• Fesoterodine  
• Flavoxate  
• Oxybutynin  
• Solifenacin  
• Tolterodine  
• TROSPiUM |
| **Antispasmodics**                | • Atropine products  
• Belladonna alkaloids  
• Dicyclomine  
• Homatropine  
• Hyoscymine products  
• Loperamide  
• Propantheline  
• Scopolamine |
GLAUCOMA, CHRONIC OPEN ANGLE

Population
- Adults.

Recommendations

NICE 2009

1. All persons with known or suspected chronic open-angle glaucoma (COAG) or ocular hypertension (OHT) should undergo the following:
   a. Intraocular pressure monitoring using tonometry.
   b. Central corneal thickness measurement.
   c. Peripheral anterior chamber depth assessments using gonioscopy.
   d. Visual field testing.
   e. Optic nerve assessment using slit-lamp exam.
2. Recommends monitoring patients with OHT at least annually for COAG (every 6 mo for high-risk patients).
3. Recommends monitoring patients with COAG every 6–12 mo based on disease progression.
4. Recommends prostaglandin analogue therapy for early-to-moderate COAG patients at risk of visual loss.
5. Consider surgery with pharmacologic augmentation for advanced COAG.
6. Recommends β-blocker drops for mild OHT until age 60 y.
7. Recommends prostaglandin analogue drops for any degree of OHT.
8. Recommends additional medication therapy for uncontrolled OHT despite single-agent therapy.

Source

Comment

1. Alternative pharmacologic treatments for OHT or suspected COAG in patients whose intraocular pressures remain elevated on monotherapy include:
   a. Prostaglandin analogues.
   b. β-blockers.
   c. Carbonic anhydrase inhibitors.
   d. Sympathomimetics.
GOUT, ACUTE ATTACKS

Population
- Adults.

Recommendations
► ACR 2012
- Therapy options for acute gout attacks.
  - Mild-to-moderate attacks involving 1–2 joints.
    - NSAIDs: full-dose naproxen, sulindac, or indomethacin is preferred.
    - Colchicine 1.2 mg PO × 1 then 0.6 mg 1 h later then 0.6 mg daily bid.
    - Corticosteroids: prednisone or prednisolone 0.5 mg/kg PO daily for 5–10 d.
  - Severe attacks or polyarticular gout.
    - Colchicine + NSAIDs.
    - Colchicine + steroids.
  - Expert opinion to continue urate-lowering therapy (eg, allopurinol) during acute attacks
  - Ice applied to affected joints can help
- Pharmacologic urate-lowering therapy.
  - Allopurinol.
    - Starting dose should not exceed 100 mg/d.
    - Uptitrate dose every 2–4 wk to max of 800 mg/d, unless renal impairment exists.
    - Desire uric acid level of <6 mg/dL.
  - Consider adding a uricosuric agent (eg, probenecid) for refractory hyperuricemia despite urate-lowering therapy.
  - Initiate allopurinol after an acute gout attack has resolved and continue prophylactic anti-inflammatory agents for 3 mo beyond achieving urate level <6 mg/dL.
    - Colchicine 0.6 mg daily bid.
    - Naproxen 250 mg PO bid.

Sources

Comment
- Consider HLAB*5801 testing prior to the initiation of allopurinol for patients at particularly high risk of allopurinol hypersensitivity reaction.
  - Highest risk group are those of Korean, Han Chinese, or Thai descent, especially if Stage 3 or higher CKD is present.
Population
– Adults with suspected gout.

Recommendation
American College of Physicians 2017
– Clinicians should use synovial fluid analysis when diagnostic testing is necessary in patients with possible gout.

Sources

Population
– Adults >18 y with acute or recurrent gout.

Recommendations
American College of Physicians 2017
– Options for treatment of acute gout include corticosteroids, NSAIDs, or colchicine.
– Corticosteroids should be considered first-line therapy in patients without contraindications. Prednisolone 35 mg orally for 5 d.
– Recommends against using long-term urate-lowering therapy in most patients with infrequent attacks (<3 attacks per year).
– Febuxostat and allopurinol are equally effective at decreasing serum urate levels.

Sources
HEADACHE

Population
~ Adults

Recommendation
▷ ACR 2012
~ Do not do imaging for uncomplicated headaches.

Source
~ http://www.choosingwisely.org/societies/american-college-of-radiology/

HEADACHE, MIGRAINE PROPHYLAXIS

Population
~ Adults.

Recommendations
▷ AAN 2012
~ The following medications have established efficacy for migraine prophylaxis:
  • Divalproex sodium.
  • Sodium valproate.
  • Topiramate.
  • Metoprolol.
  • Propranolol.
  • Timolol.
~ Frovatriptan is effective for menstrual migraine prophylaxis.
~ The following medications are probably effective for migraine prophylaxis:
  • Amitriptyline.
  • Venlafaxine.
  • Atenolol.
  • Nadolol.

Source
~ http://www.neurology.org/content/78/17/1337.full.pdf+html

Comment
~ Lamotrigine and clomipramine are ineffective for migraine prevention.
Sinus Headache

Migraine-associated symptoms are often misdiagnosed as "sinus headache" by patients and providers. Most headaches characterized as "sinus headaches" are migraines.

The International Classifications of Headache Disorders (ICHD-II) defines sinus headache by purulent nasal discharge, pathologic sinus finding by imaging, simultaneous onset of headache and sinusitis, and headache localized to specific facial and cranial areas of the sinuses.

\[ A = \text{Annotation} \]
DISEASE MANAGEMENT

MIGRAINE TREATMENT ALGORITHM—ICSI 2011

All algorithm boxes with an “A” and those that refer to other algorithm boxes link to annotation content.

Patient meets criteria for migraine

Is patient experiencing a typical headache?

A

No

Yes

Return to Diagnosis algorithm

Categorize according to peak severity based on functional impairment, duration of symptoms, and time to peak impairment

A

Mild

Moderate

Severe

Status (>72h duration)

Adjunctive therapy

A

A

Successful?

Successful?

Successful?

Chlorpromazine, IV valproate sodium, IV magnesium sulfate or prochlorperazine

Patient meets criteria for DHE?

A

A

No

Yes

Consider DHE therapy

Consultation with headache specialist

A

A

Successful?

Successful?

Successful?

No

Yes

Yes

No

Dexamethasone

A

A

Successful?

Successful?

Successful?

No

Yes

Yes

Headache resolved

Is this a hormone-related migraine?

A

Is patient a candidate for prophylactic treatment?

A

Yes

No

Continue acute treatment

Refer to: Migraine Prophylactic Treatment algorithm

Adjunctive therapy

- Rest in quiet, dark room
- IV rehydration
- Antiemetics**
  - Hydroxyzine
  - Metoclopramide
  - Prochlorperazine
  - Promethazine
- Caffeine

Adjunctive drug therapy

- APAP/ASA/Caffeine
- ASA
- Lidocaine nasal
- Midrin®
- NSAIDs, 5HT agonists (triptans)
- Almotriptan
- Eptinpro
- Frovariptan
- Naropin
- Rizatriptan
- Sumatriptan
- Sumatriptan/Naproxen
- Zolmitriptan

Mild treatment

- APAP/ASA/Caffeine
- ASA
- Lidocaine nasal
- Midrin®
- NSAIDs, 5HT agonists (triptans)

Moderate treatment

- DHE
- Ergotamine tartrate
- Lidocaine nasal
- Midrin® and others
- NSAIDs, 5HT agonists (triptans)

Severe treatment

- Prochlorperazine
- Chlorpromazine
- DHE
- Ketorolac IM
- Magnesium Sulfate IV
- 5HT agonists (triptans)

Refer to:
- Menstrual-Associated Migraine algorithm
- Perimenopausal or Menopausal Migraine algorithm
- On Estrogen-Containing Contraceptives or Considering Estrogen-Containing Contraceptives with Migraine algorithm

A = Annotation
CHAPTER 3

TENSION-TYPE HEADACHE ALGORITHM—ICSI 2011

Patient meets criteria for tension-type headache?

No

Does patient currently have a headache?

Yes

Acute treatment:
- Acetaminophen
- Aspirin
- NSAIDs
- Midrin®
- Adjunctive therapy

No

Is patient candidate for prophylactic treatment?

No

Consider referral Out of guideline

Yes

Therapy successful?

No

Consider other acute or prophylactic treatment
- Reconsider diagnosis
- Consider medication overuse
- Consider specialty referral

Yes

Continue therapy

Prophylactic treatment:
- Amitriptyline
- Other TCAs
- Venlafaxine XR
- Adjunctive therapy

A = Annotation

Adjunctive therapy
- Stress management
- Physiotherapy

Return to Diagnosis algorithm
CLUSTER HEADACHE ALGORITHM—ICSI 2011

All algorithm boxes with an “A” and those that refer to other algorithm boxes link to annotation content.

Cluster headache

Patient meets criteria for cluster headache? 
A

Yes

No

Return to diagnosis algorithm

Is patient currently in a cluster cycle?

Yes

• Reinforce patient education
• Consider pre-cluster cycle specialty consult

No

Acute treatment:
• Oxygen
• Sumatriptan SQ
• DHE
• Start prophylactic treatment A

Bridging treatment
• Corticosteroids
• Ergotamine
• Occipital nerve block A

Maintenance treatment
• Verapamil (first-line)
• Avoid alcohol consumption during cluster cycle

• Verapamil-high doses
• Steroids and others
• Lithium
• Depakote
• Topiramate A

Therapy successful?

Yes

Continue therapy through cycle, then taper

No

Therapy successful?

Yes

Consider referral

No

Consider referral

Out of guideline

A = Annotation
MENSTRUAL-ASSOCIATED MIGRAINE ALGORITHM—ICSI 2011

Patient meets criteria for menstrual-only or menstrual-associated migraine

A

Initiate treatment for migraine

Therapy successful?

Yes

Continue therapy

No

Consider cyclic prophylaxis

- NSAIDs
- Triptans
- Ergots

A

Patient improves?

Yes

Continue therapy

No

Consider consultation with headache specialist

A = Annotation

Menstrual only

- Headache occurs exclusively 2 d before and first 2 d of menstrual cycle
- Associated but not limited to menstruation
- Occurs > 6-8 d/mo

OR
- Occurs ≥ 3 d/mo when optimally treated and still debilitating

Patient improves?

Yes

Therapy successful?

Yes

Patient improves?

Yes

Consider consultation with headache specialist

A

No

Continue therapy
PERIMENOPAUSAL OR MENOPAUSAL MIGRAINE ALGORITHM—ICSI 2011

All algorithm boxes with an “A” and those that refer to other algorithm boxes link to annotation content.

Perimenopausal or menopausal with active migraine history and is a potential candidate for HT

A

Patient is willing to start HT?

Yes

Hormone therapy
  • Oral, transvaginal or transdermal estrogen
  • Progestin if indicated
  • Estrogen-containing contraceptives

Refer to the On Estrogen-Containing Contraceptives or Considering Estrogen-Containing Contraceptives with Migraine algorithm

A

No

HT: newer terminology for HRT. In this guideline, HT indicates treatment with one of several available estrogens, with or without progestin

Attempt treatment with Migraine Prophylactic Treatment algorithm

A

Yes

Successful?

Continue therapy

Yes

Successful?

A

No

Consider changing delivery system or formulation of estrogen and progestin

A

No

• Specialty consultation
  • Return to Migraine Treatment algorithm

A = Annotation
ON ESTROGEN-CONTAINING CONTRACEPTIVES OR CONSIDERING ESTROGEN-CONTAINING CONTRACEPTIVES WITH MIGRAINE ALGORITHM—ICSI 2011

All algorithm boxes with an “A” and those that refer to other algorithm boxes link to annotation content.

On estrogen-containing contraceptives or considering estrogen-containing contraceptives with migraine

- Consider adding oral or transdermal estrogen during placebo week or continuous or extended cycle contraceptive regimens
- Discontinue estrogen-containing contraceptives
- Consider progestin methods or nonhormonal contraceptive methods
- Reassess causes for concern
- Consider specialty consultation
- Return to Migraine Treatment algorithm

A = Annotation
MIGRAINE PROPHYLACTIC TREATMENT ALGORITHM—ICSI 2011

All algorithm boxes with an "A" and those that refer to other algorithm boxes link to annotation content.

Patient meets criteria for migraine headache

Prophylactic treatment
Assess factors that may trigger migraine
Treatment:
• Medication
  - β-blocker
  - Tricyclic antidepressants
  - Ca++ channel blockers
  - Antiepileptic drugs
  - Divalproex
  - Topiramate
  - Gabapentin
  - Reinforce education and lifestyle management
  - Consider other therapies (biofeedback, relaxation)
  - Screen for depression and generalized anxiety

Successful?
Yes
Continue treatment for 6–12 mo, then reassess

No
Try different first-line medication or different drug of same class

Successful?
Yes
Continue treatment for 6–12 mo, then reassess

No
Try combination of β-blockers and tricyclics

Successful?
Yes
Continue treatment for 6–12 mo, then reassess

No
Third-line prophylaxis treatment or consultation with headache specialist

Successful?
Yes

No

Successful? Success as determined by:
• Headaches decrease by ≥50% or more
• An acceptable side effect profile

A = Annotation
HEARING LOSS, SUDDEN

Population
– Adults age 18 y and older.

Recommendations
AAO-HNS 2012
– Distinguish hearing loss into sensorineural or conductive hearing loss.
– Counsel patients with incomplete recovery of hearing about the benefits of hearing aids.
– Evaluate patients with idiopathic sudden sensorineural hearing loss (ISSNHL) for retrocochlear pathology by obtaining an MRI of the internal auditory canal, auditory brainstem responses, and an audiology exam.
– Consider treatment of ISSNHL with incomplete hearing recovery with systemic or intratympanic steroids or hyperbaric oxygen therapy.
– In patients with ISSNHL, recommend against antivirals, thrombolytics, vasodilators, or antioxidants for treatment and against CT scanning of the head or routine lab testing.

Source
– http://oto.sagepub.com/content/146/3_suppl/S1.full.pdf+html

HEART FAILURE

Population
– Patients with stable, symptomatic, chronic HF, in sinus rhythm, with LVEF ≤35%, who are in sinus rhythm with a resting HR ≥70 bpm, and either are on maximally tolerated doses of β-blocker or have a contraindication to β-blocker use.

Recommendations
ACC/AHA HF Guidelines 2017
– Ivabradine (Corlanor®) was approved to reduce hospitalization from worsening HF. Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA Class II and III) stable chronic HFrEF(LVEF ≤35%) who are receiving goal-directed medical therapy, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest.
– Starting dose: 5 mg 1 tab bid. Maximum dose 7.5 mg bid (dose can be increased after 1 mo as needed based on resting HR and tolerability).
HEART FAILURE

**Stage A:** Patients with hypertension, atherosclerotic disease, diabetes mellitus, metabolic syndrome, or those using cardiotoxins or having a family history of cardiomyopathy.

**Stage B:** Patients with previous MI, LV remodeling including LVH and low EF, or asymptomatic valvular disease.

**Stage C:** Patients with known structural heart disease; shortness of breath and fatigue, reduced exercise tolerance.

**Stage D:** Patients who have marked symptoms at rest despite maximal medical therapy (eg, those who are recurrently hospitalized or cannot be safely discharged from the hospital without specialized interventions).

a. History of atherosclerotic vascular disease, diabetes mellitus, or hypertension and associated cardiovascular risk factors.

b. Recent or remote MI, regardless of ejection fraction; or reduced ejection fraction regardless of MI Hx.

c. Use ARB in patients post-MI who cannot tolerate ACE inhibitors.

d. Evidence suggests that isosorbide dinitrate plus hydralazine reduces mortality in blacks with advanced heart failure. (NEJM. 2004;351:2049)

**Comments**

Exercise training in patients with HF seems to be safe and beneficial overall in improving exercise capacity, quality of life, muscle structure, and physiologic responses to exercise. 

*Source:* Adapted from the American College of Cardiology, American Heart Association, Inc. *Circulation.* 2017. doi: 10.1161/CIR.0000000000000509.

---

**HEART FAILURE: ACCF/AHA 2013 CLASSIFICATION ON CLINICAL ASSESSMENT IN HEART FAILURE CLASS I RECOMMENDATIONS**

1. **Classification:**
   i. Heart failure with reduced ejection fraction (HFrEF) referred to as *systolic heart failure* when LVEF ≤40%.
   ii. Heart failure with preserved ejection fraction (HFpEF) referred to as *diastolic dysfunction:*
      - HFpEF when LVEF >40%

2. Lifetime risk of developing HF for Americans ≥40 y old is 20%.

3. Overall mortality is 50% in 5 y; varies with HF stage with:
   - Stage B having a 5-y mortality of 4%.
   - Stage C having a 5-y mortality of 25%.
   - Stage D having a 5-y mortality of 80%.

4. Patients with idiopathic dilated cardiomyopathy should have a 3-generational family history obtained to exclude familial disease.

5. Risk score evaluation should be considered to help predict the ultimate outcome, chronic heart failure—*Seattle Heart Failure Model.* (http://depts.washington.edu/shfm/)

6. Identify prior cardiac or noncardiac disease that may lead to HF.

7. For patients at risk of developing HF (Stage A/B), natriuretic peptide biomarker–based screening (BNP or NT-pro-BNP) and optimizing GDMT can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF.
HEART FAILURE: ACCF/AHA 2013 CLASSIFICATION ON CLINICAL ASSESSMENT IN HEART FAILURE CLASS I RECOMMENDATIONS  (Continued)

8. Obtain history to include diet or medicine nonadherence; current or past use of alcohol, illicit drugs, and chemotherapy; or recent viral illness.
9. Identify the patient’s present activity level and desired post-treatment level.
10. Assess the patient’s volume status, orthostatic BP changes, height and weight, and body mass index.
11. Hypertension and lipid disorders should be controlled in accordance with contemporary guideline to lower the risk of HF. Other risk factors should be controlled or avoided.
12. Initial blood work should measure N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP levels to support clinical judgment for diagnosis, especially in the setting of uncertainty for the diagnosis. Other labs to include CBC, chemistry panel, lipid profile, troponin I level, and TSH level.
13. 12-lead ECG should be obtained.
14. 2D echocardiogram is indicated to determine the systolic function, diastolic function, valvular function, and pulmonary artery pressure.
15. Coronary arteriography to be performed in patients with angina or significant ischemia with HF unless the patient is not eligible for surgery.
16. Initiate diuretic therapy and salt restriction if volume overloaded. Diuretics do not improve long-term survival, but improve symptoms and short-term survival. Once euvolemic and symptoms have resolved, carefully start to wean dosage as an outpatient to lowest dose possible to prevent electrolyte disorders and activation of the renin angiotensin system.
17. ACE inhibitor or ARB or ARNI (ARB plus a neprilysin inhibitor), which reduce morbidity and mortality, should be considered early in the initial course to decrease afterload unless contraindicated if decreased ejection fraction noted (systolic dysfunction). Both agents improve long-term survival. The only available ARNI is valsartan/sacubitril. Titrate dosage to that employed in clinical studies as BP allows.
18. In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality.
19. Specific beta-blockers (carvedilol, sustained release metoprolol succinate, bisoprolol) should be added to reduce morbidity and mortality. These specific β-blockers improve survival the most in systolic heart failure. Titrate dosage to heart rate 65–70 beats/min.
20. Start aldosterone antagonist in patients with moderate or severe symptoms (NYHA Class II-IV) and reduced ejection fraction. Creatinine should be <2.5 mg/dL in men and <2 mg/dL in women, and the potassium should be <5 mEq/L.
21. The combination of hydralazine and nitrates should be employed to improve outcome in African Americans with moderate-to-severe HF with decreased ejection fraction in addition to optimal therapy. If ACE inhibitor or ARB agent is contraindicated, hydralazine and nitrates may be used as alternative therapy.
22. Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF. In all patients with a recent or remote hx of CAD, CVA, PAD, or hyperlipidemia, statins should be used according to guidelines.
24. Nutritional supplements as treatment for HF are not recommended in patients with current or prior symptoms of systolic dysfunction (HFrEF).
25. Calcium channel blockers are not recommended as routine treatment for patients with HFrEF.
26. Remember that exercise training is beneficial in HF patients with decreased ejection fraction (systolic dysfunction) or preserved ejection fraction (diastolic dysfunction) once therapy is optimized.
27. Intracardiac cardiac defibrillator is indicated for secondary survival benefit in patients who survive cardiac arrest, ventricular fibrillation, or hemodynamically significant ventricular tachycardia.
28. Intracardiac cardiac defibrillator is indicated for primary survival benefit in patients with ischemic or nonischemic cardiomyopathy with EF ≤35% with New York Heart Association (NYHA) class II or III. The patient should be stable on GDMT (guideline-determined medical therapy) optimal chronic medical HF therapy and at least 40 d post-MI and a life-expectancy of at least 1 y.
29. Biventricular heart pacemaker (CRT) should be considered in refractory HF with ejection fraction equal to or less than 35% with NYHA class II and III or ambulatory class IV on GDMT. The rhythm should be sinus, with a QRS ≥150 ms, ± LBBB.
30. Long-term anticoagulation therapy is not recommended in patients with chronic systolic function while in sinus rhythm in the absence of AF, a prior thromboembolic event, or cardioembolic source.
31. In patient with nonvalvular AF and HFrEF anticoagulation with warfarin or a DOAC is recommended.
32. Aim for blood pressure less than 130/80 mm Hg.
33. In HF patients with preserved systolic function (diastolic dysfunction), randomized data on therapy are lacking. The goal is to control blood volume (diuretic), keep systolic blood pressure <130 mm Hg (β-blocker, ACE inhibitor, ARB agent, or diuretic), slow heart rate (β-blocker), and treat coronary artery ischemia. Whether β-blockers, ACE inhibitors, ARB agents, or aldosterone antagonists improve survival independently is yet to be proven.
34. Comprehensive written discharge instruction should be given to all patients. Diet, weight monitoring, medicine, and salt adherence should be emphasized. Activity should be discussed along with education of symptoms of worsening HF.
35. During a HF hospitalization, a predischARGE natriuretic peptide level (BNP or NT-proBNP) can be useful to establish a post-discharge prognosis.
36. Post-discharge appointment with physician and health care team with attention to information on discharge medications.

**Contraindications:**

- Acute decompensated HF; BP <90/50 mm Hg, SSS, sinoatrial block, third-degree AV block (unless a functioning demand pacemaker is present), resting HR <60 bpm prior to treatment, severe hepatic impairment, pacemaker dependent, concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.

**Sources**

- *Circulation.* 2017. doi: 10.1161/CIR.0000000000000509
- [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm)
- [http://pi.amgen.com/united_states/corlanor/corlanor_pi_hcp.pdf](http://pi.amgen.com/united_states/corlanor/corlanor_pi_hcp.pdf)

**Comment**

- SHIFT study showed that ivabradine reduced the time to first occurrence of hospitalization for worsening heart failure compared to placebo.
### BIOMARKERS IN CHF

<table>
<thead>
<tr>
<th>ACC/AHA Stage A/B HF</th>
<th>ACC/AHA Stage C/D HF</th>
<th>ACC/AHA Acute/Hospitalized HF</th>
</tr>
</thead>
<tbody>
<tr>
<td>At risk for HF</td>
<td>Ambulatory pts with new-onset dyspnea</td>
<td>Acute dyspnea to ED</td>
</tr>
<tr>
<td>BNP or NT-proBNP (COR Ia)</td>
<td>NYHA class II-IV</td>
<td>Hospitalized for ADHF</td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>BNP or NT-proBNP (COR II)</td>
<td>BNP or NT-proBNP (COR I)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BNP or NT-proBNP (COR II)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BNP or NT-proBNP, and cardiac troponin (COR I)</td>
</tr>
<tr>
<td><strong>Prognosis or added risk stratification</strong></td>
<td>Other biomarkers of myocardial injury or fibrosis* (COR Ia)</td>
<td>Other biomarkers of myocardial injury or fibrosis* (COR Ia)</td>
</tr>
</tbody>
</table>

Colors correspond to COR in Table 1.

*Other biomarkers of injury or fibrosis include soluble ST2 receptor, galectin-3, and high-sensitivity troponin.

ACC indicates American College of Cardiology; AHA, American Heart Association; ADHF, acute decompensated heart failure; BNP, B-type natriuretic peptide; COR, Class of Recommendation; ED, emergency department; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and pts, patients.

---

**Population**

- Patients with chronic heart failure NYHA Class II-IV, with systolic dysfunction, in sinus rhythm, with resting HR ≥75 bpm, in combination with standard therapy including β-blocker therapy or when β-blocker therapy is contraindicated or not tolerated.

**Recommendation**

- **EMA 2012**
  - Ivabradine was approved in treatment for HF.

**Source**

Comments
1. 2014 EMA review based on SIGNIFY study showed:
   - Ivabradine should not be used in combination with verapamil or diltiazem.
   - The risk of AF is increased in patient treated with ivabradine and doctors should monitor patients for AF.

HELCOBACTER PYLORI INFECTION

Population
– Adults.

Recommendations
American College of Gastroenterology 2017
– The following patients should be screened for Helicobacter pylori (H. pylori) infection—active peptic ulcer disease (PUD), a past history of PUD (unless previous cure of H. pylori infection has been documented), low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, undiagnosed dyspepsia: patients who are under the age of 60 y, patients initiating chronic treatment with a nonsteroidal anti-inflammatory drug (NSAID), unexplained iron deficiency anemia, idiopathic thrombocytopenic purpura, or a history of endoscopic resection of early gastric cancer (EGC) should be tested for H. pylori infection.
– Patients who test positive for H. pylori should be treated.
– Choice of therapy depends on prior antibiotic exposure.
– Clarithromycin triple therapy consisting of a PPI, clarithromycin, and amoxicillin or metronidazole for 14 d remains a recommended treatment in regions where H. pylori clarithromycin resistance is known to be <15% and in patients with no previous history of macrolide exposure for any reason.
– Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10–14 d is a recommended first-line treatment option. Bismuth quadruple therapy is particularly attractive in patients with any previous macrolide exposure or who are allergic to penicillin.
– Levofloxacin triple therapy consisting of a PPI, levofloxacin, and amoxicillin for 10–14 d is a suggested first-line treatment option.
DISEASE MANAGEMENT

—Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and a nitroimidazole for 10–14 d is a recommended first-line treatment option.
—Whenever *H. pylori* infection is identified and treated, testing to prove eradication should be performed using a urea breath test, fecal antigen test- or biopsy-based testing at least 4 wk after the completion of antibiotic therapy and after PPI therapy has been withheld for 1–2 wk.
—Bismuth quadruple therapy or levofloxacin salvage regimens are the preferred treatment options if a patient received a first-line treatment containing clarithromycin.

**Source**
—Cochrane Database Systematic Reviews 2013
—Recommends using longer duration therapy for PPI-based *H. pylori* therapy.

**HEMATURIA**

**Population**
—Adults with microscopic hematuria.

**Recommendations**
—AUA 2012
—Work-up and Management of Microscopic Hematuria

**Source**
**HEPATITIS B VIRUS (HBV)**

**Population**
- Adults and children with HBV infection.

**Recommendations**
- NIH 2009, AASLD 2009
  - Recommend HBV immunoglobulin and HBV vaccine to all infants born to HbsAg-positive women.
  - Recommend antiviral therapy for adults and alanine transaminase (ALT) >2x normal, moderate-severe hepatitis on biopsy, compensated cirrhosis or advanced fibrosis and HBV DNA >20,000 IU/mL; or for reactivation of chronic HBV after chemotherapy or immunosuppression.
DISEASE MANAGEMENT

- Recommend antiviral therapy in children for ALT >2× normal and HBV DNA >20,000 IU/mL for at least 6 mo.
- Optimal monitoring practices have not been defined.

Sources

Comments
1. The most important predictors of cirrhosis or hepatocellular carcinoma (HCC) in chronic HBV infection are persistently elevated HBV DNA and serum ALT levels, HBV genotype C infection, male gender, older age, and coinfection with hepatitis C virus or human immunodeficiency virus (HIV).
   a. Persons at risk for HCC should be screened by ultrasound every 6–12 mo.
2. No randomized controlled trials have demonstrated a decrease in overall mortality, liver-specific mortality, or the rate of HCC with anti-HBV therapies.
3. Consider lamivudine or interferon-α for initial anti-HBV therapy.

HEPATITIS B VIRUS INFECTION

Population
- Adults.

Recommendations

- Offer antiviral therapy to adults if:
  - Without a liver biopsy to adults with a transient elastography score ≥11 kPa.
  - HBV DNA >2000 IU/mL and ALT >30 IU/mL (males) or >19 IU/mL (females).
  - Cirrhosis and detectable HBV DNA.

- Initial antiviral options for HBV infection:
  - Peginterferon α-2a.
  - Entecavir.
  - Tenofovir disoproxil.

- Coinfection with HBV and HCV:
  - Peginterferon alfa-2a and ribavirin.
Population
– Children and young adults.

Recommendations
► NICE 2013
– Consider liver biopsy if HBV DNA >2000 IU/mL and ALT >30 IU/mL (males) or >19 IU/mL (females)
– Initial antiviral options:
  • Peginterferon α-2a.

Source

Comments
1. Consider a liver biopsy to confirm fibrosis for a transient elastography score 6–10 kPa.
2. Monitor CBC, liver panel, and renal panel at 2, 4, 12, 24, 36, and 48 wk while on interferon therapy.
3. Monitor CBC, liver panel, and renal panel at 4 wk and every 3 mo while on tenofovir therapy.

Population
– Pregnant women.

Recommendation
► NICE 2013
– Consider tenofovir disoproxil if HBV DNA >10^7 IU/mL in third trimester.

Source

Comment
– Reduces risk of HBV transmission to baby.

HEPATITIS B VIRUS TREATMENT

Population
– Adults and children with chronic hepatitis B virus infection.

Recommendations
► AASLD 2016
– Recommends antiviral treatment for immune-active chronic hepatitis B to decrease the risk of liver-related complications:
  • Pegylated-interferon.
  • Entecavir.
  • Tenofovir.
– Recommends antiviral treatment for immune-active chronic hepatitis B with compensated cirrhosis and low-level viremia.
– Recommends against antiviral treatment for immune-tolerant chronic hepatitis B.
– Test alanine aminotransferase (ALT) levels every 6 mo for immune-tolerant chronic hepatitis B.

Source
– https://guidelines.gov/summaries/summary/50013

HEPATITIS C VIRUS (HCV)

Population
– Adults with HCV infection.

Recommendations

AASLD 2009
1. Recommends education on methods to avoid transmission to others.
2. Recommends antiviral treatment for:
   a. Bridging fibrosis or compensated cirrhosis.
   b. Consideration of acute HCV infection.
3. Test quantitative HCV RNA before treatment and at 12 wk of therapy.
4. Patients who lack antibodies for hepatitis A and B viruses should receive vaccination.
5. Recommends abstaining from alcohol consumption.
6. Insufficient evidence to recommend herbal therapy.

Source

WHO 2014
– Recommends pegylated interferon with ribavirin for adults and children with chronic HCV infection.
– Recommends telaprevir or boceprevir in combination with pegylated interferon with ribavirin for genotype 1 chronic HCV infection.
– Sofosbuvir in combination with ribavirin +/- pegylated interferon for genotypes 1, 2, 3, or 4 HCV infection.

Source

Comment
1. Optimal therapy is the combination of peginterferon-α and ribavirin.
   a. Duration of therapy is 48 wk for HCV genotypes 1 and 4.
   b. Duration of therapy is 24 wk for HCV genotypes 2 and 3.
HEREDITARY HEMOCROMATOSIS (HH)

Recommendations

American Association for the Study of Liver Disease (AASLD) 2011

Clinical Features

- Asymptomatic patients with abnormal iron studies (increased ferritin and iron saturation) should be evaluated for hemochromatosis.
- All patients with liver disease should be evaluated for hemochromatosis. (Ann Intern Med. 2006;145:209)

Diagnosis

- Combination of transferrin saturation (TS) and ferritin should be done—if either abnormal (TS > 45% or ferritin > upper limit of normal) the HFE mutation analysis is indicated.
- Screening (iron studies and HFE mutation studies) is recommended for first-degree relatives. (Ann Intern Med. 2009;143:522)
- Liver biopsy is recommended for diagnosis and prognosis in patients with phenotypic markers of iron overload who are not C282Y homozygotes or compound heterozygotes (C282Y, H63D).
- Liver biopsy to stage the degree of liver disease in C282Y homozygote or compound heterozygotes if liver enzymes elevated or ferritin >1000 μg/L.

Treatment of Hemochromatosis

- Therapeutic phlebotomy weekly until ferritin level 50 to 100 μg/L.
- C282Y homozygotes who have an elevated ferritin (but <1000 μg/L) should proceed to phlebotomy without liver biopsy.
- Patients with end-organ damage due to iron overload should undergo regular phlebotomy to keep ferritin between 50 to 100 μg/L.
- Vitamin C and iron supplements should be avoided but other dietary adjustments not necessary.
- Patients should be monitored on a regular basis for reaccumulation of iron and undergo maintenance with targeted ferritin levels of 50 to 100 μg/L.

Source

- Practice guidelines. Hepatology. 2011;54:328-343
Comment

Problems in Hemochromatosis

- Symptoms besides liver function abnormalities include skin pigmentation, pancreatic dysfunction with diabetes, arthralgias, impotence, and cardiac involvement with ECG changes and heart failure.
- Other rare mutations causing phenotypic hemochromatosis include transferrin receptor 2 mutation, ferroportin mutation, and H ferritin mutation.
- The most devastating complication of hemochromatosis is a 20-fold increase in the risk of hepatocellular carcinoma (HCC). Less than 1% of patients whose ferritin has never been >1000 µg/L develop HCC, while the risk rises considerably in patients with cirrhosis and ferritin level >1000 µg/L. These patients should be screened with hepatic ultrasound every 6 mo. Alfa fetoprotein (AFP) is elevated in only 60% of patients with HCC and should not be used as a single screening test. (Liver Cancer. 2014;3:31)
- Patients with hemochromatosis are at increased risk for certain bacterial infections whose virulence is increased in the presence of iron overload. These include Listeria monocytogenes (most common in renal dialysis patients), Yersinia enterocolitica, and Vibrio vulnificus (uncooked seafood is a common source). Infections are made more virulent by iron overload of macrophages impairing their anti-bacterial activity.
- Secondary iron overload (most commonly secondary to a transfusion requirement due to blood or bone marrow disease) is best managed by iron chelation beginning when the ferritin rises above 1000 µg/L. In contrast to HH excess iron is deposited primarily in the reticuloendothelial system, although visceral iron overload does occur over time. (Blood. 2014;124:1212)

HIP FRACTURES

Population

-Elderly patients with hip fractures.

Recommendations

AAOS 2014

- Recommends preop pain control in patients with hip fractures.
- Insufficient evidence to support preop traction in hip fractures.
- Recommends hip fracture surgery within 48 h of admissions.
- Do not delay hip fracture surgery for patients on aspirin +/- clopidogrel.
• Recommends operative fixation for nondisplaced femoral neck fractures.
• Recommends unipolar or bipolar hemiarthroplasty for displaced femoral neck fractures.
• Recommends prolonged thromboprophylaxis to prevent venous thromboembolism after hip fracture surgery.
• Recommends intensive physical therapy post-discharge to improve functional outcomes.
• Recommends evaluation for osteoporosis in all patients who have sustained a hip fracture.

Source

HOARSENESs

Population
– Persons with hoarseness.

Recommendations

AAO-HNS 2009
– Recommends against the routine use of antibiotics to treat hoarseness.
– Recommends voice therapy for all patients with hoarseness and a decreased voice quality of life.
– All patients with chronic hoarseness >3 mo should undergo laryngoscopy.
– Recommends against routine use of antireflux medications unless the patient exhibits signs or symptoms of gastroesophageal reflux disease.
– Recommends against the routine use of corticosteroids to treat hoarseness.
– Recommends against screening neck imaging (CT or MRI scanning) for chronic hoarseness prior to laryngoscopy.
– Consider surgery for possible laryngeal CA, benign laryngeal soft-tissue lesions, or glottis insufficiency.
– Consider botulinum toxin injections for spasmodic dysphonia.

Source

Comment
– Nearly one-third of Americans will have hoarseness at some point in their lives.
HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Population
– HIV-infected adults and children.

Recommendations
IDSA 2009

1. Recommends education to avoid high-risk behaviors to minimize risk of HIV transmission.
2. Assess for the presence of depression, substance abuse, or domestic violence.
3. Baseline labs: CD4 count; quantitative HIV RNA by PCR (viral load); HIV genotyping; CBCD, chemistry panel, G6PD testing; fasting lipid profile; HLA B5701 test (if abacavir is used); urinalysis; PPD; *Toxoplasma* antibodies; HBsAg, HBsAb, and HCV antibodies; VDRL; urine NAAT for gonorrhea; and urine NAAT for chlamydia (except in men age <25 y); Pap smear in women.a
4. Monitoring labs:
   a. CD4 counts and HIV viral load every 3–4 mo.
   b. Frequency of repeat sexually transmitted disease (STD) screening is undefined.
   c. Annual PPD test.
   d. Persons starting antiretroviral medications should have a repeat fasting glucose and lipid panel 4–6 wk after initiation of therapy.
5. Vaccination for pneumococcal infection, influenza, varicella, hepatitis A, and HBV according to standard immunization charts.
6. All HIV-infected women of childbearing age should be counseled regarding contraception.
7. Pap smear in women every 6 mo.
8. Consider annual mammography in all women age ≥40 y.
9. Hormone replacement therapy is not recommended.
10. All women age ≥65 y should have a dual-energy x-ray absorptiometry (DXA) test of spine/hips.

Source

---

*CBCD*, complete blood count with differential; *G6PD*, glucose-6-phosphate dehydrogenase; *HBsAb*, hepatitis B surface antibody; *HBsAg*, hepatitis B surface antigen; *HLA*, human leukocyte antigen; *NAAT*, nucleic acid amplification test; *PCR*, polymerase chain reaction; *PPD*, purified protein derivative; *RNA*, ribonucleic acid; *VDRL*, Venereal Disease Research Laboratory.
Comments

1. Homosexual men and women with abnormal cervical Pap smear results and persons with a history of genital warts should undergo anogenital human papilloma virus (HPV) screening and anal Pap testing.
2. Serum testosterone level should be considered in men complaining of fatigue, ED, or decreased libido.
3. Chest x-ray should be obtained in persons with pulmonary symptoms or who have a positive PPD test result.

HUMAN IMMUNODEFICIENCY VIRUS (HIV), ANTIRETROVIRAL THERAPY (ART)

Population

–HIV-infected children.

Recommendations

HHS 2010

1. ART is recommended for all children with symptomatic HIV disease.
2. Recommends ART for:
   a. Infants age <12 mo.
   b. Asymptomatic children with HIV RNA ≥100,000 copies/mL.
   c. Children age 1–5 y with CD4 <25%.
   d. Children age ≥5 y with CD4 <350 cells/mm³.
   e. Children age ≥1 y with acquired immunodeficiency syndrome (AIDS) or symptomatic HIV infection.
3. HIV genotype testing is recommended:
   a. Prior to initiation of therapy in all treatment-naive children.
   b. Prior to changing therapy for treatment failure.
4. Recommends evaluating all children 4–8 wk after initiation of ART for possible side effects and to evaluate response to therapy.
   a. Reevaluate children every 3–4 mo thereafter.

Source


Comment

–Specific ART recommendations are beyond the scope of this book.
HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1), ANTIRETROVIRAL USE

Population
- Adults and adolescents.

Recommendations
- HHS 2013
  - Antiretroviral-naive patients should start:
    - Efavirenz/tenofovir/emtricitabine.
    - Ritonavir-boosted atazanavir/tenofovir/emtricitabine.
    - Ritonavir-boosted darunavir/tenofovir/emtricitabine.
    - Raltegravir/tenofovir/emtricitabine.
    - Rilpivirine-based regimens are an alternative.
    - Selection of a regimen should be individualized.
      - Efavirenz is teratogenic.
      - Tenofovir should be used cautiously with renal insufficiency.
      - Ritonavir-boosted atazanavir and rilpivirine should not be used with high-dose proton pump inhibitors.
  - Coreceptor tropism assay is recommended whenever a CCR5 coreceptor antagonist is considered.
  - HLA-B*5701 screening before starting abacavir.
  - Interruption of HAART is recommended for drug toxicity, intercurrent illness, or operations that precludes oral intake.
  - Management of a treatment—experienced patient is complex and should be managed by an HIV specialist.

Source

Comments
1. This guideline focuses on antiretroviral management in HIV-1-infected individuals.
2. Baseline evaluation should include:
   - CD4 T-cell count.
   - HIV-1 antibody testing.
   - HIV RNA viral load.
   - CBC, chemistry panel, liver panel, urinalysis.
   - Serologies for HAV, HBV, and HCV.
   - Fasting glucose and lipid panel.
   - HIV-1 genotypic resistance testing.
   - STD screening.
   - Psychosocial assessment.
• Substance abuse screening.
• HIV risk behavior screening.
• CD4 <350 cells/mm³
• Consider for CD4 350–500 cells/mm³
• Pregnant women as soon as possible to prevent perinatal transmission.
• Consider for preventing heterosexual transmission.
• Patients must commit to strict adherence to HAART therapy.

HUMAN IMMUNODEFICIENCY VIRUS (HIV), PREGNANCY

Population
– HIV-infected pregnant women.

Recommendations

CDC 2010
1. Recommends combination ART regimens during the antepartum period.
2. Women who were taking ART prior to conception should have their regimen reviewed (ie, teratogenic potential of drugs), but continue combination ART throughout the pregnancy.
3. Initial prenatal labs should include a CD4 count, HIV viral load, and HCV antibody.
   a. If HIV RNA is detectable (>500–1000 copies/mL), perform HIV genotypic resistance testing to help guide antepartum therapy.
4. Women who do not require ART for their own health should initiate combination ART between 14 and 28 gestational weeks and continue until delivery.
   a. Zidovudine should be a component of the regimen when feasible.
   b. Recommend against single-dose intrapartum/newborn nevirapine in addition to antepartum ART.
5. Antepartum monitoring:
   a. Monitor CD4 count every 3 mo.
   b. HIV viral load should be assessed 2–4 wk after initiating or changing ART, monthly until undetectable, and then at 34–36 wk.
   c. Recommend a first-trimester ultrasound to confirm dating.
6. Scheduled cesarean delivery is recommended for HIV-infected women who have HIV RNA levels >1000 copies/mL and intact membranes near term.
7. Intrapartum IV zidovudine is recommended for all HIV-infected pregnant women.
8. Avoid artificial rupture of membranes.
9. Avoid routine use of fetal scalp electrodes.
10. Breast-feeding is not recommended.
DISEASE MANAGEMENT

Source

Comments
1. Avoid Methergine for postpartum hemorrhage in women receiving a protease inhibitor or efavirenz.
2. If women do not receive antepartum/intrapartum ART prophylaxis, infants should receive zidovudine for 6 wk.
3. Infants born to HIV-infected women should have an HIV viral load checked at 14 d, at 1–2 mo, and at 4–6 mo.

HYPERLIPIDEMIA

2013 ACC/AHA GUIDELINES ON THE TREATMENT OF CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CV RISK IN ADULTS

MAJOR STATIN BENEFIT GROUPS

ALL SHOULD RECEIVE RX UNLESS CONTRAINDICATED

1. Clinical ASCVD
   Rx: High-intensity statin unless contraindicated or if age >70 y (moderate Rx).
2. Primary elevation of LDL-C ≥190 mg/dL
   Rx: High-intensity statin unless contraindicated, then moderate Rx.
3. Diabetes (type 1 or 2) age 40–75 y with LDL-C 70–189 mg/dL and without clinical ASCVD
   Rx: Moderate-intensity statin; high-intensity statin Rx if 10-y ASCVD risk ≥7.5%.
4. Without clinical ASCVD or diabetes with LDL-C 70–189 mg/dL and estimated 10-y ASCVD ≥7.5%
   Rx: Moderate- to high-intensity statin.

*The pooled cohort equation.

Sources
–Also available as “ASCVD Risk” app from iTunes and Google Play.

INTENSITY STATIN DRUG LEVELS

| High-Intensity Rx (lowers LDL-C >50%) | Atorvastatin 80 mg  
|                                      | Rosuvastatin 40 mg |
| Moderate-Intensity Rx (lowers LDL-C 30%–50%) | Atorvastatin 10–20 mg  
|                                      | Rosuvastatin 5–10 mg  
|                                      | Simvastatin* 20–40 mg  
|                                      | Pravastatin 40–80 mg  
|                                      | Lovastatin 40 mg  
|                                      | Fluvastatin XL 80 mg  
|                                      | Fluvastatin 40 mg bid  
|                                      | Pitavastatin 2–4 mg  
|                                      | Simvastatin 80 mg should be avoided due to high risk of drug interactions  

*aSimvastatin 80 mg should be avoided due to high risk of drug interactions
CHAPTER 3

INTENSITY STATIN DRUG LEVELS  (Continued)

<table>
<thead>
<tr>
<th>Low-Intensity Rx</th>
<th>Simvastatin 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pravastatin 10–20 mg</td>
</tr>
<tr>
<td></td>
<td>Lovastatin 20 mg</td>
</tr>
<tr>
<td></td>
<td>Fluvastatin 20–40 mg</td>
</tr>
<tr>
<td></td>
<td>Pitavastatin 1 mg</td>
</tr>
</tbody>
</table>

- If unable to tolerate moderate- to high-intensity statin therapy, consider the use of low-intensity dosages to reduce ASCVD risk.
- No RCTs have been identified that demonstrate that titration of the drug dose to specific LDL-C level improved ASCVD outcomes in primary or secondary prevention.

PRIMARY PREVENTION—GLOBAL RISK ASSESSMENT

1. Identify higher risk patients with a 10-y ASCVD risk as these are the patients mostly likely to benefit from Rx. The absolute benefit in ASCVD risk reduction is proportional to the baseline risk of the individual.
2. However, not all high-risk patients benefit; therefore, a “patient-centered” approach is required. The potential of ASCVD risk reduction, adverse effects, drug-drug interaction, and patient’s preference all must be considered. Age ≥70 y should not restrict the use of moderate-intensity statin therapy if otherwise indicated.
3. Adults ≥21 y with primary LDL-C >190 mg/dL should receive high-intensity statin Rx (10-y risk estimate not required).
4. Diabetes (type 1 or 2) age 40–75 y with LDL-C 70–189 mg/dL and without clinical ASCVD. Rx: moderate-intensity statin; high-intensity statin Rx if 10-y ASCVD risk ≥7.5%.
5. Without clinical ASCVD or diabetes with LDL-C 70–189 mg/dL and estimated 10-y ASCVD ≥7.5%. Rx: moderate- to high-intensity statin.
6. Nontraditional risk factors to consider: LDL-C ≥160 mg/dL, genetic hyperlipidemia, premature family history of ASCVD with onset <55 y in first-degree male relative or <65 y in first-degree female relative; high-sensitivity CRP ≥2 mg/L, coronary artery calcium score score >300 Agatston units or >75% for age, sex, and ethnicity, ankle brachial index <0.9, or elevated lifetime risk of ASCVD. These should be considered when:
   a. Patients who are not in the 1 of the 4 statin benefit groups.
   b. Patients in whom the decision to start statin Rx remains unclear.
7. The panel emphasizes that the benefit of statin therapy outweighs the risk of newly diagnosed diabetes.
8. No RCTs have been identified that demonstrate that titration of the drug dose to specific LDL-C level improved ASCVD outcomes in primary or secondary prevention.

http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.full.pdf
http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.full.pdf+html
LIPID AND STATIN MONITORING

**Initial**
- Prior to initiating statin, consider fasting lipid panel, ALT, HbA1C (to R/O DM).
- Baseline CK levels if the patient is at increased risk of adverse muscle events based on personal or family history of statin intolerance, muscle disease, or concomitant drugs which may have interactions with statins.

**Chronic**
- Routine CK is not indicated unless symptoms appear.
- Follow-up hepatic function if symptoms suggesting hepatic toxicity arise.
- If confusion or memory impairment occurs while on statin, evaluate for nonstatin causes or drug interactions with statin.
- Repeat second lipid panel 4–12 wk after initiating therapy to determine patient’s adherence. Then repeat lipid panel every 3–12 mo as clinically indicated.
- In METSMIN (Metabolic Syndrome in Men) cohort, statin therapy (simvastatin, atorvastatin) was associated with a 46% increased risk of type 2 diabetes (after adjustment for confounding factors, worsening of hyperglycemia, a 24% reduction in insulin sensitivity, and a 12% reduction in insulin secretion). The risk of diabetes was increased in a dose-dependent and time-dependent manner by both simvastatin and atorvastatin.


NON-STATIN CHOLESTEROL LOWERING AGENTS

- No data have demonstrated that adding a nonstatin lipid drug to statin therapy further reduces ASCVD events.
- In high-risk patients (clinical ASCVD, age <75 y; LDL-C ≥190 mg/dL; 40–75 y old with DM) who are intolerant to statins, may consider the use of nonstatin cholesterol lowering drugs.
  - **Niacin:** indicated for LDL-C elevation or fasting triglyceride ≥500 mg/dL; should be avoided with liver disease, persistent hyperglycemia, acute gout, or new onset AF.
  - **BAS:** indicated for LDL-C elevation; should be avoided with triglycerides ≥300 mg/dL.
  - **Ezetimibe:** indicated for LDL-C elevation when combine with statin monitor transaminase levels.
  - **Fibrates:** indicated for fasting triglycerides ≥500 mg/dL; should avoid the addition of Gemfibrozil to statin agent due to increased risk of muscle symptoms. Fenofibrate should be avoided if moderate/severe renal impairment. If needed, fenofibrate should only be added to a low- or moderate-intensity statin.
  - **Omega-3 fatty acids:** indicated in severe fasting triglycerides ≥500 mg/dL.
  - **New class of LDL lowering agent:** PCSK9 (proprotein convertase subtilisin kexin 9).
CHAPTER 3

NON-STATIN CHOLESTEROL LOWERING AGENTS  (Continued)

• FDA Advisory Panel (June 2015) recommended approval of:
  1. Alirocumab (Praluent®) for lowering LDL cholesterol in patients with hypercholesterolemia, citing likely benefit especially for patients with heterozygous familial hypercholesterolemia (HeFH). Other groups predicted to get special benefit include those at high CV risk or who don’t tolerate statin.
  2. Evolocumab (Repatha®) for lowering LDL-cholesterol. Studies have shown decrease in LDL cholesterol most notably in patients with heterozygous familial hypercholesterolemia.

• FOURIER trial is an ongoing study which is testing the use of evolocumab in combination with statin therapy against placebo plus statin therapy in patients with elevated cholesterol levels and existing cardiovascular disease.


2014 NLA (NATIONAL LIPID ASSOCIATION) GUIDELINES

• Population: adults >20 y old.
• Targets of therapy: non-HDL-C is more predictive than LDL-C, both are primary targets. Apolipoprotein B (apo B) is considered a secondary, optional target for therapy.
• If low/moderate ASCVD risk: Trial of lifestyle management prior to initiate drug therapy. Reduction of saturated fat and cholesterol intake, moderate physical activity, and weight loss, consider adding plant stanols/sterols, and increase viscous fiber intake. Evaluate every 6 wk for atherogenic cholesterol response. If after 12 wk, goal is not achieved, consider adding drug therapy/referral to dietician. Once goal achieved, follow every 4–6 mo to monitor adherence to lifestyle therapies.
• High/very high ASCVD risk: Lifestyle management concomitant with drug therapy. A moderate or high-intensity statin should be first-line drug therapy for treatment, unless contraindicated. In patients with very high TG, may consider TG-lowering drug (fibrates, high-dose omega 3 fatty acids, nicotinic acid) for first-line use to prevent pancreatitis. Follow every 6 wk, increasing the dosage/intensity if not at goal. If not at goal after 12 wk, refer to lipid specialist. Once at goal, follow every 4–6 mo for treatment adherence. Involve patient when making the decision to start statin.
• If TG ≥500, may consider TG-lowering drug as first-line therapy.
• If TG 500–1000 mg/dL, may start with statin if no history of pancreatitis.
• Nonstatin therapies (BAS, CAI, fibrate, nicotinic acid) may be considered (alone or in combination) in those with contraindications to statin therapy.
• For patients with statin intolerance, reducing the dose of statin, switching to a different statin or every other day statin may be considered.
• Goals: Attain levels below the goal cut points, non-HDL-C.
• For patients with ASCVD or DM, consideration should be given to use of moderate- or high-intensity statin therapy irrespective of baseline atherogenic cholesterol levels.
• Women with FH of childbearing age should receive prepregnancy counseling and instructions to stop statins, ezetimibe, and niacin at least 4 wk before discontinuing contraception and should not use these medications during pregnancy and lactation.
• During pregnancy in women with FH: Consider LDL apheresis if there is significant atherosclerotic disease or if the patient has homozygous FH.

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Treatment Goal, Non-HDL-C (LDL-C)</th>
<th>Consider Drug Therapy, Non-HDL-C (LDL-C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>&lt;130 (&lt;100)</td>
<td>≥190 (≥160)</td>
</tr>
<tr>
<td>Moderate</td>
<td>&lt;130 (&lt;100)</td>
<td>≥160 (≥130)</td>
</tr>
<tr>
<td>High</td>
<td>&lt;130 (&lt;100)</td>
<td>≥130 (≥100)</td>
</tr>
<tr>
<td>Very High</td>
<td>&lt;100 (&lt;70)</td>
<td>≥100 (≥70)</td>
</tr>
</tbody>
</table>


2014 AMERICAN DIABETES ASSOCIATION HYPERLIPIDEMIA GUIDELINES

• In all patients with hyperlipidemia and DM recommend lifestyle modifications including:
  • Diet: focusing on the reduction of saturated fat, trans fat, and cholesterol intake; increase of n-3 fatty acids, viscous fiber, and plant stanols/sterols.
  • Weight loss: if indicated.
  • Physical activity.
  • Smoke cessation.
• Regardless of baseline lipid levels, statin therapy should be added to lifestyle therapy in all patients with hyperlipidemia and DM who have overt CVD or who are without CVD, but are age >40, ≥1 CVD risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria).
• For low-risk patients, without overt CVD, age <40, consider statin in addition to lifestyle therapy if LDL-C remains >100 mg/dL or if >1 CVD risk factors.
• LDL-C targeted statin therapy remains the preferred strategy.
• LDL-C therapy goals:
  • Individuals without overt CVD: <100 mg/dL (2.6 mmol/L).
  • Individuals with overt CVD: <70 mg/dL (1.8 mmol/L) with high dose of statin is an option.
  • If drug-treated patients do not reach the above targets on maximum tolerated statin therapy, a reduction in LDL-C of 30%–40% from baseline is an alternative therapeutic goal.
• If severe hypertriglyceridemia with TG>1,000, focus on reducing the LDL-C.
• Triglyceride levels <150 mg/dL (1.7 mmol/L) and HDL-C >40 mg/dL (1 mmol/L) in men and >50 mg/dL (1.3 mmol/L) in women are desirable.
Combination therapy has been shown not to provide additional CV benefit above statin therapy alone and is not generally recommended. Statin therapy is contraindicated in pregnancy. Although there is an increased risk of incident diabetes with statin use, the CV rate reduction with statins outweighed the risk of incident diabetes even for patient with a highest risk for diabetes.


<table>
<thead>
<tr>
<th>Guidelines</th>
<th>ACC/AHA 2013</th>
<th>ESC/EAS 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk stratification tools</td>
<td>ASCVD</td>
<td>SCORE</td>
</tr>
<tr>
<td>Scope of evidence</td>
<td>Randomized control trials</td>
<td>All data covering dyslipidemia</td>
</tr>
<tr>
<td>Therapy</td>
<td>Statin Rx only</td>
<td>Statin + additional cholesterol agents</td>
</tr>
<tr>
<td>F/U LDL-C levels</td>
<td>Only for evaluation of adherence</td>
<td>To evaluate adherence, allow risk stratification and consider additional cholesterol-lowering therapies</td>
</tr>
<tr>
<td>Quality risk scores</td>
<td>Not evaluated in Asia-Pacific population</td>
<td>European country specific</td>
</tr>
<tr>
<td>Present usage</td>
<td>USA</td>
<td>Europe</td>
</tr>
</tbody>
</table>


1. Screen with lipid profile:
   - Men ≥40 y.
   - Women ≥50 y or postmenopausal with additional risk factors.
   - Evidence of atherosclerosis in any vascular bed.
   - Diabetes type 2.
   - Family history of premature cardiovascular disease (CVD).
2. Estimate total CV 10-y risk by SCORE (Systemic Coronary Risk Estimation), which has a large European cohort database, or the Framingham Risk Score.
   - If the 10-y risk is ≥5% at increased risk, recommend heart score modified to include HDL-C.
**VERY HIGH RISK—LDL-C goal <70 mg/dL**

Documented CVD by invasive or noninvasive testing, previous MI, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), other arterial revascularization procedures, ischemic cardiovascular accident (CVA), or peripheral arterial disease (PAD).

Type 2 diabetes; type 1 with end-organ disease (microalbuminuria).

Moderate-to-severe chronic kidney disease (CKD) GFR <60 mL/min/1.73 m²

Calculated 10-y risk SCORE ≥10%; FRS ≥20%.

**HIGH RISK—LDL-C goal <100 mg/dL**

Markedly elevated lipids or BP.

SCORE ≥5% and <10% for the 10-y risk of fatal cardiovascular disease (CVD);

Framingham Risk Score (FRS) ≥20%.

**MODERATE RISK—LDL-C goal <115 mg/dL**

SCORE ≥1% and <5% at 10 y; FRS 10%–20%.

Family history (FH) of premature CAD.

Obesity.

Physical inactivity.

Low HDL-C, high TGs.

**LOW RISK SCORE <1%; FRS ≤5%**

3. Lipid analysis.

LDL-C is the primary marker.

TGs, HDL-C, non-HDL-C, apolipoprotein B (apoB) (with diabetes and MetS), lipoprotein A (LpA) in selected high-risk patients with FH of premature disease. Total cholesterol (TC) adds little to assessment.

4. Lifestyle management—same as ATP recommendations with additional use of phytosterols, soy protein, red yeast rice, and polycosanol supplements.

5. Secondary causes for hypercholesterolemia: hypothyroidism, nephrotic syndrome, pregnancy, Cushing syndrome, anorexia nervosa, immunosuppressant agents, corticosteroids.

6. Drug therapy, LDL-C.

Statins—initial agent in moderate-, high-, or very-high-risk patients.

*Statin therapy in primary prevention should be limited to patients with moderate or high risk.

Combined therapy: bile acid sequestrant (BAS) + nicotinic acid, cholesterol absorption inhibitor + BAS + nicotinic acid.

7. TG >880 mg/dL—pancreatitis.

Fibrates, nicotinic acid, n-3 fatty acids.

HDL-C.

Nicotinic acid, statin, nicotinic acid + statin.

CKD stages 1–2.

Statin well tolerated; stage >3; more adverse events—use atorvastatin, fluvastatin, gemfibrozil.

MANAGEMENT OF DYSLIPIDEMIA FOR CARDIOVASCULAR DISEASE RISK REDUCTION—VETERAN AFFAIRS AND U.S. DEPARTMENT OF DEFENSE CLINICAL PRACTICE GUIDELINE 2014

- Screen all men >35, women >45, and all patients with atherosclerotic CVD (ASCVD) or equivalents.
- Equivalents of ASCVD: ACS or MI, CABG or PCI, sable obstructive CAD, CVA/TIA, atherosclerotic PVD (claudication or AAA).
- If the patient has a history of CVD or ACS, calculate 10-y CVD risk, and measure lipid levels and BP.

<table>
<thead>
<tr>
<th>10-y Risk</th>
<th>Statin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCVD (second prevention)</td>
<td>Moderate to high</td>
</tr>
<tr>
<td>&gt;12%</td>
<td>Moderate</td>
</tr>
<tr>
<td>6%–12% (with shared decision making)</td>
<td>Moderate</td>
</tr>
<tr>
<td>&lt;6%</td>
<td>None</td>
</tr>
</tbody>
</table>

- **Statin dose**

<table>
<thead>
<tr>
<th>Statin</th>
<th>Moderate (mg)</th>
<th>High (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>10–20</td>
<td>40–80</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>5–10</td>
<td>20–40</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>20–40</td>
<td></td>
</tr>
<tr>
<td>Pravastatin</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Lovastatin</td>
<td>40–80</td>
<td></td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>80 (80 daily or 40 bid)</td>
<td></td>
</tr>
</tbody>
</table>

- If risk between 6% and 12%, the 10-y CVD risk should be repeated every 2 y. If risk <6%, the 10-y CVD risk should be repeated every 5 y.
- All patients should be encouraged to make positive lifestyle changes—to follow Mediterranean diet and to optimize comorbid conditions.

EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS: SUMMARY REPORT 2013

**SUMMARY:**
- All children should have cholesterol screening once between age 9 and 11 y and once between age 17 and 21 y.
- Nonfasting total cholesterol and HDL cholesterol should be used as the screening tests.
- Clinicians may recommend low-fat or nonfat dairy at age 1 y for high-risk patients.
- If lifestyle changes are not effective, a lipid-lowering agent should be considered at age 10 y.
EVIDENCE-BASED RECOMMENDATIONS FOR DIETARY MANAGEMENT OF ELEVATED LDL-C, NON-HDL-C, AND TGs

**Grades** reflect the findings of the evidence review.

**Recommendation levels** reflect the consensus opinion of the Expert Panel.

**Supportive actions** represent expert consensus suggestions from the Expert Panel provided to support implementation of the recommendations; they are not graded.

**NOTE:** Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by 38.6; for TGs, divide by 88.6.

### ELEVATED LDL-C: CHILD 2—LDL

<table>
<thead>
<tr>
<th>2–21 y</th>
<th>Refer to a registered dietitian for family medical nutrition therapy:</th>
<th>Grade B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• 25%–30% of calories from fat, ≤7% from saturated fat, approximately 10% from monounsaturated fat; &lt;200 mg/d of cholesterol; avoid trans fats as much as possible</td>
<td>Strongly recommend</td>
</tr>
<tr>
<td></td>
<td><strong>Supportive actions:</strong></td>
<td>Grade A</td>
</tr>
<tr>
<td></td>
<td>• Plant sterol esters and/or plant stanol esters* up to 2 g/d as replacement for usual fat sources can be used after age 2 y in children with familial hypercholesterolemia.</td>
<td>Recommend</td>
</tr>
<tr>
<td></td>
<td>• Plant stanol esters as part of a regular diet are marketed directly to the public. Short-term studies show no harmful effects in healthy children.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The water-soluble fiber psyllium can be added to a low-fat, low-saturated-fat diet as cereal enriched with psyllium at a dose of 6 g/d for children 2–12 y, and 12 g/d for those ≥12 y.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• As in all children, 1 h/d of moderate- to-vigorous physical activity and &lt;2 h/d of sedentary screen time are recommended.</td>
<td></td>
</tr>
</tbody>
</table>

*Can be found added to some foods, such as some margarines.
### ELEVATED TGS OR NON–HDL-C: CHILD 2—TGs

<table>
<thead>
<tr>
<th>Age</th>
<th>Refer to a registered dietitian for family medical nutrition therapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–21 y</td>
<td>Refer to a registered dietitian for family medical nutrition therapy.</td>
</tr>
<tr>
<td></td>
<td>Grade B</td>
</tr>
<tr>
<td></td>
<td>Strongly recommend</td>
</tr>
<tr>
<td></td>
<td>• 25%–30% of calories from fat, ≤7% from saturated fat, ~10% from monounsaturated fat; &lt;200 mg/d of cholesterol; avoid trans fats as much as possible</td>
</tr>
<tr>
<td></td>
<td>Grade A</td>
</tr>
<tr>
<td></td>
<td>Recommend</td>
</tr>
<tr>
<td></td>
<td>• Decrease sugar intake:</td>
</tr>
<tr>
<td></td>
<td>• Replace simple with complex carbohydrates</td>
</tr>
<tr>
<td></td>
<td>• No sugar sweetened beverages</td>
</tr>
<tr>
<td></td>
<td>Grade B</td>
</tr>
<tr>
<td></td>
<td>Recommend</td>
</tr>
<tr>
<td></td>
<td>• Increase dietary fish to increase omega-3 fatty acids</td>
</tr>
<tr>
<td></td>
<td>Grade D</td>
</tr>
<tr>
<td></td>
<td>Recommend</td>
</tr>
</tbody>
</table>

*If child is obese, nutrition therapy should include calorie restriction, and increased activity (beyond that recommended for all children).

*The Food and Drug Administration (FDA) and the Environmental Protection Agency are advising women of childbearing age who may become pregnant, pregnant women, nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the FDA’s food information line toll free at 1-888-SAFEFOOD or visit http://www.fda.gov/downloads/Food/FoodborneIllnessContaminants/UCM312787.pdf-page=21.


### EVIDENCE-BASED RECOMMENDATIONS FOR PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA

**Grades** reflect the findings of the evidence review. **Recommendation levels** reflect the consensus opinion of the Expert Panel. **When medication is recommended, this should always be in the context of the complete cardiovascular risk profile of the patient and in consultation with the patient and the family.**

**NOTE:** Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by 38.6; for TGs, divide by 88.6.

#### Birth–10 y

<table>
<thead>
<tr>
<th>Age</th>
<th>Pharmacologic treatment is limited to children with severe primary hyperlipidemia (homozygous familial hypercholesterolemia, primary hypertriglyceridemia with TG ≥500 mg/dL) or a high-risk condition or evident cardiovascular disease; all under the care of a lipid specialist.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade C</td>
</tr>
<tr>
<td></td>
<td>Recommend</td>
</tr>
</tbody>
</table>

#### ≥10–21 y

<table>
<thead>
<tr>
<th>Age</th>
<th>Detailed FH and risk factor (RF) assessment required before initiation of drug therapy.* High-to moderate-level RFs and risk conditions (RCs).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade C</td>
</tr>
<tr>
<td></td>
<td>Strongly recommend</td>
</tr>
</tbody>
</table>

*If child is obese, nutrition therapy should include calorie restriction, and increased activity (beyond that recommended for all children).

*The Food and Drug Administration (FDA) and the Environmental Protection Agency are advising women of childbearing age who may become pregnant, pregnant women, nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the FDA’s food information line toll free at 1-888-SAFEFOOD or visit http://www.fda.gov/downloads/Food/FoodborneIllnessContaminants/UCM312787.pdf-page=21.

**LDL-C:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>If average LDL-C $\geq 250$ mg/dL&lt;sup&gt;a&lt;/sup&gt;, consult lipid specialist.</td>
<td>Grade B Strongly recommend</td>
</tr>
<tr>
<td>If average LDL-C $\geq 130$–$250$ mg/dL, or non-HDL $\geq 145$ mg/dL: • Refer to dietitian for medical nutrition therapy with Cardiovascular Health Integrated Lifestyle Diet (CHILD 1) CHILD 2-LDL $\times$ 6 mo repeat fasting lipid panel (FLP).</td>
<td>Grade A Strongly recommend</td>
</tr>
</tbody>
</table>

**Repeat FLP:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\rightarrow$ LDL-C $&lt; 130$ mg/dL, continue CHILD 2-LDL, reevaluate in 12 mo.</td>
<td>Grade A Strongly recommend</td>
</tr>
<tr>
<td>$\rightarrow$ LDL-C $\geq 190$&lt;sup&gt;b&lt;/sup&gt; mg/dL, consider initiation of statin therapy.</td>
<td>Grade A Strongly recommend</td>
</tr>
<tr>
<td>LDL-C $\geq 130$–189 mg/dL, FH (–), no other RF or RC, continue CHILD 2-LDL, reevaluate q 6 mo.</td>
<td>Grade B Recommend</td>
</tr>
<tr>
<td>$\rightarrow$ LDL-C = 160–189 mg/dL + FH positive or $\geq 1$ high-level RF/RC or $\geq 2$ moderate-level RFs/RCs, consider statin therapy.</td>
<td>Grade B Recommend</td>
</tr>
<tr>
<td>$\rightarrow$ LDL-C $\geq 130$–159 mg/dL + $\geq 2$ high-level RFs/RCs or 1 high-level + 2 moderate-level RFs/RCs, consider statin therapy.</td>
<td>Grade B Recommend</td>
</tr>
</tbody>
</table>

**Children on statin therapy should be counseled and carefully monitored.**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detailed FH and RF/RC assessment required before initiation of drug therapy.&lt;sup&gt;c&lt;/sup&gt; High- and moderate-level RFs/RCs.&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Grade C Strongly recommend</td>
</tr>
</tbody>
</table>

**TG:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>If average TG $\geq 500$ mg/dL, consult lipid specialist.</td>
<td>Grade B Recommend</td>
</tr>
<tr>
<td>If average TG $\geq 100$ mg/dL in a child &lt;10 y, $\geq 130$ mg/dL in a child age 10–19 y, TG $&lt; 500$ mg/dL: • Refer to dietitian for medical nutrition therapy with CHILD 1 CHILD 2-TG $\times$ 6 mo.</td>
<td>Grade B Strongly recommend</td>
</tr>
</tbody>
</table>
EVIDENCE-BASED RECOMMENDATIONS FOR PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA  *(Continued)*

<table>
<thead>
<tr>
<th>Repeat FLP:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• TG &lt;100 mg/dL, continue CHILD 2-TG, monitor 6–12 mo.</td>
<td>Grade B  Strongly recommend</td>
</tr>
<tr>
<td>• TG &gt;100 mg/dL, reconsult dietitian for intensified CHILD 2 TG diet counseling.</td>
<td>Grade C  Recommend</td>
</tr>
<tr>
<td>• TG ≥200–499 mg/dL, non-HDL ≥145 mg/dL, consider fish oil ± consult lipid specialist.</td>
<td>Grade D  Recommend</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non–HDL-C:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Children ≥10 y with non–HDL-C ≥145 mg/dL after LDL-C goal achieved may be considered for additional treatment with statins, fibrates, or niacin in conjunction with a lipid specialist.</td>
<td>Grade D  Optional</td>
</tr>
</tbody>
</table>

*a* Consideration of drug therapy based on the average of ≥2 FLPs, obtained at least 2 wk but no >3 mo apart.

*b* If average LDL-C ≥190 mg/dL after CHILD 2-LDL and child is age 8–9 y with + FH or ≥1 high-level RF/RC or ≥2 moderate-level RFs/RCs, statin therapy may be considered.

*c* Consideration of drug therapy based on the average of ≥2 fasting lipid profiles obtained at least 2 wk but no more than 3 mo apart.

*d* If child is obese, nutrition therapy should include calorie restriction and increased activity beyond that recommended for all children.

### MEDICATIONS FOR MANAGING HYPERLIPIDEMIA

<table>
<thead>
<tr>
<th>Type of Medication</th>
<th>Mechanism of Action</th>
<th>Major Effects</th>
<th>Examples</th>
<th>Adverse Reactions</th>
<th>FDA Approval in Youths as of This Writing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HMG CoA Reductase Inhibitors</strong></td>
<td>Inhibit cholesterol synthesis in hepatic cells, decreases cholesterol pool, resulting in upregulation of LDL receptors</td>
<td>Mainly lower LDL-C; some decrease in TG and modest increase in HDL-C</td>
<td>Atorvastatin</td>
<td>Raised hepatic enzymes, raised creatine kinase, myopathy possibly progressing to rhabdomyolysis</td>
<td>All statins listed approved as an adjunct to diet to lower LDL-C in adolescent boys and postmenarchal girls age 10–18 y (8+ y for pravastatin) with heterozygous familial hypercholesterolemia (HeFH) and LDL-C ≥190 mg/dL, or ≥160 mg/dL with FH of premature CVD and 2+ CVD risk factors in the pediatric patient.</td>
</tr>
<tr>
<td>(Statins)</td>
<td></td>
<td></td>
<td>Fluvastatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lovastatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pravastatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rosuvastatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Simvastatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Atorvastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Fluvastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Lovastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Pravastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Rosuvastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Simvastatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bile Acid Sequestrants</strong></td>
<td>Bind intestinal bile acids interrupting enterohepatic recirculation, more cholesterol converted into bile acids, decrease hepatic cholesterol pool, upregulate LDL receptors</td>
<td>Lower LDL-C; small increase in HDL; raises TG</td>
<td>Cholestyramine</td>
<td>Limited to gastrointestinal tract: gas, bloating, constipation, cramps</td>
<td>No pediatric indication listed for cholestyramine or colestipol; colesvelam indicated as monotherapy or with statin for LDL-C reduction in boys and postmenarchal girls age 10–17 y with FH after diet trial if LDL-C ≥190 mg/dL or if LDL-C ≥160 mg/dL with family history of premature CVD or 2+ more CVD risk factors in the pediatric patient.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Colestipol</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Colesevelam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of Medication</td>
<td>Mechanism of Action</td>
<td>Major Effects</td>
<td>Examples</td>
<td>Adverse Reactions</td>
<td>FDA Approval in Youths as of This Writing</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Cholesterol Absorption Inhibitors</td>
<td>Inhibit intestinal absorption of cholesterol and plant sterols, decrease hepatic cholesterol pool, upregulate LDL receptors</td>
<td>Mainly lower LDL-C; some decrease in TG and small increase in HDL-C</td>
<td>Ezetimibe</td>
<td>Myopathy, gastrointestinal upset, headache</td>
<td>No</td>
</tr>
<tr>
<td>Fibric Acid Derivatives</td>
<td>Agonist for peroxisome proliferator-activated receptor (PPAR) alfa nuclear receptors that upregulate lipoprotein lipase (LPL) and downregulate apolipoprotein C (apoC)-III, both increasing degradation of very-low-density lipoprotein C (VLDL-C) and TG. Hepatic synthesis of VLDL-C may also be decreased.</td>
<td>Mainly lower TG and raises HDL-C, with little effect on LDL-C</td>
<td>Fenofibrate, Gemfibrozil</td>
<td>Dyspepsia, constipation, myositis, anemia</td>
<td>No</td>
</tr>
<tr>
<td><strong>Nicotinic Acid (Extended Release)</strong></td>
<td>Inhibits release of free fatty acid (FFA) from adipose tissue; decreases VLDL-C and LDL-C production and HDL-C degradation</td>
<td>Lowers TG and LDL-C and raises HDL-C; can decrease Lp(a)</td>
<td>Niacin, extended release</td>
<td>Flushing, hepatic toxicity, can increase fasting blood glucose, uric acid; hyperacidity</td>
<td>Use not recommended in children &lt;2 y of age.</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td><strong>Omega-3 Fish Oil</strong></td>
<td>Decreases hepatic fatty acid (FA) and TG synthesis while enhancing FA degradation/oxidation, with subsequent reduced VLDL-C release</td>
<td>Lowers TG, raises HDL-C, increases LDL-C and LDL-C particle size</td>
<td>Omega-3 acid ethyl esters</td>
<td>Occasional gastrointestinal side effects, but no adverse effect on glucose levels or muscle or liver enzymes or bleeding</td>
<td>Only 1 FDA-approved fish oil preparation for adults, but many generic fish oil capsules commercially available.</td>
</tr>
</tbody>
</table>

CHAPTER 3

HYPERTENSION

HYPERTENSION TREATMENT—JNC 8 2014

LIFESTYLE MODIFICATIONS
- Weight reduction
- DASH/Mediterranean diet
- Dietary sodium restriction
- Exercise
- Moderate ETOH
- Cessation of smoking
- K supplementation in diet (ADA, CHEP)

PHARMACOTHERAPY
- If BP ≥140/90 mm Hg in the general population aged <60 y
- If BP ≥150/90 mm Hg in general population aged ≥60 y
- If BP ≥140/90 mm Hg in patients with DM, CKD, >60 y

First-line therapy
- Start with one of:
  - Thiazide-type diuretics
  - Calcium channel blockers
  - ACE inhibitors
  - ARBs

Second/third-line alternatives
- High doses or combination of:
  - Thiazide-type diuretics
  - Calcium channel blockers
  - ACE inhibitors
  - ARBs

Later-line alternatives
- β-blockers
- α-blockers
- α1/β-blockers (carvedilol), vasodilating β-blockers (nebivolol)
- Central α2-adrenergic agonists (clonidine)
- Direct vasodilators (hydralazine)
- Loop diuretics (furosemide)
- Aldosterone antagonists (spironolactone)
- Peripherally acting adrenergic antagonists (reserpine)

SPECIAL GROUPS
- African Americans without CKD: initiate with CCBs and thiazide
- Patients with CKD regardless of race: initiate with ACEI or ARBs
- DO NOT COMBINE ACEI with ARBs
- In patients >75 y with CKD, use CCB and thiazide-type diuretic instead of ACEI/ARBs

**JNC 8 2014 ANTIHYPERTENSIVE THERAPY**

*Initiate therapy*
- BP ≥140/90 mm Hg in the general population age <60 y old.
- BP ≥150/90 mm Hg in general population age ≥60 y old.

*Goal therapy*
- BP <140/90 mm Hg in patients <60 y old.
- BP <150/90 mm Hg in patients ≥60 y old.
- BP <140/90 mm Hg in patients with DM, CKD who are <60 y old.

*Antihypertensive therapy*
- In the general non-black population, including those with DM, initial treatment should include a thiazide-type diuretic, CCB, ACEI, or ARB.
- In the general black population, including those with DM, initial treatment should include a thiazide-type diuretic or CCB.
- In all population age ≥18 y old with CKD (+/-DM), treatment should include an ACEI/ARB to improve kidney outcomes.
- Patients with CKD regardless of race: initiate with ACEI or ARBs.
- In patients >75 y old with CKD, use CCB and thiazide-type diuretic instead of ACEI/ARBs.
- If BP cannot be reached within 1 mo increase the dose of the initial drug or add a second and then third drug from the recommended classes.

*Do not use an ACEI and ARB together!*
- β-blockers, α-blockers, central α-2-adrenergic agonists (eg, clonidine), direct vasodilators (eg, hydralazine), aldosterone receptor antagonists (eg, spironolactone), peripherally acting adrenergic antagonists (eg, reserpine), and loop diuretics (eg, furosemide) are not recommended as a first-line therapy.


**ACC/AHA/ASH 2015 ANTIHYPERTENSION THERAPY FOR PATIENTS WITH CAD**

1. *Patients with HTN and chronic stable angina*
   - Goal therapy: <140/90 mm Hg for secondary prevention of CV events on patients with HTN and CAD.
   - <130/80 mm Hg may be appropriate for patients with CAD, previous MI, stroke or TIA, or CAD equivalents (CAD, PAD, AAA).
   - Treatment should include:
     1. β-blocker in patients with a history of prior MI.
     2. ACEI/ARB if prior MI, LV systolic dysfunction, DM, or CKD.
     3. A thiazide or thiazide-like diuretic.
   - If β-blocker is contraindicated or produce intolerable side effects, a nondihydropyridine CCB may be substituted but NOT if there is LV dysfunction.
ACC/AHA/ASH 2015 ANTIHYPERTENSIVE THERAPY FOR PATIENTS WITH CAD  (Continued)

- If either angina or HTN remains uncontrolled, a long-acting dihydropyridine CCB can be added to the basic regimen of β-blocker, ACEI/ARB, and thiazide/thiazide-like diuretic. Combination of β-blocker and either of the nondihydropyridine CCB should be used with caution in patients with symptomatic CAD and HTN because of the increased risk of significant bradyarrhythmias and HF.
- There are no special contraindications in HTN patients for the use of antiplatelet or anticoagulant drugs, except that in patients with uncontrolled severe HTN who are taking antiplatelet or anticoagulant drugs, the BP should be lowered without delay to reduce the risk of hemorrhagic stroke.

2. Patients with HTN and ACS
- BP target <140/90 mm Hg in patients with HTN and ACS that are hemodynamically stable. BP target <130/80 mm Hg at the time of hospital discharge is reasonable. BP should be lowered slowly and caution is advised to avoid decreases in DBP to <60 mm Hg because this may reduce coronary artery perfusion and worsen ischemia.
- If no contraindication to β-blockers, the initial therapy of HTN should include a short-acting β₁-selective β-blocker without intrinsic sympathomimetic activity (metoprolol tartrate or bisoprolol). β-Blocker therapy should typically be initiated orally within 24 h of presentation. For patients with severe HTN or ongoing ischemia, an intravenous β-blocker (esmolol) can be considered. For hemodynamically unstable patients or when decompensated HF exists, the initiation of β-blocker therapy should be delayed until stabilization has been achieved.
- Nitrates should be considered to lower BP or relieve ongoing ischemia or pulmonary congestion. Nitrates should be avoided in patients with suspected RV infarction and in those with hemodynamic instability. Sublingual or IV nitroglycerin therapy is preferred for initial treatment and can be transitioned later to a longer-acting form if needed.
- If contraindication/intolerance/side effects to β-blocker and no presence of LV dysfunction or HF, okay to substitute with nondihydropyridine CCB (verapamil, diltiazem). If the angina or HTN is not controlled on β-blocker alone, a longer-acting dihydropyridine CCB may be added after optimal use of ACEI.
- ACEI/ARB should be added if anterior MI, persistent HTN, LV dysfunction, HF, or DM. For lower-risk ACS patients with preserved LV function and no DM, ACEI can be considered a first-line agent for BP control.
- Aldosterone antagonists are indicated for patients who are already receiving a β-blocker and ACEI after MI and have LV dysfunction and either HF or DM. Serum K levels must be monitored. These agents should be avoided in patients with elevated serum creatinine levels (≥2.5 mg/dL in men, ≥2.0 mg/dL in women) or elevated K levels (≥5.0 mEq/L).
- Loop diuretics are preferred over thiazide/thiazide-type diuretics for patients with ACS who have HF (NYHA III or IV) or for patients with CKD and estimated glomerular filtration rate <39 mL/min. If HTN remains uncontrolled despite a β-blocker, an ACEI, and an aldosterone antagonist, a thiazide/thiazide-type diuretic may be added in selected patients for BP control.
3. Patients with HTN and HF of ischemic origin

- BP target is <130/80 mm Hg, but consideration can be given to lowering the BP even further, to <130/80 mm Hg. In patients with an elevated DBP who have CAD and HF with evidence of myocardial ischemia, the BP should be lowered slowly. In older hypertensive individuals with wide pulse pressures, lowering SBP may cause very low DBP values (<60 mm Hg). This should alert the clinician to assess carefully any untoward signs or symptoms, especially those caused by myocardial ischemia and worsening HF. Octogenarians should be checked for orthostatic changes with standing, and an SBP <130 mm Hg and a DBP <65 mm Hg should be avoided.

- Treatment should include management of risk factors (dyslipidemia, obesity, DM, smoking, dietary sodium, and closely monitored exercise program).

- The patient should be treated with ACEI/ARB, β-blocker (carvedilol, metoprolol succinate, bisoprolol, or nebivolol), and aldosterone receptor antagonists. These drugs have shown to improve outcomes for patients with HF and reduced EF.

- Thiazide/thiazide-type diuretic should be used for BP control and to reverse volume overload and associated symptoms. In patients with severe HF (NYHA III or IV), or those with severe renal impairment (eGFR <30 mL/min), loop diuretics should be used for volume control, but they are less effective than thiazide/thiazide-type diuretics in lowering BP. Diuretics should be used together with an ACE/ARB and a β-blocker.

- Studies have shown equivalence of benefit of ACEI and ARB (candesartan or valsartan) in HF with reduced EF. Either class of agents is effective in lowering BP.

- The aldosterone receptor antagonists spironolactone and eplerenone have been shown to be beneficial in HF and should be included in the regimen if there is HF (NYHA III or IV) with reduced EF <40%. One or the other may be substituted for a thiazide diuretic in patients requiring a K-sparing agent. If an aldosterone receptor antagonist is administered with an ACEI/ARB in the presence of renal insufficiency, serum K level should be monitored frequently. Should not be used if creatinine level ≥2.5 mg/dL in men or ≥2.0 mg/dL in women, or if serum K level ≥5mEq/L. Spironolactone or eplerenone may be used with a thiazide/thiazide-type diuretic in resistant HTN.

- Hydralazine plus isosorbide dinitrate should be added to the regimen of diuretic, ACE inhibitor, or ARB, and β-blocker in African American patients with NYHA class III or IV HF with reduced ejection fraction. Others may benefit similarly, but this has not yet been tested.

- In patients who have hypertension and HF with preserved ejection fraction, the recommendations are to control systolic and diastolic hypertension, ventricular rate in the presence of atrial fibrillation, and pulmonary congestion and peripheral edema.

- Use of β-adrenergic blocking agents, ACEI/ARBs, or CCB in patients with HF with preserved ejection fraction and hypertension may be effective to minimize symptoms of HF.

- In IHD, the principles of therapy for acute hypertension with pulmonary edema are similar to those for STEMI and NSTEMI, as described above. If the patient is hemodynamically unstable, the initiation of these therapies should be delayed until stabilization of HF has been achieved.
ACC/AHA/ASH 2015 ANTIHYPERTENSIVE THERAPY FOR PATIENTS WITH CAD  (Continued)

- Drugs to avoid in patients with hypertension and HF with reduced ejection fraction are nondihydropyridine CCBs (such as verapamil and diltiazem), clonidine, moxonidine, and hydralazine without a nitrate. α-Adrenergic blockers such as doxazosin should be used only if other drugs for the management of hypertension and HF are inadequate to achieve BP control at maximum tolerated doses. Nonsteroidal anti-inflammatory drugs should also be used with caution in this group, given their effects on BP, volume status, and renal function.


AMERICAN SOCIETY OF HYPERTENSION (ASH) 2013 ANTIHYPERTENSIVE THERAPY

Goal therapy
- BP <150/90 mm Hg in patients ≥80 y old.
- BP <140/90 mm Hg in patients 60–79 y old.
- BP <140/90 mm Hg or <130/80 mm Hg (if tolerated), in patients <50 y old.

In patients with CKD or diabetes:
- BP <140/90 mm Hg (without proteinuria).
- BP <130/80 mm Hg (with proteinuria) or if they are at “high risk of cardiovascular disease”—no consensus.

Antihypertensive therapy
- Start lifestyle changes.
- In stage I (140–159/90–99) in patients without CV risks, some months of regularly monitored lifestyle management without drugs can be considered.
- In black patients initiate with CCB or thiazide. If unable to control BP, add ACEI/ARB. If needed add spironolactone, centrally acting agents, and β-blockers.
- In nonblack patients <60 y old initiate with ACEI/ARB. If uncontrolled, add CCB or thiazide. If needed add spironolactone, centrally acting agents, and β-blockers. In nonblack patients ≥60 y old initiate with CCB or thiazide. If needed add spironolactone, centrally acting agents, and β-blockers.


AMERICAN DIABETES ASSOCIATION (ADA) 2017 ANTIHYPERTENSIVE THERAPY

Goal therapy
- BP <140/80 mm Hg in patients with diabetes and HTN.
- BP <130/80 mm Hg in young patients and those at “high risk of cardiovascular disease.”
- BP 110–129/65–79 in pregnant patients with diabetes and chronic HTN (lower than this may be associated with impaired fetal growth).
Antihypertensive therapy

- Start lifestyle changes.
- Initiate with ACEI or ARB.
- Administer one or more antihypertensive medications at bedtime. Closely monitor eGFR, serum K levels if any ACEI/ARB/diuretic is used.
- Safe in pregnancy: methyldopa, labetalol, diltiazem, clonidine, and prazosin.


CANADIAN HYPERTENSION EDUCATION PROGRAM (CHEP) 2014/2015

ANTIHYPERTENSIVE THERAPY

- The diagnosis of HTN should be based on out-of-office measurements (home or ambulatory). Electronic (oscillometric) measurement methods are preferred to manual measurements. HBPM and ABPM identify white-coat hypertension (as well as diagnose masked hypertension). (10% may have marked hypertension).
- Risk factors cluster; therefore, the management of HTN is combining global cardiovascular risk management and vascular protection including advice and treatment for smoking cessation.
- Structured exercise prescription as lifestyle modification.
- Resistance or weight training does not adversely affect BP in normotensive or mildly hypertensive individuals.
- Stress management should be considered as an intervention in hypertensive patients in whom stress may be contributing to BP elevation.

Initiate therapy

- BP  $\geq$ 160/100 mm Hg in patients without macrovascular target organ damage or other CV risk factors.
- BP  $\geq$ 140/90 mm Hg in patients with macrovascular target organ damage or high cardiovascular risk.
- BP  $>$ 130/80 mm Hg in patients with diabetes.
- SBP  $>$ 160 mm Hg in elderly (≥60 y).

Goal therapy

- BP  $<$ 140/90 mm Hg in the general population, including those with CKD.
- BP  $<$ 130/80 mm Hg in patients with DM.
- SBP  $<$ 150 mm Hg in the elderly (≥60 y).
- SBP $<$ 140 mmHg in the elderly with cerebrovascular disease (history of CVA/TIA).
- Caution in elderly patients who are frail and in patients with CAD and have low DBP $<$ 60 mm Hg.

Antihypertensive agents

- Combination of both lifestyle modifications and antihypertensive medicines are generally necessary to achieve target blood pressures. Adopting health behaviors is integral to the management of hypertension.
- Optimum management of the hypertensive patient requires assessment and communication of overall cardiovascular risk.
CHAPTER 3

CANADIAN HYPERTENSION EDUCATION PROGRAM (CHEP) 2014/2015

ANTIHYPERTENSIVE THERAPY (Continued)

- Initial therapy should be monotherapy with a thiazide diuretic, a beta-blocker, an ACEI in non-black patients, a long-acting CCB or an ARB in patients <60 y.
  - First-line combinations: thiazide diuretic or CCB with an ACEI, ARB, or β-blocker.

**Combination of ACEI and ARB is not recommended!** Caution in combination of non-dihydropyridine and a β-blocker.

- In patients with diabetes, the combination preferred: ACEI with dihydropyridine rather than ACEI with HCTZ.
- Single pill combination therapies improve achieving optimal BP control.

- **ISH:** initial monotherapy with a thiazide diuretic, a long-acting dihydropyridine CCB, or an ARB. Combination of 2 or more first-line agents or other classes like α-blockers, ACEI, centrally acting agents, or non-dihydropyridine CCBs.
  - β-blockers are not recommended as first-line therapy for uncomplicated hypertension/uncomplicated ISH in patients ≥60 y. ACEIs are not recommended as first-line therapy for uncomplicated hypertension in black patients. α-blockers are not recommended as first-line agents for uncomplicated hypertension/uncomplicated ISH.

- The patient with hypertension attributable to atherosclerotic renal artery stenosis should be primarily medically managed, because renal angioplasty and stenting offer no benefits over optimal medical therapy alone. Renal artery angioplasty and stenting for atherosclerotic hemodynamically significant renal artery stenosis could be considered for patients with uncontrolled HTN resistant to maximally tolerated pharmacotherapy, progressive renal function loss, and acute PE.

- Global cardiovascular risk should be assessed in all hypertensive patients. Informing patients of their global risk improves the effectiveness of risk factor modification.

- Statin therapy is recommended in high-risk hypertensive patients based on having established atherosclerotic disease or at least 3 of the following: male, ≥ 55 y, smoking, type 2 diabetes, total-C/HDL-C ratio ≥ 6, premature family history of CV disease, previous stroke or TIA, LVH, ECG abnormalities, microalbuminuria or proteinuria, and peripheral vascular disease.

- Low-dose ASA should be started in hypertensive patients ≥50 y for vascular protection. Caution should be exercised if BP is not controlled.

- Advice in combination with pharmacotherapy (e.g., varenicline, bupropion, nicotine replacement therapy) should be offered to all smokers with a goal of smoking cessation.

ABPM, ambulatory BP measurement; HBPM, home BP measurement.
### IMPACT OF HEALTH BEHAVIOR MANAGEMENT ON BLOOD PRESSURE

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Systolic BP (mm Hg)</th>
<th>Diastolic BP (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet and weight control</td>
<td>−6.0</td>
<td>−4.8</td>
</tr>
<tr>
<td>Reduced salt/sodium intake &lt;2000 mg sodium (Na)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>−5.4</td>
<td>−2.8</td>
</tr>
<tr>
<td>Reduced alcohol intake (&lt;2 drinks/d)</td>
<td>−3.4</td>
<td>−3.4</td>
</tr>
<tr>
<td>DASH diet</td>
<td>−11.4</td>
<td>−5.5</td>
</tr>
<tr>
<td>Physical activity (30–40 min 5–7× week)</td>
<td>−3.1</td>
<td>−1.8</td>
</tr>
<tr>
<td>Relaxation therapies</td>
<td>−5.5</td>
<td>−3.5</td>
</tr>
</tbody>
</table>

<sup>a</sup>2000 mg sodium (Na) = 87 mmol sodium (Na) = 5 g of salt (NaCl) ~1 teaspoon of table salt.

Source: Adapted from Canadian Hypertension Education Program (CHEP) Recommendations. 2015. (www.hypertension.ca/en/chep).

### LIFESTYLE MODIFICATIONS FOR TREATMENT OF HYPERTENSION<sup>a,b</sup>

<table>
<thead>
<tr>
<th>Modification</th>
<th>Recommendation</th>
<th>Approximate SBP Reduction (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight reduction</td>
<td>Maintain normal body weight (BMI 18.5–24.9 kg/m&lt;sup&gt;2&lt;/sup&gt;).</td>
<td>5–20 mm Hg per 10-kg weight loss</td>
</tr>
<tr>
<td>Adopt DASH eating plan</td>
<td>Consume diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat.</td>
<td>8–14 mm Hg</td>
</tr>
<tr>
<td>Dietary sodium reduction</td>
<td>Reduce dietary sodium intake to less than 100 mmol/d (2.4 g sodium or 6 g sodium chloride).</td>
<td>2–8 mm Hg</td>
</tr>
<tr>
<td>Physical activity</td>
<td>Engage in regular aerobic physical activity such as brisk walking (at least 30 min/d, most days of the week).</td>
<td>4–9 mm Hg</td>
</tr>
<tr>
<td>Moderation of alcohol consumption</td>
<td>Limit consumption to no more than 2 drinks (1 oz or 30 mL ethanol; eg, 24 oz beer, 10 oz wine, or 3 oz 80-proof whiskey) per day in most men and to no more than 1 drink per day in women and lighter-weight persons.</td>
<td>2–4 mm Hg</td>
</tr>
</tbody>
</table>

DASH, dietary approaches to stop hypertension.

<sup>a</sup>For overall cardiovascular risk reduction, stop smoking.

<sup>b</sup>The effects of implementing these modifications are dose- and time-dependent and could be greater for some individuals.

DASH diet found to be effective in lowering SBP in adolescents.

### RECOMMENDED MEDICATIONS FOR COMPELLING INDICATIONS

<table>
<thead>
<tr>
<th>Compelling Indication</th>
<th>Diuretic</th>
<th>BB</th>
<th>ACEI</th>
<th>ARB</th>
<th>CCB</th>
<th>AldoANT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post-MI</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High coronary disease risk</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Recurrent stroke</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACEI, ACE inhibitor; AldoANT, aldosterone antagonist; ARB, angiotensin receptor blocker; BB, beta-blocker; CCB, calcium channel blocker.

*pCompelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed in parallel with the BP.


### COMPLICATED HYPERTENSION CHEP 2014

#### • HTN and documented CAD
- ACEI is recommended for patients with HTN and documented CAD.
- For patients with stable angina, β-blockers are preferred as initial therapy.
- Combination of ACEI with ARB is not recommended in HTN patients with CAD but absence of LV systolic dysfunction.
- In high-risk patients, combination of ACEI and a dihydropyridine CCB is preferable to an ACEI and a thiazide/thiazide-like diuretic in selected patients.
- Myocardial ischemia may be exacerbated when DBP ≤60 mm Hg—caution in lowering DBP too much. (grade D)

#### • HTN and recent STEMI/NSTEMI
- Initial therapy should include β-blocker and an ACEI or ARB. CCB may be used if β-blockers are contraindicated. Should not use nondihydropyridine CCBs with heart failure.

#### • HTN with heart failure
- When LVEF <40% ACEI/ARBs and β-blockers are recommended as initial therapy.
- Aldosterone antagonists may be added for patients with a recent CV hospitalization, acute MI, elevated BNP/NT-proBNP levels, or symptomatic cardiomyopathy NYHA class II-IV. Diuretics can be used if needed: thiazide/thiazide-like diuretic for BP control, loop diuretics for volume control.
If ACEI/ARB contraindicated or not tolerated, a combination of hydralazine and isosorbide dinitrate is recommended.

For HTN patients whose BP is not controlled, and ARB may be added to an ACEI and other antihypertensive drug treatment. (grade A) (Watch for hypotension, hyperkalemia, and worsening renal function.)

• HTN with stroke/TIA
  **Acute stroke (72 h)**
  - For patients eligible for thrombolytic therapy very high BP >185/110 mm Hg should be treated concurrently in patient receiving thrombolytic therapy for acute ischemic stroke to reduce the risk of intracranial hemorrhage.
  - For patients not eligible for thrombolytic therapy, extreme SBP elevation >220 or DBP > 120 mm Hg may be treated to reduce BP by 15% and not more than 25% over the first 24 h.

  **After acute stroke**
  - Strong consideration should be given to the initiation of antihypertensive therapy after the acute phase of a stroke or TIA.

• HTN with LVH
  - Initial therapy with ACEI/ARB, long-acting CCB, or thiazide/thiazide-like diuretics. Hydralazine and minoxidil should not be used.

• HTN with nondiabetic CKD
  - Goal BP <140/90 mm Hg.
  - If proteinuric CKD initiate with ACEI or ARB.
  - ACEI in combination with ARB is not recommended for patients with nonproteinuric CKD.

• HTN with diabetes
  - Goal BP 130/80 mm Hg.
  - Initiate with ACEI, dihydropyridine CCBS, thiazide/thiazide-like diuretic, or ARB.
  - If additional CVD, CKD, microalbuminuria, or CV risk factors, initiate with an ACEI or ARB.
  - Combination preferred: ACEI with dihydropyridine rather than ACEI with HCTZ.


REFRACTORY HYPERTENSION

**Definition:**
Failure to reach BP goal (<140/90 mm Hg, or 130/80 mm Hg in patients with diabetes, heart disease, or chronic kidney disease) using three different antihypertensive drug classes.

**Incidence:** 20%–30% of HTN patients.

**Common Causes:**
1. Nonadherence to drugs/diet.
2. Suboptimal therapy/BP measurement (fluid retention, inadequate dosage).
3. Diet/drug interactions (caffeine, cocaine, alcohol, nicotine, NSAIDs, steroids, BCP, erythropoietin, natural licorice, herbs).
4. Common secondary causes:
   - Obstructive sleep apnea.
   - Diabetes.
   - Chronic kidney disease.
Renal artery stenosis.
Obesity.
Endocrine disorders (primary hyperaldosteronism, hyperthyroidism, hyperparathyroidism, Cushing syndrome), pheochromocytoma.

Therapy:
• Exclude nonadherence and incorrect BP measurement.
• Review drug and diet history.
• Screen for secondary causes:
  History of sleep disorders/daytime sleepiness/tachycardias/BPs in both arms; routine labs: sodium, potassium, creatinine, CBC, ECG, urinalysis, blood glucose, cholesterol; additional evaluation: aldosterone: renin ratio, renal ultrasound with Doppler flow study, serum or urine catecholamine levels, morning cortisol level.
• Lifestyle therapy:
  Weight loss (10-kg weight loss results in a 5–20 mm Hg decrease in SBP); diet consult for low sodium (2.3 g daily), high fiber, and high potassium (DASH diet results in an 8–14 mm Hg decrease in SBP); exercise aerobic training results in a 4–9 mm Hg decrease in SBP; and restriction of excess alcohol (1 oz in men and 0.5 oz in women) results in a 2–4 mm Hg decrease in SBP.
• Pharmacologic therapy:
  Consider volume overload.
  • Switch from HCTZ to chlorthalidone (especially if GFR <40 mL/min).
  • Switch to loop diuretic if GFR <30 mL/min (eg, furosemide 40 mg bid).
  • Use CCB (amlodipine or nifedipine) + ACE inhibitor or ARB: Consider catecholamine excess.
  • Switch to vasodilating β-blocker (carvedilol, labetalol, nebivolol):
    Consider aldosterone excess (even with normal serum K+ level).
  • Spironolactone or eplerenone
    Finally, consider hydralazine or minoxidil.
  • If already on β-blocker, clonidine adds little BP benefit.
  • Nonpharmacologic therapy: Still under investigation.
  • Carotid baroreceptor stimulation (Hypertension. 2010;55:1-8): May lower BP 33/22 mm Hg.
• Renal artery nerve denervation (SYMPLICITY HTN-3) did not show a significant reduction of SBP in patients with resistant hypertension, 6 mo after the procedure.

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BCP, birth control pill; bid, twice a day; BP, blood pressure; CBC, complete blood count; CCB, calcium channel blocker; DASH diet, Dietary Approaches to Stop Hypertension diet; ECG, electrocardiogram; GFR, glomerular filtration rate; HCTZ, hydrochlorothiazide; HTN, hypertension; NSAIDs, nonsteroidal anti-inflammatory drugs; SBP, systolic blood pressure.

HYPERTENSION: CHILDREN AND ADOLESCENTS

Indications for antihypertensive drug therapy in children and adolescents:

• Symptomatic hypertension.
• Secondary hypertension.
• Hypertensive target organ damage.
• Diabetes (types 1 and 2).
• Persistent hypertension despite nonpharmacologic measures (weight management counseling if overweight; physical activity; diet management).


HYPERTENSION: TREATMENT IN SPECIAL POPULATIONS ESH/ESC GUIDELINES 2013

• White-coat HTN is defined as elevated BP in doctor's office with normal home BPs.
  ○ White-coat hypertension at low risk (unassociated with additional risk factors) should receive lifestyle intervention and close follow-up.
  ○ White-coat hypertension at higher risk (associated with additional risk factors, metabolic disorders, or organ damage) should receive lifestyle intervention and drug therapy.
• Masked HTN is defined as normal BP in the doctor’s office with elevated BPs at home.
  ○ Masked hypertension at low risk (with or without additional risk factors) should receive lifestyle intervention and drug therapy due to the higher CV risk.
• Elderly HTN occurs in patients ≥65 y old.
  ○ In all elderly hypertensive patients SBP >160 mm Hg should be reduced to SBP between 140 and 150 mm Hg based upon good evidence.
  ○ In fit elderly hypertensive patients <80 y old, SBP >160 mm Hg may be reduced to <140 mm Hg, if therapy is well tolerated.
  ○ Diuretics and calcium antagonist may be preferred in isolated systolic hypertension, although all medications have been used with success.
• Very elderly HTN occurs in patients ≥80 y old.
  ○ In fit very elderly patients >80 y old, SBP should be reduced to 140–150 mm Hg.
  ○ In frail very elderly patients >80 y old, SBP goal needs to be individualized.
• Hypertensive therapy during pregnancy.
  ○ Drug therapy should be started with persistent BP ≥150/95 mm Hg and BP ≥140/90 mm Hg if associated with gestational hypertension, subclinical organ damage, or if associated with symptoms.
  ○ Women with hypertension with childbearing potential should not receive renin-angiotensin system (RAS) blockers.
HYPERTENSION: TREATMENT IN SPECIAL POPULATIONS ESH/ESC GUIDELINES 2013 (Continued)

- Methyldopa and nifedipine should be initial therapy for hypertension. Labetalol and nitroprusside are the intravenous drugs of choice.
- Hypertension goal with CAD, diabetes, and nephropathy.
  - SBP goal <140 mm Hg should be considered.


HYPERTENSIVE TREATMENT IN PREGNANCY—AHA/ASA 2014 GUIDELINES

- Risk factors of pregnancy-induced hypertension: obesity, age >40 y old, chronic HTN, personal or family history of preeclampsia, gestational HTN, nulliparity, multiple pregnancy, preexisting vascular disease, collagen vascular disease, diabetes, renal disease.
- Severe hypertension per JNC VII: BP ≥160/110 mm Hg (high risk of stroke and eclampsia).
- BP goal during pregnancy: 130–155/80–105 mm Hg.

- Prevention of eclampsia recommendations
  - Women with chronic primary or secondary hypertension, or previous pregnancy-related hypertension, should take low-dose aspirin from the 12th week of gestation until delivery.
  - Calcium supplementation (of at least 1 g/d, orally) should be considered for women with low dietary intake of calcium (<600 mg/d) to prevent preeclampsia.

- Treatment of hypertension in pregnancy and postpartum recommendations
  - Severe hypertension in pregnancy should be treated with safe and effective antihypertensive medications such as methyldopa, labetalol, and nifedipine, with consideration of maternal and fetal side effects.
  - Atenolol, ARBs, and direct renin inhibitors are contraindicated in pregnancy and should not be used.
  - Because of the increased risk of future hypertension and stroke 1 to 30 y after delivery in women with a history of preeclampsia it is reasonable to:
    - Consider evaluating all women starting 6 mo to the 1 y postpartum, as well as those who are past childbearing age, for a history of preeclampsia/eclampsia, and document their history of preeclampsia/eclampsia as a risk factor.
    - Evaluate and treat for cardiovascular risk factors including hypertension, obesity, smoking, and dyslipidemia.
  - After giving birth, women with chronic hypertension should be continued on their antihypertensive regime, with dosage adjustments to reflect the decrease in volume of distribution and glomerular filtration rate that occurs following delivery. They should also be monitored carefully for the development of postpartum preeclampsia.

HYPOGONADISM, MALE

Population
– Adults.

Recommendations

EAU 2012
– Testosterone testing should be done in:
  • Pituitary masses.
  • ESRD.
  • Moderate-to-severe COPD.
  • Infertility.
  • Osteoporosis.
  • HIV infection.
  • DM type 2.
  • Signs and symptoms of hypogonadism.
– Indications for testosterone treatment are patients with low testosterone and:
  • Hypogonadism.
  • Delayed puberty.
  • Klinefelter syndrome.
  • Sexual dysfunction.
  • Low bone mass.
  • Hypopituitarism.
– Contraindications to testosterone use:
  • Prostate CA.
  • PSA >4 ng/mL.
  • Male breast CA.
  • Severe sleep apnea.
  • Male infertility.
  • Hematocrit >50%.
  • Symptomatic BPH.
– Monitor response to therapy, PSA, and hematocrit 3, 6, and 12 mo after starting therapy.

Source

Comments
1. Caused by androgen deficiency.
2. Primary hypogonadism:
   • Klinefelter syndrome.
3. Secondary hypogonadism:
   - Kallmann syndrome.
   - Pituitary tumor.
   - Renal failure.
   - Hemochromatosis.
   - Hypothyroidism.
   - Anabolic steroid abuse.
   - Morbid obesity.
   - Radiotherapy.
   - Idiopathic hypogonadotrophic hypogonadism.
   - Androgen insensitivity syndrome.

### IDENTIFYING RISK OF SERIOUS ILLNESS IN CHILDREN UNDER 5 Y

<table>
<thead>
<tr>
<th>Category</th>
<th>Green—Low Risk</th>
<th>Yellow—Intermediate Risk</th>
<th>Red—High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color of skin,</td>
<td>Normal color</td>
<td>Pallor</td>
<td>Mottled, ashen, or blue</td>
</tr>
<tr>
<td>lips, or tongue.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td>Responds normally to social</td>
<td>Abnormal response to social cues</td>
<td>No response to social cues</td>
</tr>
<tr>
<td></td>
<td>cues</td>
<td>No smile</td>
<td>Appears toxic</td>
</tr>
<tr>
<td></td>
<td>Smiles</td>
<td>Wakes only with prolonged stimulation</td>
<td>Stuporous</td>
</tr>
<tr>
<td></td>
<td>Awakens easily</td>
<td>Decreased activity</td>
<td>Weak, high-pitched cry</td>
</tr>
<tr>
<td></td>
<td>Strong cry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Normal breathing</td>
<td>Nasal flaring</td>
<td>Grunting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachypnea</td>
<td>Marked tachypnea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;50 breaths/min (6–12 mo)</td>
<td>&gt;60 breaths/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;40 breaths/min (&gt;1 y)</td>
<td>Moderate to severe chest retractions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SpO$_2$ ≤95%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary rales</td>
<td></td>
</tr>
<tr>
<td>Circulation</td>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| • Normal skin and eyes  
• Moist mucous membranes | • Nontoxic appearance |
| • Tachycardia  
  - >160 beats/min (<12 mo)  
  - >150 beats/min (12–24 mo)  
  - >140 beats/min (2–5 y)  
  • Capillary refill ≥3 s  
  • Dry mucous membranes  
  • Poor feeding  
  • Decreased urine output | • Temperature ≥39°C (age 3–6 mo)  
• Fever ≥5 d  
• Rigors  
• Swelling of a limb or joint  
• Nonweight bearing on one extremity |
| • Findings in yellow zone PLUS  
• Reduced skin turgor | • Temperature ≥38°C (<3 mo)  
• Nonblanching rash  
• Bulging fontanelle  
• Neck stiffness  
• Status epilepticus  
• Focal neurological signs  
• Focal seizures |

Source: Adapted from National Institute for Health and Care Excellence (NICE) Guideline on Feverish Illness in children: assessment and initial management in children younger than 5 years; 2013 May (Clinical Guideline no. 160).

### INDWELLING URINARY CATHETERS OR INTERMITTENT CATHETERIZATION

**Recommendation**

**AUA 2015**

– Recommends against empiric antibiotics unless the patient has symptoms of a urinary tract infection.

**Source**

INFERTILITY, MALE

Population
– Adults.

Recommendations

EAU 2012
– Assessment of male infertility includes:
  • Semen analysis.
  • Checking FSH, LH, and testosterone levels.
  • Screening for gonorrhea and Chlamydia.
  • Substance abuse screening.
– Refer patients with abnormal screens to a specialist in male infertility for potential treatments that may include clomiphene citrate, tamoxifen, human chorionic gonadotropin (hCG), dopamine agonists, or surgical treatments depending on the underlying etiology.

Source

Comment
– Infertility is defined as the inability of a sexually active couple not using contraception to conceive in 1 y.

INFLAMMATORY BOWEL DISEASE, CROHN’S DISEASE

Population
– Children, young adults, and adults with Crohn’s disease.

Recommendations

NICE 2012
– Inducing remission in Crohn’s disease.
  • Glucocorticoids are recommended for a single exacerbation in a 12-mo period.
    ° Prednisolone, methylprednisolone, or IV hydrocortisone.
  • Add azathioprine or mercaptopurine to steroids if steroids cannot be tapered or ≥2 exacerbations in last 12 mo.
  • Infliximab or adalimumab are indicated with active fistulizing refractory to conventional therapy.
– Maintaining remission.
  • Azathioprine.
  • Mercaptopurine.
DISEASE MANAGEMENT

–Managing strictures.
  • Balloon dilation is an option for single stricture that is short, straight, and accessible by colonoscopy.
–Recommend routine surveillance for osteopenia or osteoporosis.

Source

INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS

Population
–Children, young adults, and adults.

Recommendations
►NICE 2013
–Mild-to-moderate proctitis and proctosigmoiditis to achieve and maintain remission.
  • Aminosalicylate suppository or enemas.
  • Oral aminosalicylate.
  • Topical corticosteroid.
–Mild-to-moderate extensive left-sided colitis.
  • Induction dose oral aminosalicylate.
  • Consider adding oral tacrolimus to oral prednisolone if remission not achieved after 4 wk of prednisolone therapy.
  • Maintain remission with low-dose aminosalicylate.
–Severe acute ulcerative colitis
  • IV methylprednisolone.
  • Consider IV cyclosporine for those in whom steroids cannot be used or have not improved after 72 h of steroid therapy.
  • Consider a colectomy for:
    ◦ Persistent diarrhea >8 bowel movements/d.
    ◦ Fevers.
    ◦ Hemodynamic instability.
    ◦ Toxic megacolon.
    ◦ CRP >4.5 mg/dL.

Source
Comments
1. Oral prednisolone is an adjunct to aminosalicylates for proctitis or colitis if remission is not attained within 4 wk.
2. Consider adding oral azathioprine or oral mercaptopurine to maintain remission if not maintained by aminosalicylates alone.
3. Monitor bone health in children and young adults with chronic active disease or who require frequent steroid therapy.

Population
– Patients with ulcerative colitis (UC).

Recommendations
► ASCRS 2014
– Indications for colectomy:
  • Actual or impending colonic perforation.
  • Chronic UC refractory to medical therapy.
  • Development of a colonic stricture, high-grade dysplasia, or carcinoma.
– Options for patients with a UC flare that is worsening despite 96 h of primary medical therapy:
  • Add a second-line agent.
  • Surgery.

Source
– https://guidelines.gov/summaries/summary/47756

Comments
1. Procedure of choice for emergency surgery is a total or subtotal colectomy with end ileostomy.
2. Procedure of choice for elective surgery is a total proctocolectomy with ileostomy or ileal pouch-anal anastomosis.

INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS, SURGICAL TREATMENT

Population
– Patients with UC.

Recommendation
► American Society of Colon and Rectal Surgeons 2014
– Indications for surgery in UC:
  • Patients with acute colitis and actual or impending perforation.
  • Chronic UC refractory to medical therapy.
  • Presence of carcinoma or high-grade dysplasia in colon.
• Development of a colonic stricture.
• Consider a second-line agent or surgery for acute colitis that is worsening after 96 h of first-line medical therapy.

Source
–https://guidelines.gov/summaries/summary/47756

Comment
–Patient with severe diarrhea (>8 stools/d) in absence of *C. difficile* colitis and a c-reactive protein >4.5 mg/dL despite medical therapy for 72 h has an 85% chance of requiring a colectomy.

### INFLUENZA

**Population**
– Adults and children.

**Recommendations**

IDSA 2009

1. Antiviral treatment is recommended for:
   a. Lab-confirmed cases of influenza within 48 h of symptom onset.
   b. Strongly suspected influenza within 48 h of symptom onset.
   c. Hospitalized patients with severe, complicated, or progressive lab-confirmed influenza or influenza-like illness with high likelihood of complications even if >48 h from symptom onset.

2. Antiviral options include oseltamivir and zanamivir.
   a. Oseltamivir for influenza A or B: 75 mg by mouth (PO) twice daily (bid) (adults); 30 mg PO bid (≤15 kg); 45 mg PO bid (16–23 kg); 60 mg PO bid (24–40 kg); 75 mg PO bid (>40 kg or age ≥13 y) × 5 d. Avoid in children age <1 y.
   b. Zanamivir for influenza A or B: 2 puffs bid × 5 d (children age ≥7 y and adults); avoid in asthmatic patients.

Source

**Population**
– Children age 6 mo and older.
Recommendations

AAP 2013
– Oseltamivir remains the antiviral drug of choice for the management of influenza infections.
– Treatment indicated if symptom onset within 48 h and:
  • Any child hospitalized with presumed influenza or with severe, complicated, or progressive illness attributable to influenza, regardless of influenza immunization status.
  • Influenza infection of any severity in children at high risk of complications of influenza infection.

Source

Comments
1. Consider an influenza nasal swab for diagnosis during influenza season in:
   a. Persons with acute onset of fever and respiratory illness.
   b. Persons with fever and acute exacerbation of chronic lung disease.
   c. Infants and children with fever of unclear etiology.
   d. Severely ill persons with fever or hypothermia.
2. Rapid influenza antigen tests have a 70%–90% sensitivity in children and a 40%–60% sensitivity in adults.
3. Direct or indirect fluorescent antibody staining is useful in screening tests.
4. Influenza PCR may be used as a confirmatory test.

IRON DEFICIENCY ANEMIA

Population
– Adults.

Recommendations

British Society of Gastroenterology

Scope of Problem
– Iron deficiency anemia (IDA) is the most common cause of anemia and occurs in 2%–5% of adult men and postmenopausal women in the developed world.
– More than 25% of the world's population is anemic with one-half attributed to iron deficiency. (N Engl J Med. 2015;372:1832)

Diagnosis
– Serum ferritin <30, iron transferrin saturation <10%, and hypochromic, microcytic RBCs on peripheral smear. MCV Usually

**Clinical Evaluation**

– Upper and lower gastrointestinal investigations (esophagogastroduodenoscopy and colonoscopy preferred) should be done in all postmenopausal females and all male patients unless there is a history of recent non-GI significant blood loss. (Am J Med. 2001;111:439-445)

– Gastrointestinal evaluation should proceed whether or not fecal occult blood testing is positive. Iron deficiency without significant anemia should also be worked up with GI evaluation in postmenopausal women and men >40 y old. (N Engl J Med. 1993.329:1691-1695)

– If the patient is postgastrectomy upper and lower GI investigation is indicated in those >40y old. If upper and lower GI tracts are normal, small bowel visualization is indicated if the patient has symptoms of small bowel disease and/or continued fecal occult blood positive stools. (Best Pract Res Clin Haematol. 2005;18:319-322)

**Iron Replacement Therapy**

– Ferrous sulfate (65-mg elemental iron) should be administered 2 to 3 times a day depending on tolerance. Taking iron 15-30 min before a meal with orange juice or 500 mg of vitamin C will enhance absorption. Treatment should be continued for 4–8 mo to fully replete iron stores.

– 20%-25% of patients on iron therapy will have GI side effects (abdominal bloating, pain, nausea, vomiting, diarrhea/constipation). Reducing the elemental iron concentration of each dose may avoid side effects.

– In patients who continue to be intolerant of iron, noncompliant, or have diminished iron absorption intravenous iron (iron sucrose-Venofer preferred) should be given to replete iron stores and correct the anemia.

**Refractory Iron Deficiency**

– In patients who have been compliant but do not correct their iron deficiency with oral iron must have further evaluation. Many gastric bypass patients have reduced iron absorption due to bypass of the duodenum where the majority of iron absorption takes place.

– Occasionally patients have significant continued blood loss for which oral iron is insufficient to maintain iron stores. Other possible causes such as celiac sprue, H. pylori infection, and autoimmune gastritis must be evaluated and treated. (Haematologica. 2005; 90:585-595)

– Antacids and protein pump inhibitors will also reduce iron absorption. Hereditary iron-refractory iron deficiency syndrome is an autosomal recessive disorder caused by mutations affecting iron transport.
Patients with refractory iron deficiency anemia due to poor absorption are treated successfully with intravenous iron preparations.

Sources
- Gut. 2011;60:1309-1316

Comments

Clinical Correlates
- Symptoms of IDA include weakness, headache, irritability, fatigue, exercise intolerance, and restless leg syndrome. Symptoms may occur without anemia in patients with iron depletion (ferritin <30 ng/mL). As many as 40% of patients with IDA will experience pica (appetite for clay, starch, and paper products) and/or pagophagia (craving for ice) which resolves rapidly with iron repletion.
- Rarely, in severe iron deficiency, dysphagia and esophageal webs (Plummer-Vinson syndrome) occur as well as koilonychia (spoon nails), glossitis with decreased salivary flow, and alopecia also occur with severe prolonged IDA.
- Besides Gl and genitourinary blood loss, other infrequent causes of iron deficiency include intravascular hemolysis (especially paroxysmal nocturnal hemoglobinuria and microangiopathic hemolytic anemia), pulmonary hemosiderosis, and congenital IDA (germline mutation in the TMPRSS6 gene which leads to a reduction in iron absorption and mobilization).
- Optimal absorption of oral iron occurs when iron is taken 15–30 min before a meal with 500 mg of vitamin C or a glass of orange juice. 20%–25% of patients will have Gl side effects including abdominal pain, nausea, constipation, and diarrhea. Side effects are related to the amount of elemental iron delivered with each dose. The most commonly used iron preparation is ferrous sulfate that contains 65 mg of elemental iron. If patients have intolerable Gl problems, lowering the elemental iron intake by giving ferrous gluconate (28–36 mg of elemental iron) or titrating liquid ferrous sulfate (44 mg iron per 5 mL) can be successful although duration of therapy will be extended. Patients who continue to be intolerant of oral iron can be successfully treated with IV iron preparations (iron sucrose preferred). (Blood. 2014; 123:326-333. Transfusion. 2008;48:988-995)
- A simple iron absorption test can determine whether or not a patient has iron malabsorption. Check a baseline iron level and then a second iron level 2–4 h after ingesting a single 325 mg ferrous sulfate tablet with water. An increase in the iron level of at least 100 µg/dL indicates adequate absorption.
Other hypochromic, microcytic anemias should be ruled out (see Table I). Diagnosing iron deficiency in patients who also have anemia of chronic disease (ACD) is difficult. Circulating transferrin receptor (sTFR) is elevated when iron deficiency is present and a high sTFR/ferritin index is consistent with concurrent IDA and ACD. A bone marrow examination with absent stainable iron stores, although invasive, will also confirm a diagnosis of IDA in the presence of ACD. Recombinant erythropoietin is not effective in treating anemia in patients who are iron deficient. (N Engl J Med. 2014;371:324)

Indications for IV iron therapy includes refractory noncompliance or side effects, gastric bypass, iron malabsorption, and continued blood loss with IDA and inadequate iron repletion with oral therapy. IV iron causes a modest early increase in reticulocytes compared to oral iron but it still takes 8–10 wk for hemoglobin levels to normalize. Iron dextran was the first IV preparation of iron used but problems with anaphylaxis were significant. Iron sucrose (Venofer®) is effective and has a 15-fold reduction in the risk of anaphylaxis compared to iron dextran. This can be dosed at 150–200 mg once or twice a week until the calculated iron deficit is administered. Ferric gluconate complex (Ferrlecit®) is similar to iron sucrose. Ferumoxytol (Feraheme®) is composed of iron oxide nanoparticle and is approved for use only in patients with renal failure. Ferric carboxymaltose (Ferinject®) is the newest IV iron option with 1,000 mg elemental iron weekly with more rapid infusion times. Low phosphate levels have been reported with this drug. It has also been shown to be helpful in patients with iron deficiency and heart failure. (Ann Int Med. 2010;152:4-5)

### TABLE I

**THE COMMON CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA**

<table>
<thead>
<tr>
<th>Microcytic, Hypochromic Anemia</th>
<th>Ferritin Level</th>
<th>RDW</th>
<th>Hgb Electrophoresis</th>
<th>Iron/TIBC</th>
<th>Mentzer Index&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron deficiency</td>
<td>&lt;30</td>
<td>High</td>
<td>Normal</td>
<td>&lt;10%</td>
<td>&gt;13</td>
</tr>
<tr>
<td>Beta thalassemia</td>
<td>Normal</td>
<td>Normal</td>
<td>↑A&lt;sub&gt;2&lt;/sub&gt;F hemoglobin</td>
<td>~20%</td>
<td>&lt;13</td>
</tr>
<tr>
<td>Alfa thalassemia</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>~20%</td>
<td>&lt;13</td>
</tr>
<tr>
<td>Anemia of chronic disease</td>
<td>High</td>
<td>High</td>
<td>Normal</td>
<td>10%–15%</td>
<td>&gt;13</td>
</tr>
<tr>
<td>Low transferrin</td>
<td></td>
<td></td>
<td></td>
<td>Low transferrin</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin E (mutation in beta-globin gene—common in Asia)</td>
<td>Normal</td>
<td>Normal</td>
<td>↑HgbE (30% if trait 90% if homozygote)</td>
<td>~20%</td>
<td>&lt;13</td>
</tr>
</tbody>
</table>

<sup>a</sup>Mentzer index, MCV-red cell number in millions. Iron deficiency >13. Thalassemia minor <13. RDW, random distribution of width ↑ in iron deficiency.
IRRITABLE BOWEL SYNDROME (IBS)

Population
– Adults with symptoms of IBS.

Recommendations
▶ NICE 2015
– Consider IBS for any adult with any of these symptoms for at least 6 mo.
  • Abdominal pain.
  • Bloating.
  • Change in bowel habit.
– Assess all patients with possible IBS for red flag indicators that argue against IBS.
  • Unintentional weight loss.
  • Rectal bleeding.
  • Anemia.
  • Abdominal mass.
  • Change in bowel habit to looser and more frequent stools if over 60 y.
– Recommend for all patients with suspected IBS.
  • Complete blood count.
  • ESR.
  • C-reactive protein.
  • Anti-endomysial antibody and anti-tissue transglutaminase antibody to rule out celiac disease.
– Lifestyle recommendations for IBS.
  • Eat regular meals.
  • Drink at least 8 cups of non-caffeinated beverage daily.
  • Limit intake of tea, coffee, and alcohol.
  • Reduce intake of “resistant starch.”
  • Avoid sorbitol, an artificial sweeteners, for diarrhea-predominant IBS.
– Pharmacologic therapy for IBS.
  • Consider laxatives as needed (except lactulose) for constipation.
  • Consider linaclotide for refractory constipation for longer than 12 mo.
  • Consider antispasmodic agents as needed for pain.
  • Loperamide is the antimotility agent of choice for diarrhea.
  • Consider low-dose tricyclics (TCAs) as second-line treatment if antispasmodics or antimotility agents have not helped.
  • Consider SSRI therapy if TCAs are ineffective.
  • Consider cognitive behavioral therapy or hypnotherapy for IBS refractory to above therapies.
Source

KIDNEY DISEASE, CHRONIC

Population
–Adults.

Recommendations

NICE 2008

1. Recommends the modification of diet in renal disease (MDRD) equation to estimate GFR.
   a. Advise patients not to eat any meat in the 12 h before a blood test for GFR estimation.
   b. Frequency of GFR testing by CKD stage:
      i. Stages 1–2: annually.
      ii. Stage 3: every 6 mo.
      iii. Stage 4: every 3 mo.
      iv. Stage 5: every 6 wk.

2. Recommends urine albumin-to-creatinine ratio (ACR) to detect low levels of proteinuria.
   a. Levels ≥30 mg/mmol are significant.

3. Recommends checking for urinary tract malignancy for persistent hematuria.

4. Recommend renal ultrasound for:
   a. A GFR decline >5 mL/min/1.73 m² in 1 y or >10 mL/min/1.73 m² in 5 y.
   b. Persistent hematuria.
   c. Symptoms of urinary tract obstruction.
   d. Age >20 y and has a family history of polycystic kidney disease.
   e. Stages 4–5 CKD.
   f. Being considered for a renal biopsy.

5. Recommends nephrology referral for:
   a. Stages 4–5 CKD.
   b. ACR ≥70 mg/mmol.
   c. Proteinuria ≥1 g/24 h.
   d. Poorly controlled HTN.
   e. Suspected renal artery stenosis.
   f. Rapidly progressive renal impairment.
   g. Metabolic complications of CKD (anemia or hyperparathyroidism).
   h. Nephrolithiasis.
6. Recommends a check of serum calcium, phosphate, intact parathyroid hormone (iPTH), 25-OH vitamin D, and hemoglobin levels for all Stages 4–5 CKD.

Source

► Va/DoD 2014
– Recommends dietary sodium restriction to reduce hypertension and proteinuria.
– Protein restriction 0.6–0.8 g/kg/d for patients with Stage 3–4 CKD.
– Recommends administration of vaccinations against influenza, Tdap, 13-valent pneumococcal conjugate vaccine, hepatitis B virus, Zoster, and MMR vaccines.
– Recommends ACEI or ARB therapy for patients with diabetes, hypertension, or albuminuria.
– Recommends bicarbonate supplementation in CKD with metabolic acidosis.
– Recommends oral iron therapy for Stage 3 or worse CKD.
– Recommends erythropoietic-stimulating agents if hemoglobin <10 g/dL.

Source

KIDNEY DISEASE, CHRONIC–MINERAL AND BONE DISORDERS (CKD-MBDS)

Population
– Adults and children.

Recommendations
► NKF 2009
1. Recommends monitoring serum calcium, phosphorus, immunoreactive parathyroid hormone (iPTH), and alkaline phosphatase levels for:
   a. Stage 3 CKD (adults).
   b. Stage 2 CKD (children).
2. Measure 25-OH vitamin D levels beginning in stage 3 CKD.
3. Recommends treating all vitamin D deficiency with vitamin D supplementation.
4. In Stages 3–5 CKD, consider a bone biopsy before bisphosphonate therapy if a dynamic bone disease is a possibility.
5. In Stages 3–5 CKD, aim to normalize calcium and phosphorus levels.
6. In Stage 5 CKD, maintain a parathyroid hormone (PTH) level of 130–600 pg/mL.

Source
–http://kdigo.org/home/mineral-bone-disorder/

Comment
1. Options for oral phosphate binders:
   a. Calcium acetate.
   b. Calcium carbonate.
   c. Calcium citrate.
   d. Sevelamer carbonate.
   e. Lanthanum carbonate.

KIDNEY INJURY, ACUTE

Population
–Children and adults.

Recommendations
➤ NICE 2013
–Perform a urinalysis in all patients with AKI.
–Do not routinely obtain a renal ultrasound when the cause of the AKI has been identified.
–Detect AKI with any of the following criteria:
   • Rise in serum creatinine ≥0.3 mg/dL in 48 h.
   • 50% or more rise in creatinine in last 7 d.
   • Urine output <0.5 mL/kg/h.
–Refer for renal replacement therapy patients with any of the following refractory to medical management:
   • Hyperkalemia.
   • Metabolic acidosis.
   • Uremia.
   • Fluid overload.

Source
KIDNEY STONES

Population

– Adults and children with kidney stone disease.

Recommendations

EAU 2010, AUA 2014

1. Recommended imaging study for patients with acute flank pain is a noncontrast CT urogram.
2. Recommended evaluation for renal colic:
   a. Urinalysis
   b. Serum CBC, creatinine, uric acid, calcium, and albumin +/- intact parathyroid hormone.
   c. Stone analysis by x-ray crystallography or infrared spectroscopy.
3. Recommends 24-h urine analysis for complicated calcium stone disease: calcium; oxalate; citrate; creatinine; urate; magnesium; phosphate; sodium; and potassium.
4. Recommends a thiazide diuretic for patients with hypercalciuria.
5. Recommends treatment with an alkaline citrate for hypocitraturia, type 1 renal tubular acidosis (RTA), hypercalciuria, and hyperoxaluria.
6. Recommends that adults with a history of urinary stones drink sufficient water to maintain a urine output >2.5 L/d.
7. Consider use of an α-receptor blocker to facilitate spontaneous passage of ureteral stones <10 mm.
8. Consider active ureteral stone removal for persistent obstruction, failure of spontaneous passage, or the presence of severe, unremitting colic.
   a. Options include shockwave lithotripsy or ureteroscopy.
9. For calcium stones and hypercalciuria
   a. Limit sodium intake and consume 1–2 g/d of dietary calcium.
   b. Thiazide diuretic.
10. For calcium oxalate stones
    a. If high urinary oxalate, limit intake of oxalate-rich foods and maintain normal calcium consumption.
    b. If hyperuricosuria, treat with allopurinol.
11. For uric acid stones and high urinary uric acid, limit intake of non-dairy animal protein.
12. For struvite stones refractory to surgical management, consider acetohydroxamic acid therapy.
13. For uric acid or cystine stones, consider potassium citrate therapy to raise urinary pH to optimal level.
Sources

Comment
1. Patients at high risk for recurrent stone formation:
   a. ≥3 stones in 3 y.
   b. Infection stones.
   c. Urate stones.
   d. Children and adolescents with stones.
   e. Cystinuria.
   f. Primary hyperoxaluria.
   g. Type 1 RTA.
   h. Cystic fibrosis.
   i. Hyperparathyroidism.
   j. Crohn’s disease.
   k. Malabsorption syndromes.
   l. Nephrocalcinosis.
   m. Family history of kidney stone disease.

Population
– Adults with kidney stone disease.

Recommendations
➤ EAU 2013
– Recommended evaluation for renal colic:
  • Sodium, potassium.
  • CRP.
  • PT, PTT (if intervention is likely).
– Contrast-enhanced CT scan recommended if stone removal is planned and the renal anatomy needs to be assessed.
– Hyperoxaluria.
  • Oxalate restriction.
  • Pyridoxine.
– Renal colic analgesia.
  • NSAIDs.
  • Opiates.
  • Alpha-blockers.
– Management of sepsis with obstructed kidney.
  • Requires urgent decompression with a ureteral stent or percutaneous nephrostomy tubes.
  • Start antibiotics immediately.
DISEASE MANAGEMENT

- Indications for active kidney stone treatment:
  - Stone growth.
  - Acute or chronic pain.
  - Kidney infection.
  - Kidney obstruction.

EAU 2013
- Stop antiplatelets and anticoagulation before stone removal.
- Goal is to drink water to maintain a urine output >2.5 L/d.
- Struvite and infection stones:
  - Surgical removal of stones.
  - Antibiotics.
  - Urinary acidification.
  - Urease inhibition.
- Cystine stones.
  - Potassium citrate.
- Tiopronin.

Source

Population
- Children with kidney stone disease.

Recommendations
EAU 2013
- Recommends a complete metabolic work-up based on stone analysis.
- Ultrasound is the preferred imaging method in children.
- Percutaneous nephrolithotripsy is recommended for treatment of renal pelvic or calyceal stones with a diameter >20 mm.

Source

LARYNGITIS, ACUTE

Population
- Adults.

Recommendation
Cochrane Database Systematic Reviews 2015
- Insufficient evidence to support the use of antibiotics for acute laryngitis.

Source
Comment
--Many methodological flaws in studies evaluated.

MALIGNANT SPINAL CORD COMPRESSION (MSCC)

Population
--Adults with MSCC.

Recommendation
Scottish Palliative Care Guidelines 2014, National Collaborating Centre for Cancer—Metastatic Spinal Cord Compression (MSCC) 2012

--Stratify Patient for Therapy

- Patients presenting with >48 h for paraplegia—radiation for pain control, surgery only if spine is unstable.
- The chance for neurological recovery is zero. (Lancet Oncol. 2005;6:15)
- Patients presenting with significant or progressing weakness of lower extremities—if no previous history of cancer biopsy non-neural cancer if accessible. If biopsy not possible and lymphoma or myeloma unlikely give decadron 40 to 100 mg daily and take to surgery to make tissue diagnosis and relieve compression of spinal cord. (Neurology. 1989;39:1255. Lancet Neurol. 2008;7:459) If unstable, the spine should be stabilized. Taper steroids (decrease by ½ every 3 d) and begin radiation in 2–3 w. If tumor is lymphoma or myeloma, consider initiating chemotherapy and high-dose decadron. Recovery of lower extremity strength dependent on degree of paraparesis initially.
- Patients presenting with back pain but mild neurologic symptoms—if no previous cancer find site to biopsy, check PSA, serum protein electrophoresis, beta-2 microglobulin, and alfa-fetoprotein. Begin moderate-dose decadron (16 mg/d) with radiation therapy initially. Surgery reserved for progression of symptoms after starting radiation especially in radioinsensitive cancers (renal cell, sarcoma, melanoma). Recovery of neurologic function in 80%–90% range.
- Patients presenting with back pain but no neurologic symptoms—if no previous diagnosis of cancer search for site to biopsy (physical exam, PET CT scan, tumor markers) and consult radiation therapy. If myeloma or lymphoma, treat with systemic chemotherapy. Radiation is primary treatment with surgery only on progression. Low dose or no steroids is acceptable. Chance of continued lower extremity strength approaches 100%.
**DISEASE MANAGEMENT**

**Sources**

**Comment**

- **Clinical Considerations**
  - MRI with and without gadolinium of the entire spine is mandatory.
  - 30% of patients will have cord compression in more than 1 area.
  - 20% of patients presenting with MSCC have not had a previous diagnosis of cancer.
  - 5%–8% of patients with known cancer will develop MSCC during their course of disease.
  - Most common tumors associated with MSCC are lung, breast, prostate, myeloma, and lymphoma.
  - Most common site of MSCC is the thoracic spine (70%) and least common is cervical spine (10%).
  - Back pain presents in 95% of patients with average time to MSCC being 6–7 wk. Once motor, sensory, or autonomic dysfunction occur—time to total paraplegia is rapid (hours to days).
  - Indications for surgery in MSCC include lack of diagnosis, progression on radiation, unstable fracture or bone in spinal canal, and previous radiation to site of MSCC. (*Int J Oncol*. 2011;38:5. *J Clin Onc*. 2011;29:3072)
  - Posterior decompression laminectomy was standard surgery for MSCC, but now resection of tumor with bone reconstruction and stabilization is done most commonly at centers of excellence.
  - Stereotactic body radiation therapy is being used more commonly with improved results especially in radiation-resistant cancers. (*Cancer*. 2010;116:2258)

**MANAGEMENT OF VENOUS THROMBOSIS IN PATIENTS WITH CANCER**

**Population**
- Adult men and women with cancer.

**Recommendation**

- ASCO Clinical Practice Guidelines
  - Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Data are inadequate to support routine thromboprophylaxis in patients for minor procedures or short chemotherapy infusions.
Routine thrombophylaxis is not recommended for ambulatory patients with cancer. It may be considered for selected high-risk patients.

- Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive prophylaxis with either low-molecular-weight heparin (LMWH) or low-dose aspirin to prevent venous thromboembolism (VTE).

- Patients undergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 d after discharge (30-mg enoxaparin bid).

- Extending postoperative prophylaxis up to 4 wk should be considered in those undergoing major abdominal or pelvic surgery with high-risk features.

- LMWH is recommended for the initial 5 to 10 d of treatment of established deep vein thrombosis and pulmonary embolism as well as for long-term secondary prophylaxis for at least 6 mo. If the cancer remains active, LMWH should be given indefinitely.

- Use of novel oral anticoagulants is not currently recommended for patients with malignancy and VTE but trials are ongoing to prove benefit.

- Anticoagulation should not be used to extend survival of patients with end-stage cancer in the absence of other indications.

- Patients with cancer should be periodically assessed for VTE risk.

- Oncology professionals should educate patients about signs and symptoms of VTE.

Source

- J Clin Oncol. 2015;33:654-656
- J Clin Oncol. 2013;31:2189-2204

Comments

1. VTE is the second leading cause of death among cancer patients. The highest risk cancers related to VTE are stomach and pancreas (15%). Significant risk is also associated with lung cancer, lymphoma, gynecological cancer, bladder, and testis cancer (6%).

2. Prostate and breast cancer have a significantly lower risk of VTE (0.8%-2%). Other risk factors include platelet count greater than 350,000, use of red cell growth factors, white blood cell count greater than 12,000, and BMI 35 kg/m² or higher. Inferior vena cava (IVC) filters should only be used when there is documented DVT but a contraindication to anticoagulation active bleed, melanoma, renal cell cancer or choriocarcinoma with untreated brain metastasis, platelets below 30,000 or severe platelet dysfunction. The IVC filter must be removed as soon as anticoagulation is begun. The new direct oral anticoagulants are in trials but thus far have not been approved for patients with cancer and VTE.
3. It has been shown that in patients who present with unprovoked VTE, routine evaluation will discover 3%-5% of patients who have an underlying malignancy. A more extended work-up will find additional cancers, but this has not been shown to decrease the risk of dying from the underlying cancer. Therefore, extensive evaluation is not indicated.

4. Chemotherapy (1.8-fold risk) and tamoxifen (5.5-fold risk) also predispose to VTE and these patients should be followed closely. In patients who develop clot in a vein with an indwelling venous catheter are initially managed with anticoagulation with the catheter in place. If there is pain, edema, or progression of the clot, the catheter must be removed.

Sources
- J Thromb Thrombolysis. 2016;41:81-91
- NCCN guidelines on cancer associated venous thromboembolic disease. 2014.

MENINGITIS, BACTERIAL

Population
- Children and adults.

Recommendation
- Cochrane Database of Systematic Reviews 2013
  - Recommends corticosteroids prior to or when antibiotics are administered for presumed bacterial meningitis in high-income countries.

Source

Comments
1. Corticosteroids significantly reduced the incidence of hearing loss and neurological sequelae in bacterial meningitis.
2. Corticosteroids reduced mortality in meningitis from Streptococcus pneumoniae, but not with Haemophilus influenzae or Neisseria meningitidis infections.
3. No beneficial effect of corticosteroids in low-income countries.
MENOPAUSE

Population
– Menopausal women.

Recommendations

AACE 2011
– Indications for menopausal hormone therapy:
  • Severe menopausal symptoms.
  • Severe vulvovaginal atrophy.
  • Consider transdermal or topical estrogens which may reduce the risk of VTE.
  • Treatment of osteoporosis.

– Cautions with menopausal hormone therapy:
  • Avoid unopposed estrogen use in women with an intact uterus.
  • Use hormonal therapy in the lowest effective dose for the shortest duration possible.
  • Custom-compounded bioidentical hormone therapy is not recommended.
  • Not appropriate for prevention or treatment of dementia.
  • Avoid if at high risk for VTE.
  • Not recommended for prevention or treatment of cardiovascular disease.

– Contraindications of menopausal hormone therapy:
  • History of breast CA.
  • Suspected estrogen-sensitive malignancy.
  • Undiagnosed vaginal bleeding.
  • Endometrial hyperplasia.
  • History of VTE.
  • Untreated hypertension.
  • Active liver disease.
  • Porphyria cutanea tarda.

Source

Comment
– Use of hormone therapy should always occur after a thorough discussion of the risks, benefits, and alternatives of this treatment with the patient.
Recommendations

NICE 2015

– Consider short-term hormone replacement therapy (HRT) for:
  • Severe vasomotor symptoms.
  • Menopause-related depression.
  • Poor libido.
  • Urogenital atrophy.
– Consider adjuvant testosterone therapy for decreased libido despite HRT.
– Offer vaginal estrogen cream for urogenital atrophy.

Source
– https://guidelines.gov/summaries/summary/49904

Comment

– Review risks of HRT before initiating:
  • Venous thromboembolism (VTE).
  • May slightly increase risk of breast CA.

Recommendations

Endocrine Society 2015

– Recommends HRT for severe vasomotor symptoms in women less than 60 y who do not have excess cardiovascular or breast cancer risk.
– Recommends nonhormonal remedies for women at high risk of cardiovascular disease or breast cancer.
  • Options include a SSRI, SNRI, gabapentin, or pregabalin.
– For women at increased risk of VTE, recommend transdermal estrogen and progesterone for severe vasomotor symptoms.
– Recommends vaginal estrogen cream for urogenital atrophy unless history of a hormone-dependent cancer.
– Consider ospemifene trial for moderate-to-severe dyspareunia.

Source

METABOLIC SYNDROME

<table>
<thead>
<tr>
<th>METABOLIC SYNDROME: IDENTIFICATION AND MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Identification</strong></td>
</tr>
<tr>
<td><strong>Risk Factor</strong></td>
</tr>
<tr>
<td>Abdominal obesity (waist circumference)¹</td>
</tr>
<tr>
<td>Men</td>
</tr>
<tr>
<td>&gt;102 cm (&gt;40 in.)</td>
</tr>
<tr>
<td>Women</td>
</tr>
<tr>
<td>&gt;88 cm (&gt;35 in.)</td>
</tr>
<tr>
<td><strong>Defining Level</strong></td>
</tr>
</tbody>
</table>
Clinical Identification

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Defining Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides</td>
<td>≥150 mg/dL</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>&lt;40 mg/dL</td>
</tr>
<tr>
<td>Women</td>
<td>&lt;50 mg/dL</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>≥135/≥85 mm Hg</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>≥100 mg/dL</td>
</tr>
</tbody>
</table>

Management

- First-line therapy: Lifestyle modification leading to weight reduction and increased physical activity.
- Goal: ↓ Body weight by approximately 7%–10% over 6–12 mo.
- At least 30 min of daily moderate-intensity physical activity.
- Low intake of saturated fats, trans fats, and cholesterol.
- Reduced consumption of simple sugars.
- Increased intake of fruits, vegetables, and whole grains.
- Avoid extremes in intake of either carbohydrates or fats.
- Smoking cessation.
- Drug therapy for HTN, elevated LDL cholesterol, and diabetes.
- Consider combination therapy with fibrates or nicotinic acid plus a statin.
- Low-dose ASA for patients at intermediate and high risk.
- Bariatric surgery for BMI >35 mg/kg².
- If one component is identified, a systematic search for the others is indicated, together with an active approach to managing all risk factors. (Eur Heart J. 2007;28:2375-2414)
- Metabolic syndrome is associated with the presence of subclinical ischemic brain lesions independent of other risk factors. (Stroke. 2008;39:1607-1609)
- In patients with atherosclerosis, the presence of metabolic syndrome is associated with an increased risk of cardiovascular event and all-cause mortality, independent of the presence of diabetes. (Eur Heart J. 2008;29:213-223)

ASA, aspirin; BMI, body mass index; HDL, high-density lipoprotein; HTN, hypertension; LDL, low-density lipoprotein.

a NCEP ATP III definition (Circulation. 2005;112:2735-2752)—requires any three of the listed components.

b Waist circumference can identify persons at greater cardiometabolic risk than are identified by BMI alone. However, further studies are needed to establish waist circumference cutpoints that assess risk not adequately captured by BMI (Am J Clin Nutr. 2007;85:1197-1202).

Note: The WHO and International Diabetes Federation (IDF, http://www.idf.org) define metabolic syndrome slightly differently. One study found a 5-fold difference in the prevalence of metabolic syndrome depending on which of seven diagnostic criteria were used. (Metabolism. 2008;57:355-361) There is no official definition of metabolic syndrome in children, but a constellation of conditions confers significant increased risk of coronary heart disease. (Circulation. 2007;115:1948-1967)

# Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections

## Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections (MRSA) in Adults and Children

<table>
<thead>
<tr>
<th>Infection</th>
<th>Primary Therapy</th>
<th>Alternative Therapy</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Abscess associated with extensive involvement; cellulitis; systemic illness; immuno-suppression; extremes of age; involvement of face, hands, or genitalia; septic phlebitis; trauma; infected ulcer or burn; or poor response to incision and drainage | 1. Incision and drainage  
2. Antibiotics  
   a. Outpatient  
      i. Clindamycin  
      ii. Trimethoprim-sulfamethoxazole (TMP-SMX)  
   b. Inpatient  
      i. Vancomycin  
      ii. Linezolid  
      iii. Daptomycin | 1. Outpatient antibiotics  
   a. Tetracycline  
   b. Linezolid  
2. Inpatient antibiotics  
   a. Telavancin  
   b. Clindamycin | 1. Tetracyclines should not be used in children age <8 y.  
2. Vancomycin is recommended for hospitalized children.  
3. Clindamycin and linezolid are alternative choices for children. |
| Recurrent skin and soft-tissue infections (SSTIs)                        | 1. Cover draining wounds.  
2. Maintain good hygiene.  
3. Avoid reusing or sharing personal toiletries.  
4. Use oral antibiotics only for active infections. | 1. Decolonization only if recurrent SSTI despite good hygiene  
   a. Mupirocin per nares bid × 5–10 d  
   b. Chlorhexidine or dilute bleach baths twice weekly (BIW) × 1–2 wk | Screening cultures prior to decolonization or surveillance cultures after decolonization is not recommended. |
| Uncomplicated MRSA bacteremia$^a$                                      | Vancomycin × 2 wk                                                              | Daptomycin × 2 wk             | Echocardiography is recommended for all MRSA bacteremia. |
# TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS (MRSA) IN ADULTS AND CHILDREN  (Continued)

<table>
<thead>
<tr>
<th>Infection</th>
<th>Primary Therapy</th>
<th>Alternative Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRSA native valve endocarditis</td>
<td>Vancomycin × 6 wk</td>
<td>Daptomycin × 6 wk</td>
<td>1. Synergistic gentamicin or rifampin is not indicated for native valve endocarditis. 2. Vancomycin is the drug of choice for children.</td>
</tr>
<tr>
<td></td>
<td>2. Gentamicin 1 mg/kg IV q8h × 2 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA pneumonia</td>
<td>1. Vancomycin</td>
<td>Clindamycin</td>
<td>1. Duration of therapy is 7–21 d. 2. Vancomycin for children.</td>
</tr>
<tr>
<td></td>
<td>2. Linezolid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA osteomyelitis</td>
<td>1. Surgical débridement</td>
<td>1. Linezolid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Vancomycin</td>
<td>2. TMP-SMX plus rifampin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Daptomycin</td>
<td>3. Clindamycin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Duration of therapy is at least 8 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA septic arthritis</td>
<td>1. Drain or débride the joint space</td>
<td>Daptomycin</td>
<td>Duration of therapy is 3–4 wk.</td>
</tr>
<tr>
<td></td>
<td>2. Vancomycin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA meningitis</td>
<td>1. Vancomycin × 2 wk</td>
<td>1. Linezolid</td>
<td>Consider adding rifampin.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. TMP-SMX</td>
<td></td>
</tr>
</tbody>
</table>

*No endocarditis, no implanted prostheses, defervescence within 72 h, sterile blood cultures within 72 h, and no evidence of metastatic sites of infection.

MULTIPLE SCLEROSIS (MS)

Population
- Adults.

Recommendations
- AAN 2014
  1. Consider oral cannabis extract or Sativex oromucosal cannabinoid spray to patients with MS with spasticity and pain (central neuropathic pain).
  2. May consider a trial of Gingko biloba or magnetic therapy for reducing fatigue.
  3. Recommend against a low-fat diet with ω-3 fatty acid or lofepramine use or bee venom therapy to reduce relapses, depression, or fatigue.
  4. Reflexology may benefit paresthesias.

Source

MUSCLE CRAMPS

Population
- Patients with idiopathic muscle cramps.

Recommendations
- AAN 2010
  - Data are insufficient on the efficacy of calf stretching in reducing the frequency of muscle cramps.
  - AAN recommends that although quinine is likely effective, it should not be used for routine treatment of cramps. Quinine derivatives should be reserved for disabling muscle cramps.
  - Quinine derivatives are effective in reducing the frequency of muscle cramps, although the magnitude of benefit is small and than the serious side effects.

Source
NEUROCYSTICERCOSIS

Population
– Adults and children with intraparenchymal neurocysticercosis.

Recommendations

AAN 2013
– For symptomatic intraparenchymal neurocysticercosis, use albendazole plus either dexamethasone or prednisolone to decrease the number of active lesions and reduce the long-term seizure frequency.
– No evidence to support steroids alone in patients with intraparenchymal neurocysticercosis.
– It is reasonable to treat these patients with anti-epileptic drugs until the active lesions have subsided (expert opinion).

Source

NEUTROPENIA, FEBRILE

Population
– Patients with single temperature >100.9°F (38.3°C) or ≥100.4°F (38.0°C) for >1 h in the setting of neutropenia (absolute neutrophil count including granulocytes and bands <500/mm³).

Recommendation

Infectious Disease Society of America 2011
– Evaluation and Therapy
  • Two sets of blood cultures/urine C+S/chemistries. CXR/ancillary studies based on clinical evaluation. Begin antibiotics as rapidly as possible within 60 min.
• Stratify into LOW RISK (absence of comorbidity, no cardiovascular compromise, expected duration of neutropenia <7 d, compliant) vs. HIGH RISK (absolute neutrophil count [ANC] <100 comorbidity, cardiovascular compromise, unreliable, expected duration of neutropenia >7 d).
• High-risk patients must be admitted to hospital with rapid initiation of single-agent antibiotic (cefepime, imipenem, ceftazidime) or combination therapy (extended spectrum beta-lactam plus either aminoglycoside or fluoroquinolone) depending on clinical features. Add antifungal agent if continued fever and negative cultures after 4–7 d.
• Selected low-risk patients can be treated as an outpatient with oral ciprofloxacin 500 mg bid and Augmentin 875 mg bid with <5% requiring hospitalization for worsening symptoms. Close communication with patient is essential.
• Continue broad-spectrum antibiotics in both low- and high-risk groups until ANC >500. Adjust antibiotics based on positive cultures and switch to oral to complete a 10–14 d course of antibiotics.

Sources
– Clin Infect Dis. 2011;52:e56-e93
– J Clin Oncol. 2013;31:794-810

Comment
– Clinical Concerns
• Prophylactic granulocyte colony-stimulating factor (GCSF) should be used in patients on chemotherapy with an expected rate of FN of ≥20%. Secondary use of GCSF after FN shortens hospital stay by 1 d but has no impact on survival.
• Vancomycin should not be given empirically unless history of MRSA, catheter tunnel infection, presence of pneumonia, or soft-tissue infection.

"Multinational Association for Supportive Care in Cancer (MASCC)
• Symptoms no or mild = 5, moderate = 3, severe = 0
• No hypotension – 5
• No COPD – 4
• No previous fungal infection – 4
• No dehydration requiring parenteral fluids – 3
• Outpatient status – 3
• Age <60 – 2
• High risk ≤ 21; Low risk ≥ 21"
• Three other unique organisms requiring antibiotic adjustment:
  ° Vancomycin-resistant enterococci (VRE)—use linezolid or daptomycin or ceftarolin.
  ° Extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria—use imipenem, meropenem, or ertapenem.
  ° Carbapenemase-producing organism (Klebsiella)—use polymyxin-colistin or tigecycline; meropenem can be added.
• If central venous catheter (CVC) line infection suspected, draw blood cultures from CVC and peripheral vein. If CVC culture grows out >120 min before peripheral blood cultures, then CVC is the source of infection.
• CVC must be removed if infected with Staphylococcus aureus, Pseudomonas, and other gram-negative bacteria, fungi, or mycobacteria, as well as tunnel or port pocket infection. If the organism is coagulation-negative Staphylococcus, retain CVC and treat with an antibiotic for 4 to 6 wk with 85% cure rate.
• In afebrile patients with ANC <100 give oral fluoroquinolone to lower risk of severe infection.
• With ANC <100 risk of serious infection is 10% per day.

NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOW-UP CARE

Population
  ~Non-small cell lung cancer patients treated with curative intent.

Recommendation
  ▶ American College of Chest Physicians (ACCP) 2013
  ~Follow-up Program
    • Chest CT scan should be performed every 6 mo for first 2 y after resection then once a year thereafter out to 10 y (second primary in 10% who survive 1st lung cancer).
    • Routine imaging with PET scanning is not recommended.
    • Patients should be seen every 3–4 mo for 2 y then less frequently. Health-related quality of life should be assessed with each visit.
    • Surveillance biomarker testing should not be done outside of clinical trials.
    • Smoking cessation interventions recommended. Annual influenza vaccine and every 5 y pneumococcal vaccinations encouraged.

Source
  ~JAMA. 2010;303:1070
Comment

– Lung Cancer Facts
  • Only 30%–35% of patients diagnosed with NSCLC are candidates for surgery with curative intent. Lung CA is responsible for 165,000 deaths/y.
  • Cure rates are reflective of stage:
    – Stage I—65%–70%
    – Stage II—40%
    – Stage IIIA—25%
    – Stage IIIB—18%
  • Platinum-based chemotherapy is standard of care for NSCLC resected for cure. This adjuvant therapy reduces recurrence risk by 5%–10%.
  • Symptoms of local recurrence include increase or change in cough, dyspnea, and chest pain.
  • Lung cancer is the most common malignancy to metastasize to brain—headache or neurologic symptoms should be an indication for brain MRI with gadolinium.
  • In older, compromised patients with a Stage I lung cancer, less than 3 cm in size, treatment with radiosteriotactic body radiation has a 70%–75% chance of prolonged disease-free survival.

NORMAL PRESSURE HYDROCEPHALUS (NPH)

Population

– Patients with normal pressure hydrocephalus.

Recommendations

– Shunting is a treatment option for NPH with gait abnormalities.
– A positive response to a therapeutic lumbar puncture increases the chance of success with shunting.
– Patients with an impaired cerebral blood flow reactivity to acetazolamide, measured by SPECT, are more likely to respond to shunting.

Source

### MANAGEMENT OF OBESITY IN MATURE ADOLESCENTS AND ADULTS

Measure height, weight, waist circumference and calculate BMI and follow measurements regularly.

- **BMI ≥25 or waist circumference ≥40 in (men) or ≥35 in (women)?**
  - Yes
  - No
  - Normal weight (BMI 18.5–24.9)
  - Assess for major and minor comorbid conditions?

Assess for major and minor comorbid conditions?

- Is patient ready to lose weight?
  - Yes
  - No
  - Assess patient’s goals and comorbid conditions and counsel regarding weight maintenance.

- Negotiate goals and management strategy to achieve weight loss.
- Screen for depression, eating disorder, and try stopping meds that can cause weight gain.

#### BMI

<table>
<thead>
<tr>
<th>BMI</th>
<th>25–29.9</th>
<th>30–34.9</th>
<th>35–39.9</th>
<th>≥40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk</strong></td>
<td>Low</td>
<td>Moderate</td>
<td>High</td>
<td>Very High</td>
</tr>
<tr>
<td>Nutrition*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical activity*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Behavioral modification*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medications*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Surgery¶</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

- *Consider medication therapy if ≥1 major or ≥3 minor comorbid conditions* are present.
- *Consider initiating medications if BMI ≥27.
- Surgery is investigational for BMI 30–34.9.

#### Recommendations

- Encourage a healthy, balanced diet including daily intake of ≥5 servings of fruits/vegetables; 35 g fiber; <30% calories from fat; eliminate takeout, fast foods, soda, and desserts; dietician consultation for a calorie reduction between 500 and 1000 kcal/kg/d to achieve a 1–2 lb weight reduction per week.
- Recommend 30–60 min of moderate activity at least 5 d a week.
- Identify behaviors that may contribute to weight gain (stress, emotional eating, boredom) and use cognitive behavioral counseling, stimulus control, relapse prevention, and goal setting to decrease caloric intake and increase physical activity.

---

*Minor comorbid conditions*: cigarette smoking; hypertension; LDL cholesterol >130 mg/dL; HDL cholesterol <40 mg/dL (men) or <50 mg/dL (women); glucose intolerance; family history of premature CAD; age ≥65 y (men) or ≥65 y (women).

**Major comorbid conditions**: waist circumference ≥40 in. (men) or ≥35 in. (women); CAD; peripheral vascular disease; abdominal aortic aneurysm; symptomatic carotid artery disease; type 2 diabetes; and obstructive sleep apnea.

*Sulfonylureas; thiazolidinediones; olanzapine, clozapine; risperidone, quetiapine; lithium; paroxetine, citalopram, sertraline; carbamazepine; pregabalin; corticosteroids; megestrol acetate; cyproheptadine; tricyclic antidepressants; monoamine oxidase inhibitors; mirtazapine; paroxetine; and gabapentin.

Encourage a healthy, balanced diet including daily intake of ≥5 servings of fruits/vegetables; 35 g fiber; <30% calories from fat; eliminate takeout, fast foods, soda, and desserts; dietician consultation for a calorie reduction between 500 and 1000 kcal/kg/d to achieve a 1–2 lb weight reduction per week.

Recommend 30–60 min of moderate activity at least 5 d a week.

Identify behaviors that may contribute to weight gain (stress, emotional eating, boredom) and use cognitive behavioral counseling, stimulus control, relapse prevention, and goal setting to decrease caloric intake and increase physical activity.
DISEASE MANAGEMENT

Medications that are FDA approved for weight loss: phentermine; orlistat; lorcaserin phenidimetazine; diethylpropion; and benzphetamine can be used for up to 3 mo as an adjunct for weight loss.

Bariatric surgery is indicated for patients at high risk for complications. They should be motivated, psychologically stable, have no surgical contraindications, and must accept the operative risk involved.


Population
– Adults with DM 2.

Recommendations
➤ NICE 2015
– Desire BP <140/90 mm Hg.
– Desire BP <130/80 mm Hg if patient has nephropathy, retinopathy, or history of CVA.
– Recommend against antiplatelet therapy for primary prophylaxis of cardiovascular disease.
– Monitor glycohemoglobin every 3–6 mo.
– First-line therapy is metformin.

Source

OSTEOARTHRITIS (OA)

Population
– Adults.

Recommendations
➤ ACR 2012
– Nonpharmacologic recommendations for the management of hand OA
  • Evaluate ability to perform activities of daily living (ADLs).
  • Instruct in joint-protection techniques.
  • Provide assistive devices to help perform ADLs.
  • Instruct in use of thermal modalities.
  • Provide splints for trapeziometacarpal joint OA.
– Nonpharmacologic recommendations for the management of knee or hip OA
  • Participate in aquatic exercise.
  • Lose weight.
  • Start aerobic exercise program.
• Instruct in use of thermal modalities.
• Consider for knee OA:
  ° Medially directed patellar taping.
  ° Wedged insoles for either medial or lateral compartment OA.
–Pharmacologic options for OA
  • Topical capsaicin.
  • Topical or PO NSAIDs.
  • Acetaminophen.
  • Tramadol.
  • Intraarticular steroids is an option for refractory knee or hip OA.

Source

Comment
1. The following should not be used for OA:
   • Chondroitin sulfate.
   • Glucosamine.
   • Opiates (if possible).

Population
–Adults with osteoarthritis.

Recommendations
▶ NICE 2014
–Recommends exercise as a core treatment to include muscle strengthening and general aerobic fitness.
–Recommends weight loss for people who are obese.
–Recommends against acupuncture, glucosamine, chondroitin, or intra-articular hyaluronan for OA.
–Recommends against arthroscopic lavage and debridement unless knee OA with mechanical locking.
–Recommends oral analgesics include acetaminophen and/or topical NSAIDs first line.
  • Oral NSAIDs or COX-2 inhibitors at the lowest effective dose for breakthrough pain.
  • Topical capsaicin can be used as an adjunct for knee or hand OA.
–Consider referral for joint surgery for people with OA and severe joint symptoms refractory to nonsurgical treatments.

Source
–https://guidelines.gov/summaries/summary/47862
Comment
For chronic NSAID use, consider concomitant therapy with a proton pump inhibitor to prevent NSAID-induced ulcers.

OSTEOPOROSIS

Population
– Adults at risk for osteoporosis or who have confirmed osteoporosis.

Recommendations
ICSI 2011
– Evaluate all patients with a low-impact fracture for osteoporosis.
– Advise smoking cessation and alcohol moderation (≤2 drinks/d).
– Advise 1500-mg elemental calcium daily for established osteoporosis, glucocorticoid therapy, or age >65 y.
– Assess for vitamin D deficiency with a 25-hydroxy vitamin D level.
  • Treat vitamin D deficiency if present.
– Treatment of osteoporosis.
  • Bisphosphonate therapy.
  • Consider estrogen therapy in menopausal women <50 y of age.
  • Consider parathyroid hormone in women with very high risk for fracture.
– Fall prevention program.
  • Home safety evaluation.
  • Avoid medications that can cause sedation and orthostatic hypotension, or affect balance.
  • Assistive walking devices as necessary.

Source

Comments
1. All patients should have serial heights and observed for kyphosis.
2. Obtain a lateral vertebral assessment with DXA scan or x-ray if height loss exceeds 4 cm.
3. DXA bone mineral densitometry should be repeated no more than every 12–24 mo.
Population

– Postmenopausal women.

Recommendations

NAMS 2010, AACE 2010, ACOG 2012

1. Recommend maintaining a healthy weight, eating a balanced diet, avoiding excessive alcohol intake, avoiding cigarette smoking, and utilizing measures to avoid falls.

2. Recommend supplemental calcium 1200 mg/d and vitamin D₃ 800–1000 international units (IU)/d.

3. Recommend an annual check of height and weight, and assess for chronic back pain.

4. DXA of the hip, femoral neck, and lumbar spine should be measured in women age ≥65 y or postmenopausal women with a risk factor for osteoporosis.

5. Recommend repeat DXA testing every 1–2 y for women taking therapy for osteoporosis and every 2–5 y for untreated postmenopausal women.

6. Recommend against measurement of biochemical markers of bone turnover.

7. Recommend drug therapy for osteoporosis for:
   a. Osteoporotic vertebral or hip fracture.
   b. DXA with T score ≤ –2.5.
   c. DXA with T score ≤ –1 to –2.4 and a 10-y risk of major osteoporotic fracture of ≥20% or hip fracture ≥3% based on FRAX calculator, available at http://www.shef.ac.uk/FRAX/

8. Consider the use of hip protectors in women at high risk of falling.

Sources


“Previous fracture after menopause, weight <127 lb, BMI <21 kg/m², parent with a history of hip fracture, current smoker, rheumatoid arthritis, or excessive alcohol intake.”
Comments

1. Options for osteoporosis drug therapy:
   a. Bisphosphonates
      i. First-line therapy.
      ii. Options include alendronate, ibandronate, risedronate, or zoledronic acid.
      iii. Potential risk for jaw osteonecrosis.
   b. Denosumab.
      i. Consider for women at high fracture risk.
   c. Raloxifene.
      i. Second-line agent in younger women with osteoporosis.
   d. Teriparatide is an option for high fracture risk when bisphosphonates have failed.
      i. Therapy should not exceed 24 mo.
   e. Calcitonin.
      i. Third-line therapy for osteoporosis.
      ii. May be used for bone pain from acute vertebral compression fractures.

2. Vitamin D therapy should maintain a 25-OH vitamin D level between 30 and 60 ng/mL.

OSTEOPOROSIS, GLUCOCORTICOID-INDUCED

Population

–Glucocorticoid-induced osteoporosis.

Recommendations

ACR 2010

1. All patients receiving glucocorticoid therapy should receive education and assess risk factors for osteoporosis.
2. FRAX calculator should be used to place patients at low risk, medium risk, or high risk for major osteoporotic fracture.
3. If glucocorticoid treatment is expected to last >3 mo, recommend:
   a. Weight-bearing activities.
   b. Smoking cessation.
   c. Avoid >2 alcoholic drinks/d.
   d. Calcium 1200–1500 mg/d.
   e. Vitamin D 800–1000 IU/d.
   f. Fall risk assessment.
   g. Baseline DXA test and then every 2 y.
   h. Annual 25-OH vitamin D.
   i. Baseline and annual height measurement.
j. Assessment of prevalent fragility fractures.
k. X-rays of spine.
l. Assessment of degree of osteoporosis medication compliance, if applicable.

4. For postmenopausal women or men age >50 y:
   a. Low-risk group.
      i. Bisphosphonate if equivalent of prednisone ≥7.5 mg/d.
   b. Medium-risk group.
      i. Bisphosphonate if equivalent of prednisolone ≥5 mg/d.
   c. High-risk group.
      i. Bisphosphonate for any dose of glucocorticoid.

5. For premenopausal women or men age <50 y with a prevalent fragility (osteoporotic) fracture and glucocorticoid use ≥3 mo:
   a. For prednisone ≥5 mg/d, use alendronate or risedronate.
   b. For prednisone ≥7.5 mg/d, use zoledronic acid.
   c. Consider teriparatide for bisphosphonate failures.

Source

Comments
1. Clinical factors that may increase the risk of osteoporotic fracture estimated by FRAX calculator:
   a. BMI <21 kg/m²
   b. Parental history of hip fracture.
   c. Current smoking.
   d. ≥3 alcoholic drinks/d.
   e. Higher glucocorticoid doses or cumulative dose.
   f. IV pulse glucocorticoid use
   g. Declining central bone mineral density measurement

2. Bisphosphonates recommended:
   a. Low- to medium-risk patients.
      i. Alendronate.
      ii. Risedronate.
      iii. Zoledronic acid.
   b. High-risk patients.
      i. Same + teriparatide.
OTITIS EXTERNA, ACUTE (AOE)

Population
Children age 2 y or older and adults.

Recommendations

- AAO-HNS 2014
  - Recommends against systemic antimicrobials as initial therapy for diffuse, uncomplicated acute otitis externa (AOE).
  - Recommends topical antibiotics for initial therapy of AOE.
  - In the presence of a perforated tympanic membrane or tympanostomy tubes, prescribe a non-ototoxic topical antibiotic.

Source
https://guidelines.gov/summaries/summary/47795

Comment
- Recommends reassessment of the diagnosis if the patient fails to respond within 72 h of topical antibiotics.

OTITIS MEDIA, ACUTE

Population
Children age 3 mo to 18 y.

Recommendations

- AAP 2013
  1. Diagnosis should be made with pneumatic otoscopy.
  2. Children at low risk\(^a\) should use a wait-and-see approach for 48–72 h with oral analgesics.
  3. Recommends symptomatic relief with acetaminophen or ibuprofen and warm compresses to the ear.
  4. Educate caregivers about prevention of otitis media: encourage breastfeeding, feed child upright if bottle fed, avoid passive smoke exposure, limit exposure to groups of children, careful handwashing prior to handling child, avoid pacifier use >10 mo, ensure immunizations are up to date.
  5. Amoxicillin is the first-line antibiotic for low-risk children.
  6. Alternative medication if failure to respond to initial treatment within 72 h; penicillin allergy; presence of a resistant organism found on culture.

\(^a\)Children older than age 2 y without severe disease (temperature >102°F [39°C] and moderate-to-severe otalgia), otherwise healthy, do not attend daycare, and have had no prior ear infections within the last month.
7. Recommends referral to an ear, nose, and throat (ENT) specialist for a complication of otitis media: mastoiditis, facial nerve palsy, lateral sinus thrombosis, meningitis, brain abscess, or labyrinthitis.

8. Recommends against routine recheck at 10–14 d in children feeling well.

9. Management of otitis media with effusion:
   a. Educate that effusion will resolve on its own.
   b. Recommends against antihistamines or decongestants.
   c. Recommends a trial of antibiotics for 10–14 d prior to referral for tympanostomy tubes.

Source

AAFP 2013
– Do not prescribe antibiotics to children age 2–12 y with non-severe AOM when observation is an option.

Source

Comments
1. Amoxicillin is first-line therapy for low-risk children:
   a. 40 mg/kg/d if no antibiotics used in last 3 mo.
   b. 80 mg/kg/d if child is not low risk.

2. Alternative antibiotics:
   a. Amoxicillin-clavulanate.
   b. Cefuroxime axetil.
   c. Ceftriaxone.
   d. Cefprozil.
   e. Loracarbef.
   f. Cefdinir.
   g. Cefixime.
   h. Cefpodoxime.
   i. Clarithromycin.
   j. Azithromycin.
   k. Erythromycin.

Population
– Children 6 mo to 12 y.

Recommendations
AAFP 2013
– Diagnosis of AOM
   • Moderate-severe bulging of the tympanic membrane.
   • New-onset otorrrhea not due to otitis externa.
DISEASE MANAGEMENT

• Mild bulging of an intensely red tympanic membrane and new otalgia <48 h duration.

Treatment of AOM
• Analgesics and antipyretics.
• Indications for antibiotics.
  ° Children <24 mo old with bilateral AOM.
  ° Symptoms that are not improving or worsening during a 48-h to 72-h observation period.
  ° AOM associated with severe symptoms (extreme fussiness or severe otalgia).
• Observation for 48–72 h is recommended in the absence of severe symptoms and fever <102.2°F.

– Consider tympanostomy tubes for recurrent AOM (3 episodes in 6 mo or 4 episode in 1 y).

Source

Comments
1. AOM is not present in the absence of a middle ear effusion based on pneumatic otoscopy or tympanometry.
2. Amoxicillin is the preferred antibiotics if the child has not received amoxicillin in the last 30 d.
3. Augmentin is the preferred antibiotic if the child has received amoxicillin in the last 30 d.

OVARIAN CANCER FOLLOW-UP CARE

Population
– Women treated for ovarian cancer with complete response (Stage I–IV).

Recommendation
▶ NCCN 2015

– Follow-up Plan
  • Office visits every 2–4 mo for 2 y, then 3–6 mo for 3 y, then annually after 5 y.
  • Physical exam including pelvic exam and measurement of CA-125 with each visit.
  • Refer for genetic risk evaluation if not previously done.
  • Chest/abdominal/pelvic CT, MRI, PET-CT, or PET as clinically indicated due to symptoms or rising CA-125.

Source
Comment

− Clinical Points

• All patients with ovarian cancer should be screened for BRCA 1 and 2 mutations. 10% of patients with Lynch syndrome will develop ovarian cancer.

• 23,000 new cases of ovarian cancer in the United States with 14,000 deaths. 5-y survival is related to stage:

  ° Stage I—86% alive at 5 y.
  ° Stage II—68%.
  ° Stage III—38%.
  ° Stage IV—19%.

• Relapsed ovarian cancer is rarely curable, but sequential treatments and intraperitoneal chemotherapy have extended survival to 50–60 mo.

PAIN, CHRONIC

Population

− Adults with chronic noncancer pain outside of palliative and end-of-life care.

Recommendations

− CDC 2016

− This guideline is focused on opioid use for chronic pain management.

When to initiate or continue opioids for chronic pain

1. Nonpharmacologic therapy and nonopioid medications are preferred for chronic pain.

2. Opioid therapy should be used for both pain and function only if the anticipated benefits outweigh the risks.

3. Treatment goals, including goals for pain and function, should be established before starting opioid therapy for chronic pain. This plan should also address how opioid therapy will be discontinued if benefits do not outweigh the risks.

4. Clinicians must discuss with patients the risks and benefits of opioid therapy before starting opioids and periodically during therapy.

Opioid selection, follow-up and discontinuation

1. When starting opioid therapy, use immediate-release opioids, and prescribe the lowest effective dose.

2. Carefully reassess benefits and risks when increasing daily dosage to >50 morphine milligram equivalents.

3. Avoid increasing daily dosage to >90 morphine milligram equivalents or carefully justify such large doses.
4. Reassess efficacy within 4 wk
5. of starting opioid therapy for chronic pain and consider discontinuing opioids if benefits do not outweigh risks.

Assessing risk of opioid use
1. Clinicians should evaluate risks of opioid-related harms.
2. Consider offering naloxone when patients have an increased risk of opioid overdose.
3. Frequent review of prescription drug monitoring program data.
4. Recommend periodic urine drug testing.
5. Avoid concurrent opioid and benzodiazepine therapy concurrently whenever possible.
6. Offer or arrange for medication-assisted treatment for patients with opioid use disorders (e.g., buprenorphine or methadone).

Source

ICSI 2016
1. Use validated tools to assess patient’s functional status, pain, and quality of life.
2. Assess for current or prior exposure to opioids and consider checking prescription drug monitoring program data before prescribing opioids.
3. Prescribe NSAIDS and acetaminophen for dental pain.
5. Screen all patients with chronic pain for substance use disorders.
6. Recommend a multidisciplinary approach to patients with chronic pain.
7. Recommend incorporating cognitive behavioral therapy or mindfulness-based stress reduction and exercise/physical therapy to pharmacologic therapy in chronic pain patients.
8. Minimize benzodiazepine or carisoprodol use for chronic pain. If used, limit duration of therapy to 1 wk.
9. Before initiating opioids for chronic pain, providers should seeks a diagnostic cause of the pain and document objective findings on physical exam.
10. Opioid risk assessment tools and knowledge of patient’s risk of opioid-related harm should guide decision about initiation or continuation of opioids.
11. Geriatric patients should be assessed for their fall risk, cognitive impairment, respiratory function and renal/hepatic impairment prior to initiation of opioids.
12. Patients who are initiating opioids or who have their opioid dose increased should be advised not to operate heavy machinery, drive a car, or participate in any activity that may be affected by the sedating effect of opioids.

13. Long-acting opioids should be reserved for patients with opioid tolerance and in whom prescriber is confident of medication adherence.

14. Avoid daily opioid doses of >100 morphine milligram equivalents.

15. Avoid opioid use for patients with substance use disorders.

16. Urine drug screening should be done at least annually.

17. If an opioid use disorder is suspected, refer patient to an addiction specialist.

Source


PAIN, CHRONIC, CANCER RELATED

Management of Chronic Pain in Survivors of Adult Cancers: ASCO Clinical Practice Guideline

Population

- Women treated for ovarian cancer with complete response (Stage I–IV).

Recommendations

A. SCREENING AND COMPREHENSIVE ASSESSMENT

- Screen for pain at each encounter, document using quantitative or semi-quantitative tool (strength of recommendation (SOR): strong).
- Conduct comprehensive pain assessment.
- Explore multidimensional nature of pain (pain descriptors, distress, impact on function and related physical, psychological, social, and spiritual factors)—explore information about cancer treatment history, comorbid conditions, and psychiatric history, including substance abuse as well as prior treatment for pain.
- The assessment should characterize the pain, and clarify probable cause. A physical exam and diagnostic testing (if appropriate) should be done (SOR: moderate).
- Clinicians should be aware of chronic pain syndromes resulting from cancer treatment, the prevalence of the syndrome, risk factors for an individual patient, and appropriate treatment options.
- Common cancer pain syndromes.
- Evaluate and monitor for recurrent disease, second cancer or late-onset treatment effects in patients with new-onset pain (SOR: moderate).
B. TREATMENT AND CARE OPTIONS
- Clinicians should aim to enhance, comfort, improve function, limit adverse events, and ensure safety in the management of pain in cancer survivors. (SOR: moderate).
- Clinicians should engage patient and family/caregivers in all aspects of pain assessment and management (SOR: moderate).
- Clinicians should decide if other health professionals can provide further care for patients with complex needs. If necessary a referral should be made (SOR: moderate).
- Clinicians should directly refer selected patients to other professionals with expertise in physical medicine and rehabilitation, integrative therapies, interventional therapies, psychological approaches, and neurostimulation therapies (SOR: moderate).

C. PHARMACOLOGICAL INTERVENTIONS

Miscellaneous analgesics
- Clinicians may prescribe nonopioid analgesics to relieve chronic pain or improve function in cancer survivors. This includes nonsteroidal anti-inflammatory drugs, acetaminophen, and adjuvant analgesics including antidepressants and selected anticonvulsants with evidence of analgesic efficacy (antidepressant duloxetine and anticonvulsants gabapentin and pregabalin) for neuropathic pain (SOR: moderate).
- Clinicians may prescribe topical analgesics (nonsteroidal anti-inflammatory drugs, local anesthetics or compounded creams/gels containing baclofen, amitriptyline and ketamine) (SOR: moderate).
- Long-term corticosteroids are not recommended solely to relieve chronic pain (SOR: moderate).
- Clinicians may follow specific state regulations that allow access to medical cannabis for patients with chronic pain after consideration of benefits and risk (SOR: moderate).

D. OPIOIDS
- Clinicians may prescribe a trial of opioids in carefully selected cancer survivors with chronic pain who do not respond to more conservative management and who continue to experience pain-related distress or functional impairment. Non-opioid analgesics and/or adjuvants can be added as clinically necessary (SOR: moderate).
- Clinicians should assess risks of adverse effects of opioids used for pain management.
E. RISK ASSESSMENT, MITIGATION, AND UNIVERSAL PRECAUTIONS WITH OPIOID USE

–Clinicians should assess the potential risks and benefits when initiating treatment that will incorporate long-term use of opioids (SOR: moderate).

–Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids for pain control (SOR: moderate).

–Clinicians should incorporate a universal precautions approach to minimize abuse, addiction, and adverse consequences of opioid use such as opioid-related deaths. Clinicians should be cautious in co-prescribing other centrally acting drugs especially benzodiazepines (SOR: moderate).

–Clinicians should educate patients and their family regarding risk and benefits of long-term opioid therapy and the safe storage use and disposal of controlled substances.

–If opioids are no longer warranted clinicians should taper the dose to avoid withdrawal symptoms (SOR: moderate).

F. ADVERSE EFFECTS ASSOCIATED WITH LONG-TERM OPIOID USE

1. Persistent common adverse effects.
   a. Constipation mental clouding, upper GI symptoms.

2. Endocrinopathy (hypogonadism, hyperprolactinemia).
   a. Fatigue, infertility, reduced libido.
   b. Osteoporosis/osteopenia, reduced or absence of menses.

   a. Myoclonus, changes in mental status.
   b. Risk of opioid induced hyperalgesia.
   c. New onset or worsening of sleep apnea syndrome.

Sources

–J Clin Oncol. 2016;34:3325-3345
–J Pain Symptom Manage. 2016;51:1070-1090
–JAMA. 2016;315:1624-1645
DISEASE MANAGEMENT

**PAIN, NEUOPATHIC**

**Population**
- Adults with neuropathic pain.

**Recommendations**
- NICE 2013
  - Offer a choice of amitriptyline, duloxetine, gabapentin, or pregabalin as initial treatment for neuropathic pain (except trigeminal neuralgia).
  - Consider tramadol only if acute rescue therapy.
  - Consider capsaicin cream for localized neuropathic pain.
  - Recommend against the following agents:
    - Cannabis sativa extract.
    - Capsaicin patch.
    - Lacosamide.
    - Lamotrigine.
    - Levetiracetam.
    - Morphine.
    - Oxcarbazepine.
    - Topiramate.
    - Tramadol (for long-term use).
    - Venlafaxine.
  - Recommend carbamazepine as initial therapy for trigeminal neuralgia.

**Source**

**PALLIATIVE CARE OF DYING ADULTS**

**Population**
- Dying adults.

**Recommendations**
- NICE 2015
  - Care of the dying patient should be aligned with the patient's goals and wishes and cultural values.
  - Symptom management should address physical, emotional, social, and spiritual needs.
  - Determine who should be the surrogate decision maker if they cannot make their own decisions.
  - Establish if the patient has a preferred care setting.
Medical management of symptoms:

- Pain is typically managed with opioids.
- Breathlessness can be managed with opioids or benzodiazepines +/- oxygen.
- Nausea can be managed with sublingual ondansetron or promethazine suppositories.
- Anxiety can be managed with benzodiazepines.
- Delirium or agitation can be managed with antipsychotics.
- Secretions can be managed with a scopolamine patch.

Source
- https://guidelines.gov/summaries/summary/49956

### PALLIATIVE AND END-OF-LIFE CARE: PAIN MANAGEMENT

#### Principles of Analgesic Use

<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>By the mouth</td>
<td>The oral route is the preferred route for analgesics, including morphine.</td>
</tr>
<tr>
<td>By the clock</td>
<td>Persistent pain requires round-the-clock treatment to prevent further pain. As-needed (PRN) dosing is irrational and inhumane; it requires patients to experience pain before becoming eligible for relief. Relief is accomplished with long-acting delayed-release preparations (fentanyl patch, slow-release morphine, or oxycodone).</td>
</tr>
<tr>
<td>By the WHO ladder</td>
<td>If a maximum dose of medication fails to adequately relieve pain, move up the ladder, not laterally to a different drug in the same efficiency group. Severe pain requires immediate use of an opioid recommended for controlling severe pain, without progressing sequentially through Steps 1 and 2. When using a long-acting opioid, the dose for breakthrough pain should be 10% of the 24-h opioid dose (i.e., if a patient is on 100 mg/d of an extended-release morphine preparation, their breakthrough dose is 10 mg of morphine or equivalent every 1–2 h until pain relief is achieved).</td>
</tr>
<tr>
<td>Individualize treatment</td>
<td>The right dose of an analgesic is the dose that relieves pain with acceptable side effects for a specific patient.</td>
</tr>
<tr>
<td>Monitor</td>
<td>Monitoring is required to ensure the benefits of treatment are maximized while adverse effects are minimized.</td>
</tr>
</tbody>
</table>
**DISEASE MANAGEMENT**

**Use adjuvant drugs**

For example, a nonsteroidal anti-inflammatory drug (NSAID) is often helpful in controlling bone pain. Nonopioid analgesics, such as NSAIDs or acetaminophen, can be used at any step of the ladder. Adjuvant medications also can be used at any step to enhance pain relief or counteract the adverse effects of medications. Neuropathic pain should be treated with gabapentin, duloxetine, nortriptyline, or pregabalin. Moderate- to high-dose dexamethasone is effective as an adjunct to opioids in a pain crisis situation.


---

**PANCREATITIS, ACUTE (AP)**

**Population**

– Individuals with acute pancreatitis.

**Recommendations**

► ACG 2013

– The diagnosis of acute pancreatitis usually includes the presence of 2 of the 3 following criteria: (i) abdominal pain consistent with the disease, (ii) serum amylase and/or lipase greater than 3 times the upper limit of normal, and/or (iii) characteristic findings from abdominal imaging.

  - Recommend a contrast-enhanced CT scan or MRI of the pancreas if the diagnosis is unclear or if symptoms are not improving within 72 h.
  - A gallbladder ultrasound should be performed in all patients with AP.
  - All patients without a history of alcohol abuse or gallstones should have a serum triglyceride level checked.
  - Consider ICU or intermediate-level monitoring for any organ dysfunction.

– Initial management

  - Aggressive isotonic fluids at 250–500 mL/h.
  - ERCP indicated for AP associated with choledocholithiasis.
  - In the absence of cholangitis or jaundice, recommend MRCP or endoscopic ultrasound to screen for choledocholithiasis.
  - Prophylactic antibiotics for severe necrotizing AP is not recommended.
  - In patients with infected necrosis, antibiotics known to penetrate pancreatic necrosis, such as carbapenems, quinolones, and...
metronidazole, may be useful in delaying or sometimes totally avoiding intervention, thus decreasing morbidity and mortality.

- In mild AP, oral feedings with clear liquids or low-fat diet can be started immediately if there is no nausea and vomiting, and the abdominal pain has resolved.
- In severe AP, enteral nutrition is recommended to prevent infectious complications. Parenteral nutrition should be avoided, unless the enteral route is not available, not tolerated, or not meeting caloric requirements.
- Nasogastric delivery and nasojejunal delivery of enteral feeding appear comparable in efficacy and safety.
- In patients with mild AP, found to have gallstones in the gallbladder, a cholecystectomy should be performed before discharge to prevent a recurrence of AP.

  - In a patient with necrotizing biliary AP, in order to prevent infection, cholecystectomy is to be deferred until active inflammation subsides and fluid collections resolve or stabilize.
  - In stable patients with infected necrosis, surgical, radiologic, and/or endoscopic drainage should be delayed preferably for more than 4 wk to allow liquefaction of the contents and the development of a fibrous wall around the necrosis (walled-off necrosis).

Source
DISEASE MANAGEMENT

PAP SMEAR, ABNORMAL

ABNORMAL PAP SMEAR ALGORITHM

- **Benign endometrial cells**
  - Postmenopausal, irregular bleeding, or risk factors for endometrial CA?
    - Yes: Endometrial biopsy
    - No: Resume regular screening

- **Atypical glandular cells (AGC)**
  - HPV high-risk DNA - positive?
    - Yes: Colposcopy
    - No: Repeat co-testing at 1 y

- **Atypical squamous cells of undetermined significance (ASCUS)**
  - HPV DNA testing can not be performed
    - Repeat cytology at 1 y
  - HPV DNA positive?
    - Yes: Colposcopy
    - No: Repeat co-testing at 1 y

- **Atypical squamous cells, cannot exclude high-grade intraepithelial lesion (ASCUS-H)**
  - Colposcopy

- **Low-grade squamous intraepithelial lesion (LSIL)**
  - High-risk HPV positive?
    - Yes: Colposcopy
    - No: Repeat co-testing at 1 y

- **High-grade squamous intraepithelial lesion (HSIL)**
  - Colposcopy with endocervical curettage
  - Any malignant cells
    - Refer to Ob/Gyn
  - HPV high-risk DNA positive with normal cytology and woman ≥30 y old
    - High-risk HPV - positive?
      - Yes: Colposcopy
      - No: Repeat co-testing at 1.2 mo

- **ASCUS or LSL**
  - High-risk HPV - positive?
    - Yes: Colposcopy
    - No: Repeat co-testing in 1 y
  - HSL, AGC, or malignant cells
    - Treat as in ≥25 y algorithm as above

- **Postmenopausal, irregular bleeding, or risk factors for endometrial CA?**
  - Yes: Endometrial biopsy
  - No: Resume regular screening

- **Colposcopy for abnormal cytology or HPV test positive**
  - Routine screening every 3 y if both negative

**Note:** Pregnant patients should never have endocervical sampling and treatment during pregnancy is indicated only if invasive cancer is suspected.

PREOPERATIVE CARDIAC CLEARANCE FOR NONCARDIAC SURGERY

Patient scheduled for surgery with known or risk factors for CAD
(Step 1)

Emergency

Yes

Clinical risk stratification and proceed to surgery

No

ACCF (Step 2)

Yes

Evaluate and treat according to GDMT

No

Estimated perioperative risk of MACE based on combined clinical/surgical risk
(Step 3)

Low risk (<1%)
(Step 4)

No further testing
(Class III NB)

No or unknown

Proceed to surgery

Elevated risk
(Step 5)

Moderate or greater (>4 METs) functional capacity

No or unknown

Pharmacologic stress testing
(Class IIa)

Poor or unknown functional capacity (<4 METs): Will further testing impact decision making or perioperative care? (Step 6)

Yes

Coronary revascularization according to existing CPGs (Class I)

No

Proceed to surgery according to GDMT OR alternate strategies (noninvasive treatment, palliation) (Step 7)

Yes

Pharmacologic stress testing
(Class IIa)

No further testing
(Class IIb)

No further testing
(Class IIIa)

Proceed to surgery

ACS
(Step 2)

Yes

Delay elective surgery for decompensated HF, symptomatic aortic stenosis or mitral stenosis, or uncontrolled arrhythmias

No

No or unknown

No further testing according to GDMT
OR alternate strategies

No or unknown

No further testing according to GDMT
OR alternate strategies
Risk of surgical procedures:
- **Low risk**: when the combined surgical and patient characteristic predicts a risk of a major adverse cardiac event (MACE) of death or MI of <1% (eg, cataract and plastic surgery).
- **Elevated risk**: when risk of MACE ≥1%.

Calculation of risk to predict perioperative cardiac morbidity
- **RCRI** (Revised Cardiac Risk Index for perioperative risk) calculator (Lee index) assesses perioperative risk of major cardiac complications (MI, pulmonary edema, ventricular fibrillation or primary cardiac arrest, and complete heart block).
  - It can be found at [http://www.mdcalc.com/revised-cardiac-risk-index-for-preoperative-risk/](http://www.mdcalc.com/revised-cardiac-risk-index-for-preoperative-risk/)
- **For patients with a low risk of perioperative MACE, further testing is not recommended before the planned operation.**
- **The NSQIP MICA model** (American College of Surgeons National Surgical Quality Improvement Program), also known as myocardial infarction or cardiac arrest "GUPTA" risk calculator: [http://www.surgicalriskcalculator.com/miocardiacerast](http://www.surgicalriskcalculator.com/miocardiacerast)
- **ACS NSQIP Surgical Risk Calculator** (American College of Surgeons) to calculate vascular surgery risk: [http://riskcalculator.facs.org/PatientInfo/PatientInfo](http://riskcalculator.facs.org/PatientInfo/PatientInfo)

### Perioperative β-blocker therapy ACC/AHA
- β-blockers should be continued in patients undergoing surgery who have been on β-blockers chronically.
- It is reasonable for the management of β-blockers after surgery to be guided by clinical circumstances (eg, hypotension, bradycardia, bleeding), independent of when the agent was started.
- In patients with intermediate- or high-risk myocardial ischemia noted in preoperative risk stratification tests, it may be reasonable to begin perioperative β-blockers. Per ESC, for patients testing positive for preoperative stress, long-term β-blocker therapy should be used.

### Perioperative β-blocker therapy ESC
- Perioperative continuation of β-blockers is recommended in patients currently receiving this medication.
- Preoperative initiation of β-blockers may be considered in patients scheduled for high-risk surgery and who have 2 clinical risk factors or ASA (American Society of Anesthesiologists) class III (patient has severe systemic disease that is not incapacitating).
- Preoperative initiation of β-blockers may be considered in patients who have known IHD or myocardial ischemia.
- When oral β-blockade is initiated in patients who undergo noncardiac surgery, the use of atenolol or bisoprolol as a first choice may be considered.
PERIOPERATIVE CARDIOVASCULAR EVALUATION AND MANAGEMENT OF PATIENTS UNDERGOING NONCARDIAC ACC/AHA/ESC 2014 GUIDELINES  \textit{(Continued)}

<table>
<thead>
<tr>
<th><strong>Perioperative statin therapy</strong></th>
<th><strong>Perioperative statin therapy ESC</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACC/AHA</strong></td>
<td><strong>ESC</strong></td>
</tr>
<tr>
<td>Statins should be continued in patients currently taking statins and scheduled for noncardiac surgery.</td>
<td>Perioperative continuation of statins is recommended, favoring statins with a long half-life or extended-release formulation (atorvastatin, lovastatin).</td>
</tr>
<tr>
<td>Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery.</td>
<td>Preoperative initiation of statin therapy should be considered in patients undergoing vascular surgery, ideally at least 2 wk before surgery.</td>
</tr>
<tr>
<td>Perioperative initiation of statins may be considered in patients with clinical indications according to GDMT who are undergoing elevated-risk procedures.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Perioperative antiplatelet therapy</strong></th>
<th><strong>Perioperative antiplatelet therapy ESC</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACC/AHA</strong></td>
<td><strong>ESC</strong></td>
</tr>
<tr>
<td>In patients undergoing urgent noncardiac surgery during the first 4 to 6 wk after BMS or DES implantation, dual antiplatelet therapy (DAPT) should be continued unless the relative risk of bleeding outweighs the benefit of the prevention of stent thrombosis.</td>
<td>It is recommended that aspirin be continued for 4 wk after BMS implantation and for 3–12 mo after DES implantation, unless the risk of life-threatening surgical bleeding on aspirin is unacceptably high.</td>
</tr>
</tbody>
</table>

- In patients with 3 or more RCRI risk factors (eg, diabetes mellitus, HF, CAD, renal insufficiency, cerebrovascular accident), it may be reasonable to begin β-blockers before surgery.
- In patients with a compelling long-term indication for β-blocker therapy but no other RCRI risk factors, initiating β-blockers in the perioperative setting as an approach to reduce perioperative risk is of uncertain benefit.
- In patients in whom β-blocker therapy is initiated, it may be reasonable to begin perioperative β-blockers long enough in advance to assess safety and tolerability, preferably more than 1 d before surgery.
- **β-blocker therapy should not be started on the day of surgery!!!**
- Abrupt withdrawal of long-term β-blockers is harmful.

- β-blocker therapy should be initiated ideally >1 d (when possible at least 1 wk and up to 30 d) before surgery, starting with a low dose (atenolol or bisoprolol as first choice).
- Initiation of perioperative high-dose β-blockers without titration is not recommended.
- Preoperative initiation of β-blockers is not recommended in patients scheduled for low-risk surgery.
In patients who have received coronary stents and must undergo surgical procedures that mandate the discontinuation of P2Y\textsubscript{12} platelet receptor–inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y\textsubscript{12} platelet receptor–inhibitor be restarted as soon as possible after surgery.

Management of the perioperative antiplatelet therapy should be determined by a consensus of the surgeon, anesthesiologist, cardiologist, and patient, who should weigh the relative risk of bleeding versus prevention of stent thrombosis.

In patients undergoing nonemergency/nonurgent noncardiac surgery who have not had previous coronary stenting, it may be reasonable to continue aspirin when the risk of potential increased cardiac events outweighs the risk of increased bleeding.

Initiation or continuation of aspirin is not beneficial in patients undergoing elective noncardiac noncarotid surgery who have not had previous coronary stenting unless the risk of ischemic events outweighs the risk of surgical bleeding.

**Perioperative anticoagulation therapy ACC/AHA**

The role of anticoagulants (warfarin, NOAC agents) other than platelet inhibitors in the secondary prevention of myocardial ischemia or MI has not been elucidated.

The risk of bleeding for any surgical procedure must be weighed against the benefit of remaining on anticoagulants on a case-by-case basis.

**Perioperative anticoagulation therapy ESC**

Patients at high risk of thromboembolism treated with vitamin K antagonists (VKAs) such as AF with CHA\textsubscript{2}DS\textsubscript{2}-VASc score ≥4, or mechanical prosthetic heart valves, newly inserted biological prosthetic valves, mitral valvular repair (within the last 3 mo) or recent venous thromboembolism (within 3 mo), or thrombophilia.

Continuation of aspirin, in patients previously thus treated, may be considered in the perioperative period, and should be based on an individual decision that depends on the perioperative bleeding risk, weighed against the risk of thrombotic complications.

Discontinuation of aspirin therapy, in patients previously treated with it, should be considered in those in whom hemostasis is anticipated to be difficult to control during surgery.

Continuation of P2Y\textsubscript{12} inhibitor treatment should be considered for 4 wk after BMS implantation and for 3–12 mo after DES implantation, unless the risk of life-threatening surgical bleeding on this agent is unacceptably high.

In patients treated with P2Y\textsubscript{12} inhibitors, who need to undergo surgery, postponing surgery for at least 5 d after cessation of ticagrelor and clopidogrel—and for 7 d in the case of prasugrel—if clinically feasible, should be considered unless the patient is at high risk of an ischemic event.
### Timing of elective noncardiac surgery in patients with previous PCI ACC/AHA

- Elective noncardiac surgery should be delayed 14 d after balloon angioplasty and at least 30 d (ideally 3 mo) after BMS implantation.
- Elective noncardiac surgery should optimally be delayed 365 d after drug-eluting stent (DES) implantation.
- In patients in whom noncardiac surgery is required, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.

### Timing of elective noncardiac surgery in patients with previous PCI ESC

- It is recommended that, except for high-risk patients, asymptomatic patients who have undergone CABG in the past 6 y be sent for nonurgent, noncardiac surgery without angiographic evaluation.
- Consideration should be given to performing nonurgent, noncardiac surgery in patients with recent BMS implantation after a minimum of 4 wk and ideally 3 mo following the intervention.

---

**WILL NEED BRIDGING** with unfractionated heparin (UFH) or therapeutic-dose LMWH. There is better evidence for the efficacy and safety of LMWH in comparison with UFH in bridging to surgery.

- In minor procedures (cataract, minor dermatologic procedures) it may be reasonable to continue anticoagulation preoperatively.
- NOAC agents do not appear to be acutely reversible, no reversible agent available at this time.
- Patients with prosthetic valves taking vitamin K antagonists may require bridging therapy.
- For patients with AF and normal renal function undergoing elective procedures during which hemostatic control is essential, such as major surgery, spine surgery, and epidural catheterization, discontinuation of anticoagulants for ≥48 h is suggested. Monitoring activated partial thromboplastin time for dabigatran and prothrombin time for apixaban and rivaroxaban may be helpful; a level consistent with control levels suggests a low serum concentration of the anticoagulant.

- The overall recommendation is to stop NOACs for 2–3 times their respective biological half-lives prior to surgery in surgical interventions with “normal” bleeding risk, and 4–5 times the biological half-lives before surgery in surgical interventions with high bleeding risk.
- Because of the fast “on” effect of NOACs (in comparison with VKAs), resumption of treatment after surgery should be delayed for 1–2 (in some cases 3–5) d, until postsurgical bleeding tendency is diminished.

---
### DISEASE MANAGEMENT

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elective noncardiac surgery after DES implantation may be considered after 180 d if the risk of further delay is greater than the expected risks of ischemia and stent.</td>
<td>Consideration should be given to performing nonurgent, noncardiac surgery in patients who have had recent DES implantation no sooner than 12 mo following the intervention. This delay may be reduced to 6 mo for the new generation DES.</td>
</tr>
<tr>
<td>Elective noncardiac surgery should not be performed within 30 d after BMS implantation or within 12 mo after DES implantation in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively.</td>
<td>In patients who have had recent balloon angioplasty, surgeons should consider postponing noncardiac surgery until at least 2 wk after the intervention.</td>
</tr>
<tr>
<td>Elective noncardiac surgery should not be performed within 14 d of balloon angioplasty in patients in whom aspirin will need to be discontinued perioperatively.</td>
<td></td>
</tr>
</tbody>
</table>


### PARACENTESIS

**Population**
- Adults with ascites

**Recommendation**
- AASLD 2014
  - Do not routinely administer fresh frozen plasma prior to a paracentesis.

**Source**

### PERIPHERAL ARTERIAL DISEASE

**Population**
- Adults with lower extremity peripheral arterial disease (PAD).

**Recommendations**
- ACC/AHA 2016, NICE 2012
  - In patients with history or physical examination findings suggestive of PAD, the resting ankle-brachial index (ABI), with or without segmental pressures and waveforms, is recommended to establish the diagnosis.
– Resting ABI results should be reported as abnormal (ABI ≤0.90), borderline (ABI 0.91–0.99), normal (1.00–1.40), or noncompressible (ABI >1.40).
– Toe-brachial index (TBI) should be measured to diagnose patients with suspected PAD when the ABI >1.40 (noncompressible).
– Duplex ultrasound, CTA, or MRA of the lower extremities is useful to diagnose anatomic location and severity of stenosis for patients with symptomatic PAD in whom revascularization is considered.
– Antiplatelet therapy with aspirin alone (range 75–325 mg/d) or clopidogrel alone (75 mg/d), smoking cessation, a statin, and good glycemic control are recommended to reduce MI, stroke, and vascular death in patients with symptomatic PAD.
– Cilostazol is an effective therapy to improve symptoms and increase walking distance in patients with claudication.
– Patients with PAD should have an annual influenza vaccination.
– In patients with claudication, a supervised exercise program is recommended to improve functional status and QoL and to reduce leg symptoms.
– Patients with PAD and diabetes mellitus should be counseled about self–foot examination and healthy foot behaviors.
– Endovascular procedures are effective as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease.
– Endovascular procedures are recommended to establish in-line blood flow to the foot in patients with nonhealing wounds or gangrene.
– When surgical revascularization is performed, bypass to the popliteal artery with autogenous vein is recommended in preference to prosthetic graft material.
– In patients with critical limb ischemia, revascularization should be performed when possible and bypass to the popliteal or infrapopliteal arteries (ie, tibial, pedal) should be constructed with suitable autogenous vein.
– In patients with acute limb ischemia (ALI), systemic anticoagulation with heparin should be administered immediately unless contraindicated.
– Patients with ALI should be monitored and treated (e.g., fasciotomy) for compartment syndrome after revascularization.
– Amputation should be performed as the first procedure in patients with a nonsalvageable limb.

**Source**

**Source**
Comments

1. Recommend bare metal stents when stenting people with intermittent claudication.
2. An autologous vein bypass is preferred when possible for infrainguinal bypass surgery.
3. Bypass surgery is recommended over stenting for aortoiliac or femoropopliteal stenosis causing intermittent claudication or critical limb ischemia.
4. Stenting is an option for complete aortoiliac occlusion.

PHARYNGITIS, ACUTE

APPROACH TO ACUTE PHARYNGITIS

Symptoms of possible streptococcal pharyngitis: close exposure to strep throat; sudden onset of sore throat; exudative tonsillitis; tender anterior cervical adenopathy; fever; absence of rhinorrhea, cough, hoarseness, oral ulcers; headache and abdominal pain may be present with other symptoms in pt >3 ya

Obtain a rapid strep test and backup strep culture

Negative and low likelihood of bacterial pharyngitisb

Negative and high likelihood of bacterial pharyngitis

Educate and offer home remedies

Send throat strep culture

Positive

Symptoms improved at 48–72 h?

No

Yes

Start penicillin or amoxicillin if rapid strep test is positive (clindamycin or azithromycin if PCN-allergic)

Symptoms improved at 1 wk?

Yes

No

Reevaluate and consider testing for mononucleosis

Complete 10 d antibiotic course

Reevaluate for complications:
- Lemierre’s syndrome
- Peritonsillar or retropharyngeal abscess
- Intracranial extension of infection
- Mono testing (if appropriate)

Reevaluate testing for mononucleosis

Continue symptomatic therapy

Negative

Symptoms improved at 1 wk?

No

Yes

Symptoms resolved at 48–72 h?

No

Yes

Diagnostic studies for GAS is not indicated for children <3 y because acute rheumatic fever is very rare in this age group.

Low likelihood of GAS if rhinorrhea, cough, hoarseness, or oral ulcers.

Source: IDSA 2012 guidelines on group A Streptococcus (GAS) pharyngitis.
Choosing Wisely 2013, Society of Thoracic Surgeons 2013
- Recommends against preoperative stress testing prior to noncardiac thoracic surgery in patients who have no cardiac history and good functional status.
- Recommends against routine evaluation of carotid artery disease prior to cardiac surgery in the absence of symptoms or other high-risk criteria.

Source

Choosing Wisely 2013, American College of Physicians 2013
- Recommends against preoperative chest radiography in the absence of a clinical suspicion for intrathoracic pathology.

Source
- http://www.choosingwisely.org/societies/american-college-of-physicians/

### Delay Times for Non-Emergent Surgery

<table>
<thead>
<tr>
<th>Event</th>
<th>Wait Times</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTCA</td>
<td>14 d</td>
</tr>
<tr>
<td>Bare metal stent</td>
<td>30 d</td>
</tr>
<tr>
<td>Drug-eluting stent</td>
<td>At least 6 mo</td>
</tr>
<tr>
<td>CABG</td>
<td>6–8 wk</td>
</tr>
<tr>
<td>After ischemic stroke</td>
<td>3–6 mo</td>
</tr>
<tr>
<td>After acute MI</td>
<td>2–3 mo</td>
</tr>
</tbody>
</table>

Sources
- JAMA. 2014;312:269-277

### When to Bridge Anticoagulation for None Emergent Operation
- AF with MS
- AF with prosthetic valve
- AF with ischemic stroke <3 mo
- NVAF and CHA2DS2-VASC score ≥6
- Mechanical MV
- Caged or tilted mechanical AV
- VT <3 mo or severe thrombophilia
Choosing Wisely 2013, American Society of Echocardiography 2013

- Recommends avoiding echocardiograms for preoperative/perioperative assessment of patients with no history of symptoms of heart disease.

Sources
- JACC. 2017;69:871
- NEJM. 2015;373:823
- JAMA Intern Med. 2015;175:1163

PLATELET TRANSFUSION

Population
- Adults and children.

Recommendation

American Association of Blood Banks (AABB) 2014

- Practical Considerations
  - Transfusion with a single apheresis unit or a pool of 4 to 6 whole-blood-derived platelet concentrates is indicated for patients with therapy-induced platelet counts of <10,000 (<20,000 if infection).
  - Prophylactic platelet transfusions are indicated for patients having elective central venous catheter (CVC) placement with platelet count <20,000 and for those having elective diagnostic lumbar puncture or major nonneurological surgery with <50,000 platelets.
  - Platelet transfusions are not recommended for nonthrombocytopenic patients having cardiopulmonary bypass surgery unless they have perioperative bleeding with thrombocytopenia or evidence of platelet dysfunction.

Sources
- Ann Intern Med. 2015;162:205-213
- Blood. 2014;123:1146-1151

Comment

- Clinical Correlation
  - These guidelines do not pertain to ITP, TTP, or heparin-induced thrombocytopenia. Platelet transfusion may worsen these immune-mediated diseases and should not be given unless there is major life-threatening bleeding. (Blood. 2015; 125:1470)
  - No strong evidence was found for platelet transfusion with intracranial bleed in patients taking antiplatelet drugs or in patients
undergoing neurosurgery with platelets <100,000 although platelets >100,000 is current clinical practice.

- Guidelines emphasize that clinical judgment and not a specific platelet count should be paramount in decision making.
- Beware that the risk of bacterial infection with platelet transfusion is 1 in 3000 (5 times more common than RBC transfusions).  
  (Transfusion. 2013; 55:1603)

**PLEURAL EFFUSION, MALIGNANT**

**Symptomatic Patients**

1. Patients with symptoms should have initial therapeutic thoracentesis to relieve symptoms. The recommended amount of fluid removed per session is 1000-1500 mL. The rate of reaccumulation of the pleural effusion, and the patient's clinical and symptomatic response and prognosis will help to guide the subsequent choice of therapy.
2. Outpatient therapeutic thoracentesis alone may be indicated for patients with survival expected to be less than 1 mo and/or poor performance status (PS) and/or slow reaccumulation of the pleural effusion (ie, more than 1 mo).
3. Patients should be considered for more definitive intervention after the first or second thoracentesis.
4. Treatment options:
   (A) Indwelling (tunneled) pleural catheter (considered for patients with trapped lung who obtain some relief following thoracentesis) or patients who want to avoid hospitalization or discomfort of pleurodesis.  
   (B) Talc pleurodesis (Talc poudrage) via thoracoscopy consider for patients with longer projected survival and those who don't want an indwelling catheter. This approach is contraindicated for patients with trapped lung.
   (C) Talc pleurodesis (slurry) via chest tube - Indicated for patients with longer anticipated survival or contraindication to thoracoscopy. Contraindicated for patients with trapped lung.
   (D) Chemotherapy may be considered as an adjunct treatment option. In particular, patients undergoing first line systemic therapy for tumors with high response rates (small cell lung cancer and lymphoma), may avoid the previously discussed definitive treatments.

**Population**

- Adult men and women with lung cancer or metastatic malignancy to the lung with a malignant pleural effusion.
Recommendations


- All treatment decisions should be guided by patient preferences.
- Selection of a treatment approach is largely dependent on projected duration of survival and availability of adequate resources.
- The management of a malignant pleural effusion (MPE) should be individualized and these patients should be commonly presented to a multidisciplinary Tumor Board for advice. (JAMA. 2012;307:2432).
- Management of MPE is palliative and treatment decisions should focus on type of malignancy, patient's symptoms, life expectancy, functional status, quality of life, and goals of therapy. Palliative therapy goals should improve patient's quality of life through (1) relief of dyspnea and (2) less need for reintervention and reduced hospitalizations and length of stay.

Diagnostic and Baseline Investigations

1. A chest x-ray (CXR) should be used to detect the presence of a pleural effusion. A lateral decubitus CXR may be used to differentiate pleural liquid from pleural thickening.
2. CT scans can detect very small effusions (less than 10 mL of fluid). A thoracic ultrasound can also document the presence of pleural effusions.
3. Undiagnosed effusions of more than 1 cm from the chest wall on lateral decubitus CXR should be diagnostically evaluated by ultrasound-assisted thoracentesis. In patients with advanced cancer thoracentesis for small effusions is unnecessary.
4. All effusions should be sent for cytology if a patient does not have a diagnosis of a MPE. A minimum of 50-60 mL of pleural fluid should be withdrawn for analysis. Other studies including cell count and differential, gram stain and culture, pH, glucose, protein, and lactate dehydrogenase (LDH) will help separate transudate from exudate. Increased amounts of fluid (100 to 200 cc) can be sent for a cell block and molecular testing (eg, epidermal growth factor receptor mutation, Alk gene rearrangement and ROS 1 rearrangement).
5. All patients with a diagnosis of significant MPE should be referred to pulmonologist and/or thoracic surgery for treatment options.
6. Chest ultrasound is recommended at point of care for any thoracentesis or percutaneous chest drain placement (including indwelling pleural catheter (IPC)).
7. Treatment is not required in asymptomatic patients but follow-up should be frequent especially if large MPE present.
Comment

- Indwelling pleural catheter (IPC-pleurex catheter) requires a regular outpatient drainage schedule that may be a burden for the patient or caregiver. This issue needs to be addressed. Complications from IPCs are uncommon. The infection rate is 5% with more than half the patients responding to antibiotics without removing the catheter. (Chest. 2013; 144:1597). Other problems with IPCs include pneumothorax (5.9%), cellulitis (3.4%), obstruction/clogging (3.7%), and unspecified catheter malfunction (9.1%). The most common adverse events with talc pleurodesis include fever, pain, and GI symptoms. Less common are cardiac arrhythmia, dyspnea, systemic inflammatory response, empyema, and talc dissemination.

Sources

  65(Suppl 2):132

POLYCYSTIC OVARY SYNDROME

Population

- Adolescent and adult women.

Recommendations

Endocrine Society 2013

1. Diagnosis if 2 of 3 criteria are met:
   a. Androgen excess.
   b. Ovulatory dysfunction.
   c. Polycystic ovaries.
2. Treatment
   a. Hormonal contraceptives for menstrual irregularities, acne, and hirsutism.
   b. Exercise and diet for weight management.
   c. Clomiphene citrate recommended for infertility.
   d. Recommends against the use of metformin, inositols, or thiazolidinediones.

Source

AAP AND AFP PERINATAL AND POSTNATAL GUIDELINES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast-feeding</td>
<td>Strongly recommends education and counseling to promote breast-feeding.</td>
</tr>
<tr>
<td>Hemoglobinopathies</td>
<td>Strongly recommends ordering screening tests for hemoglobinopathies in neonates.</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>Perform ongoing systematic assessments during the neonatal period for the risk of an infant developing severe hyperbilirubinemia.</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>Strongly recommends ordering screening tests for phenylketonuria in neonates.</td>
</tr>
<tr>
<td>Thyroid function</td>
<td>Strongly recommends ordering screening tests for thyroid function abnormalities in neonates.</td>
</tr>
</tbody>
</table>


PNEUMONIA

PNEUMONIA, COMMUNITY-ACQUIRED: EVALUATION

<table>
<thead>
<tr>
<th>Diagnostic Testing</th>
<th>Admission Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>• CXR or other chest imaging required for diagnosis</td>
<td>• Severity of illness (eg, CURB-65) and prognostic indices (eg, PSI) support decision</td>
</tr>
<tr>
<td>• Sputum Gram stain and culture</td>
<td>• One must still recognize social and individual factors</td>
</tr>
<tr>
<td>• Outpatients: optional</td>
<td></td>
</tr>
<tr>
<td>• Inpatients: if unusual or antibiotic resistance suspected</td>
<td></td>
</tr>
</tbody>
</table>

CURB-65 (Thorax. 2003;58:337-382)

<table>
<thead>
<tr>
<th>Clinical Factor</th>
<th>Points</th>
<th>Demographic Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>Men age</td>
<td>Age in years</td>
</tr>
<tr>
<td>BUN &gt;19 mg/dL</td>
<td>1</td>
<td>Women age</td>
<td>Age in years –10</td>
</tr>
<tr>
<td>Respiratory rate ≥30 breaths/min</td>
<td>1</td>
<td>Nursing home resident</td>
<td>+10</td>
</tr>
<tr>
<td>Systolic BP &lt;90 mm Hg OR Diastolic BP ≤60 mm Hg</td>
<td>1</td>
<td>Coexisting illnesses</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>1</td>
<td>Neoplastic disease</td>
<td>+30</td>
</tr>
<tr>
<td>Total points</td>
<td></td>
<td>Liver disease</td>
<td>+20</td>
</tr>
</tbody>
</table>

CURB-65 ≥2 suggests need for hospitalization


<table>
<thead>
<tr>
<th>Clinical Factor</th>
<th>Points</th>
<th>Demographic Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>Men age</td>
<td>Age in years</td>
</tr>
<tr>
<td>BUN &gt;19 mg/dL</td>
<td>1</td>
<td>Women age</td>
<td>Age in years –10</td>
</tr>
<tr>
<td>Respiratory rate ≥30 breaths/min</td>
<td>1</td>
<td>Nursing home resident</td>
<td>+10</td>
</tr>
<tr>
<td>Systolic BP &lt;90 mm Hg OR Diastolic BP ≤60 mm Hg</td>
<td>1</td>
<td>Coexisting illnesses</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>1</td>
<td>Neoplastic disease</td>
<td>+30</td>
</tr>
<tr>
<td>Total points</td>
<td></td>
<td>Liver disease</td>
<td>+20</td>
</tr>
</tbody>
</table>

Pneumonia Severity Index

<table>
<thead>
<tr>
<th>Clinical Factor</th>
<th>Points</th>
<th>Demographic Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>Men age</td>
<td>Age in years</td>
</tr>
<tr>
<td>BUN &gt;19 mg/dL</td>
<td>1</td>
<td>Women age</td>
<td>Age in years –10</td>
</tr>
<tr>
<td>Respiratory rate ≥30 breaths/min</td>
<td>1</td>
<td>Nursing home resident</td>
<td>+10</td>
</tr>
<tr>
<td>Systolic BP &lt;90 mm Hg OR Diastolic BP ≤60 mm Hg</td>
<td>1</td>
<td>Coexisting illnesses</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>1</td>
<td>Neoplastic disease</td>
<td>+30</td>
</tr>
<tr>
<td>Total points</td>
<td></td>
<td>Liver disease</td>
<td>+20</td>
</tr>
</tbody>
</table>

Pneumonia Severity Index

<table>
<thead>
<tr>
<th>Clinical Factor</th>
<th>Points</th>
<th>Demographic Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>Men age</td>
<td>Age in years</td>
</tr>
<tr>
<td>BUN &gt;19 mg/dL</td>
<td>1</td>
<td>Women age</td>
<td>Age in years –10</td>
</tr>
<tr>
<td>Respiratory rate ≥30 breaths/min</td>
<td>1</td>
<td>Nursing home resident</td>
<td>+10</td>
</tr>
<tr>
<td>Systolic BP &lt;90 mm Hg OR Diastolic BP ≤60 mm Hg</td>
<td>1</td>
<td>Coexisting illnesses</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>1</td>
<td>Neoplastic disease</td>
<td>+30</td>
</tr>
<tr>
<td>Total points</td>
<td></td>
<td>Liver disease</td>
<td>+20</td>
</tr>
</tbody>
</table>

Pneumonia Severity Index

<table>
<thead>
<tr>
<th>Clinical Factor</th>
<th>Points</th>
<th>Demographic Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>Men age</td>
<td>Age in years</td>
</tr>
<tr>
<td>BUN &gt;19 mg/dL</td>
<td>1</td>
<td>Women age</td>
<td>Age in years –10</td>
</tr>
<tr>
<td>Respiratory rate ≥30 breaths/min</td>
<td>1</td>
<td>Nursing home resident</td>
<td>+10</td>
</tr>
<tr>
<td>Systolic BP &lt;90 mm Hg OR Diastolic BP ≤60 mm Hg</td>
<td>1</td>
<td>Coexisting illnesses</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>1</td>
<td>Neoplastic disease</td>
<td>+30</td>
</tr>
<tr>
<td>Total points</td>
<td></td>
<td>Liver disease</td>
<td>+20</td>
</tr>
</tbody>
</table>
## PNEUMONIA, COMMUNITY-ACQUIRED: EVALUATION (Continued)

<table>
<thead>
<tr>
<th>Score</th>
<th>In-hospital mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.7%</td>
</tr>
<tr>
<td>1</td>
<td>3.2%</td>
</tr>
<tr>
<td>2</td>
<td>3.0%</td>
</tr>
<tr>
<td>3</td>
<td>17%</td>
</tr>
<tr>
<td>4</td>
<td>42%</td>
</tr>
<tr>
<td>5</td>
<td>57%</td>
</tr>
</tbody>
</table>

| Physical exam findings                  | +10          |
| Altered mental status                  | +20          |
| Respiratory rate 30 breaths/min        | +20          |
| Systolic BP <90 mm Hg                   | +20          |
| Temperature <95°F (35°C)                | +15          |
| Temperature >104°F (40°C)               | +15          |
| Pulse >125 beats/min                    | +10          |
| Laboratory and radiographic findings   |              |
| Arterial blood pH <7.35                 | +30          |
| BUN >30 mg/dL                          | +20          |
| Sodium level <130 mmol/L               | +20          |
| Glucose level >250 mg/dL               | +10          |
| Hematocrit <30%                        | +10          |
| PaO₂ <60 mm Hg or O₂ saturation <90%   | +10          |
| Pleural effusion                       | +10          |

Add up total points to estimate mortality risk:

<table>
<thead>
<tr>
<th>Class</th>
<th>Points</th>
<th>Overall Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt;51</td>
<td>0.1%</td>
</tr>
<tr>
<td>II</td>
<td>51–70</td>
<td>0.6%</td>
</tr>
<tr>
<td>III</td>
<td>71–90</td>
<td>0.9%</td>
</tr>
<tr>
<td>IV</td>
<td>91–130</td>
<td>9.5%</td>
</tr>
<tr>
<td>V</td>
<td>&gt;130</td>
<td>26.7%</td>
</tr>
</tbody>
</table>

BP, blood pressure; BUN, blood urea nitrogen; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure, 65 of age and older; CXR, chest x-ray; PSI, pneumonia severity index.

# Pneumonia, Community-Acquired: Suspected Pathogens

**Source:** IDSA, ATS, 2007

<table>
<thead>
<tr>
<th>Condition and Risk Factors</th>
<th>Commonly Encountered Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholism</td>
<td><em>Streptococcus pneumoniae</em>, oral anaerobes, <em>Klebsiella pneumoniae</em>, <em>Acinetobacter</em> species, <em>Mycobacterium tuberculosis</em></td>
</tr>
<tr>
<td>COPD and/or smoking</td>
<td><em>Haemophilus influenzae</em>, <em>Pseudomonas aeruginosa</em>, <em>Legionella</em> species, <em>S. pneumoniae</em>, <em>Moraxella catarrhalis</em>, <em>Chlamydia pneumoniae</em></td>
</tr>
<tr>
<td>Aspiration</td>
<td>Gram-negative enteric pathogens, oral anaerobes</td>
</tr>
<tr>
<td>Lung abscess</td>
<td>CA-MRSA, oral anaerobes, endemic fungal pneumonia, <em>M. tuberculosis</em>, and atypical mycobacteria</td>
</tr>
<tr>
<td>Exposure to bat or bird droppings</td>
<td><em>Histoplasma capsulatum</em></td>
</tr>
<tr>
<td>Exposure to birds</td>
<td><em>Chlamydophila psittaci</em> (if poultry: avian influenza)</td>
</tr>
<tr>
<td>Exposure to rabbits</td>
<td><em>Francisella tularensis</em></td>
</tr>
<tr>
<td>Exposure to farm animals or parturient cats</td>
<td><em>Coxiella burnetii</em> (Q fever)</td>
</tr>
<tr>
<td>HIV infection (early)</td>
<td><em>S. pneumoniae</em>, <em>H. influenzae</em>, and <em>M. tuberculosis</em></td>
</tr>
<tr>
<td>HIV infection (late)</td>
<td>The pathogens listed for early infection plus <em>Pneumocystis jirovecii</em>, <em>Cryptococcus</em>, <em>Histoplasma</em>, <em>Aspergillus</em>, atypical mycobacteria (especially <em>Mycobacterium kansasii</em>), <em>P. aeruginosa</em>, <em>H. influenzae</em></td>
</tr>
<tr>
<td>Hotel or cruise ship stay in previous 2 wk</td>
<td><em>Legionella</em> species</td>
</tr>
<tr>
<td>Travel to or residence in southwestern United States</td>
<td><em>Coccidioides</em> species, <em>hantavirus</em></td>
</tr>
<tr>
<td>Travel to or residence in Southeast and East Asia</td>
<td><em>Burkholderia pseudomallei</em>, avian influenza, SARS</td>
</tr>
<tr>
<td>Influenza active in community</td>
<td><em>Influenza</em>, <em>S. pneumoniae</em>, <em>Staphylococcus aureus</em>, <em>H. influenzae</em></td>
</tr>
<tr>
<td>Cough ≥2 wk with whoop or posttussive vomiting</td>
<td><em>Bordetella pertussis</em></td>
</tr>
<tr>
<td>Structural lung disease (eg, bronchiectasis)</td>
<td><em>P. aeruginosa</em>, <em>Burkholderia cepacia</em>, and <em>S. aureus</em></td>
</tr>
<tr>
<td>Injection drug use</td>
<td><em>S. aureus</em>, anaerobes, <em>M. tuberculosis</em>, and <em>S. pneumoniae</em></td>
</tr>
<tr>
<td>Endobronchial obstruction</td>
<td>Anaerobes, <em>S. pneumoniae</em>, <em>H. influenzae</em>, <em>S. aureus</em></td>
</tr>
<tr>
<td>In context of bioterrorism</td>
<td><em>Bacillus anthracis</em> (anthrax), <em>Yersinia pestis</em> (plague), <em>F. tularensis</em> (tularemia)</td>
</tr>
</tbody>
</table>

CA-MRSA, community-acquired methicillin-resistant *S. aureus*; COPD, chronic obstructive pulmonary disease; SARS, severe acute respiratory syndrome.

*Sources: IDSA 2007, ATS 2007.*
PREGNANCY, POSTPARTUM HEMORRHAGE (PPH)

Population
– Pregnant women.

Recommendations
WHO 2012
– Uterotonics for the treatment of PPH.
  • Intravenous oxytocin is the recommended agent.
  • Alternative uterotonics:
    ° Misoprostol 800 μg sublingual.
    ° Metylergonovine 0.2 mg IM.
    ° Carboprost 0.25 mg IM.
– Additional interventions for PPH.
  • Isotonic crystalloid resuscitation.
  • Bimanual uterine massage.
– Therapeutic options for persistent PPH.
  • Tranexamic acid is recommended for persistent PPH refractory to oxytocin.
  • Uterine artery embolization.
  • Balloon tamponade.
– Therapeutic options for a retained placenta.
  • Controlled cord traction with oxytocin 10 IU IM/IV.
  • Manual removal of placenta.
    ° Give single dose of first-generation antibiotic for prophylaxis against endometritis.
  • Recommend against methylergonovine, misoprostol, or carboprost (Hemabate) for retained placenta.

Source

Comment
– Misoprostol 800–1000 μg can also be administered as a rectal suppository for PPH related to uterine atony.
**PREGNANCY, PREMATURE RUPTURE OF MEMBRANES**

**Population**
– Pregnant women.

**Recommendations**

- **ACOG 2013**
  - Women with preterm premature rupture of membranes before 32 gestational weeks at risk for imminent delivery should be considered for intravenous magnesium sulfate treatment for its fetal neuroprotective effect.
  - For women with premature rupture of membranes at 37 gestational weeks or more, labor should be induced if spontaneous labor does not occur near the time of presentation.
  - At 34 gestational weeks or greater, delivery is recommended for all women with ruptured membranes.
  - In the setting of ruptured membranes, therapeutic tocolysis is not recommended.
  - Outpatient management of preterm premature rupture of membranes is not recommended.

**Source**

- **Cochrane Database of Systematic Reviews 2013**
  - Routine antibiotics should be prescribed for women with preterm rupture of membranes prior to 37 gestational weeks.

**Source**
– http://www.cochrane.org/CD001058/PREG_antibiotics-for-preterm-rupture-of-membranes

**Comment**
– 22 studies involving over 6800 pregnant women with PROM prior to 37 gestational weeks were analyzed. Routine antibiotics decreased the incidence of chorioamnionitis (RR 0.66), prolonged pregnancy by at least 7 d (RR 0.79), and decreased neonatal infection (RR 0.67), but had no effect on perinatal mortality compared with placebo.

**PREGNANCY, PRETERM LABOR**

**Population**
– Pregnant women.
**Recommendations**

- ACOG 2012, Cochrane Database of Systematic Reviews 2013
  - Single dose of corticosteroids for pregnant women between 24 and 34 gestational weeks who may deliver within 7 d.
  - Magnesium sulfate for possible preterm delivery prior to 32 wk for neuroprotection.
  - Tocolytic options for up to 48 h.
    - β-agonists.
    - Nifedipine.
    - Indomethacin.
  - No role for antibiotics in preterm labor and intact membranes.
  - Bedrest and hydration have not been shown to prevent preterm birth and should not be routinely recommended.

**Sources**

- http://www.cochrane.org/CD003096/PREG_hydration-for-treatment-of-preterm-labour

**Comments**

1. Magnesium sulfate administered prior to 32 wk reduces the severity and risk of cerebral palsy.
2. Cochrane analysis found no difference in the incidence of preterm delivery comparing hydration and bedrest with bedrest alone.

---

**PREGNANCY, PRETERM LABOR, TOCOLYSIS**

**Population**

- Pregnant women in preterm labor.

**Recommendations**

- RCOG 2011
  - There is no clear evidence that tocolysis improves perinatal outcomes and therefore it is reasonable not to use them.
  - Nifedipine and atosiban have comparable effectiveness in delaying birth up to 7 d.
  - Avoid the use of multiple tocolytic drugs simultaneously.
  - Maintenance tocolytic therapy following threatened preterm labor is not recommended.

**Source**


**Comment**

- Tocolysis may be considered for women with suspected preterm labor who require in utero transfer or to complete a course of corticosteroids.
PREGNANCY, ROUTINE PRENATAL CARE

ROUTINE PRENATAL CARE

Preconception Visit
1. Measure height, weight, blood pressure, and total and HDL cholesterol.
2. Determine rubella, rubeola, and varicella immunity status.
3. Assess all patients for pregnancy risk: substance abuse, domestic violence, sexual abuse, psychiatric disorders, risk factors for preterm labor, exposure to chemicals or infectious agents, hereditary disorders, gestational diabetes, or chronic medical problems.
4. Educate patients about proper nutrition; offer weight reduction strategies for obese patients.
5. Immunize if not current on the following: Tdap (combined tetanus, diphtheria, and pertussis vaccine), MMR (measles, mumps, rubella), varicella, or hepatitis B vaccine.
6. Initiate folic acid 400–800 μg/d; 4 mg/d for a history of a child affected by a neural tube defect.

Initial Prenatal Visit
1. Medical, surgical, social, family, and obstetrical history, and do complete examination.
2. Pap smear, urine NAAT for gonorrhea and Chlamydia, and assess for history of genital herpes.
3. Consider a varicella antibody test if the patient unsure about prior varicella infection.
4. Urinalysis for proteinuria and glucosuria, and urine culture for asymptomatic bacteriuria.
5. Order prenatal labs to include a complete blood count, blood type, antibody screen, rubella titer, VDRL, hepatitis B surface antigen, and an HIV test.
6. Order an obstetrical ultrasound for dating if any of the following: beyond 16-wk gestational age, unsure of last menstrual period, size/date discrepancy on examination, or for inability to hear fetal heart tones by 12 gestational weeks.
7. Discuss fetal aneuploidy screening and counseling regardless of maternal age.
8. Prenatal testing offered for sickle cell anemia (African descent), thalassemia (African, Mediterranean, Middle Eastern, Southeast Asians), Canavan disease and Tay-Sachs (Jewish patients), cystic fibrosis (whites and Ashkenazi Jews), and fragile X syndrome (family history of nonspecified mental retardation).
9. Place a tuberculosis skin test for all medium- to high-risk patients. a
10. Consider a 1-h 50-g glucose tolerance test for certain high-risk groups. b
11. Obtain an operative report in all women who have had a prior cesarean section.
12. Psychosocial risk assessment for mood disorders, substance abuse, or domestic violence.

Frequency of Visits for Uncomplicated Pregnancies
1. Every 4 wk until 28 gestational weeks; q 2 wk from 28 to 36 wk; weekly >36 wk.

Routine Checks at Follow-up Prenatal Visits
1. Assess weight, blood pressure, and urine for glucose and protein.
2. Exam: edema, fundal height, and fetal heart tones at all visits; fetal presentation starting at 36 wk.
3. Ask about regular uterine contractions, leakage of fluid, vaginal bleeding, or decreased fetal movement.
4. Discuss labor precautions.
# ROUTINE PREGNATAL CARE (Continued)

## Antepartum Lab Testing

1. All women should be offered first trimester, second trimester, or combined testing to screen for fetal aneuploidy; invasive diagnostic testing for fetal aneuploidy should be available to all women regardless of maternal age.
   - a. First trimester.
   - b. Second trimester screening options: amniocentesis at 14 wk; a Quad Marker Screen at 16–18 wk; and/or a screening ultrasound with nuchal translucency assessment.

2. Consider serial transvaginal sonography of the cervix every 2–3 wk to assess cervical length for patients at high risk for preterm delivery starting at 16 wk.

3. No role for routine bacterial vaginosis screening.

4. 1-h 50-g glucose tolerance test in all women between 24 and 28 wk.

5. Rectovaginal swab for group B streptococcal (GBS) testing between 35 and 37 wk.

6. Recommend weekly amniotic fluid assessments and twice weekly nonstress testing starting at 41 wk.

## Prenatal Counseling

1. Cessation of smoking, drinking alcohol, or use of any illicit drugs.

2. Avoid cat litter boxes, hot tubs, certain foods (ie, raw fish or unpasteurized cheese).


4. Inquire about domestic violence and depression at initial visit, at 28 wk, and at postpartum visit.

5. Recommend regular mild-to-moderate exercise 3 or more times a week.

6. Avoid high-altitude activities, scuba diving, and contact sports during pregnancy.


8. Discuss postpartum contraceptive options (including tubal sterilization) during third trimester.

9. Discuss analgesia and anesthesia options and offer prenatal classes at 24 wk.

10. Discuss repeat C-section vs. vaginal birth after cesarean (if applicable).

11. Discuss the option of circumcision if a boy is delivered.

12. Avoid air travel and long train or car trips beyond 36 wk.

## Prenatal Interventions

1. Suppressive antiviral medications starting at 36 wk for women with a history of genital herpes.

2. Cesarean delivery is indicated for women who are HIV positive or have active genital herpes and are in labor.

3. For patients who report a history of abuse, offer interventions and resources to increase their safety during and after pregnancy.

4. For patients with severe depression, consider treatment with an SSRI (avoid paroxetine if possible).
5. Rh immune globulin 300 μg IM for all Rh-negative women with negative antibody screens between 26 and 28 wk.

6. Refer for nutrition counseling at 10–12 wk for BMI <20 kg/m² or at any time during pregnancy for inadequate weight gain.

7. Start prenatal vitamins with iron and folic acid 400–800 μg/d and 1200 mg elemental calcium/d starting at 4 wk preconception (or as early as possible during pregnancy) and continued until 6 wk postpartum.

8. Give inactivated influenza vaccine IM to all pregnant women during influenza season.

9. Consider progesterone therapy IM weekly or intravaginally daily to women at high risk for preterm birth.

10. Recommend an external cephalic version at 37 wk for all noncephalic presentations.

11. Offer labor induction to women at 41 wk by good dates.

12. Treat all women with confirmed syphilis with penicillin G during pregnancy.

13. Treat all women with gonorrhea with ceftriaxone; follow treatment with a test of cure.

14. Treat all women with Chlamydia with azithromycin; follow treatment with a test of cure.

15. Treat all GBS-positive women with penicillin G when in labor or with spontaneous rupture of membranes.

Postpartum Interventions

1. Treat all infants born to HBV-positive women with hepatitis B immunoglobulin (HBIG) and initiate HBV vaccine series within 12 h of life.

2. All women with a positive tuberculosis skin test and no evidence of active disease should receive a postpartum chest x-ray; treat with isoniazid 300 mg PO daily for 9 mo if chest x-ray is negative.

3. Administer a Tdap booster if tetanus status is unknown or the lastTd (tetanus-diphtheria) vaccine was >10 y ago.

4. Administer an MMR vaccine to all rubella nonimmune women.

5. Offer HPV vaccine to all women ≤26 wk who have not been immunized.

6. Initiate contraception.

7. Repeat Pap smear at 6-wk postpartum check.

*Postgastrectomy, gastric bypass, immunosuppressed (HIV-positive, diabetes, renal failure, chronic steroid/immunosuppressive therapy, head/neck or hematologic malignancies), silicosis, organ transplant recipients, malabsorptive syndromes, alcoholics, intravenous drug users, close contacts of persons with active pulmonary tuberculosis, medically underserved, low socioeconomic class, residents/employees of long-term care facilities and jails, health care workers, and immigrants from endemic areas.

*Overweight (BMI ≥25 kg/m²) and an additional risk factor: physical inactivity; first-degree relative with DM; high-risk ethnicity (eg, African American, Latino, Native American, Asian American, Pacific Islander); history of gestational diabetes mellitus (GDM); prior baby with birthweight >9 lb; unexplained stillbirth or malformed infant; HTN on therapy or with BP ≥140/90 mm Hg; HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L); polycystic ovary syndrome; history of impaired glucose tolerance or HgbA1c ≥5.7%; acanthosis nigricans; cardiovascular disease; or ≥2+ glucosuria.

Source: Adapted from ACOG ICSI Guideline on Routine Prenatal Care, July 2010. (http://www.icsi.org/prenatal_care_4/prenatal_care_routine_full_version_2.html).
CHAPTER 3

PREGNANCY, SUBSTANCE ABUSE

Population
– Pregnant or postpartum patients using alcohol or illicit drugs.

Recommendations
WHO 2014
– Health care providers should ask all pregnant women about their use of alcohol and other illicit drugs at every prenatal visit.
– Health care providers should offer a brief intervention and individualized care to all pregnant women using alcohol or drugs.
– Health care providers should refer pregnant women with alcohol or cocaine or methamphetamine abuse to a detoxification center.
  • Women with opioid addiction should continue a structured opioid maintenance program with either methadone or buprenorphine.
  • Women with a benzodiazepine addiction should gradually wean the dose.
– Mothers with a substance abuse history should be encouraged to breast-feed unless the risks outweigh the benefits.
– Carefully monitor and treat infants of substance abusing mothers.

Source

PREOPERATIVE CLEARANCE

Population
– Asymptomatic population without cardiac history.

Recommendations
Choosing Wisely 2014, ACC 2014
– Recommends against stress cardiac imaging or advanced noninvasive imaging as a preoperative assessment in patients scheduled to undergo low-risk noncardiac surgery.

Source

PRESSURE ULCERS

Population
– Adults at risk for pressure ulcers.
**Recommendations**

**NICE 2014**
1. Regular documentation of ulcer size.
2. Debride any necrotic tissue if present with sharp debridement or autolytic debridement.
3. Nutritional supplementation for patients who are malnourished.
4. Recommend a pressure-redistributing foam mattress.
5. Negative pressure wound therapy, electrotherapy, or hyperbaric oxygen therapy is not routinely recommended.
6. Antibiotics are only indicated for superimposed cellulitis or underlying osteomyelitis.

*Source*

**Population**
–Patients with pressure ulcers.

**Recommendations**

**ACP 2015**
–Recommends nutritional supplementation with protein and amino acids to reduce wound size.
–Use hydrocolloid or foam dressings to reduce wound size.
–Use electrical stimulation as adjunctive therapy to accelerate wound healing.

*Source*

**Comment**
–Moderate-quality evidence supports the addition of electrical stimulation to standard therapy to accelerate healing of Stage II–IV ulcers.

## PROCEDURAL SEDATION

**ACEP 2014**

**Population**
–Adults or children.

**Recommendations**
1. No preprocedural fasting needed prior to procedural sedation.
2. Recommends continuous capnometry and oximetry to detect hypoventilation.
3. During procedural sedation, a nurse or other qualified individual must be present for continuous monitoring in addition to the procedural operator.

4. Safe options for procedural sedation in children and adults include ketamine, propofol, and etomidate.

Source

Comments
1. The combination of ketamine and propofol is also deemed to be safe for procedural sedation in children and adults.

2. Alfentanil can be safely administered to adults for procedural sedation.

PROSTATE CANCER FOLLOW-UP CARE

Population
– Prostate cancer survivors.

Recommendations
– ASCO 2015

– Surveillance for Prostate Cancer Patient Recurrence
  • Measure serum PSA (prostate-specific antigen) every 4–12 mo (depending on recurrence risk) for the first 5 y then recheck annually thereafter.
  • Survivors with elevated or rising PSA levels should be evaluated as soon as possible by their primary treating specialist.
  • Perform an annual direct rectal examination.
  • Adhere to ASCO screening and early detection guidelines for 2nd cancers (increased risk of bladder and colon cancer after pelvic radiation).

– Assessment and Management of Physical and Psychosocial Effects of PC and Treatment
  • Anemia related to androgen deprivation therapy (ADT).
  • Bowel dysfunction and symptoms especially rectal bleeding.
  • Cardiovascular and metabolic effects for men receiving ADT—follow USPSTF guidelines for evaluation and screening for cardiovascular risk factors.
  • Assess for distress and depression and refer to appropriate specialist.
  • Osteoporosis and fracture risk in men on ADT—do baseline DEXA (dual energy x-ray absorptiometry) scan and support with calcium, vitamin D, and bisphosphonates as indicated.
  • Sexual dysfunction—phosphodiesterase type 5 inhibitors may help—refer to appropriate specialist.
• Urinary dysfunction (incontinence and leakage)—refer to urology specialist.
• Vasomotor symptoms (hot flushes) in men receiving ADT—selective serotonin or noradrenergic reuptake inhibitors or gabapentin may be helpful. Low-dose progesterone may be helpful in refractory patients.

Source

Comments
– General health promotion can be helpful
  • Counsel survivors to achieve and maintain a healthy weight by limiting consumption of high-caloric food and beverages.
  • Counsel survivors to engage in at least 150 min/wk of physical activity.
  • Improve dietary pattern with more fruits and vegetables and whole grains.
  • Encourage intake of at least 600 IU of vitamin D per day as well as sources of calcium not to exceed 1200 mg/d.
  • Counsel survivors to avoid or limit alcohol consumption to no more than 2 drinks/d.
  • Counsel survivors to avoid tobacco products.

– Rising PSA in patients with nonmetastatic PC
  • A PSA ≥ 0.2 ng/mL on 2 consecutive tests is reflective of recurrent prostate cancer. These patients are treated with pelvic radiation with improvement in 10-y survival and freedom from recurrence. The earlier radiation is started after a PSA rise, the better the outcome. Patients who have had previous radiation to the prostate occasionally undergo surgery but most are treated with ADT or cryoablation. (JCO. 2009;27:4300-4305) A recent trial adding ADT to radiation in this setting increased disease-free progression. (Eur Urol. 2016;69:802)
  • Routine CT or bone scanning is not indicated but evaluate new symptoms even if PSA not rising (transformation to small cell carcinoma in 5% of patients).
  • In newly relapsed patients with visceral metastasis and/or more than 4 separate bone lesions a combination of concurrent androgen deprivation and taxotere chemotherapy is associated with a 15%–20% increased survival at 5 y vs. sequential therapy. (N Engl J Med. 2015;373:737. Lancet. 2016;387:1163)
CHAPTER 3

PSORIASIS AND PSORIATIC ARTHRITIS

Population
– Adults.

Recommendations

AAD 2010
– Treatment options for patients with limited plaque-type psoriasis.
  • First-line therapy:
    ◦ Topical corticosteroids.
    ◦ Topical calcipotriene/calcitriol.
    ◦ Topical calcipotriene/steroid.
    ◦ Topical tazarotene.
    ◦ Topical calcineurin inhibitors (flexural surfaces and face).
    ◦ Targeted phototherapy.
  • Second-line therapy:
    ◦ Systemic agents.
– Treatment of extensive plaque-type psoriasis.
  • First-line therapy:
    ◦ UVB phototherapy ± acitretin.
    ◦ Topical PUVA.
  • Second-line therapy:
    ◦ Acitretin + biologic.
    ◦ Cyclosporine + biologic.
    ◦ Cyclosporine + methotrexate.
    ◦ Methotrexate + biologic.
    ◦ UVB + biologic.
– Treatment of palmoplantar psoriasis.
  • First-line therapy:
    ◦ Topical corticosteroids.
    ◦ Topical calcipotriene/calcitriol.
    ◦ Topical calcipotriene/steroid.
    ◦ Topical tazarotene.
  • Second-line therapy:
    ◦ Acitretin.
    ◦ Targeted UVB.
    ◦ Topical PUVA.
  • Third-line therapy:
    ◦ Adalimumab.
    ◦ Alefacept.
    ◦ Cyclosporine.
DISEASE MANAGEMENT

- Etanercept.
- Infliximab.
- Methotrexate.
- Ustekinumab.

- Treatment of erythrodermic psoriasis.
  - Acitretin.
  - Adalimumab.
  - Cyclosporine.
  - Infliximab.
  - Methotrexate.
  - Ustekinumab.

- Treatment of psoriatic arthritis.
  - First-line therapy:
    - Adalimumab.
    - Etanercept.
    - Golimumab.
    - Infliximab.
    - Methotrexate.
    - Tumor necrosis factor (TNF) blocker + methotrexate.
  - Second-line therapy:
    - Ustekinumab and methotrexate.

Sources

Comment
- Use of potent topical corticosteroids should be limited to 4 wk duration.

PSORIASIS, PLAQUE-TYPE

Population
- Adults.

Recommendations
AAP 2009

Topical Therapies
1. Topical therapies are most effective for mild-to-moderate disease.
2. Topical corticosteroids daily—bid:
   a. Cornerstone of therapy.
   b. Limit Class I topical steroids to 4 wk maximum.
3. Topical agents that have proven efficacy when combined with topical corticosteroids:
   a. Topical vitamin D analogues.
   b. Topical tazarotene.
   c. Topical salicylic acid.
4. Emollients applied 1–3 times daily are a helpful adjunct.

Source

Comments
1. Approximately 2% of population has psoriasis.
2. 80% of patients with psoriasis have mild-to-moderate disease.
3. Topical steroid toxicity:
   a. Local: skin atrophy, telangiectasia, striae, purpura, or contact dermatitis.
   b. Hypothalamic-pituitary—adrenal axis may be suppressed with prolonged use of medium- to high-potency steroids.

Recommendations

AAD 2009

–Systemic Therapies
1. Indicated for severe, recalcitrant, or disabling psoriasis.
2. Methotrexate (MTX):
   a. Dose: 7.5–30 mg PO weekly.
   b. Monitor CBC and liver panel monthly.
3. Cyclosporine:
   a. Initial dose: 2.5–3 mg/kg divided bid.
   b. Monitor for nephrotoxicity, HTN, and hypertrichosis.
4. Acitretin:
   a. Dose: 10–50 mg PO daily.
   b. Monitor: liver panel.

Source

Comments
1. MTX contraindications: pregnancy; breast-feeding; alcoholism; chronic liver disease; immunodeficiency syndromes; cytopenias; hypersensitivity reaction.
2. Cyclosporine contraindications: CA; renal impairment; uncontrolled HTN.
3. Acitretin contraindications: pregnancy, chronic liver, or renal disease.
**PSYCHIATRIC PATIENTS IN THE EMERGENCY DEPARTMENT**

**Population**
- Adult patients presenting to ED with psychiatric symptoms

**Recommendations**
- No role for routine laboratory testing. Medical history, examination, and previous psychiatric diagnoses should guide testing.
- No role for routine neuroimaging studies in the absence of focal neurological deficits.
- Risk assessment tools should not be used in isolation to identify low-risk adults who are safe for ED discharge if they presented with suicidal ideations.
- Ketamine is one option for immediate sedation in severely agitated adults who may be violent or aggressive.

**Source**

---

**PULMONARY NODULES**

**Population**
- Adults with pulmonary nodules.

**Recommendations**
- Do not recommend nodule follow-up or further work-up for nodules with:
  - Size <5 mm.
  - Diffuse, central, or laminated pattern of calcification or fat.
  - Perifissural or subpleural nodules that are <1 cm and homogenous, smooth or solid with a lentiform or triangular shape.
- Recommend thin-slice CT surveillance for nodules 5–8 mm after 3 mo and 1 y.
  - No further surveillance needed for stable nodules after 1 y.
- Recommend using the Brock model for initial risk assessment of pulmonary nodules 8 mm or larger in patients who have ever smoked.
- Consider a PET-CT scan for patients with a pulmonary nodule and an initial risk of malignancy >10%.
Suggestions for pulmonary nodules management:

- Serial CT scans when the malignancy risk is <10%.
- CT-guided biopsy when the risk of malignancy is 10%–70%.
- Video-assisted thoracoscopic surgery when the chance of malignancy exceeds 70%.
- Consider bronchoscopy when a bronchus sign is present on CT scan.

Source

https://guidelines.gov/summaries/summary/49569

RED BLOOD CELL (RBC) TRANSFUSION

Population

- General population, male and female.

Recommendation

American Association of Blood Banks (AABB)

- Hospitalized, hemodynamically stable patients—restrictive transfusion strategy preferred (see Table II).
  - For nonsurgical patients transfusion considered at hemoglobin of 7 g/dL or less.
  - In post-op surgical patients transfusion considered at hemoglobin of 8 g/dL or less.
  - Patients with heart disease should be treated with restrictive transfusion strategy (trigger hemoglobin 7-8 g/dL). Erythrocyte-stimulating agents should not be used because of increased thrombotic risk.
  - In symptomatic patients (chest pain, tachycardia, hypotension, or heart failure) or with continued hemorrhage, clinical judgment should supervene.
  - In patients meeting criteria for transfusion, give only as much as necessary to raise hemoglobin to recommended levels (1 unit of red blood cells will raise hemoglobin by 1 g/dL).
  - Leukocyte reduction (either at the time of collection or filtration at the time of transfusion) is necessary to decrease febrile, nonhemolytic transfusion reactions, decrease risk of cytomegalovirus (CMV) transmission, and decrease risk of HLA-allo immunization but does not prevent transfusion associated graft vs. host disease (TA-GVHD).
TABLE II

RED BLOOD CELL—TRANSFUSION GUIDELINES FOR HEMODYNAMICALLY STABLE PATIENTS

<table>
<thead>
<tr>
<th>Patient Situation</th>
<th>Transfusion Threshold</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU(^a)</td>
<td>Hgb ≤7 g/dL</td>
<td>High</td>
</tr>
<tr>
<td>Post-op</td>
<td>Hgb ≤8 g or symptoms(^b)</td>
<td>High</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>Hgb ≤8 or symptoms(^b)</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

\(^a\)Guidelines for non-ICU hospitalized patients have not been determined.
\(^b\)Includes chest pain, hypoxia, hypotension and tachycardia, CHF, and ischemic bowel.

Comment

- Important Information
  - 15 million units of red blood cells are transfused annually in the US and 85 million transfused annually worldwide.
  - Transfusion carries significant risk of infection, immunosuppression, hemolytic transfusion reaction, transfusion related acute lung injury (TRALI) (see Table III).
  - Nineteen trials were evaluated by AABB assessing noninferiority of restrictive vs liberal transfusion policy. There was no statistically significant difference although a trend for lower mortality in the patients treated by the restrictive transfusion policy was noted.
  - Patients with pharmacologically treatable anemia such as iron deficiency or B\(_{12}\) or folate deficiency should not be transfused unless they are significantly symptomatic.
  - Transfusion of red cells should be given slowly over first 15 min and completed within 4 h.

TABLE III

NONINFECTIONOUS COMPLICATIONS OF BLOOD TRANSFUSION

<table>
<thead>
<tr>
<th>Complication</th>
<th>Incidence</th>
<th>Diagnosis</th>
<th>Rx and Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute hemolytic transfusion reaction (AHTR)</td>
<td>1:40,000</td>
<td>Serum-free hemoglobin, Coombs</td>
<td>Fluids to keep urine output &gt;1 mL/kg/h, pressors, treat DIC, fatal in 1.8 × 10(^6) RBC exposures</td>
</tr>
<tr>
<td>Delayed transfusion reaction (HTR)</td>
<td>1:3000–5000</td>
<td>Timing (10–14 d after tx)–(+), Coombs, ↑ LDH, indirect bilirubin, reticulocyte count—Ab often to Kidd or Rh</td>
<td>Identify responsible antigen, transfuse compatible blood if necessary</td>
</tr>
</tbody>
</table>
### Noninfectious Complications of Blood Transfusion (Continued)

<table>
<thead>
<tr>
<th>Complication</th>
<th>Incidence</th>
<th>Diagnosis</th>
<th>Rx and Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febrile non-HTR</td>
<td>0.1%–1%</td>
<td>Exclude AHTR — ↓ risk with leucocyte depletion — starts within 2 h of transfusion</td>
<td>Acetaminophen PO, support and reassurance</td>
</tr>
<tr>
<td>Allergic (urticarial)</td>
<td>1%–3%</td>
<td>Urticaria, pruritus but no fever — caused by antibody to donor-plasma proteins</td>
<td>Hold tx — give antihistamines and complete tx. when symptoms resolve</td>
</tr>
<tr>
<td>Anaphylactic</td>
<td>1:20,000–50,000</td>
<td>Hypotension, bronchospasm, urticaria, anxiety, rule out hemolysis</td>
<td>Epinephrine 1:1000 — 0.2–0.5 mL SQ, steroids, antihistamine</td>
</tr>
<tr>
<td>Transfusion-related acute lung injury (TRALI)</td>
<td>1:10,000</td>
<td>HLA or neutrophil antibodies in donor blood hypoxia, bilateral lung infiltrates, and fever within 6 h of transfusion</td>
<td>Supportive care — steroids ineffective mortality — 10%–20% (most common cause of transfusion-related fatality)</td>
</tr>
</tbody>
</table>

### Recommendation

**AABB**

− Prevention of TA-GVHD* — High risk
  − High-risk situations include product donated by family member or HLA-selected donor.
  − Acute leukemia and Hodgkin and non-Hodgkin lymphoma patients on therapy.
  − Allogenic or autologous hemopoietic progenitor cell transplant recipient.
  − Aplastic anemia patients on antithymocyte globulin and/or cyclosporine.
  − Purine analogues and other drugs affecting T-cell count and function — fludarabine, clofarabine, bendamustine, nelarabine, alemtuzumab, and temozolomide.
  − Recommended preventive strategy is 2500 cGy of radiation to product to be transfused. This dose will destroy T cells. Shelf life of irradiated product is 28 d.
  − Infection complications of transfusion are now very rare (see Table IV).

*A-GVHD, transfusion-associated graft-versus-host disease*
TABLE IV

INFECTION COMPLICATIONS OF TRANSFUSION

<table>
<thead>
<tr>
<th>Transfusion-Transmitted Organism</th>
<th>Risk per Unit of Blood Transfused</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>1 in 1,467,000</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>1 in 1,149,000</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>1 in 282,000</td>
</tr>
<tr>
<td>West Nile virus</td>
<td>Rare</td>
</tr>
<tr>
<td>Cytomegalovirus (CMV)</td>
<td>70%–80% of donors are carriers, leukodepletion ↓ risk but in situation of significant immunosuppression gives CMV-negative blood</td>
</tr>
<tr>
<td>Bacterial infection</td>
<td>1 in 3000—5-fold more common in platelet vs. RBC transfusion</td>
</tr>
<tr>
<td>Parasitic infection (Babesiosis, malaria, Chagas disease)</td>
<td>Rare</td>
</tr>
</tbody>
</table>

Sources
- Blood. 2012;119:1757-1767
- Crit Care Med. 2008;36:2667-2674
- JAMA 2016;316:1984

Comment
- Caution in the immunosuppressed:
  - Must be aware of circumstances that increase risk of TA-GVHD in order to initiate protective strategy. If TA-GVHD does occur mortality approaches 100%.
  - In immunosuppressed patients and in donating family members with shared genes, targeting T cells from the donor may not be eliminated through immunologic attack. These surviving T cells then interact with host cellular antigens damaging skin, liver, GI tract, and lung with high mortality.
  - With polymerase chain reaction (PCR) and antibody screening transfusion-related infection complications are rare. Bacterial infection and sepsis occurs 50-fold more commonly with platelet transfusion vs. red blood cell transfusion.
  - Immune-compromised patients needing transfusion should have CMV serology checked and if antibodies not present CMV-negative blood should be given (70%–80% of recipients are antibody positive).
RENNAL CANCER (RCC) FOLLOW-UP CARE

Recommendations

NCCN 2016

– Stage I—Follow-up after a partial or radical nephrectomy
  • History and physical (H&P) every 6 mo for 2 y then annually up to 5 y after surgery.
  • Comprehensive metabolic panel or other blood tests as indicated every 6 mo for 2 y then annually until 5 y.

– Abdominal imaging after partial nephrectomy
  • Baseline abdominal CT, MRI, or US within 3–9 mo of surgery. If initial scan-negative abdominal imaging may be considered annually for 3 y based on overall risk factors.

– After radical nephrectomy
  • Abdominal CT, MRI, or US within 3–12 mo of surgery.
  • If initial post-op imaging is negative, abdominal imaging beyond 12 mo may be done at the discretion of the physician.
  • Chest x-ray or CT annually for 3 y then as indicated clinically.

– Stage II or III—follow-up after radical nephrectomy
  • H & P every 3–6 mo for 3 y then annually up to 5 y after radical nephrectomy, then as clinically indicated.
  • Comprehensive metabolic panel, LDH, and C-reactive protein every 6 mo for 2 y then annually up to 5 y.

– Abdominal imaging after radical nephrectomy
  • Baseline abdominal CT or MRI within 3–6 mo then CT, MRI, or US every 3–6 mo for 3 y then annually up to 5 y.
  • Chest imaging—baseline chest CT within 3–6 mo.
  • Pelvic, brain, or spinal imaging as clinically indicated. Nuclear bone scan as clinically indicated.

Source
– J Clin Onc. 2014; j32:4059

Comments

– RCC staging
  • Stage I—Tumor <7 cm N0M0
  • Stage II—Tumor >7cm limited to kidney N0M0
  • Stage III—Any tumor size with regional node metastasis
  • Stage IV—T4 (spread beyond Gerota’s fascia—any T, any N, M (systemic metastases)
– **Features of high risk for relapse**
  - Stage III, size of tumor, high grade (Fuhrman 3 or 4), coagulative tumor necrosis (5x increase risk of death). (*British J Urol.* 2009; 103:165)

– **Paraneoplastic syndromes in RCC and clinical caveats**
  - Anemia, hepatic dysfunction, fever, hypercalcemia, cachexia, erythrocytosis, thrombocytosis, polymyalgia rheumatica. (*Lancet.* 1998; 352:1691)
  - Chemotherapy no longer used in treatment of RCC. Multi-targeted tyrosine kinase inhibitors and checkpoint immune blockade are treatments of choice. High-dose interleukin-2 is used occasionally in young, fit patients. (*NEJM.* 2015;373:1803. *NEJM.* 2013;369:722)
  - In patients with small-volume metastasis a nephrectomy to remove the primary has resulted in a prolongation of survival. (*N Engl J Med.* 2001;345:1655)
  - In selected patients with low-volume, limited, resectable metastatic disease, surgical removal of the metastasis increases overall survival with occasional long-term remission. (*Cancer.* 2011;117:2873)
  - The use of adjuvant therapy with multi-targeted tyrosine kinase inhibitors does not extend progression-free or overall survival in a placebo-controlled trial. (*Lancet.* 2016; published online March 14, 2016). A 2nd trial in higher risk patients did show a survival benefit with adjuvant TKI inhibitors. (*N Engl J Med.* 2016; 375:2246)

### CANCER SURVIVORSHIP: LATE EFFECTS OF CANCER TREATMENTS

<table>
<thead>
<tr>
<th>CA Treatment History</th>
<th>Late Effects</th>
<th>Periodic Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any CA experience</td>
<td>Psychosocial disorders(^b)</td>
<td></td>
</tr>
<tr>
<td>Any chemotherapy</td>
<td>Oral and dental abnormalities</td>
<td>Dental examination and cleaning (every 6 mo)</td>
</tr>
<tr>
<td>Chemotherapy—alkylating agents (cyclophosphamide, melphalan, ifosfamide, chlorambucil, nitrosoureas)(^a)</td>
<td>Gonadal dysfunction, Hematologic disorders(^c), Ocular toxicity(^d), Pulmonary toxicity, Renal toxicity(^e), Urinary tract toxicity(^g)</td>
<td>Pubertal assessment (yearly) in adults if symptoms of hypogonadism present History, examination for bleeding disorder; CBC/differential (yearly) Visual acuity, funduscopic examination, evaluation by ophthalmologist (yearly if ocular tumors, TBI, or ≥30 Gy; otherwise, every 3 y) CXR, PFTs (at entry into long-term follow-up, then as clinically indicated)</td>
</tr>
</tbody>
</table>

\(^a\) Cyclophosphamide, melphalan, ifosfamide, chlorambucil, nitrosoureas

\(^b\) Includes anxiety, depression, post-traumatic stress disorder

\(^c\) Anemia, neutropenia

\(^d\) Cataracts, retinopathy

\(^e\) Proteinuria, hypertension

\(^f\) Nephritis

\(^g\) Bladder cancer, hydronephrosis, urinary tract infection
CANCER SURVIVORSHIP: LATE EFFECTS OF CANCER TREATMENTS  (Continued)

<table>
<thead>
<tr>
<th>CA Treatment History</th>
<th>Late Effects</th>
<th>Periodic Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA Treatment History</td>
<td>Blood pressure (yearly); electrolytes, BUN, creatinine, Ca++, Mg++, PO4–, urinalysis (at entry into long-term follow-up, then clinically as indicated) Bone marrow injury with myelodysplasia</td>
<td></td>
</tr>
</tbody>
</table>
| Chemotherapy—antitumor antibiotics (anthracycline, epirubicin)
<p>| Cardiac toxicity&lt;sup&gt;a&lt;/sup&gt;                  | ECHO or MUGA; ECG at entry into long-term follow-up, periodic thereafter (↑ frequency if chest radiation); fasting glucose, lipid panel (every 3–5 y) |
| Hematologic disorders&lt;sup&gt;c&lt;/sup&gt;            | See “Chemotherapy—Alkylating agents”—risk of acute myelocytic leukemia       |
| Chemotherapy—antitumor antibiotics (mitomycin C, bleomycin)&lt;sup&gt;e&lt;/sup&gt; | Pulmonary toxicity&lt;sup&gt;e&lt;/sup&gt; Renal injury&lt;sup&gt;f&lt;/sup&gt;                      | Chest x-ray and pulmonary function tests at end of exposure to bleomycin, with re-evaluation as clinically indicated Monitor urinalysis and creatinine (mito C) |
| Chemotherapy—antimetabolites (cytarabine, MTX) (high-dose IV, intrathecal)&lt;sup&gt;i&lt;/sup&gt; | Clinical leukoencephalopathy&lt;sup&gt;i&lt;/sup&gt; Neurocognitive deficits            | Full neurologic examination (yearly) Neuropsychological evaluation (at entry into long-term follow-up, then as clinically indicated) |
| Chemotherapy—epipodophyllotoxins (Ixabepilone)&lt;sup&gt;u&lt;/sup&gt; | Hematologic disorders (causes AML with specific 11q 23 translocation)&lt;sup&gt;u&lt;/sup&gt; | See “Chemotherapy—alkylating agents” Hematologic disorders, AML gonadal dysfunction |
| Chemotherapy heavy metals (cis-platinum, carboplatin) | Dyslipidemia/ hypertension and increased risk of cardiovascular disease Gonadal dysfunction Hematologic disorders&lt;sup&gt;c&lt;/sup&gt; Ototoxicity&lt;sup&gt;j&lt;/sup&gt; Peripheral sensory neuropathy Renal toxicity&lt;sup&gt;j&lt;/sup&gt; | See “Chemotherapy—alkylating agents” Fasting lipid panel at entry. Complete pure tone audiogram or brainstem auditory-evoked response (yearly × 2 then as indicated by symptoms) Examination yearly for at least 5 y Increased risk of renal insufficiency, neuropathy and cardiac events – lab work and careful F/U at least yearly |</p>
<table>
<thead>
<tr>
<th>Chemotherapy—microtubular inhibitors (taxanes, eribulin)</th>
<th>Peripheral neuropathy</th>
<th>Examination yearly for 2–3 y If neuropathy persistent – duloxetine or venlafaxine may help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy—nonclassical alkylators (dacarbazine and temozolomide)</td>
<td>Gonadal dysfunction Reduced CD4 count Hematologic disorders</td>
<td>See &quot;Chemotherapy—alkylating agents&quot; Monitor for opportunistic infections (CD4 count at 6 and 12 mo)</td>
</tr>
<tr>
<td>Chemotherapy—plant alkaloids (vincristine, vinorelbine, vinblastin)</td>
<td>Peripheral sensory neuropathy Raynaud phenomenon</td>
<td>Yearly history/examination. May have persistent neuropathy—duloxetine may help</td>
</tr>
<tr>
<td>Chemotherapy—purine agonists (fludarabine, pentostatin)</td>
<td>Hematologic disorders Reduction in CD4 count</td>
<td>See “Chemotherapy—alkylating agents” Monitor for infection</td>
</tr>
<tr>
<td>Corticosteroids (dexamethasone, prednisone)</td>
<td>Ocular toxicity Avascular osteonecrosis Osteopenia/osteoporosis</td>
<td>Musculoskeletal examination (yearly)</td>
</tr>
<tr>
<td>Targeted biologic therapy • Monoclonal antibodies • Trastuzumab (anti–HER-2) • Rituximab (anti-CD20 antibody to B lymphocyte receptor) • Panitumumab, cetuximab (anti-EGFR)</td>
<td>Cardiac dysfunction is usually reversible Reduction in immunoglobulins and increased risk of infection</td>
<td>Monitor 2D echo for ejection fraction every 3 mo during therapy and as needed for symptoms Monitor quantitative immunoglobulins if increased frequency of infection</td>
</tr>
<tr>
<td>Multi-targeted tyrosine kinase inhibitors (TKIs) • Erlotinib • Carbozantinib • Regorafenib • Sunitinib • Sorafenib • Axitinib • Pazopanib • Imatinib • Lenvatinib • Dasatinib • Nilotinib • Lapatinib</td>
<td>Fatigue, diarrhea, hypertension, liver injury while on drug but little long-term toxicity. Hand and foot syndrome (palmar–plantar, erythrodysesthesia) vascular injury, fluid retention, renal dysfunction</td>
<td>Routine monitoring for end-organ damage after completion of therapy not indicated</td>
</tr>
</tbody>
</table>
## CANCER SURVIVORSHIP: LATE EFFECTS OF CANCER TREATMENTS (Continued)

<table>
<thead>
<tr>
<th>CA Treatment History</th>
<th>Late Effects</th>
<th>Periodic Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune-mediated therapy</strong> (checkpoint inhibitors)</td>
<td>Autoimmunity—colitis, hepatitis, dermatitis, thyroiditis, hypophysitis, rare myocardial injury Adrenal insufficiency, pneumonitis—often reversible but not always Gonadal dysfunction Growth hormone deficiency (children and adolescents) Hyperthyroidism Hyperprolactinemia Hypothyroidism</td>
<td>Check hormone levels every 4 to 6 mo Cortisol and ACTH stimulation testing based on clinical symptoms TSH, free thyroxine (T₄) yearly Prolactin level (as clinically indicated) Monitor for pituitary insufficiency based on clinical findings Major activity in Lung cancer, Hodgkin’s lymphoma, and renal cell cancer</td>
</tr>
<tr>
<td><strong>Chemotherapy drugs with minimal long-term toxicity effects</strong></td>
<td>Mild reduction in bone marrow and renal reserve Neuropathy Mild bone marrow suppression</td>
<td>Routine monitoring for end-organ dysfunction is not indicated Monitor neuropathy and platelet count. These problems largely reversed when treatment stops</td>
</tr>
<tr>
<td><strong>Drug-Antibody Conjugates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Bretuximab vedotin (anti-CD30 antibody—in Hodgkin lymphoma and T-cell lymphoma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• TDM1 (Kadcyla®) Her2-directed Herceptin linked to chemo for Her2 positive breast cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### DISEASE MANAGEMENT

<table>
<thead>
<tr>
<th>Radiation therapy (field- and dose-dependent)</th>
<th>Cardiac toxicity(^{a}) (chest radiation)</th>
<th>8 AM serum cortisol (yearly × 15 y, and as clinically indicated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central adrenal insufficiency (pediatric brain tumors)</td>
<td>Neurologic examination (yearly)</td>
<td>Head/neck examination (yearly) — persistent dry mouth</td>
</tr>
<tr>
<td>Cerebrovascular complications(^{b})</td>
<td>Blood culture when temperature ≥101°F (38.3°C), rapid institution of empiric antibiotics — increased infection risk with poor spleen function</td>
<td>Increased risk of breast cancer with mediastinal radiation in women 15–35 y old — breast MRI yearly</td>
</tr>
<tr>
<td>Pulmonary injury with symptoms(^{c})</td>
<td></td>
<td>Surveillance for 2nd cancers related to therapeutic radiation</td>
</tr>
<tr>
<td>Functional asplenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bowel injury and obstruction</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AML, acute myelocytic leukemia; BMI, body mass index; BUN, blood urea nitrogen; CBC, complete blood count; CXR, chest x-ray; ECG, electrocardiogram; ECHO, echocardiogram; IV, intravenous; MTX, methotrexate; MUGA, multiple-gated acquisition scan; PFTs, pulmonary function tests; TBI, total-body irradiation; TSH, thyroid-stimulating hormone.

\(^{a}\)Chemotherapeutic agents, by mechanism of action:
- **Alkylating agents:** busulfan, carmustine (BCNU), chlorambucil, cyclophosphamide, ifosfamide, lomustine (CCNU), mechlorethamine, melphalan, procarbazine, thiotepe.
- **Antimetabolites:** MTX, cytosine arabinoside, gemcitabine.
- **Heavy metals:** carboplatin, cisplatin, oxaliplatin.
- **Nonclassical alkylators:** dacarbazine (DTIC), temozolomide.
- **Anthracycline antibiotics:** daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone.
- **Antitumor antibiotics:** bleomycin, mitomycin C.
- **Plant alkaloids:** vinblastine, vincristine, vinorelbine.
- **Purine agonists:** fludarabine, pentostatin, cladribine.
- **Epipodophyllotoxins:** etoposide (VP16), teniposide (VM26).

\(^{b}\)Psychosocial disorders: mental health disorders, risky behaviors, psychosocial disability because of pain, fatigue, limitations in health care/insurance access, “chemo brain” syndrome.

\(^{c}\)Hematologic disorders: acute myeloid leukemia, myelodysplasia.

\(^{d}\)Ocular toxicity: cataracts, orbital hypoplasia, lacrimal duct atrophy, xerophthalmia, keratitis, telangiectasias, retinopathy, optic chiasm neuropathy, endophthalmitis, chronic painful eye, maculopathy, glaucoma.

\(^{e}\)Pulmonary toxicity: pulmonary fibrosis, interstitial pneumonitis, restrictive lung disease, obstructive lung disease. Increased sensitivity to oxygen toxicity — keep FiO\(_2\) ≤28% in patients with previous bleomycin exposure.

\(^{f}\)Renal toxicity: glomerular and tubular renal insufficiency, hypertension, hemolytic uremic syndrome.

\(^{g}\)Urinary tract toxicity: hemorrhagic cystitis, bladder fibrosis, dysfunctional voiding, vesicoureteral reflux, hydrenephrosis, bladder malignancy.

\(^{h}\)Cardiac toxicity: cardiomyopathy, arrhythmias, left ventricular dysfunction, congestive heart failure, pericarditis, pericardial fibrosis, valvular disease, myocardial infarction, atherosclerotic heart disease.

Clinical leukoencephalopathy: spasticity, ataxia, dysarthria, dysphagia, hemiparesis, seizures.

Ototoxicity: sensorineural hearing loss, tinnitus, vertigo, tympanosclerosis, otosclerosis, eustachian tube dysfunction, conductive hearing loss.
CANCER SURVIVORSHIP: LATE EFFECTS OF CANCER TREATMENTS  (Continued)

Oncologic disorders: secondary benign or malignant neoplasm, especially breast CA after mantle radiation, gastrointestinal malignancy after paraaortic radiation for seminoma of the testis.

Cerebrovascular complications: stroke and occlusive cerebral vasculopathy.

Note: Guidelines for surveillance and monitoring for late effects after treatment for adult CAs, available via the National Comprehensive Cancer Network, Inc. (NCCN). (http://www.nccn.org/professionals/physician_gls).


RENAL MASSES, SMALL

Population

– Adults with small renal masses SRM (<4 cm).

Recommendations

ASCO Guidelines (J Clin Oncol. 2017; 35:668-680)

– Based on tumor-specific findings and competing risks of mortality all patients with an SRM (<4 cm in size) should be considered for renal tumor biopsy (RTB) when the results may alter management (strength of recommendation: strong).

– Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy (end-stage renal disease, SRM <1 cm, life expectancy <5 y).

– Partial nephrectomy (PN) for SRM is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach (recommendation: strong).

– Percutaneous thermal ablation should be considered an option for patients who possess tumors such that complete ablation will be achieved. A biopsy should be obtained before or at the time of ablation (recommendation: moderate).

– Radical nephrectomy for SRM should be reserved only for patients who possess a tumor of significant complexity that is not amenable to PN or where PN may result in unacceptable morbidity even when performed at centers of excellence. Referral to experienced surgeon and a center with experience should be considered (recommendation: strong).

– Referral to a nephrologist should be considered if CKD (GFR<45 mL/min) or progressive CKD develops after treatment, especially if associated with proteinuria (recommendation: moderate).
Comments

SRM are commonly discovered incidentally during diagnostic evaluation for other medical conditions. A significant number of SRM are benign. As the size increases (especially >4 cm), the likelihood of malignancy increases. Imaging with MRI, CT scans, and ultrasound cannot make an absolute diagnosis of malignancy, necessitating a core biopsy if possible. About 10%-15% of patients will have a nondiagnostic biopsy and must be followed closely and rebiopsied if the mass is growing. Radiofrequency ablation (RFA) is commonly used to ablate small cancers but should have a biopsy done first to document malignancy.

Decision regarding therapy in patients with significant comorbidities is difficult. The Charleston Comorbidity Index (CCI) is a tool that can predict 1-y mortality. In patients with a short life expectancy, surveillance and supportive care are the best approach for this population. Partial nephrectomy is the treatment of choice for SRM that are amenable to nephron-sparing surgery. Radical nephrectomy in the past has been the procedure of choice in managing small RCC. Today partial nephrectomy is preferred and radical nephrectomy now is the treatment of choice in <30% of patients with SRM.

Sources

- *Eur Urol*. 2015;67

RESPIRATORY TRACT INFECTIONS, LOWER

Population

- Adults.

Recommendations

ESCMID 2011

- For *Streptococcus* pneumonia:
  - Erythromycin MIC >0.5 mg/L predicts clinical failure.
  - Penicillin MIC ≤8 mg/L predicts IV penicillin susceptibility.
- The role of community-acquired MRSA in community-acquired pneumonia (CAP) is poorly defined in Europe.
- A C-reactive protein (CRP) <2 mg/dL at presentation with symptoms >24 h makes pneumonia highly unlikely; a CRP >10 mg/dL makes pneumonia likely.
– Indications for antibiotics in lower respiratory tract infections (LRTIs):
  • Suspected pneumonia.
  • Acute exacerbation of COPD with increased dyspnea, sputum volume, and sputum purulence.
– Evaluation of patients admitted for CAP.
  • Two sets of blood cultures.
  • Pleural fluid analysis is indicated when a significant parapneumonic effusion exists.
  • Sputum Gram stain and culture should be obtained if a purulent sputum sample can be obtained.
  • Consider testing for urine pneumococcal antigen.
  • Antibiotic duration for CAP should not exceed 8 d.

Source

Comments
1. Consider aspiration pneumonia in patients with a pneumonia and dysphagia.
2. Empiric antibiotics of choice for LRTI in outpatient setting are amoxicillin or tetracycline.

RESPIRATORY TRACT INFECTIONS, UPPER

Population
– Adults.

Recommendation
► IDSA 2015
  – Do not prescribe antibiotics for upper respiratory tract infections.

Source

Comments
1. Consider aspiration pneumonia in patients with a pneumonia and dysphagia.
2. Empiric antibiotic of choice for LRTI in outpatient setting is amoxicillin or tetracycline.
RESTLESS LEGS SYNDROME AND PERIODIC LIMB MOVEMENT DISORDERS

Population
– Adults.

Recommendation
American Academy of Neurology 2016, American Academy of Sleep Medicine 2012
– Recommends for moderate to severe restless legs syndrome (RLS).
  • Strong evidence for following meds:
    ° Pramipexole.
    ° Rotigotine.
    ° Cabergoline.
    ° Gabapentin.
  • Moderate evidence for:
    ° Ropinirole.
    ° Pregabalin.
    ° IV ferric carboxymaltose.
– For primary RLS with periodic limb movements of sleep.
  ° Ropinirole.
– For primary RLS with concomitant anxiety or depression.
  ° Ropinirole.
  ° Pramipexole.
  ° Gabapentin.
– For RLS and ferritin <75 μg/L.
  ° Ferrous sulfate with vitamin C.
– For RLS with ESRD on hemodialysis.
  ° Vitamin C and E supplementation.
  ° Consider adding ropinirole, levodopa, or exercise.

Sources

Comments
1. Potential for heart valve damage with pergolide and cabergoline.
2. Insufficient evidence to support any pharmacological treatment for periodic limb movement disorder.
RHEUMATOID ARTHRITIS (RA), BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)

Population
- Adults.

Recommendations

► ACR 2008

1. Anti–TNF-α agents
   a. A tuberculosis (TB) skin test or IGRA must be checked before initiating these medications.
   b. Any patient with latent TB needs at least 1 mo treatment prior to the initiation of a TNF-α or biologic agent.
   c. Recommended for all patients with high disease activity and presence of poor prognostic features of any duration of disease
2. Recommended for patients with disease ≥6 mo who have failed nonbiologic DMARD therapy and have moderate-to-high disease activity, especially if poor prognostic features are present.
3. Abatacept has same indications as anti–TNF-α agents.
4. Rituximab has same indications as anti–TNF-α agents.
5. Recommends withholding all biologic DMARDs 1 wk before or after surgery.

Comment
1. Anti–TNF-α agents, abatacept, and rituximab all contraindicated in:
   a. Serious bacterial, fungal, and viral infections, or with latent TB.
   b. Acute viral hepatitis or Child's B or Child's C cirrhosis.
   c. Instances of a lymphoproliferative disorder treated ≤5 y ago; decompensated congestive heart failure (CHF); or any demyelinating disorder.

Recommendations

► ACR 2012

1. Target low disease activity or remission.
2. MTX or leflunomide monotherapy may be used for patients with any disease severity or duration.
3. Hydroxychloroquine or minocycline monotherapy recommended if low disease activity and duration ≤24 mo.
4. Sulfasalazine recommended for all disease durations and without poor prognostic features.4

4Functional limitation, presence of rheumatoid nodules, secondary Sjögren syndrome, RA vasculitis, Felty syndrome, and RA lung disease.
5. MTX plus either hydroxychloroquine or leflunomide recommended for moderate-to-high disease activity regardless of disease duration.

6. MTX plus sulfasalazine recommended for high disease activity and poor prognostic features.

### RHINITIS

#### MANAGEMENT OF NONINFECTIOUS RHINITIS

**Symptoms of rhinitis:** pruritus of eyes, nose, palate, and ears; watery, rhinorrhea; sneezing; nasal congestion; and postnasal drip

**Signs and symptoms suggest allergic etiology**

**Imaging:** No role for routine sinonasal imaging

**Signs/symptoms suggest structural etiology?**

- Allergen avoidance
- Medication therapy
  - Antihistamines: sneezing, rhinorhea, nasal itch
  - Nasal steroids: sneezing, rhinorhea, nasal itch, congestion, and eye itch
  - Nasal ipratropium: rhinorhea and congestion
  - Leukotriene inhibitors not recommended as primary therapy
  - Cromolyn sodium: weak for sneezing, rhinorhea, nasal itch, and congestion

**Symptoms improved?**

- Yes
  - Consider further diagnostic testing
    - Allergy skin testing
    - Radioallergosorbent (RAST) tests
    - Consider referral to a specialist for immunotherapy
    - Consider infant turbinate reduction for patients with nasal airway obstruction despite medical rx
  - Continue therapy
    - Follow-up as appropriate

- No
  - Consider referral to specialist

**Nonallergic rhinitis**

- Initiate symptomatic therapy:
  - Antihistamines
  - Nasal steroids
  - Nasal ipratropium
  - Azelastine nasal spray
  - Oral decongestant
  - Saline nasal spray
  - Increase fluid intake

**Yes**
Sources
- ICSI, JAN 2011; AAO-HNSF, FEB 2015

Comment
1. Contraindications to DMARD therapy:
   a. Serious bacterial, fungal, or viral infections.
   b. Only DMARDs safe with latent TB are hydroxychloroquine, minocycline, and sulfasalazine.
   c. Avoid MTX for interstitial pneumonitis and for creatinine clearance <30 mL/min.
   d. Avoid MTX and leflunomide for cytopenias, hepatitis, pregnancy, and breast-feeding (also minocycline).
   e. Avoid all DMARDs in Child's B or Child's C cirrhosis.

SCIATICA

Population
- People age ≥16 y with suspected sciatica.

Recommendations

NICE 2016

For low-back pain with sciatica
1. Do not routinely offer imaging in a primary care setting to patient with low-back pain with or without sciatica.
2. Continue aerobic exercise program.
3. Consider spinal manipulation or soft tissue massage as part of treatment for sciatica.
4. Consider cognitive behavioral therapy as part of treatment for sciatica.
5. Promote return to work and normal activities.
6. Consider NSAIDs and low-dose opioids for acute sciatica.
7. For acute, severe sciatica can consider epidural steroid injection.
8. Recommend against opioids and anticonvulsants for chronic low-back pain with sciatica.
9. Consider spinal decompression for people with disabling sciatica for neurological deficits or chronic symptoms refractory to medical management, and spine imaging is consistent with sciatica symptoms.
10. No proven benefit for belts, corsets, foot orthotics, rocker sole shoes, spine traction, acupuncture, ultrasound, transcutaneous electrical nerve stimulation (TENS), and interferential therapy for patients with sciatica.
Source

SEIZURES

Population
– Adults.

Recommendations

ACEP 2014
1. For first generalized convulsive seizure, ED physicians need not initiate chronic antiepileptic therapy.
   a. A precipitating medical condition should be sought.
   b. Need not admit patients who have returned to their clinical baseline.
2. If known seizure disorder, antiepileptic therapy in ED can be administered orally or by IV.
3. For status epilepticus:
   a. First-line therapy is benzodiazepines.
   b. Options for second-line therapy: phenytoin, fosphenytoin, valproic acid, levetiracetam.

Source

Comment
– For refractory status epilepticus, consider intubation and use of a propofol infusion.

Population
– Adults with first unprovoked seizure.

Recommendations

AAN 2015
– Patient education.
   • Recurrent seizures occur most frequently in the first 2 y.
   • Over the long term (>3 y), immediate antiepileptic drug (AED) therapy in unlikely to improve the prognosis for sustained seizure remission.
– Indications for immediate antiepileptic therapy are based on clinical risk of a recurrent seizure.
–Risk factors for a recurrent seizure include:
  • Brain injury.
  • Prior stroke.
  • Abnormal EEG with epileptiform activity.
  • Structural abnormality on brain imaging.
  • Nocturnal seizure.

Source
–https://guidelines.gov/summaries/summary/49218

SEIZURES, FEBRILE

Population
–Children 6 mo to 5 y old.

Recommendations
AAP 2011
–A lumbar puncture should be performed in any child who presents with a fever and seizure and has meningeal signs or whose history is concerning for meningitis.
–Lumbar puncture is an option in children 6–12 mo of age who present with a fever and seizure and are not up to date with their *Haemophilus influenzae* or *Streptococcus pneumoniae* vaccinations.
–Lumbar puncture is an option in a child presenting with a fever and a seizure who has been pretreated with antibiotics.
–Studies that should not be performed for a simple febrile seizure:
  • An EEG.
  • Routine labs including a basic metabolic panel, calcium, phosphorus, magnesium, glucose, or CBC.
  • Neuroimaging.

Source
–http://pediatrics.aappublications.org/content/127/2/389.full.pdf+html

Comment
–A febrile seizure is a seizure accompanied by fever (T ≥100.4°F [38°C]) without CNS infection in a child age 6 mo to 5 y.
### SEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES

<table>
<thead>
<tr>
<th>Infection</th>
<th>Recommended Treatment</th>
<th>Alternative Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chancroid</td>
<td>• Azithromycin 1 g PO × 1</td>
<td>• Ciprofloxacin 500 mg PO bid for 3 d</td>
</tr>
<tr>
<td></td>
<td>• Ceftriaxone 250 mg IM × 1</td>
<td>• Erythromycin base 500 mg PO tid for 7 d</td>
</tr>
<tr>
<td>First episode of genital HSV</td>
<td>• Acyclovir 400 mg PO tid × 7–10 d</td>
<td>• Acyclovir 200 mg PO 5 times a day for 7–10 d</td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 250 mg PO tid × 7–10 d</td>
<td>• Valacyclovir 1 g PO bid × 7–10 d**</td>
</tr>
<tr>
<td></td>
<td>• Valacyclovir 1 g PO bid × 7–10 d</td>
<td></td>
</tr>
<tr>
<td>Suppressive therapy for genital HSV</td>
<td>• Acyclovir 400 mg PO bid</td>
<td>• Valacyclovir 1 g PO daily</td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 250 mg PO bid</td>
<td></td>
</tr>
<tr>
<td>Episodic therapy for recurrent genital HSV</td>
<td>• Acyclovir 400 mg PO tid × 5 d</td>
<td>• Acyclovir 800 mg PO bid × 5 d</td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 125 mg PO bid × 5 d</td>
<td>• Acyclovir 800 mg PO tid × 2 d</td>
</tr>
<tr>
<td></td>
<td>• Valacyclovir 500 mg PO bid × 3 d</td>
<td>• Famciclovir 1000 mg PO bid × 1</td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 800 mg PO bid × 5 d</td>
<td>• Famciclovir 500 mg PO × 1 then 250 mg bid × 2 d</td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 500 mg PO bid × 1</td>
<td>• Valacyclovir 1 g PO daily × 5 d</td>
</tr>
<tr>
<td></td>
<td>• Valacyclovir 1 g PO bid × 5 d</td>
<td></td>
</tr>
<tr>
<td>Suppressive therapy for HIV-positive patients</td>
<td>• Acyclovir 400–800 mg PO bid–tid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 500 mg PO bid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Valacyclovir 500 mg PO bid</td>
<td></td>
</tr>
<tr>
<td>Episodic therapy for recurrent genital HSV in HIV-positive patients</td>
<td>• Acyclovir 400 mg PO tid × 5–10 d</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Famciclovir 500 mg PO bid × 5–10 d</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Valacyclovir 1 g PO bid × 5–10 d</td>
<td></td>
</tr>
<tr>
<td>Granuloma inguinale (Donovanosis)</td>
<td>• Doxycycline 100 mg PO bid × ≥3 wk and until all lesions have completely healed</td>
<td>• Azithromycin 1 g PO weekly × ≥3 wk</td>
</tr>
<tr>
<td></td>
<td>• Ciprofloxacin 750 mg PO bid × ≥3 wk</td>
<td>• Erythromycin base 500 mg PO QID × ≥3 wk</td>
</tr>
<tr>
<td>Infection</td>
<td>Recommended Treatment</td>
<td>Alternative Treatment</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• TMP-SMX 1 double-strength (160/800 mg) tablet PO bid × ≥3 wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Continue all of these treatments until all lesions have completely healed</td>
</tr>
<tr>
<td>Lymphogranuloma venereum</td>
<td>• Doxycycline 100 mg PO bid for × 21 d</td>
<td>• Erythromycin base 500 mg PO qid × 21 d</td>
</tr>
<tr>
<td>Syphilis in adults</td>
<td>• Benzathine penicillin G 2.4 million units IM × 1</td>
<td></td>
</tr>
<tr>
<td>Syphilis in infants and children</td>
<td>• Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units × 1</td>
<td></td>
</tr>
<tr>
<td>Early latent syphilis in adults</td>
<td>• Benzathine penicillin G 2.4 million units IM × 1</td>
<td></td>
</tr>
<tr>
<td>Early latent syphilis in children</td>
<td>• Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units × 1</td>
<td></td>
</tr>
<tr>
<td>Late latent syphilis or latent syphilis of unknown duration in adults</td>
<td>• Benzathine penicillin G 2.4 million units IM weekly × 3 doses</td>
<td></td>
</tr>
<tr>
<td>Late latent syphilis or latent syphilis of unknown duration in children</td>
<td>• Benzathine penicillin G 50,000 units/kg, up to the adult dose of 2.4 million units, IM weekly × 3 doses</td>
<td></td>
</tr>
<tr>
<td>Tertiary syphilis</td>
<td>• Benzathine penicillin G 2.4 million units IM weekly × 3 doses</td>
<td></td>
</tr>
<tr>
<td>Neurosyphilis</td>
<td>• Aqueous crystalline penicillin G 3–4 million units IV q4h × 10–14 d PLUS</td>
<td>• Procaine penicillin 2.4 million units IM daily × 10–14 d PLUS</td>
</tr>
<tr>
<td>Syphilis, pregnant women</td>
<td>• Pregnant women should be treated with the penicillin regimen appropriate for their stage of infection</td>
<td>• Probenecid 500 mg PO qid × 10–14 d</td>
</tr>
<tr>
<td>Disease Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Congenital syphilis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Aqueous crystalline penicillin G 50,000 units/kg/dose IV q12h × 7 d; then q8h × 3 more days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Procaine penicillin G 50,000 units/kg/dose IM daily × 10 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Benzathine penicillin G 50,000 units/kg/dose IM × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Older children with syphilis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Aqueous crystalline penicillin G 50,000 units/kg IV q4–6h × 10 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nongonococcal urethritis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Azithromycin 1 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Doxycycline 100 mg PO bid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base 500 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin ethylsuccinate 800 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Levofloxacin 500 mg PO daily × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Ofloxacin 300 mg PO bid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recurrent or persistent urethritis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Metronidazole 2 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Tinidazole 2 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cervicitis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Azithromycin 1 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Doxycycline 100 mg PO bid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia infections in adolescents, adults</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Azithromycin 1 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Doxycycline 100 mg PO bid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base 500 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin ethylsuccinate 800 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Levofloxacin 500 mg PO daily × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Ofloxacin 300 mg PO bid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia infections in pregnancy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Azithromycin 1 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Amoxicillin 500 mg PO tid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base 500 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin ethylsuccinate 800 mg PO qid × 7 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmia neonatorum from Chlamydia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base or ethylsuccinate 50 mg/kg/d PO qid × 14 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia trachomatis pneumonia in infants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base or ethylsuccinate 50 mg/kg/d PO qid × 14 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia infections in children &lt;45 kg</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythromycin base or ethylsuccinate 50 mg/kg/d PO qid × 14 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia infections in children ≥45 kg and age &lt;8 y</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Azithromycin 1 g PO × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>Recommended Treatment</td>
<td>Alternative Treatment</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td><em>Chlamydia</em> infections in children age ≥8 y</td>
<td>• Azithromycin 1 g PO × 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg PO bid × 7 d</td>
<td></td>
</tr>
<tr>
<td>Uncomplicated gonococcal infections of the cervix, urethra, pharynx, or rectum in adults or children &gt;45 kg</td>
<td>• Ceftriaxone 250 mg IM × 1 PLUS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Azithromycin 1 g PO × 1 OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg daily × 7 d</td>
<td></td>
</tr>
<tr>
<td>Gonococcal conjunctivitis in adults or children &gt;45 kg</td>
<td>• Ceftriaxone 1 g IM × 1</td>
<td></td>
</tr>
<tr>
<td>Gonococcal meningitis or endocarditis in adults or children &gt;45 kg</td>
<td>• Ceftriaxone 1 g IV q12h</td>
<td></td>
</tr>
<tr>
<td>Disseminated gonococcal infection in adults or children &gt;45 kg</td>
<td>• Ceftriaxone 1 g IV/IM daily</td>
<td>• Cefotaxime 1 g IV q8h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Ceftizoxime 1 g IV q8h</td>
</tr>
<tr>
<td>Ophthalmia neonatorum caused by gonococcus</td>
<td>• Ceftriaxone 25–50 mg/kg, not to exceed 125 mg, IV/IM × 1</td>
<td></td>
</tr>
<tr>
<td>Prophylactic treatment of infants born to mothers with gonococcal infection</td>
<td>• Ceftriaxone 25–50 mg/kg, not to exceed 125 mg, IV/IM × 1</td>
<td></td>
</tr>
<tr>
<td>Uncomplicated gonococcal infections of the cervix, urethra, pharynx, or rectum in children ≤45 kg</td>
<td>• Ceftriaxone 125 mg IM × 1</td>
<td></td>
</tr>
<tr>
<td>Gonococcal infections with bacteremia or arthritis in children or adults</td>
<td>• Ceftriaxone 50 mg/kg (maximum dose 1 g) IM/IV daily × 7 d</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ophthalmia neonatorum prophylaxis</td>
<td>• Erythromycin (0.5%) ophthalmic ointment in each eye × 1</td>
<td></td>
</tr>
<tr>
<td>Bacterial vaginosis</td>
<td>• Metronidazole 500 mg PO bid × 7 d&lt;br&gt;• Metronidazole gel 0.75%, 1 applicator (5 g) IVag daily × 5 d&lt;br&gt;• Clindamycin cream 2%, 1 applicator (5 g) IVag qhs × 7 d&lt;sup&gt;d&lt;/sup&gt;</td>
<td>• Tinidazole 2 g PO daily × 3 d&lt;br&gt;• Clindamycin 300 mg PO bid × 7 d&lt;br&gt;• Clindamycin ovules 100 mg IVag qhs × 3 d</td>
</tr>
<tr>
<td>Bacterial vaginosis in pregnancy</td>
<td>• Metronidazole 500 mg PO bid × 7 d&lt;br&gt;• Metronidazole 250 mg PO tid × 7 d&lt;br&gt;• Clindamycin 300 mg PO bid × 7 d</td>
<td></td>
</tr>
<tr>
<td>Trichomoniasis</td>
<td>• Metronidazole 2 g PO × 1&lt;sup&gt;c&lt;/sup&gt;&lt;br&gt;• Tinidazole 2 g PO × 1</td>
<td></td>
</tr>
<tr>
<td>Candidal vaginitis</td>
<td>• Butoconazole 2% cream 5 g IVag × 3 d&lt;br&gt;• Clotrimazole 1% cream 5 g IVag × 7–14 d&lt;br&gt;• Clotrimazole 2% cream 5 g IVag × 3 d&lt;br&gt;• Nystatin 100,000-unit vaginal tablet, 1 tablet IVag × 14 d&lt;br&gt;• Miconazole 2% cream 5 g IVag × 7 d&lt;br&gt;• Miconazole 4% cream 5 g IVag × 3 d&lt;br&gt;• Miconazole 100-mg vaginal suppository, one suppository IVag × 7 d&lt;br&gt;• Miconazole 200-mg vaginal suppository, one suppository IVag × 3 d&lt;br&gt;• Miconazole 1200-mg vaginal suppository, one suppository IVag × 1</td>
<td>• Fluconazole 150-mg oral tablet, 1 tablet in single dose</td>
</tr>
</tbody>
</table>

<sup>a</sup> PO = orally, PO = per os
<sup>b</sup> IVag = intra-vaginally
<sup>c</sup> qhs = 3 times a day
<sup>d</sup> d = days
<table>
<thead>
<tr>
<th>Infection</th>
<th>Recommended Treatment</th>
<th>Alternative Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Tioconazole 6.5% ointment 5 g IVag × 1</td>
<td>• Clindamycin 900 mg IV q8h <strong>PLUS</strong></td>
</tr>
<tr>
<td></td>
<td>• Terconazole 0.4% cream 5 g IVag × 7 d</td>
<td>• Gentamicin loading dose IV or IM (2 mg/kg of body weight), followed by a maintenance</td>
</tr>
<tr>
<td></td>
<td>• Terconazole 0.8% cream 5 g IVag × 3 d</td>
<td>dose (1.5 mg/kg) q8h. Single daily dosing (3–5 mg/kg) can be substituted.</td>
</tr>
<tr>
<td></td>
<td>• Terconazole 80-mg vaginal suppository, 1 suppository IVag</td>
<td><strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>× 3 d</td>
<td>• Ampicillin/sulbactam 3 g IV q6h <strong>PLUS</strong></td>
</tr>
<tr>
<td>Severe pelvic inflammatory</td>
<td>• Cefotetan 2 g IV q12h <strong>OR</strong></td>
<td><strong>OR</strong></td>
</tr>
<tr>
<td>disease</td>
<td>• Cefoxitin 2 g IV q6h <strong>PLUS</strong></td>
<td>• Doxycycline 100 mg PO/IV bid</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg PO/IV bid</td>
<td></td>
</tr>
<tr>
<td>Mild-to-moderate pelvic</td>
<td>• Ceftriaxone 250 mg IM × 1 <strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td>inflammatory disease</td>
<td>• Cefoxitin 2 g IM × 1 and probenecid 1 g PO × 1 <strong>PLUS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg PO bid × 14 d ± metronidazole 500 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO bid × 14 d</td>
<td></td>
</tr>
<tr>
<td>Epididymitis</td>
<td>• Ceftriaxone 250 mg IM × 1 <strong>PLUS</strong></td>
<td>• Levofloxacin 500 mg PO daily × 10 d</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg PO bid × 10 d</td>
<td>• Ofloxacin 300 mg PO bid × 10 d</td>
</tr>
<tr>
<td>External genital warts</td>
<td>Provider-Administered:</td>
<td>Patient-Administered:</td>
</tr>
<tr>
<td></td>
<td>• Cryotherapy every 1–2 wk</td>
<td>• Podofilox 0.5% solution or gel</td>
</tr>
<tr>
<td></td>
<td>• Podophyllin resin 10%–25% in a compound tincture of</td>
<td>• Imiquimod 5% cream</td>
</tr>
<tr>
<td></td>
<td>benzoin</td>
<td>• Sinecatechins 15% ointment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease</th>
<th>Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical warts</td>
<td>• Biopsy to exclude high-grade SIL must be performed before treatment is initiated</td>
</tr>
<tr>
<td>Vaginal warts</td>
<td>• TCA or BCA 80%–90% applied only to warts, repeated weekly</td>
</tr>
<tr>
<td>Urethral meatal warts</td>
<td>• Cryotherapy every 1–2 wk • TCA or BCA 80%–90% applied only to warts, repeated weekly</td>
</tr>
<tr>
<td>Anal warts</td>
<td>• Cryotherapy every 1–2 wk • TCA or BCA 80%–90% applied only to warts, repeated weekly • Surgical removal by tangential scissor excision, tangential shave excision, curettage, or electrosurgery</td>
</tr>
<tr>
<td>Proctitis</td>
<td>• Ceftriaxone 250 mg IM × 1 PLUS • Doxycycline 100 mg PO bid × 7 d</td>
</tr>
<tr>
<td>Pediculosis pubis</td>
<td>• Permethrin 1% cream rinse applied to affected areas and washed off after 10 min • Pyrethrins with piperonyl butoxide applied to the affected area and washed off after 10 min • Malathion 0.5% lotion applied for 8–12 h and then washed off • Ivermectin 250 μg/kg PO, repeated in 2 wk</td>
</tr>
<tr>
<td>Scabies</td>
<td>• Permethrin cream (5%) applied to all areas of the body from the neck down and washed off after 8–14 h • Ivermectin 200 μg/kg PO, repeat in 2 wk • Lindane (1%) 1 oz of lotion (or 30 g of cream) applied in a thin layer to all areas of the body from the neck down and thoroughly washed off after 8 h</td>
</tr>
</tbody>
</table>

BCA, bichloroacetic acid; bid, twice a day; h, hour(s); HIV, human immunodeficiency virus; HSV, herpes simplex virus; IM, intramuscular; IV, intravenous; IVag, intravaginally; PO, by mouth; q, every; qhs, at bedtime; qid, four 4 times a day; SIL, squamous intraepithelial lesion; TCA, trichloroacetic acid; tid, 3 times a day; TMP-SMX, trimethoprim-sulfamethoxazole.

*Treatment can be extended if healing is incomplete after 10 d of therapy.

*Consider concomitant treatment of gonorrhea.

*Avoid alcohol during treatment and for 24 h after treatment is completed.

*Clindamycin cream may weaken latex condoms and diaphragms during treatment and for 5 d thereafter.

SINUSITIS

Population
– Children age 1–18 y.

Recommendation

ACEP 2013
– Avoid prescribing antibiotics in the ER for patients presenting with uncomplicated acute sinusitis.

Source

Comment
– Improvement of symptoms should occur within 72 h of antibiotic initiation.

SINUSITIS, ACUTE BACTERIAL

Population
– Children age 1–18 y with acute bacterial sinusitis.

Recommendations

AAP 2013
– Presumptive acute sinusitis if child with acute URI and one of the following:
  • Nasal discharge or persistent cough lasting more than 10 d.
  • Worsening course.
  • Severe onset with fever ≥102.2°F and purulent nasal discharge for at least 3 d.
– Recommend against imaging studies for uncomplicated sinusitis.
– Contrast-enhanced CT scan of sinuses for any suspicion of orbital or CNS involvement.
– Recommend antibiotics for any sinusitis with a severe onset or worsening course.
  • Amoxicillin +/- clavulanate is first-line therapy.
  • Persistent cough or rhinorrhea in the absence of severe symptoms may be managed with ongoing observation.

Source
– https://guidelines.gov/summaries/summary/46939
STROKE, ACUTE ISCHEMIC

Population
– Adults age 18 y and older presenting to the emergency department with an acute ischemic stroke.

Recommendations

AHA/ASA 2016
– For otherwise medically eligible patients ≥18 y of age, intravenous alteplase administration within 3 h is equally recommended for patients <80 y of age AND ≥80 y of age.
– For severe stroke symptoms, intravenous alteplase is indicated within 3 h from symptom onset of ischemic stroke (even for NIHSS >22).
– Intravenous alteplase treatment in the 3- to 4.5-h time window is also recommended for those patients <80 y of age without a history of both diabetes mellitus and prior stroke, NIHSS score <25, not taking any anticoagulants, and without imaging evidence of ischemic injury involving more than one-third of the MCA territory.
– In patients with end-stage renal disease on hemodialysis and normal aPTT, intravenous alteplase is recommended.

Stroke Rehabilitation
– It is recommended that stroke survivors receive rehabilitation at an intensity commensurate with anticipated benefit and tolerance.
– During hospitalization and inpatient rehabilitation, regular skin assessments are recommended with objective scales of risk such as the Braden scale.
– Regular turning, good skin hygiene, and use of specialized mattresses, wheelchair cushions, and seating are recommended until mobility returns.
– Resting ankle splints used at night and during assisted standing may be considered for prevention of ankle contracture in the hemiplegic limb.
– In ischemic stroke, prophylactic-dose subcutaneous heparin (UFH or LMWH) should be used for the duration of the acute and rehabilitation hospital stay or until the stroke survivor regains mobility.
– Remove a Foley catheter within 24 h of hospitalization if possible.
– Assessment of urinary retention through bladder scanning or intermittent catheterizations after voiding while recording volumes is recommended for patients with urinary incontinence or retention.
– It is recommended that individuals with stroke discharged to the community participate in exercise programs with balance training to reduce falls.
- It is recommended that individuals with stroke be provided a formal fall prevention program during hospitalization.
- Administration of a structured depression inventory such as the Patient Health Questionnaire-2 is recommended to routinely screen for poststroke depression. Antidepressants should be prescribed to all patients with depression.
- It is recommended that individuals with stroke residing in long-term care facilities be evaluated for calcium and vitamin D supplementation.
- It is recommended that all individuals with stroke be provided a formal assessment of their ADLs and IADLs, communication abilities, and functional mobility before discharge from acute care hospitalization and the findings be incorporated into the care transition and the discharge planning process.
- Assess speech, language, cognitive communication, pragmatics, reading, and writing; identify communicative strengths and weaknesses; and identify helpful compensatory strategies.

Sources

ACEP 2015, AAN 2015
- IV tissue plasminogen activator (tPA) should be offered to patients presenting to the ED with an acute ischemic stroke if within 3 h of symptom onset and the hospital has systems in place to safely administer the medication.
- IV tPA may be offered to patients presenting to the ED with an acute ischemic stroke if between 3–4.5 h of symptom onset and the hospital has systems in place to safely administer the medication.

Source
- https://guidelines.gov/summaries/summary/49538
**STROKE, RECURRENCE**

**Population**
- Atrial fibrillation.

**Recommendations**

▲ AHA/ASA 2014

1. For most patients with a stroke or TIA in the setting of AF, it is reasonable to initiate oral anticoagulation within 14 d after the onset of neurological symptoms. In the presence of high risk for hemorrhagic conversion (ie, large infarct, hemorrhagic transformation on initial imaging, uncontrolled hypertension, or hemorrhage tendency), it is reasonable to delay initiation of oral anticoagulation beyond 14 d.

2. VKA therapy (Class I; Level of Evidence A), apixaban (Class I; Level of Evidence A), and dabigatran (Class I; Level of Evidence B) are all indicated for the prevention of recurrent stroke in patients with nonvalvular AF, whether paroxysmal or permanent. Rivaroxaban is reasonable for the prevention of recurrent stroke in patients with nonvalvular AF.

3. For patients with ischemic stroke or TIA and AF who are unable to take oral anticoagulants, aspirin alone is recommended. The addition of clopidogrel to aspirin therapy might be reasonable.

4. The usefulness of closure of the left atrial appendage with the WATCHMAN device in patients with ischemic stroke or TIA and AF is uncertain.

**Population**
- Hypertension.

**Recommendation**

▲ AHA/ASA 2014

- Initiation of BP therapy is indicated for previously untreated patients with ischemic stroke or TIA who after the first several days have an established SBP ≥140 mm Hg or DBP ≥90 mm Hg. In patients previously treated for HTN, resumption of BP therapy is indicated beyond the first several days for both prevention of recurrent stroke and other vascular events. Goals: <140/90 mm Hg; for recent lacunar stroke reasonable SBP target <130 mm Hg.
Population
– Dyslipidemia.

Recommendation
▶ AHA/ASA 2014
– Intensive lipid-lowering effects are recommended in patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, an LDL-C ≥100 mg/dL and with/without evidence of other clinical ASCVD.

Population
– Glucose disorders.

Recommendation
▶ AHA/ASA 2014
– All patients should be screened for DM (HgbA1c).

Population
– Obesity

Recommendation
▶ AHA/ASA 2014
– Calculate BMI for all patients and start weight-loss management when necessary.

Population
– Sleep apnea.

Recommendation
▶ AHA/ASA 2014
– A sleep study might be considered for patients with history of CVA or TIA on the basis of very high prevalence in this population.

Population
– MI and thrombus.

Recommendation
▶ AHA/ASA 2014
– VKA therapy (INR: 2–3) for 3 mo may be considered in patients with ischemic stroke or TIA in the setting of acute anterior STEMI.
Population
– Cardiomyopathy.

Recommendation
AHA/ASA 2014
– In patients with ischemic stroke or TIA in sinus rhythm who have left atrial or left ventricular thrombus demonstrated by echocardiography or other imaging modality, anticoagulant therapy with a VKA is recommended for ≥3 mo.

Population
– Valvular heart disease.

Recommendations
AHA/ASA 2014
– For patients with ischemic stroke or TIA who have rheumatic mitral valve disease and AF, long-term VKA therapy with an INR target of 2.5 (range 2.0–3.0) is recommended.
– For patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended.

Population
– Prosthetic heart valve.

Recommendations
AHA/ASA 2014
– For patients with a mechanical aortic valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 2.5 (range, 2.0–3.0).
– For patients with a mechanical mitral valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 3.0 (range, 2.5–3.5).
– For patients with a mechanical mitral or aortic valve who have a history of ischemic stroke or TIA before its insertion and who are at low risk for bleeding, the addition of aspirin 75 to 100 mg/d to VKA therapy is recommended.
– For patients with a bioprosthetic aortic or mitral valve, a history of ischemic stroke or TIA before its insertion, and no other indication for anticoagulation therapy beyond 3 to 6 mo from the valve placement, long-term therapy with aspirin 75 to 100 mg/d is recommended in preference to long-term anticoagulation.
Population
- Aortic arch atheroma.

Recommendation
▶ AHA/ASA 2014
- For patients with an ischemic stroke or TIA and evidence of aortic arch atheroma, antiplatelet therapy is recommended.

Population
- PFO.

Recommendations
▶ AHA/ASA 2014
- For patients with an ischemic stroke or TIA and a PFO who are not undergoing anticoagulation therapy, antiplatelet therapy is recommended.
- For patients with an ischemic stroke or TIA and both a PFO and a venous source of embolism, anticoagulation is indicated, depending on stroke characteristics. When anticoagulation is contraindicated, an inferior vena cava filter is reasonable.
- For patients with a cryptogenic ischemic stroke or TIA and a PFO without evidence for DVT, available data do not support a benefit for PFO closure.
- In the setting of PFO and DVT, PFO closure by a transcatheter device might be considered, depending on the risk of recurrent DVT.

Population
- Homocysteinemia.

Recommendation
▶ AHA/ASA 2014
- Routine screening for hyperhomocysteinemia among patients with a recent ischemic stroke or TIA is not indicated.

Population
- Hypercoagulation.

Recommendations
▶ AHA/ASA 2014
- The usefulness of screening for thrombophilic states in patients with ischemic stroke or TIA is unknown.
- Antiplatelet therapy is recommended in patients who are found to have abnormal findings on coagulation testing after an initial ischemic stroke or TIA if anticoagulation therapy is not administered.
Population
– Sickle cell disease.

Recommendation
AHA/ASA 2014
- For patients with sickle cell disease and prior ischemic stroke or TIA, chronic blood transfusions to reduce hemoglobin S to <30% of total hemoglobin are recommended.

Population
– Pregnancy.

Recommendations
AHA/ASA 2014
1. In the presence of a high-risk condition that would require anticoagulation outside of pregnancy, the following options are reasonable:
   a. LMWH twice daily throughout pregnancy, with dose adjusted to achieve the LMWH manufacturer’s recommended peak anti-Xa level 4 h after injection, OR
   b. Adjusted-dose UFH throughout pregnancy, administered subcutaneously every 12 h in doses adjusted to keep the midinterval aPTT at least twice control or to maintain an anti-Xa heparin level of 0.35 to 0.70 U/mL, OR
   c. UFH or LMWH (as above) until the 13th week, followed by substitution of a VKA until close to delivery, when UFH or LMWH is resumed
2. For pregnant women receiving adjusted-dose LMWH therapy for a high-risk condition that would require anticoagulation outside of pregnancy, and when delivery is planned, it is reasonable to discontinue LMWH ≥24 h before induction of labor or cesarean section.
3. In the presence of a low-risk situation in which antiplatelet therapy would be the treatment recommendation outside of pregnancy, UFH or LMWH, or no treatment may be considered during the first trimester of pregnancy depending on the clinical situation.

Population
– Breast-feeding
Recommendations

AHA/ASA 2014

– In the presence of a high-risk condition that would require anticoagulation outside of pregnancy, it is reasonable to use warfarin, UFH, or LMWH.
– In the presence of a low-risk situation in which antiplatelet therapy would be the treatment recommendation outside of pregnancy, low-dose aspirin use may be considered.

Sources

– http://stroke.ahajournals.org

AHA/ASA ISCHEMIC STROKE GUIDELINES 2013

• Physicians should use stroke assessment tools like the Cincinnati Prehospital Stroke Scale or the Los Angeles Prehospital Stroke Screen to aid in prompt assessment.
• The role of 9-1-1 emergency systems should be recommended to ensure prompt transport of patients to the appropriate emergency system.
• Physicians should encourage their local hospitals to become Primary Care Centers or Comprehensive Care Centers.
• Neurology imaging is essential. If not available, teleradiology systems should be encouraged to allow for prompt diagnosis.
• A multidisciplinary stroke team should be established including physicians, nurses, and laboratory and radiology personnel.
• An emergency department stroke protocol should exist to allow prompt evaluation and initiation of fibrinolytic treatment within 60 min. This should include a stroke severity scale such as NIHSS.
• Noncontrast CT of the head is the first imaging test suggested to exclude intracerebral hemorrhage. A noncontrast CT or MRI is recommended before fibrinolysis is started. These tests should be interpreted within 45 min of patient’s arrival.
• Consideration of intravenous recombinant tissue-type plasminogen activator (rtPA) should be considered in all ischemic stroke patients who meet the indications and have no exclusion criteria.
• Imaging with noncontrast CT or MRI is indicated in all patients presenting with transient neurologic symptoms (TIA). The MRI is the test of choice. The test should be performed within 24 h of presentation.
• Sources of hyperthermia should be investigated and treatment should be started.
• Hypertension for hypertension during a stroke should be withheld until BP 220/120 mm Hg. If the BP exceeds that level, it should be lowered by 15% during the first 24 h. BP goals are lower if the patient is to receive rtPA.
• Treat persistent hyperglycemia at ranges of 140–180 mg/dL.
• Intravenous rtPA should be administered to all eligible patients even if intraarterial treatments are being considered. Intraarterial fibrinolysis should be considered with major strokes of <6 h duration involving the middle cerebral artery. This procedure should be performed only in stroke centers.
• Urgent anticoagulation to prevent recurrent stroke or improve symptoms is not recommended.
• Aspirin within 24–48 h after stroke is recommended. ASA administration within 24 h postfibrinolysis is not recommended.
• Stroke Units, which give comprehensive specialized stroke care, are recommended.


INTRACRANIAL STROKE AHA/ASA GUIDELINES 2014

• For patients with recent (<30 d) stroke or TIA attributable to severe stenosis (70%–99%) of a major intracranial artery, the addition of clopidogrel 75 mg daily in addition to ASA for 90 d might be reasonable.
• The combination of aspirin and clopidogrel might be considered for initiation within 24 h of a minor ischemic stroke or TIA and for continuation for 90 d.
• For patients with a stroke or TIA attributable to 50%–99% stenosis of a major intracranial artery, maintenance of SBP <140 mm Hg, and high-intensity statin therapy are recommended.
• For patients with a stroke or TIA attributable to moderate stenosis (50%–69%) of a major intracranial artery, angioplasty or stenting is not recommended given the low rate of stroke on medical management and the inherent periprocedural risk of endovascular treatment.
• For patients with stroke or TIA attributable to severe stenosis (70%–99%) of a major intracranial artery, stenting with the Wingspan stent system is not recommended as an initial treatment, even for patients who were taking an antithrombotic agent at the time of the stroke or TIA.
• For patients with severe stenosis (70%–99%) of a major intracranial artery and recurrent TIA or stroke after institution of aspirin and clopidogrel therapy, achievement of systolic BP <140 mm Hg, and high-intensity statin therapy, the usefulness of angioplasty alone or placement of a Wingspan stent or other stents is unknown and is considered investigational.

SYNCOPE

Population
—Adults presenting with syncope.

Recommendations
► ACC/AHA 2017

ADDITIONAL EVALUATION AND DIAGNOSIS FOR SYNCOPE

<table>
<thead>
<tr>
<th>Initial evaluation</th>
<th>Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>history, physical exam, ECG (Class I)</td>
<td>Stress testing (Class IIa)†</td>
</tr>
<tr>
<td>No additional evaluation needed*</td>
<td>TTE (Class IIa)†</td>
</tr>
<tr>
<td>Targeted blood testing (Class IIa)†</td>
<td>EPS (Class IIa)†</td>
</tr>
<tr>
<td>Initial evaluation suggests reflex syncope</td>
<td>MRA or CT (Class IIb)†</td>
</tr>
<tr>
<td>Tilt-table testing (Class IIa)†</td>
<td>Options</td>
</tr>
<tr>
<td>Initial evaluation suggests CV abnormalities</td>
<td>Implantable cardiac monitor (Class IIa)†</td>
</tr>
<tr>
<td>Cardiac monitor selected based on frequency and nature (Class I)</td>
<td>Ambulatory external cardiac monitor (Class IIa)†</td>
</tr>
<tr>
<td>Options</td>
<td></td>
</tr>
</tbody>
</table>

Initial Evaluation of Syncope

HISTORICAL CHARACTERISTICS ASSOCIATED WITH INCREASED PROBABILITY OF CARDIAC AND NONCARDIAC CAUSES OF SYNCOPE

More Often Associated with Cardiac Causes of Syncope

- Older age (>60 y)
- Male sex
- Presence of known ischemic heart disease, structural heart disease, previous arrhythmias, or reduced ventricular function
- Brief prodrome, such as palpitations, or sudden loss of consciousness without prodrome
- Syncope during exertion
- Syncope in the supine position
• Low number of syncope episodes (1 or 2)
• Abnormal cardiac examination
• Family history of inheritable conditions or premature SCD (<50 y of age)
• Presence of known congenital heart disease

**More Often Associated with Noncardiac Causes of Syncope**

• Younger age
• No known cardiac disease
• Syncope only in the standing position
• Positional change from supine or sitting to standing
• Presence of prodrome: nausea, vomiting, feeling warmth
• Situational triggers: cough, laugh, micturition, defecation, deglutition
• Frequent recurrence and prolonged history of syncope with similar characteristics

**SCD, sudden cardiac death.**

**Historical Features of Cardiac vs. Non-cardiac Syncope**

<table>
<thead>
<tr>
<th>Cardiac Arrhythmic Conditions</th>
<th>Cardiac or Vascular Nonarrhythmic Conditions</th>
<th>Noncardiac Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Sustained or symptomatic VT</td>
<td>• Cardiac ischemia</td>
<td>• Severe anemia/gastrointestinal bleeding</td>
</tr>
<tr>
<td>• Symptomatic conduction system disease or Mobitz II or third-degree heart block</td>
<td>• Severe aortic stenosis</td>
<td>• Major traumatic injury due to syncope</td>
</tr>
<tr>
<td>• Symptomatic bradycardia or sinus pauses not related to neurally mediated syncope</td>
<td>• Cardiac tamponade</td>
<td>• Persistent vital sign abnormalities</td>
</tr>
<tr>
<td>• Symptomatic SVT</td>
<td>• HCM</td>
<td></td>
</tr>
<tr>
<td>• Pacemaker, ICD malfunction</td>
<td>• Severe prosthetic valve dysfunction</td>
<td></td>
</tr>
<tr>
<td>• Inheritable cardiovascular conditions predisposing to arrhythmias</td>
<td>• Pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aortic dissection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acute HF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Moderate-to-severe LV dysfunction</td>
<td></td>
</tr>
</tbody>
</table>
Serious Medical Conditions Associated with Syncope

INDICATIONS FOR HOSPITALIZATION FOR SYNOCOPE EVALUATIONS

Syncope initial evaluation

Serious medical conditions present? (Table 7)

Yes

Inpatient evaluation (Class I)

Manage presumptive reflex-mediated syncope in outpatient setting (Class IIa)

Structured ED observation protocol for intermediate-risk pts (Class IIa)

Manage selected pts with suspected cardiac syncope in outpatient setting (Class IIIb)

No

Recommended Tests for Syncope

- EKG.
- Complete blood count, basic metabolic panel, and other targeted labs based on clinical assessment.
- Echocardiogram if structural heart disease is suspected.
- Stress test if exertional syncope of unclear etiology.
- Continuous telemetry monitoring for patients admitted to hospital.
- Prolonged cardiac monitoring if arrhythmic syncope is suspected.
- Electrophysiologic study if syncope of suspected arrhythmic etiology with negative cardiac monitoring.

Other Interventions for Syncope

- Implantable cardioverter-defibrillator (ICD) implantation is recommended in patients with arrhythmogenic right ventricular cardiomyopathy who present with syncope and have a documented sustained ventricular arrhythmia.

Sources

SYPHILIS

Population
– Adults.

Recommendations
► IDSA 2011
– Penicillin G 2.4 million units is drug of choice for early syphilis.
– Cerebrospinal fluid (CSF) analysis is indicated if:
  • Early syphilis infection and neurologic symptoms.
  • Late latent syphilis.
– HIV-infected patients with rapid plasma reagent (RPR) titer ≥1:32 or CD4 <350 cells/mm³.
– Patients with early syphilis do not achieve a ≥4-fold decline in RPR titers within 12 mo.
– Doxycycline is second-line therapy for early syphilis in penicillin-allergic patients.
– Ceftriaxone is second-line therapy for neurosyphilis in penicillin-allergic patients.

Source
– http://cid.oxfordjournals.org/content/53/suppl_3/S110.abstract

Comment
– Avoid doxycycline in pregnancy.

THROMBOCYTOPENIA-IMMUNE MEDIATED

Population
– Adults.

Recommendations
► American Society of Hematology (ASH)—Evidence-Based Practice Guidelines for ITP 2011

Diagnosis
• Diagnosis of exclusion—no reliable diagnostic test (including antiplatelet antibody studies). Bone marrow examination not necessary irrespective of age in patients with typical immune thrombocytopenia purpura (ITP) (healthy with isolated thrombocytopenia with large normal-appearing platelets on peripheral blood smear). Testing patients for underlying hepatitis C and HIV is recommended. Testing for another underlying illness (rheumatologic disorders, lymphoproliferative disease, Helicobacter pylori infection, antiphospholipid syndrome) is based on history and physical exam.
- **Treatment of newly diagnosed ITP**: Treat if platelet count <30,000 with or without bleeding. Longer courses of corticosteroids (prednisone 0.5-2 mg/kg daily with taper) is preferred over shorter courses of high-dose corticosteroids (40 mg of decadron daily x 4) or intravenous immune globulin (IVIG). IVIG should be used with corticosteroids when a more rapid rise in platelet count if platelets <30,000, second-line therapy (Rituxan is required. Either IVIG or anti-D immune globulin (in patients that are Rh(+) and spleen in place) can be used as first-line therapy if corticosteroids are contraindicated. Dose of IVIG should be 1 g/kg as a one-time dose that may be repeated as necessary. *(Lancet Haematol. 2016;3:e489) (Blood. 2016;127:296)* (see Table V).

- **Treatment of patients who are unresponsive or relapse after initial therapy**: Splenectomy, either laparoscopic or open, should be done at least 2 to 4 wk after vaccination with pneumococcal, meningococcal, and *Haemophilus influenzae* b vaccine. Splenectomy is significantly more effective in patients less than 40 yr old compared to the elderly. Thrombopoietin receptor agonists (romiplostim or eltrombopag) are used often in second-line therapy after steroids and IVIG failure or after splenectomy relapse to maintain an adequate platelet count. *(Blood. 2012;120:960. J Thromb Haemost. 2015;13:457. Lancet. 2008;371:395. Blood. 2013;121:537)*

  - Thrombopoietin receptor agonists can be used in patients at risk for bleeding who have failed one line of therapy but have not had a splenectomy. Response rate is 80%–90%. Rituximab may be considered in patients at risk of bleeding who have failed one line of therapy, including splenectomy. *(N Engl J Med. 2011;366:734. Blood. 2014;124:3228)*

**TABLE V**

<table>
<thead>
<tr>
<th>FIRST-LINE THERAPY FOR ITP</th>
<th>RR</th>
<th>% WITH SUSTAINED RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORTICOSTEROIDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone 0.5–2 mg/kg/d for 2 wk followed by taper</td>
<td>70%–80%</td>
<td>10-y disease-free—13%–15%</td>
</tr>
<tr>
<td>Dexamethasone 40 mg daily for 4 d every 2–4 wk for 1–4 cycles</td>
<td>90%</td>
<td>As high as 50% (2–5 y follow-up)</td>
</tr>
<tr>
<td>IV anti-D immune globulin 50–75 μg/kg—warning regarding brisk hemolysis and rare DIC</td>
<td>80%</td>
<td>Usually lasts 3–4 wk, but may persist for months in some patients</td>
</tr>
<tr>
<td>IVIG 0.4 g/kg/d × 5 d or 1 g/kg/d for 1–2 d</td>
<td>80%</td>
<td>Transient benefit lasting 2–4 wk</td>
</tr>
</tbody>
</table>
Treatment of ITP after splenectomy

- No further treatment is indicated in asymptomatic patients with platelet count >30,000.
- If platelets <30,000, second-line therapy (Rituxan, thrombopoietin receptor agonists, and immunosuppression) should be used (see Table VI).

Treatment of ITP in pregnancy

- In pregnant patients requiring therapy, corticosteroids or IVIG should be used. Romiplostim and eltrombopag are not approved for use in pregnant women.
- For refractory patients, splenectomy can be performed during second trimester. For pregnant women with ITP, method of delivery is based upon obstetrical indications.

Treatment of specific forms of secondary ITP (see Table VII).

- HCV-associated: Antiviral therapy should be considered in absence of contraindications. Initial therapy in this setting should be IVIG.
- HIV-associated: HIV treatment should be considered first unless patient has significant bleeding complications. If ITP therapy is required use corticosteroids, IVIG, anti-D immune globulin, and romiplostim or eltrombopag. Refractory patients should have a splenectomy.
- H. pylori-associated: Eradication therapy of newly diagnosed active H. pylori infection (stool antigen, urea breath test, endoscopic biopsy) will result in resolution of ITP in 25%-35% of patients.

Sources

- Blood. 2016;128:1547
- Blood. 2011;117:4190-4207
- Blood. 2010;115:168-186

### TABLE VI

<table>
<thead>
<tr>
<th>SELECTED SECOND-LINE THERAPY OPTIONS IN ADULT ITP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TPO RECEPTOR AGONIST</strong></td>
</tr>
<tr>
<td>Eltrombopag 25–75 mg orally daily</td>
</tr>
<tr>
<td>Romiplostim 1–10 μg/kg SQ weekly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Immunosuppression</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Azathioprine 1–2 mg/kg</td>
<td>40%</td>
</tr>
<tr>
<td>Cyclosporine 5 mg/kg/d for 6 d then 2.5–3 m/kg/d to titrate blood levels of 100 to 200 mg/mL</td>
<td>50%–60%</td>
</tr>
<tr>
<td>Cytoxan 1–2 mg/kg orally or IV (0.3–1 g/m²) for 113 doses every 2–4 wk</td>
<td>30%–60%</td>
</tr>
<tr>
<td>Rituximab 375 mg/m² weekly × 4</td>
<td>50%–60% respond—sustained &gt;3–5 y in 10%–15%</td>
</tr>
</tbody>
</table>
CHAPTER 3

SELECTED SECOND-LINE THERAPY OPTIONS IN ADULT ITP (Continued)

<table>
<thead>
<tr>
<th>TPO RECEPTOR AGONIST</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncertain Mechanism</td>
<td></td>
</tr>
<tr>
<td>Danazol 200 mg 2–4× daily (orally)</td>
<td>~50%</td>
</tr>
<tr>
<td>Vinca alkaloid 1–2 mg IV weekly to max of 6 mg</td>
<td>~30% variable</td>
</tr>
</tbody>
</table>

TABLE VII

UNDERLYING CAUSES ASSOCIATED WITH ITP

- Drug induced (trimethoprim-sulfa, rifampin, carbamazepine, vancomycin, quinine derivatives, and many more).
- Systemic lupus/Sjögren syndrome, and other rheumatologic diseases.
- Infections—hepatitis C, HIV, cytomegalovirus (CMV), Helicobacter pylori, Epstein-Barr virus (EBV), varicella.
- Indolent lymphomas, breast and colon cancer.
- Vaccinations—mostly in children.
- Common variable immunodeficiency—almost exclusively in children.

Comment

- Clinical Information
  - Be aware of autosomal dominant hereditary macrothrombocytopenia. Platelets are large, hypogranular, and misshapen with counts between 30 and 60,000. Bleeding is modest but is often confused with ITP. The treatment is with platelet transfusion for significant bleeding. Treatment for ITP is ineffective.
  - TTP (thrombotic thrombocytopenic purpura) should always be excluded. These patients will be ill with low-grade fever, muscle aches, chest pain, and altered mental status. They will have thrombocytopenia and a hemolytic anemia with red cell fragmentation, elevated reticulocyte count, and significant elevation of lactate dehydrogenase. This is a medical emergency and should be treated urgently with plasma exchange.
  - In the elderly, myelodysplastic syndrome is common, but isolated thrombocytopenia occurs in <10%. ITP is by far the most common cause of isolated thrombocytopenia, even in elderly patients.
  - Treating patients for active H. pylori infection with new-onset ITP will result in a durable complete remission in up to 50% of patients.
  - Be alert to pseudothrombocytopenia caused by platelet clumping in response to ethylenediaminetetraacetic acid (EDTA). Reviewing the peripheral smear or repeating the platelet count in a citrated or heparinized tube is needed to make the diagnosis.
  - Platelet transfusion should be considered along with standard therapy when there is life-threatening hemorrhage (usually brain or
GI tract). The platelet count usually will not rise significantly, but bleeding can be slowed. Do not give prophylactic platelets based on platelet counts <5000 or for minor bleeding.

- Anti-D immune globulin therapy (WinRho) is associated with a small percentage of patients developing disseminated intravascular coagulation (DIC) and resultant death. Close monitoring of patients is required. This therapeutic approach is used much less frequently because of complications and more effective new drugs.

**Population**

- Pediatric.

**Recommendations**

- **ASH**

  - **Diagnosis:** Bone marrow (BM) examination unnecessary in children and adolescents with typical features of ITP (isolated thrombocytopenia, large, morphologically normal platelets, asymptomatic except for bleeding). BM also not necessary in patients failing intravenous IVIG therapy or before splenectomy.

  - **Initial management:** Children with no or mild bleeding (bruising, petechiae) can be managed with observation alone regardless of platelet count. For patients requiring therapy, a single dose of IVIG (0.8–1 g/kg) or short-course corticosteroid should be used as first-line therapy. Anti-D immune globulin (WinRho) can be used as first-line therapy in Rh-positive, nonsplenectomized children needing treatment.

  - **Second-line treatment for pediatric ITP:** Rituximab can be considered if bleeding ongoing despite IVIG, anti-D immune globulin, and steroids. Rituximab can be considered an alternative to splenectomy or in patients not responding to splenectomy. High-dose dexamethasone (0.6/kg/d × 4 d q 4 wk) may be considered for patients with bleeding and persistent thrombocytopenia despite appropriate therapy.

  - **Splenectomy:** Consider for children and adolescents with chronic ITP who have significant or persistent bleeding and lack of responsiveness or intolerance to other standard therapies. It is recommended not to do splenectomy for at least 12 mo after start of ITP treatment unless severe disease with significant serious bleeding risks. Splenectomy in patients over 45 y old has a significant risk of recurrence of thrombocytopenia compared to splenectomy in patients younger than 45 y. *(Blood. 2013;121:4457–4462. Blood. 2010;115:168–186. Pediatr Blood Cancer. 2009;53:652–654. Blood. 2014;124:3295)*

**Comments**

- **Clinical Considerations**

  - Measurement of immunoglobulin to exclude common variable immune deficiency (CVID) is common practice as ITP can be the presenting feature of CVID.
In a study of 332 children with typical ITP with bone marrow—no leukemia—only 1 child was found with BM aplasia.

Recommendation for treatment focuses on severity of bleeding, not platelet cell count. In a study of 505 children with platelets <20,000 and skin bleeding, only 3 patients developed severe bleeding and none had intracranial hemorrhage.

The older the child or adolescent, the more likely they are to have chronic ITP (defined as platelet count <150,000 at 6-mo follow-up). Rate for children age 3–12 mo = 23%; children >12 mo and <10 y = 28%; and children >10 y = 47%.

Anti-D immune globulin therapy more effective at 75 vs. 50 μg/kg, but increased toxicity including small percentage with DIC. Drop in hemoglobin averages 1.6 g/dL.

Response rate to splenectomy is 70%–80%, but unless a child has severe unresponsive disease, delay the splenectomy for at least 12 mo since 20 to 30% will have spontaneous remission.

Patients undergoing splenectomy should be immunized at least 2 wk before surgery with pneumococcal, meningococcal, and *H. influenzae* type b vaccine.

Effectiveness of rituximab varies from 30% to 50% in different trials. Serious side effects include serum sickness, severe hepatitis in hepatitis B carriers, and rare cases of multifocal leukoencephalopathy.

MMR (measles, mumps, rubella) vaccination-induced ITP occurs in 2.6 per 100,000 vaccine doses. ITP following natural measles or rubella infection ranges from 600 to 1200 per 100,000 cases, justifying the overall clinical benefit of the vaccine.

Thrombopoietin receptor agonists (romiplostim and eltrombopag) are active agents for ITP in adults but have not been adequately studied in children. Ongoing studies show benefit but not yet approved by FDA.

### THROMBOCYTOPENIA, HEPARIN-INDUCED

**Population**

– Adults.

**Recommendation**

➤ ACCP 2012, ASH 2016

**Diagnosis and Therapy**

* Diagnosis: Maintain high suspicion. If no prior heparin in the last 90 d, monitor platelet count in patients receiving heparin every 2 d from days 4 to 14. If previous exposure to heparin within 90 d, monitor from day 1. If platelets drop 30%–50%, suspect HIT and use 4Ts scoring model (see Table VIII) to assess likelihood of
HIT. If intermediate-to-high probability, treat for HIT and send immunologic (enzyme-linked immunosorbent assay [ELISA]) and functional testing (platelet serotonin release assay).

- **Treatment:** Stop all sources of heparin and give vitamin K if the patient is on warfarin to restore proteins C and S. Begin a direct thrombin inhibitor (argatroban or danaparoid). Fondaparinux is also a safe and effective alternative. (*N Engl J Med.* 2013;368:737-744) Avoid platelet transfusion unless life-threatening bleeding. DO NOT start warfarin until platelet count is >150,000 and overlap with argatroban is for at least 5 d with the INR therapeutic for the last 2 d.

- Patients who have not had clot should be anticoagulated for 6–8 wk.
- In patients with clot, systemic anticoagulation should be continued for a minimum of 3 mo.
- Patients with renal insufficiency should be treated with argatroban, and in patients with liver dysfunction, fondaparinux and danaparoid are preferred. In patients with acute HIT and those who are antibody-positive should be treated with bivalirudin if urgent cardiac surgery is needed, but it is preferable to delay surgery if possible.
- A direct oral anticoagulant (DOAC) can be substituted for warfarin to complete the course of anticoagulation.

### TABLE VIII

<table>
<thead>
<tr>
<th>DIAGNOSTIC TOOL FOR DIAGNOSIS OF HIT</th>
<th>2 POINTS</th>
<th>1 POINT</th>
<th>0 POINT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombocytopenia</td>
<td>• Fall in platelet count &gt;50% and nadir of ≥20,000 AND • No surgery in preceding 3 d</td>
<td>• &gt;50% fall in platelets but with surgery in preceding 3 d • 30%–50% platelet fall with nadir 10–19,000</td>
<td>• &lt;30% fall in platelets • Any platelet fall with nadir &lt;10,000</td>
</tr>
<tr>
<td>Timing of platelet fall</td>
<td>• 5–10 d after start of heparin • Platelet fall &lt;5 d with heparin exposure within past 30 d</td>
<td>• Platelet fall after day 10 • Platelet fall &lt;5 d with heparin exposure in past 100 d</td>
<td>• Platelet fall ≤ day 4 without exposure to heparin in last 100 d</td>
</tr>
</tbody>
</table>
### Diagnostic Tool for Diagnosis of HIT (Continued)

<table>
<thead>
<tr>
<th>4Ts</th>
<th>2 Points</th>
<th>1 Point</th>
<th>0 Point</th>
</tr>
</thead>
</table>
| Thrombosis or other sequelae | • Confirmed new venous or arterial thrombosis  
• Skin necrosis at heparin injection sites  
• Anaphylactoid reaction to IV heparin | • Progressive or recurrent thrombosis while on heparin  
• Erythematous skin reaction at heparin injection sites | Thrombosis suspected |
| Other causes of thrombocytopenia | • No alternative cause of platelet drop evident | • At least one other possible cause of drop in platelet count | Definite or highly likely cause present  
• Sepsis  
• Chemotherapy within 20 d  
• DIC  
• Drug-induced ITP  
• Posttransfusion purposes |

High probability: 6–8 points; intermediate probability: 4–5 points; low probability: ≤3 points.

### Comment — Clinical Input

- Highest risk for HIT is in postsurgical patients treated with UFH.
- UFH is 8 to 10 fold more likely to cause HIT compared to LMWH. Low molecular weight heparin is equal if not better than UFH. UFH should be used only in patients with significant renal insufficiency.
- Fondaparinux (Arixtra*) — Synthetic pentasaccharide inhibiting factor X activity and is safe to be used in HIT, although direct thrombin inhibitors have previously been the anticoagulants of choice.
- Platelet counts can mildly decrease in the first 4 d after starting heparin but this is not immunologically mediated and is not associated with thrombosis. (*Blood*. 2016; 128:348)
- HIT is an immune-mediated disorder triggered by the formation of antibodies to a heparin/platelet factor 4 antigen complex. The complex binds to platelet FC receptors, causing activation of the platelet microparticle release and increased risk of clotting.
- Both VTE and arterial clotting occur in the HIT syndrome in a ratio of 3:1. Adrenal infarction with shock from arterial thrombosis has been reported.
DISEASE MANAGEMENT

- HIT occurs very rarely in patients <40 y old. HIT is increased in females 2.4-fold compared to males.
- The median platelet count in HIT is 60,000 and seldom falls below 20,000. HIT-associated thrombosis shows a propensity to occur in areas of vessel injury (sites of central venous catheter, arterial line insertion, or other vascular interventions).
- The development of HIT is not related to the degree of exposure to heparin. A single flush of an IV line or 1 dose of prophylactic heparin can trigger the HIT syndrome. If HIT is not recognized, further administration of heparin will lead to significant increased risk of clot, morbidity, and mortality. (N Engl J Med. 2006;355:809-817. JAMA. 2004;164:361-369)
- The 4T scoring system is most accurate in the low-risk subset, with a negative predictive value of 0.998. (Blood. 2012;120: 4160-4167) (See Table VIII)

THROMBOCYTOPENIA, THROMBOTIC PURPURA (TTP)

Population
- Acquired TTP in adults and children.

Recommendations
- British Committee for Standards in Haematology (Br J Haematol. 150:323) 2012

Approach to Diagnosis and Therapy
- Diagnosis of TTP should be made on clinical history, laboratory tests, and review of the peripheral blood smear. Diagnosis is suspected if evidence of Coombs-negative microangiopathic hemolytic anemia (MAHA), elevated lactate dehydrogenase (LDH), and thrombocytopenia.
- TTP should be treated as a medical emergency. ADAMTS-13 (von Willebrand factor [vWF] cleaving enzyme) is low in >90% of patients with TTP, but treatment should be started as rapidly as possible and not wait for test results to return.
- Three units of fresh-frozen plasma should be given while a large-bore catheter is placed for plasma exchange, which should begin within 6 h of presentation.
- Serologic testing for HIV, hepatitis B and hepatitis C viruses, and autoantibodies should be done. Young women should have a pregnancy test.
- Plasma exchange (PEX) should be started with 40 mL/kg body weight plasma volume (PV) exchanges. The volume of exchange
can be reduced to 30 mL/kg body weight as clinical conditions and lab studies improve.

• Intensification in frequency of PEX to twice a day should be considered if platelet count is not rising and LDH remains high. (Transfusion. 2008;48:349)

• Daily PEX should continue for a minimum of 2 d after platelet count >150,000 and then stopped. Steroids (usually 1 mg/kg of prednisone equivalent) is often given, although benefits are uncertain.

• In patients with neurologic and/or cardiac pathology (associated with increased mortality), rituximab should be used at a dose of 375 mg/m² weekly for 4 doses. (Blood. 2011;118:1746. N Engl J Med. 2014;370:847)

• Cyclosporin or tacrolimus should be considered in patients with acute and chronic relapsing TTP. The benefit of aspirin in TTP is uncertain, but it is safe at a dose of 81 mg/d with a platelet count >50,000. In patients who relapse, 20%–25% repeat the plasma exchange protocol and add rituximab weekly. The majority of relapses occur in first 30 d after remission.

• PEX should be restarted if platelets <50,000 with the addition of rituximab. If ADAMTS-13 level drops to <5% without a drop in platelets, rituximab alone should be considered. (Blood. 2010;116:4060)

---Supportive Therapy---

• Red-cell transfusion as clinically indicated.

• Folate supplementation during active hemolysis.

• Platelet transfusions are CONTRAINDICATED in TTP unless life-threatening hemorrhage (brain or GI tract).

• Thromboprophylaxis with LMWH once platelet count >50,000.

• Caplacizumab is a monoclonal antibody to VWF protein interfering with platelet binding and improves course of TTP. (N Engl J Med. 2016;374:511)

---Sources---

--Sem Throm Haemat. 2006;32:81, Blood. 2015; 125:3860
--Br J Haematol. 2008;142:819
--Transfusion. 2010;50:868

---Comment---

---Clinical Insight---

• Classic pentad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, fever, CNS symptoms, hematuria—now most commonly MAHA and thrombocytopenia only at diagnosis. Time
is critical to outcome. Expedited treatment associated with better survival.

- Autoimmune disease with IgG antibody to ADAMTS-13 which prevents cleavage of large high-molecular-weight vWF. vWF binds to platelet receptor GPIB and the resulting complex obstructs the microvasculature leading to red cell fragmentation, thrombocytopenia, and organ ischemia.
- Plasma exchange is not a curative therapy, but protects the patient until antibody levels decline either spontaneously or with use of corticosteroids and rituximab.
- Mortality prior to intervention of plasma exchange in the early 1980s was 85%-90%; today the mortality is 10%-15%.
- Prognosis can be predicted using the Wyllie index of adverse features including age >40 y, hemoglobin <9.0, and fever >100.5°F (38°C) at time of diagnosis. Predictions based on 0, 1, 2, or 3 of these features resulted in mortality at 6 mo of 12.5%, 14.0%, 31.3%, and 61%, respectively. (Br J Haematol. 2005;132:204)
- Precipitating factors associated with the onset of acquired TTP include drugs (quinine, ticlopidine, clopidogrel, simvastatin, trimethoprim, and interferon), HIV infection, and pregnancy (usually in the second trimester). Removal of the fetus has not been shown to affect the course of TTP in pregnancy.
- Congenital TTP is rare, with <200 patients described worldwide. Onset usually is in later infancy or childhood. Patients may present as adults, with pregnancy as a common precipitant. Diagnosis is made by ADAMTS-13 activity <5%, with absence of antibody and confirmation of mutations in ADAMTS-13 gene. Treatment is with fresh-frozen plasma administration prophylactically every 10–20 d.
- Responding patients with acquired TTP will relapse at a rate of 20%-30%, most commonly in the first month following successful therapy. Studies show monitoring ADAMTS-13 levels and instituting rituximab proactively can decrease the rate of disease relapse. (Br J Haematol 2007; 136-145. Blood. 2011;118:1746)
- Hemolytic uremic syndrome (HUS) clinically resembles TTP, but has a different pathophysiology, and PEX is of minimal benefit. This illness is commonly caused by bacterial toxins (Shiga-like toxin from Escherichia coli) or drugs (quinine, gemcitabine, mitomycin C). It is also associated with malignancy and autoimmune disease. In HUS, there is disruption of the endothelium and release of high-molecular-weight vWF that overwhelms the cleaving capacity of ADAMTS-13. An antibody to ADAMTS-13 is not involved. Renal failure dominates the clinical picture and 15%-20% succumb to the disease. (Br J Haematol. 2010;148:37. N Engl J Med. 2014;371:654)
CHAPTER 3

THYROID DISEASE, HYPERTHYROIDISM

Population
– Adults.

Recommendations

American Thyroid Association 2016
– The etiology of thyrotoxicosis should be determined. If the diagnosis is not apparent, consider obtaining a thyroid receptor antibody level (TRAb) +/- determination of the radioactive iodine uptake (RAIU).
– Beta-adrenergic blockade is recommended in all patients with symptomatic thyrotoxicosis.
– Patients with overt Graves’ hyperthyroidism should be treated with either radioiodine (RAI) therapy, antithyroid drugs (ATDs), or thyroidectomy.
– A pregnancy test should be obtained within 48 h prior to treatment in any woman with childbearing potential who is to be treated with RAI.
– Recheck a T4, T3, and TSH level in 4–8 wk after RAI therapy.
– Prior to initiating ATD therapy for Graves’ disease (GD), we suggest that patients have a baseline complete blood count with differential (CBCD), and a liver profile.
– Obtain a CBCD for patients on ATD therapy with a febrile illness or a sore throat.
– If near-total or total thyroidectomy is chosen as treatment for GD, patients should be rendered euthyroid prior to the procedure with ATD pretreatment, with beta-adrenergic blockade. Potassium iodide should be given in the immediate preoperative period.
– Wean beta-blockers following thyroidectomy.
– Thyroid multinodular goiters or thyroid adenomas with hyperthyroidism should be treated with surgery or RAI.
– Subclinical hyperthyroidism should be treated in all individuals >65 of age, and in patients with cardiac disease, osteoporosis, or symptoms of hyperthyroidism when the TSH is persistently <0.1 mU/L.

Source

AACE 2011
– Radioactive iodine uptake scan should be performed when the etiology of thyrotoxicosis is unclear.
– ß-blockade should be prescribed to elderly patients and considered for all patients with symptomatic thyrotoxicosis.
DISEASE MANAGEMENT

–Graves’ disease.
  • Options for Graves’ disease treatment:
    + 131I therapy.
    + Antithyroid medications.
    + Thyroidectomy.
–Patients with Graves’ disease and increased risk of complications should be pretreated with methimazole and beta-blockers prior to 131I therapy.
  • Advise smoking cessation.
  • Graves’ ophthalmopathy should have steroids and 131I therapy.
–131I therapy.
  • A pregnancy test should be checked within 48 h of administering 131I therapy.
  • Assess patients 1–2 mo after 131I therapy with a free T4 and total triiodothyronine (T3) level.
  • Consider retreatment with 131I therapy if hyperthyroidism persists 6 mo after 131I treatment.
–Antithyroid drug therapy.
  • Methimazole is the preferred antithyroid drug except during the first trimester of pregnancy.
  • A CBC with differential should be obtained whenever a patient taking antithyroid drugs develops a febrile illness or pharyngitis.
  • Recommend measurement of TSH receptor antibody level prior to stopping antithyroid drug therapy.
–Thyroidectomy.
  • Indicated for toxic multinodular goiter or toxic adenoma.
  • Wean beta-blockers postoperative.
  • Follow serial calcium or intact PTH levels postoperative.
  • Start levothyroxine 1.6 μg/kg/d immediately postoperative.
  • Check a serum TSH level 6–8 wk postoperative.
–Thyroid storm should be treated with β-blockers, antithyroid drugs, inorganic iodide, corticosteroid therapy, volume resuscitation, and acetaminophen.

Source
**Recommendations**

**AACE 2012**

- Replacement dosing of levothyroxine is 1.6 μg/kg/d.
- Recommends checking antithyroid peroxidase antibodies (TPOAb) in patients with subclinical hypothyroidism or recurrent miscarriages.
- Recommends treating hypothyroid patients with levothyroxine if:
  - TSH > 10 mIU/L.
  - Symptomatic.
  - Positive TPOAb.

**Source**


---

**THYROID DISEASE, PREGNANCY AND POSTPARTUM**

**Population**

- Women during and immediately after pregnancy.

**Recommendations**

**ATA 2011, ATA 2017**

- Hypothyroidism in pregnancy is defined as:
  - An elevated TSH (>2.5 mIU/L) and a suppressed free thyroxine (FT$_4$).
  - TSH ≥ 10 mIU/L (irrespective of FT$_4$).
  - Subclinical hypothyroidism is defined as a TSH 2.5–9.9 mIU/L and a normal FT$_4$
- Insufficient evidence to support treatment of subclinical hypothyroidism in pregnancy.
- Goal therapy is to normalize TSH levels.
- PTU is the preferred antithyroid drug (ATD) in pregnancy.
- Monitor TSH levels every 4 wk when treating thyroid disease in pregnancy.
- Measure a TSH receptor antibody level at 20–24 wk for any history of Graves’ disease.
- All pregnant and lactating women should ingest at least 250-μg iodine daily.
- All pregnant women with thyroid nodules should undergo thyroid ultrasound and TSH testing.
- Patients found to have thyroid cancer during pregnancy would ideally undergo surgery during second trimester.
- Transient hCG-mediated TSH suppression in early pregnancy should not be treated with ATD therapy.
GD during pregnancy should be treated with the lowest possible dose of ATD needed to keep the mother’s thyroid hormone levels at or slightly above the reference range for total T4 and T3 values in pregnancy (1.5 times above nonpregnant reference ranges in the second and third trimesters), and the TSH below the reference range for pregnancy.

Pregnancy is a relative contraindication to thyroidectomy and should only be used when medical management has been unsuccessful or ATDs cannot be used.

Sources


–2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-390


Comment

–Surgery for well-differentiated thyroid carcinoma can often be deferred until postpartum period.
THYROID NODULES

MANAGEMENT OF THYROID NODULES

- TSH normal or high
- Nodule >1 cm
- Nodule <1 cm but suspicious for CA by clinical or thyroid US criteria

Benign

- History, Exam, TSH, and thyroid US

Hyperfunctioning nodule

- TSH low AND thyroid US has no suspicious features

Nonfunctioning nodule

- ultrasound-guided FNA of nodule

- Evaluate and treat for hyperthyroidism

Follicular cytology

Hürthle cell cytology

Malignant cells

Suspicious cells on cytology

Nondiagnostic cytology

Hyperfunctioning nodule

- \(^{123}\)I thyroid scan

- \(^{123}\)I thyroid scan

- Nonfunctioning nodule

- Ultrasound-guided FNA of nodule

- Thyroid surgery

- Repeat ultrasound-guided FNA of nodule

Clinical Risk Factors for Thyroid Cancer

- History of head/neck irradiation
- Family history of medullary or papillary thyroid cancer or MEN type 2 syndrome
- Age <14 or >70 y
- Male sex
- Growing nodule
- Firm, hard, or fixed nodule
- Cervical lymphadenopathy
- Dysphonia
- Dysphagia
- Dyspnea

Ultrasound Features Suspicious for Thyroid cancer

- Marked hypoechochogenicity of nodule
- Microcalcifications present
- Irregular margins
- Chaotic architecture
- Nodule that is more tall than wide
- Abnormal vascularity

Sources: AACE, June 2010; ATA, November 2009.
TINNITUS

Population
− Adults and children.

Recommendations
AAO-HNS 2014
− Recommend a thorough history and exam on patients with tinnitus.
− Recommend a comprehensive audiologic examination for unilateral or persistent tinnitus or any associated hearing impairment.
− Recommend imaging studies only for unilateral tinnitus, pulsatile tinnitus, asymmetric hearing loss, or focal neurological abnormalities.
− Recommend a hearing aid for tinnitus with hearing loss.
− Consider cognitive behavioral training or sound therapy for persistent, bothersome tinnitus.
− Recommend against medical or herbal therapy or transcranial magnetic stimulation for tinnitus.

Source
− http://www.guideline.gov/content.aspx?id=48751

TOBACCO ABUSE, SMOKING CESSATION

Population
− Adults, including pregnant women who smoke tobacco.

Recommendations
USPSTF 2015
− Current evidence is insufficient to recommend electronic nicotine delivery systems for tobacco cessation in adults, including pregnant women.
− Current evidence is insufficient to assess the benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women.

Source
− https://guidelines.gov/summaries/summary/49684
TOBACCO CESSATION TREATMENT ALGORITHM

Five A's
1. Ask about tobacco use.
2. Advise to quit through clear, personalized messages.
3. Assess willingness to quit.
4. Assist to quit, including referral to Quit Lines (eg, 1-800-NO-BUTTS).
5. Arrange follow-up and support.

*Physicians can assist patients to quit by devising a quit plan, providing problem-solving counseling, providing intratreatment social support, helping patients obtain social support from their environment/friends, and recommending pharmacotherapy for appropriate patients. Use caution in recommending pharmacotherapy in patients with medical contraindications, those smoking <10 cigarettes per day, pregnant/breast-feeding women, and adolescent smokers. As of March 2005, Medicare covers costs for smoking cessation counseling for those who (1) have a smoking-related illness; (2) have an illness complicated by smoking; or (3) take a medication that is made less effective by smoking. (http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=130).


MOTIVATING TOBACCO USERS TO QUIT

Five R's
1. Relevance: personal
2. Risks: acute, long term, environmental
3. Rewards: have patient identify (eg, save money, better food taste)
4. Road blocks: help problem-solve
5. Repetition: at every office visit
## Tobacco Cessation Treatment Options

<table>
<thead>
<tr>
<th>Pharmacotherapy</th>
<th>Precautions/Contraindications</th>
<th>Side Effects</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bupropion SR</strong></td>
<td>History of seizure, eating disorder</td>
<td>Insomnia, Dry mouth</td>
<td>150 mg every morning for 3 d, then 150 mg bid (Begin treatment 1–2 wk prequit) 7–12 wk maintenance up to 6 mo Zyban (prescription only)</td>
</tr>
<tr>
<td><strong>Nicotine gum</strong></td>
<td>—</td>
<td>Mouth soreness, Dyspepsia</td>
<td>1–24 cigarettes/d; 2-mg gum (up to 24 pieces/d) 25+ cigarettes/d; 4-mg gum (up to 24 pieces/d) Up to 12 wk Nicorette, Nicorette Mint (OTC only)</td>
</tr>
<tr>
<td><strong>Nicotine inhaler</strong></td>
<td>—</td>
<td>Local irritation of mouth and throat</td>
<td>6–16 cartridges/d Up to 6 mo Nicotrol Inhaler (prescription only)</td>
</tr>
<tr>
<td><strong>Nicotine nasal spray</strong></td>
<td>—</td>
<td>Nasal irritation</td>
<td>8–40 doses/d 3–6 mo Nicotrol NS (prescription only)</td>
</tr>
<tr>
<td><strong>Nicotine patch</strong></td>
<td>—</td>
<td>Local skin reaction, Insomnia</td>
<td>21 mg/24 h Then 2 wk Then 2 wk 8 wk NicoDerm CQ (OTC only), generic patches (prescription and OTC) Nicotrol (OTC only)</td>
</tr>
<tr>
<td>Pharmacotherapy</td>
<td>Precautions/Contraindications</td>
<td>Side Effects</td>
<td>Dosage</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Varenicline</td>
<td>Renal impairment</td>
<td>Nausea Abnormal dreams</td>
<td>0.5 mg qd for 3 d, then 0.5 mg bid for 4 d, then 1.0 mg PO bid</td>
</tr>
</tbody>
</table>

Second-Line Pharmacotherapies (not approved for use for smoking cessation by the FDA)

<table>
<thead>
<tr>
<th>Pharmacotherapy</th>
<th>Precautions/Contraindications</th>
<th>Side Effects</th>
<th>Dosage</th>
<th>Duration</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonidine</td>
<td>Rebound hypertension</td>
<td>Dry mouth Drowsiness Dizziness Sedation</td>
<td>0.15–0.75 mg/d</td>
<td>3–10 wk</td>
<td>Oral clonidine—generic, Catapres (prescription only), transdermal Catapres (prescription only)</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>Risk of arrhythmias</td>
<td>Sedation Dry mouth</td>
<td>75–100 mg/d</td>
<td>12 wk</td>
<td>Nortriptyline HCL—generic (prescription only)</td>
</tr>
</tbody>
</table>

bid, twice daily; FDA, Food and Drug Administration; OTC, over-the-counter; PO, by mouth; qd, every day.

*The information contained within this table is not comprehensive. Please see package inserts for additional information.

Source: U.S. Public Health Service.
**TONSILECTOMY**

**Population**
- Children.

**Recommendations**
- AAO-HNS 2011
  - Recommends against routine perioperative antibiotics for tonsillectomy.
  - Tonsillectomy indicated for:
    - Tonsillar hypertrophy with sleep-disordered breathing.
    - Recurrent throat infections for ≥7 episodes of recurrent throat infection in last year; ≥5 episodes of recurrent throat infection per year in last 2 y; or ≥3 episodes of recurrent throat infection per year in last 3 y.
  - Recommends posttonsillectomy pain control.

**Source**

**TRANSFUSION THERAPY, ALTERNATIVES TO RED BLOOD CELL TRANSFUSION**

**Population**
- Adults and children over 1 y.

**Recommendation**
- NICE 2015
  - Alternatives to blood transfusion
    - Do not recommend erythropoietin therapy for surgical patients unless patient has anemia and meets the criteria for blood transfusion, but declines it because of religious beliefs.
    - Iron therapy is recommended for all patients before and after surgery to patients with iron-deficiency anemia.
      - Oral iron therapy is standard.
      - Intravenous iron can be considered for patients:
        - i. Who cannot tolerate oral iron.
        - ii. Who cannot absorb oral iron.
        - iii. When the time interval before surgery is too short for oral iron to be effective.
• Offer tranexamic acid (TXA) for people undergoing surgery who are expected to have at least moderate blood loss.
• Consider cell salvage with TXA for patients undergoing surgery who are expected to have a very high volume of blood loss.

Source
- https://guidelines.gov/summaries/summary/49905

Comment
- Consider cell salvage therapy for cardiac surgery, complex vascular surgery, major obstetrical procedures, and pelvic reconstruction or scoliosis surgery.

**TRANSFUSION THERAPY, CRYOPRECIPITATE**

**Population**
- Adults and children over 1 y.

**Recommendations**

NICE 2015
- Recommends cryoprecipitate for patients with significant bleeding and fibrinogen level <150 mg/dL.
- Consider cryoprecipitate for patients who require an invasive procedure or surgery with high risk of bleeding and fibrinogen level <100 mg/dL.

Source
- https://guidelines.gov/summaries/summary/49905

**TRANSFUSION THERAPY, FRESH FROZEN PLASMA (FFP)**

**Population**
- Adults and children over 1 y.

**Recommendations**

NICE 2015
- Consider FFP transfusion for patients with active bleeding and prothrombin time or activated partial thromboplastin time ratios above 1.5.
- Do not recommend FFP transfusions for patients with an abnormal coagulation profile who are not actively bleeding.
**DISEASE MANAGEMENT**

Source

Comment
– Typical dose of FFP is 15 mL/kg.

**TRANSFUSION THERAPY, PLATELET TRANSFUSION**

**Population**
– Adults and children over 1 y.

**Recommendations**

NICE 2015
– Recommend single-unit platelet transfusion for patients with bleeding and platelet count $<30 \times 10^9$ per liter.
– Consider higher threshold (up to $100 \times 10^9$ per liter) for:
  • Major hemorrhage.
  • CNS or ocular bleeding.
– Prophylactic platelet transfusions for:
  • Platelet count $<10 \times 10^9$ per liter.
– Consider platelet transfusion for patients having invasive procedures or surgery and have a platelet count $<50 \times 10^9$ per liter.
  • Threshold for transfusion may be as high as $100 \times 10^9$ per liter for CNS or eye surgery.

Source

Comment
– Prophylactic platelet transfusions not necessarily recommended for:
  • Chronic bone marrow failure.
  • Autoimmune thrombocytopenia.
  • Heparin-induced thrombocytopenia.
  • Thrombotic thrombocytopenic purpura.
**TRANSFUSION THERAPY, PROTHROMBIN COMPLEX CONCENTRATE**

**Population**
– Adults and children over 1 y.

**Recommendation**

▲ NICE 2015
– Recommend for emergency reversal of warfarin anticoagulation in patients with:
  • Severe bleeding.
  • Suspected intracranial hemorrhage.

**Source**

**TRANSFUSION THERAPY, RED BLOOD CELL TRANSFUSION**

**Population**
– Adults and children over 1 y.

**Recommendations**

▲ NICE 2015
– Recommend a restrictive red blood cell transfusion threshold at a hemoglobin 7 g/dL for most patients.
– Consider a red blood cell transfusion threshold at a hemoglobin 8 g/dL for:
  • Acute coronary syndrome.
– Consider single unit transfusions for adults with no active bleeding.

**Source**

**TRAUMATIC BRAIN INJURY**

**Recommendation**

▲ ACEP 2013
– Avoid CT scan of head for minor head trauma in patients who are low risk based on validated decision rules.

**Source**
TREMOR, ESSENTIAL

Population
~ Adults.

Recommendations
~ AAN 2011
  ~ Recommends treatment with propranolol or primidone.
  ~ Alternative treatment options include alprazolam, atenolol, gabapentin, sotalol, or topiramate.
  ~ Recommends against treatment with levetiracetam, pindolol, trazodone, acetazolamide, or 3,4-diaminopyridine.

Source
~ http://www.neurology.org/content/77/19/1752.full.pdf+html

Comment
~ Unilateral thalamotomy may be effective for severe refractory essential tremors.

TUBERCULOSIS (TB), DIAGNOSIS

Population
~ Adults suspected of having active TB.

Recommendations
~ NICE 2016
  ~ Perform a chest X-ray in all patients.
  ~ Obtain three early-morning sputum samples for AFB smear and culture.

Source
~ https://guidelines.gov/summaries/summary/49964

Comment
~ Consider sputum for nucleic acid amplification for mycobacterium tuberculosis complex if the person has HIV disease, need for a large contact tracing, or need for rapid diagnosis.
TUBERCULOSIS (TB), EXTRAPULMONARY DIAGNOSIS

Population

– Adults suspected of having extrapulmonary TB.

Recommendations

➤ NICE 2016

– To diagnose TB send fluid for adenosine deaminase and nucleic acid amplification for mycobacterium tuberculosis complex (pleural fluid, cerebrospinal fluid, ascitic fluid, pericardial fluid, synovial fluid).

– Option for TB diagnosis is tissue biopsy.

• Bone biopsy for osteomyelitis.
• Pleural biopsy for pleural TB.
• Peritoneal biopsy for peritoneal TB.
• Pericardial biopsy for pericardial TB.
• Synovial biopsy for synovial TB.

Source


TUBERCULOSIS (TB), EXTRA-PULMONARY MANAGEMENT

Population

– Adults suspected of having extra-pulmonary TB.

Recommendations

➤ NICE 2016

– Refer the patient to a clinician with expertise in TB management.

– Report suspect to local public health office for case management and contact screening.

– Start patients on RIPE (rifampin, isoniazid, pyrazinamide, and ethambutol) therapy.

– Consider adjunctive corticosteroids for TB with CNS or pericardial involvement.

Source


Comments

1. TB treatment regimens are modified based on TB sensitivities.
2. Typical duration of treatment for TB with CNS involvement is 12 mo.
**TUBERCULOSIS (TB), MANAGEMENT**

**Population**

- Adults suspected of having active TB.

**Recommendations**

- ATS/CDC/IDSA 2016

### WHEN TO INITIATE ANTI-TUBERCULOSIS MEDICATION

<table>
<thead>
<tr>
<th>Patient</th>
<th>Risk for progression/dissemination (eg, HIV, TNF alpha inhibitor)</th>
<th>Elevated concern for adverse treatment events (eg, severe liver disease, pregnancy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt; 2 years</td>
<td>TB exposure risk (eg, contact, born in higher TB incidence country)</td>
<td>No TB exposure risk</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory/Radiographic</th>
<th>Radiographic imaging consistent with TB</th>
<th>Radiographic imaging not consistent with TB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt; 2 years</td>
<td>Evidence of Mtb infection (eg, positive TST or IGRA)</td>
<td></td>
</tr>
<tr>
<td>Extended time to microbiologic confirmation (eg, Rapid molecular test not available)</td>
<td>Pathologic findings consistent with TB</td>
<td></td>
</tr>
<tr>
<td>AFB smear positive</td>
<td>Rapid molecular test positive</td>
<td></td>
</tr>
<tr>
<td>AFB smear negative, Rapid molecular test positive</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical status/Suspicion</th>
<th>Life-threatening disease</th>
<th>Symptoms typical for TB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternative diagnosis less likely</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Public Health</th>
<th>Concern for loss to follow-up</th>
<th>Low transmission risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>High transmission risk (eg, congregate setting, corrections)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favors Treatment Initiation Favors Delayed or No Treatment
CHAPTER 3

TREATMENT OF DRUG-SUSCEPTIBLE TUBERCULOSIS

Table 2. Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Intensive Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Drug1</td>
<td>Interval and Dose2 (Minimum Duration)</td>
</tr>
<tr>
<td>1</td>
<td>INH, Rif, PZA, EMB</td>
<td>7 dv/k for 56 doses (8 w) or 5 dv/k for 40 doses (8 w)</td>
</tr>
<tr>
<td>2</td>
<td>INH, Rif, PZA, EMB</td>
<td>7 dv/k for 56 doses (8 w) or 5 dv/k for 40 doses (8 w)</td>
</tr>
<tr>
<td>3</td>
<td>INH, Rif, PZA, EMB</td>
<td>3 tiv/k weekly for 24 doses (8 w)</td>
</tr>
<tr>
<td>4</td>
<td>INH, Rif, PZA, EMB</td>
<td>7 dv/k for 14 doses then twice weekly for 12 doses</td>
</tr>
</tbody>
</table>

Abbreviations: DOT, directly observed therapy; EMB, ethambutol; HIV, human immunodeficiency virus; INH, isoniazid; PZA, pyrazinamide; Rif, rifampin.

1 When DOT is used, drugs may begin 5 days per week and the necessary number of doses is adjusted accordingly. Although there are no studies that compare 5 with 7-daily doses, extensive experience indicates this would be an effective practice. DOT should be used when drugs are administered 7 days per week.

2 Other combinations may be appropriate in certain circumstances; additional details are provided in the section “Recommended Treatment Regimens.”

3 Based on expert opinion; patients with cavitary disease on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (D1-week) continuation phase.

4 Pyridoxine (100 mg/d) is given with INH to all persons at risk of neuropathy (e.g., pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic renal failure; or patients with advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100–200 mg/d.

5 See [3],[4]. Alternatively, some US tuberculosis control programs have administered intensive phase regimens 5 days per week for 15 doses (3 weeks), then twice weekly for 12 doses.

Source


NICE 2016

– Refer the patient to a clinician with expertise in TB management.
– Report suspect to local public health office for case management and contact screening.
– Isolate patients in negative pressure rooms within the hospital.
– Start patients on RIPE therapy (rifampin, isoniazid, pyrazinamide, and ethambutol).

Source


Comments

1. TB treatment regimens are modified based on TB sensitivities.
2. Typical duration of treatment for pulmonary TB is 6 mo.
3. Consider de-escalation of hospital isolation after 2 wk of therapy if:
   - Resolution of cough.
   - Afebrile for a week.
   - Immunocompetent patient.
   - No extensive disease by x-ray.
   - Initial smear grade was 2+ or less.
TUBERCULOSIS (TB), MANAGEMENT OF LATENT TB

Population
- Adults and children who have latent TB.

Recommendations
▶ NICE 2016
- High-risk individuals younger than 35 y with latent TB should be offered:
  - 3 mo of rifampin and isoniazid (with pyridoxine).
  - 6 mo of isoniazid (with pyridoxine).
- Offer adults HIV, HBV, and HCV testing before starting treatment for latent TB.
- Offer high-risk individuals between 35 and 65 y latent TB therapy if hepatotoxicity is not a concern.

Source
- https://guidelines.gov/summaries/summary/49964

Comment
- High-risk patients with latent TB:  
  - HIV-positive.
  - Younger than 5 y.
  - Excessive alcohol intake.
  - Injection drug users.
  - Solid organ transplant recipients.
  - Hematologic malignancies.
  - Undergoing chemotherapy.
  - Prior jejunoileal bypass.
  - Diabetes.
  - Chronic kidney disease.
  - Prior gastrectomy.
  - Receiving treatment with anti-tumor necrosis factor med or other biologic agents.
CHAPTER 3

TUBERCULOSIS (TB), MULTIDRUG-RESISTANT (MDR-TB)

Population
– Patients with suspected or proven drug-resistant tuberculosis.

Recommendations
WHO 2011
– Rapid drug susceptibility testing of isoniazid and rifampicin is recommended at the time of TB diagnosis.
– Recommends sputum smear microscopy and culture to monitor patients with MDR-TB.
– Recommends addition of a later-generation fluoroquinolone, ethionamide, pyrazinamide, and a parenteral agent ± cycloserine for ≥8 mo.
– Recommends total treatment duration of 20 mo.

Source

TYMPANOSTOMY TUBES

Population
– Children 6 mo to 12 y.

Recommendations
AAO 2013
– Clinicians should not perform tympanostomy tube insertion for children with:
  • A single episode of otitis media with effusion (OME) of <3 mo duration.
  • Recurrent acute otitis media without effusion.
– Clinicians should obtain a hearing test if OME persists for at least 3 mo or if tympanostomy tube insertion is being considered.
– Clinicians should offer bilateral tympanostomy tube insertion to children with:
  • Bilateral OME for at least 3 mo AND documented hearing impairment.
  • Recurrent acute otitis media with effusions.
  • Tympanostomy tube insertion is an option for chronic symptomatic OME associated with balance problems, poor school performance, behavioral problems, or ear discomfort thought to be due to OME.
**Source**

**Comment**
–No need for prophylactic water precautions (avoidance of swimming or water sports or use of earplugs) for children with tympanostomy tubes.

### ULCERS, STRESS

**Recommendation**

► SHM 2013

–Do not prescribe medications for stress ulcer prophylaxis to medical inpatients unless they are at high risk for GI complications.

**Source**

### URINARY INCONTINENCE, OVERACTIVE BLADDER

**Population**
–Adults.

**Recommendations**

► American Urologic Association 2014

–Rule out a urinary tract infection.
–Recommend checking a post-void residual to rule out overflow incontinence.
–First-line treatments:
  • Bladder training.
  • Bladder control strategies.
  • Pelvic floor muscle training.
–Second-line treatments:
  • Antimuscarinic meds.
  –Darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium.
  –Contraindicated with narrow-angle glaucoma or gastroparesis.
– Third-line treatments:
  • Sacral neuromodulation.
  • Peripheral tibial nerve stimulation.
  • Intradetrusor botulinum toxin A.
– Recommend against indwelling urinary catheters.

Source

### URINARY INCONTINENCE, STRESS

#### Population
– Adult women.

#### Recommendations

- AUA 2017

Source:
# AUA SUI ALGORITHM 2017

**Female Stress Urinary Incontinence: AUA/SUFU Evaluation and Treatment Algorithm**

**EVALUATION (INDICATIONS)**

<table>
<thead>
<tr>
<th>Initial evaluation</th>
<th>Additional evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The initial evaluation of patients desiring to undergo surgical intervention should include the following components:</td>
<td>Additional evaluation should be performed in the following scenarios:</td>
</tr>
<tr>
<td>• History</td>
<td>• Lack of definitive diagnosis</td>
</tr>
<tr>
<td>• Physical exam</td>
<td>• Inability to demonstrate SUI</td>
</tr>
<tr>
<td>• Demonstration of SUI</td>
<td>• Known/Suspected NLUTD</td>
</tr>
<tr>
<td>• PVR assessment</td>
<td>• Abnormal urinalysis</td>
</tr>
<tr>
<td>• Urinalysis</td>
<td>• Urgency-predominant MUI</td>
</tr>
<tr>
<td></td>
<td>• Elevated PVR</td>
</tr>
<tr>
<td></td>
<td>• High-grade POP (if SUI not demonstrated with POP reduction)</td>
</tr>
<tr>
<td></td>
<td>• Evidence of significant voiding dysfunction</td>
</tr>
<tr>
<td></td>
<td>Additional evaluation may be performed in the following scenarios:</td>
</tr>
<tr>
<td></td>
<td>• Concomitant OAB symptoms</td>
</tr>
<tr>
<td></td>
<td>• Failure of prior anti-incontinence surgery</td>
</tr>
<tr>
<td></td>
<td>• Prior POP surgery</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cystoscopy</th>
<th>Urodynamics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Should not be performed unless there is a concern for lower urinary tract abnormalities</td>
<td>May be omitted when SUI is clearly demonstrated</td>
</tr>
</tbody>
</table>

| In patients who wish to undergo treatment, physicians should counsel regarding the availability of observation, pelvic floor muscle training, other non-surgical options, and surgical interventions. Physicians should counsel patients on potential complications specific to the treatment options. |

<table>
<thead>
<tr>
<th>CYSTOSCOPY</th>
<th>URODYNAMICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Should not be performed unless there is a concern for lower urinary tract abnormalities</td>
<td>May be omitted when SUI is clearly demonstrated</td>
</tr>
</tbody>
</table>

## TREATMENT

**Non-Surgical**
- Continence pessary
- Vaginal inserts
- Pelvic floor muscle exercises

**Surgical**
- Bulking agents
- Midurethral sling (synthetic)
- Autologous fascia pubovaginal sling
- Burch colposuspension

If a midurethral sling surgery is selected, either the retropubic or transobturator midurethral sling may be offered. A single incision sling may be offered to index patients if they are informed as to the immaturity of evidence regarding their efficacy and safety. Physicians must discuss the specific risks and benefits of mesh as well as alternatives to a mesh sling.

## SPECIAL CASES

1. Fixed immobile urethra
   - Pubovaginal sling
   - Retropubic midurethral sling
   - Urethral bulking agents

2. Concomitant surgery for POP repair and SUI
   - Any incontinence procedure

3. Concomitant NLUTD
   - Surgical treatment following appropriate evaluation and counseling

4. Child-bearing, diabetes, obesity, geriatric
   - Surgical treatment following appropriate evaluation and counseling

MUI= mixed urinary incontinence; NLUTD= neurogenic lower urinary tract dysfunction; OAB= overactive bladder; POP= pelvic organ prolapse; PVR= post-void residual; SUI= stress urinary incontinence

---

**ACP 2014**

- Recommends pelvic floor muscle training and bladder training for urinary incontinence in women.

**Source**

### INITIAL MANAGEMENT OF URINARY INCONTINENCE IN MEN: EAU 2011

**History**
- Post-micturition dribble
- Incontinence on physical activity (usually post-prostatectomy)
- Incontinence with mixed symptoms
- Urgency/frequency, with or without incontinence

**Clinical assessment**
- General assessment
- Urinary symptom assessment and symptom score (including frequency-volume chart and questionnaire)
- Assess quality of life and desire for treatment
- Physical examination: abdominal, rectal, sacral neurological
- Urinalysis ± urine culture if infected, treat and reassess
- Assessment of pelvic floor muscle function
- Assess post-void residual (PVR) urine

**Presumed diagnosis**
- Stress incontinence presumed due to sphincteric incompetence
- Mixed incontinence (treat most bothersome symptom first)
- Urge incontinence presumed due to detrusor overactivity

**Management**
- Urethral milking
- Pelvic floor muscle contraction

**Discuss treatment options with the patient**
- Lifestyle interventions
- Pelvic floor muscle training ± biofeedback
- Scheduled voiding (bladder training)
- Incontinence products
- Antimuscarinics (overactive bladder ± urgency incontinence) and α-adrenergic antagonists (if also bladder outlet obstruction)

**Complicated** incontinence
- Recurrent or "total" incontinence
- Incontinence associated with:
  - Pain
  - Hematuria
  - Recurrent infection
  - Voiding symptoms
  - Prostate irradiation
  - Radical pelvic surgery

**Any other abnormality detected (eg., significant PVR)**

**SPECIALIZED MANAGEMENT**
INITIAL MANAGEMENT OF URINARY INCONTINENCE IN WOMEN: EAU 2011

### History
- Incontinence on physical activity
- Incontinence with mixed symptoms
- Incontinence or frequency, with or without urgency incontinence

### Presumed diagnosis
- Stress incontinence presumed due to sphincteric incompetence
- Mixed incontinence (treat most bothersome symptom first)
- Overactive bladder (OAB), with or without URGENCY INCONTINENCE, presumed due to detrusor overactivity

### Clinical assessment
- General assessment
- Urinary symptom assessment (including frequency-volume chart and questionnaire)
- Assess quality of life and desire for treatment
- Physical examination: abdominal, pelvic, perineal
- Cough test to demonstrate stress incontinence if appropriate
- Urinalysis ± urine culture if infected, treat and reassess if appropriate
- Assess oestrogen status and treat as appropriate
- Assess voluntary pelvic floor muscle contraction
- Assess post-void residual urine

### Management
- Lifestyle interventions
- Pelvic floor muscle training for SUI or OAB
- Bladder retraining for OAB
- Duloxetine* (SUI) or antimuscarinic (OAB ± urgency incontinence)

### Failure
- Other adjuncts, such as electrical stimulation
- Vaginal devices, urethral inserts

### Specialized management
- If other abnormality found, e.g.,
  - Significant post-void residual
  - Significant pelvic organ prolapse
  - Pelvic mass

*Subject to local regulatory approval
URINARY TRACT INFECTIONS (UTIS)

Population

- Adult women.

Recommendations


1. Screening for and treatment of asymptomatic bacteriuria are not recommended.

2. Recommend duration of antibiotics:
   a. Uncomplicated cystitis: 3 d.
      i. Nitrofurantoin requires 5–7 d of therapy.
   b. Uncomplicated pyelonephritis: 7–10 d.
   c. Complicated pyelonephritis or UTI: 3–5 d after control/elimination of complicating factors and defervescence.

3. Recommended empiric antibiotics for uncomplicated cystitis:
   a. TMP-SMX.
   b. Fluoroquinolones.
   c. Nitrofurantoin macrocrystals.
   d. Beta-lactam antibiotics are alternative agents.

4. Recommended empiric antibiotics for complicated UTI or uncomplicated pyelonephritis:
   a. Fluoroquinolones.
   b. Ceftriaxone.
   c. Aminoglycosides.

5. Recommended empiric antibiotics for complicated pyelonephritis:
   a. Fluoroquinolones.
   b. Piperacillin-tazobactam.
   c. Carbapenem.
   d. Aminoglycosides.

- Recommend a urinalysis or dipstick testing for symptoms of a UTI: dysuria, urinary frequency, suprapubic pain, or hematuria.

- Empiric antibiotics for UTI:
  - Trimethoprim-sulfamethoxazole × 3 d (not recommended if local resistance rate >20%).
  - Nitrofurantoin monohydrate × 5 d.
  - Fosfomycin 3 g PO × 1.

- Consider a fluoroquinolone for symptoms of pyelonephritis or for refractory UTI.

\*\*\*\*\*

Common abbreviations:

- TMP-SMX only if regional *Escherichia coli* resistance is <20%; fluoroquinolones include ciprofloxacin, ofloxacin, or levofloxacin.
- Amoxicillin-clavulanate, cefdinir, cefaclor, or cefpodoxime-proxetil. Cephalexin may be appropriate in certain settings.
DISEASE MANAGEMENT

Sources
–http://cid.oxfordjournals.org/content/52/5/e103.full.pdf+html

Comments
1. EAU recommends 7 d of antibiotics for men with uncomplicated cystitis.
2. EAU suggests the following options for antimicrobial prophylaxis of recurrent uncomplicated UTIs in nonpregnant women:
   a. Nitrofurantoin 50 mg PO daily.
   b. TMP-SMX 40/200 mg/d.
3. EAU suggests the following options for antimicrobial prophylaxis of recurrent uncomplicated UTIs in pregnant women:
   a. Cephalexin 125 mg PO daily.
4. Once urine culture and sensitivity results are known, antibiotics can be adjusted to the narrowest spectrum antibiotic.

Population
–Febrile children 2–24 mo.

Recommendations
➤ AAP 2011
–Diagnosis of a UTI if:
   • Pyuria ≥50,000 colonies/mL single uropathogenic organism.
   • Recommend a renal and bladder ultrasound in all infants 2–24 mo with a febrile UTI.
–Treat febrile UTIs with 7–14 d of antibiotics.
–Antibiotic prophylaxis is not indicated for a history of febrile UTI.
–A voiding cystourethrogram (VCUG) is indicated if ultrasound reveals hydronephrosis, renal scarring, or other findings of high-grade vesicoureteral reflux, and for recurrent febrile UTIs.

Source
–http://pediatrics.aappublications.org/content/128/3/595.full.pdf+html?sid=c1de42b3-c89b-4fd2-9592-359087823171

Comments
1. Urine obtained through catheterization has a 95% sensitivity and 99% specificity for UTI.
2. Bag urine cultures have a specificity of approximately 63% with an unacceptably high false-positive rate. Only useful if the cultures are negative.
URINARY TRACT SYMPTOMS, LOWER

Population
– Adult men.

Recommendations

NICE 2010, EAU 2011
– All men with LUTS should have a thorough history and exam, including a prostate examination, and a review of current medications.
– Recommends supervised bladder training exercises and consider anticholinergic medications for symptoms suggestive of an overactive bladder.
– Recommends an α-blocker for men with moderate-to-severe LUTS.
– Consider a 5-α-reductase inhibitor for men with LUTS with prostate size larger than 30 g.
– For men with refractory obstructive urinary symptoms despite medical therapy, offer 1 of 3 surgeries: transurethral resection, transurethral vaporization, or laser enucleation of the prostate.

Sources

*Alfuzosin, doxazosin, tamsulosin, or terazosin.
**VALVULAR HEART DISEASE**

**Population**
- Adults with valvular heart disease.

**Recommendations for Aortic Stenosis**

- **Severe AS**
  - **Symptomatic (stage D)**
    - **Low surgical risk**
      - **Surgical AVR (Class I)**
    - **Intermediate surgical risk**
      - **Surgical AVR or TAVR (Class I)**
    - **High surgical risk**
      - **Surgical AVR (Class I)**
    - **Prohibitive surgical risk**
      - **TAVR (Class I)**

**AVR** = aortic valve replacement
**TAVR** = transcatheter aortic valve replacement

**Recommendations for Mitral Regurgitation**

- **Primary MR**
  - **Symptomatic (stage C)**
    - **LVFS >30%**
      - **MV Repair (IIa)**
    - **LVFS 30% to ≤40% or LVEDD >40 mm (stage C2)**
      - **MV Surgery* (I)**
  - **Asymptomatic (stage C)**
    - **MV Surgery* (IIb)**

- **Progressive MR**
  - **Symptomatic severe MR (stage C3)**
    - **MV Repair (IIa)**
  - **Asymptomatic severe MR (stage C1)**
    - **Periodic Monitoring**
  - **Progressive MR (stage B)**
    - **Persistent NTM class IIa symptoms**
      - **MV Surgery* (IIb)**
  - **CABG Rx**
    - **HF Rx**
      - **Consider CRT**

**MV Surgery** = mitral valve surgery
**MV Repair** = mitral valve repair

*AVR, aortic valve replacement; TAVR, transcatheter aortic valve replacement.*
MV repair is preferred over MV replacement when possible. 

AF, atrial fibrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; EF, ejection fraction; ERO, effective regurgitant orifice; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; MV, mitral valve; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; Rx, therapy.

Recommendations

ACC/AHA 2017

- Indications for valve surgery during initial hospitalization before completion of full course of antibiotics is indicated for infective endocarditis (IE) associated with:
  - Valve dysfunction resulting in symptoms of HF.
  - Left-sided IE caused by *S. aureus*, fungal, or other highly resistant organisms.
  - Complicated by heart block, annular or aortic abscess, or destructive penetrating lesions.
  - Evidence of persistent infection as manifested by persistent bacteremia or fevers lasting longer than 5 to 7 days after onset of appropriate antimicrobial therapy.

- Surgery is recommended for patients with prosthetic valve endocarditis and relapsing infection (defined as recurrence of bacteremia after a complete course of appropriate antibiotics and subsequently negative blood cultures) without other identifiable source for portal of infection.

- Complete removal of pacemaker or defibrillator systems, including all leads and the generator, is indicated as part of the early management plan in patients with IE with documented infection of the device or leads.

VALVULAR ADULT HEART DISEASE 2014 ACC/AHA GUIDELINES

Aortic Stenosis (AS)

- Transthoracic echocardiogram (TTE) is recommended as initial evaluation with known or suspected aortic stenosis to establish the diagnosis and to determine the severity of the stenosis.
- Exercise treadmill testing is rarely indicated but helpful to evaluate patients who have discordant echo/clinical findings (i.e., moderate or severe stenosis in the absence of expected symptoms). Previously undetected symptoms of chest pain, shortness of breath, exertional dizziness, or syncope may be identified to prevent sudden death.
- Hypertension should be treated in the presence of significant AS.
- Statin therapy does not prevent the progression of the AS.
• No medical therapy is available to address symptoms or disease progression.
• Aortic valve replacement (AVR) is indicated in symptomatic patients with a mean gradient >40 mm Hg; aortic valve replacement is indicated in asymptomatic patients with decreased systolic function (EF<50%) and mean gradient >40 mm Hg (valve gradient is underestimated with systolic dysfunction).
• Transcatheter aortic valve replacement (TAVR) should be considered in patients with a high surgical risk, marked frailty, associated comorbidities, and minimal associated coronary artery disease who have the same indication for AVR and have a 12-mo life expectancy.
• Percutaneous aortic balloon dilation procedure should be considered a “bridging therapy” to AVR or TAVR therapy.

**Aortic Insufficiency (AI)**
• Transthoracic echocardiogram is recommended as initial evaluation with known or suspected aortic insufficiency to establish the diagnosis and to determine the severity if there is insufficiency.
• Cardiac magnetic resonance (CMR) is an alternative form of evaluation if the TTE is nondiagnostic or suboptimal.
• Hypertension should be treated to keep SBP <140 mm Hg with nondihydropyridine calcium channel blocker, ACE inhibitor, or ARB agent.
• Aortic valve replacement: symptomatic person with severe AI regardless of the systolic function; asymptomatic patient with severe AI and systolic dysfunction <50% or with end systolic volume (ESD) >50 mm.

**Mitral Stenosis (MS)**
• Transthoracic echocardiogram is recommended as initial evaluation with known or suspected mitral stenosis to establish the diagnosis and to determine the severity if there is stenosis.
• Transesophageal echocardiogram (TEE) should be considered prior to sending the patient for percutaneous mitral balloon commissurotomy (PMBC) to exclude the presence of left atrial thrombus.
• Warfarin is indicated in patients with mitral stenosis and atrial fibrillation, prior embolic event, or intracardiac thrombus.
• Heart rate control in atrial fibrillation is imperative to allow optimal diastolic filling time across the stenotic valve.
• PMBC is indicated in symptomatic patients with severe mitral stenosis (MVA <1.5 cm²) with no atrial thrombus and no or minimal mitral insufficiency.
• Mitral valve replacement is indicated if balloon commissurotomy is contraindicated in a patient with severe symptoms and severe mitral stenosis.

**Mitral Regurgitation (MR)**
• Transthoracic echocardiogram is recommended as initial evaluation with known or suspected mitral regurgitation to establish the diagnosis and to determine the severity if there is insufficiency, left atrial and ventricular size, and right ventricular function.
• Cardiac magnetic resonance (CMR) is an alternative form of evaluation if the TTE is nondiagnostic or suboptimal.
VALVULAR ADULT HEART DISEASE 2014 ACC/AHA GUIDELINES  (Continued)

• Mitral valve replacement or repair is indicated in a symptomatic patient with severe regurgitation if the systolic function (EF) is >30%.
• Mitral valve replacement is indicated in an asymptomatic patient with severe mitral regurgitation if the systolic function (EF) is between 30% and 60% or the left ventricular end systolic dimension (LVESD) >40%.


VENOUS THROMBOEMBOLISM, DEEP VENOUS THROMBOSIS (DVT)

Population
- Patients with DVT (lower and upper extremity).

Recommendations
- ACCP 2016, ACP 2012
  - For diagnostic work-up of DVT/PE, see Figures I–III.
  - Treatment Variables
    • Initial heparin based regimen with unfractionated heparin (UFH) 80 units/kg bolus, then 18 units/kg/h titrated to partial thromboplastin time (PTT), enoxaparin 1 mg/kg SQ q12h or 1.5 mg/kg SQ daily.
    • Fondaparinux 5 mg (<50 kg), 7.5 mg (50–100 kg) or 10 mg (>100 kg) SQ daily.
    • Start warfarin (≤10 mg) on day 1 and overlap with heparin for at least 5 d with therapeutic INR for last 2 d. Rivaroxaban, dabigatran, apixaban and edoxaban are all now approved by FDA to treat acute DVT and PE history (DOACs—direct oral anticoagulants)—see Table IX. Extended treatment has shown protection from further clot with minimal bleeding risk. Rivaroxaban is now approved in acute coronary syndrome. (N Engl J Med. 2010;363:2499-2510. N Engl J Med. 2012;366:1287-1297. Am J Coll Cardiol. 2013; 62:286) In setting of unprovoked DVT or PE men have a 50% increased risk of recurrent clot compared to women. (Medicine. 2014;93:309)
• Outpatient management of VTE with rivaroxaban, apixaban, edoxaban, or dabigatran is acceptable if the patient does not have any of the following: >80 y old, history of cancer, hx of COPD, CHF, pulse >110, BP <100, O₂ sat <90.
• Knee-high GCS (graduated compression stockings) with 30-40 mm Hg pressure at ankles for 2 y will reduce postthrombotic syndrome risk by 50%.

Source
–Chest. 2016;149:315-352

Comments
1. Clinical findings alone are poor predictors of DVT.
2. Early ambulation on heparin is safe.
3. With iliofemoral thrombosis and significant swelling, thrombolysis or surgical thrombectomy not recommended unless significant symptoms.
4. Inferior vena cava (IVC) filter indicated if DVT and significant uncontrolled bleeding precluding anticoagulation. (Chest. 2016; 150:1182)

FIGURE I

DIAGNOSIS AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) WELLS CRITERIA

<table>
<thead>
<tr>
<th>DVT Variable</th>
<th>Score</th>
<th>PE Variable</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active cancer</td>
<td>1</td>
<td>Clinical evidence of DVT</td>
<td>3.0</td>
</tr>
<tr>
<td>Paralysis/immobilization</td>
<td>1</td>
<td>Other dx less likely than PE</td>
<td>3.0</td>
</tr>
<tr>
<td>Bedridden for &gt;3 d or major surgery</td>
<td>1</td>
<td>Heart rate &gt;100</td>
<td>1.5</td>
</tr>
<tr>
<td>within 4 wk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entire leg swollen</td>
<td>1</td>
<td>Immobile &gt;3 d or major surgery</td>
<td>1.5</td>
</tr>
<tr>
<td>within 4 wk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenderness along deep vein</td>
<td>1</td>
<td>Previous DVT/PE</td>
<td>1.5</td>
</tr>
<tr>
<td>Calf swelling &gt;3 cm</td>
<td>1</td>
<td>Hemoptysis</td>
<td>1.0</td>
</tr>
<tr>
<td>Pitting edema (unilateral)</td>
<td>1</td>
<td>Malignancy</td>
<td>1.0</td>
</tr>
<tr>
<td>Collateral superficial veins</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative dx more likely than DVT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Score and Probability—DVT            |       | Score and Probability—PE         |       |
| High—3 or greater (75% risk of DVT)  |       | High—6 or greater (>70% risk of PE) |
| Moderate—1 or 2 (20% risk of DVT)    |       | Moderate—2–6 (20–30% risk of PE)  |
| Low—0 (3% risk of DVT)               |       | Low—less than 2 (2–3% risk of PE) |

**Note:** Pretest probability (PTP) of VTE guides clinical evaluation—Wells criteria for PTP of DVT and PE.

5. With provoked clot, anticoagulate for 3 mo if precipitating problem solved.\(^a\)

6. Continue anticoagulation indefinitely if provoking problem continues.

7. In cancer-related clots, continue low-molecular-weight heparin (LMWH), do not transition to warfarin if cancer still active. *(Blood. 2014;123:3972)*

8. In unprovoked clot, anticoagulate for 3 mo then weigh risk of bleeding to benefit of prolonged anticoagulation to prevent clot; consider thrombophilia evaluation, including hereditary factors and surgery, cancer, hormones, pregnancy, travel, inflammatory bowel disease, nephritic syndrome, hemolytic anemia, immobilization, trauma, CHF, myeloproliferative disorders, stroke, central venous catheter, rheumatologic disorders.

\(^a\)Surgery, cancer, hormones, pregnancy, travel, inflammatory bowel disease, nephritic syndrome, hemolytic anemia, immobilization, trauma, CHF, myeloproliferative disorders, stroke, central venous catheter, rheumatologic disorders.
antiphospholipid antibody syndrome. Men have a 50% increase in recurrent clot compared to women and if first clot is a PE indefinite anticoagulation is advised because of high risk of the next event being a PE (60% vs. 20%) compared to those with VTE only.

9. Rivaroxaban and other DOACs should not be used in pregnancy or in patients with liver disease.

10. Risk factors for warfarin bleeding—age >65 y, history of stroke, history of GI bleed, and recent comorbidity (MI, Hct <30, creatinine...
<table>
<thead>
<tr>
<th>Agent</th>
<th>Target</th>
<th>Dosing</th>
<th>Monitoring</th>
<th>Half-life</th>
<th>Time to Peak Plasma Concentration</th>
<th>Specific Reversible Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin</td>
<td>Vitamin K epoxide</td>
<td>Once daily</td>
<td>INR–adjusted</td>
<td>40 h</td>
<td>72–96 h</td>
<td>Vitamin K PCC</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Thrombin</td>
<td>Fixed—once or twice daily</td>
<td>None</td>
<td>14–17 h</td>
<td>2 h</td>
<td>Idarucizumab</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Factor Xa</td>
<td>Fixed—once or twice daily</td>
<td>None</td>
<td>5–9 h (50 y old)</td>
<td>2.5–4 h</td>
<td>Developed—needs FDA approved</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Factor Xa</td>
<td>Fixed twice daily</td>
<td>None</td>
<td>8–15 h</td>
<td>3 h</td>
<td>None</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>Factor Xa</td>
<td>Give once daily</td>
<td>None</td>
<td>10–14 h</td>
<td>1-2 h</td>
<td>None</td>
</tr>
</tbody>
</table>

*Do not use new oral anticoagulants in patients with mechanical valves. Warfarin is superior. Warfarin is likely superior to new oral anticoagulants in patients with antiphospholipid antibody syndrome.

*If significant bleed on warfarin, give vitamin K, and 4-factor prothrombin complex concentrate (PCC/K - centra) or recombinant FVIIa if not controlled.

*If significant bleed, no standard of care. Aggressively treat source of bleed; consider 4-factor PCC or recombinant FVIIa. Agents to reverse anticoagulation with new oral anticoagulants will be available soon.
>1.5, diabetes). If all 4 factors present, 40% risk of significant bleed in 12 mo; 0.4% of patients on warfarin die of bleeding yearly. (Chest. 2016;149:315. Am J Med. 2011;124:111)

11. Patients with mild symptoms and good support system can be treated as outpatient with rivaroxaban (direct factor Xa inhibitor), other DOACs, or with lovenox and warfarin.

12. Calf and iliofemoral thrombosis have increased incidence of false-negative compression ultrasound—recommend CT or MR venogram or venography for suspected iliofemoral thrombosis, and for calf thrombosis follow-up compression ultrasound (CUS) in 5–7 d is acceptable.


14. Consider high thrombophilic risk in patients with recurrent VTE or patients with first unprovoked VTE who have the following characteristics:
   - Are <50 y old.
   - Family history of VTE.
   - Unusual site of thrombosis.
   - Massive venous thrombosis.


16. In patients with the antiphospholipid antibody syndrome and a new venous thrombosis, transition to warfarin is superior to using the new oral anti-coagulants. (Am J Hematol. 2014;89:1017)

---

**VENOUS THROMBOEMBOLISM, PULMONARY EMBOLUS (PE)**

**Population**
- Diagnosed pulmonary embolism.

**Recommendations**
- ACCP 2016, ACP 2011
  - Approach to initial anticoagulation is the same as DVT.
  - If patient is hypotensive without high bleeding risk and tachycardiac, systemically administered thrombolytic therapy is recommended.
  - In a patient with acute PE associated with hypotension with contraindications to or failed thrombolysis or in shock that is likely to
lead to rapid death, catheter-assisted thrombus removal is indicated if appropriate expertise and resources are available.

- In patients whose first episode of VTE is an unprovoked PE, extended anticoagulation beyond 3 mo is preferred unless high risk of bleeding.

**Source**

> Chest. 2016;149:315-352

**Comments**

**Clinical Observations**

- Patients whose first VTE is a PE will have a 3-fold increased risk of a second clot being a PE compared to patients with DVT only. (N Engl J Med. 2010;363:266)

- In patients with unprovoked PE or DVT elevated d-dimer at the time of discontinuation of warfarin or 2–3 wk after stopping anticoagulants predicts for a 3- to 5-fold increase in risk of clot over the next 12 mo. (Blood. 2010;115:481)

- The presence of a permanent IVC filter does not mandate continuous anticoagulation unless documented recurrent clot problems

- Unprovoked clot has risk of recurrent clot in first 12 mo of 8%–12% vs. 3% for patients with provoked clot. (JAMA. 2011;305:1336)

- Patients with intermediate or high pretest probability (PTP) of PE should be treated with heparin before diagnostic work-up is complete.

- Asymptomatic PE (found incidentally on chest CT) should be treated with same protocol as symptomatic PE. (Blood. 2015; 125:1877)

- Emerging data suggest the use of aspirin (100 mg PO daily) may reduce the risk of recurrent clot in patients with unprovoked VTE after 6 to 12 mo of warfarin therapy. (N Engl J Med. 2012;366:1959)

- Patients with significant risk of recurrent clot, on long term anticoagulation with reduced dose of a DOAC have continued protection from clot and reduced risk of bleeding (rivaroxiban—10 mg/d, apixaban 2.5 mg bid. (N Engl J Med. 2017;376:1279. N Engl J Med. 2017;376:1211)

### VERTIGO, BENIGN PAROXYSMAL POSITIONAL (BPPV)

**Population**

- Adults.

**Recommendations**

- AAO-HNS 2008

  - Recommends the Dix-Hallpike maneuver to diagnose posterior semicircular canal BPPV.

  - Recommends treatment of posterior semicircular canal BPPV with a particle repositioning maneuver.
DISEASE MANAGEMENT

–If the Dix-Hallpike test result is negative, recommends a supine roll test to diagnose lateral semicircular canal BPPV.
–Recommends offering vestibular rehabilitation exercises for the initial treatment of BPPV.
–Recommends evaluating patients for an underlying peripheral vestibular or central nervous system disorder if they have an initial treatment failure of presumed BPPV.
–Recommends against routine radiologic imaging for patients with BPPV.
–Recommends against routine vestibular testing for patients with BPPV.
–Recommends against routine use of antihistamines or benzodiazepines for patients with BPPV.

Source

Comment
–BPPV is the most common vestibular disorder in adults, afflicting 2.4% of adults at some point during their lives.

VITAMIN DEFICIENCIES

Population
–All patients with or suspected of having serum cobalamin and folate deficiency.

Recommendations

• Serum cobalamin <200 ng/L suggests cobalamin deficiency.
• Patients with normal cobalamin level but high suspicion of cobalamin deficiency should undergo methylmalonic acid (MMA) testing.
• Patients with cobalamin deficiency or unexplained anemia, neuropathy, or glossitis (regardless of cobalamin level) should have an anti-intrinsic factor antibody test to rule out pernicious anemia.
• Initial therapy for cobalamin deficiency is vitamin B₁₂ 1 mg IM TIW for 3 wk and then maintenance therapy.
• Maintenance therapy is either 1 mg IM every 3 mo (if no neurologic symptoms) or every 2 mo (if neurologic symptoms) or vitamin B₁₂ 2 mg PO daily.
• Serum folate level <7 nmol/L (<3 μg/L) indicates folate deficiency.

Source

Comment
–Recommends against anti-parietal cell antibody to test for pernicious anemia.
Appendices
<table>
<thead>
<tr>
<th>Instrument Name</th>
<th>Screening Questions/Scoring</th>
<th>Threshold Score</th>
<th>Sensitivity/Specificity (%)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAGE(^a)</td>
<td>See page 501</td>
<td>&gt;1</td>
<td>77/58</td>
<td>Am J Psychiatry. 1974;131:1121</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;3</td>
<td>29/92</td>
<td></td>
</tr>
<tr>
<td>AUDIT</td>
<td>See pages 501-502</td>
<td>&gt;4</td>
<td>87/70</td>
<td>BMJ. 1997;314:420</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;5</td>
<td>77/84</td>
<td>J Gen Intern Med. 1998;13:379</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;6</td>
<td>66/90</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)The CAGE may be less applicable to binge drinkers (e.g., college students), the elderly, and minority populations.
### Screening Procedures for Problem Drinking

#### 1. CAGE Screening Test
- Have you ever felt the need to cut down on drinking?
- Have you ever felt annoyed by criticism of your drinking?
- Have you ever felt guilty about your drinking?
- Have you ever taken a morning eye opener?

**Interpretation:** Two “yes” answers are considered a positive screen. One “yes” answer should arouse a suspicion of alcohol abuse.

#### 2. The Alcohol Use Disorder Identification Test (AUDIT)
(Scores for response categories are given in parentheses. Scores range from 0 to 40, with a cutoff score of ≥5 indicating hazardous drinking, harmful drinking, or alcohol dependence.)

1. **How often do you have a drink containing alcohol?**
   - (0) Never  
   - (1) Monthly or less  
   - (2) Two to four times a month  
   - (3) Two or three times a week  
   - (4) Four or more times a week

2. **How many drinks containing alcohol do you have on a typical day when you are drinking?**
   - (0) 1 or 2  
   - (1) 3 or 4  
   - (2) 5 or 6  
   - (3) 7 to 9  
   - (4) 10 or more

3. **How often do you have 6 or more drinks on 1 occasion?**
   - (0) Never  
   - (1) Less than monthly  
   - (2) Monthly  
   - (3) Weekly  
   - (4) Daily or almost daily

4. **How often during the last year have you found that you were not able to stop drinking once you had started?**
   - (0) Never  
   - (1) Less than monthly  
   - (2) Monthly  
   - (3) Weekly  
   - (4) Daily or almost daily

5. **How often during the last year have you failed to do what was normally expected of you because of drinking?**
   - (0) Never  
   - (1) Less than monthly  
   - (2) Monthly  
   - (3) Weekly  
   - (4) Daily or almost daily

6. **How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?**
   - (0) Never  
   - (1) Less than monthly  
   - (2) Monthly  
   - (3) Weekly  
   - (4) Daily or almost daily

7. **How often during the last year have you had a feeling of guilt or remorse after drinking?**
   - (0) Never  
   - (1) Less than monthly  
   - (2) Monthly  
   - (3) Weekly  
   - (4) Daily or almost daily
<table>
<thead>
<tr>
<th></th>
<th>8. How often during the last year have you been unable to remember what happened the night before because you had been drinking?</th>
<th>9. Have you or has someone else been injured as a result of your drinking?</th>
<th>10. Has a relative or friend or a doctor or other health worker been concerned about your drinking or suggested you cut down?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(0) Never</td>
<td>(0) No</td>
<td>(0) No</td>
</tr>
<tr>
<td></td>
<td>(1) Less than monthly</td>
<td>(2) Yes, but not in the last year</td>
<td>(2) Yes, but not in the last year</td>
</tr>
<tr>
<td></td>
<td>(2) Monthly</td>
<td>(4) Yes, during the last year</td>
<td>(4) Yes, during the last year</td>
</tr>
<tr>
<td></td>
<td>(3) Weekly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(4) Daily or almost daily</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Instrument Name</th>
<th>Screening Questions/Scoring</th>
<th>Threshold Score</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beck Depression Inventory (short form)</td>
<td>See pages 506-507</td>
<td>0–4: None or minimal depression 5–7: Mild depression 8–15: Moderate depression &gt;15: Severe depression</td>
<td>Postgrad Med. 1972;81</td>
</tr>
<tr>
<td>Geriatric Depression Scale</td>
<td>See page 508</td>
<td>≥15: Depression</td>
<td>J Psychiatr Res. 1983;17:37</td>
</tr>
<tr>
<td>PRIME-MD © (mood questions)</td>
<td>1. During the last month, have you often been bothered by feeling down, depressed, or hopeless? 2. During the last month, have you often been bothered by little interest or pleasure in doing things?</td>
<td>“Yes” to either question*</td>
<td>JAMA. 1994;272:1749</td>
</tr>
<tr>
<td>Patient Health Questionnaire (PHQ-9) ©</td>
<td><a href="http://www.pfizer.com/phq-9/">http://www.pfizer.com/phq-9/</a> See pages 504-505</td>
<td>Major depressive syndrome: if answers to #1a or b and ≥5 of #1a–i are at least “More than half the days” (count #1i if present at all) Other depressive syndrome: if #1a or b and 2–4 of #1a–i are at least “More than half the days” (count #1i if present at all) 5–9: mild depression 10–14: moderate depression 15–19: moderately severe depression 20–27: severe depression</td>
<td>JAMA. 1999;282:1737</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J Gen Intern Med. 2001;16:606</td>
</tr>
</tbody>
</table>

*Sensitivity 86%–96%; specificity 57%–75%. Source: ©Pfizer Inc.
### SCREENING INSTRUMENTS: DEPRESSION

#### PHQ-9 DEPRESSION SCREEN, ENGLISH

*Over the past 2 weeks, how often have you been bothered by any of the following problems?*

<table>
<thead>
<tr>
<th>Problem</th>
<th>Not at all</th>
<th>Several days</th>
<th>&gt;Half the days</th>
<th>Nearly every day</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>b. Feeling down, depressed, or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>c. Trouble falling or staying asleep, or sleeping too much</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>d. Feeling tired or having little energy</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>e. Poor appetite or overeating</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>f. Feeling bad about yourself—or that you are a failure or that you</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>have let yourself or your family down</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g. Trouble concentrating on things, such as reading the newspaper or</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>watching television</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>h. Moving or speaking so slowly that other people could have noticed</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>or the opposite—being so fidgety or restless that you have been moving</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>around a lot more than usual?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>i. Thoughts that you would be better off dead or of hurting yourself</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>in some way</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For office coding: Total Score*  

<table>
<thead>
<tr>
<th>Score</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
</table>

**Major depressive syndrome:** If ≥5 items present scored ≥2 and one of the items is depressed mood (b) or anhedonia (a). If item "i" is present, then this counts, even if score = 1.

**Depressive screen positive:** If at least one item ≥2 (or item "i" is ≥1).

*Source:* From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was developed by Drs. Robert L., et al. For research information, contact Dr. Spitzer at rls8@columbia.edu. PRIME-MD® is a trademark of Pfizer Inc. Copyright © 1999 Pfizer Inc. All rights reserved. Reproduced with permission. For office coding: Maj Dep Syn if answer to #2a or b and ≥5 of #2a–i are at least "More than half the days" (count #2i if present at all). Other Dep Syn if #2a or b and 2, 3, or 4 of #2a–i are at least “More than half the days” (count #2i if present at all).
### SCREENING INSTRUMENTS: DEPRESSION

#### PHQ-9 DEPRESSION SCREEN, SPANISH

Durante las últimas 2 semanas, ¿con qué frecuencia le han molestado los siguientes problemas?

<table>
<thead>
<tr>
<th></th>
<th>Nunca</th>
<th>Varios días</th>
<th>&gt;La mitad de los días</th>
<th>Casi todos los días</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>b.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>c.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>d.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>e.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>f.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>g.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>h.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>i.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

*For office coding: Total Score*

Source: From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was developed by Drs. Robert L., et al. For research information, contact Dr. Spitzer at rls8@columbia.edu. PRIME-MD® is a trademark of Pfizer Inc. Copyright © 1999 Pfizer Inc. All rights reserved. Reproduced with permission. For office coding: Maj Dep Syn if answer to #2a or b and ≥5 of #2a–i are at least "More than half the days" (count #2i if present at all). Other Dep Syn if #2a or b and 2, 3, or 4 of #2a–i are at least "More than half the days" (count #2i if present at all).
SCREENING INSTRUMENTS: DEPRESSION

BECK DEPRESSION INVENTORY, SHORT FORM

**Instructions:** This is a questionnaire. On the questionnaire are groups of statements. Please read the entire group of statements in each category. Then pick out the one statement in that group that best describes the way you feel today, that is, right now! Circle the number beside the statement you have chosen. If several statements in the group seem to apply equally well, circle each one. Sum all numbers to calculate a score.

*Be sure to read all the statements in each group before making your choice.*

<table>
<thead>
<tr>
<th>Category</th>
<th>Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. Sadness</strong></td>
<td>3. I am so sad or unhappy that I can't stand it.</td>
</tr>
<tr>
<td></td>
<td>2. I am blue or sad all the time and I can't snap out of it.</td>
</tr>
<tr>
<td></td>
<td>1. I feel sad or blue.</td>
</tr>
<tr>
<td></td>
<td>0. I do not feel sad.</td>
</tr>
<tr>
<td><strong>B. Pessimism</strong></td>
<td>3. I feel that the future is hopeless and that things cannot improve.</td>
</tr>
<tr>
<td></td>
<td>2. I feel I have nothing to look forward to.</td>
</tr>
<tr>
<td></td>
<td>1. I feel discouraged about the future.</td>
</tr>
<tr>
<td></td>
<td>0. I am not particularly pessimistic or discouraged about the future.</td>
</tr>
<tr>
<td><strong>C. Sense of failure</strong></td>
<td>3. I feel I am a complete failure as a person (parent, husband, wife).</td>
</tr>
<tr>
<td></td>
<td>2. As I look back on my life, all I can see is a lot of failures.</td>
</tr>
<tr>
<td></td>
<td>1. I feel I have failed more than the average person.</td>
</tr>
<tr>
<td></td>
<td>0. I do not feel like a failure.</td>
</tr>
<tr>
<td><strong>D. Dissatisfaction</strong></td>
<td>3. I am dissatisfied with everything.</td>
</tr>
<tr>
<td></td>
<td>2. I don't get satisfaction out of anything anymore.</td>
</tr>
<tr>
<td></td>
<td>1. I don't enjoy things the way I used to.</td>
</tr>
<tr>
<td></td>
<td>0. I am not particularly dissatisfied.</td>
</tr>
<tr>
<td><strong>E. Guilt</strong></td>
<td>3. I feel as though I am very bad or worthless.</td>
</tr>
<tr>
<td></td>
<td>2. I feel quite guilty.</td>
</tr>
<tr>
<td></td>
<td>1. I feel bad or unworthy a good part of the time.</td>
</tr>
<tr>
<td></td>
<td>0. I don't feel particularly guilty.</td>
</tr>
<tr>
<td><strong>F. Self-dislike</strong></td>
<td>3. I hate myself.</td>
</tr>
<tr>
<td></td>
<td>2. I am disgusted with myself.</td>
</tr>
<tr>
<td></td>
<td>1. I am disappointed in myself.</td>
</tr>
<tr>
<td></td>
<td>0. I don't feel disappointed in myself.</td>
</tr>
<tr>
<td><strong>G. Self-harm</strong></td>
<td>3. I would kill myself if I had the chance.</td>
</tr>
<tr>
<td></td>
<td>2. I have definite plans about committing suicide.</td>
</tr>
<tr>
<td></td>
<td>1. I feel I would be better off dead.</td>
</tr>
<tr>
<td></td>
<td>0. I don't have any thoughts of harming myself.</td>
</tr>
</tbody>
</table>
H. Social withdrawal
3 I have lost all of my interest in other people and don't care about them at all.
2 I have lost most of my interest in other people and have little feeling for them.
1 I am less interested in other people than I used to be.
0 I have not lost interest in other people.

I. Indecisiveness
3 I can't make any decisions at all anymore.
2 I have great difficulty in making decisions.
1 I try to put off making decisions.
0 I make decisions about as well as ever.

J. Self-image change
3 I feel that I am ugly or repulsive looking.
2 I feel that there are permanent changes in my appearance and they make me look unattractive.
1 I am worried that I am looking old or unattractive.
0 I don't feel that I look worse than I used to.

K. Work difficulty
3 I can't do any work at all.
2 I have to push myself very hard to do anything.
1 It takes extra effort to get started at doing something.
0 I can work about as well as before.

L. Fatigability
3 I get too tired to do anything.
2 I get tired from doing anything.
1 I get tired more easily than I used to.
0 I don't get any more tired than usual.

M. Anorexia
3 I have no appetite at all anymore.
2 My appetite is much worse now.
1 My appetite is not as good as it used to be.
0 My appetite is no worse than usual.

**GERIATRIC DEPRESSION SCALE**

**Choose the best answer for how you felt over the past week**

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes/No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Are you basically satisfied with your life?</td>
<td>yes/no</td>
</tr>
<tr>
<td>2. Have you dropped many of your activities and interests?</td>
<td>yes/no</td>
</tr>
<tr>
<td>3. Do you feel that your life is empty?</td>
<td>yes/no</td>
</tr>
<tr>
<td>4. Do you often get bored?</td>
<td>yes/no</td>
</tr>
<tr>
<td>5. Are you hopeful about the future?</td>
<td>yes/no</td>
</tr>
<tr>
<td>6. Are you bothered by thoughts you can’t get out of your head?</td>
<td>yes/no</td>
</tr>
<tr>
<td>7. Are you in good spirits most of the time?</td>
<td>yes/no</td>
</tr>
<tr>
<td>8. Are you afraid that something bad is going to happen to you?</td>
<td>yes/no</td>
</tr>
<tr>
<td>9. Do you feel happy most of the time?</td>
<td>yes/no</td>
</tr>
<tr>
<td>10. Do you often feel helpless?</td>
<td>yes/no</td>
</tr>
<tr>
<td>11. Do you often get restless and fidgety?</td>
<td>yes/no</td>
</tr>
<tr>
<td>12. Do you prefer to stay at home, rather than going out and doing new things?</td>
<td>yes/no</td>
</tr>
<tr>
<td>13. Do you frequently worry about the future?</td>
<td>yes/no</td>
</tr>
<tr>
<td>14. Do you feel you have more problems with memory than most?</td>
<td>yes/no</td>
</tr>
<tr>
<td>15. Do you think it is wonderful to be alive now?</td>
<td>yes/no</td>
</tr>
<tr>
<td>16. Do you often feel downhearted and blue?</td>
<td>yes/no</td>
</tr>
<tr>
<td>17. Do you feel pretty worthless the way you are now?</td>
<td>yes/no</td>
</tr>
<tr>
<td>18. Do you worry a lot about the past?</td>
<td>yes/no</td>
</tr>
<tr>
<td>19. Do you find life very exciting?</td>
<td>yes/no</td>
</tr>
<tr>
<td>20. Is it hard for you to get started on new projects?</td>
<td>yes/no</td>
</tr>
<tr>
<td>21. Do you feel full of energy?</td>
<td>yes/no</td>
</tr>
<tr>
<td>22. Do you feel that your situation is hopeless?</td>
<td>yes/no</td>
</tr>
<tr>
<td>23. Do you think that most people are better off than you are?</td>
<td>yes/no</td>
</tr>
<tr>
<td>24. Do you frequently get upset over little things?</td>
<td>yes/no</td>
</tr>
<tr>
<td>25. Do you frequently feel like crying?</td>
<td>yes/no</td>
</tr>
<tr>
<td>26. Do you have trouble concentrating?</td>
<td>yes/no</td>
</tr>
<tr>
<td>27. Do you enjoy getting up in the morning?</td>
<td>yes/no</td>
</tr>
<tr>
<td>28. Do you prefer to avoid social gatherings?</td>
<td>yes/no</td>
</tr>
<tr>
<td>29. Is it easy for you to make decisions?</td>
<td>yes/no</td>
</tr>
<tr>
<td>30. Is your mind as clear as it used to be?</td>
<td>yes/no</td>
</tr>
</tbody>
</table>

One point for each is response suggestive of depression. (Specifically “no” responses to questions 1, 5, 7, 9, 15, 19, 21, 27, 29, and 30, and “yes” responses to the remaining questions are suggestive of depression.)

A score of ≥15 yields a sensitivity of 80% and a specificity of 100%, as a screening test for geriatric depression. *Clin Gerontol.* 1982;1:37.

MODIFIED CHECKLIST FOR AUTISM IN TODDLERS, REVISED WITH FOLLOW-UP (M-CHAT-R/F)

Instructions: Please answer these questions about your child. Keep in mind how your child usually behaves. If you have seen your child do the behavior a few times, but he or she does not usually do it, then please answer no. Please circle YES or NO for every question. Thank you very much!

1. If you point at something across the room, does your child look at it? (FOR EXAMPLE, if you point at a toy or an animal, does your child look at the toy or animal?)  
   YES or NO

2. Have you ever wondered if your child might be deaf?  
   YES or NO

3. Does your child play pretend or make-believe? (FOR EXAMPLE, pretend to drink from an empty cup, pretend to talk on a phone, or pretend to feed a doll or stuffed animal?)  
   YES or NO

4. Does your child like climbing on things? (FOR EXAMPLE, furniture, playground equipment, or stairs)  
   YES or NO

5. Does your child make unusual finger movements near his or her eyes? (FOR EXAMPLE, does your child wiggle his or her fingers close to his or her eyes?)  
   YES or NO

6. Does your child point with one finger to ask for something or to get help? (FOR EXAMPLE, pointing to a snack or a toy that is out of reach)  
   YES or NO

7. Does your child point with one finger to show you something interesting? (FOR EXAMPLE, pointing to an airplane in the sky or a big truck in the road)  
   YES or NO

8. Is your child interested in other children? (FOR EXAMPLE, does your child watch other children, smile at them, or go to them?)  
   YES or NO

9. Does your child show you things by bringing them to you or holding them up for you to see—not to get help, but just to share? (FOR EXAMPLE, showing you a flower, a stuffed animal, or a toy truck)  
   YES or NO

10. Does your child respond when you call his or her name? (FOR EXAMPLE, does he or she look up, talk or babble, or stop what he or she is doing when you call his or her name?)  
    YES or NO

11. When you smile at your child, does he or she smile back at you?  
    YES or NO

12. Does your child get upset by everyday noises? (FOR EXAMPLE, does your child scream or cry to noise such as a vacuum cleaner or loud music?)  
    YES or NO

13. Does your child walk?  
    YES or NO

14. Does your child look you in the eye when you are talking to him or her, playing with him or her, or dressing him or her?  
    YES or NO
### MODIFIED CHECKLIST FOR AUTISM IN TODDLERS, REVISED WITH FOLLOW-UP (M-CHAT-R/F) (Continued)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes or No</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. Does your child try to copy what you do? (For example, wave bye-bye, clap, or make a funny noise when you do)</td>
<td></td>
</tr>
<tr>
<td>16. If you turn your head to look at something, does your child look around to see what you are looking at?</td>
<td></td>
</tr>
<tr>
<td>17. Does your child try to get you to watch him or her? (For example, does your child look at you for praise, or say &quot;look&quot; or &quot;watch me&quot;?)</td>
<td></td>
</tr>
<tr>
<td>18. Does your child understand when you tell him or her to do something? (For example, if you don’t point, can your child understand &quot;put the book on the chair&quot; or &quot;bring me the blanket&quot;?)</td>
<td></td>
</tr>
<tr>
<td>19. If something new happens, does your child look at your face to see how you feel about it? (For example, if he or she hears a strange or funny noise, or sees a new toy, will he or she look at your face?)</td>
<td></td>
</tr>
<tr>
<td>20. Does your child like movement activities? (For example, being swung or bounced on your knee)</td>
<td></td>
</tr>
</tbody>
</table>

### Scoring:
- For all items except 2, 5, and 12, ‘NO’ response indicates autism spectrum disorder risk.
- Low-risk: 0–2; no further action required.
- Medium-risk: 3–7; administer the follow-up (M-CHAT-R/F); if score remains ≥2, screening is positive.
- High-risk: ≥8; refer immediately for diagnostic evaluation and early intervention.

### Source:
## Functional Assessment Screening in the Elderly

<table>
<thead>
<tr>
<th>Target Area</th>
<th>Assessment Procedure</th>
<th>Abnormal Result</th>
<th>Suggested Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vision</td>
<td>Inquire about vision changes, Snellen chart testing.</td>
<td>Presence of vision changes; inability to read &gt;20/40</td>
<td>Refer to ophthalmologist.</td>
</tr>
<tr>
<td>Hearing</td>
<td>Whisper a short, easily answered question such as “What is your name?” in each ear while the examiner’s face is out of direct view. Use audioscope set at 40 dB; test using 1000 and 2000 Hz. Brief hearing loss screener.</td>
<td>Inability to answer question. Inability to hear 1000 or 2000 Hz in both ears or inability to hear frequencies in either ear. Brief hearing loss screen score ≥3</td>
<td>Examine auditory canals for cerumen and clean if necessary. Repeat test; if still abnormal in either ear, refer for audiometry and possible prosthesis.</td>
</tr>
<tr>
<td>Balance and gait</td>
<td>Observe the patient after instructing as follows: “Rise from your chair, walk 10 ft, return, and sit down.” Check orthostatic blood pressure and heart rate.</td>
<td>Inability to complete task in 15 s</td>
<td>Performance-Oriented Mobility Assessment (POMA). Consider referral for physical therapy.</td>
</tr>
<tr>
<td>Continence of urine</td>
<td>Ask, “Do you ever lose your urine and get wet?” If yes, then ask, “Have you lost urine on at least 6 separate days?”</td>
<td>“Yes” to both questions</td>
<td>Ascertain frequency and amount. Search for remediable causes, including local irritations, polyuric states, and medications. Consider urologic referral.</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Ask, “Without trying, have you lost 10 lb or more in the last 6 mo?” Weigh the patient. Measure height.</td>
<td>“Yes” or weight is below acceptable range for height</td>
<td>Do appropriate medical evaluation.</td>
</tr>
</tbody>
</table>
### Functional Assessment Screening in the Elderly (Continued)

<table>
<thead>
<tr>
<th>Mental status</th>
<th>Instruct as follows: “I am going to name three objects (pencil, truck, and book). I will ask you to repeat their names now and then again a few minutes from now.”</th>
<th>Inability to recall all three objects after 1 min</th>
<th>Administer Folstein Mini-Mental State Examination. If score is &lt;24, search for causes of cognitive impairment. Ascertain onset, duration, and fluctuation of overt symptoms. Review medications. Assess consciousness and affect. Do appropriate laboratory tests.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>Ask, “Do you often feel sad or depressed?” or “How are your spirits?” “Yes” or “Not very good, I guess”</td>
<td>“Yes” or “Not very good, I guess”</td>
<td>Administer Geriatric Depression Scale or PHQ-9. If positive, check for antihypertensive, psychotropic, or other pertinent medications. Consider appropriate pharmacologic or psychiatric treatment.</td>
</tr>
<tr>
<td>ADL-IADL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Ask, “Can you get out of bed yourself?” “Can you dress yourself?” “Can you make your own meals?” “Can you do your own shopping?” “No” to any question</td>
<td>“No” to any question</td>
<td>Corroborate responses with patient’s appearance; question family members if accuracy is uncertain. Determine reasons for the inability (motivation compared with physical limitation). Institute appropriate medical, social, or environmental interventions.</td>
</tr>
<tr>
<td>Home environment</td>
<td>Ask, “Do you have trouble with stairs inside or outside of your home?” Ask about potential hazards inside the home with bathtubs, rugs, or lighting.</td>
<td>“Yes”</td>
<td>Evaluate home safety and institute appropriate countermeasures.</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>-------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>Social support</td>
<td>Ask, “Who would be able to help you in case of illness or emergency?”</td>
<td>—</td>
<td>List identified persons in the medical record. Become familiar with available resources for the elderly in the community.</td>
</tr>
<tr>
<td>Pain</td>
<td>Inquire about pain.</td>
<td>Presence of pain</td>
<td>Pain inventory.</td>
</tr>
<tr>
<td>Dentition</td>
<td>Oral examination.</td>
<td>Poor dentition</td>
<td>Dentistry referral.</td>
</tr>
<tr>
<td>Falls</td>
<td>Inquire about falls in past year and difficulty with walking or balance.</td>
<td>Presence of falls or gait/balance problems</td>
<td>Falls evaluation.</td>
</tr>
</tbody>
</table>

*Activities of Daily Living—Instrumental Activities of Daily Living.

For older adults, minimize exposure to potentially inappropriate medications. Below is a summary of the 2015 American Geriatric Society Beers Criteria to prevent adverse drug events in older patients.

### SELECTED MEDICATIONS TO AVOID IN OLDER ADULTS

These medications carry risks specific to an older population and should be avoided except in specific situations.

<table>
<thead>
<tr>
<th>Class of Medications</th>
<th>Reason to Avoid</th>
<th>Exceptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Generation Antihistamines (ie, diphenhydramine, hydroxyzine, promethazine, etc.)</td>
<td>Clearance is reduced as age advances; risk of confusion and other anticholinergic effects</td>
<td>Diphenhydramine for acute allergic reaction may be appropriate</td>
</tr>
<tr>
<td>Antiparkinsonian agents (ie, benztropine, trihexyphenidyl)</td>
<td>More effective agents exist for Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td>Antispasmodics (ie, atropine, belladonna alkaloids, dicyclomine, etc)</td>
<td>Risk of confusion and other anticholinergic effects</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Pulmonary, hepato-, and neurotoxicity with long-term use; safer alternatives exist for UTI ppx.</td>
<td></td>
</tr>
<tr>
<td>Alpha-1 blockers, peripheral (ie, doxazosin, prazosin, terazosin)</td>
<td>High risk of orthostatic hypotension</td>
<td></td>
</tr>
<tr>
<td>Alpha blockers, central (ie, clonidine, guanfacine, methyldopa)</td>
<td>Risk of CNS effect, bradycardia, orthostatic hypotension.</td>
<td>Clonidine may be appropriate in some cases as adjunctive agent in refractory HTN.</td>
</tr>
<tr>
<td>Digoxin</td>
<td>AFib: more effective alternatives exist and mortality may increase.</td>
<td>May be appropriate in some cases as adjunctive agent for refractory symptomatic atrial fibrillation or heart failure. If used, avoid doses &gt;0.125 mg/d.</td>
</tr>
<tr>
<td>Drug</td>
<td>Side Effects</td>
<td>Indications</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>Risk of hypotension, myocardial ischemia</td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Afib: More toxicity than other agents</td>
<td>May be appropriate for rhythm control if LVH or significant heart failure</td>
</tr>
<tr>
<td>Antidepressants with anticholinergic profile (ie, amitriptyline, nortriptyline, paroxetine)</td>
<td>Sedating; orthostatic hypotension; anticholinergic effects including confusion</td>
<td></td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Antipsychotics, 1st &amp; 2nd generation</td>
<td>Risk of CVA, cognitive decline.</td>
<td>Schizophrenia, bipolar disorder</td>
</tr>
<tr>
<td>Barbiturates (ie, phenobarbital, butalbital)</td>
<td>Risk of overdose at low dosages, dependence, escalating dose due to tolerance</td>
<td></td>
</tr>
<tr>
<td>Nonbenzodiazepine hypnotics (ie, zolpidem, zaleplon, eszopiclone)</td>
<td>Similar to benzodiazepine risk; minimal improvement in sleep</td>
<td></td>
</tr>
<tr>
<td>Androgens (ie, testosterone, methyltestosterone)</td>
<td>Cardiac problems; contraindicated in prostate cancer</td>
<td>Lab-verified symptomatic hypogonadism.</td>
</tr>
<tr>
<td>Estrogen, +/- progestin</td>
<td>Risk of breast and endometrial cancer; no evidence for cardioprotection or cognitive protection in elderly.</td>
<td>Vaginal estrogens safe/effective for vaginal dryness.</td>
</tr>
<tr>
<td>Insulin on a sliding scale</td>
<td>Hypoglycemia risk; no outcome benefit in outpatient or inpatient settings.</td>
<td></td>
</tr>
<tr>
<td>Megestrol</td>
<td>Does not improve weight; higher risk of VTE and death.</td>
<td></td>
</tr>
</tbody>
</table>
### SELECTED MEDICATIONS TO AVOID IN OLDER ADULTS  *(Continued)*

<table>
<thead>
<tr>
<th>Medication</th>
<th>Side Effect/safety Concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfonylureas of longer duration <em>(ie, glyburide, chlorpropamide)</em></td>
<td>Severe prolonged hypoglycemia</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Extrapyramidal effects</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td><em>Clostridium difficile</em> infection; osteopenia/osteoporosis</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>Short-courses <em>(ie, &lt;8 wk)</em>. May be appropriate to treat severe conditions such as erosive esophagitis, Barrett's esophagus, or for prevention in high-risk patients <em>(ie, NSAID or corticosteroid use)</em></td>
</tr>
<tr>
<td>NSAIDs <em>(ie, high-dose aspirin, ibuprofen, naproxen, indomethacin, ketorolac, etc.)</em></td>
<td>GI bleed or peptic ulcer disease. Some <em>(ie, indomethacin, ketorolac)</em> carry higher risk of AKI.</td>
</tr>
<tr>
<td>Muscle relaxants <em>(ie, cyclobenzaprine, methocarbamol, carisoprodol)</em></td>
<td>Anticholinergic effects, sedation, fracture risk; minimal efficacy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drug(s) to Avoid</th>
<th>Potential Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Failure</td>
<td>– NSAIDs, COX-2 inhibitors &lt;br&gt;– Calcium channel blockers, nondihydropyridine  &lt;br&gt;– Thiazolidinediones &lt;br&gt;– Cilostazol &lt;br&gt;– Dronedarone</td>
<td>Heart failure exacerbation due to fluid retention</td>
</tr>
<tr>
<td>Syncope</td>
<td>– Acetylcholinesterase inhibitors &lt;br&gt;– Alpha-1 blockers, peripheral (i.e., terazosin, prazosin, doxazosin) &lt;br&gt;– Tricyclic antidepressants &lt;br&gt;– Olanzapine</td>
<td>Bradycardia, orthostatic hypotension</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>– Chlorpromazine &lt;br&gt;– Clozapine &lt;br&gt;– Olanzapine &lt;br&gt;– Tramadol</td>
<td>Lower seizure threshold</td>
</tr>
<tr>
<td>Delirium</td>
<td>– Anticholinergics &lt;br&gt;– Antipsychotics &lt;br&gt;– Benzodiazepines &lt;br&gt;– Chlorpromazine &lt;br&gt;– Corticosteroids &lt;br&gt;– H2-receptor antagonists (i.e., ranitidine, famotidine, cimetidine) &lt;br&gt;– Meperidine &lt;br&gt;– Sedative hypnotics</td>
<td>Delirium</td>
</tr>
</tbody>
</table>
### SELECT MEDICATIONS TO AVOID IN OLDER ADULTS WITH CHRONIC CONDITIONS

<table>
<thead>
<tr>
<th>Condition</th>
<th>Medications</th>
<th>Side Effects</th>
</tr>
</thead>
</table>
| **Dementia/cognitive impairment**| – Anticholinergics  
  – Benzodiazepines  
  – H2-receptor antagonists (ie, ranitidine, famotidine, cimetidine)  
  – Nonbenzodiazepine hypnotics (ie, zolpidem, zaleplon, eszopiclone)  
  – Antipsychotics | Adverse CNS effects |
| **Fractures or falls**           | – Anticonvulsants  
  – Antipsychotics  
  – Benzodiazepines  
  – Nonbenzodiazepine hypnotics (ie, zolpidem, zaleplon, eszopiclone)  
  – Tricyclic antidepressants  
  – SSRIs  
  – Opioids | More fall risk due to ataxia, impaired psychomotor function, syncope |
| **Insomnia**                     | – Oral decongestants (ie, pseudoephedrine, phenylephrine)  
  – Stimulants (ie, modafinil, methylphenidate, amphetamine)  
  – Theobromides (ie, caffeine, theophylline) | CNS stimulants |
| **Parkinson’s disease**          | – Antipsychotics (exceptions: aripiprazole, quetiapine, clozapine)  
  – Antiemetics (ie, metoclopramide, promethazine) | Worsened Parkinson’s symptoms due to dopamine-receptor antagonization |
<table>
<thead>
<tr>
<th>Condition</th>
<th>Medications</th>
<th>Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcers, gastric or duodenal</td>
<td>- Aspirin (&gt;325 mg/d or higher)</td>
<td>Exacerbation or new ulcers</td>
</tr>
<tr>
<td></td>
<td>- NSAIDs (except COX-2 selective inhibitors)</td>
<td></td>
</tr>
<tr>
<td>CKD</td>
<td>- NSAIDs (all)</td>
<td>Risk of AKI and further decline</td>
</tr>
<tr>
<td>Urinary incontinence, women</td>
<td>- Estrogen (except intravaginal)</td>
<td>Aggravation of incontinence</td>
</tr>
<tr>
<td></td>
<td>- Peripheral alpha-1 antagonists (ie, doxazosin, prazosin, terazosin)</td>
<td></td>
</tr>
<tr>
<td>Lower urinary tract symptoms, BPH</td>
<td>- Anticholinergics (except: antimuscarinics when used for urinary incontinence)</td>
<td></td>
</tr>
</tbody>
</table>
SELECT MEDICATIONS TO USE WITH CAUTION IN OLDER ADULTS
These medications carry increased risk of adverse events in patients of older age.

<table>
<thead>
<tr>
<th>Medication(s)</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin (for primary prevention of cardiovascular events)</td>
<td>Evidence does not support that the benefit is greater than risk in patients older than 80 y</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Increased risk of GI bleed vs. warfarin in adults older than 75 y old</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Increased risk of bleeding in adults older than 75 y old</td>
</tr>
<tr>
<td>– Antipsychotics</td>
<td>SIADH or hyponatremia</td>
</tr>
<tr>
<td>– Diuretics</td>
<td></td>
</tr>
<tr>
<td>– Carbamazepine</td>
<td></td>
</tr>
<tr>
<td>– Carboplatin</td>
<td></td>
</tr>
<tr>
<td>– Cyclophosphamide</td>
<td></td>
</tr>
<tr>
<td>– Cisplatin</td>
<td></td>
</tr>
<tr>
<td>– Mirtazipine</td>
<td></td>
</tr>
<tr>
<td>– Oxcarbazepine</td>
<td></td>
</tr>
<tr>
<td>– SNRIs</td>
<td></td>
</tr>
<tr>
<td>– SSRIs</td>
<td></td>
</tr>
<tr>
<td>– TCAs</td>
<td></td>
</tr>
<tr>
<td>– Vincristine</td>
<td></td>
</tr>
<tr>
<td>Vasodilators</td>
<td>Syncope</td>
</tr>
</tbody>
</table>
SCREENING AND PREVENTION GUIDELINES IN PERSPECTIVE: PGPC 2012

The following tables highlight areas where differences exist between various organizations’ guideline recommendations and areas where a new direction appears to be developing as a result of new or updated guidelines.

1. Areas of significant difference in guideline recommendations

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>Organization</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescent Alcohol Abuse</td>
<td>USPSTF/AAFP Bright Futures/NIAAA</td>
<td>Evidence insufficient Screen annually</td>
</tr>
<tr>
<td>Breast CA Screening, Women Age 40–49 y</td>
<td>UK-NHS ACP USPSTF/AAFP</td>
<td>Routine screening not recommended Mammogram and CBE yearly starting at age 40 y—high-risk patients (&gt;20% lifetime risk of breast CA) add annual MRI Mammography ± breast examination every 2 y beginning at age 50 y and stop at age 75. In women age 40–50 y, counsel regarding risks and benefits; it should no longer be done routinely</td>
</tr>
<tr>
<td>Breast CA Screening, Women Age 50–70 y</td>
<td>UK-NHS USPSTF/AAFP ACS</td>
<td>Mammography screening every 3 y Mammography screening every 2 y Annual mammography screening</td>
</tr>
<tr>
<td>Cervical CA Screening, Women Age &lt;50 y</td>
<td>UK-NHS ACS</td>
<td>Begin screening every 3 y after age 25 y Screen beginning at age 21 y no matter when sexual activity started; screen annually (or every 2 y if liquid-based Pap smear) until age 30, then every 3 y if consecutive negative Pap smear results. HPV testing can be added after age 30 y. If Pap smears and HPV testing are both negative, the frequency of testing can be every 5 y</td>
</tr>
</tbody>
</table>

04_Esherick_Ch04.indd   565
04_Esherick_Ch04.indd   565
<table>
<thead>
<tr>
<th>Screening and Prevention Guidelines in Perspective: PGPC 2012 (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prostate CA Screening, Men Age &gt;50 y</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>UK-NHS</td>
</tr>
<tr>
<td>ACS</td>
</tr>
<tr>
<td>Do not use PSA-based screening for prostate cancer at any age—evidence suggests harms outweigh benefits</td>
</tr>
<tr>
<td>Informed decision making</td>
</tr>
<tr>
<td>Discuss screening PSA and digital rectal examination. Discuss risks and benefits including treatment options and side effects of treatment. Do not do PSA screen unless patient desires</td>
</tr>
<tr>
<td><strong>Testicular CA Screening</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>ACS</td>
</tr>
<tr>
<td>Recommend against screening</td>
</tr>
<tr>
<td>Perform testicular examination as part of routine CA-related checkup</td>
</tr>
<tr>
<td><strong>Depression, Children and Adolescents</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>CTF/NICE</td>
</tr>
<tr>
<td>Bright Futures</td>
</tr>
<tr>
<td>Insufficient evidence to recommend for or against screening</td>
</tr>
<tr>
<td>Annual screening for behaviors/emotions that indicate depression or risk of suicide</td>
</tr>
<tr>
<td><strong>Family Violence and Abuse, Children and Adolescents</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>Family Violence Prevention Fund</td>
</tr>
<tr>
<td>Insufficient evidence to recommend for or against screening</td>
</tr>
<tr>
<td>Assess caregivers/parents and adolescent patients at least annually</td>
</tr>
<tr>
<td><strong>Hearing Loss, Newborns</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>Joint Committee on Infant Hearing</td>
</tr>
<tr>
<td>Insufficient evidence to recommend for or against screening during the postpartum hospitalization</td>
</tr>
<tr>
<td>All infants should be screened for neonatal or congenital hearing loss</td>
</tr>
<tr>
<td><strong>Thyroid Screening, Adults</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>ATA</td>
</tr>
<tr>
<td>Evidence insufficient to recommend for or against screening</td>
</tr>
<tr>
<td>Screen all women age &gt;35 y at 5-y intervals</td>
</tr>
<tr>
<td><strong>Glaucoma, Adults</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>AOA</td>
</tr>
<tr>
<td>Evidence insufficient to recommend for or against screening</td>
</tr>
<tr>
<td>Comprehensive eye examination every 2 y age 18–60 y, then every year age &gt;60</td>
</tr>
<tr>
<td><strong>Diabetes Mellitus, Gestational</strong></td>
</tr>
<tr>
<td>USPSTF/AAFP</td>
</tr>
<tr>
<td>ADA</td>
</tr>
<tr>
<td>Evidence insufficient to recommend for or against screening asymptomatic pregnant women</td>
</tr>
<tr>
<td>Risk assess all women at first prenatal visit</td>
</tr>
</tbody>
</table>
2. New directions resulting from new or updated guidelines

<table>
<thead>
<tr>
<th>HIV screening: Opt-out screening for practically everyone, actively recommended against written informed consent.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocarditis prophylaxis: Now targets those at increased risk of complications from endocarditis, rather than risk of endocarditis.</td>
</tr>
<tr>
<td>Perioperative guidelines: New data have emerged on beta blockade that is not reflected in current guidelines. Two randomized trials of perioperative metoprolol found that perioperative metoprolol does not appear to be effective in reducing postoperative death rates among unselected patients.</td>
</tr>
<tr>
<td>Osteoporosis:</td>
</tr>
<tr>
<td>• WHO Fracture Risk Algorithm (FRAX) developed to calculate the 1-y probability of fracture to guide treatment decisions.</td>
</tr>
<tr>
<td>• Screening recommendations for men.</td>
</tr>
<tr>
<td>• Recommendation to measure and supplement serum 25-OH vitamin D levels.</td>
</tr>
<tr>
<td>Diabetes type 2 prevention: New recommendation to consider metformin for those at very high risk of developing diabetes.</td>
</tr>
</tbody>
</table>

CA, cancer; CBE, clinical breast examination; HIV, human immunodeficiency syndrome; HPV, human papillomavirus; MRI, magnetic resonance imaging; PSA, prostate-specific antigen.
### 95th Percentile of Blood Pressure for Boys

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>5%</th>
<th>10%</th>
<th>25%</th>
<th>50%</th>
<th>75%</th>
<th>95%</th>
<th>5%</th>
<th>10%</th>
<th>25%</th>
<th>50%</th>
<th>75%</th>
<th>90%</th>
<th>95%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>104</td>
<td>105</td>
<td>107</td>
<td>109</td>
<td>110</td>
<td>113</td>
<td>63</td>
<td>63</td>
<td>64</td>
<td>65</td>
<td>66</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td>4</td>
<td>106</td>
<td>107</td>
<td>109</td>
<td>111</td>
<td>112</td>
<td>115</td>
<td>66</td>
<td>67</td>
<td>68</td>
<td>69</td>
<td>70</td>
<td>71</td>
<td>71</td>
</tr>
<tr>
<td>5</td>
<td>108</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>116</td>
<td>69</td>
<td>70</td>
<td>71</td>
<td>72</td>
<td>73</td>
<td>74</td>
<td>74</td>
</tr>
<tr>
<td>6</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>117</td>
<td>72</td>
<td>72</td>
<td>73</td>
<td>74</td>
<td>75</td>
<td>76</td>
<td>76</td>
</tr>
<tr>
<td>7</td>
<td>110</td>
<td>111</td>
<td>113</td>
<td>115</td>
<td>117</td>
<td>119</td>
<td>74</td>
<td>74</td>
<td>75</td>
<td>76</td>
<td>77</td>
<td>78</td>
<td>78</td>
</tr>
<tr>
<td>8</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>119</td>
<td>75</td>
<td>76</td>
<td>77</td>
<td>78</td>
<td>79</td>
<td>79</td>
<td>80</td>
</tr>
<tr>
<td>9</td>
<td>113</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>119</td>
<td>121</td>
<td>76</td>
<td>77</td>
<td>78</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>81</td>
</tr>
<tr>
<td>10</td>
<td>115</td>
<td>116</td>
<td>117</td>
<td>119</td>
<td>121</td>
<td>122</td>
<td>77</td>
<td>78</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>81</td>
<td>82</td>
</tr>
<tr>
<td>11</td>
<td>117</td>
<td>118</td>
<td>119</td>
<td>121</td>
<td>123</td>
<td>124</td>
<td>78</td>
<td>78</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>82</td>
</tr>
<tr>
<td>12</td>
<td>119</td>
<td>120</td>
<td>122</td>
<td>123</td>
<td>125</td>
<td>127</td>
<td>78</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>82</td>
<td>83</td>
</tr>
<tr>
<td>13</td>
<td>121</td>
<td>122</td>
<td>124</td>
<td>126</td>
<td>128</td>
<td>129</td>
<td>79</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>14</td>
<td>124</td>
<td>125</td>
<td>127</td>
<td>128</td>
<td>130</td>
<td>132</td>
<td>80</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>83</td>
<td>84</td>
<td>84</td>
</tr>
<tr>
<td>15</td>
<td>126</td>
<td>127</td>
<td>129</td>
<td>131</td>
<td>133</td>
<td>134</td>
<td>81</td>
<td>81</td>
<td>82</td>
<td>83</td>
<td>84</td>
<td>85</td>
<td>85</td>
</tr>
<tr>
<td>16</td>
<td>129</td>
<td>130</td>
<td>132</td>
<td>134</td>
<td>135</td>
<td>137</td>
<td>82</td>
<td>83</td>
<td>83</td>
<td>84</td>
<td>85</td>
<td>86</td>
<td>87</td>
</tr>
<tr>
<td>17</td>
<td>131</td>
<td>132</td>
<td>134</td>
<td>136</td>
<td>138</td>
<td>139</td>
<td>84</td>
<td>85</td>
<td>86</td>
<td>87</td>
<td>87</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td>Age (y)</td>
<td>Systolic Blood Pressure (mm Hg) by Percentile of Height</td>
<td>Diastolic Blood Pressure (mm Hg) by Percentile of Height</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5% 10% 25% 50% 75% 90% 95%</td>
<td>5% 10% 25% 50% 75% 90% 95%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>104 104 105 107 108 109 110</td>
<td>65 66 66 67 68 68 69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>105 106 107 108 110 111 112</td>
<td>68 68 68 70 71 71 72</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>107 107 108 110 111 112 113</td>
<td>70 71 71 72 73 73 74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>108 109 110 111 113 114 115</td>
<td>72 72 73 74 74 74 75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>110 111 112 113 115 116 116</td>
<td>73 73 73 74 74 74 75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>112 112 114 115 116 118 118</td>
<td>75 75 75 76 76 76 77</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>114 114 115 117 118 119 120</td>
<td>76 76 76 77 77 77 78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>116 116 117 119 120 121 122</td>
<td>77 77 77 77 78 78 79</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>118 118 119 121 122 123 124</td>
<td>78 78 78 78 79 79 80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>119 120 121 123 124 125 126</td>
<td>79 79 79 79 80 80 81</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>121 122 123 124 125 126 127</td>
<td>80 80 80 80 81 81 82</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>123 123 125 126 127 129 129</td>
<td>81 81 81 81 82 82 83</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>124 125 126 127 129 130 131</td>
<td>82 82 82 82 83 83 84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>125 126 127 130 131 132 132</td>
<td>82 82 82 82 83 83 84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>125 126 127 130 131 132 132</td>
<td>82 83 83 83 84 85 86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## BODY MASS INDEX (BMI) CONVERSION TABLE

<table>
<thead>
<tr>
<th>Height in Inches (cm)</th>
<th>BMI 25 kg/m²</th>
<th>BMI 27 kg/m²</th>
<th>BMI 30 kg/m²</th>
<th>Body weight in pounds (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 (147.32)</td>
<td>119 (53.98)</td>
<td>129 (58.51)</td>
<td>143 (64.86)</td>
<td>129 (58.51)</td>
</tr>
<tr>
<td>59 (149.86)</td>
<td>124 (56.25)</td>
<td>133 (60.33)</td>
<td>148 (67.13)</td>
<td>133 (60.33)</td>
</tr>
<tr>
<td>60 (152.40)</td>
<td>128 (58.06)</td>
<td>138 (62.60)</td>
<td>153 (69.40)</td>
<td>138 (62.60)</td>
</tr>
<tr>
<td>61 (154.94)</td>
<td>132 (59.87)</td>
<td>143 (64.86)</td>
<td>158 (71.67)</td>
<td>143 (64.86)</td>
</tr>
<tr>
<td>62 (157.48)</td>
<td>136 (61.69)</td>
<td>147 (66.68)</td>
<td>164 (74.39)</td>
<td>147 (66.68)</td>
</tr>
<tr>
<td>63 (160.02)</td>
<td>141 (63.96)</td>
<td>152 (68.95)</td>
<td>169 (76.66)</td>
<td>152 (68.95)</td>
</tr>
<tr>
<td>64 (162.56)</td>
<td>145 (65.77)</td>
<td>157 (71.22)</td>
<td>174 (78.93)</td>
<td>157 (71.22)</td>
</tr>
<tr>
<td>65 (165.10)</td>
<td>150 (68.04)</td>
<td>162 (73.48)</td>
<td>180 (81.65)</td>
<td>162 (73.48)</td>
</tr>
<tr>
<td>66 (167.64)</td>
<td>155 (70.31)</td>
<td>167 (75.75)</td>
<td>186 (84.37)</td>
<td>167 (75.75)</td>
</tr>
<tr>
<td>67 (170.18)</td>
<td>159 (72.12)</td>
<td>172 (78.02)</td>
<td>191 (86.64)</td>
<td>172 (78.02)</td>
</tr>
<tr>
<td>68 (172.72)</td>
<td>164 (74.39)</td>
<td>177 (80.29)</td>
<td>197 (89.36)</td>
<td>177 (80.29)</td>
</tr>
<tr>
<td>69 (175.26)</td>
<td>169 (76.66)</td>
<td>182 (82.56)</td>
<td>203 (92.08)</td>
<td>182 (82.56)</td>
</tr>
<tr>
<td>70 (177.80)</td>
<td>174 (78.93)</td>
<td>188 (85.28)</td>
<td>207 (93.90)</td>
<td>188 (85.28)</td>
</tr>
<tr>
<td>71 (180.34)</td>
<td>179 (81.19)</td>
<td>193 (87.54)</td>
<td>215 (97.52)</td>
<td>193 (87.54)</td>
</tr>
<tr>
<td>72 (182.88)</td>
<td>184 (83.46)</td>
<td>199 (90.27)</td>
<td>221 (100.25)</td>
<td>199 (90.27)</td>
</tr>
<tr>
<td>73 (185.42)</td>
<td>189 (85.73)</td>
<td>204 (92.53)</td>
<td>227 (102.97)</td>
<td>204 (92.53)</td>
</tr>
<tr>
<td>74 (187.96)</td>
<td>194 (88.00)</td>
<td>210 (95.26)</td>
<td>233 (105.69)</td>
<td>210 (95.26)</td>
</tr>
<tr>
<td>75 (190.50)</td>
<td>200 (90.72)</td>
<td>216 (97.98)</td>
<td>240 (108.86)</td>
<td>216 (97.98)</td>
</tr>
<tr>
<td>76 (193.04)</td>
<td>205 (92.99)</td>
<td>221 (100.25)</td>
<td>246 (111.59)</td>
<td>221 (100.25)</td>
</tr>
</tbody>
</table>

**Metric conversion formula** = weight (kg)/height (m²)

**Example of BMI calculation:**
A person who weighs 78.93 kg and is 177 cm tall has a BMI of 25:

\[
\frac{78.93 \text{ kg}}{1.77 \text{ m}^2} = 25
\]

**BMI categories:**
- Underweight = <18.5
- Normal weight = 18.5–24.9
- Overweight = 25–29.9
- Obesity = ≥30

**Nonmetric conversion formula** = \( [\text{weight (lb)}/\text{height (in}^2\text{)})] \times 704.5

**Example of BMI calculation:**
A person who weighs 164 lb and is 68 in. (or 5'8") tall has a BMI of 25:

\[
\left(\frac{164 \text{ lb}}{68 \text{ in}^2}\right) \times 704.5 = 25
\]


### ESTIMATE OF 10-Y CARDIAC RISK FOR MEN

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–34</td>
<td>-9</td>
</tr>
<tr>
<td>35–39</td>
<td>-4</td>
</tr>
<tr>
<td>40–44</td>
<td>0</td>
</tr>
<tr>
<td>45–49</td>
<td>3</td>
</tr>
<tr>
<td>50–54</td>
<td>6</td>
</tr>
<tr>
<td>55–59</td>
<td>8</td>
</tr>
<tr>
<td>60–64</td>
<td>10</td>
</tr>
<tr>
<td>65–69</td>
<td>11</td>
</tr>
<tr>
<td>70–74</td>
<td>12</td>
</tr>
<tr>
<td>75–79</td>
<td>13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cholesterol</th>
<th>Age 20–39</th>
<th>Age 40–49</th>
<th>Age 50–59</th>
<th>Age 60–69</th>
<th>Age 70–79</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;160</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>160–199</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>200–239</td>
<td>7</td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>240–279</td>
<td>9</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>≥280</td>
<td>11</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Points</th>
<th>Age 20–39</th>
<th>Age 40–49</th>
<th>Age 50–59</th>
<th>Age 60–69</th>
<th>Age 70–79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non smoker</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Smoker</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
## ESTIMATE OF 10-Y CARDIAC RISK FOR MEN\(^a\)  (Continued)

<table>
<thead>
<tr>
<th>High-Density Lipoprotein (mg/dL)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥60</td>
<td>-1</td>
</tr>
<tr>
<td>50–59</td>
<td>0</td>
</tr>
<tr>
<td>40–49</td>
<td>1</td>
</tr>
<tr>
<td>&lt;40</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systolic Blood Pressure (mm Hg)</th>
<th>If Untreated</th>
<th>If Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;120</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>120–129</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>130–139</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>140–159</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>≥160</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Point Total</th>
<th>10-y Risk %</th>
<th>Point Total</th>
<th>10-y Risk %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0</td>
<td>&lt;1</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>16</td>
<td>25</td>
</tr>
<tr>
<td>7</td>
<td>3</td>
<td>≥17</td>
<td>≥30</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Framingham point scores.

### ESTIMATE OF 10-Y CARDIAC RISK FOR WOMEN

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–34</td>
<td>−7</td>
</tr>
<tr>
<td>35–39</td>
<td>−3</td>
</tr>
<tr>
<td>40–44</td>
<td>0</td>
</tr>
<tr>
<td>45–49</td>
<td>3</td>
</tr>
<tr>
<td>50–54</td>
<td>6</td>
</tr>
<tr>
<td>55–59</td>
<td>8</td>
</tr>
<tr>
<td>60–64</td>
<td>10</td>
</tr>
<tr>
<td>65–69</td>
<td>12</td>
</tr>
<tr>
<td>70–74</td>
<td>14</td>
</tr>
<tr>
<td>75–79</td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Cholesterol</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;160</td>
<td>0</td>
</tr>
<tr>
<td>160–199</td>
<td>4</td>
</tr>
<tr>
<td>200–239</td>
<td>8</td>
</tr>
<tr>
<td>240–279</td>
<td>11</td>
</tr>
<tr>
<td>≥280</td>
<td>13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cholesterol</th>
<th>Age 20–39</th>
<th>Age 40–49</th>
<th>Age 50–59</th>
<th>Age 60–69</th>
<th>Age 70–79</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;160</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>160–199</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>200–239</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>240–279</td>
<td>11</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>≥280</td>
<td>13</td>
<td>10</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsmoker</td>
<td>0</td>
</tr>
<tr>
<td>Smoker</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age 20–39</th>
<th>Age 40–49</th>
<th>Age 50–59</th>
<th>Age 60–69</th>
<th>Age 70–79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsmoker</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Smoker</td>
<td>9</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>
### ESTIMATE OF 10-Y CARDIAC RISK FOR WOMEN

(Continued)

<table>
<thead>
<tr>
<th>High-Density Lipoprotein (mg/dL)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥60</td>
<td>-1</td>
</tr>
<tr>
<td>50–59</td>
<td>0</td>
</tr>
<tr>
<td>40–49</td>
<td>1</td>
</tr>
<tr>
<td>&lt;40</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systolic Blood Pressure (mm Hg)</th>
<th>If Untreated</th>
<th>If Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;120</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>120–129</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>130–139</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>140–159</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>≥160</td>
<td>4</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Point Total</th>
<th>10-y Risk %</th>
<th>Point Total</th>
<th>10-y Risk %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;9</td>
<td>&lt;1</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>19</td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>1</td>
<td>20</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>1</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>13</td>
<td>2</td>
<td>22</td>
<td>17</td>
</tr>
<tr>
<td>14</td>
<td>2</td>
<td>23</td>
<td>22</td>
</tr>
<tr>
<td>15</td>
<td>3</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>16</td>
<td>4</td>
<td>≥25</td>
<td>≥30</td>
</tr>
</tbody>
</table>

*Framingham point scores.

# ESTIMATE OF 10-Y STROKE RISK FOR MEN

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Points</th>
<th>Untreated Systolic Blood Pressure (mm Hg)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>54–56</td>
<td>0</td>
<td>97–105</td>
<td>0</td>
</tr>
<tr>
<td>57–59</td>
<td>1</td>
<td>106–115</td>
<td>1</td>
</tr>
<tr>
<td>60–62</td>
<td>2</td>
<td>116–125</td>
<td>2</td>
</tr>
<tr>
<td>63–65</td>
<td>3</td>
<td>126–135</td>
<td>3</td>
</tr>
<tr>
<td>66–68</td>
<td>4</td>
<td>136–145</td>
<td>4</td>
</tr>
<tr>
<td>69–72</td>
<td>5</td>
<td>146–155</td>
<td>5</td>
</tr>
<tr>
<td>73–75</td>
<td>6</td>
<td>156–165</td>
<td>6</td>
</tr>
<tr>
<td>76–78</td>
<td>7</td>
<td>166–175</td>
<td>7</td>
</tr>
<tr>
<td>79–81</td>
<td>8</td>
<td>176–185</td>
<td>8</td>
</tr>
<tr>
<td>82–84</td>
<td>9</td>
<td>186–195</td>
<td>9</td>
</tr>
<tr>
<td>85</td>
<td>10</td>
<td>196–205</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treated Systolic Blood Pressure (mm Hg)</th>
<th>Points</th>
<th>History of Diabetes</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>97–105</td>
<td>0</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>106–112</td>
<td>1</td>
<td>Yes</td>
<td>2</td>
</tr>
<tr>
<td>113–117</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>118–123</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>124–129</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>130–135</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>136–142</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>143–150</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>151–161</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>162–176</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>177–205</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarette Smoking</td>
<td>Points</td>
<td>Cardiovascular Disease</td>
<td>Points</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------</td>
<td>------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>3</td>
<td>Yes</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atrial Fibrillation</th>
<th>Points</th>
<th>Left Ventricular Hypertrophy on Electrocardiogram</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>0</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>Yes</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Point Total</th>
<th>10-y Risk</th>
<th>Point Total</th>
<th>10-y Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>16</td>
<td>22</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>17</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>18</td>
<td>29</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>19</td>
<td>33</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>20</td>
<td>37</td>
</tr>
<tr>
<td>6</td>
<td>5</td>
<td>21</td>
<td>42</td>
</tr>
<tr>
<td>7</td>
<td>6</td>
<td>22</td>
<td>47</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>23</td>
<td>52</td>
</tr>
<tr>
<td>9</td>
<td>8</td>
<td>24</td>
<td>57</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>25</td>
<td>63</td>
</tr>
<tr>
<td>11</td>
<td>11</td>
<td>26</td>
<td>68</td>
</tr>
<tr>
<td>12</td>
<td>13</td>
<td>27</td>
<td>74</td>
</tr>
<tr>
<td>13</td>
<td>15</td>
<td>28</td>
<td>79</td>
</tr>
<tr>
<td>14</td>
<td>17</td>
<td>29</td>
<td>84</td>
</tr>
<tr>
<td>15</td>
<td>20</td>
<td>30</td>
<td>88</td>
</tr>
</tbody>
</table>

10-y Risk ____% 

## Estimate of 10-Y Stroke Risk for Women

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Points</th>
<th>Untreated Systolic Blood Pressure (mm Hg)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>54–56</td>
<td>0</td>
<td>95–106</td>
<td>1</td>
</tr>
<tr>
<td>57–59</td>
<td>1</td>
<td>107–118</td>
<td>2</td>
</tr>
<tr>
<td>60–62</td>
<td>2</td>
<td>119–130</td>
<td>3</td>
</tr>
<tr>
<td>63–64</td>
<td>3</td>
<td>131–143</td>
<td>4</td>
</tr>
<tr>
<td>65–67</td>
<td>4</td>
<td>144–155</td>
<td>5</td>
</tr>
<tr>
<td>68–70</td>
<td>5</td>
<td>156–167</td>
<td>6</td>
</tr>
<tr>
<td>71–73</td>
<td>6</td>
<td>168–180</td>
<td>7</td>
</tr>
<tr>
<td>74–76</td>
<td>7</td>
<td>181–192</td>
<td>8</td>
</tr>
<tr>
<td>77–78</td>
<td>8</td>
<td>193–204</td>
<td>9</td>
</tr>
<tr>
<td>79–81</td>
<td>9</td>
<td>205–216</td>
<td>10</td>
</tr>
<tr>
<td>82–84</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treated Systolic Blood Pressure (mm Hg)</th>
<th>Points</th>
<th>History of Diabetes</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>95–106</td>
<td>1</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>107–113</td>
<td>2</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>114–119</td>
<td>3</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>120–125</td>
<td>4</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>126–131</td>
<td>5</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>132–139</td>
<td>6</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>140–148</td>
<td>7</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>149–160</td>
<td>8</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>161–204</td>
<td>9</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>205–216</td>
<td>10</td>
<td>Yes</td>
<td>3</td>
</tr>
</tbody>
</table>
### ESTIMATE OF 10-Y STROKE RISK FOR WOMEN (Continued)

<table>
<thead>
<tr>
<th>Cigarette Smoking</th>
<th>Points</th>
<th>Cardiovascular Disease</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>0</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>3</td>
<td>Yes</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atrial Fibrillation</th>
<th>Points</th>
<th>Left Ventricular Hypertrophy on Electrocardiogram</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>0</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>6</td>
<td>Yes</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Point Total</th>
<th>10-y Risk %</th>
<th>Point Total</th>
<th>10-y Risk %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>16</td>
<td>19</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>17</td>
<td>23</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>18</td>
<td>27</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>19</td>
<td>32</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>20</td>
<td>37</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>21</td>
<td>43</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>22</td>
<td>50</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>23</td>
<td>57</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>24</td>
<td>64</td>
</tr>
<tr>
<td>10</td>
<td>6</td>
<td>25</td>
<td>71</td>
</tr>
<tr>
<td>11</td>
<td>8</td>
<td>26</td>
<td>78</td>
</tr>
<tr>
<td>12</td>
<td>9</td>
<td>27</td>
<td>84</td>
</tr>
<tr>
<td>13</td>
<td>11</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>13</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>16</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>

**Source:** Modified Framingham Stroke Risk Profile. *Circulation*. 2006;113:e873-e923.
IMMUNIZATION SCHEDULE

**Figure 1.** Recommended immunization schedule for children and adolescents aged 18 y or younger – United States, 2017. (For those who fall behind or start late, see the catch-up schedule [Figure 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>18-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV) (RV1 2-dose series; RV5 3-dose series)</td>
<td></td>
<td></td>
<td></td>
<td>1-dose</td>
<td>2-dose</td>
<td>See footnote 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP: &lt;7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-dose</td>
<td>2-dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-dose</td>
<td>2-dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-dose</td>
<td>2-dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV: &lt;18 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-dose</td>
<td>2-dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (IIV) 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal polisaccharide (Hib-MenceCY: &lt;2 mos; MenACWY-CRM: 2-6 mos; MenACWY-D: 5-9 mos; MenACWY-CRM: 10-23 mos)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (Tdap: &gt;7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** The above recommendations must be read along with the footnotes of this schedule.
Figure 2. Catch-up immunization schedule for persons age 4 mo through 18 y who start late or who are more than 1 mo behind—United States, 2017.

The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Figure 1 and the footnotes that follow.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age for First Dose</th>
<th>Minimum Interval Between Doses</th>
<th>Date 1 to Dose 2</th>
<th>Date 2 to Dose 3</th>
<th>Date 3 to Dose 4</th>
<th>Date 4 to Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>Birth</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>At least 16 weeks after first dose</td>
<td>At least 16 weeks after the final dose</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Hemophilus influenzae type b</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Streptococcus pneumonia, Haemophilus influenzae type b</td>
<td>7 years</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>9 years</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
</tr>
</tbody>
</table>

**NOTE:** The above recommendations must be read along with the footnotes of this schedule.
**VACCINE INDICATIONS:**

- Pregnancy
- Immunocompromised status (excluding HIV infection)
- HIV infection
  - CD4+ count (cells/μL)
- Kidney failure, end-stage renal disease, on hemodialysis
- Heart disease, chronic lung disease
- CSF leaks/cochlear implants
- Asplenia and persistent complement component deficiencies
- Chronic liver disease
- Diabetes

**Recommended Vaccines:**

1. Hepatitis B
2. Rotavirus
3. Diphtheria, tetanus, & acellular pertussis (DTaP)
4. Haemophilus influenzae type b
5. Pneumococcal conjugate
6. Inactivated poliovirus
7. Influenza
8. Measles, mumps, rubella
9. Varicella
10. Hepatitis A
11. Meningococcal ACWY
12. Tetanus, diphtheria, & acellular pertussis (Tdap)
13. Human papillomavirus
14. Meningococcal B
15. Pneumococcal polysaccharide

**Vaccination Schedule:**

- Scoring system: 1 (recommended), 0 (not recommended), <0 (contraindicated)

**NOTE:** The above recommendations must be read along with the footnotes of this schedule.
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2017

For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.

For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.

Additional information
- For information on contraindications and precautions for the use of a vaccine and for additional information regarding that vaccine, vaccine providers should consult the ACIP General Recommendations on Immunization and the relevant ACIP statement, available online at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
- Vaccine doses administered >4 days before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid doses and should be reported as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 1. Recommended and minimum ages and intervals between vaccine doses, in MMWR, General Recommendations on Immunization and Reports, 56:66–No.2, available online at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
- Information on travel vaccine requirements and recommendations is available at www.cdc.gov/travel/.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. Created by the National Childhood Vaccine Injury Act of 1986, it provides compensation to people found to be injured by certain vaccines. All vaccines within the recommended childhood vaccination schedule are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information: see www.hrsa.gov/vaccinecompensation/index.html.

1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
   
   Routine vaccination:
   - At birth:
     - Administer monovalent HepB vaccine to all newborns within 24 hours of birth.
   - For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) at age 9 through 12 months (preferably at the next well-child visit or 1 to 2 months after completion of the HepB series if the series was delayed.
   - If mother’s HBsAg status is unknown, within 12 hours of birth, administer HepB vaccine regardless of birth weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if mother is HBsAg-positive, also administer HBIG to infants weighing 2,000 grams or more as soon as possible, but no later than age 7 days.
   - Doses following the birth dose:
     - The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks.
     - Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on schedule of 0, 1 to 2 months, and 6 months, starting as soon as feasible (see figure 2).
     - Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks); administer the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final (third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks.
     - Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose.
     - Catch-up vaccination:
       - Unvaccinated persons should complete a 3-dose series.
       - A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years.
   - For other catch-up guidance, see Figure 2.
   - Rotavirus (RV) vaccine. (Minimum age: 6 weeks for both RV1 [Rotarix] and RV2 [RotaTeq])
     - Routine vaccination:
       - Administer a series of RV vaccine to all infants as follows:
         1. If Rotarix is used, administer a 2-dose series at ages 2 and 4 months.
         2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months.
       - If any dose in the series was Rotarix or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered.
     - Catch-up vaccination:
       - The maximum age for the first dose in the series is 14 weeks; 8 days’ vaccination should not be initiated for infants aged 15 weeks, 6 days, or older.
       - For other catch-up guidance, see Figure 2.
   - Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-IPV [KinderQuadracel]: 4 years)
     - Routine vaccination:
       - Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided that at least 6 months have elapsed since the third dose.
       - Inadvertent administration of fourth DTaP dose early: If the fourth dose of DTaP was administered at least 4 months after the third dose of DTaP and the child was 12 months of age or older, it does not need to be repeated. Catch-up vaccination:
         - The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
       - For other catch-up guidance, see Figure 2.
   - Haemophilus influenzae type b (HiB) conjugate vaccine. (Minimum age: 6 weeks for PRP-T [ActHIB], DTaP-IPV/HiB [Pentacel], Hibermix, and HiB-MeneCV [MenHibrix]), PRP-OMP [PediaVaxHiB])
     - Routine vaccination:
       - Administer a 2- or 3-dose HiB vaccine primary series and a booster dose (dose 3 or 4, depending on vaccine used in primary series) at age 12 through 15 months to complete a full HiB vaccine series.
       - The primary series with ActHIB, MenHibrix, Hibermix, or Pentacel consists of 3 doses and should be administered at ages 2, 4, and 6 months. The primary series with PediaVaxHiB consists of 2 doses and should be administered at ages 2 and 4 months; a dose at age 6 months is not indicated.
       - One booster dose (dose 3 or 4, depending on vaccine used in primary series) of any HiB vaccine should be administered at age 12 through 15 months.
       - For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(08):11-12, available at www.cdc.gov/mmwr/WR/rr6308.pdf.


583

CHAPTER 4
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.

Catch-up vaccination:
- If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series.
- If both doses were PRP-OH (PedvaxHIB or OMNIvax) and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after the second dose.
- If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later.
- If first dose is administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be administered 6 weeks later.
- For unvaccinated children aged 15-59 months, administer only 1 dose.
- For other catch-up guidance, see Figure 2.

Vaccination of persons with high-risk conditions:
- For children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before age 12 months, should receive 2 additional doses of Hib vaccine. If weeks apart: children who received 2 or more doses of Hib vaccine before age 12 months should receive 1 additional dose.
- For patients younger than age 5 years undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion.
- Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least 4 weeks apart.
- A single dose of any Hib-containing vaccine should be administered to unimmunized* children and adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should be administered at least 14 days before procedure.
- Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized* persons aged 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unimmunized* persons 5 through 18 years of age with HIV infection.
* Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are considered unimmunized.

5. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)

Routine vaccination with PCV13:
- Administer 4-dose series of PCV13 at ages 2, 4, and 6 months and at age 12 through 15 months.

Catch-up vaccination with PCV13:
- Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.
- For other catch-up guidance, see Figure 2.

Vaccination of persons with high-risk conditions with PCV13 and PPSV23:
- All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
- For children aged 2 through 5 years with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; solid organ transplantation; or congenital anomalies.
- Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of PCV13 was received previously.
- Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incomplete schedule of fewer than 3 doses of PCV13 was received previously.
- The minimum interval between doses of PCV13 is 8 weeks.

6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)

Routine vaccination:
- Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose.

Catch-up vaccination:
- In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
- If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose.
- A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.
- If both oral polio vaccine (OPV) and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age. If only OPV was administered, and all doses were given prior to age 4 years, 1 dose of IPV should be given at 4 years or older, at least 4 weeks after the last OPV dose.
- IPV is not routinely recommended for U.S. residents aged 18 years or older.
- For other catch-up guidance, see Figure 2.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.

7. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 18 years for recombinant influenza vaccine [RIV].) Routine vaccination:
   Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56[No. RR-4], available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children aged 7 through 12 years, the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks.

8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine vaccination) Routine vaccination:
   - Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first dose.
   - Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be vaccinated with 2 doses of MMR vaccine; the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least 4 weeks later.
   - Administer 2 doses of MMR vaccine to children aged 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least 4 weeks later.

Catch-up vaccination:
   - Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.

9. Varicella (VAR) vaccine. (Minimum age: 12 months) Routine vaccination:
   - Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.
   - Administer a single dose of MMR or MMRv vaccine at age 11 through 12 years, with a booster dose at age 16 years.
   - For children aged 2 months through 18 years with high-risk conditions, see “Meningococcal conjugate ACWY vaccine of persons with high-risk conditions and other persons at increased risk of disease” below.

Catch-up vaccination:
   - Administer Menactra or Meneveo vaccine at age 13 through 18 years if not previously vaccinated.
   - If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years, with a minimum interval of at least 8 weeks between doses.
   - If the first dose is administered at age 16 years or older, a booster dose is not needed.
   - For other catch-up guidance, see Figure 2.

Clinical discretion:
   - Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) who are not at increased risk for meningococcal disease may be vaccinated with a 2-dose series of either Bexsero (8, 0–12 months) or Trumenba (6, 6 months) vaccine to provide short-term protection against most strains of serogroup B meningococcal disease. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.
   - If the second dose of Trumenba is given at an interval of >6 months, a third dose should be given at least 6 months after the first dose; the minimum interval between the second and third doses is 6 weeks.

10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months) Routine vaccination:
   - Initiate the 2-dose HepA vaccine series at ages 12 through 23 months; separate the 2 doses by 6 to 18 months.
   - Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose.
   - For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may be administered if immunity against hepatitis A virus infection is desired.

Catch-up vaccination:
   - The minimum interval between the 2 doses is 6 months.

Special populations:
   - Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection. This includes persons traveling to or working in countries that have high or intermediate endemicity of infection; men having sex with men; users of injection drugs persons who work with HIV-infected primates or with HIV in a research laboratory; persons with clotting factor disorders; persons with chronic liver disease; and persons who anticipate close, personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. The first dose should be administered as soon as the adoption is planned, Ideally, 2 or more weeks before the arrival of the adoptee.

11. Meningococcal vaccines. (Minimum age: 6 weeks for Hib-MenCv [MenHibrix], 2 months for MenACWY-D [Menveo], 9 months for MenACWY-D [Menactra], 10 years for serogroup B meningococcal [MenB] vaccines: MenB-4C [Bexsero] and MenB-PRP [Trumenba]) Routine vaccination:
   - Administer a single dose of Menactra or Meneveo vaccine at age 11 through 12 years, with a booster dose at age 16 years.
   - For children aged 2 months through 18 years with high-risk conditions, see “Meningococcal conjugate ACWY vaccine of persons with high-risk conditions and other persons at increased risk of disease” below.”
Figure 3. Vaccines that might be indicated for children and adolescents age 18 y or younger based on medical indications.

For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.

- Menactra
  - Children with anatomic or functional asplenia or HIV infection
    - Children 24 months and older who have not received a complete series. Administer 2 primary doses at least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease) or HIV infection, do not administer Menactra until age 2 years and at least 4 weeks after the completion of all PCV13 doses.
  - Children with persistent complement component deficiency
    - Children 9 through 23 months, Administer 2 primary doses at least 12 weeks apart.
    - Children 24 months and older who have not received a complete series. Administer 2 primary doses at least 8 weeks apart.
  - All high-risk children
    - If Menactra is to be administered to a child at high risk for meningococcal disease, it is recommended that Menactra be given either before or at the same time as DTaP.

Meningococcal B vaccination of persons with high-risk conditions and other persons at increased risk of disease:
- Children with anatomic or functional asplenia (including sickle cell disease) or children with persistent complement component deficiency includes persons with inherited or chronic deficiencies in C1, C4, C5, properdin, factor D, factor H, or taking eculizumab (Soliris):
  - Bexsero or Trumenba
    - Persons 10 years or older who have not received a complete series. Administer a 2-dose series of Bexsero, with doses at least 1 month apart, or a 3-dose series of Trumenba, with the second dose at least 1-2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.

For children who travel to or reside in countries where meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or the Hajj:
- Administer an age-appropriate formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj because it does not contain serogroups A or W.

For children at risk during an outbreak attributable to a vaccine-serogroup:
- For serogroup A, C, W, or Y: Administer or complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo.
- For serogroup B: Administer a 2-dose series of Bexsero, with doses at least 1 month apart, or a 3-dose series of Trumenba, with the second dose at least 1-2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.

For other catch-up recommendations for these persons and complete information on use of meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, see meningococcal MMWR publications, available at: www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmwr.html.

12. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum age: 10 years for both Boostrix and Adacel)

Routine vaccination:
- Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
- Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid containing vaccine. Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferably during the early part of gestational weeks 27 through 36), regardless of time since prior Td or Tdap vaccination.

Catch-up vaccination:
- Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap vaccine as 1 dose (preferably the first in the catch-up series) if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 years may be administered.
- Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose, followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter.

Inadvertent doses of DTaP vaccine:
- If administered inadvertently to a child aged 7 through 10 years, the dose may count as part of the catch-up series. This dose may count as the adolescent Tdap dose, or the child may receive a Tdap booster dose at age 11 through 12 years.
- If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted as the adolescent Tdap booster.

13. Human papillomavirus (HPV) vaccines. (Minimum age: 9 years for 4-HPV [Gardasil] and 9-HPV [Gardasil 9])

Routine and catch-up vaccination:
- Administer a 2-dose series of HPV vaccine on a schedule of 0, 6-12 months to all adolescents aged 11 or 12 years. The vaccination series can start at age 9 years.
- Administer HPV vaccine to all adolescents through age 18 years who were not previously adequately vaccinated. The number of recommended doses is based on age at administration of the first dose.
- For persons initiating vaccination before age 15, the recommended immunization schedule is 2 doses of HPV vaccine at 0, 6-12 months.
- For persons initiating vaccination at age 15 years or older, the recommended immunization schedule is 3 doses of HPV vaccine at 0, 1-2, 6 months.
- A vaccine dose administered at a shorter interval should be readministered at the recommended interval.
- In a 2-dose schedule of HPV vaccine, the minimum interval is 5 months between the first and second dose. If the second dose is administered at a shorter interval, a third dose should be administered a minimum of 12 weeks after the second dose and a minimum of 5 months after the first dose.
- In a 3-dose schedule of HPV vaccine, the minimum interval is 4 weeks between the first and second dose, 12 weeks between the second and third dose, and 5 months between the first and third dose. If a vaccine dose is administered at a shorter interval, it should be readministered after another minimum interval has been met since the most recent dose.

Special populations:
- For children with history of sexual abuse or assault, administer HPV vaccine beginning at age 9 years.
- Immunocompromised persons*, including those with human immunodeficiency virus (HIV) infection, should receive a 3-dose series at 0, 1-2, and 6 months, regardless of age at vaccine initiation.
- Note: HPV vaccine is not recommended during pregnancy; however, there is no evidence that the vaccine poses harm. If a woman is found to be pregnant prior to initiating the vaccination series, no intervention is needed; the remaining vaccine doses should be delayed until after the pregnancy. Pregnancy testing is not needed before HPV vaccination.

### Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–21 years</th>
<th>22–26 years</th>
<th>27–59 years</th>
<th>60–64 years</th>
<th>≥ 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 dose annually</td>
</tr>
<tr>
<td>Td/Tdap²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Substitute Tdap for Td once, then Td booster every 10 yrs</td>
</tr>
<tr>
<td>MMR³</td>
<td></td>
<td></td>
<td></td>
<td>1 or 2 doses depending on indication</td>
<td></td>
</tr>
<tr>
<td>VAR⁴</td>
<td></td>
<td></td>
<td></td>
<td>2 doses</td>
<td></td>
</tr>
<tr>
<td>HZV⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 dose</td>
</tr>
<tr>
<td>HPV–Female⁶</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Male⁶</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13⁷</td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td>1 dose</td>
</tr>
<tr>
<td>PPSV23⁷</td>
<td></td>
<td></td>
<td>1 or 2 doses depending on indication</td>
<td>1 dose</td>
<td></td>
</tr>
<tr>
<td>HepA⁸</td>
<td></td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
</tr>
<tr>
<td>HepB⁹</td>
<td></td>
<td></td>
<td></td>
<td>3 doses</td>
<td></td>
</tr>
<tr>
<td>MenACWY or MPSV4¹⁰</td>
<td></td>
<td></td>
<td></td>
<td>1 or more doses depending on indication</td>
<td></td>
</tr>
<tr>
<td>MenB¹⁰</td>
<td></td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
</tr>
<tr>
<td>Hib¹¹</td>
<td></td>
<td></td>
<td></td>
<td>1 or 3 doses depending on indication</td>
<td></td>
</tr>
</tbody>
</table>

---

- **Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection**
- **Recommended for adults with additional medical conditions or other indications**
- **No recommendation**
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy</th>
<th>Immuno-compromised (excluding HIV infection)</th>
<th>HIV infection CD4+ count (cells/µL)</th>
<th>Asplenia, persistent complement deficiencies</th>
<th>Kidney failure, end-stage renal disease, on hemodialysis</th>
<th>Heart or lung disease, chronic alcoholism</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Health care personnel</th>
<th>Men who have sex with men</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1-6,9</td>
<td>3-7,9,11</td>
<td>≥ 200</td>
<td>11,10</td>
<td>7,9</td>
<td>7,9</td>
<td>6,8,9</td>
<td>3,4,9</td>
<td>5,6</td>
<td>6</td>
</tr>
<tr>
<td>Influenza</td>
<td>1 dose</td>
<td>1 dose annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td/Tdap</td>
<td>1 dose</td>
<td>Substitute Tdap for Td once, then Td booster every 10 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>contraindicated</td>
<td>1 or 2 doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR</td>
<td>contraindicated</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZV</td>
<td>contraindicated</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Female</td>
<td>3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Male</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23</td>
<td>1, 2, or 3 doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY or MPSV4</td>
<td>1 or more doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>3 doses post-HSCT recipients only</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection**
- **Recommended for adults with additional medical conditions or other indications**
- **Contraindicated**
- **No recommendation**
Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2017

1. Influenza vaccination
   General information:
   - All persons aged 6 months or older who do not have a contraindication should receive annual influenza vaccination with an age-appropriate formulation of inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV).
   - In addition to standard-dose IIV, available options for adults in specific age groups include high-dose or adjuvanted IIV for adults aged 65 years or older, intranasal IIV for adults aged 18 through 64 years, and RIV for adults aged 18 years or older.
   - Note: Live attenuated influenza vaccine (LAIV) should not be used during the 2016–2017 influenza season. A list of currently available influenza vaccines is available at www.cdc.gov/flu/professionals/vaccines/vaccine.htm.

   Special populations:
   - Adults with a history of egg allergy who have only lived exposure to egg should receive age-appropriate IIV or RIV.
   - Adults with a history of egg allergy other than hives, e.g., anaphylaxis, respiratory distress, lightheadedness, or recurrent emesis, or who required epinephrine or another emergency medical intervention, may receive age-appropriate IIV or RIV. The selected vaccine should be administered in an inpatient or outpatient medical setting and under the supervision of a healthcare provider who is able to recognize and manage severe allergic conditions.
   - Pregnant women and women who might become pregnant in the upcoming influenza season should receive IIV.

2. Tetanus, diphtheria, and acellular pertussis vaccination
   General information:
   - Adults who have not received tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) or for whom pertussis vaccination status is unknown should receive 1 dose of Tdap followed by a tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap should be administered regardless of when a tetanus or diphtheria toxoid-containing vaccine was last received.
   - Adults with an unknown or incomplete history of a 3-dose primary series with tetanus and diphtheria toxoid-containing vaccines should receive the primary series that includes 1 dose of Tdap. Unvaccinated adults should receive the first 2 doses at least 4 weeks apart and the third dose 12 months after the second dose.
   - Notes: Information on the use of Td or Tdap in tetanus prophylaxis in wound management is available at www.cdc.gov/mmwr/preview/ mmwrhtml/mm5711a7.htm.

   Special populations:
   - Pregnant women should receive 1 dose of Tdap during each pregnancy, preferably during the early part of gestational weeks 26 through 32.

3. Measles, mumps, and rubella vaccination
   General information:
   - Adults born in 1957 or later who lack adequate evidence of immunity to measles, mumps, and rubella virus (MMR) unless they have a medical contraindication to the vaccine, e.g., pregnancy or severe immunodeficiency.
   - Notes: Acceptable evidence of immunity to measles, mumps, or rubella (as defined below) should be redefined if an individual is vaccinated and returns to a heavily vaccinated area or if there is evidence of a recent increase in measles cases. Documentation of healthcare provider-diagnosed disease without laboratory confirmation is not acceptable evidence of immunity.

   Special populations:
   - Pregnant women who do not have evidence of immunity to rubella should receive 1 dose of MMR upon completion or termination of pregnancy and before discharge from the healthcare facility, non-pregnant women of childbearing age with evidence of rubella immunity should receive 1 dose of MMR.
   - Adults with primary or acquired immunodeficiency including malignancies affecting the bone marrow or lymphatic system, systemic immunosuppressive therapy, or cellular immunodeficiency should not receive MMR.
   - Adults with human immunodeficiency virus (HIV) infection and CD4+ T lymphocyte count <200 cells/μL should receive 2 doses of MMR 8 weeks apart. Adults with HIV infection and CD4+ T lymphocyte count ≥200 cells/μL should not receive MMR.
   - Adults who work in healthcare facilities should receive 2 doses of MMR at least 28 days apart. Healthcare personnel born before 1975 who were unvaccinated and lack laboratory evidence of measles, mumps, or rubella immunity should receive 2 doses of MMR 4 weeks apart and receive an additional dose 4 weeks after the second dose.
   - Adults who are at risk for exposure to 2 doses of MMR at least 28 days apart for measles or mumps, or 1 dose of MMR for rubella.
   - Adults who are in multiracial education institutions or places of concern internationally should receive 2 doses of MMR at least 28 days apart.
   - Adults who received inactivated (killed) measles vaccine or measles vaccine of unknown type during years 1963–1967 should be revaccinated with 1 dose of MMR.
   - Adults who were vaccinated before 1979 with either inactivated mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection, e.g., work in a healthcare facility, should be considered for revaccination with 2 doses of MMR at least 28 days apart.

4. Varicella vaccination
   General information:
   - Adults without evidence of immunity to varicella (defined below) should receive 2 doses of single-antigen varicella vaccine (VVM) at 4–8 weeks apart, or a second dose of varicella vaccine if the first dose was not administered at least 4 weeks after the first dose.
   - Persons without evidence of immunity for whom VVM is not appropriate should be vaccinated with persons at high risk for serious complications, e.g., healthcare personnel and household contacts of individuals with immunocompromising conditions, who live or work in an environment in which transmission of varicella virus is likely, e.g., teachers, childcare workers, and residents and staff in institutional settings, adults who live in or work in environments in which varicella transmission has been reported, e.g., college students, residents, and staff members of correctional institutions, and military personnel non-pregnant women of childbearing age, adolescents, and adults living in households with children and international travelers.

   Notes: Evidence of immunity to varicella in adults in the U.S. born before 1980 for women and healthcare personnel, U.S. born before 1990 for non-immune individuals, documentation of 2 doses of VMM at least 4 weeks apart, history of varicella or herpes zoster diagnosis or verification of varicella or herpes zoster disease by a healthcare provider, or laboratory evidence of immunity or disease.

   Special populations:
   - Pregnant women should be assessed for evidence of varicella immunity. Pregnant women who do not have evidence of immunity should receive the first dose of VVM upon completion or termination of pregnancy and before discharge from the healthcare facility, and the second dose 4–8 weeks after the first dose.
   - Healthcare providers should assess and ensure that healthcare provider personnel have evidence of immunity to varicella.
   - Adults with malignancies should assess and ensure that healthcare provider personnel have evidence of immunity to varicella.

5. Herpes zoster vaccination
   General information:
   - Adults aged 60 years or older should receive 1 dose of herpes zoster vaccine (HZV), regardless of whether they had a prior episode of herpes zoster.

   Special populations:
   - Adults aged 50 years or older with chronic medical conditions may receive HZV unless they have a medical contraindication, e.g., pregnancy or serious immunodeficiency.
   - Adults with malignancy, including those that affect the bone marrow or lymphatic system or who receive systemic immunosuppressive therapy, should not receive HZV.
   - Adults with human immunodeficiency virus (HIV) infection and CD4+ T lymphocyte count <200 cells/μL should not receive HZV.

6. Human papillomavirus vaccination
   General information:
   - Adults females through age 26 years and adults males through age 21 years who have not been previously vaccinated with the 4-valent HPV vaccine should receive a 3-dose series of HPV vaccine at 0, 1, and 6 months. Males aged 22 through 26 years may be vaccinated with a 3-dose series of HPV vaccine at 0, 1, and 6 months.
   - Adults females through age 26 years and adults males through age 21 years (and males aged 22 through 26 years who may receive HPV vaccination) who initiated the HPV vaccination series before age 19 years and received 2 doses at least 5 months apart are considered adequately vaccinated and do not need an additional dose of HPV vaccine.
   - Adults females through age 26 years and adults males through age 21 years (and males aged 22 through 26 years who may receive HPV vaccination) who initiated the HPV vaccination series before age 19 years and received 1 dose or 2 doses less than 5 months apart, are not considered adequately vaccinated and should receive 1 additional dose of HPV vaccine.
   - Note: HPV vaccination is routinely recommended for children age 11 or 12 years for adults who had initiated but did not complete the HPV vaccination series before age 19 years according to the above and other factors (described below) to determine if they have been adequately vaccinated.

   Special populations:
   - Men who have sex with men through age 26 years who have not received any HPV vaccine should receive a 3-dose series of HPV vaccine at 0.1.2, and months.
   - Adults females and males through age 26 years with immunocompromising conditions (described below), including those with human immunodeficiency virus (HIV) infection, should receive a 3-dose series of HPV vaccine at 0.1.2, and months.
   - Pregnant women are not recommended to receive HPV vaccines, although there is no evidence that the vaccine poses harm if a woman is found to be pregnant after initiating the HPV vaccination series, delay the remaining doses until after the pregnancy. No other intervention is needed. Pregnancy testing is not needed before administering HPV vaccine.
   - Note: Immunocompromising conditions for which a 3-dose series of HPV vaccine is indicated are primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, e.g., B-lymphocyte antibody deficiency, complement or partial T lymphocyte defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, and immunosuppressive therapy.
7. Pneumococcal vaccination

General information
- Adults who are immunocompetent and aged 65 years or older should receive a 2-valent pneumococcal polysaccharide vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 year later.

Notes: Adults are recommended to receive 1 dose of PCV13 and 1 dose of PPSV23 if they were not previously vaccinated.

8. Hepatitis B vaccination

General information
- Adults who seek protection from hepatitis B virus infection may receive a 2-dose series of single-antigen hepatitis B vaccine (HepB). If any dose of PPSV23 is indicated for adults, it should be administered at least 1 year after the last dose of PCV13.

Special populations
- Adults aged 19 through 64 years with chronic heart disease including congestive heart failure and cardiomyopathies (including hypertrophic, chronic lung disease including chronic obstructive lung disease, emphysema, and asthma, chronic liver disease including cirrhosis, and HIV infection. These individuals should receive 1 dose of PPSV23 at age 65 years or older. If they receive 1 dose of PPSV23 at age 65 years or older, they should receive PCV13 and another dose of PPSV23 1 year after PCV13 and at least 5 years after the most recent dose of PPSV23.
- Adults aged 19 through 64 years with immunocompromising conditions or functional or anatomical asplenia (described below) should receive PCV13 and a dose of PPSV23 at 1 year after PCV13. If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least 8 weeks after PCV13 at least 5 years after the most recent dose of PPSV23.
- Adults aged 19 through 64 years with cerebrotendinous xanthomatosis or cystic fibrosis should receive PCV13 and a dose of PPSV23 at 1 year after PCV13. If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least 8 weeks after PCV13 at least 5 years after the most recent dose of PPSV23.

Notes: Immunocompromising conditions are indications for vaccination for pneumococcal and influenza vaccine are as follows: congenital or acquired immunodeficiency including HIV infection; chronic renal failure requiring hemodialysis or peritoneal dialysis; chronic hepatic disease including cirrhosis; chronic pulmonary disease including chronic obstructive pulmonary disease; chronic cardiovascular disease including congestive heart failure; chronic renal disease including chronic renal failure; chronic medical conditions, including malignancy, and multiple myeloma; solid organ transplants and receiving immunosuppressant therapy for long-term systemic corticosteroid and radiation therapy. Anatomical or functional asplenia indicates the individual is at high risk for infection or death from invasive pneumococcal disease and other hemopneumoniaeum. Congenital or acquired aplasia, splenic dysfunction, and splenectomy are indications for pneumococcal vaccination.

9. Hepatitis A vaccination

General information
- Adults who seek protection from hepatitis A virus infection may receive a 2-dose series of single-antigen hepatitis A vaccine (HepA). If any dose of PPSV23 is indicated for adults, it should be administered at least 1 year after the last dose of PCV13.

Special populations
- Adults who have any of the following indications should receive a HepA series: chronic liver disease, receive clotting factor concentrates, men who have sex with men, use injection to non-injection drugs, or work with hepatitis A virus-infected primates or in a hepatitis A research laboratory setting.

10. Meningococcal vaccination

Special populations
- Adults with antimicrobial or functional aplasia or persistent complement component deficiencies should receive a 2-dose primary series of serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) at least 2 months apart and revaccinated every 5 years. They should also receive a series of serogroup B meningococcal vaccine (MenB) with either a 2-dose series of MenB-4C (Brevet) at least 1 month apart or a 2-dose series of MenB-FHp (Trumenab) at 0, 1–2, and 6 months.

- Adults with human immunodeficiency virus (HIV) infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY at least 2 months apart and revaccinated every 5 years. Those who previously received 1 dose of MenACWY should receive a second dose at least 2 months after the first dose. Adults with HIV infection are not routinely recommended to receive MenB because meningococcal disease in this population is caused primarily by serogroups C, W, and Y.

- Microbiologists who are routinely exposed to large volumes of hepatitis meningococcal should receive 1 dose of MenACWY and revaccinated every 5 years if the risk for infection remains, and either a 2-dose series of MenB-4C, at least 1 month apart or a 3-dose series of MenB-FHp at 0, 1–2, and 6 months.

- Adults at risk because of a meningococcal disease outbreak should receive a 2-dose series of MenACWY at least 1 month apart. Adults at risk for outbreaks of MenACWY are usually defined as those who have contacts with individuals with meningococcal disease.

- Adult military recruits should receive 1 dose of MenACWY and revaccinated every 5 years if the risk for infection remains. First year college students aged 21 years or younger who live in residence halls should receive 1 dose of MenACWY if they have not received MenACWY at age 16 years or older.

- Young adults aged 16 years through 20 years (preferred age range is 16 through 18 years) who are healthy and not at increased risk for meningococcal disease above may receive either a 2-dose series of MenB-4C at least 1 month apart or a 2-dose series of MenB-FHp at 1–2 months and MenACWY at 1–2, and 6 months.

- Adults with human immunodeficiency virus (HIV) infection who have not been previously vaccinated should receive a 2-dose series of MenACWY at least 2 months apart and revaccinated every 5 years.

- MenACWY and MenB are not interchangeable; i.e., the same vaccine should be used for all doses to complete the series. There is no recommendation for MenACWY followed by MenB.

11. Haemophilus influenzae type b vaccination

Special populations
- Adults who have antimicrobial or functional aplasia or sickle cell disease, or are undergoing effective hemodialysis should receive 1 dose of Haemophilus influenzae type b conjugate vaccine (Hib) if they have not been previously vaccinated. Adults who have not been previously vaccinated should receive 1 dose of Hib at least 4 weeks interval 0–12 months after transplant recipients or greater than 12 months.

- Adults with antimicrobial or functional or cell transplant (HCT) should receive 3 doses of Hib at least 4 weeks interval 0–12 months after transplant recipients or greater than 12 months. These doses should be administered at least 14 days before first dose.

- Adults with immunocompromise following hematopoietic stem cell transplantation (HSCT) should receive 3 doses of Hib at least 4 weeks interval 0–12 months after transplant recipients or greater than 12 months. These doses should be administered at least 28 days before first dose.
Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017.

### Table. Contraindications and precautions for vaccines recommended for adults aged 19 years or older*

The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions that increase the chance of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine recipients. For a person with a severe allergy to latex, e.g., anaphylaxis, vaccines supplied in viols or syringes that contain natural rubber latex should not be administered unless the benefit of vaccination clearly outweighs the risk for a potential allergic reaction. For latex allergies other than anaphylaxis, vaccines supplied in viols or syringes that contain dry, natural rubber or natural rubber latex may be administered.

#### Contraindications and precautions for vaccines routinely recommended for adults

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Contraindications</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines routinely recommended for adults</td>
<td>- Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component</td>
<td>- Moderate or severe acute illness with or without fever</td>
</tr>
</tbody>
</table>

**Additional contraindications and precautions for vaccines routinely recommended for adults**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Additional Contraindications</th>
<th>Additional Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV</td>
<td>- History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination</td>
<td>- Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent enuresis; or required epinephrine or another emergency medical intervention (IV may be administered in an inpatient or outpatient medical setting and under the supervision of a healthcare provider who is able to recognize and manage severe allergic conditions)</td>
</tr>
<tr>
<td>RV</td>
<td>- History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination</td>
<td>- RV should not be used during 2016-2017 influenza season</td>
</tr>
<tr>
<td>Tdap/Td</td>
<td>- For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, or prolonged seizures, not attributable to another identifiable cause within 7 days of administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular pertussis toxoid.</td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>- Severe immunodeficiency, e.g., hemolytic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, or human immunodeficiency virus (HIV) infection with severe immunocompromise</td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>- Severe immunodeficiency, e.g., hemolytic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, or HIV infection with severe immunocompromise</td>
<td></td>
</tr>
<tr>
<td>VAR</td>
<td>- Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)*</td>
<td></td>
</tr>
<tr>
<td>HDV</td>
<td>- Severe immunodeficiency, e.g., hemolytic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, or HIV infection with severe immunocompromise</td>
<td></td>
</tr>
<tr>
<td>HPV-vaccine</td>
<td>- Pregnancy</td>
<td></td>
</tr>
<tr>
<td>PCV13</td>
<td>- Severe allergic reaction to any vaccine containing diphteria toxoid</td>
<td></td>
</tr>
</tbody>
</table>

* For additional information on use of influenza vaccines among persons with egg allergy, see CDC Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2016–17 influenza season. MMWR 2016;65(09):915–54. Available at www.cdc.gov/mmwr/volumes/65/mm6509.htm. **MMR may be administered together with VAR or CVX on the same day, if not administered on the same day, separate live vaccines by at least 28 days. **Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for two or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immunosuppressive medications or with immune suppression because of other reasons. **Vaccines should be deferred for the appropriate interval if replacement immune globulin products are being administered. See CDC General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 2011;60(RR-2). Available at www.cdc.gov/mmwr/volumes/60/mm6002.htm. **Mumps vaccination may temporarily suppress tuberculin skin testing. Measles-containing vaccine may be administered on the same day as tuberculin skin testing or should be postponed for at least 4 weeks after vaccination.


#### Acronyms of vaccines recommended for adults

- HepA: Hepatitis A vaccine
- HepA/HepB: Hepatitis A and Hepatitis B vaccines
- HepB: Hepatitis B vaccine
- Hib: Hemophilus influenzae type B conjugate vaccine
- HPV: Human papillomavirus vaccine
- HDV: Hepatitis delta virus
- IV: Inactivated influenza vaccine
- live attenuated influenza vaccine
- meningococcal conjugate vaccine
- meningococcal vaccine
- tetanus and diphtheria toxoids
- tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
- varicella vaccine
- meningococcal conjugate vaccine
- polyvalent vaccine
- Enterobacter cloacae
### PROFESSIONAL SOCIETIES AND GOVERNMENTAL AGENCIES

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Name</th>
<th>Internet Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACE</td>
<td>American Association of Clinical Endocrinologists</td>
<td><a href="http://www.aace.com">http://www.aace.com</a></td>
</tr>
<tr>
<td>AAD</td>
<td>American Academy of Dermatology</td>
<td><a href="http://www.aad.org">http://www.aad.org</a></td>
</tr>
<tr>
<td>AAFP</td>
<td>American Academy of Family Physicians</td>
<td><a href="http://www.aafp.org">http://www.aafp.org</a></td>
</tr>
<tr>
<td>AAHPM</td>
<td>American Academy of Hospice and Palliative Medicine</td>
<td><a href="http://www.aahpm.org">http://www.aahpm.org</a></td>
</tr>
<tr>
<td>AAN</td>
<td>American Academy of Neurology</td>
<td><a href="http://www.aan.com">http://www.aan.com</a></td>
</tr>
<tr>
<td>AAP</td>
<td>American Academy of Pediatrics</td>
<td><a href="http://www.aap.org">http://www.aap.org</a></td>
</tr>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
<td><a href="http://www.acc.org">http://www.acc.org</a></td>
</tr>
<tr>
<td>ACCP</td>
<td>American College of Chest Physicians</td>
<td><a href="http://www.chestnet.org">http://www.chestnet.org</a></td>
</tr>
<tr>
<td>ACIP</td>
<td>Advisory Committee on Immunization Practices</td>
<td><a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a></td>
</tr>
<tr>
<td>ACOG</td>
<td>American Congress of Obstetricians and Gynecologists</td>
<td><a href="http://www.acog.com">http://www.acog.com</a></td>
</tr>
<tr>
<td>ACP</td>
<td>American College of Physicians</td>
<td><a href="http://www.acponline.org">http://www.acponline.org</a></td>
</tr>
<tr>
<td>ACR</td>
<td>American College of Radiology</td>
<td><a href="http://www.acr.org">http://www.acr.org</a></td>
</tr>
<tr>
<td>ACS</td>
<td>American College of Rheumatology</td>
<td><a href="http://www.rheumatology.org">http://www.rheumatology.org</a></td>
</tr>
<tr>
<td>ACSM</td>
<td>American College of Sports Medicine</td>
<td><a href="http://www.acsm.org">http://www.acsm.org</a></td>
</tr>
<tr>
<td>ADA</td>
<td>American Diabetes Association</td>
<td><a href="http://www.diabetes.org">http://www.diabetes.org</a></td>
</tr>
<tr>
<td>AGA</td>
<td>American Gastroenterological Association</td>
<td><a href="http://www.gastro.org">http://www.gastro.org</a></td>
</tr>
<tr>
<td>AGS</td>
<td>American Geriatrics Society</td>
<td><a href="http://www.americangeriatrics.org">http://www.americangeriatrics.org</a></td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
<td><a href="http://www.americanheart.org">http://www.americanheart.org</a></td>
</tr>
<tr>
<td>ANA</td>
<td>American Nurses Association</td>
<td><a href="http://www.nursingworld.org">http://www.nursingworld.org</a></td>
</tr>
<tr>
<td>AOA</td>
<td>American Optometric Association</td>
<td><a href="http://www.aoa.org">http://www.aoa.org</a></td>
</tr>
</tbody>
</table>
### PROFESSIONAL SOCIETIES AND GOVERNMENTAL AGENCIES  *(Continued)*

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Name</th>
<th>Internet Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA</td>
<td>American Stroke Association</td>
<td><a href="http://www.strokeassociation.org">http://www.strokeassociation.org</a></td>
</tr>
<tr>
<td>ASAM</td>
<td>American Society of Addiction Medicine</td>
<td><a href="http://www.asam.org">http://www.asam.org</a></td>
</tr>
<tr>
<td>ASCCP</td>
<td>American Society for Colposcopy and Cervical Pathology</td>
<td><a href="http://www.asccp.org">http://www.asccp.org</a></td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
<td><a href="http://www.asco.org">http://www.asco.org</a></td>
</tr>
<tr>
<td>ASCRS</td>
<td>American Society of Colon and Rectal Surgeons</td>
<td><a href="http://www.fascrs.org">http://www.fascrs.org</a></td>
</tr>
<tr>
<td>ASGE</td>
<td>American Society for Gastrointestinal Endoscopy</td>
<td><a href="http://asge.org">http://asge.org</a></td>
</tr>
<tr>
<td>ASHA</td>
<td>American Speech-Language-Hearing Association</td>
<td><a href="http://www.asha.org">http://www.asha.org</a></td>
</tr>
<tr>
<td>ASN</td>
<td>American Society of Neuroimaging</td>
<td><a href="http://www.asnweb.org">http://www.asnweb.org</a></td>
</tr>
<tr>
<td>ATA</td>
<td>American Thyroid Association</td>
<td><a href="http://www.thyroid.org">http://www.thyroid.org</a></td>
</tr>
<tr>
<td>AUA</td>
<td>American Urological Association</td>
<td><a href="http://auanet.org">http://auanet.org</a></td>
</tr>
<tr>
<td>BASHH</td>
<td>British Association for Sexual Health and HIV</td>
<td><a href="http://www.bashh.org">http://www.bashh.org</a></td>
</tr>
<tr>
<td>Bright Futures</td>
<td>Bright Futures, British Association for Sexual Health and HIV</td>
<td><a href="http://brightfutures.org">http://brightfutures.org</a></td>
</tr>
<tr>
<td>BGS</td>
<td>British Geriatrics Society</td>
<td><a href="http://www.bgs.org.uk">http://www.bgs.org.uk</a></td>
</tr>
<tr>
<td>BSAC</td>
<td>British Society for Antimicrobial Chemotherapy</td>
<td><a href="http://www.bsac.org.uk">http://www.bsac.org.uk</a></td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
<td><a href="http://www.cdc.gov">http://www.cdc.gov</a></td>
</tr>
<tr>
<td>COG</td>
<td>Children's Oncology Group</td>
<td><a href="http://www.childrensoncologygroup.org">http://www.childrensoncologygroup.org</a></td>
</tr>
<tr>
<td>CSVS</td>
<td>Canadian Society for Vascular Surgery</td>
<td><a href="http://canadianvascular.ca">http://canadianvascular.ca</a></td>
</tr>
<tr>
<td>CTF</td>
<td>Canadian Task Force on Preventive Health Care</td>
<td><a href="http://canadiantaskforce.ca">http://canadiantaskforce.ca</a></td>
</tr>
<tr>
<td>EASD</td>
<td>European Association for the Study of Diabetes</td>
<td><a href="http://www.easd.org">http://www.easd.org</a></td>
</tr>
<tr>
<td>EAU</td>
<td>European Association of Urology</td>
<td><a href="http://www.uroweb.org">http://www.uroweb.org</a></td>
</tr>
<tr>
<td>ERS</td>
<td>European Respiratory Society</td>
<td><a href="http://ersnet.org">http://ersnet.org</a></td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
<td><a href="http://www.escardio.org">http://www.escardio.org</a></td>
</tr>
<tr>
<td>ESH</td>
<td>European Society of Hypertension</td>
<td><a href="http://www.eshonline.org">http://www.eshonline.org</a></td>
</tr>
<tr>
<td>Organization</td>
<td>Description</td>
<td>Web Address</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ICSI</td>
<td>Institute for Clinical Systems Improvement</td>
<td><a href="http://www.icsi.org">http://www.icsi.org</a></td>
</tr>
<tr>
<td>IDF</td>
<td>International Diabetes Federation</td>
<td><a href="http://www.idf.org">http://www.idf.org</a></td>
</tr>
<tr>
<td>NAPNAP</td>
<td>National Association of Pediatric Nurse Practitioners</td>
<td><a href="http://www.napnap.org">http://www.napnap.org</a></td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
<td><a href="http://www.cancer.gov/cancerinformation">http://www.cancer.gov/cancerinformation</a></td>
</tr>
<tr>
<td>NEI</td>
<td>National Eye Institute</td>
<td><a href="http://www.nei.nih.gov">http://www.nei.nih.gov</a></td>
</tr>
<tr>
<td>NHLBI</td>
<td>National Heart, Lung, and Blood Institute</td>
<td><a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a></td>
</tr>
<tr>
<td>NIAAA</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td><a href="http://www.niaaa.nih.gov">http://www.niaaa.nih.gov</a></td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Clinical Excellence</td>
<td><a href="http://www.nice.org.uk">http://www.nice.org.uk</a></td>
</tr>
<tr>
<td>NIP</td>
<td>National Immunization Program</td>
<td><a href="http://www.cdc.gov/vaccines">http://www.cdc.gov/vaccines</a></td>
</tr>
<tr>
<td>NKF</td>
<td>National Kidney Foundation</td>
<td><a href="http://www.kidney.org">http://www.kidney.org</a></td>
</tr>
<tr>
<td>NOF</td>
<td>National Osteoporosis Foundation</td>
<td><a href="http://www.nof.org">http://www.nof.org</a></td>
</tr>
<tr>
<td>NTSB</td>
<td>National Transportation Safety Board</td>
<td><a href="http://www.ntsb.gov">http://www.ntsb.gov</a></td>
</tr>
<tr>
<td>SCF</td>
<td>Skin Cancer Foundation</td>
<td><a href="http://www.skincancer.org">http://www.skincancer.org</a></td>
</tr>
<tr>
<td>SGIM</td>
<td>Society of General Internal Medicine</td>
<td><a href="http://www.sgim.org">http://www.sgim.org</a></td>
</tr>
<tr>
<td>SKI</td>
<td>Sloan-Kettering Institute</td>
<td><a href="http://www.mskcc.org/mskcc/html/5804.cfm">http://www.mskcc.org/mskcc/html/5804.cfm</a></td>
</tr>
<tr>
<td>SVU</td>
<td>Society for Vascular Ultrasound</td>
<td><a href="http://www.svunet.org">http://www.svunet.org</a></td>
</tr>
<tr>
<td>UK-NHS</td>
<td>United Kingdom National Health Service</td>
<td><a href="http://www.nhs.uk">http://www.nhs.uk</a></td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
<td><a href="http://www.who.int/en">http://www.who.int/en</a></td>
</tr>
</tbody>
</table>
This page intentionally left blank
Index

A
Abdominal aortic aneurysm (AAA) management, 177–180
  pharmacologic therapy, 178–179
  surgical therapy, 178–180
  risk factors, 177–178
  rupture, risk of, 177–178
  screening for, 1–4
Abuse and violence
  prevention of, 122
  screening for, 70–71, 566
Acamprosate, for alcohol use disorders, 186
ACC/AHA/ASH antihypertensive therapy for patients with CAD (2015), 359–362
ACC/AHA Guidelines on the Treatment of Cholesterol (2013), 343
Acetaminophen, for osteoarthritis, 406
Acetazolamide, for central sleep apnea (CSAS), 191
Aclidinium bromide, for chronic obstructive pulmonary disease management, 232
Active surveillance (AS) for management of localized prostate cancer, 183–184
Acute bacterial sinusitis, management of, 480
Acute kidney injury
  management, 386
  prevention, 142–143
Acute otitis externa (AOE)
  management, 411
Acute pancreatitis (AP), management of, 421–422
Acute pharyngitis, management of, 431–433
Adalimumab, for Crohn’s disease, 374
AD (atopic dermatitis), management of, 196–197
Adenocarcinoma of gastroesophageal junction, screening for, 4
Adolescents
  with asthma, 193–196
  with attention-deficit hyperactivity disorder (ADHD)
    nonpharmacologic management, 213–214
  with Chlamydia infections, 475
  with Crohn’s disease, 374–375
  with depression, 269
    SSRI suicide risk, 269
  with diabetes mellitus (DM), type 1, 271–272
  with human immunodeficiency virus (HIV) infection, 339–343
  with hyperlipidemia, 351–352
  with hypertension, 369
  obesity management, 404–405
  with otitis media, acute, 411–413
  with polycystic ovary syndrome, 436
  prevention
    immunizations, 579–585
    motor vehicle injury, 143
    obesity, 153
    sexually transmitted infections (STIs), 158
    tobacco use, 168–169
  with sciatica, 470–471
  screening for
    alcohol abuse and dependence, 5–6
    attention-deficit/hyperactivity disorder, 8–9
    cholesterol and lipid disorders, 53–54
    depression, 65, 566
    family violence and abuse, 566
    genital herpes simplex virus human immunodeficiency virus (HIV), 81–82, 567
    hypertension, 82–83
    illicit drug use, 85
    motor vehicle safety, 88
    scoliosis, 94
Adolescents (Continued)
  skin cancer (melanoma), 46
  testicular cancer, 47–48
  tobacco use, 98–99
  with ulcerative colitis, 376–377

Adrenal incidentalomas, management of, 184

Adults
  with abdominal aortic aneurysm (AAA), 177–180
  with abnormal liver chemistries, evaluating, 181–183
  with abnormal Pap smear, 423
  with acute diarrhea, 280–281
  with acute pancreatitis, 421–423
  with adrenal incidentalomas, 184
  with alcohol use disorders, 185–186
  with anaphylaxis, 186–187
  with androgen deficiency syndrome, 187
  with ankylosing spondylitis or spondyloarthritis, 189–190
  with anxiety, 190
  with ascites, 192–193, 429
  with asthma, 193–196
  with asymptomatic bacteriuria, 196
  with atrial fibrillation, 197–212
  with bacterial meningitis, 393
  with Barrett esophagus, 219
  with Bell’s palsy, 220–221
  with benign prostatic hyperplasia, 221–222
  with breast cancer. See Breast cancer with bronchitis, acute, 224
  with cancer, management of venous thrombosis in, 391–393
  with cancer and anemia
    use of erythropoietic agents, 188–189
  with carbon monoxide poisoning, 224
  with carotid artery disease, 225–226
  with cataract, 227–228
  with celiac disease, 228
  with central sleep apnea, 190–191
  with cerumen impaction, 228–229
  with chronic obstructive pulmonary disease (COPD)
    exacerbations, 229–230
    stable, 230–233
  with chronic open-angle glaucoma (COAG), 312
  with chronic pain, 414–418
  cancer related, 416–418
  with Clostridium difficile colitis, 235–237
  with cobalamin (B12) deficiency, 233–234
  with a common cold, 238
  with concussion, 238–239
  contraception, 240–253
  with coronary artery disease, 254–265
  with Crohn’s disease, 374–375
  with Cushing’s syndrome, 266
  with delirium, 266
  dementia, 267–268
    Alzheimer disease, 268
    feeding tubes in, 269
  with diabetes mellitus (DM), type 1, 271–273
  with diabetes mellitus (DM), type 2, 273–280
  with diabetic foot problems, inpatient management, 270
  with diffuse large B-cell lymphoma (DLBCL) stages I through IV, 282–283
  dying, palliative care for, 419–421
  with dyspepsia, 283–285
  with dysphagia, 295
  with eating disorders, 285–286
  with epilepsy, 287–288
  with erectile dysfunction, 288–289
  with essential tremor, 517
  with febrile neutropenia, 400–402
  with gallstones, 289
  with gastric cancer, 112
  geriatrics. See Geriatrics; Older adults
  with gout, 313–314
    acute attacks, 313–314
    recurrent gout, 314
    suspected gout, 314
  with headache, 315–324. See also Headache
  with heart failure, 324–330
  with Helicobacter pylori infection, 330–331
  with hepatitis B virus, 332–335
  with hepatitis C virus, 335
INDEX

with hereditary hemochromatosis, 336–337
with hoarseness, 338
with human immunodeficiency virus (HIV) infection, 339–343
with hyperlipidemia, 343–357
with hypogonadism, male, 371–372
with indwelling urinary catheters, 373
with infertility, male, 374
with influenza, 377–378
with intermittent catheterization, 373
with iron deficiency anemia, 378–382
with irritable bowel syndrome, 383–384
with kidney disease, chronic (CKD), 384–386
with kidney injury, acute, 386
with kidney stones, 387–389
with laryngitis, acute, 389–390
with localized prostate cancer, 183–184
with low back pain, 216–218, 470
with lower extremity peripheral arterial disease, 429–431
with lower gastrointestinal bleeding, 298–291
with lower respiratory tract infections, 465–466
with lower urinary tract symptoms, 530
with lung cancer
- pleural effusion, 434–436
- with malignant spinal cord compression, 390–391
- menopausal, 394–395
- with metabolic syndrome, 395–396
- with methicillin-resistant Staphylococcus aureus infections, 397–398
- with microscopic hematuria, 331–332
- with multiple sclerosis (MS), 399
- with muscle cramps, 399
- with neurocysticercosis, 400
- with neuropathic pain, 419
- with nonmetastatic colorectal cancer, follow-up care, 237–238
- with non-small cell lung cancer, follow-up care, 402–403
- with normal pressure hydrocephalus, 403
- obesity management, 404–405
- with obstructive sleep apnea (OSA), 191–192
- older. See Older adults
- with osteoarthritis, 405–407
- osteoporosis, 407–410
- glucocorticoid-induced, 409–410
- with otitis externa, acute, 411
- with ovarian cancer that had a complete response, follow-up care for, 413–414
- with periodic limb movement disorders, 467
- with pharyngitis, acute, 431
- platelet transfusion, 433–434
- with polycystic ovary syndrome, 436
- with pressure ulcers, 446–447
- prevention
- back pain, low, 104
- breast cancer, 104–107
- catheter-related bloodstream infections, 116–117
- cervical cancer, 107–108
- chronic obstructive pulmonary disease, 120
- colitis, Clostridium difficile, 118–119
- colorectal cancer, 108–110
- concussion, 119
- dental caries, 121
- diabetes mellitus (DM), type 2, 121–122
- domestic violence, 122
- driving risk, 122–123
- endocarditis, 123–124, 567
- endometrial cancer, 110
- gout, 126
- hormone replacement therapy, 127–128
- human immunodeficiency virus (HIV), opportunistic infections, 128–133
- hypertension (HTN), 138–139
- immunizations, 139–140, 586–590
- influenza vaccine, 141–142
- kidney injury, acute (contrast-induced nephropathy), 142–143
- liver cancer, 112
- lung cancer, 113
Adults (Continued)
myocardial infarction, aspirin therapy for, 144–145
myocardial infarction, dietary therapy for, 145
myocardial infarction, special populations, 148–152
myocardial infarction, statin therapy for, 146–148
neural tube defects, 152–153
obesity, 153–154
oral cancer, 113–114
ovarian cancer, 114–115
pressure ulcers, 157–158
prostate cancer, 115
sexually transmitted infections (STIs), 158
stroke, 159–167
procedural sedation, 448
prostate cancer survivors, follow-up care, 448–449
with psoriasis or psoriatic arthritis, 450–452
psychiatric patients in the emergency department, 185, 453
with pulmonary nodules, 453–454
red blood cell transfusion, 454–457
with renal cancer, follow-up care, 458–459
with renal masses, small, 464–465
with restless legs syndrome, 467
with rheumatoid arthritis
biologic disease-modifying antirheumatic drugs (DMARDs), 468–469
with sciatica, 470–471
screening for
abdominal aortic aneurysm, 1–4
adenocarcinoma of gastroesophageal junction, 33–34
alcohol abuse and dependence, 5
Barrett esophagus, 10–11
bladder cancer, 11–12
BRCA1 and BRCA2 mutations, 20
breast cancer, 13–21
carotid artery stenosis, asymptomatic, 49–50
celiac disease, 50–51
cervical cancer, 22–25
chlamydia, 51–52
cholesterol and lipid disorders, 53–59
chronic obstructive pulmonary disease (COPD), 60
colorectal cancer, 26–32
coronary artery disease, 60–63
dementia, 64
depression, 64
diabetes mellitus, 68–69
endometrial cancer, 32–33
family violence and abuse, 70–71
gastric cancer, 34
genital herpes simplex virus, 80
gestational diabetes mellitus (GDM), 67, 566
glaucoma, 72, 566
gonorrhea, 72–73
hepatitis B virus infection, 77–79
hepatitis C virus infection, chronic, 79–80
hereditary hemochromatosis, 75–77
human immunodeficiency virus (HIV), 81–82, 567
hypertension, 83–85
illicit drug use, 85
kidney disease, chronic, 86
liver cancer (hepatocellular carcinoma), 34–35
lung cancer, 35–37
obesity, 89–90
oral cancer, 37–38
osteoporosis, 90–91
ovarian cancer, 38–40
pancreatic cancer, 40
pelvic examinations, 92
prostate cancer, 41–45
skin cancer (melanoma), 46–47
sleep apnea, 94
syphilis, 95–96
testicular cancer, 47–48
thyroid cancer, 48–49, 566
thyroid disease, 96, 566
tobacco use, 98
tuberculosis, latent, 99
vitamin D deficiency, 101
with seizures, 471–472
with sexually transmitted diseases. See Sexually transmitted diseases
with skin cancer, 116
smoking cessation, 509–512
with stress ulcers, 523
stroke. See Stroke
with sudden hearing loss, 324
with syncope, 490–492
with syphilis, 493
with thrombocytopenia, heparin-
induced, 498–501
with thrombocytopenia, immune
mediated, 493–497
with thrombocytopenia, thrombotic
purpura, 501–503
with thyroid disease, hyperthyroidism,
504–506
with thyroid nodules, 508
with tinnitus, 509
with tuberculosis. See Tuberculosis (TB)
with upper gastrointestinal bleeding,
291–292
with upper respiratory infections, 466
with urinary incontinence, 523–527
with urinary tract infections (UTIs),
528–529
with valvular heart disease, 531–534
with venous thromboembolism (VTE)
prophylaxis in nonsurgical patients,
169–172
prophylaxis in surgical patients,
173–175
with vertigo, benign paroxysmal
positional, 540–541
Albumin, for ascites due to cirrhosis, 192
Albuterol, for COPD management, 232
Alcohol abuse and dependence
disorders, management of, 185–186
screening for, 5–6
screening instruments, 544–546,
565
American Diabetes Association
antihypertensive therapy guidelines
(2017), 362–363
hyperlipidemia guidelines (2014),
347–348
American Society of Hypertension
antihypertensive therapy
guidelines (2013), 362
Aminosalicylate, for ulcerative colitis, 375
Amitriptyline
for migraine prophylaxis, 315
for neuropathic pain, 419
Amoxicillin
for acute otitis media, 412
for Helicobacter pylori infection, 330–331
Analgesic ladder
low back pain, 217
Anal warts, 479
Anaphylaxis, management of, 186–187
Androgen deficiency syndrome, management of, 187
Anemia
screening for, 6–7
use of erythropoietic agents, 188–189
Aneuplody, fetal, screening for, 71
Ankylosing spondylitis, management of,
189–190
Ann Arbor staging system (lymphoma),
282
Antepartum lab testing, 444
Anticholinergics, for COPD management,
232
Antithrombotic strategies following
coronary artery stenting, 207
Anxiety, management of, 190
AOE (acute otitis externa), management
of, 411
Aortic insufficiency, 531–533
Aortic stenosis, 531–533
AP (acute pancreatitis), management of,
421–422
Apixaban (Eliquis)
for atrial fibrillation, 203, 206
switching from/to warfarin, 203
Apnea
central sleep apnea (CSAS)
management, 190–191
obstructive sleep apnea (OSA)
management, 191–192
screening for, 94
INDEX

Arformoterol, for COPD management, 232
Aromatase inhibitors, for breast cancer primary prevention, 106
AS (active surveillance) for management of localized prostate cancer, 183–184
Ascites due to cirrhosis, management of, 192–193
ASDs (autism spectrum disorders) evaluation and screening, 9, 215–216
Aspirin colorectal cancer primary prevention, 109 for myocardial infarction, 144–145
Asthma management, 193–196 stepwise approach, 193–196 prevention, 103
Astroesophageal junction, adenocarcinoma of screening for, 4
Atefollol, for migraine prophylaxis, 315
Atopic dermatitis (AD), management of, 196–197
Benign paroxysmal positional vertigo (BPPV), management of, 540–541
Benign prostatic hyperplasia (BPH), management of, 221–222
Beta₂-agonists, for COPD management, 232
Beta blockers
perioperative, new guidelines for, 567
Bile acid sequestrants, for managing hyperlipidemia, 355
Biologic disease-modifying antirheumatic drugs (DMARDs), for rheumatoid arthritis (RA), 468–469
Biphosphonates, for osteoporosis, 409
Bismuth quadruple therapy, for *Helicobacter pylori* infection, 330–331
Bladder cancer, screening for, 11–12
Blood pressure
impact of health behavior management on, 365
95th percentile
boys, 568
girls, 569
Body mass index (BMI) conversion table, 570
BPH (benign prostatic hyperplasia), management of, 221–222
BPPV (benign paroxysmal positional vertigo), management of, 540–541
BRCA1 and BRCA2 mutations, 14–19, 38–39
bilateral mastectomy to decrease risk of breast cancer, 19
salpingo-oophorectomy to decrease risk of breast cancer, 19
testing for, 20
Breast cancer
early stage, 222–224
follow-up care, 222–224
mammography, harms of, 21
prevention, 104–107
alcohol, 104–105
aromatase inhibitors, 106
breast-feeding, 107
dense breasts, 107
e xercise, 106–107
factors of unproven or disproven association, 105
hormone replacement therapy, 104
ionizing radiation to chest and mediastinum, 104
minimize known risk factor exposure, 104–105
obesity, 104
pregnancy before age 20 y, 107
prophylactic salpingo-oophorectomy among BRCA-positive women, 106
raloxifene (postmenopausal women), 106
tamoxifen (postmenopausal and high-risk premenopausal women), 105
therapeutic approaches to reduce breast cancer risk, 105–107
screening for, 13–21
guidelines in perspective 565
testing for BRCA1 and BRCA2 mutations, 20
Breast-feeding anticoagulation and, 488
breast cancer primary prevention, 107
Bronchitis, acute, management of, 224
Bupropion SR, for smoking cessation, 511
C
CAD (coronary artery disease). See Coronary artery disease (CAD)
CAGE screening test, 544–546
children and adolescents, not validated in, 6
Calcineurin inhibitors, topical, for atopic dermatitis, 196
Calcitonin, for osteoporosis, 409
CAM (Confusion Assessment Method), 266
Canadian Hypertension Education Program antihypertensive therapy guidelines (2014/2015), 363–364
Canadian National Breast Screening Study, 18
Cancer. See specific cancer—e.g., Breast cancer, Colorectal cancer, Lung cancer, etc.
Cancer survivorship  
- late effects of cancer treatments, 459–464
Candidal vaginitis, 477–478
Caprini risk stratification model, 173, 175
Capsaicin, topical  
- for neuropathic pain, 419
- for osteoarthritis, 406
Carbamazepine  
- for focal seizures, 288
- for generalized tonic-clonic seizures, 288
- for trigeminal neuralgia, 419
Carbon monoxide poisoning, management of, 224
Cardiac risk, 10-y  
- men, 571–572
- women, 573–574
Cardioversion, urgent, 197
Carotid artery disease  
- management, 225–226
- post-CVA or stroke, 226
Carotid artery stenosis (CAS)  
- (asymptomatic), screening for, 49–50
Cataract  
- evaluation, 227–228
- management, 227–228
- screening for, 100
Catheterization, intermittent, management of, 373
Catheter-related bloodstream infections, prevention of, 116–117
CDH1 gene (hereditary gastric cancer), 34
Celiac disease  
- management, 228
- screening for, 50–51
Central sleep apnea (CSAS)  
- management, 190–191
- acetazolamide, 191
- nocturnal oxygen therapy, 191
- positive airway pressure therapy, 190–191
- triazolam, 191
- zolpidem, 191
Cerumen impaction, management of, 228–229
Cervical cancer  
- prevention, 107–108
- cigarette smoke (active or passive), 107
- high parity, 107
- HPV-16/HPV-18 vaccination, 108
- long-term use of oral contraceptives, 107
- minimize risk factor exposure, 107
- screening with PAP smears, 108
- therapeutic approaches, 108
- screening for, 22–25, 565
Cervical warts, 479
Chek 2 mutations, 17
Children  
- with anaphylaxis, 186–187
- with asthma, 193–196
- with asymptomatic bacteriuria, 196
- with attention-deficit hyperactivity disorder (ADHD), 212–214
- nonpharmacologic management, 213–214
- with bacterial meningitis, 393
- with celiac disease, 228
- with cerumen impaction, 228–229
- with Chlamydia infections, 475–476
- with chronic kidney disease mineral and bone disorders, 385–386
- with Clostridium difficile colitis, 235–236
- with a common cold, 238
- with concussion, 238–239
- with Crohn's disease, 374–375
- with Cushing's syndrome, 266
- with depression, 269
- with diabetes mellitus (DM), type 1, 271–272
- with diabetes mellitus (DM), type 2, 273–280
- with eating disorders, 285–286
- with epilepsy, 287–288
- with febrile seizures, 472
- gonococcal infections, 476
- with hepatitis B virus, 332–335
- with human immunodeficiency virus (HIV), 339–343
- with hyperlipidemia, 351–352
- with hypertension, 369
- identifying risk of serious illness in children under 5 y, 372–373
- with idiopathic constipation, 239–240
- with influenza, 377–378
with kidney injury, acute, 386
with kidney stones, 387–389
with latent tuberculosis, 521
with methicillin-resistant *Staphylococcus aureus* infections, 397–398
with neurocysticercosis, 400
with otitis externa, acute, 411
with otitis media, acute, 411–413
platelet transfusion, 433–434
prevention
  - asthma, 103
  - catheter-related bloodstream infections, 116–117
  - colitis, *Clostridium difficile*, 118–119
  - concussion, 119
  - dental caries, 121
  - human immunodeficiency virus (HIV), opportunistic infections, 128, 134–137
  - hypertension (HTN), 138–139
  - immunizations, 140, 579–585
  - kidney injury, acute (contrast-induced nephropathy), 142–143
  - motor vehicle injury, 143
  - obesity, 153–154
  - otitis media, 155
  - pressure ulcers, 157–158
  - tobacco use, 168–169
  - procedural sedation, 448
screening for
  - alcohol abuse and dependence, 5
  - anemia, 6–7
  - attention-deficit/hyperactivity disorder, 8–9
  - autism spectrum disorders, 9, 215–216
  - celiac disease, 50–51
  - cholesterol and lipid disorders, 53–54
  - colorectal cancer, 28–29
  - depression, 64, 566
  - diabetes mellitus, 68
  - familial adenomatous polyposis (FAP), 29–30
  - family violence and abuse, 70–71, 566
  - growth abnormalities, 74
  - hepatitis B virus infection, 78
  - hypertension, 82–83
  - lead poisoning, 86–87
  - motor vehicle safety, 88
  - obesity, 89
  - skin cancer (melanoma), 46
  - speech and language delay, 94–95
  - tobacco use, 98–99
  - visual impairment, glaucoma, or cataract, 100
  - with sinusitis, 480
  - with syphilis, 474–475
  - with thrombocytopenia, immune mediated, 497–498
  - with thrombocytopenia, thrombotic purpura, 501–503
  - with tinnitus, 509
  - tonsillectomy, 513
  - with tympanostomy tubes, 522–523
  - with ulcerative colitis, 376–377
  - Chlamydia, screening for, 51–52
  - Cholesterol absorption inhibitors, for managing hyperlipidemia, 356
  - Cholesterol and lipid disorders, screening for, 53–59
  - Cholesterol guidelines differences (2014), 348
  - Chronic kidney disease (CKD) management, 384–386
    - mineral and bone disorders, 385–386
  - screening for, 86
  - Chronic obstructive pulmonary disease (COPD)
    - exacerbations management, 229–230
    - prevention, 120
    - screening for, 60
    - stable
      - common medications, 232
    - management, 230–235
  - Chronic stable angina, 254–256
  - Cigarette smoke (active or passive) cervical cancer primary prevention, 107
  - Ciprofloxacin, for acute diarrhea in adults, 281
  - Cirrhosis, ascites from management, 192–193
  - Citalopram, for depression, 269
  - Clarithromycin, for *Helicobacter pylori* infection, 330–331
  - Clonidine, for smoking cessation, 512
INDEX

Clostridium difficile colitis, management of, 235–237
Cluster headache algorithm, 319
Cobalamin (B₁₂) deficiency, management of, 233–234
Colitis, Clostridium difficile management, 235–237
prevention, 118–119
Colonoscopy, 27–32
Colorectal cancer (CRC)
follow-up care, 237–238
prevention of aspirin, 109
exercise, 108
interventions without benefit, 109–110
minimize risk factor exposure, 108–109
NSAIDs, 109
nutrition, 108
polyp removal, 109
postmenopausal combination hormone replacement, 109
therapeutic approaches, 109–110
screening for, 26–31
colonoscopy, 27–32
CT colonoscopy (CTC), 31
double-contrast barium enema (DCBE), 31
fecal occult blood test (FOBT), 26–29, 31–32
flexible sigmoidoscopy, 26–28, 30
multi-targeted DNA stool testing (cologuard), 28
Combined pill and progestin-only pill, effectiveness in contraception, 241
Common cold, management of, 238
Community-acquired pneumonia, 437–439
evaluation, 437–438
suspected pathogens, 439
Complicated hypertension, 366–367
Concussion
management, 238–239
prevention, 119
Condoms, effectiveness of, 240
female condoms, 240
male condoms, 240
Confusion Assessment Method (CAM), 266
Congenital syphilis, 475
Constipation, idiopathic, management of, 239–240
Contraception, 240–253
emergency, 253–254
U.S. medical eligibility criteria, recommendations for medical conditions added, 249–253
WHO medical eligibility criteria, changes in, 242–248
women experiencing an unintended pregnancy with contraception use, 240–241
COPD (chronic obstructive pulmonary disease)
exacerbations
management, 229–230
prevention, 120
screening for, 60
stable
common medications, 232
management, 230–235
Corlanor (ivabradine), for heart failure, 324, 329
Coronary artery disease (CAD)
management, 254–265
elevated troponin level, 260
long-term antiplatelet therapy, 261
patients with chronic stable angina, 254–256
ST-elevation myocardial infarction, 259
stent therapy use of triple anticoagulation treatment, 261–264
unstable angina, 257–258
women, 264–265
screening for, 60–63
Corticosteroids, topical, for atopic dermatitis, 196
CRC (colorectal cancer). See Colorectal cancer (CRC)
Crohn's disease, management of, 374–375
Cryoprecipitate, 514
CSAS (central sleep apnea). See Central sleep apnea (CSAS)
INDEX

CT colonoscopy (CTC), 31
Cushing’s syndrome (CS), management of, 266
Cyclosporine, for ulcerative colitis, 375

Dabigatran etexilate (Pradaxa)
for atrial fibrillation, 201, 206
converting from/to parenteral anticoagulants, 201
discontinue before invasive or surgical procedures, 201
switching to warfarin, 201
DASH eating plan, to treat hypertension, 365
DCBE (double-contrast barium enema), 31
DDH (developmental dysplasia of the hip), screening for, 66
Deep venous thrombosis (DVT), management of, 534–539
Delirium
management, 266–267
postoperative management, 267
Dementia
Alzheimer disease
management, 268
management, 267–268
feeding tubes, 269
screening for, 64
Denosumab, for osteoporosis, 409
Dense breasts
breast cancer primary prevention, 107
Dental caries
prevention, 121
home-use topical fluoride agents, 169
Depo-Provera, effectiveness of, 241
Depression
management, 269
screening for, 64–65
instruments, 547–552, 566
Developmental dysplasia of the hip (DDH), screening for, 66
Diabetes mellitus, gestational (GDM)
management, 270–271
screening for, 67
Diabetes mellitus (DM)
myocardial infarction prevention, 149–150
Diabetes mellitus (DM), type 1
management, 271–273
Diabetes mellitus (DM), type 2
management, 273–280
algorithm, 279
injectable medications, 278
oral medications, 277
prevention, 121–122, 567
screening for, 67–69
Diabetic foot problems, inpatient management of, 270
Diaphragm, effectiveness of, 240
Diarrhea, acute
management, 280–281
antibiotic recommendations, 280–281
Dietary therapy
colorectal cancer primary prevention, 108
DASH eating plan, to treat hypertension, 365
for myocardial infarction, 144–145
Diffuse large B-cell lymphoma (DLBCL) stages I through IV, management of, 282–283
Digital mammography vs. film screen mammography, 14
Digital rectal exam (DRE), 41
Direct oral anticoagulants (DOACs), for atrial fibrillation, 200–206
Disease-modifying antirheumatic drugs (DMARDs), for rheumatoid arthritis (RA), 468–469
Diuretics, 366
Divalproex sodium, for migraine prophylaxis, 315
Dix-Hallpike maneuver, 540–541
DLBCL (diffuse large B-cell lymphoma) stages I through IV, management of, 282–283
DM (diabetes mellitus). See Diabetes mellitus entries
DOACs (direct oral anticoagulants), for atrial fibrillation, 200–206
Domestic violence
prevention of, 122
screening for, 70–71, 566
Donepezil, for Alzheimer disease, 268
Double-contrast barium enema (DCBE), 31
DRE (digital rectal exam), 41
Driving risk, prevention of, 122–123
Dronedarone, not for use in patients with chronic atrial fibrillation, 161
Duloxetine, for neuropathic pain, 419
Dutasteride, for prostate cancer primary prevention, 115
DVT (deep venous thrombosis), management of, 534–539
Dyspepsia, management of, 283–285
Dysphagia, management of, 285

E
Eating disorders
management, 285–286
psychiatric, 285
Eclampsia, prevention of, 370
Ectopic pregnancy, management of, 286–287
ED (erectile dysfunction), management of, 288–289
Eloxaban (Savaysa)
for atrial fibrillation, 204–206
switching to/from edoxaban, 205–206
Efavirenz, for HIV-1 infection, 341
Elderly. See Older adults
Eliquis (apixaban)
for atrial fibrillation, 203, 206
switching from/to warfarin, 203
Emtricitabine, for HIV-1 infection, 341
Endocarditis, prevention of, 123–124, 567
Endometrial cancer
primary prevention, 110
increasing parity and lactation, 110
minimize risk factor exposure, 110
oral contraception, 110
therapeutic approaches, 110
weight loss, 110
screening for, 31–33
harms of screening, 32
Epididymitis, 478
Epilepsy, management of, 287–288
Erectile dysfunction (ED), management of, 288–289
Erythromycin
for gonorrhea, ophthalmia neonatorum, 126
Erythropoietic agents
for anemia, 188–189
for patients with cancer and anemia, 188–189
Esophagus cancer
primary prevention
minimize risk factor exposure, 111
therapeutic approaches, 111
Essential tremor, management of, 517
Estrogen-containing contraceptives with migraine algorithm, 322
Ethosuximide, for absence seizures, 288
European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidemia (2011), 348–349
Evra patch, effectiveness of, 240
Exercise
breast cancer primary prevention, 106–107
colorectal cancer primary prevention, 108
to treat hypertension, 365
External genital warts, 478–479
Extrapulmonary tuberculosis
diagnosis, 518
management, 518
Ezetimibe, for lowering cholesterol, 345

F
Falls in older adults
prevention, 124–125
screening for, 69–70
Familial adenomatous polyposis (FAP)
screening for, 29, 566
Family violence and abuse
prevention of, 122
screening for, 70–71
Febrile neutropenia, management of, 400–402
Febrile seizures, management of, 472
Fecal occult blood test (FOBT), 26–29
  gFOBT (guaiac based), 26, 31–32
  iFOBT (immunochemical based), 26, 28, 31
Female sterilization, effectiveness of, 241
Fetal aneuploidy, screening for, 71
FFP (fresh frozen plasma), 514–515
Fibrates, for lowering cholesterol, 345
Fibric acid derivatives, for managing hyperlipidemia, 356
Finasteride, for prostate cancer primary prevention, 115
Flexible sigmoidoscopy, 26–28, 30
Fluoxetine, for depression, 269
FOBT (fecal occult blood test). See Fecal occult blood test (FOBT)
Formoterol, for COPD management, 232
Fractures, prevention of, 125
Fresh frozen plasma (FFP), 514–515
Furosemide, for ascites due to cirrhosis, 192

G
Gabapentin, for neuropathic pain, 419
GAD (generalized anxiety disorder), 190
Galantamine, for Alzheimer disease, 268
Gallstones, management of, 289
Gastric cancer
  primary prevention, 111–112
  *Helicobacter pylori* eradication, 112
  minimize risk factor exposure, 111–112
  therapeutic approaches, 112
  screening for, 33
Gastroesophageal reflux disease (GERD), 33–34
Gastrointestinal bleeding, lower, management of, 289–291
Gastrointestinal bleeding, upper (UGIB), management of, 291–292
GBS (group B streptococcal) infection prevention, 127
  screening for, 73
Generalized anxiety disorder (GAD), 190
Geriatric Depression Scale, 547, 552
Geriatrics, 293–311. See also Older adults
Gestational diabetes mellitus (GDM)
  management, 270–271
  screening for, 67, 566
  gFOBT (guaiac based fecal occult blood test), 26, 31–32
Glaucoma
  chronic open angle
    management, 312
    screening for, 72, 566
  Glaucoma, screening for, 100
Gonorrhea
  preventing ophthalmia neonatorum, 125–126
  screening for, 72–73
Gout
  acute attacks
    management, 313–314
    prevention, 126
Governmental agencies and professional societies, 591–593
Graves’ disease, 505
Group B streptococcal (GBS) infection prevention, 127
  screening for, 73
Growth abnormalities, infant
  screening for, 74
Guaiac based fecal occult blood test (gFOBT), 26, 31–32
H
HBV (hepatitis B virus). See Hepatitis B virus (HBV)
HCV (hepatitis C virus)
  chronic, screening for, 79–80
  management, 335
Headache
  cluster headache algorithm, 319
  diagnosis algorithm, 316
  estrogen-containing contraceptives with migraine algorithm, 322
  management, 315–323
  menstrual-associated migraine algorithm, 320
  migraine prophylaxis, 315, 323
INDEX

Headache (Continued)
migraine treatment algorithm, 317
perimenopausal or menopausal migraine
algorithm, 321
tension-type headache treatment
algorithm, 318
Hearing impairment
screening for, 74–75
newborns, 566
Hearing loss, sudden, management of, 324
Heart failure
management, 324–330
biomarkers in congestive heart failure, 329
clinical assessment in heart failure
class I recommendations, 325–327
heart failure with reduced ejection
fraction, 328
stages, 325
Heart rate control, for atrial fibrillation
patients, 197–198
*Helicobacter pylori*

gastric cancer primary prevention, 112
infection management, 330–331
Hematuria, management of, 331–332
Hemochromatosis (hereditary)
screening for, 75–77
Hemoglobinopathies, screening for, 77
Hemorrhage, postpartum
management, 440
prevention, 155–156
Heparin-induced thrombocytopenia,
management of, 498–501
Hepatitis B virus (HBV)
management, 332–335
infection, 333–334
screening for, 77–79
treatment, 334–335
Hepatitis C virus (HCV)
chronic, screening for, 79–80
management, 335
Hereditary hemochromatosis (HH)
diagnosis, 336
management, 336–337
problems in, 337
treatment, 336
Hereditary thrombophilic disorders, 172
Hereditary nonpolyposis colorectal cancer
(HNPCC), 28
Herpes simplex virus (HSV), genital,
screening for, 80
High parity
cervical cancer primary prevention, 107
Hip fractures, management of,
337–338
Hoarseness, management of, 338
Hormone replacement therapy, 127–128
breast cancer primary prevention, 104
HPV (human papillomavirus). See Human
papillomavirus (HPV)
HTN (hypertension). See Hypertension
(HTN)
Human immunodeficiency virus (HIV)
management, 339–343
antiretroviral therapy (ART), 340
pregnancy, 342–343
opportunistic infections
prevention, 128–137
screening for, 81–82, 567
Human immunodeficiency virus-1
(HIV-1)
management
antiretroviral use, 341–342
Human papillomavirus (HPV)
testing, for cervical cancer, 22–24
vaccination, 22–23
HPV-16/HPV-18 vaccination for
cervical cancer primary
prevention, 108
Hydrocephalus, normal pressure (NPH),
management of, 403
Hydrocortisone, for Crohn's disease, 374
Hyperlipidemia, management of,
343–357
ACC/AHA Guidelines (2013), 343
American Diabetes Association
Hyperlipidemia Guidelines
(2014), 347–348
children and adolescents (expert panel
guidelines, 2013), 350–352
cholesterol guidelines differences (2014),
348
European Society of Cardiology/
European Atherosclerosis Society
Guidelines (2011), 348–349

05_Esherick_Index.indd   608
14/11/17   6:06 pm
evidence-based recommendations for dietary management of elevated LDL-C, 351
evidence-based recommendations for dietary management of elevated triglycerides, 352
evidence-based recommendations for dietary management of non-HDL-C, 352
evidence-based recommendations for pharmacologic treatment of dyslipidemia, 352–354
intensity statin drug levels, 343–344
lipid and statin monitoring, 345
medications for managing, 355–357
non-statin cholesterol lowering agents, 345–346
primary prevention—global risk assessment, 344
Hypertension (HTN)
management, 358–370
ACC/AHA/ASH antihypertensive therapy for patients with CAD (2015), 359–362
American Diabetes Association antihypertensive therapy guidelines (2017), 362–363
American Society of Hypertension antihypertensive therapy (2013), 362
Canadian Hypertension Education Program antihypertensive therapy guidelines (2014/2015), 363–364
children and adolescents, 369
complicated hypertension, 366–367
impact of health behavior management on blood pressure, 365
JNC 8 (2014), 358–359
lifestyle modifications, 365
medications, 366
in pregnancy, 370
refractory hypertension, 367–368
prevention, 138–139
screening for adults, 83–85
children and adolescents, 82–83
stroke prevention, 163–167
Hyperthyroidism, management of, 504–506
Hypogonadism, male, management of, 371–372
IBS (irritable bowel syndrome), management of, 383–384
Idiopathic sudden sensorineural hearing loss (ISSNHL), 324
iFOBT (immunochemical based fecal occult blood test), 26, 28, 31
IgA tissue transglutaminase (TTG) test, for celiac disease, 51
Illicit drug use, screening for, 85
Immune mediated thrombocytopenia management, 493–498
Immunizations
adolescents, 579–585
adults, 139, 586–590
infants and children, 140, 579–585
schedule of, 579–590
Immunochemical based fecal occult blood test (iFOBT), 26, 28, 31
Implanon, effectiveness of, 241
Incidentalomas, adrenal, management of, 184
Incontinence, urinary, management of in men, 526
overactive bladder, 523–524
stress, 524–525
in women, 525, 527
Increasing parity and lactation endometrial cancer primary prevention, 110
Indacaterol, for COPD management, 232
Indwelling urinary catheters, management of, 373
Infants with Chlamydia infections, 475–476
with diabetes mellitus (DM), type 1, 271–272
with gonococcal infections, 476
Infants (Continued)
immunizations, 140
prevention
dental caries, 121
human immunodeficiency virus (HIV), opportunistic infections, 128, 134–137
immunizations, 140, 579–585
influenza vaccine, 141–142
motor vehicle injury, 143
sudden infant death syndrome (SIDS), 167
screening for
anemia, 6–7
cholesterol and lipid disorders, 53–54
developmental dysplasia of the hip (DDH), 66
growth abnormalities, 74
with syphilis, 474–475
Infertility, male, management of, 374
Inflammatory bowel disease, 374–377
Crohn's disease, 374–375
management, 374–375
ulcerative colitis, 375–377
management, 375–377
surgical treatment, 376–377
Infliximab, for Crohn's disease, 374
Influenza
chemoprophylaxis, 140–141
management, 377–378
vaccination, 141–142
Insulin
injectable, 278
oral, 277
Intermittent catheterization, management of, 373
Intracranial neurocysticercosis, 400
Ionizing radiation to chest and mediastinum
breast cancer primary prevention, 104
Ipratropium bromide, for COPD management, 232
Iron deficiency anemia
clinical evaluation, 379–381
diagnosis, 379–380
management, 378–382
iron replacement therapy, 379
refractory iron deficiency, 379–380
Irritable bowel syndrome (IBS), management of, 383–384
ISSNHL (idiopathic sudden sensorineural hearing loss), 324
Ivabradine (Corlanor), for heart failure, 324, 329
J
JNC 8 (2014), 358–359
K
Kidney disease, chronic (CKD)
management, 384–386
mineral and bone disorders, 385–386
screening for, 86
Kidney injury, acute
management, 386
prevention, 142
Kidney stones, management of, 387–389
L
Labetalol, for hypertension, 370
Lamotrigine
for absence seizures, 288
for focal seizures, 288
for generalized tonic-clonic seizures, 288
Language and speech delay, screening for, 94–95
Laparoscopy, for ectopic pregnancy, 287
Laryngitis, acute, management of, 389–390
Latent syphilis, 474
Latent tuberculosis
management, 521
screening for, 99
LDCT (low-dose CT), for lung cancer, 35–36
Lead poisoning, screening for, 86–88
Levalbuterol, for COPD management, 232
Levetiracetam
for focal seizures, 288
for generalized tonic-clonic seizures, 288
for myoclonic seizures, 288
Levofloxacin
for acute diarrhea in adults, 281
for Helicobacter pylori infection, 330
Lifestyle modifications, for hypertension, 138–139, 365
Lipid and cholesterol disorders, screening for, 53–59
Liver cancer
  primary prevention, 112
  screening for, 34–35
Liver chemistries, abnormal, evaluating, 181–183
  aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level, 181
  elevated serum total bilirubin, 182
  serum alkaline phosphatase, 182
Low back pain
  evaluation, 218
  management, 216–218
  analgesic ladder, 217
  nonpharmacologic, 216–218
  pharmacologic, 216–218
  sciatica, 470–471
  prevention, 104
Low-dose CT (LDCT), for lung cancer, 35–36
Lower respiratory tract infections, management of, 465–466
Lower urinary tract symptoms, management of, 530
Lung cancer
  non-small cell lung cancer (NSCLC)
    follow-up care, 402–403
    primary prevention, 113
    minimize risk factor exposure, 113
    therapeutic approaches, 113
    screening for, 35–37
  Lynch syndrome, 28–29, 33–34

M
Male hypogonadism, 371–372
Male infertility, 374
Male sterilization, effectiveness of, 241
Malignant spinal cord compression (MSCC), management of, 390–391
MALT (mucosa-associated lymphoid tissue), 330
Mammography, harms and benefits of, 13–20, 21
Masked hypertension, 369
MDR-TB (multidrug-resistant tuberculosis), management of, 522
Melanoma, screening for, 46–47
Memantine, for Alzheimer disease, 268
Meningitis, bacterial, management of, 393
Menopausal or perimenopausal migraine algorithm, 321
Menopause, management of, 394–395
Menstrual-associated migraine algorithm, 320
Mercaptopurine, for Crohn’s disease, 374
Metabolic syndrome
  identification, 395–396
  management, 395–396
Metformin
  for diabetes mellitus type 2, 277
  new recommendations, 277, 567
Methicillin-resistant Staphylococcus aureus infections, management of, 397–398
Methotrexate, for ectopic pregnancy, 286
Methyldopa, for hypertension, 370
Methylphenidate, for attention deficit/hyperactivity disorder (ADHD), 213
Methylprednisolone
  for Crohn’s disease, 374
  for ulcerative colitis, 375–376
Metoprolol
  for migraine prophylaxis, 315
  perioperative, new guidelines for, 567
Metronidazole, for Helicobacter pylori infection, 330
Migraine prophylaxis, 315, 323
Migraine treatment algorithm, 317
MI (myocardial infarction)
  aspirin therapy, 144–145
  dietary therapy, 145
  special populations, 148–152
  statin therapy, 146–148
Minimizing risk factor exposure
  cervical cancer primary prevention, 107
  colorectal cancer primary prevention, 108–109
  endometrial cancer primary prevention, 110
  gastric cancer primary prevention, 111–112
  lung cancer primary prevention, 113
  oral cancer primary prevention, 113
Minimizing risk factor exposure (Continued)
prostate cancer primary prevention, 115
skin cancer primary prevention, 116
Mirena intrauterine device, effectiveness
of, 241
Mitral regurgitation, 531, 533
Mitral stenosis, 533
Modified Checklist for Autism in Toddlers,
Revised with Follow-Up
(M-CHAT-R/F), 553–554
Motor vehicle injury, 143
Motor vehicle safety, screening for, 88
MSCC (malignant spinal cord compression),
management of, 390–391
Mucosa-associated lymphoid tissue
(MALT), 330
Multidrug-resistant tuberculosis (MDR-
TB), management of, 522
Multi-parametric MRI scanning
for detection of prostate cancer, 44, 184
Multiple sclerosis (MS), management of, 399
Multi-targeted DNA stool testing
(cologuard), 28
Muscle cramps, management of, 399
Myocardial infarction (MI)
aspirin therapy, 144–145
dietary therapy, 145
special populations, 148–152
statin therapy, 146–148
Liver cancer, 112
Sudden infant death syndrome (SIDS), 167
Screening, 88–89
Hearing impairment, 74–75, 566
Hemoglobinopathies, 77
Metabolic screening test, 88–89
Phenylketonuria (PKU), 93
Thyroid disease, 96–97
Niacin, for lowering cholesterol, 345
Nicotine gum, for smoking cessation, 511
Nicotine inhaler, for smoking cessation,
511
Nicotine nasal spray, for smoking
cessation, 511
Nicotine patch, for smoking cessation, 511
Nicotinic acid, for managing
hyperlipidemia, 357
Nifedipine, for hypertension, 370
Nitroimidazole, for Helicobacter pylori
infection, 330–331
Nitroprusside, for hypertension, 370
Nocturnal oxygen therapy, for central sleep
apnea (CSAS), 191
Noncardiac surgery, preoperative cardiac
clearance for, 424
Non-emergent surgery
delay times for, 432
when to bridge anticoagulation, 432
Non-small cell lung cancer (NSCLC)
follow-up care, 402–403
Non-statin cholesterol lowering agents,
345–346
Nonvalvular new oral anticoagulation
agents
for atrial fibrillation, 200
Normal pressure hydrocephalus (NPH),
management of, 403
Nortriptyline, for smoking cessation, 512
NSAIDs
for ankylosing spondylitis or
spondyloarthritis, 189–190
for colorectal cancer primary prevention,
109
for osteoarthritis, 406–407
NSCLC (non-small cell lung cancer)
follow-up care, 402–403
Neonatal
prevention
gonorrhea, ophthalmia neonatorum,
125–126
Neural tube defects, prevention of, 152–153
Neurocysticercosis, management of, 400
Neurosyphilis, 474
Neutropenia, febrile, management of,
400–402
NAD
(f) test, for chlamydia
Nadolol, for migraine prophylaxis, 315
Naltrexone, for alcohol use disorders, 186
National Lipid Association Guidelines
(2014), 346–347
Neural tube defects, prevention of, 152–153
Neurocysticercosis, management of, 400
Neurosyphilis, 474
Neutropenia, febrile, management of,
400–402
Newborns
prevention
gonorrhea, ophthalmia neonatorum,
125–126
Neural tube defects, prevention of, 152–153
Neurocysticercosis, management of, 400
Neurosyphilis, 474
Neutropenia, febrile, management of,
400–402
Newborns
prevention
gonorrhea, ophthalmia neonatorum,
125–126
Nutrition
colorectal cancer primary prevention, 108
DASH eating plan, to treat hypertension, 365
for myocardial infarction, 144–145
NuvaRing, effectiveness of, 241

O
OA (osteoarthritis)
management, 405–407
nonpharmacologic recommendations, 405–406
pharmacologic options, 406
Obesity
breast cancer primary prevention, 104
management, 404–405
prevention, 153–154
screening for, 89–90
Obstructive sleep apnea (OSA)
diagnosis
comprehensive sleep evaluation, 191
polysomnogram, 191
management, 191–192
mandibular advancement devices, 192
nocturnal CPAP (continuous positive airway pressure), 192
weight loss, 192
Ocular hypertension (OHT), 312
Ofloxacin, for acute diarrhea in adults, 281
Older adults
adverse drug events, preventing, 558
delirium, 266–267
dementia, 267–268
drugs with strong anticholinergic properties, 311
functional assessment screening, 555–557
with hip fractures, 337–338
with hypertension, 369
medications to avoid, 558–563
medications to use with caution, 564
osteoporosis, 407–410
glucocorticoid-induced, 409–410
palliative care of dying adults, 419–421
with postoperative delirium, 267
potentially inappropriate medication use
(Beers criteria), 293–310
prevention
adverse drug events, 558–564
falls, 69–70, 124–125
fractures, 125
influenza vaccine, 141–142
motor vehicle injury, 143
osteoporotic hip fractures, 154–155
screening for
ADL-IADL, 556
balance and gait, 555
continence of urine, 555
dentition, 557
depression, 556
falls, 557
family violence and abuse, 70–71
functional assessment, 555–557
hearing, 555
home environment, 557
medications to avoid, 558–563
medications to use with caution, 564
mental status, 556
nutrition, 555
osteoporosis, 567
pain, 557
social support, 557
vision, 100, 555
Omega-3 fish oil
for lowering cholesterol, 345
for managing hyperlipidemia, 357
Ophthalmia neonatorum
prevention, 125–126
prophylaxis, 477
treatment, 475–476
Opioids
for chronic, non-cancer-related pain
assessing risk of opioid use, 415
opioid selection, follow-up, and discontinuation, 414–415
for women treated for ovarian cancer
with complete response, 416–418
adverse effects associated with long-term opioid use, 418
risk assessment, mitigation, and universal precautions with opioid use, 418
Oral cancer
primary prevention, 113–114
minimize risk factor exposure, 113
therapeutic approaches, 114
screening
routine screening not recommended, 38
Oral contraceptives
cervical cancer primary prevention, 107
endometrial cancer primary prevention, 110
OSA (obstructive sleep apnea). See Obstructive sleep apnea (OSA)
Osteoarthritis (OA)
management, 405–407
nonpharmacologic recommendations, 405–406
pharmacologic options, 406
Osteoporosis
glucocorticoid-induced
management, 409–410
management, 407–409
screening for, 90–91
updated guidelines, 567
Osteoporotic hip fractures prevention, 154–155
Otitis externa, acute (AOE), management of, 411
Otitis media
diagnosis, 412–413
management, 411–413
prevention, 155
Ovarian cancer
follow-up care, 413–414
primary prevention, 114–115
minimize risk factor exposure, 114
obesity, 114
oral contraceptives, 114
prophylactic salpingo-oophorectomy, 115
therapeutic approaches, 114–115
screening for, 38–40
survivors, management of chronic pain in, 416–418
opioids, 417–418
pharmacological interventions, 417
screening and comprehensive assessment, 416
treatment and care options, 417
Ovulation contraception method, effectiveness of, 240
Oxcarbazepine
for focal seizures, 288
for generalized tonic-clonic seizures, 288
P
Padua Prediction scale, 169, 171
Pain
chronic
assessing risk of opioid use, 415
cancer related, management, 416–418
management, 414–418
nonpharmacologic therapy, 414
opioid selection, follow-up, and discontinuation, 414–415
neuropathic
management, 419
PALB2 mutations, 17
Palliative care of dying adults, 419–421
pain management, 419–421
by the clock, 420
individualize treatment, 420
monitor, 420
by the mouth, 420
use adjuvant drugs, 421
by the WHO ladder, 420
Pancreatic cancer, screening for routine screening not recommended, 40
Pancreatitis, acute (AP), management of, 411–413
Paracentesis, 429
ParaGard intrauterine device, effectiveness of, 241
Patient Health Questionnaire (PHQ-9), 547–549
PCSK9 (proprotein convertase subtilisin kexin 9), for lowering cholesterol, 345
Pediculosis pubis, 479
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG (polyethylene glycol), for oral disimpaction,</td>
<td>239</td>
</tr>
<tr>
<td>Pelvic examinations,</td>
<td>92</td>
</tr>
<tr>
<td>Pelvic inflammatory disease,</td>
<td>478</td>
</tr>
<tr>
<td>Peptic ulcer disease (PUD),</td>
<td>330</td>
</tr>
<tr>
<td>PE (pulmonary embolus) management,</td>
<td>539–540</td>
</tr>
<tr>
<td>Perimenopausal or menopausal migraine algorithm,</td>
<td>321</td>
</tr>
<tr>
<td>Peripheral arterial disease, management of,</td>
<td>429–431</td>
</tr>
<tr>
<td>Pharyngitis, acute, management of,</td>
<td>431–433</td>
</tr>
<tr>
<td>Phenylketonuria (PKU), screening for,</td>
<td>93</td>
</tr>
<tr>
<td>Phototherapy, for atopic dermatitis,</td>
<td>197</td>
</tr>
<tr>
<td>Platelet transfusion,</td>
<td>433–434, 515</td>
</tr>
<tr>
<td>Pleural effusion, malignant, management of,</td>
<td>434–436</td>
</tr>
<tr>
<td>Pneumonia, community acquired,</td>
<td>437–439</td>
</tr>
<tr>
<td>suspected pathogens,</td>
<td>439</td>
</tr>
<tr>
<td>Polycystic ovary syndrome, management of,</td>
<td>436–437</td>
</tr>
<tr>
<td>Polyethylene glycol (PEG), for oral disimpaction,</td>
<td>239</td>
</tr>
<tr>
<td>Polyp removal, for colorectal cancer primary prevention,</td>
<td>109</td>
</tr>
<tr>
<td>Positive airway pressure therapy for central sleep apnea (CSAS),</td>
<td>190–191</td>
</tr>
<tr>
<td>Postmenopausal combination hormone replacement colorectal cancer primary prevention,</td>
<td>109</td>
</tr>
<tr>
<td>Postpartum hemorrhage (PPH) management,</td>
<td>440</td>
</tr>
<tr>
<td>prevention,</td>
<td>155–156</td>
</tr>
<tr>
<td>Postpartum interventions,</td>
<td>445</td>
</tr>
<tr>
<td>PPI, for Helicobacter pylori infection,</td>
<td>330–331</td>
</tr>
<tr>
<td>Pradaxa (dabigatran etexilate) for atrial fibrillation,</td>
<td>201, 206</td>
</tr>
<tr>
<td>converting from/to parenteral anticoagulants,</td>
<td>201</td>
</tr>
<tr>
<td>discontinue before invasive or surgical procedures,</td>
<td>201</td>
</tr>
<tr>
<td>switching to warfarin,</td>
<td>201</td>
</tr>
<tr>
<td>Preconception visit,</td>
<td>443</td>
</tr>
<tr>
<td>Prednisolone for Crohn's disease,</td>
<td>374</td>
</tr>
<tr>
<td>for gout,</td>
<td>314</td>
</tr>
<tr>
<td>for ulcerative colitis,</td>
<td>375</td>
</tr>
<tr>
<td>Preeclampsia, prevention of,</td>
<td>156</td>
</tr>
<tr>
<td>Pregabalin, for neuropathic pain,</td>
<td>419</td>
</tr>
<tr>
<td>Pregnancy before age 20, for breast cancer primary prevention,</td>
<td>107</td>
</tr>
<tr>
<td>anemia, screening for,</td>
<td>6–7</td>
</tr>
<tr>
<td>anticoagulation and,</td>
<td>487</td>
</tr>
<tr>
<td>bacterial vaginosis screening for,</td>
<td>10</td>
</tr>
<tr>
<td>treatment,</td>
<td>477</td>
</tr>
<tr>
<td>bacteriuria, asymptomatic, screening for,</td>
<td>9–10</td>
</tr>
<tr>
<td>cesarean section,</td>
<td>117–118</td>
</tr>
<tr>
<td>ectopic,</td>
<td>286–287</td>
</tr>
<tr>
<td>laparoscopy,</td>
<td>287</td>
</tr>
<tr>
<td>methotrexate,</td>
<td>286</td>
</tr>
<tr>
<td>transvaginal ultrasound (TVUS),</td>
<td>286</td>
</tr>
<tr>
<td>gestational diabetes mellitus (GDM), screening for,</td>
<td>67, 566</td>
</tr>
<tr>
<td>group B streptococcal (GBS) infection,</td>
<td>127</td>
</tr>
<tr>
<td>HIV infection during,</td>
<td>342–343</td>
</tr>
<tr>
<td>hypertension,</td>
<td>369–370</td>
</tr>
<tr>
<td>perinatal and postnatal guidelines,</td>
<td>437</td>
</tr>
<tr>
<td>breast-feeding,</td>
<td>437</td>
</tr>
<tr>
<td>hemoglobinopathies,</td>
<td>437</td>
</tr>
<tr>
<td>hyperbilirubinemia,</td>
<td>437</td>
</tr>
<tr>
<td>phenylketonuria,</td>
<td>437</td>
</tr>
<tr>
<td>thyroid function abnormalities,</td>
<td>437</td>
</tr>
<tr>
<td>postpartum hemorrhage (PPH) management,</td>
<td>440</td>
</tr>
<tr>
<td>prevention,</td>
<td>155–156</td>
</tr>
<tr>
<td>premature rupture of membranes, management of,</td>
<td>441</td>
</tr>
<tr>
<td>prenatal care, routine,</td>
<td>443–445</td>
</tr>
</tbody>
</table>
Pregnancy (Continued)

preterm labor
management, 441–442
tocolysis, 442
prevention
postpartum hemorrhage, 155–156
preeclampsia, 156
preterm birth, 156
surgical site infections (SSIs), 168
screening for
alcohol abuse and dependence, 5–6
diabetes mellitus (DM) type 2, 67–69
fetal aneuploidy, 71
genital herpes simplex virus, 80
gestational diabetes mellitus (GDM), 67
hepatitis B virus infection, 78–79
hepatitis C virus infection, chronic, 79
human immunodeficiency virus (HIV), 81
illicit drug use, 85
lead poisoning, 87–88
Rh (D) incompatibility, 93
syphilis, 95–96
thyroid disease, 97
tobacco use, 98
smoking cessation, 509–512
substance abuse, 446
syphilis, 474
thyroid disease, 506–507
Prenatal care, routine, 443–445
antepartum lab testing, 444
frequency of visits for uncomplicated pregnancies, 443
initial prenatal visit, 443
postpartum interventions, 445
preconception visit, 443
prenatal counseling, 444
prenatal interventions, 444–445
routine checks at follow-up prenatal visits, 443
Preoperative clearance, 446
cardiac clearance for noncardiac surgery, 424
Pressure ulcers
management, 446–447
prevention, 157–158
Preterm birth, prevention of, 156
Prime-MD (mood questions), 547
Procedural sedation, management of, 447–448
Proctitis, 479
Professional societies and governmental agencies, 591–593
Propanolol, for migraine prophylaxis, 315
Prophylactic salpingo-oophorectomy among BRCA-positive women
breast cancer primary prevention, 106
Prostate cancer
African American men have double the risk, 45
follow-up care, 448–449
localized
active surveillance (AS) for
management of, 183–184
primary prevention, 115
dutasteride, 115
finasteride, 115
minimize risk factor exposure, 115
therapeutic and preventive approaches, 115
vitamins and minerals, 115
screening for, 41–45
in perspective, 566
Prostate-specific antigen (PSA), 41–45, 448–449
Prothrombin complex concentrate, 516
Proton pump inhibitors, for dyspepsia, 284
Prozac, to prevent relapse in patients with bulimia nervosa, 286
Psoriasis, plaque-type
management, 451–452
Psoriasis and psoriatic arthritis
management, 450–451
Psychiatric patients in the emergency department, management of, 185, 453
PTEN mutations, 17
PUD (peptic ulcer disease), 330
Pulmonary embolus (PE) management, 539–540
Pulmonary nodules
management, 453–454
R
Radical prostatectomy, 44
Raloxifene
  breast cancer primary prevention in postmenopausal women, 106
  for osteoporosis, 409
Raltegravir, for HIV-1 infection, 341
RCC (renal cancer) follow-up care, 458–464
Red blood cell (RBC) transfusion, 454–457, 516
  alternatives to, 513–514
  hemodynamically stable patients, 455
  infectious complications of, 457
  noninfectious complications of, 455–456
Refractory hypertension, 367–368
Refractory iron deficiency, 379–380
Renal cancer (RCC) follow-up care, 458–464
Renal masses, small, management of, 464–465
Respiratory infections, upper, management of, 466
Respiratory tract infections, lower, management of, 465–466
Restless legs syndrome and periodic limb movement disorders, management of, 467
Rh (D) incompatibility, screening for, 93
Rheumatoid arthritis (RA), biologic disease-modifying antirheumatic drugs (DMARDs), 468–469
Rhinitis, management of, 469–470
Rhythm control, for atrial fibrillation patients, 208–209
Rifaximin, for acute diarrhea in adults, 281
Rilpivirine, for HIV-1 infection, 341
Ritonavir, for HIV-1 infection, 341
Rivaroxaban, for atrial fibrillation, 202, 206
Rivastigmine, for Alzheimer disease, 268
Roflumilast, for COPD management, 232
Salmeterol, for COPD management, 232
Salpingo-oophorectomy to decrease risk of breast cancer in BRCA1 and BRCA2 carriers, 19
SAMe, TT2, R2, score, 162, 167
Savaysa (edoxaban)
  for atrial fibrillation, 204–206
  switching to/from edoxaban, 205–206
Scabies, 479
Sciatica, management of, 470–471
Scoliosis, screening for, 94
Screening and prevention guidelines in perspective (PGPC2012), 565–567
Screening with PAP smears, for cervical cancer primary prevention, 108
Sedation, procedural, management of, 447–448
Seizures
  febrile management, 472
  management, 471–472
Seniors. See Older adults
Serious illness risk, identifying in children under 5 y, 372–373
Sertraline, for anxiety, 190
Sexually transmitted diseases, management of, 473–479
  bacterial vaginosis, 477
  cervicitis, 475
  chancroid, 473
Chlamydia infections in adolescents and adults, 475
Chlamydia infections in infants and children, 475–476
  gonococcal infections in adults, 476
  gonococcal infections in infants and children, 476
  granuloma inguinale (Donovanosis), 473
  HIV-positive patients, suppressive therapy for, 473
  HSV, 473
Lymphogranuloma venereum, 474
  nongonococcal urethritis, 475
  recurrent or persistent urethritis, 475
  syphilis in adults, 474–475
  syphilis in infants and children, 474–475
Sexually transmitted infections (STIs), prevention of, 158
SIDS (sudden infant death syndrome), prevention of, 167
Sildenafil, for erectile dysfunction, 289
Sinusitis
  acute bacterial management, 480
  management, 480
Skin cancer
  primary prevention, 116
  minimize risk factor exposure, 116
  therapeutic approaches, 116
Skin cancer (melanoma), screening for, 46–47
Sleep apnea. See Apnea
Smoking cessation, 168–169, 509–512
  for dyspepsia, 284
  motivating tobacco users to quit (Five R’s), 510
  myocardial infarction prevention, 150
  treatment algorithm (Five A’s), 510
  treatment options, 511–512
Sodium reduction, to treat hypertension, 365
Sodium valproate
  for absence seizures, 288
  for focal seizures, 288
  for generalized tonic-clonic seizures, 288
  for migraine prophylaxis, 315
  for myoclonic seizures, 288
Speech and language delay, screening for, 94–95
Spermicides, effectiveness of 240
Spinal cord compression, malignant (MSCC), management of, 390–391
Spiral CT, for lung cancer, 36
Spondyloarthritis, management of, 189–190
Sponge (contraceptive method), effectiveness of, 240
Squamous cell skin cancer, 46
Standard Days contraception method, effectiveness of, 240
Staphylococcus aureus infections, methicillin-resistant management, 397–398
Statins, 355–357
  for abdominal aortic aneurysm (AAA), 197
  intensity drug levels, 343–344
  monitoring, 345
  for myocardial infarction, 146–148
ST-elevation myocardial infarction, 259
Stent therapy use of triple anticoagulation treatment, 261–264
Steroids, intraarticular, for osteoarthritis, 406
STIs (sexually transmitted infections), prevention of, 158
Stress ulcers, management of, 523
Stroke
  acute ischemic management, 481–482, 488–489
  rehabilitation, 481–482
  prevention, 159
  in atrial fibrillation patients, 159–162
  in special populations, 163–167
  recurrence management, 483–489
  risk for atrial fibrillation patients, 211–212
  men, 575–576
  women, 577–578
Substance abuse during pregnancy, 446
Sudden infant death syndrome (SIDS), prevention of, 167
Surgical site infection (SSI) prevention, 168
Syncope
  evaluation and diagnosis
    more often associated with cardiac causes, 490–491
    more often associated with noncardiac causes, 491
    serious medical conditions associated with, 492
  management, 490–492
  tests for, 492
Syphilis
  management, 493
  screening for, 95–96
T
  T-ACE, to screen pregnant women for alcohol abuse and dependence, 5
  Tadalafil, for erectile dysfunction, 289
  Tamoxifen
    breast cancer primary prevention in postmenopausal and high-risk premenopausal women, 105
to decrease risk of contralateral breast cancer in BRCA-mutated breast patients, 19

increases risk of endometrial cancer, 110

TB (tuberculosis). See Tuberculosis (TB)

Tenofovir, for HIV-1 infection, 341

Tension-type headache treatment algorithm, 318

Teriparatide, for osteoporosis, 409

Tertiary syphilis, 474

Testicular cancer screening in perspective, 566

Tetracycline, for Helicobacter pylori infection, 330

Thiamine, for alcohol use disorders, 185

Thrombocytopenia

heparin-induced management, 498–501

immune mediated management, 493–498

thrombotic purpura (TTP) management, 501–503

Thromboembolic risk scores

atrial fibrillation, 211–212

Thromboembolism, prevention in atrial fibrillation patients, 199

Thrombotic purpura (TTP), management of, 501–503

Thyroid cancer, screening for, 48–49, 566

Thyroid disease

management hyperthyroidism, 504–506

pregnancy and postpartum, 506–507

screening for, 96–97, 566

Thyroid nodules, management of, 508

Timolol, for migraine prophylaxis, 315

Tinnitus, management of, 509

Tiotropium, for COPD management, 232

TIPSS (transjugular intrahepatic portosystemic shunt)

for ascites due to cirrhosis, 192

TNFi (tumor necrosis factor inhibitor) therapy, for ankylosing spondylitis or spondyloarthritis, 189–190

Tobacco use. See Smoking Cessation

Tomosynthesis (three-dimensional mammography), 16

Tonsillectomy, 513

Topiramate

for generalized tonic-clonic seizures, 288

for migraine prophylaxis, 315

for myoclonic seizures, 288

TP53 mutations, 17

“Traffic light system” for identifying risk of serious illness in children under 5 y, 372–373

Tramadol, for osteoarthritis, 406

Transfusion therapy

alternatives to red blood cell transfusion, 513–514

cryoprecipitate, 514

fresh frozen plasma (FFP), 514–515

platelet transfusion, 515

prothrombin complex concentrate, 516

red blood cell transfusion, 516

Transjugular intrahepatic portosystemic shunt (TIPSS)

for ascites due to cirrhosis, 192

Transvaginal ultrasound (TVUS), for ectopic pregnancy, 286

Traumatic brain injury, management of, 516

Tremor, essential, management of, 517

Triazolam, for central sleep apnea (CSAS), 191

Trichomoniasis, 477

Troponin level, elevated, 260

TTO (thrombotic purpura), management of, 501–503

Tuberculosis (TB)

diagnosis, 517

extrapulmonary diagnosis, 518

management, 518

latent management, 521

screening for, 99

management, 519–521

multidrug-resistant (MDR-TB) management, 522

Tumor necrosis factor inhibitor (TNFi) therapy, for ankylosing spondylitis or spondyloarthritis, 189–190

TVUS (transvaginal ultrasound), for ectopic pregnancy, 286

TWEAK

alcohol abuse and dependence, screening pregnant women for, 5
Two-Day contraception method (TM), effectiveness of, 240
Tympanostomy tubes, management of, 522–523

U
Ulcerative colitis
management, 375–377
surgical treatment, 376–377
Ulcers, stress, management of, 523
Unstable angina, 257–258
Upper respiratory infections, management of, 466
Urethral meatal warts, 479
Urinary catheters, indwelling, management of, 373
Urinary incontinence management in men, 526
overactive bladder, 523–524
stress, 524–525
in women, 525, 527
Urinary tract infections (UTIs), management of, 528–529
Urinary tract symptoms, lower, management of, 530
Urine nucleic amplification acid test (NAAT), for chlamydia

V
Vaginal warts, 479
Vaginosis, bacterial, screening for, 10
Valvular heart disease
management, 531–534
aortic insufficiency, 531–533
aortic stenosis, 531–533
mitral regurgitation, 531, 533
mitral stenosis, 533
Vardenafil, for erectile dysfunction, 289
Varenicline, for smoking cessation, 512
Venlafaxine, for migraine prophylaxis, 315
Venous thromboembolism (VTE)
deep venous thrombosis (DVT) management, 534–539
prevention in surgical patients, 173–175
prophylaxis in nonsurgical patients, 170–173
pulmonary embolus (PE) management, 539–540
Warfarin
for atrial fibrillation, 199, 206, 210
HAS-BLED bleeding risk score, 210
switching from/to, 201–204
Weight loss
for dyspepsia, 284
decrease endometrial cancer primary prevention, 110
to treat hypertension, 365
Wells criteria (for venous thromboembolism), 535
White-coat hypertension, 369
Withdrawal, effectiveness as a contraceptive method 240
Women’s Health Initiative (WHI), 33
X
Xarelto (rivaroxaban), 206
for atrial fibrillation, 202
discontinue at least 24 h before surgery, 202
switching to warfarin, 202
Z
Zidovudine, for HIV infection in pregnancy, 342
Zinc, for common colds, 238
Zolpidem, for central sleep apnea (CSAS), 191
Venous thrombosis in patients with cancer, 391–393
Vertigo, benign paroxysmal positional (BPPV), management of, 540–541
Very elderly hypertension, 369
Violence and abuse
prevention of, 122
screening for, 70–71, 566
Visual impairment, screening for, 100
Vitamin deficiencies
management, 541
vitamin D, screening for, 101
Vitamins and minerals, for prostate cancer primary prevention, 115
Venous thromboembolism (VTE)
Venous thromboembolism in patients with cancer, 391–393
Vertigo, benign paroxysmal positional (BPPV), management of, 540–541
Very elderly hypertension, 369
Violence and abuse
prevention of, 122
screening for, 70–71, 566
Visual impairment, screening for, 100
Vitamin deficiencies
management, 541
vitamin D, screening for, 101
Vitamins and minerals, for prostate cancer primary prevention, 115
Venous thromboembolism (VTE)